PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Felson, DT; McLaughlin, S; Goggins, J; LaValley, MP; Gale, E; Totterman, S; Li, W; Hill, C; Gale, D				Felson, DT; McLaughlin, S; Goggins, J; LaValley, MP; Gale, E; Totterman, S; Li, W; Hill, C; Gale, D			Bone marrow edema and its relation to progression of knee osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Article							JOINT SPACE WIDTH; RADIOGRAPHIC FEATURES; CLINICAL-TRIAL; MODIFYING DRUG; SCINTIGRAPHY; ALIGNMENT; PAIN	Background: While factors affecting the course of knee osteoarthritis are mostly unknown, lesions on bone scan and mechanical malalignment increase risk for radiographic deterioration. Bone marrow edema lesions on magnetic resonance imaging correspond to bone scan lesions. Objective: To determine whether edema lesions in the subarticular bone in patients with knee osteoarthritis identify knees at high risk for radiographic progression and whether these lesions are associated with limb malalignment. Design: Natural history study. Setting: A Veterans Administration hospital in Boston, Massachusetts. Patients: Persons 45 years of age and older with symptomatic knee osteoarthritis. Measurements: Baseline assessments included magnetic resonance imaging of the knee and fluoroscopically positioned radiography. During follow-up at 15 and 30 months, patients underwent repeated radiography; at 15 months, long-limb films were obtained to assess mechanical alignment. Progression was defined as an increase over follow-up in medial or lateral joint space narrowing, based on a semi-quantitative grading. Generalized estimating equations were used to evaluate the relation of medial bone marrow edema lesions to medial progression and lateral lesions to lateral progression, before and after adjustment for limb alignment. Results: Of 256 patients, 223 (87.1%) participated in at least one follow-up examination. Medial bone marrow lesions were seen mostly in patients with varus limbs, and lateral lesions were seen mostly in those with valgus limbs. Twenty-seven of 75 knees with medial lesions (36.0%) showed medial progression versus 12 of 148 knees without lesions (8.1%) (odds ratio for progression, 6.5 [95% Cl, 3.0 to 14.0]). Approximately 69% of knees that progressed medially had medial lesions, and lateral lesions conferred a marked risk for lateral progression. These increased risks were attenuated by 37% to 53% after adjustment for limb alignment. Conclusion: Bone marrow edema is a potent risk factor for structural deterioration in knee osteoarthritis, and its relation to progression is explained in part by its association with limb alignment.	Boston Univ, Sch Med, Boston, MA 02118 USA; Vet Affairs Boston Hlth Care Syst, Boston, MA USA; Univ Rochester, Rochester, NY USA	Boston University; University of Rochester	Felson, DT (corresponding author), Boston Univ, Sch Med, 715 Albany St,A203, Boston, MA 02118 USA.		McLaughlin, Sara/S-3521-2019; LaValley, Michael/AAA-2030-2020	LaValley, Michael/0000-0002-8488-5170; Felson, David/0000-0002-2668-2447	NIAMS NIH HHS [AR47785] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ALTMAN RD, 1995, OSTEOARTHR CARTILAGE, V3, P3; ANDRIACCHI TP, 1994, ORTHOP CLIN N AM, V25, P395; BERGMAN AG, 1994, SKELETAL RADIOL, V23, P445; Boegard T, 1999, ANN RHEUM DIS, V58, P20, DOI 10.1136/ard.58.1.20; Brandt KD, 2002, J RHEUMATOL, V29, P1308; Buckland-Wright JC, 2003, J RHEUMATOL, V30, P329; BUCKLANDWRIGHT C, 1995, OSTEOARTHR CARTILAGE, V3, P71; BUCKLANDWRIGHT JC, 1995, ANN RHEUM DIS, V54, P263, DOI 10.1136/ard.54.4.263; DIEPPE P, 1993, ANN RHEUM DIS, V52, P557, DOI 10.1136/ard.52.8.557; Felson DT, 2001, ANN INTERN MED, V134, P541, DOI 10.7326/0003-4819-134-7-200104030-00007; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; HUTTON CW, 1986, ANN RHEUM DIS, V45, P622, DOI 10.1136/ard.45.8.622; JOHNSON F, 1980, J BONE JOINT SURG BR, V62, P346, DOI 10.1302/0301-620X.62B3.7410467; Lavalley MP, 2002, ARTHRIT RHEUM-ARTHR, V47, P255, DOI 10.1002/art.10453; Lazzarini KM, 1997, RADIOLOGY, V202, P540, DOI 10.1148/radiology.202.2.9015087; LEDINGHAM J, 1995, ANN RHEUM DIS, V54, P53, DOI 10.1136/ard.54.1.53; MAZZUCA S, 2000, 46 ANN ORTH RES SOC; Mazzuca SA, 1997, OSTEOARTHR CARTILAGE, V5, P217, DOI 10.1016/S1063-4584(97)80017-9; MCALINDON TEM, 1991, ANN RHEUM DIS, V50, P14, DOI 10.1136/ard.50.1.14; MORELAND JR, 1987, J BONE JOINT SURG AM, V69A, P745, DOI 10.2106/00004623-198769050-00016; Rangger C, 1998, ACTA ORTHOP SCAND, V69, P291, DOI 10.3109/17453679809000933; Rothman KJ., 2002, EPIDEMIOLOGY INTRO, P181; SCHOUTEN JSAG, 1992, ANN RHEUM DIS, V51, P932, DOI 10.1136/ard.51.8.932; Sharma L, 2001, JAMA-J AM MED ASSOC, V286, P188, DOI 10.1001/jama.286.2.188; Zanetti M, 2000, RADIOLOGY, V215, P835, DOI 10.1148/radiology.215.3.r00jn05835; Zhang YQ, 1996, J RHEUMATOL, V23, P1130	27	532	556	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				330	336		10.7326/0003-4819-139-5_Part_1-200309020-00008	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965956				2022-12-24	WOS:000185037500003
J	Barnes, JW; Tischkau, SA; Barnes, JA; Mitchell, JW; Burgoon, PW; Hickok, JR; Gillette, MU				Barnes, JW; Tischkau, SA; Barnes, JA; Mitchell, JW; Burgoon, PW; Hickok, JR; Gillette, MU			Requirement of mammalian Timeless for circadian rhythmicity	SCIENCE			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; DROSOPHILA TIMELESS; CLOCK; MPER1; EXPRESSION; ANTAGONISM; ORTHOLOG; GENETICS; LOOP; RNA	Despite a central circadian role in Drosophila for the transcriptional regulator Timeless (dTim), the relevance of mammalian Timeless (mTim) remains equivocal. Conditional knockdown of mTim protein expression in the rat suprachiasmatic nucleus (SCN) disrupted SCN neuronal activity rhythms, and altered levels of known core clock elements. Full-length mTim protein (mTIM-fl) exhibited a 24-hour oscillation, whereas a truncated isoform (mTIM-s) was constitutively expressed. mTIM-fl associated with the mammalian clock Period proteins (mPERs) in oscillating SCN cells. These data suggest that mTim is required for rhythmicity and is a functional homolog of dTim on the negative-feedback arm of the mammalian molecular clockwork.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Gillette, MU (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022155, F32NS011134, F32NS010170, F32NS011158, R01NS035859] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL067007, HL67007] Funding Source: Medline; NIGMS NIH HHS [GM07143] Funding Source: Medline; NINDS NIH HHS [NS22155, NS11134, R01 NS035859, R01 NS022155, NS11158, NS10170, NS35859] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akiyama M, 1999, J NEUROSCI, V19, P1115; Albrecht U, 2002, J APPL PHYSIOL, V92, P1348, DOI 10.1152/japplphysiol.00759.2001; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Earnest DJ, 1999, SCIENCE, V283, P693, DOI 10.1126/science.283.5402.693; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Gerhold LM, 2002, J COMP NEUROL, V450, P135, DOI 10.1002/cne.10307; Gotter AL, 2000, NAT NEUROSCI, V3, P755, DOI 10.1038/77653; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Harney JP, 1996, ENDOCRINOLOGY, V137, P3696, DOI 10.1210/en.137.9.3696; Hastings M H, 1999, J Neurosci, V19, pRC11; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Koike N, 1998, FEBS LETT, V441, P427, DOI 10.1016/S0014-5793(98)01597-X; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Li ZX, 2000, P NATL ACAD SCI USA, V97, P10038, DOI 10.1073/pnas.97.18.10038; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; Sakamoto S, 2000, BIOCHEM BIOPH RES CO, V279, P131, DOI 10.1006/bbrc.2000.3927; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Tischkau S A, 1999, J Neurosci, V19, pRC15; Tischkau SA, 2003, J BIOL CHEM, V278, P718, DOI 10.1074/jbc.M209241200; Wakamatsu H, 2001, NEUROREPORT, V12, P127, DOI 10.1097/00001756-200101220-00033; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	24	153	162	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					439	442		10.1126/science.1086593	http://dx.doi.org/10.1126/science.1086593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564007				2022-12-24	WOS:000185963200041
J	Matsuo, T; Yamaguchi, S; Mitsui, S; Emi, A; Shimoda, F; Okamura, H				Matsuo, T; Yamaguchi, S; Mitsui, S; Emi, A; Shimoda, F; Okamura, H			Control mechanism of the circadian clock for timing of cell division in vivo	SCIENCE			English	Article							DNA-SYNTHESIS; PARTIAL-HEPATECTOMY; WEE1 KINASE; LIVER; RHYTHM; PROLIFERATION; MOUSE; RAT; EXPRESSION; CDC2	Cell division in many mammalian tissues is associated with specific times of day, but just how the circadian clock controls this timing has not been clear. Here, we show in the regenerating liver ( of mice) that the circadian clock controls the expression of cell cycle-related genes that in turn modulate the expression of active Cyclin B1-Cdc2 kinase, a key regulator of mitosis. Among these genes, expression of wee1 was directly regulated by the molecular components of the circadian clockwork. In contrast, the circadian clockwork oscillated independently of the cell cycle in single cells. Thus, the intracellular circadian clockwork can control the cell-division cycle directly and unidirectionally in proliferating cells.	Kobe Univ, Grad Sch Med, Dept Brain Sci, Div Mol Brain Sci,Chuo Ku, Kobe, Hyogo 6500017, Japan; Yamaguchi Univ, Dept Phys Informat & Biol, Yamaguchi 7538512, Japan	Kobe University; Yamaguchi University	Okamura, H (corresponding author), Kobe Univ, Grad Sch Med, Dept Brain Sci, Div Mol Brain Sci,Chuo Ku, Kobe, Hyogo 6500017, Japan.	okamurah@kobe-u.ac.jp	MATSUO, Takuya/I-7493-2014	Okamura, Hitoshi/0000-0002-3013-4881				Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; BADE EG, 1966, EXP CELL RES, V44, P676, DOI 10.1016/0014-4827(66)90484-8; Barbason H, 1995, IN VIVO, V9, P539; BARBIROLI B, 1971, SCIENCE, V172, P738, DOI 10.1126/science.172.3984.738; BARNUM CYRUS P., 1957, TEXAS REPTS BIOL AND MED, V15, P134; Bjarnason GA, 2001, AM J PATHOL, V158, P1793, DOI 10.1016/S0002-9440(10)64135-1; Bjarnason GA, 2000, PROG CELL CYC RES, V4, P193; BROWN WR, 1991, J INVEST DERMATOL, V97, P273, DOI 10.1111/1523-1747.ep12480379; BUCHI KN, 1991, GASTROENTEROLOGY, V101, P410, DOI 10.1016/0016-5085(91)90019-H; Garcia MN, 2001, CELL BIOL INT, V25, P179, DOI 10.1006/cbir.2000.0585; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Higgins GM, 1931, ARCH PATHOL, V12, P186; JAFFE JJ, 1954, ANAT REC, V120, P935, DOI 10.1002/ar.1091200408; Kawasaki H, 2001, EMBO J, V20, P4618, DOI 10.1093/emboj/20.16.4618; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Laconi S, 1999, J HEPATOL, V31, P1069, DOI 10.1016/S0168-8278(99)80320-1; Levi F, 2002, CHRONOBIOL INT, V19, P1, DOI 10.1081/CBI-120002676; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MATSUO T, UNPUB; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Rothblum-Oviatt CJ, 2001, CELL GROWTH DIFFER, V12, P581; SCHEVING LE, 1983, AM J ANAT, V168, P433, DOI 10.1002/aja.1001680405; SCHEVING LE, 1974, ACTA ANAT, V88, P411; Smaaland R, 1996, Prog Cell Cycle Res, V2, P241; SOUTO M, 1985, Chronobiology International, V2, P169, DOI 10.3109/07420528509055556; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323	32	853	895	4	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					255	259		10.1126/science.1086271	http://dx.doi.org/10.1126/science.1086271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	12934012				2022-12-24	WOS:000185825900033
J	Emanuel, EJ				Emanuel, EJ			The lessons of SARS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PHYSICIANS; AIDS	Given the low mortality and morbidity of the severe acute respiratory syndrome (SARS) compared with other public health scourges, is the attention devoted to it misdirected? The SARS experience has provided at least 4 enduring lessons. First, by providing a test of the capacity of each part of the public health system, from national to local and hospital responses, it has better prepared the world for the anticipated and much-feared next real pandemic. Second, SARS has reemphasized that from housing, sexual practices, and slaughtering techniques to health care capacity, the situation in other, especially developing, countries affects us. Global cooperation is necessary not only for justice but to ensure our own health. Third, despite trends toward commercialization, easier lives, and self-centered individualism, the response of health care professionals to SARS reaffirmed dedication to caring for the sick even at great personal risks as the core ethical principle of medicine. Finally, SARS also emphasized the importance of the duty of health care administrators and senior physicians to rapidly institute procedures to maximize the safety of frontline physicians and nurses. These lessons will be valuable far beyond the SARS episode.	NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Emanuel, EJ (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bldg 10,1C118, Bethesda, MD 20892 USA.							Billings M., INFLUENZA PANDEMIC 1; *CAN ASS EM PHYS, GUID MAN SEV AC RESP; *CDCP, 2002, REP TUB US 2001 ATL; *COUNC ETH JUD AFF, 2002, AM MED ASS COD MED E; CROSBY AW, 1990, AM FORGOTTEN PANDEMI; DEFOE D, 1987, J PLAGUE YEAR; EMANUEL EJ, 1988, NEW ENGL J MED, V318, P1686, DOI 10.1056/NEJM198806233182511; FREEDMAN B, 1988, HASTINGS CENT REP, V18, pS20, DOI 10.2307/3562422; *HLTH CAN, 2003, CAN SARS NUMB AUG 12; KOLOTA F, 1999, FLU STORY GREAT INFL; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Park Katharine., 1985, DOCTORS MED EARLY RE; Reilley B, 2003, NEW ENGL J MED, V348, P1951, DOI 10.1056/NEJMp030080; *UNAIDS, 2002, AIDS EP UPD 2002; VIETS J, 1989, SURG URGES AIDS TEST, P1; *WHO, WHAT MAL; *WHO, 2002, TUB FACT SHEET 104; World Health Organization, 2003, SEV AC RESP SYNDR SA; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924	19	51	53	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					589	591		10.7326/0003-4819-139-7-200310070-00011	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530230				2022-12-24	WOS:000185748800007
J	Wiese, MF				Wiese, MF			British hospitals and different versions of the Glasgow coma scale: telephone survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Kings Coll Hosp London, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Wiese, MF (corresponding author), Kings Coll Hosp London, Denmark Hill, London SE5 9RS, England.	wiese@doctors.org.uk						*AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP S; Diringer MN, 1997, ARCH NEUROL-CHICAGO, V54, P606, DOI 10.1001/archneur.1997.00550170078017; Lenfant F, 1997, ANN FR ANESTH, V16, P239, DOI 10.1016/S0750-7658(97)86408-8; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81	5	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	2003	327	7418					782	783		10.1136/bmj.327.7418.782	http://dx.doi.org/10.1136/bmj.327.7418.782			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525875	Bronze, Green Published			2022-12-24	WOS:000185805100019
J	Clubb, R; Mason, G				Clubb, R; Mason, G			Captivity effects on wide-ranging carnivores	NATURE			English	Editorial Material							DEPRIVATION; PHYLOGENY; ECOLOGY; SIZE		Univ Oxford, Dept Zool, Anim Behav Res Grp, Oxford OX1 3PS, England	University of Oxford	Clubb, R (corresponding author), Univ Oxford, Dept Zool, Anim Behav Res Grp, S Parks Rd, Oxford OX1 3PS, England.							Bahr NI, 1998, PHYSIOL BEHAV, V64, P429, DOI 10.1016/S0031-9384(98)00057-2; Bininda-Emonds ORP, 1999, BIOL REV, V74, P143, DOI 10.1017/S0006323199005307; CLUBB RE, 2001, THESIS U OXFORD; DAWKINS MS, 1988, APPL ANIM BEHAV SCI, V20, P209, DOI 10.1016/0168-1591(88)90047-0; GITTLEMAN JL, 1986, J MAMMAL, V67, P23, DOI 10.2307/1380998; GITTLEMAN JL, 1982, BEHAV ECOL SOCIOBIOL, V10, P57, DOI 10.1007/BF00296396; Lewis M.H., 1996, STEREOTYPED MOVEMENT, P37; Mason GJ, 2001, NATURE, V410, P35, DOI 10.1038/35065157; Meier J.E., 1986, P842; Mellen J.D., 1998, 2 NATURE ENV ENRICHM, P329; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; Robbins TW, 1996, J PSYCHOPHARMACOL, V10, P39, DOI 10.1177/026988119601000107; Woodroffe R, 1998, SCIENCE, V280, P2126, DOI 10.1126/science.280.5372.2126	13	239	247	9	330	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					473	474		10.1038/425473a	http://dx.doi.org/10.1038/425473a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523435	Green Published			2022-12-24	WOS:000185648100033
J	Kefalov, V; Fu, YB; Marsh-Armstrong, N; Yau, KW				Kefalov, V; Fu, YB; Marsh-Armstrong, N; Yau, KW			Role of visual pigment properties in rod and cone phototransduction	NATURE			English	Article							RETINAL CONES; DARK NOISE; ABSORPTION-SPECTRA; XENOPUS-LAEVIS; PHOTORECEPTORS; SENSITIVITY; RHODOPSIN; GREEN; TRANSDUCIN; COMPONENTS	Retinal rods and cones share a phototransduction pathway involving cyclic GMP(1). Cones are typically 100 times less photosensitive than rods and their response kinetics are several times faster(2),but the underlying mechanisms remain largely unknown. Almost all proteins involved in phototransduction have distinct rod and cone variants. Differences in properties between rod and cone pigments have been described, such as a 10-fold shorter lifetime of the meta-II state (active conformation) of cone pigment(3-6) and its higher rate of spontaneous isomerization(7,8), but their contributions to the functional differences between rods and cones remain speculative. We have addressed this question by expressing human or salamander red cone pigment in Xenopus rods, and human rod pigment in Xenopus cones. Here we show that rod and cone pigments when present in the same cell produce light responses with identical amplification and kinetics, thereby ruling out any difference in their signalling properties. However, red cone pigment isomerizes spontaneously 10,000 times more frequently than rod pigment. This high spontaneous activity adapts the native cones even in darkness, making them less sensitive and kinetically faster than rods. Nevertheless, additional factors are probably involved in these differences.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute	Yau, KW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.			Kefalov, Vladimir/0000-0002-1659-008X	NEI NIH HHS [R01 EY014596, R37 EY006837, R01 EY006837-16A1, R37 EY006837-14, R37 EY006837-13, R37 EY006837-15S1, R01 EY014596-01, R01 EY014596-02, R01 EY006837, R37 EY006837-15] Funding Source: Medline; NIDCD NIH HHS [R01 DC006904, R01 DC006904-03] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006837, R01EY014596, R37EY006837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006904] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARLOW HB, 1958, VISUAL PROBLEMS COLO, V2, P617; BAYLOR DA, 1987, INVEST OPHTH VIS SCI, V28, P34; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BOWMAKER JK, 1980, J PHYSIOL-LONDON, V298, P501, DOI 10.1113/jphysiol.1980.sp013097; Govardovskii VI, 2000, VISUAL NEUROSCI, V17, P509, DOI 10.1017/S0952523800174036; HAROSI FI, 1975, J GEN PHYSIOL, V66, P357, DOI 10.1085/jgp.66.3.357; HAROSI FI, 1994, VISION RES, V34, P1359, DOI 10.1016/0042-6989(94)90134-1; IMAI H, 1995, BIOCHEMISTRY-US, V34, P10525, DOI 10.1021/bi00033a026; Imai H, 1997, BIOCHEMISTRY-US, V36, P12773, DOI 10.1021/bi970809x; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Lyubarsky AL, 2000, J NEUROSCI, V20, P2209; Ma JX, 2001, NEURON, V32, P451, DOI 10.1016/S0896-6273(01)00482-2; Makino CL, 1999, BIOPHYS J, V77, P1024, DOI 10.1016/S0006-3495(99)76953-5; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; Miller James L., 1994, Current Opinion in Neurobiology, V4, P488, DOI 10.1016/0959-4388(94)90048-5; MILLER JL, 1993, VISUAL NEUROSCI, V10, P653, DOI 10.1017/S0952523800005356; Moritz OL, 2001, J BIOL CHEM, V276, P28242, DOI 10.1074/jbc.M101476200; NAKATANI K, 1989, J PHYSIOL-LONDON, V409, P525, DOI 10.1113/jphysiol.1989.sp017511; OKADA T, 1994, BIOCHEMISTRY-US, V33, P4940, DOI 10.1021/bi00182a024; Palacios AG, 1998, VISUAL NEUROSCI, V15, P319, DOI 10.1017/S0952523898152136; Rieke F, 1996, BIOPHYS J, V71, P2553, DOI 10.1016/S0006-3495(96)79448-1; Rieke F, 2000, NEURON, V26, P181, DOI 10.1016/S0896-6273(00)81148-4; Sampath AP, 2002, BIOPHYS J, V83, P184, DOI 10.1016/S0006-3495(02)75160-6; Starace DM, 1997, J BIOL CHEM, V272, P1095, DOI 10.1074/jbc.272.2.1095; Tachibanaki S, 2001, P NATL ACAD SCI USA, V98, P14044, DOI 10.1073/pnas.241396898; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WHITMORE AV, 1989, J COMP PHYSIOL A, V166, P103; WITKOVSKY P, 1981, VISION RES, V21, P867, DOI 10.1016/0042-6989(81)90187-5; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9	30	97	100	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					526	531		10.1038/nature01992	http://dx.doi.org/10.1038/nature01992			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523449	Green Accepted			2022-12-24	WOS:000185648100048
J	Buchan, JC; Alberts, SC; Silk, JB; Altmann, J				Buchan, JC; Alberts, SC; Silk, JB; Altmann, J			True paternal care in a multi-male primate society	NATURE			English	Article							BARBARY MACAQUES; MACACA-SYLVANUS; FEMALE BABOONS; BODY ODOR; BEHAVIOR; CHIMPANZEES; PREFERENCES; SAMPLES; HUMANS; CHOICE	Although male parental care is rare among mammals 1, adult males of many cercopithecine primate species provide care for infants and juveniles. This care is often in the form of grooming, carrying, support in agonistic interactions, and protection against infanticide(2,3). For these behaviours to be interpreted as true parental care, males must selectively direct care towards their own offspring and this care must result in fitness benefits(4). With the exception of males defending probable offspring from infanticide(5), male primates living in multi-male, multi-female social groups have not been shown to selectively direct care towards their own offspring(6,7). We determined paternity for 75 juveniles in a population of wild savannah baboons (Papio cynocephalus) and collected data on interventions in agonistic disputes by adult males on behalf of juveniles as a form of male care. Here we show that adult males differentiate their offspring from unrelated juveniles and selectively support their offspring in agonistic disputes. As support in agonistic disputes is likely to contribute to rank acquisition and protect juveniles from injury and stress(2,3,5), this can be considered true parental care.	Duke Univ, Dept Biol, Durham, NC 27708 USA; Natl Museums Kenya, Inst Primate Res, Nairobi, Kenya; Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Brookfield Zoo, Dept Conservat Biol, Brookfield, IL 60513 USA	Duke University; University of California System; University of California Los Angeles; Princeton University	Alberts, SC (corresponding author), Duke Univ, Dept Biol, Box 90338, Durham, NC 27708 USA.			Buchan, John/0000-0003-1005-7011				Alberts SC, 1999, P ROY SOC B-BIOL SCI, V266, P1501, DOI 10.1098/rspb.1999.0807; ALBERTS SC, 1995, BEHAV ECOL SOCIOBIOL, V36, P397, DOI 10.1007/BF00177335; Altmann J, 1996, P NATL ACAD SCI USA, V93, P5797, DOI 10.1073/pnas.93.12.5797; Borries C, 1999, BEHAV ECOL SOCIOBIOL, V46, P350, DOI 10.1007/s002650050629; HALPIN ZT, 1991, KIN RECOGNITION, P220; Hauber ME, 2001, TRENDS NEUROSCI, V24, P609, DOI 10.1016/S0166-2236(00)01916-0; Hausfater G., 1975, DOMINANCE REPROD BAB; Jacob S, 2002, NAT GENET, V30, P175, DOI 10.1038/ng830; Marshall TC, 1998, MOL ECOL, V7, P639, DOI 10.1046/j.1365-294x.1998.00374.x; Menard N, 2001, CR ACAD SCI III-VIE, V324, P601, DOI 10.1016/S0764-4469(01)01339-7; Morin PA, 2001, MOL ECOL, V10, P1835, DOI 10.1046/j.0962-1083.2001.01308.x; Ober C, 1997, AM J HUM GENET, V61, P497, DOI 10.1086/515511; Palombit RA, 1997, ANIM BEHAV, V54, P599, DOI 10.1006/anbe.1996.0457; Parr LA, 1999, NATURE, V399, P647, DOI 10.1038/21345; Paul A, 1996, ANIM BEHAV, V51, P155, DOI 10.1006/anbe.1996.0013; SHAIKH A A, 1982, Primates, V23, P444, DOI 10.1007/BF02381326; Sherman Paul W., 1997, P69; Silk JB, 2002, INT J PRIMATOL, V23, P849, DOI 10.1023/A:1015581016205; SILK JB, IN PRESS ANIM BEHAV; Singh D, 2001, P ROY SOC B-BIOL SCI, V268, P797, DOI 10.1098/rspb.2001.1589; Smith K, 2003, P ROY SOC B-BIOL SCI, V270, P503, DOI 10.1098/rspb.2002.2277; Smith KL, 2000, AM J PRIMATOL, V51, P219; Smuts B., 1992, FATHER CHILD RELATIO, P1, DOI DOI 10.1002/AJHB.1310060321; Soltis J, 2000, BEHAV ECOL SOCIOBIOL, V48, P195, DOI 10.1007/s002650000224; Taberlet P, 1996, NUCLEIC ACIDS RES, V24, P3189, DOI 10.1093/nar/24.16.3189; TRIVERS RL, 1972, SEXUAL SELECTION DES; van Schaik Carel, 1996, Evolutionary Anthropology, V5, P152, DOI 10.1002/(SICI)1520-6505(1996)5:5<152::AID-EVAN3>3.3.CO;2-9; Wedekind C, 1997, P ROY SOC B-BIOL SCI, V264, P1471, DOI 10.1098/rspb.1997.0204; WEDEKIND C, 1995, P ROY SOC B-BIOL SCI, V260, P245, DOI 10.1098/rspb.1995.0087; Widdig A, 2001, P NATL ACAD SCI USA, V98, P13769, DOI 10.1073/pnas.241210198; WOODROFFE R, 1994, TRENDS ECOL EVOL, V9, P294, DOI 10.1016/0169-5347(94)90033-7	31	246	255	3	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2003	425	6954					179	181		10.1038/nature01866	http://dx.doi.org/10.1038/nature01866			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968180				2022-12-24	WOS:000185236000042
J	Hylek, EM; Go, AS; Chang, YC; Jensvold, NG; Henault, LE; Selby, JV; Singer, DE				Hylek, EM; Go, AS; Chang, YC; Jensvold, NG; Henault, LE; Selby, JV; Singer, DE			Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTITHROMBOTIC THERAPY; BLEEDING COMPLICATIONS; COST-EFFECTIVENESS; RISK-FACTORS; WARFARIN; ASPIRIN; THROMBOEMBOLISM; COMMUNITY; PROPHYLAXIS; OUTPATIENTS	Background: The incidence of stroke in patients with atrial fibrillation is greatly reduced by oral anticoagulation, with the full effect seen at international normalized ratio (INR) values of 2.0 or greater. The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation-related stroke is not known but is central to the choice of the target INR. Methods: We studied incident ischemic strokes in a cohort of 13,559 patients with nonvalvular atrial fibrillation. Strokes were identified through hospitalization data bases and validated on the basis of medical records, which also provided information on the use of warfarin or aspirin, the INR at admission, and coexisting illnesses. The severity of stroke was graded according to a modified Rankin scale. Thirty-day mortality was ascertained from hospitalization and mortality files. Results: Of 596 ischemic strokes, 32 percent occurred during warfarin therapy, 27 percent during aspirin therapy, and 42 percent during neither type of therapy. Among patients who were taking warfarin, an INR of less than 2.0 at admission, as compared with an INR of 2.0 or greater, independently increased the odds of a severe stroke in a proportional-odds logistic-regression model (odds ratio, 1.9; 95 percent confidence interval, 1.1 to 3.4) across three severity categories and the risk of death within 30 days (hazard ratio, 3.4; 95 percent confidence interval, 1.1 to 10.1). An INR of 1.5 to 1.9 at admission was associated with a mortality rate similar to that for an INR of less than 1.5 (18 percent and 15 percent, respectively). The 30-day mortality rate among patients who were taking aspirin at the time of the stroke was similar to that among patients who were taking warfarin and who had an INR of less than 2.0. Conclusions: Among patients with nonvalvular atrial fibrillation, anticoagulation that results in an INR of 2.0 or greater reduces not only the frequency of ischemic stroke but also its severity and the risk of death from stroke. Our findings provide further evidence against the use of lower INR target levels in patients with atrial fibrillation.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gen Med Div,Clin Epidemiol Unit, Boston, MA 02114 USA; Kaiser Permanente No Calif, Div Res, Oakland, CA USA; Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hylek, EM (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gen Med Div,Clin Epidemiol Unit, 50 Staniford St,9th Fl, Boston, MA 02114 USA.		Go, Alan S./AAE-7745-2019	Hylek, Elaine/0000-0001-8263-8304	NIA NIH HHS [5 R01 AG15478] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; *AM MED ASS, 1999, INT CLASS DIS, V2; *AM MED ASS, 1999, INT CLASS DIS, V1; [Anonymous], 2001, CIRCULATION, V104, P2118; [Anonymous], 1994, ARCH INTERN MED, V154, P2254; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; Blackshear JL, 1996, LANCET, V348, P633; BOGOUSSLAVSKY J, 1990, NEUROLOGY, V40, P1046, DOI 10.1212/WNL.40.7.1046; BRITTON M, 1985, STROKE, V16, P182, DOI 10.1161/01.STR.16.2.182; CANDELISE L, 1991, STROKE, V22, P169, DOI 10.1161/01.STR.22.2.169; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; Eckman MH, 1998, ARCH INTERN MED, V158, P1669, DOI 10.1001/archinte.158.15.1669; Evans A, 2001, ARCH INTERN MED, V161, P1443, DOI 10.1001/archinte.161.11.1443; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Go AS, 2002, CIRCULATION, V106, P515; Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004; GUSTAFSSON C, 1991, J INTERN MED, V230, P11, DOI 10.1111/j.1365-2796.1991.tb00400.x; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hart RG, 2000, CEREBROVASC DIS, V10, P39, DOI 10.1159/000016023; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Kaarisalo MM, 1997, STROKE, V28, P311, DOI 10.1161/01.STR.28.2.311; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI; Lamassa M, 2001, STROKE, V32, P392, DOI 10.1161/01.STR.32.2.392; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lin HJ, 1996, STROKE, V27, P1760, DOI 10.1161/01.STR.27.10.1760; Longstreth WT, 2001, NEUROLOGY, V56, P368, DOI 10.1212/WNL.56.3.368; Man-Son-Hing M, 1999, ARCH INTERN MED, V159, P677, DOI 10.1001/archinte.159.7.677; MANNING WJ, 1995, ARCH INTERN MED, V155, P2193, DOI 10.1001/archinte.155.20.2193; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; Miller VT, 1996, NEUROLOGY, V46, P238, DOI 10.1212/WNL.46.1.238; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Penado S, 2002, AM J MED, V112, P572, DOI 10.1016/S0002-9343(02)01063-X; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; SANDERCOCK P, 1992, BRIT MED J, V305, P1460, DOI 10.1136/bmj.305.6867.1460; SHERMAN DG, 1984, ARCH NEUROL-CHICAGO, V41, P708, DOI 10.1001/archneur.1984.04050180030011; Thomson R, 2000, LANCET, V355, P1466; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	45	947	993	1	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1019	1026		10.1056/NEJMoa022913	http://dx.doi.org/10.1056/NEJMoa022913			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968085				2022-12-24	WOS:000185223100003
J	Melendez, A; Talloczy, Z; Seaman, M; Eskelinen, EL; Hall, DH; Levine, B				Melendez, A; Talloczy, Z; Seaman, M; Eskelinen, EL; Hall, DH; Levine, B			Autophagy genes are essential for dauer development and life-span extension in C-elegans	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; MACROAUTOPHAGY; SENESCENCE; LONGEVITY; NEMATODE; MUTANTS; VACUOLE; DAF-2	Both dauer formation (a stage of developmental arrest) and adult life-span in Caenorhabditis elegans are negatively regulated by insulin-like signaling, but little is known about cellular pathways that mediate these processes. Autophagy, through the sequestration and delivery of cargo to the lysosomes, is the major route for degrading long-lived proteins and cytoplasmic organelles in eukaryotic cells. Using nematodes with a loss-of-function mutation in the insulin-like signaling pathway, we show that bec-1, the C. elegans ortholog of the yeast and mammalian autophagy gene APG6/VPS30/beclin1, is essential for normal dauer morphogenesis and life-span extension. Dauer formation is associated with increased autophagy and also requires C. elegans orthologs of the yeast autophagy genes APG1, APG7, APG8, and AUT10. Thus, autophagy is a cellular pathway essential for dauer development and life-span extension in C. elegans.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Albert Einstein Coll Med, Ctr C Elegans Anat, Bronx, NY 10461 USA	Columbia University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Kiel; Yeshiva University; Albert Einstein College of Medicine	Levine, B (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	levine@cancercenter.columbia.edu	Eskelinen, Eeva-Liisa/AAF-3496-2019	Eskelinen, Eeva-Liisa/0000-0003-0006-7785	NATIONAL CANCER INSTITUTE [R01CA084254] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR012596] Funding Source: NIH RePORTER; NCI NIH HHS [CA84254] Funding Source: Medline; NCRR NIH HHS [R24 RR012596, RR 12596] Funding Source: Medline; NIH HHS [R24 OD010943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALBERT PS, 1988, DEV BIOL, V126, P270, DOI 10.1016/0012-1606(88)90138-8; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Bergamini E, 1995, AGING-CLIN EXP RES, V7, P473, DOI 10.1007/BF03324374; Doelling JH, 2002, J BIOL CHEM, V277, P33105, DOI 10.1074/jbc.M204630200; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gems D, 1998, GENETICS, V150, P129; GOLDEN JW, 1985, MOL GEN GENET, V198, P534, DOI 10.1007/BF00332953; GORDON PB, 1987, BIOCHIM BIOPHYS ACTA, V929, P128, DOI 10.1016/0167-4889(87)90167-4; Hanaoka H, 2002, PLANT PHYSIOL, V129, P1181, DOI 10.1104/pp.011024; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; KENYON C, 1997, C ELEGANS, V2, P791; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; LIU ZC, 1989, GENE DEV, V3, P2039, DOI 10.1101/gad.3.12b.2039; MELENDEZ A, UNPUB; OGURA K, 1994, GENE DEV, V8, P2389, DOI 10.1101/gad.8.20.2389; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; QU X, UNPUB; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL, 1997, C ELEGANS, P739; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E	31	979	1037	6	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1387	1391		10.1126/science.1087782	http://dx.doi.org/10.1126/science.1087782			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958363				2022-12-24	WOS:000185116400044
J	Kurtz, J; Franz, K				Kurtz, J; Franz, K			Evidence for memory in invertebrate immunity	NATURE			English	Editorial Material							HOST		Max Planck Inst Limnol, Dept Evolut Ecol, D-24306 Plon, Germany	Max Planck Society	Kurtz, J (corresponding author), Max Planck Inst Limnol, Dept Evolut Ecol, August Thienemann Str 2, D-24306 Plon, Germany.		Kurtz, Joachim/A-9678-2008	Kurtz, Joachim/0000-0002-7258-459X				Carius HJ, 2001, EVOLUTION, V55, P1136, DOI 10.1111/j.0014-3820.2001.tb00633.x; FAULHABER LM, 1992, IMMUNOLOGY, V75, P378; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; KLEIN J, 1989, SCAND J IMMUNOL, V29, P499, DOI 10.1111/j.1365-3083.1989.tb01152.x; Kurtz J, 2002, EXP PARASITOL, V100, P36, DOI 10.1006/expr.2001.4681; Little TJ, 2003, CURR BIOL, V13, P489, DOI 10.1016/S0960-9822(03)00163-5; Marques MRF, 2000, AQUACULTURE, V191, P23, DOI 10.1016/S0044-8486(00)00417-8; Rolff J, 2003, SCIENCE, V301, P472, DOI 10.1126/science.1080623; Schmid-Hempel P, 2003, TRENDS ECOL EVOL, V18, P27, DOI 10.1016/S0169-5347(02)00013-7; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0	11	295	308	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					37	38		10.1038/425037a	http://dx.doi.org/10.1038/425037a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955131				2022-12-24	WOS:000185089200028
J	Agrawal, M; Emanuel, EJ				Agrawal, M; Emanuel, EJ			Ethics of phase 1 oncology studies - Reexamining the arguments and data	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							I CLINICAL-TRIALS; QUALITY-OF-LIFE; RENAL-CELL CARCINOMA; ABL TYROSINE KINASE; INFORMED CONSENT; CANCER-PATIENTS; THERAPEUTIC RESPONSE; ANTICANCER AGENTS; FUNCTIONAL STATUS; DESIGN	Phase 1 oncology trials are critical to improving the treatment of cancer. Critics have raised 2 fundamental ethical challenges about phase 1 cancer research: the paucity of benefits with substantial risks and poor-quality informed consent. Despite 3 decades of controversy about phase 1 oncology research, there is little critical analysis of the arguments or of the data relevant to these questions. Existing but old data reveal that about 5% of patients in phase 1 trials experience shrinkage of their tumor, with a 0.5% mortality rate. In some notable cases, patients in phase 1 trials have been cured or sustained long-term remissions. Limited data suggest that patients in phase 1 trials may have better quality of life than comparable patients receiving supportive care. More important, the risks and benefits of phase 1 trials are not clearly worse than risk-benefit ratios used by the US Food and Drug Administration to approve chemotherapeutic agents for clinical use. The objections based on informed consent are deficiencies of disclosure, understanding, and voluntariness. The available data do not support the claim that disclosure is deficient. Although studies evaluating patient understanding have substantial methodological problems, they demonstrate that more than 70% of patients understand that they may not directly benefit even when they hope they will personally benefit. Finally, a closer look at issues of voluntariness reveals that patients with advanced cancer who participate in phase 1 research may have a different set of values than do critics and are not coerced. Overall, it appears that phase 1 oncology trials satisfy the requirement for a favorable risk-benefit ratio and that patients who enroll provide adequate informed consent.	NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA; NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Agrawal, M (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bldg 10,Room 1C118,10 Ctr Dr, Bethesda, MD 20892 USA.							Agrawal Manish, 2002, J Palliat Med, V5, P729, DOI 10.1089/109662102320880552; *AM CANC SOC, 2003, CANC FACTS FIG; Annas G J, 1992, Health Matrix Clevel, V2, P119; [Anonymous], 1986, HIST THEORY INFORM C; Arbuck SG, 1996, ANN ONCOL, V7, P567; BERDEL WE, 1988, ANTICANCER RES, V8, P313; BERG JW, 2001, INFORMED CONSENT LEG; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Campbell S, 1999, J ADV NURS, V30, P335, DOI 10.1046/j.1365-2648.1999.01079.x; Cheng JD, 2000, J CLIN ONCOL, V18, P421, DOI 10.1200/JCO.2000.18.2.421; Cohen L, 2002, UROL ONCOL, V7, P119, DOI 10.1016/S1078-1439(01)00182-X; Cox K, 2000, PSYCHO-ONCOL, V9, P314, DOI 10.1002/1099-1611(200007/08)9:4<314::AID-PON464>3.3.CO;2-3; Creemers GJ, 1996, J CLIN ONCOL, V14, P3056, DOI 10.1200/JCO.1996.14.12.3056; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; Daugherty C K, 2000, IRB, V22, P6, DOI 10.2307/3564113; Daugherty CK, 1997, ANN INTERN MED, V126, P892, DOI 10.7326/0003-4819-126-11-199706010-00008; DECOSTER G, 1990, ANN ONCOL, V1, P175, DOI 10.1093/oxfordjournals.annonc.a057716; Dent SF, 1996, ANN ONCOL, V7, P561; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; EMANUEL EJ, 1995, J CLIN ONCOL, V13, P1049, DOI 10.1200/JCO.1995.13.5.1049; EPSTEIN AM, 1989, MED CARE, V27, P91; ESTEY E, 1986, CANCER TREAT REP, V70, P1105; Fisher B, 2001, JNCI-J NATL CANCER I, V93, P112, DOI 10.1093/jnci/93.2.112; Francis RJ, 2002, BRIT J CANCER, V87, P600, DOI 10.1038/sj.bjc.6600517; Frei E, 1997, CANCER J, V3, P127; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; HIGBY DJ, 1974, CANCER, V33, P1219, DOI 10.1002/1097-0142(197405)33:5<1219::AID-CNCR2820330505>3.0.CO;2-U; Hope-Stone L D, 1997, Eur J Cancer Care (Engl), V6, P267, DOI 10.1046/j.1365-2354.1997.00053.x; Horng S, 2002, NEW ENGL J MED, V347, P2134, DOI 10.1056/NEJMsa021182; Hutchison C, 1998, Eur J Cancer Care (Engl), V7, P15, DOI 10.1046/j.1365-2354.1998.00062.x; Itoh K, 1997, BRIT J CANCER, V76, P107, DOI 10.1038/bjc.1997.344; ITOH K, 1994, CANCER CHEMOTH PHARM, V34, P451, DOI 10.1007/BF00685653; Joffe S, 2001, LANCET, V358, P1772, DOI 10.1016/S0140-6736(01)06805-2; King NMP, 2000, J LAW MED ETHICS, V28, P332, DOI 10.1111/j.1748-720X.2000.tb00685.x; KODISH E, 1992, J CLIN ONCOL, V10, P1810, DOI 10.1200/JCO.1992.10.11.1810; Lippman ME, 2001, JNCI-J NATL CANCER I, V93, P80, DOI 10.1093/jnci/93.2.80; LIPSETT MB, 1982, JAMA-J AM MED ASSOC, V248, P941, DOI 10.1001/jama.248.8.941; MAGAZINER J, 1988, J CLIN EPIDEMIOL, V41, P1065, DOI 10.1016/0895-4356(88)90076-5; MCCUSKER J, 1984, MED CARE, V22, P789, DOI 10.1097/00005650-198409000-00002; MELINK TJ, 1992, ANTI-CANCER DRUG, V3, P571, DOI 10.1097/00001813-199212000-00003; MEROPOL NJ, 2002, P AM SOC CLIN ONC MA; Meslin Eric M, 1990, IRB, V12, P7, DOI 10.2307/3563683; Miller M, 2000, HASTINGS CENT REP, V30, P34, DOI 10.2307/3527646; Miller M, 2001, Int Anesthesiol Clin, V39, P13; Moore S, 2001, J ADV NURS, V33, P738, DOI 10.1046/j.1365-2648.2001.01715.x; *NAT BIOETH ADV CO, 1998, RES INV PERS MENT DI; PENMAN DT, 1984, J CLIN ONCOL, V2, P849, DOI 10.1200/JCO.1984.2.7.849; Quantin X, 2000, AM J CLIN ONCOL-CANC, V23, P192, DOI 10.1097/00000421-200004000-00017; RATAIN MJ, 1993, J NATL CANCER I, V85, P1637, DOI 10.1093/jnci/85.20.1637; RODENHUIS S, 1984, EUR J CANCER CLIN ON, V20, P457, DOI 10.1016/0277-5379(84)90229-3; RUBENSTEIN LZ, 1984, J GERONTOL, V39, P686, DOI 10.1093/geronj/39.6.686; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Sherliker L, 2000, PATIENT EDUC COUNS, V40, P11, DOI 10.1016/S0738-3991(99)00047-6; Simon R, 1997, JNCI-J NATL CANCER I, V89, P1138, DOI 10.1093/jnci/89.15.1138; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Smith TL, 1996, J CLIN ONCOL, V14, P287, DOI 10.1200/JCO.1996.14.1.287; Stolberg Sheryl Gay, 2000, NY TIMES 0215 NY TIMES 0215, P20; TOMAMICHEL M, 1995, ANN ONCOL, V6, P363, DOI 10.1093/oxfordjournals.annonc.a059185; van Luijn HEM, 2002, ANN ONCOL, V13, P1307, DOI 10.1093/annonc/mdf209; VONHOFF DD, 1991, INVEST NEW DRUG, V9, P115, DOI 10.1007/BF00194562; Weijer C, 2000, J LAW MED ETHICS, V28, P344, DOI 10.1111/j.1748-720X.2000.tb00686.x; Wertheimer A, 1987, COERCION; Yoder L H, 1997, Oncol Nurs Forum, V24, P891; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615	66	142	143	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1075	1082		10.1001/jama.290.8.1075	http://dx.doi.org/10.1001/jama.290.8.1075			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715FA	12941681				2022-12-24	WOS:000184958900027
J	Kenniston, JA; Baker, TA; Fernandez, JM; Sauer, RT				Kenniston, JA; Baker, TA; Fernandez, JM; Sauer, RT			Linkage between ATP consumption and mechanical unfolding during the protein processing reactions of an AAA(+) degradation machine	CELL			English	Article							PROTEASES DEGRADE; ESCHERICHIA-COLI; CLPXP; SPECIFICITY; HYDROLYSIS; STABILITY; TRANSLOCATION; RECOGNITION; DYNAMICS; ATPASES	Proteolytic machines powered by ATP hydrolysis bind proteins with specific peptide tags, denature these substrates, and translocate them into a sequestered compartment for degradation. To determine how ATP is used during individual reaction steps, we assayed ClpXP degradation of ssrA-tagged titin variants with different stabilities in native and denatured forms. The rate of ATP turnover was 4-fold slower during denaturation than translocation. Importantly, this reduced turnover rate was constant during denaturation of native variants with different stabilities, but total ATP consumption increased with substrate stability, suggesting an iterative application of a uniform, mechanical unfolding force. Destabilization of substrate structure near the degradation tag accelerated degradation and dramatically reduced ATP consumption, revealing an important role for local protein stability in resisting denaturation. The ability to denature more stable proteins simply by using more ATP endows ClpX with a robust unfolding activity required for its biological roles in degradation and complex disassembly.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Columbia University	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	bobsauer@mit.edu		Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-15706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015706, R37AI015706] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Burton BM, 2001, MOL CELL, V8, P449, DOI 10.1016/S1097-2765(01)00307-0; Burton RE, 2003, PROTEIN SCI, V12, P893, DOI 10.1110/ps.0237603; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; CARRIONVASQUEZ M, 2003, IN PRESS NAT STRUCT; Chamberlain AK, 1996, NAT STRUCT BIOL, V3, P782, DOI 10.1038/nsb0996-782; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Fowler SB, 2001, STRUCTURE, V9, P355, DOI 10.1016/S0969-2126(01)00596-2; Fowler SB, 2002, J MOL BIOL, V322, P841, DOI 10.1016/S0022-2836(02)00805-7; Gonciarz-Swiatek M, 1999, J BIOL CHEM, V274, P13999, DOI 10.1074/jbc.274.20.13999; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Herman C, 2003, MOL CELL, V11, P659, DOI 10.1016/S1097-2765(03)00068-6; Hollien J, 1999, P NATL ACAD SCI USA, V96, P13674, DOI 10.1073/pnas.96.24.13674; Improta S, 1996, STRUCTURE, V4, P323, DOI 10.1016/S0969-2126(96)00036-6; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Li HB, 2000, NAT STRUCT BIOL, V7, P1117; Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3; Maier B, 2002, P NATL ACAD SCI USA, V99, P16012, DOI 10.1073/pnas.242523299; Marszalek PE, 1999, NATURE, V402, P100, DOI 10.1038/47083; Matouschek A, 2003, CURR OPIN STRUC BIOL, V13, P98, DOI 10.1016/S0959-440X(03)00010-1; Neuwald AF, 1999, GENOME RES, V9, P27; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wah DA, 2002, CHEM BIOL, V9, P1237, DOI 10.1016/S1074-5521(02)00268-5; Wang JM, 1997, CELL, V91, P447, DOI 10.1016/S0092-8674(00)80431-6	36	220	222	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2003	114	4					511	520		10.1016/S0092-8674(03)00612-3	http://dx.doi.org/10.1016/S0092-8674(03)00612-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941278	Bronze			2022-12-24	WOS:000184928800013
J	Kurisu, G; Zhang, HM; Smith, JL; Cramer, WA				Kurisu, G; Zhang, HM; Smith, JL; Cramer, WA			Structure of the cytochrome b(6)f complex of oxygenic photosynthesis: Tuning the cavity	SCIENCE			English	Article							IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; BC(1) COMPLEX; MEMBRANE-PROTEINS; PHOTOSYSTEM-II; BOVINE HEART; BC COMPLEXES; B/F COMPLEX	The cytochrome b(6)f complex provides the electronic connection between the photosystem I and photosystem II reaction centers of oxygenic photosynthesis and generates a transmembrane electrochemical proton gradient for adenosine triphosphate synthesis. A 3.0 angstrom crystal structure of the dimeric b(6)f complex from the thermophilic cyanobacterium Mastigocladus laminosus reveals a large quinone exchange cavity, stabilized by lipid, in which plastoquinone, a quinone-analog inhibitor, and a novel heme are bound. The core of the b(6)f complex is similar to the analogous respiratory cytochrome bc(1) complex, but the domain arrangement outside the core and the complement of prosthetic groups are strikingly different. The motion of the Rieske iron-sulfur protein extrinsic domain, essential for electron transfer, must also be different in the b(6)f complex.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Osaka University	Cramer, WA (corresponding author), Purdue Univ, Dept Biol Sci, 915 W State St, W Lafayette, IN 47907 USA.	wac@bilbo.bio.purdue.edu	KURISU, GENJI/ABA-5960-2020; KURISU, GENJI/AAD-7109-2022	KURISU, GENJI/0000-0002-5354-0807; KURISU, GENJI/0000-0002-5354-0807	NIGMS NIH HHS [GM-38323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038323, R01GM038323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Carrell CJ, 1999, BIOCHEMISTRY-US, V38, P9590, DOI 10.1021/bi9903190; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRAMER WA, 1991, ENERGY TRANSDUCTION, pCH6; Gao XG, 2002, BIOCHEMISTRY-US, V41, P11692, DOI 10.1021/bi026252p; Garavito RM, 2001, J BIOL CHEM, V276, P32403, DOI 10.1074/jbc.R100031200; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; HAUSKA G, 1996, OXYGENIC PHOTOSYNTHE; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JOLIOT P, 1988, BIOCHIM BIOPHYS ACTA, V933, P319, DOI 10.1016/0005-2728(88)90039-4; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kallas T, 1994, MOL BIOL CYANOBACTER, V1, P259, DOI DOI 10.1007/978-94-011-0227-8_9; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; KRAMER DM, 1993, BIOCHIM BIOPHYS ACTA, V1183, P72, DOI 10.1016/0005-2728(93)90006-2; LAVERGNE J, 1983, BIOCHIM BIOPHYS ACTA, V725, P25, DOI 10.1016/0005-2728(83)90220-7; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Pierre Y, 1997, J BIOL CHEM, V272, P21901, DOI 10.1074/jbc.272.35.21901; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; RIEDEL A, 1991, J BIOL CHEM, V266, P17838; Roberts AG, 2001, BIOCHEMISTRY-US, V40, P13407, DOI 10.1021/bi015774m; Sainz G, 2000, BIOCHEMISTRY-US, V39, P9164, DOI 10.1021/bi0004596; Schunemann V, 1999, BIOCHEMISTRY-US, V38, P8981, DOI 10.1021/bi990080n; STROEBEL D, COMMUNICATION; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TURRO NJ, 1965, MOL PHOTOCHEM, P92; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; Whitelegge JP, 2002, MOL CELL PROTEOMICS, V1, P816, DOI 10.1074/mcp.M200045-MCP200; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yan JS, 2003, J BIOL CHEM, V278, P20925, DOI 10.1074/jbc.M212616200; ZHANG H, UNPUB; Zhang HM, 1999, J BIOL CHEM, V274, P1581, DOI 10.1074/jbc.274.3.1581; Zhang HM, 2003, P NATL ACAD SCI USA, V100, P5160, DOI 10.1073/pnas.0931431100; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	42	579	622	7	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2003	302	5647					1009	1014		10.1126/science.1090165	http://dx.doi.org/10.1126/science.1090165			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14526088				2022-12-24	WOS:000186396300037
J	Yla-Herttuala, S				Yla-Herttuala, S			Percutaneous transcoronary venous access for cellular cardiomyoplasty	LANCET			English	Editorial Material							GENE-TRANSFER; TRANSPLANTATION; REGENERATION; CELLS		Univ Kuopio, Kuopio Univ Hosp, Gene Therapy Unit, AI Virtanen Inst, FIN-70211 Kuopio, Finland; Univ Kuopio, Kuopio Univ Hosp, Gene Therapy Unit, Dept Med, FIN-70211 Kuopio, Finland	Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland	Yla-Herttuala, S (corresponding author), Univ Kuopio, Kuopio Univ Hosp, Gene Therapy Unit, AI Virtanen Inst, FIN-70211 Kuopio, Finland.			Yla-Herttuala, Seppo/0000-0001-7593-2708				Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Boekstegers P, 2000, GENE THER, V7, P232, DOI 10.1038/sj.gt.3301079; Losordo DW, 2002, CIRCULATION, V105, P2012, DOI 10.1161/01.CIR.0000015982.70785.B7; Orlic D, 2002, CIRC RES, V91, P1092, DOI 10.1161/01.RES.0000046045.00846.B0; Thompson CA, 2003, J AM COLL CARDIOL, V41, P1964, DOI 10.1016/S0735-1097(03)00397-8; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694	7	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1252	1252		10.1016/S0140-6736(03)14614-4	http://dx.doi.org/10.1016/S0140-6736(03)14614-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575965				2022-12-24	WOS:000186036900004
J	Zhang, OH; Yoshimatsu, Y; Hildebrand, J; Frisch, SM; Goodman, RH				Zhang, OH; Yoshimatsu, Y; Hildebrand, J; Frisch, SM; Goodman, RH			Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating the transcriptional corepressor CtBP	CELL			English	Article							TERMINAL-BINDING-PROTEIN; DROSOPHILA EMBRYO; ACTIVATION; REPRESSOR; RECEPTOR; KINASE; CREB; PHOSPHORYLATION; ACETYLATION; ASSOCIATION	Genetic knockout of the transcriptional corepressor CtBP in mouse embryo fibroblasts upregulates several genes involved in apoptosis. We predicted, therefore, that a propensity toward apoptosis might be regulated through changes in cellular CtBP. To identify pathways involved in this regulation, we screened a mouse embryo cDNA library with an E1A-CtBP complex and identified the homeodomain interacting protein kinase 2 (HIPK2), which had previously been linked to UV-directed apoptosis through its ability to phosphorylate p53. Expression of HIPK2 or exposure to UV irradiation reduced CtBP levels via a proteosome-mediated pathway. The UV effect was prevented by coexpression of kinase-inactive HIPK2 or reduction in HIPK2 levels via siRNA. Mutation of the residue phosphorylated by HIPK2 prevented UV- and HIPK2-directed CtBP clearance. Finally, reduction in CtBP levels, either by genetic knockout or siRNA, promoted apoptosis in p53-deficient cells. These findings provide a pathway for UV-induced apoptosis in cells lacking p53.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Burnham Inst, La Jolla, CA 92037 USA	Oregon Health & Science University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Sanford Burnham Prebys Medical Discovery Institute	Zhang, OH (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	zhangq@ohsu.edu	Yoshimatsu, Yasuhiro/AAY-2259-2020	Yoshimatsu, Yasuhiro/0000-0002-3571-1596	NATIONAL CANCER INSTITUTE [K01CA096561, R01CA115468] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA096561, R01 CA115468-05, R01 CA115468] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; BODE AM, 2003, SCI STKE; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Iordanov MS, 2002, MOL CELL BIOL, V22, P5380, DOI 10.1128/MCB.22.15.5380-5394.2002; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; La Rosee-Borggreve A, 1999, MECH DEVELOP, V89, P133, DOI 10.1016/S0925-4773(99)00219-1; Lai ZC, 1999, GENETICS, V152, P299; Landon, 1977, Methods Enzymol, V47, P145; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Melhuish TA, 2000, J BIOL CHEM, V275, P39762, DOI 10.1074/jbc.C000416200; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shih HM, 1996, P NATL ACAD SCI USA, V93, P13896, DOI 10.1073/pnas.93.24.13896; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535; Zhang QH, 2000, MOL CELL BIOL, V20, P4970, DOI 10.1128/MCB.20.14.4970-4978.2000; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598	31	186	194	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					177	186		10.1016/S0092-8674(03)00802-X	http://dx.doi.org/10.1016/S0092-8674(03)00802-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567915	Bronze			2022-12-24	WOS:000186039200009
J	Marsicano, G; Goodenough, S; Monory, K; Hermann, H; Eder, M; Cannich, A; Azad, SC; Cascio, MG; Gutierrez, SO; van der Stelt, M; Lopez-Rodriguez, ML; Casanova, E; Schutz, G; Zieglgansberger, W; Di Marzo, V; Behl, C; Lutz, B				Marsicano, G; Goodenough, S; Monory, K; Hermann, H; Eder, M; Cannich, A; Azad, SC; Cascio, MG; Gutierrez, SO; van der Stelt, M; Lopez-Rodriguez, ML; Casanova, E; Schutz, G; Zieglgansberger, W; Di Marzo, V; Behl, C; Lutz, B			CB1 cannabinoid receptors and on-demand defense against excitotoxicity	SCIENCE			English	Article							N-ACYLETHANOLAMINE PHOSPHOLIPIDS; ACUTE NEURONAL INJURY; ANANDAMIDE; BRAIN; RAT; ENDOCANNABINOIDS; GLUTAMATE; MICE; NEUROPROTECTION; NEUROTOXICITY	Abnormally high spiking activity can damage neurons. Signaling systems to protect neurons from the consequences of abnormal discharge activity have been postulated. We generated conditional mutant mice that lack expression of the cannabinoid receptor type 1 in principal forebrain neurons but not in adjacent inhibitory interneurons. In mutant mice, the excitotoxin kainic acid (KA) induced excessive seizures in vivo. The threshold to KA-induced neuronal excitation in vitro was severely reduced in hippocampal pyramidal neurons of mutants. KA administration rapidly raised hippocampal levels of anandamide and induced protective mechanisms in wild-type principal hippocampal neurons. These protective mechanisms could not be triggered in mutant mice. The endogenous cannabinoid system thus provides on-demand protection against acute excitotoxicity in central nervous system neurons.	Max Planck Inst Psychiat, Clin Neuropharmacol Grp, D-80804 Munich, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; Univ Munich, Klinikum Grosshadern, Clin Anaesthesiol, D-81377 Munich, Germany; CNR, Inst Biomol Chem, Endocannabinoid Res Grp, I-80078 Naples, Italy; Univ Complutense, Dept Organ Chem, E-28040 Madrid, Spain; German Canc Res Ctr, Div Mol Biol Cell 1, D-69120 Heidelberg, Germany	Max Planck Society; Johannes Gutenberg University of Mainz; University of Munich; Consiglio Nazionale delle Ricerche (CNR); Complutense University of Madrid; Helmholtz Association; German Cancer Research Center (DKFZ)	Lutz, B (corresponding author), Max Planck Inst Psychiat, Clin Neuropharmacol Grp, Kraepelinstr 2-10, D-80804 Munich, Germany.	lutz@mpipsykl.mpg.de	Casanova, Emilio/Y-6553-2019; Ortega-Gutierrez, Silvia/ABC-7653-2021; Lutz, Beat/AFK-6229-2022; Ortega-Gutierrez, Silvia/I-1935-2017; Di Marzo, Vincenzo/AAD-7742-2019; Lutz, Beat/AAG-4538-2022; Marsicano, Giovanni/I-9603-2016; Lopez-Rodriguez, Maria L/S-6342-2016	Casanova, Emilio/0000-0001-7992-5361; Ortega-Gutierrez, Silvia/0000-0002-0257-6754; Di Marzo, Vincenzo/0000-0002-1490-3070; Lopez-Rodriguez, Maria L/0000-0001-8607-1085; Eder, Matthias/0000-0002-2579-2628; Marsicano, Giovanni/0000-0003-3804-1951; Behl, Christian/0000-0001-8453-2378				Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Cadas H, 1996, J NEUROSCI, V16, P3934; Casanova E, 2001, GENESIS, V31, P37, DOI 10.1002/gene.1078; Chan GCK, 1998, J NEUROSCI, V18, P5322, DOI 10.1523/JNEUROSCI.18-14-05322.1998; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Clement AB, 2003, J NEUROSCI, V23, P3916; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Croxford JL, 2003, CNS DRUGS, V17, P179, DOI 10.2165/00023210-200317030-00004; de Lago E, 2002, EUR J PHARMACOL, V449, P99, DOI 10.1016/S0014-2999(02)01996-9; Derkinderen P, 2003, J NEUROSCI, V23, P2371; Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Ferrer I, 2002, ACTA NEUROPATHOL, V103, P391, DOI 10.1007/s00401-001-0481-9; Gratacos E, 2001, J NEUROCHEM, V78, P1287, DOI 10.1046/j.1471-4159.2001.00538.x; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 2002, J NEUROCHEM, V82, P154, DOI 10.1046/j.1471-4159.2002.00961.x; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Katona I, 1999, J NEUROSCI, V19, P4544; Marsicano G, 1999, EUR J NEUROSCI, V11, P4213, DOI 10.1046/j.1460-9568.1999.00847.x; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; MARSICANO G, UNPUB; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; McNamara JO, 1999, NATURE, V399, pA15, DOI 10.1038/399a015; MECHOULAM R, 2002, SCI STKE, pRE1; Moesgaard B, 2003, LIPIDS, V38, P387, DOI 10.1007/s11745-003-1073-1; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Selley DE, 2001, J NEUROCHEM, V77, P1048, DOI 10.1046/j.1471-4159.2001.00308.x; Tandon P, 1999, NEUROSCIENCE, V91, P293, DOI 10.1016/S0306-4522(98)00609-5; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Veldhuis WB, 2003, J NEUROSCI, V23, P4127; Wallace MJ, 2002, EUR J PHARMACOL, V452, P295, DOI 10.1016/S0014-2999(02)02331-2; Zhang JH, 2002, NAT GENET, V30, P416, DOI 10.1038/ng859	40	920	958	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					84	88		10.1126/science.1088208	http://dx.doi.org/10.1126/science.1088208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526074				2022-12-24	WOS:000185678500039
J	Lee, HH; Norris, A; Weiss, JB; Frasch, M				Lee, HH; Norris, A; Weiss, JB; Frasch, M			Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers	NATURE			English	Article							ANAPLASTIC LYMPHOMA KINASE; CELL FATES; DROSOPHILA MESODERM; BOX-GENE; FUSION; IDENTIFICATION; SEGMENTATION; EMBRYOGENESIS; SPECIFICATION; INDUCTION	The secreted protein Jelly belly (Jeb) is required for an essential signalling event in Drosophila muscle development. In the absence of functional Jeb, visceral muscle precursors are normally specified but fail to migrate and differentiate(1). The structure and distribution of Jeb protein implies that Jeb functions as a signal to organize the development of visceral muscles(1). Here we show that the Jeb receptor is the Drosophila homologue of anaplastic lymphoma kinase (Alk), a receptor tyrosine kinase of the insulin receptor superfamily. Human ALK was originally identified as a proto-oncogene, but its normal function in mammals is not known(2). In Drosophila, localized Jeb activates Alk and the downstream Ras/mitogen-activated protein kinase cascade to specify a select group of visceral muscle precursors as muscle-patterning pioneers. Jeb/Alk signalling induces the myoblast fusion gene dumbfounded (duf; also known as kirre) as well as org-1, a Drosophila homologue of mammalian TBX1, in these cells.	Oregon Hlth Sci Univ, Portland, OR 97201 USA; Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA	Oregon Health & Science University; Icahn School of Medicine at Mount Sinai	Weiss, JB (corresponding author), Oregon Hlth Sci Univ, 3181 SW Sam Jackson Pk Rd NRC3, Portland, OR 97201 USA.		Frasch, Manfred/H-7002-2013	Frasch, Manfred/0000-0003-1373-9798; LEE, HSIU-HSIANG/0000-0001-7707-8461				AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Azpiazu N, 1996, GENE DEV, V10, P3183, DOI 10.1101/gad.10.24.3183; Baldini A, 2002, HUM MOL GENET, V11, P2363, DOI 10.1093/hmg/11.20.2363; BATE M, 1990, DEVELOPMENT, V110, P791; Baylies MK, 2001, CURR OPIN GENET DEV, V11, P431, DOI 10.1016/S0959-437X(00)00214-8; BODMER R, 1993, DEVELOPMENT, V118, P719; Carmena A, 1998, GENE DEV, V12, P3910, DOI 10.1101/gad.12.24.3910; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Dworak HA, 2002, BIOESSAYS, V24, P591, DOI 10.1002/bies.10115; Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gabay L, 1997, DEVELOPMENT, V124, P3535; Gobron S, 1999, NEUROSCIENCE, V88, P655, DOI 10.1016/S0306-4522(98)00252-8; Ishihara T, 2002, CELL, V109, P639, DOI 10.1016/S0092-8674(02)00748-1; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Klapper R, 2002, MECH DEVELOP, V110, P85, DOI 10.1016/S0925-4773(01)00567-6; Lee HH, 2000, DEVELOPMENT, V127, P5497; Li L, 2000, J EXP MED, V191, P1077, DOI 10.1084/jem.191.6.1077; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Porsch M, 1998, GENE, V212, P237, DOI 10.1016/S0378-1119(98)00180-2; Riechmann V, 1997, DEVELOPMENT, V124, P2915; San Martin B, 2001, DEVELOPMENT, V128, P3331; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Sym M, 1999, CELL, V98, P25, DOI 10.1016/S0092-8674(00)80603-0; Weiss JB, 2001, CELL, V107, P387, DOI 10.1016/S0092-8674(01)00540-2; Zaffran S, 2001, GENE DEV, V15, P2900	30	133	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					507	512		10.1038/nature01916	http://dx.doi.org/10.1038/nature01916			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523446				2022-12-24	WOS:000185648100044
J	Perkins, TT; Dalal, RV; Mitsis, PG; Block, SM				Perkins, TT; Dalal, RV; Mitsis, PG; Block, SM			Sequence-dependent pausing of single lambda exonuclease molecules	SCIENCE			English	Article							BACTERIOPHAGE-LAMBDA; ESCHERICHIA-COLI; RNA-POLYMERASE; DNA; FORCE; TRANSLOCATION; ENDS	Lambda exonuclease processively degrades one strand of duplex DNA, moving 5'-to-3' in an ATP-independent fashion. When examined at the single-molecule level, the speeds of digestion were nearly constant at 4 nanometers per second (12 nucleotides per second), interspersed with pauses of variable duration. Long pauses, occurring at stereotypical locations, were strand-specific and sequence-dependent. Pause duration and probability varied widely. The strongest pause, GGCGATTCT, was identified by gel electrophoresis. Correlating single-molecule dwell positions with sequence independently identified the motif GGCGA. This sequence is found in the left lambda cohesive end, where exonuclease inhibition may contribute to the reduced recombination efficiency at that end.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Praelux Inc, Lawrenceville, NJ 08646 USA	Stanford University; Stanford University; Stanford University	Perkins, TT (corresponding author), Natl Inst Stand & Technol, 325 Broadway, Boulder, CO 80309 USA.			Perkins, Thomas/0000-0003-4826-9490	NHGRI NIH HHS [HG 011821-01] Funding Source: Medline; NIGMS NIH HHS [GM 57035, R01 GM057035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057035, R37GM057035] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; Dohoney KM, 2001, NATURE, V409, P370, DOI 10.1038/35053124; DOKTYCZ MJ, 1995, J BIOL CHEM, V270, P8439, DOI 10.1074/jbc.270.15.8439; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; Kovall RA, 1998, P NATL ACAD SCI USA, V95, P7893, DOI 10.1073/pnas.95.14.7893; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; Lang MJ, 2002, BIOPHYS J, V83, P491, DOI 10.1016/S0006-3495(02)75185-0; LITTLE JW, 1967, J BIOL CHEM, V242, P679; Mitsis PG, 1999, NUCLEIC ACIDS RES, V27, P3057, DOI 10.1093/nar/27.15.3057; RADDING CM, 1966, J MOL BIOL, V18, P235, DOI 10.1016/S0022-2836(66)80243-7; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; STAHL FW, 1972, P NATL ACAD SCI USA, V69, P3598, DOI 10.1073/pnas.69.12.3598; Subramanian K, 2003, NUCLEIC ACIDS RES, V31, P1585, DOI 10.1093/nar/gkg266; TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; WU R, 1971, J MOL BIOL, V57, P491, DOI 10.1016/0022-2836(71)90105-7; Yang Q, 1997, BIOCHEMISTRY-US, V36, P2744, DOI 10.1021/bi9622682	22	117	126	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1914	1918		10.1126/science.1088047	http://dx.doi.org/10.1126/science.1088047			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	12947034	Green Accepted			2022-12-24	WOS:000185536700053
J	Yan, H; Park, SH; Finkelstein, G; Reif, JH; LaBean, TH				Yan, H; Park, SH; Finkelstein, G; Reif, JH; LaBean, TH			DNA-templated self-assembly of protein arrays and highly conductive nanowires	SCIENCE			English	Article							CONSTRUCTION; COMPUTATION; MACHINE	A DNA nanostructure consisting of four four-arm junctions oriented with a square aspect ratio was designed and constructed. Programmable self-assembly of 4x4 tiles resulted in two distinct lattice morphologies: uniform-width nanoribbons and two-dimensional nanogrids, which both display periodic square cavities. Periodic protein arrays were achieved by templated self-assembly of streptavidin onto the DNA nanogrids containing biotinylated oligonucleotides. On the basis of a two-step metallization procedure, the 4x4 nanoribbons acted as an excellent scaffold for the production of highly conductive, uniform-width, silver nanowires.	Duke Univ, Dept Comp Sci, Durham, NC 27708 USA; Duke Univ, Dept Phys, Durham, NC 27708 USA	Duke University; Duke University	Yan, H (corresponding author), Duke Univ, Dept Comp Sci, Durham, NC 27708 USA.	hy1@cs.duke.edu; thl@cs.duke.edu	Reif, John H/C-2684-2008; LaBean, Thomas H/G-2859-2011	LaBean, Thomas H/0000-0002-6739-2059				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Benenson Y, 2001, NATURE, V414, P430, DOI 10.1038/35106533; Braich RS, 2002, SCIENCE, V296, P499, DOI 10.1126/science.1069528; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; FENG L, IN PRESS ANGEW CHEM; Ford WE, 2001, ADV MATER, V13, P1793, DOI 10.1002/1521-4095(200112)13:23<1793::AID-ADMA1793>3.0.CO;2-V; Keren K, 2002, SCIENCE, V297, P72, DOI 10.1126/science.1071247; LaBean T. H., 2003, COMPUTATIONAL BIOL G, P35; LaBean TH, 2000, J AM CHEM SOC, V122, P1848, DOI 10.1021/ja993393e; Li JWJ, 2002, NANO LETT, V2, P315, DOI [10.1021/nl015713+, 10.1021/n1015713+]; Liu QH, 2000, NATURE, V403, P175, DOI 10.1038/35003155; Mao CD, 1999, NATURE, V397, P144, DOI 10.1038/16437; Mao CD, 1999, J AM CHEM SOC, V121, P5437, DOI 10.1021/ja9900398; Mao CD, 2000, NATURE, V407, P493, DOI 10.1038/35035038; Mirkin CA, 2000, INORG CHEM, V39, P2258, DOI 10.1021/ic991123r; Monson CF, 2003, NANO LETT, V3, P359, DOI 10.1021/nl034016+; Niemeyer CM, 1998, ANGEW CHEM INT EDIT, V37, P2265, DOI 10.1002/(SICI)1521-3773(19980904)37:16<2265::AID-ANIE2265>3.0.CO;2-F; Patolsky F, 2002, ANGEW CHEM INT EDIT, V41, P2323, DOI 10.1002/1521-3773(20020703)41:13<2323::AID-ANIE2323>3.0.CO;2-H; Richter J, 2000, ADV MATER, V12, P507, DOI 10.1002/(SICI)1521-4095(200004)12:7<507::AID-ADMA507>3.0.CO;2-G; Seeman NC, 1999, TRENDS BIOTECHNOL, V17, P437, DOI 10.1016/S0167-7799(99)01360-8; Seeman NC, 2003, NATURE, V421, P427, DOI 10.1038/nature01406; Sha RJ, 2000, CHEM BIOL, V7, P743, DOI 10.1016/S1074-5521(00)00024-7; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998; Winfree E, 2000, J BIOMOL STRUCT DYN, P263; Xiao SJ, 2002, J NANOPART RES, V4, P313, DOI 10.1023/A:1021145208328; Yan H, 2002, NATURE, V415, P62, DOI 10.1038/415062a; Yan H, 2003, P NATL ACAD SCI USA, V100, P8103, DOI 10.1073/pnas.1032954100; Yurke B, 2000, NATURE, V406, P605, DOI 10.1038/35020524	29	1458	1543	11	644	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1882	1884		10.1126/science.1089389	http://dx.doi.org/10.1126/science.1089389			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512621				2022-12-24	WOS:000185536700043
J	von Schwedler, UK; Stuchell, M; Muller, B; Ward, DM; Chung, HY; Morita, E; Wang, HE; Davis, T; He, GP; Cimbora, DM; Scott, A; Krausslich, HG; Kaplan, J; Morham, SG; Sundquist, WI				von Schwedler, UK; Stuchell, M; Muller, B; Ward, DM; Chung, HY; Morita, E; Wang, HE; Davis, T; He, GP; Cimbora, DM; Scott, A; Krausslich, HG; Kaplan, J; Morham, SG; Sundquist, WI			The protein network of HIV budding	CELL			English	Article							LATE-DOMAIN; MULTIVESICULAR-BODY; PLASMA-MEMBRANE; VIRUS; TSG101; HRS; GAG; P6; TRAFFICKING; UBIQUITIN	HIV release requires TSG101, a cellular factor that sorts proteins into vesicles that bud into multivesicular bodies (MVB). To test whether other proteins involved in MVB biogenesis (the class E proteins) also participate in HIV release, we identified 22 candidate human class E proteins. These proteins were connected into a coherent network by 43 different protein-protein interactions, with AIP1 playing a key role in linking complexes that act early (TSG101/ESCRT-I) and late (CHMP4/ESCRT-III) in the pathway. AIP1 also binds the HIV-1 p6(Gag) and EIAV p9(Gag) proteins, indicating that it can function directly in virus budding. Human class E proteins were found in HIV-1 particles, and dominant-negative mutants of late-acting human class E proteins arrested HIV-1 budding through plasmal and endosomal membranes. These studies define a protein network required for human MVB biogenesis and indicate that the entire network participates in the release of HIV and probably many other viruses.	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Klinikum Heidelburg, Abt Virol, D-69120 Heidelberg, Germany; Myriad Pharmaceut Inc, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Ruprecht Karls University Heidelberg; Myriad Genetics, Inc	Sundquist, WI (corresponding author), Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA.	wes@biochem.utah.edu	Morita, Eiji/D-2453-2015	Morita, Eiji/0000-0002-3781-6121; Muller, Barbara/0000-0001-5726-5585				Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6; Biscone MJ, 2002, CURR OPIN PHARMACOL, V2, P529, DOI 10.1016/S1471-4892(02)00200-X; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Cook RF, 1998, J VIROL, V72, P1383, DOI 10.1128/JVI.72.2.1383-1393.1998; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; Denzer K, 2000, J CELL SCI, V113, P3365; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.1831413100; Gross I, 1997, EUR J BIOCHEM, V249, P592, DOI 10.1111/j.1432-1033.1997.t01-1-00592.x; Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000; Howard TL, 2001, J CELL SCI, V114, P2395; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Kamura T, 2001, J BIOL CHEM, V276, P16528, DOI 10.1074/jbc.M010142200; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Licata JM, 2003, J VIROL, V77, P1812, DOI 10.1128/JVI.77.3.1812-1819.2003; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; Muller B, 2002, J VIROL, V76, P1015, DOI 10.1128/JVI.76.3.1015-1024.2002; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; POMILLOS O, 2002, NAT STRUCT BIOL, V9, P812; POMILLOS O, 2003, J CELL BIOL, V162, P425; POMILLOS O, 2002, EMBO J, V21, P2397; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; Puffer BA, 1997, J VIROL, V71, P6541, DOI 10.1128/JVI.71.9.6541-6546.1997; Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x; Scheuring S, 2001, J MOL BIOL, V312, P469, DOI 10.1006/jmbi.2001.4917; SHERER NM, 2003, IN PRESS TRAFFIC; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vincent O, 2003, MOL CELL BIOL, V23, P1647, DOI 10.1128/MCB.23.5.1647-1655.2003; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000	52	656	691	0	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					701	713		10.1016/S0092-8674(03)00714-1	http://dx.doi.org/10.1016/S0092-8674(03)00714-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505570	Bronze			2022-12-24	WOS:000185464000008
J	Allen, MR				Allen, MR			Possible or probable?	NATURE			English	Editorial Material									Univ Oxford, Dept Phys, Oxford OX11 0QXJ, England	University of Oxford	Allen, MR (corresponding author), Univ Oxford, Dept Phys, Oxford OX11 0QXJ, England.		Allen, Myles R/A-5172-2012					ALLEN MR, P 2002 EOMWF PRED SE, P275; Houghton J. T., 2001, CLIMATE CHANGE 2001; Schneider SH, 2002, CLIMATIC CHANGE, V52, P441, DOI 10.1023/A:1014221225434	3	22	22	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					242	242		10.1038/425242a	http://dx.doi.org/10.1038/425242a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679894				2022-12-24	WOS:000185370900023
J	Gray, N; Boyle, P				Gray, N; Boyle, P			The future of the nicotine-addiction market	LANCET			English	Editorial Material							HEALTH		European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Gray, N (corresponding author), European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy.		Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610				Gray N, 2000, TOB CONTROL, V9, P351, DOI 10.1136/tc.9.3.351; Henningfield JE, 2001, TOB CONTROL, V10, P253, DOI 10.1136/tc.10.3.253; Ramstrom L., 2000, NICOTINE PUBLIC HLTH, P159; Sumner W, 2003, TOB CONTROL, V12, P124, DOI 10.1136/tc.12.2.124; 1991, LANCET, V337, P1191; DATABASE ED RESOURCE	6	20	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					845	846		10.1016/S0140-6736(03)14348-6	http://dx.doi.org/10.1016/S0140-6736(03)14348-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678968				2022-12-24	WOS:000185329400005
J	Cecchi, F; Olivotto, I; Gistri, R; Lorenzoni, R; Chiriatti, G; Camici, PG				Cecchi, F; Olivotto, I; Gistri, R; Lorenzoni, R; Chiriatti, G; Camici, PG			Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR HYPERTROPHY; POSITRON-EMISSION TOMOGRAPHY; MYOCARDIAL PERFUSION ABNORMALITIES; SUDDEN-DEATH; VASODILATOR RESERVE; ATRIAL-FIBRILLATION; CLINICAL COURSE; CARDIAC-ARREST; ISCHEMIA; RISK	Background: Microvascular dysfunction, reflected by an inadequate increase in myocardial blood flow in response to dipyridamole infusion, is a recognized feature of hypertrophic cardiomyopathy. Its long-term effect on the prognosis is unknown. We prospectively evaluated a cohort of patients with hypertrophic cardiomyopathy after they had undergone quantitative assessment of myocardial blood flow by positron-emission tomography (PET). Methods: Fifty-one patients (New York Heart Association class I or II) were followed for a mean (+/-SD) of 8.1+/-2.1 years after PET. Twelve subjects with atypical chest pain served as controls. Measurement of flow was performed at base line and after the infusion of the coronary vasodilator dipyridamole, with the use of nitrogen-13-labeled ammonia. Patients were then divided into three equal groups with increasing values of myocardial blood flow. Results: The response of myocardial blood flow to dipyridamole was severely blunted in the patients, as compared with the controls (1.50+/-0.69 vs. 2.71+/-0.94 ml per minute per gram of tissue, P<0.001). Sixteen patients (31 percent) had an unfavorable outcome (death from cardiovascular causes, progression to New York Heart Association class III or IV, or sustained ventricular arrhythmias requiring the implantation of a cardioverter-defibrillator) 2.2 to 9.1 years after PET. Reduced blood flow in response to dipyridamole was strongly associated with an unfavorable outcome. Multivariate analysis showed that among patients in the lowest of the three flow groups the age-adjusted relative hazard of death from cardiovascular causes was 9.6 (P=0.02) and the relative hazard of an unfavorable outcome (a combined end point) was 20.1 (P=0.003), as compared with patients in the two other flow groups. Specifically, all four patients who died from heart failure and three of five who died suddenly were in this subgroup. Conclusions: In patients with hypertrophic cardiomyopathy, the degree of microvascular dysfunction is a strong, independent predictor of clinical deterioration and death. Severe microvascular dysfunction is often present in patients with mild or no symptoms and may precede clinical deterioration by years.	Azienda Osped Careggi, Reg Referral Ctr Myocardial Dis, Florence, Italy; Osped Lucca, Cardiol Unit, Lucca, Italy; Osped Pescia, Cardiol Unit, Pescia, Italy; CNR, Inst Clin Physiol, I-56100 Pisa, Italy; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Med Res Ctr, London SW7 2AZ, England	University of Florence; Azienda Ospedaliero Universitaria Careggi; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Imperial College London	Cecchi, F (corresponding author), Via Jacopo Nardi 30, I-50132 Florence, Italy.		Olivotto, Iacopo/AAC-5950-2022; Camici, Paolo/AAN-1959-2020; Lorenzoni, Roberto/G-4139-2018	Olivotto, Iacopo/0000-0003-1751-9266; Camici, Paolo/0000-0001-5584-0750; Cecchi, Franco/0000-0002-2035-5621; Lorenzoni, Roberto/0000-0002-5703-715X				Basso C, 2000, HUM PATHOL, V31, P988, DOI 10.1053/hupa.2000.16659; CAMICI P, 1991, J AM COLL CARDIOL, V17, P879, DOI 10.1016/0735-1097(91)90869-B; CAMICI PG, 1991, CORONARY ARTERY DIS, V2, P837; CANNON RO, 1991, CIRCULATION, V83, P1660, DOI 10.1161/01.CIR.83.5.1660; CANNON RO, 1985, CIRCULATION, V71, P234, DOI 10.1161/01.CIR.71.2.234; CECCHI F, 1995, J AM COLL CARDIOL, V26, P1529, DOI 10.1016/0735-1097(95)00353-3; Choudhury L, 1997, EUR HEART J, V18, P108; Choudhury L, 1999, BASIC RES CARDIOL, V94, P49, DOI 10.1007/s003950050126; DILSIZIAN V, 1993, J AM COLL CARDIOL, V22, P796, DOI 10.1016/0735-1097(93)90193-5; Elliott PM, 1996, EUR HEART J, V17, P1056; Elliott PM, 2001, LANCET, V357, P420, DOI 10.1016/S0140-6736(00)04005-8; Elliott PM, 2000, J AM COLL CARDIOL, V36, P2212, DOI 10.1016/S0735-1097(00)01003-2; GISTRI R, 1994, AM J CARDIOL, V74, P363, DOI 10.1016/0002-9149(94)90404-9; Gnecchi-Ruscone T, 1999, MUSCLE NERVE, V22, P1549, DOI 10.1002/(SICI)1097-4598(199911)22:11<1549::AID-MUS10>3.0.CO;2-A; Krams R, 1998, CIRCULATION, V97, P230, DOI 10.1161/01.CIR.97.3.230; Lazzeroni E, 1997, CIRCULATION, V96, P4268; Lorenzoni R, 1998, AM HEART J, V136, P972, DOI 10.1016/S0002-8703(98)70152-8; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 2000, CIRCULATION, V102, P858; Maron BJ, 2000, NEW ENGL J MED, V342, P365, DOI 10.1056/NEJM200002103420601; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MARON BJ, 1986, J AM COLL CARDIOL, V8, P545, DOI 10.1016/S0735-1097(86)80181-4; Maron MS, 2003, NEW ENGL J MED, V348, P295, DOI 10.1056/NEJMoa021332; MCKENNA WJ, 1990, BRIT HEART J, V63, P287; Neglia D, 2002, CIRCULATION, V105, P186, DOI 10.1161/hc0202.102119; OGARA PT, 1987, CIRCULATION, V76, P1214, DOI 10.1161/01.CIR.76.6.1214; Olivotto I, 2003, J AM COLL CARDIOL, V41, P315, DOI 10.1016/S0735-1097(02)02713-4; Olivotto I, 2001, CIRCULATION, V104, P2517, DOI 10.1161/hc4601.097997; Rajappan K, 2002, CIRCULATION, V105, P470, DOI 10.1161/hc0402.102931; Schwartzkopff B, 1998, J AM COLL CARDIOL, V31, P1089, DOI 10.1016/S0735-1097(98)00036-9; Spirito P, 2000, NEW ENGL J MED, V342, P1778, DOI 10.1056/NEJM200006153422403; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; STAFFORD WJ, 1986, J AM COLL CARDIOL, V7, P701, DOI 10.1016/S0735-1097(86)80484-3; TANAKA M, 1986, BRIT HEART J, V55, P575; UDELSON JE, 1989, CIRCULATION, V79, P1052, DOI 10.1161/01.CIR.79.5.1052; Yoshida N, 1998, J AM COLL CARDIOL, V32, P1938, DOI 10.1016/S0735-1097(98)00498-7	36	526	550	2	17	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1027	1035		10.1056/NEJMoa025050	http://dx.doi.org/10.1056/NEJMoa025050			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968086				2022-12-24	WOS:000185223100004
J	Han, SC; Tang, RH; Anderson, LK; Woerner, TE; Pei, ZM				Han, SC; Tang, RH; Anderson, LK; Woerner, TE; Pei, ZM			A cell surface receptor mediates extracellular Ca2+ sensing in guard cells	NATURE			English	Article							CALCIUM; ARABIDOPSIS; PLANT; OSCILLATIONS; REGULATOR; PROTEINS; CHANNEL; BINDING	Extracellular Ca2+ (Ca-o(2+)) is required for various physiological and developmental processes in animals and plants(1-3). In response to varied Ca-o(2+) levels, plants maintain relatively constant internal Ca2+ content, suggesting a precise regulatory mechanism for Ca2+ homeostasis(4). However, little is known about how plants monitor Ca-o(2+) status and whether Ca-o(2+)-sensing receptors exist. The effects of Ca-o(2+) on guard cells in promoting stomatal closure by inducing increases in the concentration of cytosolic Ca2+ ([Ca2+](i))(5-8) provide a clue to Ca-o(2+) sensing. Here we have used a functional screening assay in mammalian cells 9 to isolate an Arabidopsis complementary DNA clone encoding a Ca2+-sensing receptor, CAS. CAS is localized to the plasma membrane, exhibits low-affinity/high-capacity Ca2+ binding, and mediates Ca-o(2+)-induced [Ca2+](i) increases. CAS is expressed predominantly in the shoot, including guard cells. Repression of CAS disrupts Ca-o(2+) signalling in guard cells, and impairs bolting (swift upward growth at the transition to seed production) in response to Ca2+ deficiency, so we conclude that CAS may be a primary transducer of Ca-o(2+) in plants.	Duke Univ, Dept Biol, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA; Duke Univ, Dept Chem, Durham, NC 27708 USA	Duke University; Duke University	Pei, ZM (corresponding author), Duke Univ, Dept Biol, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA.	zpei@duke.edu		Han, Shengcheng/0000-0002-4039-7589; Tang, Ruhang/0000-0003-4918-3525; Pei, Zhen-Ming/0000-0003-1473-696X				Allen GJ, 2001, NATURE, V411, P1053, DOI 10.1038/35082575; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; CLARKSON DT, 1984, PLANT CELL ENVIRON, V7, P449, DOI 10.1111/j.1365-3040.1984.tb01435.x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; Li X, 1999, CELL, V98, P329, DOI 10.1016/S0092-8674(00)81962-5; LONERAGAN JF, 1969, AUST J AGR RES, V20, P465, DOI 10.1071/AR9690465; Luan S, 2002, PLANT CELL, V14, pS389, DOI 10.1105/tpc.001115; MACROBBIE EAC, 1992, PHILOS T R SOC B, V338, P5, DOI 10.1098/rstb.1992.0124; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCAINSH MR, 1995, PLANT CELL, V7, P1207, DOI 10.1105/tpc.7.8.1207; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Pei ZM, 1998, P NATL ACAD SCI USA, V95, P6548, DOI 10.1073/pnas.95.11.6548; Roelfsema MRG, 2002, NEW PHYTOL, V153, P425, DOI 10.1046/j.1469-8137.2002.00344.x; Sanders D, 2002, PLANT CELL, V14, pS401, DOI 10.1105/tpc.002899; Sattelmacher B, 2001, NEW PHYTOL, V149, P167, DOI 10.1046/j.1469-8137.2001.00034.x; Schroeder JI, 2001, NATURE, V410, P327, DOI 10.1038/35066500; SCHWARTZ A, 1985, PLANT PHYSIOL, V79, P1003, DOI 10.1104/pp.79.4.1003; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; Wakabayashi H, 2002, BIOCHEMISTRY-US, V41, P8485, DOI 10.1021/bi025589o	26	163	179	5	63	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					196	200		10.1038/nature01932	http://dx.doi.org/10.1038/nature01932			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968184				2022-12-24	WOS:000185236000047
J	Garrison, A				Garrison, A			Between a rock and a hard place	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUNTINGTONS-DISEASE		Duke Univ, Sch Med, Durham, NC 27706 USA	Duke University	Garrison, A (corresponding author), Duke Univ, Sch Med, Durham, NC 27706 USA.							Beauchamp TL, 2001, PRINCIPLES BIOMEDICA, V5th; Bernstein T, 1994, RADON RENTAL HOUSING; CLOUSER KD, 1990, J MED PHILOS, V15, P219, DOI 10.1093/jmp/15.2.219; FAGOTLARGEAULT A, 1994, PRINCIPLES HLTH CARE; Feigin A, 2002, CURR OPIN NEUROL, V15, P483, DOI 10.1097/00019052-200208000-00013; Goizet C, 2002, NEUROLOGY, V59, P1330, DOI 10.1212/01.WNL.0000032255.75650.C2; Jonsen A. R., 1988, ABUSE CASUISTRY HIST; Lammers, 1998, MORAL MED THEOLOGICA; LUYNCH A, 1990, HASTINGS CENT REP, V20, P31; McAbee GN, 1998, PEDIATRICS, V102, P140, DOI 10.1542/peds.102.1.140; NICHOLSON RH, 1994, PRINCIPLES HLTH CARE; NOZICK R, 1968, NATURAL LAW FORUM, V13, P1; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, SCREEN COUNS GEN CON; TERRENOIRE G, 1943, J MED ETHICS, V1879, P92	14	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1217	1218		10.1001/jama.290.9.1217	http://dx.doi.org/10.1001/jama.290.9.1217			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12953008				2022-12-24	WOS:000185090400021
J	van Oijen, AM; Blainey, PC; Crampton, DJ; Richardson, CC; Ellenberger, T; Xie, XS				van Oijen, AM; Blainey, PC; Crampton, DJ; Richardson, CC; Ellenberger, T; Xie, XS			Single-molecule kinetics of lambda exonuclease reveal base dependence and dynamic disorder	SCIENCE			English	Article							DNA DIGESTION; ELASTICITY; TENSION	We used a multiplexed approach based on flow-stretched DNA to monitor the enzymatic digestion of lambda-phage DNA by individual bacteriophage lambda exonuclease molecules. Statistical analyses of multiple single-molecule trajectories observed simultaneously reveal that the catalytic rate is dependent on the local base content of the substrate DNA. By relating single-molecule kinetics to the free energies of hydrogen bonding and base stacking, we establish that the melting of a base from the DNA is the rate-limiting step in the catalytic cycle. The catalytic rate also exhibits large fluctuations independent of the sequence, which we attribute to conformational changes of the enzyme-DNA complex.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	Xie, XS (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	xie@chemistry.harvard.edu	van Oijen, Antoine/I-3167-2014	van Oijen, Antoine/0000-0002-1794-5161; Blainey, Paul/0000-0002-4889-8783	NIGMS NIH HHS [5R01GM61577-03, R01GM55390-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061577, R01GM055390] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bommarito S, 2000, NUCLEIC ACIDS RES, V28, P1929, DOI 10.1093/nar/28.9.1929; Bustamante C, 2003, NATURE, V421, P423, DOI 10.1038/nature01405; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Dapprich J, 1999, CYTOMETRY, V36, P163, DOI 10.1002/(SICI)1097-0320(19990701)36:3<163::AID-CYTO3>3.0.CO;2-R; Dickson KS, 2000, J BIOL CHEM, V275, P15828, DOI 10.1074/jbc.M910044199; Fersht A. R., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; Kovall RA, 1998, P NATL ACAD SCI USA, V95, P7893, DOI 10.1073/pnas.95.14.7893; Lam WC, 2002, BIOCHEMISTRY-US, V41, P3943, DOI 10.1021/bi0120603; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Matsuura S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e79; Mitsis PG, 1999, NUCLEIC ACIDS RES, V27, P3057, DOI 10.1093/nar/27.15.3057; Polakowski R, 2000, J AM CHEM SOC, V122, P4853, DOI 10.1021/ja994488j; Rauch C, 2002, J MOL BIOL, V324, P491, DOI 10.1016/S0022-2836(02)01089-6; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Strick TR, 1998, BIOPHYS J, V74, P2016, DOI 10.1016/S0006-3495(98)77908-1; Strick TR, 1996, SCIENCE, V271, P1835, DOI 10.1126/science.271.5257.1835; Subramanian K, 2003, NUCLEIC ACIDS RES, V31, P1585, DOI 10.1093/nar/gkg266; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614; Xie XS, 2002, J CHEM PHYS, V117, P11024, DOI 10.1063/1.1521159; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	28	273	288	4	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1235	1238		10.1126/science.1084387	http://dx.doi.org/10.1126/science.1084387			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947199	Green Submitted			2022-12-24	WOS:000185003500042
J	Geng, Y; Yu, QY; Sicinska, E; Das, M; Schneider, JE; Bhattacharya, S; Rideout, WM; Bronson, RT; Gardner, H; Sicinski, P				Geng, Y; Yu, QY; Sicinska, E; Das, M; Schneider, JE; Bhattacharya, S; Rideout, WM; Bronson, RT; Gardner, H; Sicinski, P			Cyclin E ablation in the mouse	CELL			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; HISTONE GENE-TRANSCRIPTION; CELL-FREE SYSTEM; S-PHASE; DROSOPHILA EMBRYOGENESIS; RETINOBLASTOMA PROTEIN; DNA-REPLICATION; HUMAN CANCERS; COMPLEX; CDK2	E type cyclins (E1 and E2) are believed to drive cell entry into the S phase. It is widely assumed that the two E type cyclins are critically required for proliferation of all cell types. Here, we demonstrate that E type cyclins are largely dispensable for mouse development. However, endoreplication of trophoblast giant cells and megakaryocytes is severely impaired in the absence of cyclin E. Cyclin E-deficient cells proliferate actively under conditions of continuous cell cycling but are unable to reenter the cell cycle from the quiescent Go state. Molecular analyses revealed that cells lacking cyclin E fail to normally incorporate MCM proteins into DNA replication origins during G(0)-->S progression. We also found that cyclin E-deficient cells are relatively resistant to oncogenic transformation. These findings define a molecular function for E type cyclins in cell cycle reentry and reveal a differential requirement for cyclin E in normal versus oncogenic proliferation.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Oxford, Dept Cardiovasc Med, Oxford OX3 7BN, England; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA; Biogen Inc, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Oxford; Massachusetts Institute of Technology (MIT); Whitehead Institute; Tufts University; Tufts University; Biogen	Sicinski, P (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.		Bhattacharya, Shoumo/F-4127-2010	Bhattacharya, Shoumo/0000-0002-5571-0478	NATIONAL CANCER INSTITUTE [R01CA083688, R01CA085296] Funding Source: NIH RePORTER; NCI NIH HHS [CA83688, CA85296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Cross JC, 2002, MOL CELL ENDOCRINOL, V187, P207, DOI 10.1016/S0303-7207(01)00703-1; Cross JC, 2000, SEMIN CELL DEV BIOL, V11, P105, DOI 10.1006/scdb.2000.0156; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Fay DS, 2000, DEVELOPMENT, V127, P4049; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P13138, DOI 10.1073/pnas.231487798; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hogan B., 1986, MANIPULATING MOUSE E; Kaufman M.H., 1999, ANATOMICAL BASIS MOU; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Madine MA, 2000, J STRUCT BIOL, V129, P198, DOI 10.1006/jsbi.2000.4218; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; Schneider JE, 2003, J MOL CELL CARDIOL, V35, P217, DOI 10.1016/S0022-2828(02)00291-2; SEARLE AG, 1974, MUTAT RES, V22, P63, DOI 10.1016/0027-5107(74)90009-8; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Su TT, 1998, J CELL BIOL, V140, P451, DOI 10.1083/jcb.140.3.451; Tanaka M, 1997, DEV BIOL, V190, P55, DOI 10.1006/dbio.1997.8685; Webb S, 1998, CIRC RES, V82, P645, DOI 10.1161/01.RES.82.6.645; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002; Zybina EV, 1996, INT REV CYTOL, V165, P53, DOI 10.1016/S0074-7696(08)62220-2	53	538	546	1	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					431	443		10.1016/S0092-8674(03)00645-7	http://dx.doi.org/10.1016/S0092-8674(03)00645-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941272	Bronze			2022-12-24	WOS:000184928800007
J	Rahn, T; Eiler, JM; Boering, KA; Wennberg, PO; McCarthy, MC; Tyler, S; Schauffler, S; Donnelly, S; Atlas, E				Rahn, T; Eiler, JM; Boering, KA; Wennberg, PO; McCarthy, MC; Tyler, S; Schauffler, S; Donnelly, S; Atlas, E			Extreme deuterium enrichment in stratospheric hydrogen and the global atmospheric budget of H-2	NATURE			English	Article							LIQUEFIED PETROLEUM GAS; ISOTOPIC COMPOSITION; MOLECULAR-HYDROGEN; RATE COEFFICIENTS; AIR; TRITIUM; LEAKAGE; CARBON; IMPACT	Molecular hydrogen (H-2) is the second most abundant trace gas in the atmosphere after methane(1) (CH4). In the troposphere, the D/H ratio of H-2 is enriched by 120parts per thousand relative to the world's oceans(2-4). This cannot be explained by the sources of H-2 for which the D/H ratio has been measured to date (for example, fossil fuels and biomass burning)(5,6). But the isotopic composition of H-2 from its single largest source-the photochemical oxidation of methane-has yet to be determined. Here we show that the D/H ratio of stratospheric H-2 develops enrichments greater than 440parts per thousand, the most extreme D/H enrichment observed in a terrestrial material. We estimate the D/H ratio of H-2 produced from CH4 in the stratosphere, where production is isolated from the influences of non-photochemical sources and sinks, showing that the chain of reactions producing H-2 from CH4 concentrates D in the product H-2. This enrichment, which we estimate is similar on a global average in the troposphere, contributes substantially to the D/H ratio of tropospheric H-2.	CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Calif Irvine, Earth Syst Sci Dept, Irvine, CA 92697 USA; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	California Institute of Technology; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Irvine; National Center Atmospheric Research (NCAR) - USA; California Institute of Technology	Rahn, T (corresponding author), Los Alamos Natl Lab, EES-6,MS-D462, Los Alamos, NM 87545 USA.	trahn@lanl.gov	Rahn, Thom/C-5211-2012; McCarthy, Michael/E-5970-2010; Atlas, Elliot/AAE-4605-2021; Atlas, Elliot/J-8171-2015; Wennberg, Paul O/A-5460-2012	Wennberg, Paul O/0000-0002-6126-3854; Boering, Kristie/0000-0003-0920-0503; Atlas, Elliot/0000-0003-3847-5346				BLAKE DR, 1995, SCIENCE, V269, P953, DOI 10.1126/science.269.5226.953; Boering KA, 1996, SCIENCE, V274, P1340, DOI 10.1126/science.274.5291.1340; Brasseur G., 1984, AERONOMY MIDDLE ATMO; Chen TY, 2001, GEOPHYS RES LETT, V28, P2193, DOI 10.1029/2000GL012703; DEMORE WB, 1997, CHEM KINETICS PHOTOC, P278; EHHALT D, 1963, J GEOPHYS RES, V68, P3747, DOI 10.1029/JZ068i013p03747; EHHALT DH, 1989, J GEOPHYS RES-ATMOS, V94, P9831, DOI 10.1029/JD094iD07p09831; FRIEDMAN I, 1974, J GEOPHYS RES, V79, P785, DOI 10.1029/JC079i006p00785; Gerst S, 2000, J GEOPHYS RES-ATMOS, V105, P26433, DOI 10.1029/2000JD900387; Gerst S, 2001, J GEOPHYS RES-ATMOS, V106, P5021, DOI 10.1029/2000JD900593; GONSIOR B, 1966, TELLUS, V18, P256; Hauglustaine DA, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001156; HOLTON JR, 1990, J ATMOS SCI, V47, P392, DOI 10.1175/1520-0469(1990)047<0392:OTGEOM>2.0.CO;2; Hurst DF, 1999, J GEOPHYS RES-ATMOS, V104, P8191, DOI 10.1029/1998JD100092; KHALIL MAK, 1990, NATURE, V347, P743, DOI 10.1038/347743a0; Leshin LA, 1996, GEOCHIM COSMOCHIM AC, V60, P2635, DOI 10.1016/0016-7037(96)00122-6; MOORTGAT GK, 1983, J CHEM PHYS, V78, P1185, DOI 10.1063/1.444911; NEWMAN PA, 2002, J GEOPHYS RES, V107; Novelli PC, 1999, J GEOPHYS RES-ATMOS, V104, P30427, DOI 10.1029/1999JD900788; Rahn T, 2002, GEOCHIM COSMOCHIM AC, V66, P2475, DOI 10.1016/S0016-7037(02)00858-X; Rice AL, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003042; ROBERT F, 1982, GEOCHIM COSMOCHIM AC, V46, P81, DOI 10.1016/0016-7037(82)90293-9; Saueressig G, 2001, J GEOPHYS RES-ATMOS, V106, P23127, DOI 10.1029/2000JD000120; Saueressig G, 1996, GEOPHYS RES LETT, V23, P3619, DOI 10.1029/96GL03292; SCHAUFFLER SM, 2003, J GEOPHYS RES, V108, DOI DOI 10.1029/2001JGD002040; Taatjes CA, 1999, CHEM PHYS LETT, V306, P33, DOI 10.1016/S0009-2614(99)00420-0; Talukdar RK, 1996, CHEM PHYS LETT, V253, P177, DOI 10.1016/0009-2614(96)00203-5; Talukdar RK, 1996, J PHYS CHEM-US, V100, P3037, DOI 10.1021/jp9518724	28	73	74	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					918	921		10.1038/nature01917	http://dx.doi.org/10.1038/nature01917			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931182				2022-12-24	WOS:000184843600035
J	Flanagan, JR; Johansson, RS				Flanagan, JR; Johansson, RS			Action plans used in action observation	NATURE			English	Article							GRASP REPRESENTATIONS; MAGNETIC STIMULATION; PREMOTOR CORTEX; MIRROR NEURONS; EYE-MOVEMENTS; MOTOR; IMITATION; COORDINATION; MODULATION; LOCALIZATION	How do we understand the actions of others? According to the direct matching hypothesis, action understanding results from a mechanism that maps an observed action onto motor representations of that action(1-4). Although supported by neurophysiological (1,5-13) and brain- imaging(3,14-18) studies, direct evidence for this hypothesis is sparse. In visually guided actions, task-specific proactive eye movements are crucial for planning and control (19-22). Because the eyes are free to move when observing such actions, the direct matching hypothesis predicts that subjects should produce eye movements similar to those produced when they perform the tasks. If an observer analyses action through purely visual means, however, eye movements will be linked reactively to the observed action. Here we show that when subjects observe a block stacking task, the coordination between their gaze and the actor's hand is predictive, rather than reactive, and is highly similar to the gaze-hand coordination when they perform the task themselves. These results indicate that during action observation subjects implement eye motor programs directed by motor representations of manual actions and thus provide strong evidence for the direct matching hypothesis.	Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada; Queens Univ, Ctr Neurosci Studies, Kingston, ON K7L 3N6, Canada; Umea Univ, Dept Integrat Med Biol, Physiol Sect, SE-90187 Umea, Sweden	Queens University - Canada; Queens University - Canada; Umea University	Flanagan, JR (corresponding author), Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada.		Johansson, Roland S/A-5890-2009	Johansson, Roland S/0000-0003-3288-8326				Allison T, 2000, TRENDS COGN SCI, V4, P267, DOI 10.1016/S1364-6613(00)01501-1; Avikainen S, 2002, NEUROIMAGE, V15, P640, DOI 10.1006/nimg.2001.1029; BALLARD DH, 1995, J COGNITIVE NEUROSCI, V7, P66, DOI 10.1162/jocn.1995.7.1.66; BALLARD DH, 1992, PHILOS T R SOC B, V337, P331, DOI 10.1098/rstb.1992.0111; Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763; DIPELLEGRINO G, 1992, EXP BRAIN RES, V91, P176, DOI 10.1007/BF00230027; FADIGA L, 1995, J NEUROPHYSIOL, V73, P2608, DOI 10.1152/jn.1995.73.6.2608; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; Gangitano M, 2001, NEUROREPORT, V12, P1489, DOI 10.1097/00001756-200105250-00038; Grafton ST, 1996, EXP BRAIN RES, V112, P103; Hari R, 1998, P NATL ACAD SCI USA, V95, P15061, DOI 10.1073/pnas.95.25.15061; Iacoboni M, 1999, SCIENCE, V286, P2526, DOI 10.1126/science.286.5449.2526; Iacoboni M, 2001, P NATL ACAD SCI USA, V98, P13995, DOI 10.1073/pnas.241474598; Johansson RS, 2001, J NEUROSCI, V21, P6917, DOI 10.1523/JNEUROSCI.21-17-06917.2001; JOHANSSON RS, 1992, CURR OPIN NEUROBIOL, V2, P815, DOI 10.1016/0959-4388(92)90139-C; Kohler E, 2002, SCIENCE, V297, P846, DOI 10.1126/science.1070311; Koski L, 2002, CEREB CORTEX, V12, P847, DOI 10.1093/cercor/12.8.847; Land M, 1999, PERCEPTION, V28, P1311, DOI 10.1068/p2935; Land MF, 2000, NAT NEUROSCI, V3, P1340, DOI 10.1038/81887; Land MF, 1997, PHILOS T ROY SOC B, V352, P1231, DOI 10.1098/rstb.1997.0105; Mataric MJ, 1998, COGNITIVE BRAIN RES, V7, P191, DOI 10.1016/S0926-6410(98)00025-1; Nishitani N, 2000, P NATL ACAD SCI USA, V97, P913, DOI 10.1073/pnas.97.2.913; PERRY HM, 1989, BONE MINERAL RES, V6, P113; Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060; Rizzolatti G, 1996, EXP BRAIN RES, V111, P246; Rizzolatti G, 1999, ARCH ITAL BIOL, V137, P85; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; Strafella AP, 2000, NEUROREPORT, V11, P2289, DOI 10.1097/00001756-200007140-00044; Umilta MA, 2001, NEURON, V31, P155, DOI 10.1016/S0896-6273(01)00337-3	29	472	478	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					769	771		10.1038/nature01861	http://dx.doi.org/10.1038/nature01861			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917683				2022-12-24	WOS:000184733900038
J	Villunger, A; Michalak, EM; Coultas, L; Mullauer, F; Bock, G; Ausserlechner, MJ; Adams, JM; Strasser, A				Villunger, A; Michalak, EM; Coultas, L; Mullauer, F; Bock, G; Ausserlechner, MJ; Adams, JM; Strasser, A			p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa	SCIENCE			English	Article							COLORECTAL-CANCER CELLS; BCL-2 FAMILY; DNA-DAMAGE; P53; DEATH; GENE; THYMOCYTES; EXPRESSION; INDUCTION; SURVIVAL	Apoptosis provoked by DNA damage requires the p53 tumor suppressor, but which of the many p53-regulated genes are required has remained unknown. Two genes induced by this transcription factor, noxa and puma (bbc3), stand out, because they encode BH3-only proteins, proapoptotic members of the Bcl-2 family required to initiate apoptosis. In mice with either noxa or puma disrupted, we observed decreased DNA damage-induced apoptosis in fibroblasts, although only loss of Puma protected lymphocytes from cell death. Puma deficiency also protected cells against diverse p53-independent cytotoxic insults, including cytokine deprivation and exposure to glucocorticoids, the kinase inhibitor staurosporine, or phorbol ester. Hence, Puma and Noxa are critical mediators of the apoptotic responses induced by p53 and other agents.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Innsbruck, Inst Pathophysiol, A-6020 Innsbruck, Austria	Walter & Eliza Hall Institute; University of Innsbruck	Villunger, A (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	andreas.villunger@uibk.ac.at; strasser@wehi.edu.au	Adams, Jerry M/E-1199-2013; Strasser, Andreas/C-7581-2013	Strasser, Andreas/0000-0002-5020-4891; Adams, Jerry/0000-0002-4360-8628; Michalak, Ewa/0000-0002-5772-2122; Ausserlechner, Michael/0000-0002-1015-2302				Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SENTMAN CL, 1991, CELL, V67, P79; SHIBUE T, 2003, GENE DEV, V2, P2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; VILLUNGER A, UNPUB; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	24	1030	1065	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1036	1038		10.1126/science.1090072	http://dx.doi.org/10.1126/science.1090072			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14500851				2022-12-24	WOS:000186396300045
J	Pellino, JL; Sontheimer, EJ				Pellino, JL; Sontheimer, EJ			R2D2 leads the silencing trigger to mRNA's death star	CELL			English	Editorial Material							REQUIREMENTS; INTERFERENCE; RDE-1; GENE	During RNA interference (RNAi), Dicer generates short interfering RNAs (siRNAs), which then guide target mRNA cleavage by the RISC complex. Now, Liu et al. identify R2D2, a Dicer-associated protein that is important for siRNA incorporation into RISC, thus linking the initiation and execution phases of RNAi.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Pellino, JL (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.			Sontheimer, Erik/0000-0002-0881-0310				Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	10	6	12	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					132	133		10.1016/S0092-8674(03)00806-7	http://dx.doi.org/10.1016/S0092-8674(03)00806-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567910	Bronze			2022-12-24	WOS:000186039200004
J	Barzilai, N; Atzmon, G; Schechter, C; Schaefer, EJ; Cupples, AL; Lipton, R; Cheng, S; Shuldiner, AR				Barzilai, N; Atzmon, G; Schechter, C; Schaefer, EJ; Cupples, AL; Lipton, R; Cheng, S; Shuldiner, AR			Unique lipoprotein phenotype and genotype associated with exceptional longevity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTER TRANSFER PROTEIN; HIGH-DENSITY-LIPOPROTEINS; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; PARTICLE-SIZE; GENE POLYMORPHISMS; HEPATIC LIPASE; HDL; ATHEROSCLEROSIS; CHOLESTEROL	Context Individuals with exceptional longevity have a lower incidence and/or significant delay in the onset of age-related disease, and their family members may inherit biological factors that modulate aging processes and disease susceptibility. Objective To identify specific biological and genetic factors that are associated with or reliably define a human longevity phenotype. Design, Setting, and Participants In a case-control design, 213 Ashkenazi Jewish probands with exceptional longevity (mean [SDI age, 98.2 [5.3] years) and their offspring (n=216; mean [SD] age, 68.3 [6.7] years) were recruited from 1998 to 2002, while an age-matched control group of Ashkenazi Jews (n=258) and participants from the Framingham Offspring Study (n = 589) were accepted as control groups. Main Outcome Measures Detailed questionnaires, physical examination, and blood samples were taken, including assessment of lipids and lipoprotein subclass levels and particle sizes by proton nuclear magnetic resonance. Samples were also genotyped for the codon 405 isoleucine to valine (1405V) variation in the cholesteryl ester transfer protein (CETP) gene, which is involved in regulation of lipoprotein and its particle sizes. Results High-density lipoprotein (HDL) and low-density lipoprotein (LDL) particle sizes were significantly higher in probands compared with both control groups (P=.001 for both), independent of plasma levels of HDL and LDL cholesterol and apolipoprotein A1 and B. This phenotype was also typical of the proband's offspring but not of the age-matched controls. The HDL and LDL particle sizes were significantly larger in offspring and controls without hypertension or cardiovascular disease, (P=.001 and P=.008, respectively). Furthermore, lipoprotein particle sizes, but not plasma LDL levels, were significantly higher in offspring and controls without the metabolic syndrome (P<.001). Probands and offspring had a 2.9- and 3.6-fold (in men) and 2.7- and 1.5-fold (in women) increased frequency, respectively, of homozygosity for the 405 valine allele of CETP (VV genotype), respectively, compared with controls (P<.001 for both). Those probands with the VV genotype had increased lipoprotein sizes and lower serum CETP concentrations. Conclusions Individuals with exceptional longevity and their offspring have significantly larger HDL and LDL particle sizes. This phenotype is associated with a lower prevalence of hypertension, cardiovascular disease, the metabolic syndrome, and increased homozygosity for the 1405V variant in CETP. These findings suggest that lipoprotein particle sizes are heritable and promote a healthy aging phenotype.	Yeshiva Univ Albert Einstein Coll Med, Inst Aging Res, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Community & Family Med, Bronx, NY 10461 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Baltimore, MD USA; Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Roche Mol Syst Inc, Dept Human Genet, Alameda, CA USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University System of Maryland; University of Maryland Baltimore; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; Tufts University; United States Department of Agriculture (USDA); Boston University; Roche Holding	Barzilai, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Inst Aging Res, Ctr Diabet Res & Training, Belfer Bldg 701,1300 Morris Pk Ave, Bronx, NY 10461 USA.	barzilai@aecom.yu.edu		Cupples, L. Adrienne/0000-0003-0273-7965; Shuldiner, Alan/0000-0001-9921-4305	NCRR NIH HHS [M01-RR12248] Funding Source: Medline; NIA NIH HHS [R01 AG-18728-01A1] Funding Source: Medline; NIDDK NIH HHS [DK 20541] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR012248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541, P30DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018728] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arai T, 2000, CLIN CHIM ACTA, V301, P103, DOI 10.1016/S0009-8981(00)00328-4; Arai Y, 2003, J MOL MED, V81, P102, DOI 10.1007/s00109-002-0407-6; Asztalos BF, 2002, J LIPID RES, V43, P1701, DOI 10.1194/jlr.M200037-JLR200; Atzmon G, 2002, J GERONTOL A-BIOL, V57, pM712, DOI 10.1093/gerona/57.11.M712; ATZMON G, IN PRESS J AM GERIAT; Austin M A, 2000, Curr Atheroscler Rep, V2, P200, DOI 10.1007/s11883-000-0021-4; AUSTIN MA, 1993, GENET EPIDEMIOL, V10, P599, DOI 10.1002/gepi.1370100645; Barzilai N, 1999, J GERONTOL A-BIOL, V54, pB89, DOI 10.1093/gerona/54.3.B89; Barzilai N, 2001, J AM GERIATR SOC, V49, P76, DOI 10.1046/j.1532-5415.2001.49013.x; Barzilai N, 2001, J GERONTOL A-BIOL, V56, pM83, DOI 10.1093/gerona/56.2.M83; Blake GJ, 2002, CIRCULATION, V106, P1930, DOI 10.1161/01.CIR.0000033222.75187.B9; Boekholdt SM, 2003, J LIPID RES, V44, P1080, DOI 10.1194/jlr.R200018-JLR200; Bruce C, 1998, J LIPID RES, V39, P1071; Cheng S, 1999, GENOME RES, V9, P936, DOI 10.1101/gr.9.10.936; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Falconer D. S., 1996, INTRO QUANTATIVE GEN; FUNKE H, 1994, CIRCULATION, V90, P241; Garvey WT, 2003, DIABETES, V52, P453, DOI 10.2337/diabetes.52.2.453; Goto A, 2001, ATHEROSCLEROSIS, V159, P153, DOI 10.1016/S0021-9150(01)00476-2; Grundy SM, 1999, J LIPID RES, V40, P229; Gudnason V, 1999, EUR J CLIN INVEST, V29, P116, DOI 10.1046/j.1365-2362.1999.00412.x; Herrera VLM, 1999, NAT MED, V5, P1383, DOI 10.1038/70956; IKEWAKI K, 1995, J CLIN INVEST, V96, P1573, DOI 10.1172/JCI118196; Kakko S, 2000, EUR J CLIN INVEST, V30, P18; Kakko S, 2001, EUR J CLIN INVEST, V31, P593, DOI 10.1046/j.1365-2362.2001.00859.x; Kraus WE, 2002, NEW ENGL J MED, V347, P1483, DOI 10.1056/NEJMoa020194; Kuivenhoven JA, 1997, ARTERIOSCL THROM VAS, V17, P560, DOI 10.1161/01.ATV.17.3.560; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; Lancaster, 1997, Medscape Womens Health, V2, P7; Libby P, 2001, AM J CARDIOL, V88, p3N; Okumura K, 2002, ATHEROSCLEROSIS, V161, P425, DOI 10.1016/S0021-9150(01)00653-0; Otvos James D, 2002, Clin Lab, V48, P171; OTVOS JD, 1992, CLIN CHEM, V38, P1632; Pascot A, 2002, ATHEROSCLEROSIS, V160, P399, DOI 10.1016/S0021-9150(01)00579-2; Perls T, 2002, MECH AGEING DEV, V123, P231, DOI 10.1016/S0047-6374(01)00348-7; Perls TT, 2002, P NATL ACAD SCI USA, V99, P8442, DOI 10.1073/pnas.122587599; Puca AA, 2001, P NATL ACAD SCI USA, V98, P10505, DOI 10.1073/pnas.181337598; Rader DJ, 2000, MOL MED TODAY, V6, P170, DOI 10.1016/S1357-4310(00)01673-7; SAKAI N, 1995, EUR J CLIN INVEST, V25, P332, DOI 10.1111/j.1365-2362.1995.tb01710.x; SCHAEFER EJ, 1994, J LIPID RES, V35, P779; Verghese J, 2002, NEW ENGL J MED, V347, P1761, DOI 10.1056/NEJMoa020441; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764	43	428	451	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2030	2040		10.1001/jama.290.15.2030	http://dx.doi.org/10.1001/jama.290.15.2030			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CX	14559957				2022-12-24	WOS:000185924200027
J	Kannus, P; Parkkari, J; Khan, K				Kannus, P; Parkkari, J; Khan, K			Hip protectors need an evidence base	LANCET			English	Editorial Material							OSTEOPOROTIC FRACTURES; FALLING CONDITIONS; IMPACT; PREVENTION; FORCE		Tampere Univ, Sch Med, Dept Surg, FIN-33520 Tampere, Finland; Univ Hosp, FIN-33520 Tampere, Finland; Tampere Res Ctr Sports Med, UKK Inst Hlth Promot Res, Tampere, Finland; Univ British Columbia, Dept Family Practice, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, BC Womens Hosp Osteoporosis Program, Vancouver, BC V5Z 1M9, Canada	Tampere University; UKK Institute; University of British Columbia; University of British Columbia	Kannus, P (corresponding author), Tampere Univ, Sch Med, Dept Surg, FIN-33520 Tampere, Finland.							Birks YF, 2003, AGE AGEING, V32, P442, DOI 10.1093/ageing/32.4.442; Colon-Emeric CS, 2003, AGE AGEING, V32, P47, DOI 10.1093/ageing/32.1.47; Dennison E, 2000, HORM RES, V54, P58, DOI 10.1159/000053299; Dolan P, 1998, OSTEOPOROSIS INT, V8, P611, DOI 10.1007/s001980050107; Ekman A, 1997, LANCET, V350, P563, DOI 10.1016/S0140-6736(05)63140-6; Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101; Kannus P, 1999, LANCET, V353, P802, DOI 10.1016/S0140-6736(98)04235-4; Kannus P, 1999, BONE, V25, P229, DOI 10.1016/S8756-3282(99)00154-4; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; McColl A, 1998, J PUBLIC HEALTH MED, V20, P196, DOI 10.1093/oxfordjournals.pubmed.a024743; PARKKARI J, 1995, J BONE MINER RES, V10, P1437; Parkkari J, 1997, CALCIFIED TISSUE INT, V60, P354, DOI 10.1007/s002239900242; Parkkari J, 1998, AGE AGEING, V27, P225, DOI 10.1093/ageing/27.2.225; Parkkari J, 1999, CALCIFIED TISSUE INT, V65, P183; Wei TS, 2001, OSTEOPOROSIS INT, V12, P1050, DOI 10.1007/PL00004184	15	15	15	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1168	1169		10.1016/S0140-6736(03)14554-0	http://dx.doi.org/10.1016/S0140-6736(03)14554-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568734				2022-12-24	WOS:000185924100004
J	Konje, JC; Huppertz, B; Bell, SC; Taylor, DJ; Kaufmann, P				Konje, JC; Huppertz, B; Bell, SC; Taylor, DJ; Kaufmann, P			3-dimensional colour power angiography for staging human placental development	LANCET			English	Article							ANGIOGENESIS	Maldevelopment of placental villous trees and their blood vessels results in impaired fetal growth, which can greatly compromise fetal, neonatal, childhood, and adulthood health. There are no means of directly assessing such maldevelopment. We have applied a new technique of imaging (colour power angiography [CPA]) with 3-dimensional reconstruction to assess directly villous development in human pregnancy in vivo in 20 uncomplicated pregnancies from 13 to 38 weeks' gestation. The chronology of villous trees was much the same in 3-dimensional CPA, scanning electron micrography, and classical histology from controls matched by age. This approach provides a unique opportunity to examine normal placental development directly, and should provide the bases for real-time investigation of placental pathology and a robust method for diagnosis and surveillance during pregnancy.	Univ Leicester, Dept Obstet & Gynaecol, Fetal Growth & Dev Res Grp, Leicester, Leics, England; Univ Technol, Univ Hosp, Inst Anat 2, Aachen, Germany	University of Leicester; RWTH Aachen University; RWTH Aachen University Hospital	Konje, JC (corresponding author), Univ Leicester, Dept Obstet & Gynaecol, Fetal Growth & Dev Res Grp, Leicester, Leics, England.	jck4@le.ac.uk	Huppertz, Berthold/I-2331-2019	Huppertz, Berthold/0000-0003-4814-2158				BERNISCHKE K, 2000, PATHOLOGY HUMAN PLAC; GRANNUM PAT, 1979, AM J OBSTET GYNECOL, V133, P915, DOI 10.1016/0002-9378(79)90312-0; Kadyrov M, 1998, LANCET, V352, P1747, DOI 10.1016/S0140-6736(98)02069-8; KAUFMANN P, 1987, PLACENTA, V8, P235, DOI 10.1016/0143-4004(87)90047-6; Todros T, 1999, OBSTET GYNECOL, V93, P499, DOI 10.1016/S0029-7844(98)00440-2	5	36	36	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1199	1201		10.1016/S0140-6736(03)14514-X	http://dx.doi.org/10.1016/S0140-6736(03)14514-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568743				2022-12-24	WOS:000185924100013
J	Binswanger, HP				Binswanger, HP			Willingness to pay for AIDS treatment: myths and realities	LANCET			English	Editorial Material									World Bank, Africa Reg, Washington, DC 20433 USA	The World Bank	Binswanger, HP (corresponding author), World Bank, Africa Reg, 1818 H St NW, Washington, DC 20433 USA.		Binswanger, Hans/M-6883-2013	Binswanger, Hans/0000-0002-6323-1418				BINSWANGER H, 2002, 14 C AIDS BARC JUL 7; Binswanger HP, 2001, SCIENCE, V292, P221, DOI 10.1126/science.1057504; DESCLAUX A, 2001, INITIATIVE SENEGALAI; DO M, 14 INT HIV AIDS C 20; DONNELLY J, 2001, BOSTON GLOBE BO 0607, P8; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; MSELLATI P, 2002, ACCES TRAITEMENTS VI; RIVERS B, FILLING FUNDING GAP; ROSEN S, 2003, HARVARD BUSINESS FEB, P80; SIMON J, 2000, HIV AIDS COMMONWEALT, P4; *UNAIDS, FACT SHEET IMPACT HI; *UNAIDS, 2002, GLOB AIDS EP BARC JU; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; World Health Organization, 2002, SCAL ANT THER RES LT	14	9	9	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 4	2003	362	9390					1152	1153		10.1016/S0140-6736(03)14473-X	http://dx.doi.org/10.1016/S0140-6736(03)14473-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728HA	14550705				2022-12-24	WOS:000185710700026
J	Webber, LJ; Stubbs, S; Stark, J; Trew, GH; Margara, R; Hardy, K; Franks, S				Webber, LJ; Stubbs, S; Stark, J; Trew, GH; Margara, R; Hardy, K; Franks, S			Formation and early development of follicles in the polycystic ovary	LANCET			English	Article							TERM-FOLLOW-UP; WOMEN; HORMONE; GROWTH; CELLS	Background Polycystic ovary syndrome is the most common cause of anovulatory infertility. It has long-term health implications and is an important risk factor for type 2 diabetes. However, little is known about the cause of polycystic ovaries. We have used detailed morphological analysis to assess the hypothesis that there is an intrinsic ovarian abnormality that affects the earliest stages of follicular development. Methods We took small cortical biopsies during routine laparoscopy from 24 women with normal ovaries and regular cycles and from 32 women with polycystic ovaries, 16 of whom had regular, ovulatory cycles and 16 of whom had oligomenorrhoea. We used computerised image analysis to assess the density and developmental stage of small preantral follicles in serial sections of fixed tissue. Findings Median density of small preantral follicles, including those at primordial and primary stages, was six-fold greater in biopsies from polycystic ovaries in anovulatory women than in normal ovaries (p=0.009). In both ovulatory and anovulatory women with polycystic ovaries, we noted a significant increase in the percentage of early growing (primary) follicles and a reciprocal decrease in the proportion of primordial follicles compared with normal ovaries. Interpretation Our findings indicate that there are fundamental differences between polycystic and normal ovaries in early follicular development, suggesting an intrinsic ovarian abnormality. The increased density of small preantral follicles in polycystic ovaries could result from increased population of the fetal ovary by germ cells, or from decreased rate of loss of oocytes during late gestation, childhood, and puberty.	Hammersmith Hosp, Imperial Coll London, Inst Reprod & Dev Biol, Wolfson & Weston Res Ctr Family Hlth, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Dept Math, London SW7 2AZ, England	Imperial College London; Imperial College London	Franks, S (corresponding author), Hammersmith Hosp, Imperial Coll London, Inst Reprod & Dev Biol, Wolfson & Weston Res Ctr Family Hlth, London W12 0NN, England.	s.franks@imperial.ac.uk	Norman, Robert J/A-1155-2007	Norman, Robert J/0000-0002-3118-3896; Webber, Lisa/0000-0003-3129-9212				Abbott DH, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740001; BAKER TG, 1963, PROC R SOC SER B-BIO, V158, P417, DOI 10.1098/rspb.1963.0055; BALEN AH, 1995, HUM REPROD, V10, P2107, DOI 10.1093/oxfordjournals.humrep.a136243; DAHLGREN E, 1992, FERTIL STERIL, V57, P505; DUNAIF A, 1987, J CLIN ENDOCR METAB, V65, P499, DOI 10.1210/jcem-65-3-499; Durlinger ALL, 2002, ENDOCRINOLOGY, V143, P1076, DOI 10.1210/en.143.3.1076; FARQUHAR CM, 1994, AUST NZ J OBSTET GYN, V34, P67, DOI 10.1111/j.1479-828X.1994.tb01041.x; Franks S, 1997, HUM REPROD, V12, P2641, DOI 10.1093/humrep/12.12.2641; FRANKS S, 1989, CLIN ENDOCRINOL, V31, P87, DOI 10.1111/j.1365-2265.1989.tb00457.x; GillingSmith C, 1997, CLIN ENDOCRINOL, V47, P93, DOI 10.1046/j.1365-2265.1997.2321049.x; GILLINGSMITH C, 1994, J CLIN ENDOCR METAB, V79, P1158, DOI 10.1210/jc.79.4.1158; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; Gougeon A, 1996, ENDOCR REV, V17, P121, DOI 10.1210/er.17.2.121; Hovatta O, 1997, HUM REPROD, V12, P1032; Hughesdon P E, 1982, Obstet Gynecol Surv, V37, P59, DOI 10.1097/00006254-198202000-00001; KURILO LF, 1981, HUM GENET, V57, P86; Lass A, 1997, HUM REPROD, V12, P1028; MELICA F, 1995, INT J FERTIL MENOP S, V40, P79; POLSON DW, 1988, LANCET, V1, P870; ROBINSON S, 1993, CLIN ENDOCRINOL, V39, P351, DOI 10.1111/j.1365-2265.1993.tb02376.x; Teixeira FL, 2002, J CLIN ENDOCR METAB, V87, P1337, DOI 10.1210/jc.87.3.1337; Vendola K, 1999, HUM REPROD, V14, P2328, DOI 10.1093/humrep/14.9.2328; Wild S, 2000, CLIN ENDOCRINOL, V52, P595, DOI 10.1046/j.1365-2265.2000.01000.x; Willis DS, 1998, J CLIN ENDOCR METAB, V83, P3984, DOI 10.1210/jc.83.11.3984; Wright CS, 1999, HUM REPROD, V14, P1555, DOI 10.1093/humrep/14.6.1555; Zawadzki JK, 1992, POLYCYSTIC OVARY SYN, P59	26	311	335	1	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1017	1021		10.1016/S0140-6736(03)14410-8	http://dx.doi.org/10.1016/S0140-6736(03)14410-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522531				2022-12-24	WOS:000185564600008
J	Caldeira, K; Wickett, ME				Caldeira, K; Wickett, ME			Anthropogenic carbon and ocean pH	NATURE			English	Editorial Material							DIOXIDE; CYCLE; CO2		Lawrence Livermore Natl Lab, Energy & Environm Directorate, Livermore, CA 94550 USA; Lawrence Livermore Natl Lab, Ctr Appl Sci Comp, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Caldeira, K (corresponding author), Lawrence Livermore Natl Lab, Energy & Environm Directorate, 7000 East Ave, Livermore, CA 94550 USA.	kenc@llnl.gov	Moe, Kaitlin/P-5316-2019; Caldeira, Ken/E-7914-2011	Caldeira, Ken/0000-0002-4591-643X				Beerling DJ, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001637; CALDEIRA K, 1993, PALEOCEANOGRAPHY, V8, P515, DOI 10.1029/93PA01163; Caldeira K, 2000, GEOPHYS RES LETT, V27, P225, DOI 10.1029/1999GL002364; Caldeira K, 2000, SCIENCE, V287, P620, DOI 10.1126/science.287.5453.620; Caldeira K., 1999, SCIENCE, V286, P2043, DOI DOI 10.1126/SCIENCE.286.5447.2043A; CROWLEY TJ, 2001, SCIENCE, V292, P780; Houghton JT, 2001, CONTRIBUTION WORKING; Kleypas JA, 1999, SCIENCE, V284, P118, DOI 10.1126/science.284.5411.118; MARLAND G, 2002, TRENDS COMPENDIUM DA; Pan J., 2001, CLIMATE CHANGE 2001; Riebesell U, 2000, NATURE, V407, P364, DOI 10.1038/35030078; SANYAL A, 1995, NATURE, V373, P234, DOI 10.1038/373234a0; Seibel BA, 2001, SCIENCE, V294, P319, DOI 10.1126/science.1065301	13	2375	2502	35	1010	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					365	365		10.1038/425365a	http://dx.doi.org/10.1038/425365a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508477	Green Published			2022-12-24	WOS:000185502300029
J	Holmes, KC; Angert, I; Kull, FJ; Jahn, W; Schroder, RR				Holmes, KC; Angert, I; Kull, FJ; Jahn, W; Schroder, RR			Electron cryo-microscopy shows how strong binding of myosin to actin releases nucleotide	NATURE			English	Article							RABBIT SKELETAL-MUSCLE; MOTOR DOMAIN; COMPLEX; CONTRACTION; VISUALIZATION; ACTOMYOSIN; MICROSCOPY; MOLSCRIPT; MECHANISM; KINESIN	Muscle contraction involves the cyclic interaction of the myosin cross-bridges with the actin filament, which is coupled to steps in the hydrolysis of ATP(1). While bound to actin each cross-bridge undergoes a conformational change, often referred to as the "power stroke"(2), which moves the actin filament past the myosin filaments; this is associated with the release of the products of ATP hydrolysis and a stronger binding of myosin to actin. The association of a new ATP molecule weakens the binding again, and the attached cross-bridge rapidly dissociates from actin. The nucleotide is then hydrolysed, the conformational change reverses, and the myosin cross-bridge reattaches to actin. X-ray crystallography has determined the structural basis of the power stroke, but it is still not clear why the binding of actin weakens that of the nucleotide and vice versa. Here we describe, by fitting atomic models of actin and the myosin cross-bridge into high-resolution electron cryo-microscopy three-dimensional reconstructions, the molecular basis of this linkage. The closing of the actin-binding cleft when actin binds is structurally coupled to the opening of the nucleotide-binding pocket.	Max Planck Inst Med Res, Dept Biophys, D-69120 Heidelberg, Germany	Max Planck Society	Holmes, KC (corresponding author), Max Planck Inst Med Res, Dept Biophys, Jahnstr 29, D-69120 Heidelberg, Germany.		Schröder, Rasmus R/S-6220-2016	Holmes, Kenneth/0000-0001-8894-9453				Angert I, 2000, ULTRAMICROSCOPY, V81, P203, DOI 10.1016/S0304-3991(99)00190-4; CONIBEAR PB, IN PRESS NATURE STRU; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Geeves M. A., 1995, Biophysical Journal, V68, P194; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; JAHN W, 1995, J MICROSC-OXFORD, V179, P333, DOI 10.1111/j.1365-2818.1995.tb03649.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; LOBAU V, 1997, THESIS U STUTTGART; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Naber N, 2003, SCIENCE, V300, P798, DOI 10.1126/science.1082374; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REUBOLD T, IN PRESS NATURE STRU; Sasaki N, 1999, J BIOL CHEM, V274, P37840, DOI 10.1074/jbc.274.53.37840; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SCHROEDER RR, 2002, P 15 INT C EL MICR, V3, P443; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; Volkmann N, 2003, P NATL ACAD SCI USA, V100, P3227, DOI 10.1073/pnas.0536510100; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; YAGLE AE, 1999, DISCRETE TOMOGRAPHY; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200	31	300	303	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					423	427		10.1038/nature02005	http://dx.doi.org/10.1038/nature02005			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508495				2022-12-24	WOS:000185502300047
J	Konishi, A; Shimizu, S; Hirota, J; Takao, T; Fan, YH; Matsuoka, Y; Zhang, LL; Yoneda, Y; Fujii, Y; Skouitchi, AI; Tsujimoto, Y				Konishi, A; Shimizu, S; Hirota, J; Takao, T; Fan, YH; Matsuoka, Y; Zhang, LL; Yoneda, Y; Fujii, Y; Skouitchi, AI; Tsujimoto, Y			Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks	CELL			English	Article							CYTOCHROME-C RELEASE; BCL-2 PROTEIN FAMILY; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; P53-DEPENDENT APOPTOSIS; IN-VIVO; P53-INDUCED APOPTOSIS; CONFORMATIONAL-CHANGE; BAX; P53	It is poorly understood how apoptotic signals arising from DNA damage are transmitted to mitochondria, which release apoptogenic factors into the cytoplasm that activate downstream destruction programs. Here, we identify histone H1.2 as a cytochrome c-releasing factor that appears in the cytoplasm after exposure to X-ray irradiation. While all nuclear histone H1 forms are released into the cytoplasm in a p53-dependent manner after irradiation, only H1.2, but not other H1 forms, induced cytochrome c release from isolated mitochondria in a Bak-dependent manner. Reducing H1.2 expression enhanced cellular resistance to apoptosis induced by X-ray irradiation or etoposide, but not that induced by other stimuli including TNF-alpha and UV irradiation. H1.2-deficient mice exhibited increased cellular resistance in thymocytes and the small intestine to X-ray-induced apoptosis. These results indicate that histone H1.2 plays an important role in transmitting apoptotic signals from the nucleus to the mitochondria following DNA double-strand breaks.	Osaka Univ, Sch Med, Dept Post Genom & Dis, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, JST, SORST, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, JST, CREST, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka 5650871, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Osaka University; Osaka University; Nagoya City University; Nagoya City University; Yeshiva University; Albert Einstein College of Medicine	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Post Genom & Dis, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp	Konishi, Akimitsu/J-4024-2019	Konishi, Akimitsu/0000-0002-3291-0821	NCI NIH HHS [R01 CA079057] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Albig W, 1997, HUM GENET, V101, P284, DOI 10.1007/s004390050630; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Attardi LD, 2000, GENE DEV, V14, P704; Bleher R, 1999, CHROMOSOMA, V108, P308, DOI 10.1007/s004120050382; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Fan YH, 2001, MOL CELL BIOL, V21, P7933, DOI 10.1128/MCB.21.23.7933-7943.2001; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Franke K, 1998, BBA-GENE STRUCT EXPR, V1398, P232, DOI 10.1016/S0167-4781(98)00062-1; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kratzmeier M, 1999, BIOCHEM J, V337, P319, DOI 10.1042/0264-6021:3370319; LENNOX RW, 1983, J BIOL CHEM, V258, P262; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MATSUOKA Y, 1994, J CELL SCI, V107, P693; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PEPE I, 1990, BIOCHIM BIOPHYS ACTA, V1041, P14, DOI 10.1016/0167-4838(90)90116-W; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Shimizu S, 1996, ONCOGENE, V12, P2251; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Tanaka M, 2001, DEVELOPMENT, V128, P655; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vignali M, 1998, NAT STRUCT BIOL, V5, P1025, DOI 10.1038/4133; Vila R, 2000, PROTEIN SCI, V9, P627; Wang XD, 2001, GENE DEV, V15, P2922; Wang ZF, 1997, J MOL BIOL, V271, P124, DOI 10.1006/jmbi.1997.1166; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wolf BB, 2002, CURR BIOL, V12, pR177, DOI 10.1016/S0960-9822(02)00736-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	59	253	269	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					673	688		10.1016/S0092-8674(03)00719-0	http://dx.doi.org/10.1016/S0092-8674(03)00719-0			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505568	Bronze			2022-12-24	WOS:000185464000006
J	Xu, L; Wei, Y; Reboul, J; Vaglio, P; Shin, TH; Vidal, M; Elledge, SJ; Harper, JW				Xu, L; Wei, Y; Reboul, J; Vaglio, P; Shin, TH; Vidal, M; Elledge, SJ; Harper, JW			BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3	NATURE			English	Article							CAENORHABDITIS-ELEGANS; C-ELEGANS; CYCLIN-E; DEGRADATION; GENE; FAMILY; MEI-1	Programmed destruction of regulatory proteins through the ubiquitin-proteasome system is a widely used mechanism for controlling signalling pathways(1,2). Cullins(3) are proteins that function as scaffolds for modular ubiquitin ligases typified by the SCF (Skp1-Cul1-F-box) complex(4-6). The substrate selectivity of these E3 ligases is dictated by a specificity module that binds cullins. In the SCF complex, this module is composed of Skp1, which binds directly to Cul1, and a member of the F-box family of proteins(4-7). F-box proteins bind Skp1 through the F-box motif(7), and substrates by means of carboxy-terminal protein interaction domains(1,2,5). Similarly, Cul2 and Cul5 interact with BC-box-containing specificity factors through the Skp1-like protein elongin C-2. Cul3 is required for embryonic development in mammals and Caenorhabditis elegans(8-10) but its specificity module is unknown. Here we report the identification of a large family of BTB-domain proteins as substrate-specific adaptors for C. elegans CUL-3. Biochemical studies using the BTB protein MEL-26 and its genetic target MEI-1 (refs 12, 13) indicate that BTB proteins merge the functional properties of Skp1 and F-box proteins into a single polypeptide.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell & Mol Biol, Houston, TX 77030 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Harper, JW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.	wade_harper@hms.harvard.edu	Reboul, Jerome/P-9103-2016	Reboul, Jerome/0000-0002-5513-4546; Vaglio, Philippe/0000-0003-2900-5596; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG011085] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dow MR, 1998, GENETICS, V150, P119; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; PINTARD L, 2003, NATURE          0903, DOI DOI 10.1038/NATURE01959; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Srayko M, 2000, GENE DEV, V14, P1072; Uren AG, 1996, TRENDS BIOCHEM SCI, V21, P244, DOI 10.1016/0968-0004(96)30022-4; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Winston JT, 1999, GENE DEV, V13, P2751, DOI 10.1101/gad.13.21.2751; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	23	378	396	1	35	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 18	2003	425	6955					316	321		10.1038/nature01985	http://dx.doi.org/10.1038/nature01985			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679922				2022-12-24	WOS:000185370900050
J	Sharp, D				Sharp, D			Faster, higher, stronger ... and deeper?	LANCET			English	Editorial Material							SCUBA-DIVERS		Lancet, London NW1 7BY, England		Sharp, D (corresponding author), Lancet, 32 Jamestown Rd, London NW1 7BY, England.							*BBC NEWS, TIT BOUGHT NAT; *INT ASS DEV APN, 2002, REG REC REC VERS 5 2; *INT ASS FREE DIV, IAFDS OFF REP A MEST; Nakayama H, 2003, EMERG MED J, V20, P332, DOI 10.1136/emj.20.4.332; Taylor DM, 2003, WILD ENVIRON MED, V14, P83, DOI 10.1580/1080-6032(2003)014[0083:ESDIAA]2.0.CO;2	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					846	846		10.1016/S0140-6736(03)14349-8	http://dx.doi.org/10.1016/S0140-6736(03)14349-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678969				2022-12-24	WOS:000185329400006
J	Papineni, P				Papineni, P			Children of bad memories	LANCET			English	Article									UCL, Int Hlth & Med Educ Ctr, London N19 5LW, England	University of London; University College London	Papineni, P (corresponding author), UCL, Int Hlth & Med Educ Ctr, London N19 5LW, England.	p.papineni@ucl.ac.uk		Papineni, Padmasayee/0000-0001-6923-1542				Carpenter RC, 2000, HUM RIGHTS QUART, V22, P428, DOI 10.1353/hrq.2000.0020; *HUM RIGHTS WATCH, 1996, SHATT LIV SEX VIOL R; Lewis M, 1998, SHAME INTERPERSONAL; SANDHER H, 2000, WOMEN VIOLENCE WAR W; Stiglmayer Alexandra, 1994, MASS RAPE WAR WOMEN	5	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					825	826		10.1016/S0140-6736(03)14277-8	http://dx.doi.org/10.1016/S0140-6736(03)14277-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	719DN	13678880				2022-12-24	WOS:000185188500025
J	Pacala, SW; Bulte, E; List, JA; Levin, SA				Pacala, SW; Bulte, E; List, JA; Levin, SA			False alarm over environmental false alarms	SCIENCE			English	Editorial Material							ECONOMIC-GROWTH; KUZNETS CURVE; AIR-POLLUTION		Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Tilburg Univ, Dept Econ, NL-5000 LE Tilburg, Netherlands; Univ Maryland, Dept Econ, College Pk, MD 20742 USA; Univ Maryland, AREC Dept, Presidents Council Econ Advisers, College Pk, MD 20742 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA	Princeton University; Tilburg University; University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; National Bureau of Economic Research	Pacala, SW (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.		Levin, Simon A/J-1218-2014	Levin, Simon A/0000-0002-8216-5639; List, John/0000-0002-1740-3848; Bulte, Erwin/0000-0001-9491-5268				Andreoni J, 2001, J PUBLIC ECON, V80, P269, DOI 10.1016/S0047-2727(00)00110-9; AOROA S, 1998, S EC J, V65, P691; ARROW K, 1995, SCIENCE, V268, P520, DOI 10.1126/science.268.5210.520; GROSSMAN GM, 1995, Q J ECON, V110, P353, DOI 10.2307/2118443; Grubb M, 2002, ANNU REV ENERG ENV, V27, P271, DOI 10.1146/annurev.energy.27.122001.083408; Jaeger W., 1998, THEORETICAL BASIS EN; Kinzig AP, 2003, AMBIO, V32, P330, DOI 10.1639/0044-7447(2003)032[0330:CWUACF]2.0.CO;2; Lesser J. A., 1997, ENV EC POLICY; LOMBORG B, 2001, SKEPTICAL ENV, P168; LUTTER R, 2000, REGULATION, V23; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; SELDEN TM, 1994, J ENVIRON ECON MANAG, V27, P147, DOI 10.1006/jeem.1994.1031; VISCUSI WK, 1993, J ECON LIT, V31, P1912; POLLUTION ABATEMENT	14	18	18	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1187	1188		10.1126/science.1086646	http://dx.doi.org/10.1126/science.1086646			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	715ZC	12947184	Green Published			2022-12-24	WOS:000185003500025
J	Takagi, J; Yang, YT; Liu, JH; Wang, JH; Springer, TA				Takagi, J; Yang, YT; Liu, JH; Wang, JH; Springer, TA			Complex between nidogen and laminin fragments reveals a paradigmatic beta-propeller interface	NATURE			English	Article							BASEMENT-MEMBRANE FORMATION; RECEPTOR-RELATED PROTEIN-5; EGF-LIKE MOTIF; GAMMA-1 CHAIN; BINDING-SITE; BONE-DENSITY; MODULE; GENE; PROTEOGLYCAN; LIPOPROTEIN	Basement membranes are fundamental to tissue organization and physiology in all metazoans. The interaction between laminin and nidogen is crucial to the assembly of basement membranes(1-4). The structure of the interacting domains reveals a six-bladed Tyr-Trp-Thr-Asp (YWTD) beta-propeller domain in nidogen bound to laminin epidermal-growth-factor-like (LE) modules III3-5 in laminin (LE3-5). Laminin LE module 4 binds to an amphitheatre-shaped surface on the pseudo-6-fold axis of the beta-propeller, and LE module 3 binds over its rim. A Phe residue that shutters the water-filled central aperture of the beta-propeller, the rigidity of the amphitheatre, and high shape complementarity enable the construction of an evolutionarily conserved binding surface for LE4 of unprecedentedly high affinity for its small size(5). Hypermorphic mutations in the Wnt co-receptor LRP5 (refs 6-9) suggest that a similar YWTD beta-propeller interface is used to bind ligands that function in developmental pathways. A related interface, but shifted off-centre from the pseudo-6-fold axis and lacking the shutter over the central aperture, is used in the low-density lipoprotein receptor for an intramolecular interaction that is regulated by pH in receptor recycling(10).	Ctr Blood Res, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Wang, JH (corresponding author), Ctr Blood Res, 800 Huntington Ave, Boston, MA 02115 USA.							Baumgartner R, 1996, J MOL BIOL, V257, P658, DOI 10.1006/jmbi.1996.0192; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dong LJ, 2002, LAB INVEST, V82, P1617, DOI 10.1097/01.LAB.0000042240.52093.0F; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Jeon H, 2001, NAT STRUCT BIOL, V8, P499, DOI 10.1038/88556; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Mayer U, 1997, EUR J BIOCHEM, V245, P745, DOI 10.1111/j.1432-1033.1997.t01-1-00745.x; Mayer U, 1998, ANN NY ACAD SCI, V857, P130, DOI 10.1111/j.1749-6632.1998.tb10113.x; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; Murshed M, 2000, MOL CELL BIOL, V20, P7007, DOI 10.1128/MCB.20.18.7007-7012.2000; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; Poschl E, 1996, EMBO J, V15, P5154, DOI 10.1002/j.1460-2075.1996.tb00899.x; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schymeinsky J, 2002, MOL CELL BIOL, V22, P6820, DOI 10.1128/MCB.22.19.6820-6830.2002; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; TIMPL R, 1999, GUIDEBOOK EXTRACELLU, P455; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Willem M, 2002, DEVELOPMENT, V129, P2711; YNES RO, 2000, J CELL BIOL, V150, pF89	30	116	122	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					969	974		10.1038/nature01873	http://dx.doi.org/10.1038/nature01873			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931195				2022-12-24	WOS:000184843600048
J	Rokas, A; Williams, BL; King, N; Carroll, SB				Rokas, A; Williams, BL; King, N; Carroll, SB			Genome-scale approaches to resolving incongruence in molecular phylogenies	NATURE			English	Article							COMBINING DATA; SEQUENCE DATA; GENES; DNA; COMPLEX; DUPLICATION; EVOLUTION; POSITION; TREES	One of the most pervasive challenges in molecular phylogenetics is the incongruence between phylogenies obtained using different data sets, such as individual genes. To systematically investigate the degree of incongruence, and potential methods for resolving it, we screened the genome sequences of eight yeast species and selected 106 widely distributed orthologous genes for phylogenetic analyses, singly and by concatenation. Our results suggest that data sets consisting of single or a small number of concatenated genes have a significant probability of supporting conflicting topologies. By contrast, analyses of the entire data set of concatenated genes yielded a single, fully resolved species tree with maximum support. Comparable results were obtained with a concatenation of a minimum of 20 genes; substantially more genes than commonly used but a small fraction of any genome. These results have important implications for resolving branches of the tree of life.	Univ Wisconsin, Howard Hughes Med Inst, Mol Biol Lab, RM Bock Labs, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, Mol Biol Lab, RM Bock Labs, 1525 Linden Dr, Madison, WI 53706 USA.	sbcarrol@wisc.edu	Rokas, Antonis/A-9775-2008	Rokas, Antonis/0000-0002-7248-6551				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Averof M, 2000, SCIENCE, V287, P1283, DOI 10.1126/science.287.5456.1283; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; Bergthorsson U, 2003, NATURE, V424, P197, DOI 10.1038/nature01743; Blair JE, 2002, BMC EVOL BIOL, V2, DOI 10.1186/1471-2148-2-7; Brown JR, 2001, NAT GENET, V28, P281, DOI 10.1038/90129; BULL JJ, 1993, SYST BIOL, V42, P384, DOI 10.2307/2992473; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; CUMMINGS MP, 1995, MOL BIOL EVOL, V12, P814; Cunningham CW, 1997, MOL BIOL EVOL, V14, P733, DOI 10.1093/oxfordjournals.molbev.a025813; Giribet G, 2001, NATURE, V413, P157, DOI 10.1038/35093097; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Graybeal A, 1998, SYST BIOL, V47, P9, DOI 10.1080/106351598260996; Hall TA, 1999, NUCL ACIDS S SERIES, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; Hillis DM, 1996, MOL SYSTEMATICS; Huelsenbeck JP, 1996, TRENDS ECOL EVOL, V11, P152, DOI 10.1016/0169-5347(96)10006-9; HUELSENBECK JP, 1995, SYST BIOL, V44, P17, DOI 10.2307/2413481; Hwang UW, 2001, NATURE, V413, P154, DOI 10.1038/35093090; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Knoll AH, 1999, SCIENCE, V284, P2129, DOI 10.1126/science.284.5423.2129; Kopp A, 2002, SYST BIOL, V51, P786, DOI 10.1080/10635150290102410; Kurtzman CP, 2003, FEMS YEAST RES, V3, P417, DOI 10.1016/S1567-1356(03)00012-6; Langkjaer RB, 2003, NATURE, V421, P848, DOI 10.1038/nature01419; Lopez P, 2002, MOL BIOL EVOL, V19, P1; Loytynoja A, 2001, P NATL ACAD SCI USA, V98, P10202, DOI 10.1073/pnas.181187698; Maddison WP, 1997, SYST BIOL, V46, P523, DOI 10.2307/2413694; Martin AP, 2002, SYST BIOL, V51, P570, DOI 10.1080/10635150290069995; MasonGamer RJ, 1996, SYST BIOL, V45, P524, DOI 10.2307/2413529; Moreira D, 2000, NATURE, V405, P69, DOI 10.1038/35011054; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; Naumov GI, 2000, INT J SYST EVOL MICR, V50, P1931, DOI 10.1099/00207713-50-5-1931; Naylor GJP, 1998, SYST BIOL, V47, P61, DOI 10.1080/106351598261030; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; PHILIPPE H, 1994, DEVELOPMENT, P15; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Rieseberg LH, 1996, ACTA BOT NEERL, V45, P243; Rokas A, 2003, EVOL DEV, V5, P346, DOI 10.1046/j.1525-142X.2003.03042.x; Sanderson MJ, 2002, ANNU REV ECOL SYST, V33, P49, DOI 10.1146/annurev.ecolsys.33.010802.150509; Satta Y, 2000, MOL PHYLOGENET EVOL, V14, P259, DOI 10.1006/mpev.2000.0704; Soltis PS, 1999, NATURE, V402, P402, DOI 10.1038/46528; Sullivan J, 1996, SYST BIOL, V45, P375, DOI 10.2307/2413571; Swofford, 2001, PAUP PHYLOGENETIC AN, DOI DOI 10.1111/J.0014-3820.2002.TB00191.X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wendel J.F., 1998, MOL SYSTEMATICS PLAN, VII, P265, DOI DOI 10.1007/978-1-4615-5419-6_10; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wong S, 2002, P NATL ACAD SCI USA, V99, P9272, DOI 10.1073/pnas.142101099; YANG ZH, 1994, MOL BIOL EVOL, V11, P316	50	1117	1140	0	116	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					798	804		10.1038/nature02053	http://dx.doi.org/10.1038/nature02053			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574403				2022-12-24	WOS:000186118500036
J	Campbell, DB; Black, GJ; Carter, LM; Ostro, SJ				Campbell, DB; Black, GJ; Carter, LM; Ostro, SJ			Radar evidence for liquid surfaces on Titan	SCIENCE			English	Article							DIELECTRIC-PROPERTIES; ICY SATELLITES; ATMOSPHERE; TELESCOPE	Arecibo radar observations of Titan at 13-centimeter wavelength indicate that most of the echo power is in a diffusely scattered component but that a small specular component is present for about 75% of the subearth locations observed. These specular echoes have properties consistent with those expected for areas of liquid hydrocarbons. Knowledge of the areal extent and depth of any deposits of liquid hydrocarbons could strongly constrain the history of Titan's atmosphere and surface.	Cornell Univ, Natl Astron & Ionosphere Ctr, Ithaca, NY 14853 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Univ Virginia, Dept Astron, Charlottesville, VA 22903 USA; CALTECH, Jet Prop Lab 300 233, Pasadena, CA 91109 USA	Cornell University; Cornell University; University of Virginia; California Institute of Technology	Campbell, DB (corresponding author), Cornell Univ, Natl Astron & Ionosphere Ctr, Space Sci Bldg, Ithaca, NY 14853 USA.	campbell@astro.cornell.edu	Carter, Lynn/D-2937-2012	Carter, Lynn/0000-0002-6245-4142; Black, Gregory/0000-0001-7237-8270				CAMPBELL DB, 1978, ICARUS, V34, P254, DOI 10.1016/0019-1035(78)90166-5; COUSTENIS A, 1995, ICARUS, V118, P87, DOI 10.1006/icar.1995.1179; EVANS JV, 1968, RADAR ASTRONOMY, pCH4; Ghafoor NAL, 2000, J GEOPHYS RES-PLANET, V105, P12077, DOI 10.1029/1999JE001066; Gibbard SG, 1999, ICARUS, V139, P189, DOI 10.1006/icar.1999.6095; Griffith CA, 1998, NATURE, V395, P575, DOI 10.1038/26920; Griffith CA, 2003, SCIENCE, V300, P628, DOI 10.1126/science.1081897; HAGFORS T, 1964, J GEOPHYS RES, V69, P3779, DOI 10.1029/JZ069i018p03779; Lorenz RD, 1998, ICARUS, V136, P344, DOI 10.1006/icar.1998.6017; Lorenz RD, 2001, GEOPHYS RES LETT, V28, P215, DOI 10.1029/2000GL012199; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; Meier R, 2000, ICARUS, V145, P462, DOI 10.1006/icar.2000.6360; MUHLEMAN DO, 1990, SCIENCE, V248, P975, DOI 10.1126/science.248.4958.975; OSTRO SJ, 1992, J GEOPHYS RES-PLANET, V97, P18227, DOI 10.1029/92JE01992; Rodriguez S, 2003, ICARUS, V164, P213, DOI 10.1016/S0019-1035(03)00125-8; SAGAN C, 1982, NATURE, V300, P731, DOI 10.1038/300731a0; Smith PH, 1996, ICARUS, V119, P336, DOI 10.1006/icar.1996.0023; THOMPSON WR, 1990, ICARUS, V86, P336, DOI 10.1016/0019-1035(90)90224-W	18	86	86	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	2003	302	5644					431	434		10.1126/science.1088969	http://dx.doi.org/10.1126/science.1088969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14526087				2022-12-24	WOS:000185963200038
J	Lee, CH; Chawla, A; Urbiztondo, N; Liao, D; Boisvert, WA; Evans, RM				Lee, CH; Chawla, A; Urbiztondo, N; Liao, D; Boisvert, WA; Evans, RM			Transcriptional repression of atherogenic inflammation: Modulation by PPAR delta	SCIENCE			English	Article							REDUCES ATHEROSCLEROSIS; GENE-EXPRESSION; DEFICIENT MICE; MACROPHAGES; GAMMA; BCL-6; COREPRESSOR; ABSENCE	The formation of an atherosclerotic lesion is mediated by lipid-laden macrophages (foam cells), which also establish chronic inflammation associated with lesion progression. The peroxisome proliferator-activated receptor (PPAR) gamma promotes lipid uptake and efflux in these atherogenic cells. In contrast, we found that the closely related receptor PPARdelta controls the inflammatory status of the macrophage. Deletion of PPARdelta from foam cells increased the availability of inflammatory suppressors, which in turn reduced atherosclerotic lesion area by more than 50%. We propose an unconventional ligand-dependent transcriptional pathway in which PPARdelta controls an inflammatory switch through its association and disassociation with transcriptional repressors. PPARdelta and its ligands may thus serve as therapeutic targets to attenuate inflammation and slow the progression of atherosclerosis.	Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA; Brigham & Womens Hosp, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Salk Institute; Harvard University; Brigham & Women's Hospital	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019; Lee, Chih-Hao/E-9635-2018	Evans, Ronald/0000-0002-9986-5965; Lee, Chih-Hao/0000-0002-3898-6421	NHLBI NIH HHS [HL69474] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069474] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Dawson TC, 1999, ATHEROSCLEROSIS, V143, P205; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Huynh KD, 2000, GENE DEV, V14, P1810; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Lee C., UNPUB; Lee CH, 2002, TRENDS ENDOCRIN MET, V13, P331, DOI 10.1016/S1043-2760(02)00668-9; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102-1211; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200	22	482	519	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					453	457		10.1126/science.1087344	http://dx.doi.org/10.1126/science.1087344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	12970571				2022-12-24	WOS:000185963200045
J	Wilkinson, MJ; Elliott, LJ; Allainguillaume, J; Shaw, MW; Norris, C; Welters, R; Alexander, M; Sweet, J; Mason, DC				Wilkinson, MJ; Elliott, LJ; Allainguillaume, J; Shaw, MW; Norris, C; Welters, R; Alexander, M; Sweet, J; Mason, DC			Hybridization between Brassica napus and B-rapa on a national scale in the United Kingdom	SCIENCE			English	Article							OILSEED RAPE; HERBICIDE RESISTANCE; WILD RELATIVES; MOVEMENT; POLLINATION; TRANSGENE; IMPACT; CROPS	Measures blocking hybridization would prevent or reduce biotic or environmental change caused by gene flow from genetically modified (GM) crops to wild relatives. The efficacy of any such measure depends on hybrid numbers within the legislative region over the life-span of the GM cultivar. We present a national assessment of hybridization between rapeseed (Brassica napus) and B. rapa from a combination of sources, including population surveys, remote sensing, pollen dispersal profiles, herbarium data, local Floras, and other floristic databases. Across the United Kingdom, we estimate that 32,000 hybrids form annually in waterside B. rapa populations, whereas the less abundant weedy populations contain 17,000 hybrids. These findings set targets for strategies to eliminate hybridization and represent the first step toward quantitative risk assessment on a national scale.	Univ Reading, Sch Plant Sci, Reading RG6 6AS, Berks, England; Univ Reading, Nat Environm Res Council, Environm Syst Sci Ctr, Reading RG6 6AL, Berks, England; Ctr Ecol & Hydrol, Winfrith, Dorset, England	University of Reading; University of Reading; UK Centre for Ecology & Hydrology (UKCEH)	Wilkinson, MJ (corresponding author), Univ Reading, Sch Plant Sci, Reading RG6 6AS, Berks, England.	m.j.wilkinson@rdg.ac.uk	Shaw, Michael/A-1926-2011	Shaw, Michael/0000-0002-6993-048X; Wilkinson, Michael/0000-0002-9881-6993	Biotechnology and Biological Sciences Research Council [GM114202] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Dale PJ, 2002, NAT BIOTECHNOL, V20, P567, DOI 10.1038/nbt0602-567; Dandy J.E., 1975, HYBRIDIZATION FLORA, P444; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; Davenport IJ, 2000, INT J REMOTE SENS, V21, P3567, DOI 10.1080/014311600750037598; JAMES C, 2002, ISAAA BRIEFS, V27; JORGENSEN RB, 1994, AM J BOT, V81, P1620, DOI 10.2307/2445340; Metz PLJ, 1997, THEOR APPL GENET, V95, P442, DOI 10.1007/s001220050581; RAYBOULD AF, 1993, J APPL ECOL, V30, P199, DOI 10.2307/2404623; Rieger MA, 2002, SCIENCE, V296, P2386, DOI 10.1126/science.1071682; Rosellini D, 2001, EUPHYTICA, V118, P313, DOI 10.1023/A:1017568201732; SCHEFFLER JA, 1994, TRANSGENIC RES, V3, P263, DOI 10.1007/BF01973586; TIMMONS AM, 1995, EUPHYTICA, V85, P417, DOI 10.1007/BF00023975; Trewavas AJ, 2001, EMBO REP, V2, P455, DOI 10.1093/embo-reports/kve123; Waines JG, 2003, CROP SCI, V43, P451, DOI 10.2135/cropsci2003.0451; Wilkinson MJ, 2003, TRENDS PLANT SCI, V8, P208, DOI 10.1016/S1360-1385(03)00057-8; Wilkinson MJ, 2000, MOL ECOL, V9, P983, DOI 10.1046/j.1365-294x.2000.00986.x; Zuo JR, 2000, CURR OPIN BIOTECH, V11, P146, DOI 10.1016/S0958-1669(00)00073-2	17	130	145	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	2003	302	5644					457	459		10.1126/science.1088200	http://dx.doi.org/10.1126/science.1088200			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14551318				2022-12-24	WOS:000185963200046
J	Madsen, EB; Madsen, LH; Radutoiu, S; Olbryt, M; Rakwalska, M; Szczyglowski, K; Sato, S; Kaneko, T; Tabata, S; Sandal, N; Stougaard, J				Madsen, EB; Madsen, LH; Radutoiu, S; Olbryt, M; Rakwalska, M; Szczyglowski, K; Sato, S; Kaneko, T; Tabata, S; Sandal, N; Stougaard, J			A receptor kinase gene of the LysM type is involved in legume perception of rhizobial signals	NATURE			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; PISUM-SATIVUM-L; LOTUS-JAPONICUS; NODULE ORGANOGENESIS; NODULATION FACTORS; SYMBIOTIC MUTANTS; HOST-SPECIFICITY; MELILOTI; PEA; BACTERIAL	Plants belonging to the legume family develop nitrogen-fixing root nodules in symbiosis with bacteria commonly known as rhizobia. The legume host encodes all of the functions necessary to build the specialized symbiotic organ, the nodule, but the process is elicited by the bacteria(1-3). Molecular communication initiates the interaction, and signals, usually flavones, secreted by the legume root induce the bacteria to produce a lipochitin-oligosaccharide signal molecule (Nod-factor), which in turn triggers the plant organogenic process(4-7). An important determinant of bacterial host specificity is the structure of the Nodfactor, suggesting that a plant receptor is involved in signal perception and signal transduction initiating the plant developmental response(8,9). Here we describe the cloning of a putative Nod-factor receptor kinase gene (NFR5) from Lotus japonicus. NFR5 is essential for Nod-factor perception and encodes an unusual transmembrane serine/ threonine receptor-like kinase required for the earliest detectable plant responses to bacteria and Nod-factor. The extracellular domain of the putative receptor has three modules with similarity to LysM domains known from peptidoglycan-binding proteins and chitinases. Together with an atypical kinase domain structure this characterizes an unusual receptor-like kinase.	Univ Aarhus, Dept Mol Biol, Gene Express Lab, DK-8000 Aarhus C, Denmark; Agr & Agri Food Canada, SCPFRC, London, ON NV5 4T3, Canada; Kazusa DNA Res Inst, Chiba 2920812, Japan	Aarhus University; Agriculture & Agri Food Canada; Kazusa DNA Research Institute	Stougaard, J (corresponding author), Univ Aarhus, Dept Mol Biol, Gene Express Lab, Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.	stougaard@mb.au.dk	poinssot, benoit/B-2569-2009; Sato, Shusei/A-3616-2015	poinssot, benoit/0000-0001-5890-4318; Sato, Shusei/0000-0002-0293-5366; Olbryt, Magdalena/0000-0001-9961-6427; Stougaard, Jens/0000-0002-9312-2685				Amon P, 1998, PLANT CELL, V10, P781; ARDOUREL M, 1994, PLANT CELL, V6, P1357, DOI 10.1105/tpc.6.10.1357; Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; Bras CP, 2000, MOL PLANT MICROBE IN, V13, P475, DOI 10.1094/MPMI.2000.13.4.475; BUTLER AR, 1991, EUR J BIOCHEM, V199, P483, DOI 10.1111/j.1432-1033.1991.tb16147.x; DUC G, 1989, PLANT SCI, V60, P207, DOI 10.1016/0168-9452(89)90168-4; ENGVILD KC, 1987, THEOR APPL GENET, V74, P711, DOI 10.1007/BF00247546; HANDBERG K, 1992, PLANT J, V2, P487, DOI 10.1111/j.1365-313X.1992.00487.x; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; KNEEN BE, 1994, J HERED, V85, P129, DOI 10.1093/oxfordjournals.jhered.a111410; Krusell L, 2002, NATURE, V420, P422, DOI 10.1038/nature01207; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; Long SR, 1996, PLANT CELL, V8, P1885, DOI 10.1105/tpc.8.10.1885; LOPEZLARA IM, 1995, MOL MICROBIOL, V15, P627, DOI 10.1111/j.1365-2958.1995.tb02372.x; Nakamura Y, 2002, DNA RES, V9, P63, DOI 10.1093/dnares/9.2.63; Niwa S, 2001, MOL PLANT MICROBE IN, V14, P848, DOI 10.1094/MPMI.2001.14.7.848; Radutoiu S, 2003, NATURE, V425, P585, DOI 10.1038/nature02039; Sandal N, 2002, GENETICS, V161, P1673; Schauser L, 1998, MOL GEN GENET, V259, P414, DOI 10.1007/s004380050831; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; Schneider A, 2002, THEOR APPL GENET, V104, P1312, DOI 10.1007/s00122-002-0896-2; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; Steen A, 2003, J BIOL CHEM, V278, P23874, DOI 10.1074/jbc.M211055200; Stougaard J, 1995, Methods Mol Biol, V49, P49; Stougaard J, 2001, CURR OPIN PLANT BIOL, V4, P328, DOI 10.1016/S1369-5266(00)00181-3; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841; Szczyglowski K, 1998, MOL PLANT MICROBE IN, V11, P684, DOI 10.1094/MPMI.1998.11.7.684; TRUCHET G, 1989, MOL GEN GENET, V219, P65, DOI 10.1007/BF00261158; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; Wegel E, 1998, MOL PLANT MICROBE IN, V11, P933, DOI 10.1094/MPMI.1998.11.9.933; Wikstrom N, 2001, P ROY SOC B-BIOL SCI, V268, P2211, DOI 10.1098/rspb.2001.1782	31	647	707	7	138	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					637	640		10.1038/nature02045	http://dx.doi.org/10.1038/nature02045			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534591				2022-12-24	WOS:000185801000042
J	Radutoiu, S; Madsen, LH; Madsen, EB; Felle, HH; Umehara, Y; Gronlund, M; Sato, S; Nakamura, Y; Tabata, S; Sandal, N; Stougaard, J				Radutoiu, S; Madsen, LH; Madsen, EB; Felle, HH; Umehara, Y; Gronlund, M; Sato, S; Nakamura, Y; Tabata, S; Sandal, N; Stougaard, J			Plant recognition of symbiotic bacteria requires two LysM receptor-like kinases	NATURE			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; LEGUME LOTUS-JAPONICUS; ALFALFA ROOT HAIRS; RHIZOBIUM-MELILOTI; NOD FACTORS; HOST-SPECIFICITY; MUTANTS; GENE; EXPRESSION; DOMAIN	Although most higher plants establish a symbiosis with arbuscular mycorrhizal fungi, symbiotic nitrogen fixation with rhizobia is a salient feature of legumes. Despite this host range difference, mycorrhizal and rhizobial invasion shares a common plant-specified genetic programme controlling the early host interaction. One feature distinguishing legumes is their ability to perceive rhizobial-specific signal molecules. We describe here two LysM-type serine/threonine receptor kinase genes, NFR1 and NFR5, enabling the model legume Lotus japonicus to recognize its bacterial microsymbiont Mesorhizobium loti. The extracellular domains of the two transmembrane kinases resemble LysM domains of peptidoglycan- and chitin-binding proteins, suggesting that they may be involved directly in perception of the rhizobial lipochitin-oligosaccharide signal. We show that NFR1 and NFR5 are required for the earliest physiological and cellular responses to this lipochitin-oligosaccharide signal, and demonstrate their role in the mechanism establishing susceptibility of the legume root for bacterial infection.	Univ Aarhus, Dept Mol Biol, Gene Express Lab, DK-8000 Aarhus C, Denmark; Univ Giessen, Inst Bot 1, D-35390 Giessen, Germany; Kazusa DNA Res Inst, Chiba 2920812, Japan	Aarhus University; Justus Liebig University Giessen; Kazusa DNA Research Institute	Stougaard, J (corresponding author), Univ Aarhus, Dept Mol Biol, Gene Express Lab, Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.	stougaard@mb.au.dk	poinssot, benoit/B-2569-2009; Nakamura, Yasukazu/T-9038-2019; Sato, Shusei/A-3616-2015	poinssot, benoit/0000-0001-5890-4318; Sato, Shusei/0000-0002-0293-5366; Stougaard, Jens/0000-0002-9312-2685; Nakamura, Yasukazu/0000-0002-6782-5715				Amon P, 1998, PLANT CELL, V10, P781; Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; Ben Amor B, 2003, PLANT J, V34, P495, DOI 10.1046/j.1365-313X.2003.01743.x; Bras CP, 2000, MOL PLANT MICROBE IN, V13, P475, DOI 10.1094/MPMI.2000.13.4.475; BUTLER AR, 1991, EUR J BIOCHEM, V199, P483, DOI 10.1111/j.1432-1033.1991.tb16147.x; Colebatch G, 2002, MOL PLANT MICROBE IN, V15, P411, DOI 10.1094/MPMI.2002.15.5.411; DUC G, 1989, PLANT SCI, V60, P215, DOI 10.1016/0168-9452(89)90169-6; EHRHARDT DW, 1992, SCIENCE, V256, P998, DOI 10.1126/science.10744524; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; Felle HH, 2000, PLANT PHYSIOL, V124, P1373, DOI 10.1104/pp.124.3.1373; FELLE HH, 1995, PLANT J, V7, P939, DOI 10.1046/j.1365-313X.1995.07060939.x; Felle HH, 1998, PLANT J, V13, P455, DOI 10.1046/j.1365-313X.1998.00041.x; Gadkar V, 2001, PLANT PHYSIOL, V127, P1493, DOI 10.1104/pp.010783; Gerard CJ, 2000, MOL DIAGN, V5, P39, DOI 10.1016/S1084-8592(00)00009-6; GOVERS F, 1991, MOL GEN GENET, V228, P160, DOI 10.1007/BF00282461; Gressent F, 1999, P NATL ACAD SCI USA, V96, P4704, DOI 10.1073/pnas.96.8.4704; HANDBERG K, 1992, PLANT J, V2, P487, DOI 10.1111/j.1365-313X.1992.00487.x; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; JORIS B, 1992, FEMS MICROBIOL LETT, V91, P257; Kaneko T, 2003, DNA RES, V10, P27, DOI 10.1093/dnares/10.1.27; Kistner C, 2002, TRENDS PLANT SCI, V7, P511, DOI 10.1016/S1360-1385(02)02356-7; KOSUGI S, 1990, PLANT SCI, V70, P133, DOI 10.1016/0168-9452(90)90042-M; Kosuta S, 2003, PLANT PHYSIOL, V131, P952, DOI 10.1104/pp.011882; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LOPEZLARA IM, 1995, MOL MICROBIOL, V15, P627, DOI 10.1111/j.1365-2958.1995.tb02372.x; Madsen EB, 2003, NATURE, V425, P637, DOI 10.1038/nature02045; Niwa S, 2001, MOL PLANT MICROBE IN, V14, P848, DOI 10.1094/MPMI.2001.14.7.848; Parniske M, 2000, CURR OPIN PLANT BIOL, V3, P320, DOI 10.1016/S1369-5266(00)00088-1; Ponting CP, 1999, J MOL BIOL, V289, P729, DOI 10.1006/jmbi.1999.2827; Sandal N, 2002, GENETICS, V161, P1673; Schauser L, 1998, MOL GEN GENET, V259, P414, DOI 10.1007/s004380050831; Schauser L, 1999, NATURE, V402, P191, DOI 10.1038/46058; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; SCHLAMAN HRM, 1991, J BACTERIOL, V173, P4277, DOI 10.1128/JB.173.14.4277-4287.1991; Shaw SL, 2003, PLANT PHYSIOL, V131, P976, DOI 10.1104/pp.005546; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; Steen A, 2003, J BIOL CHEM, V278, P23874, DOI 10.1074/jbc.M211055200; Stougaard J, 1995, Methods Mol Biol, V49, P49; Stougaard J, 2001, CURR OPIN PLANT BIOL, V4, P328, DOI 10.1016/S1369-5266(00)00181-3; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841; Szczyglowski K, 1998, MOL PLANT MICROBE IN, V11, P684, DOI 10.1094/MPMI.1998.11.7.684; Szczyglowski K, 2003, PLANT PHYSIOL, V131, P935, DOI 10.1104/pp.017186; Timmers ACJ, 1998, DEVELOPMENT, V125, P339; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; Walker SA, 2000, P NATL ACAD SCI USA, V97, P13413, DOI 10.1073/pnas.230440097; Webb KJ, 2000, MOL PLANT MICROBE IN, V13, P606, DOI 10.1094/MPMI.2000.13.6.606; Wegel E, 1998, MOL PLANT MICROBE IN, V11, P933, DOI 10.1094/MPMI.1998.11.9.933	47	784	851	15	225	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					585	592		10.1038/nature02039	http://dx.doi.org/10.1038/nature02039			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534578				2022-12-24	WOS:000185801000028
J	Roberts, SE; Goldacre, MJ				Roberts, SE; Goldacre, MJ			Time trends and demography of mortality after fractured neck of femur in an English population, 1968-98: database study	BRITISH MEDICAL JOURNAL			English	Article							PROXIMAL FEMORAL FRACTURE; HIP FRACTURE; STROKE INCIDENCE; MONICA PROJECT; CORONARY-EVENT; CASE-FATALITY; SURVIVAL; ENGLAND; RATES; ADMISSIONS	Objectives To investigate time trends in mortality after admission to hospital for fractured neck of femur from 1968 to 1998, and to report on the effects of demographic factors on mortality. Design Analysis of hospital inpatient statistics for fractured neck of femur, incorporating linkage to death certificates. Setting Four counties in southern England. Subjects 32 590 people aged 65 years or over admitted to hospital with fractured neck of femur between 1968 and 1998. Main outcome measures Case fatality nates at 30,90, and 365 days after admission, and standardised mortality ratios at monthly intervals up to one year after admission. Results Case fatality rates declined between the 1960s and the early 1980s, but there was no appreciable fall thereafter. They increased sharply with increasing age: for example, fatality rates at 30 days in 1984-98 increased from 4% in men aged 64-69 years to 3 1 % in those aged greater than or equal to90. They were higher in men than women, and in social classes IV and V than in classes I and R. In the first month after fracture, standardised mortality ratios in women were 16 times higher, and those in men 12 times higher, than mortality in the same age group in the general population Conclusions The high mortality rates, and the fact that they have not fallen over the past 20 years, reinforce the need for measures to prevent osteoporosis and falls and their consequences in elderly people. Whether post-fracture mortality has fallen to an irreducible minimum, or whether further decline is possible, is unclear.	Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Oxford	Roberts, SE (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.							Balacco Giuseppe, 2000, Molecular Biology Today, V1, P23; Balasegaram S, 2001, J PUBLIC HEALTH MED, V23, P11, DOI 10.1093/pubmed/23.1.11; BERINGER TRO, 1991, ULSTER MED J, V60, P28; BOEREBOOM FTJ, 1992, NETH J MED, V41, P4; BOYCE WJ, 1985, LANCET, V1, P150; Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140-6736(98)09075-8; Evans JG, 1997, J EPIDEMIOL COMMUN H, V51, P424, DOI 10.1136/jech.51.4.424; EVANS JG, 1979, AGE AGEING, V8, P246, DOI 10.1093/ageing/8.4.246; FALCH JA, 1993, BONE, V14, P643, DOI 10.1016/8756-3282(93)90086-P; Fitzpatrick P, 2001, IRISH J MED SCI, V170, P49, DOI 10.1007/BF03167722; Goldacre MJ, 2002, BRIT MED J, V325, P868, DOI 10.1136/bmj.325.7369.868; HEDLUND R, 1987, CLIN ORTHOP RELAT R, P132; Kannus P, 1999, LANCET, V353, P802, DOI 10.1016/S0140-6736(98)04235-4; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; LAU EMC, 1993, MED J AUSTRALIA, V158, P604, DOI 10.5694/j.1326-5377.1993.tb137627.x; *ORG EC COOP DEV, 2003, DIS BAS COMP HLTH SY; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Volmink JA, 1998, HEART, V80, P40, DOI 10.1136/hrt.80.1.40; Walker N, 1999, NEW ZEAL MED J, V112, P269; WEATHERALL M, 1994, NEW ZEAL MED J, V107, P308; Wolfe CDA, 2000, STROKE, V31, P2074, DOI 10.1161/01.STR.31.9.2074	25	222	232	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					771	774		10.1136/bmj.327.7418.771	http://dx.doi.org/10.1136/bmj.327.7418.771			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525871	Green Published, Bronze			2022-12-24	WOS:000185805100015
J	Skinner, J; Weinstein, JN; Sporer, SM; Wennberg, JE				Skinner, J; Weinstein, JN; Sporer, SM; Wennberg, JE			Racial, ethnic, and geographic disparities in rates of knee arthroplasty among Medicare patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; RESIDENTIAL SEGREGATION; REVASCULARIZATION PROCEDURES; DECISION-MAKING; UNITED-STATES; HEALTH-CARE; FOLLOW-UP; TOTAL HIP; OSTEOARTHRITIS; REPLACEMENT	BACKGROUND: There are large variations in the use of knee arthroplasty among Medicare enrollees according to race or ethnic group and sex. Are racial and ethnic disparities more pronounced in some regions than in others, and if so, why? METHODS: We used all Medicare fee-for-service claims data for 1998 through 2000 to determine the incidence of knee arthroplasty according to Hospital Referral Region, sex, and race or ethnic group. A total of 430,726 knee arthroplasties were performed during the three-year study period. RESULTS: At the national level, the annual rate of knee arthroplasty was higher for non-Hispanic white women (5.97 procedures per 1000) than for Hispanic women (5.37 per 1000) and black women (4.84 per 1000). The rate for non-Hispanic white men (4.82 procedures per 1000) was higher than that for Hispanic men (3.46 per 1000) and more than double that for black men (1.84 per 1000). The rates were significantly lower for black men than for non-Hispanic white men in nearly every region of the country (P<0.05). For the Hispanic population and for black women, racial or ethnic disparities at the national level were due in part to geographic differences rather than to differences in the rates for different racial and ethnic groups within geographic areas. Residential segregation and low income levels contributed to racial and ethnic disparities in arthroplasty rates. CONCLUSIONS: In the Medicare population, the rate of surgical treatment for osteoarthritis of the knee varies dramatically according to sex, race or ethnic group, and region. These variations underscore the importance of geography and sex in determining racial or ethnic barriers to health care.	Dartmouth Hitchcock Med Ctr, Dept Orthoped, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Ctr Evaluat Clin Sci & Community & Family Med, Lebanon, NH USA; Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA	Dartmouth College; Dartmouth College; Dartmouth College; National Bureau of Economic Research	Weinstein, JN (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Orthoped, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	james.weinstein@dartmouth.edu	Sporer, Scott/AAQ-6186-2020		NIAMS NIH HHS [U01-AR45444-01A1, 60-AR048094-01A1] Funding Source: Medline; NIA NIH HHS [KO1 AG00752, P01 AG019783-03, P01 AG19783, P01 AG019783] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR048094, U01AR045444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG000752, P01AG019783] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acevedo-Garcia D, 2000, SOC SCI MED, V51, P1143, DOI 10.1016/S0277-9536(00)00016-2; ALTONJI J, 2000, HDB LABOR EC C, V3; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; Arday SL, 2000, HEALTH CARE FINANC R, V21, P107; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; BLINDER AS, 1973, J HUM RESOUR, V8, P436, DOI 10.2307/144855; Callaghan JJ, 2000, J BONE JOINT SURG AM, V82A, P487, DOI 10.2106/00004623-200004000-00004; CHANDRA A, 2003, 9513 NAT BUR EC RES; Cromley EK., 2002, GIS PUBLIC HLTH; Deaton A., 1997, The analysis of household surveys: a microeconometric approach to development policy.; *DEP COMM, 2002, CENS 2000 SUMM FIL 3; DIEHR P, 1992, MED CARE, V30, P484, DOI 10.1097/00005650-199206000-00003; Duncan OD, 1955, AM SOCIOL REV, V20, P210, DOI 10.2307/2088328; Escalante A, 2000, ARTHRITIS RHEUM-US, V43, P390, DOI 10.1002/1529-0131(200002)43:2<390::AID-ANR20>3.0.CO;2-R; Ferguson JA, 1998, ARCH INTERN MED, V158, P1450, DOI 10.1001/archinte.158.13.1450; FISHER L, 1993, BIOSTATISTICS METHOD, P769; FORMAN MD, 1983, J RHEUMATOL, V10, P282; GLAESER E, 2001, SURVEY SERIES RACIAL, P1; Gomes C, 2001, IDENTIFYING SOURCES; Hawker G, 1998, J BONE JOINT SURG AM, V80A, P163, DOI 10.2106/00004623-199802000-00003; Hawker GA, 2000, NEW ENGL J MED, V342, P1016, DOI 10.1056/NEJM200004063421405; Hawker GA, 2001, MED CARE, V39, P206, DOI 10.1097/00005650-200103000-00002; Hirsch R, 2001, ARTHRITIS RHEUM, V44, pS225; Ibrahim SA, 2001, ARTHRIT RHEUM-ARTHR, V45, P340, DOI 10.1002/1529-0131(200108)45:4<340::AID-ART346>3.0.CO;2-5; Ibrahim SA, 2002, MED CARE, V40, P44; KATZ JN, 1994, ARTHRITIS RHEUM, V37, P687, DOI 10.1002/art.1780370512; Katz JN, 2001, JAMA-J AM MED ASSOC, V286, P1506, DOI 10.1001/jama.286.12.1506; Lavernia CJ, 1997, CLIN ORTHOP RELAT R, P134; MASSEY DS, 1988, SOC FORCES, V67, P281, DOI 10.2307/2579183; MIYASAKA KC, 1997, CLIN ORTHOP RELAT R, V345, P29; Nelson AR, 2002, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; OAXACA RL, 1975, J HUM RESOUR, V10, P529, DOI 10.2307/144990; Petersen LA, 2002, MED CARE, V40, P86; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON MGE, 1992, J BONE JOINT SURG AM, V74A, P1530, DOI 10.2106/00004623-199274100-00012; Phelan EA, 2001, SPINE, V26, P206, DOI 10.1097/00007632-200101150-00016; Polednak AP, 1996, AM J PUBLIC HEALTH, V86, P723, DOI 10.2105/AJPH.86.5.723; Schneider EC, 2001, ANN INTERN MED, V135, P328, DOI 10.7326/0003-4819-135-5-200109040-00009; Schulman KA, 1999, NEW ENGL J MED, V340, P1130; Schwartz LM, 1999, NEW ENGL J MED, V341, P279, DOI 10.1056/NEJM199907223410411; Sedlis SP, 1997, J CLIN EPIDEMIOL, V50, P899, DOI 10.1016/S0895-4356(97)00089-9; WEINSTEIN J, 2000, DARTMOUTH ATLAS MUSC; Weinstein JN, 2000, SPINE, V25, P1; WENNBERG J, 1986, NEW ENGL J MED, V314, P310, DOI 10.1056/NEJM198601303140509; Wennberg JE, 1999, DARTMOUTH ATLAS HLTH; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wilson Marcus Garvey, 1994, Ethnicity and Disease, V4, P57	48	402	403	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2003	349	14					1350	1359		10.1056/NEJMsa021569	http://dx.doi.org/10.1056/NEJMsa021569			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	727EM	14523144				2022-12-24	WOS:000185644000011
J	Tucker, T; Slack, C				Tucker, T; Slack, C			Not if but how? Caring for HIV-1 vaccine trial participants in South Africa	LANCET			English	Editorial Material									S African AIDS Vaccine Initiat, ZA-7505 Tygerberg, South Africa; Univ Natal, HIV AIDS Vaccines Eth Grp, ZA-3200 Pietermaritzburg, South Africa	University of Kwazulu Natal	Tucker, T (corresponding author), S African AIDS Vaccine Initiat, POB 19070, ZA-7505 Tygerberg, South Africa.							Benatar SR, 2000, BMJ-BRIT MED J, V321, P824, DOI 10.1136/bmj.321.7264.824	1	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					995	995		10.1016/S0140-6736(03)14374-7	http://dx.doi.org/10.1016/S0140-6736(03)14374-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14513854				2022-12-24	WOS:000185489600027
J	Chen, JG; Willard, FS; Huang, J; Liang, JS; Chasse, SA; Jones, AM; Siderovski, DP				Chen, JG; Willard, FS; Huang, J; Liang, JS; Chasse, SA; Jones, AM; Siderovski, DP			A seven-transmembrane RGS protein that modulates plant cell proliferation	SCIENCE			English	Article							HETEROTRIMERIC G-PROTEIN; ALPHA-SUBUNIT; ARABIDOPSIS; REGULATOR; EXPRESSION; GPA1	G protein coupled receptors (GPCRs) at the cell surface activate heterotrimeric G proteins by inducing the G protein alpha (Galpha) subunit to exchange guanosine diphosphate for guanosine triphosphate. Regulators of G protein signaling (RGS) proteins accelerate the deactivation of Galpha subunits to reduce GPCR signaling. Here we identified an RGS protein (AtRGS1) in Arabidopsis that has a predicted structure similar to a GPCR as well as an RGS box with GTPase accelerating activity. Expression of AtRGS1 complemented the pheromone supersensitivity phenotype of a yeast RGS mutant, sst2Delta. Loss of AtRGS1 increased the activity of the Arabidopsis Galpha subunit, resulting in increased cell elongation in hypocotyls in darkness and increased cell production in roots grown in light. These findings suggest that AtRGS1 is a critical modulator of plant cell proliferation.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, UNC Neurosci Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Yangzhou Univ, Coll Biosci & Biotechnol, Yangzhou 225009, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Yangzhou University	Jones, AM (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	alan_jones@unc.edu	Chen, Jin-Gui/AFV-6337-2022; Siderovski, David Peter/AAA-9603-2019; Chen, Jin-Gui/A-4773-2011	Chen, Jin-Gui/0000-0002-1752-4201; Siderovski, David Peter/0000-0002-0688-8210; Chen, Jin-Gui/0000-0002-1752-4201	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065989, P01GM065533, R01GM062338, R01GM055316, R29GM055316] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM065989-02, GM65533, GM055316, GM65989, R01 GM065989-01, R01 GM065989-03, GM62338, R01 GM065989-04, R01 GM065989] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Assmann SM, 2002, PLANT CELL, V14, pS355, DOI 10.1105/tpc.001792; de Alba E, 1999, J MOL BIOL, V291, P927, DOI 10.1006/jmbi.1999.2989; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HUANG H, 1994, INT J PLANT SCI, V155, P3, DOI 10.1086/297142; Jones AM, 2003, PLANT PHYSIOL, V131, P1623, DOI 10.1104/pp.102.017624; Jones AM, 2002, CURR OPIN PLANT BIOL, V5, P402, DOI 10.1016/S1369-5266(02)00288-1; Kim MC, 2002, NATURE, V416, P447, DOI 10.1038/416447a; Kimple RJ, 2003, COMB CHEM HIGH T SCR, V6, P399; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ullah H, 2003, PLANT CELL, V15, P393, DOI 10.1105/tpc.006148; Ullah H, 2001, SCIENCE, V292, P2066, DOI 10.1126/science.1059040	18	241	266	4	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1728	1731		10.1126/science.1087790	http://dx.doi.org/10.1126/science.1087790			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500984				2022-12-24	WOS:000185387700046
J	Pintard, L; Willis, JH; Willems, A; Johnson, JLF; Srayko, M; Kurz, T; Glaser, S; Mains, PE; Tyers, M; Bowerman, B; Peter, M				Pintard, L; Willis, JH; Willems, A; Johnson, JLF; Srayko, M; Kurz, T; Glaser, S; Mains, PE; Tyers, M; Bowerman, B; Peter, M			The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DEGRADATION; GENE; FAMILY; MEI-1; COMPLEX; TARGET; MEMBER	Many biological processes, such as development and cell cycle progression are tightly controlled by selective ubiquitin-dependent degradation of key substrates. In this pathway, the E3-ligase recognizes the substrate and targets it for degradation by the 26S proteasome. The SCF (Skp1-Cul1-F-box) and ECS (Elongin C-Cul2-SOCS box) complexes are two well-defined cullin-based E3-ligases(1-3). The cullin subunits serve a scaffolding function and interact through their C terminus with the RING-finger-containing protein Hrt1/Roc1/Rbx1, and through their N terminus with Skp1 or Elongin C, respectively. In Caenorhabditis elegans, the ubiquitin-ligase activity of the CUL-3 complex is required for degradation of the microtubule-severing protein MEI-1/katanin at the meiosis-to-mitosis transition(4). However, the molecular composition of this cullin-based E3-ligase is not known. Here we identified the BTB-containing protein MEL-26 as a component required for degradation of MEI-1 in vivo. Importantly, MEL-26 specifically interacts with CUL-3 and MEI-1 in vivo and in vitro, and displays properties of a substrate-specific adaptor. Our results suggest that BTB-containing proteins may generally function as substrate-specific adaptors in Cul3-based E3-ubiquitin ligases.	ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med Genet & Microbiol, Toronto, ON M5G 1X5, Canada; Univ Calgary, Genes & Dev Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Oregon; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Calgary; University of Calgary	Pintard, L (corresponding author), ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland.	lionel.pintard@bc.biol.ethz.ch; matthias.peter@bc.biol.ethz.ch	PINTARD, Lionel/H-3756-2018; pintard, lionel/AAD-8356-2020; Kurz, Thimo/E-4116-2012; Srayko, Martin/A-3755-2014; Tyers, Michael/ABE-3194-2021; PINTARD, Lionel/AAP-7361-2020	PINTARD, Lionel/0000-0003-0286-4630; PINTARD, Lionel/0000-0003-0286-4630; Kurz, Thimo/0000-0003-0700-6993; Peter, Matthias/0000-0002-2160-6824; Srayko, Martin/0000-0003-0196-0364				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bomont P, 2000, NAT GENET, V26, P370, DOI 10.1038/81701; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRENNER S, 1974, GENETICS, V77, P71; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; CLARKMAGUIRE S, 1994, J CELL BIOL, V126, P199, DOI 10.1083/jcb.126.1.199; Dow MR, 1998, GENETICS, V150, P119; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; HARPER JW, 1993, CELL, V75, P805; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; MAINS PE, 1990, GENETICS, V126, P593; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seibert V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-22; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Srayko M, 2000, GENE DEV, V14, P1072; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wolf DA, 1999, CURR BIOL, V9, P373, DOI 10.1016/S0960-9822(99)80165-1; XU L, 2003, NATURE          0903, DOI DOI 10.1038/NATURE01985; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	27	337	351	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2003	425	6955					311	316		10.1038/nature01959	http://dx.doi.org/10.1038/nature01959			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679921				2022-12-24	WOS:000185370900049
J	Quigg, A; Finkel, ZV; Irwin, AJ; Rosenthal, Y; Ho, TY; Reinfelder, JR; Schofield, O; Morel, FMM; Falkowski, PG				Quigg, A; Finkel, ZV; Irwin, AJ; Rosenthal, Y; Ho, TY; Reinfelder, JR; Schofield, O; Morel, FMM; Falkowski, PG			The evolutionary inheritance of elemental stoichiometry in marine phytoplankton	NATURE			English	Article							CADMIUM; ZINC	Phytoplankton is a nineteenth century ecological construct for a biologically diverse group of pelagic photoautotrophs that share common metabolic functions but not evolutionary histories(1). In contrast to terrestrial plants, a major schism occurred in the evolution of the eukaryotic phytoplankton that gave rise to two major plastid superfamilies(2-4). The green superfamily appropriated chlorophyll b, whereas the red superfamily uses chlorophyll c as an accessory photosynthetic pigment(5). Fossil evidence suggests that the green superfamily dominated Palaeozoic oceans. However, after the end-Permian extinction, members of the red superfamily rose to ecological prominence. The processes responsible for this shift are obscure. Here we present an analysis of major nutrients and trace elements in 15 species of marine phytoplankton from the two superfamilies. Our results indicate that there are systematic phylogenetic differences in the two plastid types where macronutrient (carbon:nitrogen:phosphorus) stoichiometries primarily reflect ancestral pre-symbiotic host cell phenotypes, but trace element composition reflects differences in the acquired plastids. The compositional differences between the two plastid superfamilies suggest that changes in ocean redox state strongly influenced the evolution and selection of eukaryotic phytoplankton since the Proterozoic era.	Rutgers State Univ, Inst Marine & Coastal Sci, Environm Biophys & Mol Ecol Program, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Geol Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Coastal Ocean Observat Lab, New Brunswick, NJ 08901 USA; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Princeton University	Quigg, A (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, Environm Biophys & Mol Ecol Program, New Brunswick, NJ 08901 USA.	aquigg@imcs.rutgers.edu; falko@imcs.rutgers.edu	Ho, Tung-Yuan/F-2323-2017; Reinfelder, John/C-7214-2016; Morel, Francois M M/A-8107-2008; Quigg, Antonietta S/A-9345-2010; Finkel, Zoe V/B-9626-2008; Irwin, Andrew/B-2245-2008; Schofield, Oscar/H-4169-2018	Reinfelder, John/0000-0002-3737-604X; Finkel, Zoe V/0000-0003-4212-3917; Irwin, Andrew/0000-0001-7784-2319; Schofield, Oscar/0000-0003-2359-4131				Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cullen JT, 2001, J ANAL ATOM SPECTROM, V16, P1307, DOI 10.1039/b104398f; Delwiche CF, 1999, AM NAT, V154, pS164, DOI 10.1086/303291; Des Marais DJ, 2000, SCIENCE, V289, P1703; Falkowski P.G., 2013, AQUATIC PHOTOSYNTHES; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; Falkowski PG, 2000, J PHYCOL, V36, P3, DOI 10.1046/j.1529-8817.2000.99161.x; FALKOWSKI PG, 1981, PLANT PHYSIOL, V68, P969, DOI 10.1104/pp.68.4.969; FALKOWSKI PG, IN PRESS COCCOLITHOP; Geider RJ, 2002, EUR J PHYCOL, V37, P1, DOI 10.1017/S0967026201003456; Grzebyk D, 2003, J PHYCOL, V39, P259, DOI 10.1046/j.1529-8817.2003.02082.x; HAECKEL E, 1990, PLANKTON STUDIEN VER; HO TY, UNPUB J PHYCOL; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [DOI 10.1080/10618600.1996.10474713, 10.2307/1390807]; LEE JG, 1995, MAR ECOL PROG SER, V127, P305, DOI 10.3354/meps127305; Martin W, 2002, P NATL ACAD SCI USA, V99, P12246, DOI 10.1073/pnas.182432999; Palmer JD, 2003, J PHYCOL, V39, P4, DOI 10.1046/j.1529-8817.2003.02185.x; PRICE N M, 1988, Biological Oceanography, V6, P443; PRICE NM, 1990, NATURE, V344, P658, DOI 10.1038/344658a0; Raven JA, 1999, PHOTOSYNTH RES, V60, P111, DOI 10.1023/A:1006282714942; Redfield A. C., 1934, P176; Sterner R.W., 2002, ECOLOGICAL STOICHIOM, DOI DOI 10.1086/382444; Sverdrup H.U., 1942, OCEANS; Venables W., 2013, MODERN APPL STAT S, V53, P86; Whitfield M, 2001, ADV MAR BIOL, V41, P1, DOI 10.1016/S0065-2881(01)41002-9; Williams R.J.P., 1996, NATURAL SELECTION CH	27	379	395	9	208	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2003	425	6955					291	294		10.1038/nature01953	http://dx.doi.org/10.1038/nature01953			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679916				2022-12-24	WOS:000185370900044
J	Bleharski, JR; Li, HY; Meinken, C; Graeber, TG; Ochoa, MT; Yamamura, M; Burdick, A; Sarno, EN; Wagner, M; Rollinghoff, M; Rea, TH; Colonna, M; Stenger, S; Bloom, BR; Eisenberg, D; Modlin, RL				Bleharski, JR; Li, HY; Meinken, C; Graeber, TG; Ochoa, MT; Yamamura, M; Burdick, A; Sarno, EN; Wagner, M; Rollinghoff, M; Rea, TH; Colonna, M; Stenger, S; Bloom, BR; Eisenberg, D; Modlin, RL			Use of genetic profiling in leprosy to discriminate clinical forms of the disease	SCIENCE			English	Article							INTRACELLULAR INFECTION; CELL RESPONSES; EXPRESSION; LESIONS; ACTIVATION; PATHOGENS; RECEPTORS; PATTERNS; SUBSETS; GAMMA	Leprosy presents as a clinical and immunological spectrum of disease. With the use of gene expression pro. ling, we observed that a distinction in gene expression correlates with and accurately classifies the clinical form of the disease. Genes belonging to the leukocyte immunoglobulin-like receptor (LIR) family were significantly up-regulated in lesions of lepromatous patients suffering from the disseminated form of the infection. In functional studies, LIR-7 suppressed innate host defense mechanisms by shifting monocyte production from interleukin-12 toward interleukin-10 and by blocking antimicrobial activity triggered by Toll-like receptors. Gene expression profiles may be useful in de. ning clinical forms of disease and providing insights into the regulation of immune responses to pathogens.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, UCLA Dept Energy Inst Genom & Proteom, Howard Hughes Med Inst, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Erlangen Nurnberg, Inst Klin Mikrobiol Immunol & Hyg, D-91054 Erlangen, Germany; Okayama Univ, Grad Sch Med & Dent, Okayama, Japan; Univ Miami, Dept Dermatol & Cutaneous Surg, Miami, FL 33101 USA; Inst Oswaldo Cruz, Leprosy Lab, BR-20001 Rio De Janeiro, Brazil; Klinikum Nurnberg, Med Klin 3, D-90340 Nurnberg, Germany; Univ So Calif, Sch Med, Dermatol Sect, Los Angeles, CA 90033 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Harvard Univ, Sch Publ Hlth, Off Dean, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Erlangen Nuremberg; Okayama University; University of Miami; Fundacao Oswaldo Cruz; Klinikum Nurnberg Nord; University of Southern California; Washington University (WUSTL); Harvard University; Harvard T.H. Chan School of Public Health	Modlin, RL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.		Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X; Ochoa, Maria T/0000-0001-6550-5008; Graeber, Thomas/0000-0001-8574-9181; Nunes Sarno, Euzenir/0000-0003-0129-2159; Colonna, Marco/0000-0001-5222-4987	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI147868, R01AI022553, R01AI047868, R37AI047868, R22AI022553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040312] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 47868, AI 22553, AI 07118] Funding Source: Medline; NIAMS NIH HHS [AR 40312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; BLEHARSKI JR, UNPUB; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Borges L, 2000, CYTOKINE GROWTH F R, V11, P209, DOI 10.1016/S1359-6101(00)00007-1; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EISEN MB, TREEVIEW 1 60; Garcia VE, 2001, J IMMUNOL, V167, P5719, DOI 10.4049/jimmunol.167.10.5719; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Jullien D, 1997, J IMMUNOL, V158, P800; Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864; MODLIN RL, 1983, J AM ACAD DERMATOL, V8, P182, DOI 10.1016/S0190-9622(83)70021-6; MODLIN RL, 1988, P NATL ACAD SCI USA, V85, P1213, DOI 10.1073/pnas.85.4.1213; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Nakajima H, 1999, J IMMUNOL, V162, P5; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Sieling PA, 1999, J IMMUNOL, V162, P1851; SIELING PA, 1994, J IMMUNOL, V153, P3639; SIELING PA, 1995, J IMMUNOL, V154, P2775; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	23	125	130	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1527	1530		10.1126/science.1087785	http://dx.doi.org/10.1126/science.1087785			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970564				2022-12-24	WOS:000185255300048
J	Christensen, EF; Hoyer, CCS				Christensen, EF; Hoyer, CCS			Prehospital tracheal intubation in severely injured patients: a Danish observational study	BRITISH MEDICAL JOURNAL			English	Article							TRAUMA		Aarhus Univ Hosp, Dept Anaesthesiol & Intens Care Med, DK-8000 Aarhus, Denmark	Aarhus University	Christensen, EF (corresponding author), Aarhus Univ Hosp, Dept Anaesthesiol & Intens Care Med, DK-8000 Aarhus, Denmark.		Høyer, Christian Bjerre/H-3393-2019; Christensen, Erika Frischknecht/H-8753-2017	Høyer, Christian Bjerre/0000-0001-5917-1777; Christensen, Erika Frischknecht/0000-0003-3673-9694				Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; Sethi D, 2003, COCHRANE LIB	3	19	21	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					533	534		10.1136/bmj.327.7414.533	http://dx.doi.org/10.1136/bmj.327.7414.533			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958112	Green Published, Bronze			2022-12-24	WOS:000185283700017
J	Wegner, KM; Kalbe, M; Kurtz, J; Reusch, TBH; Milinski, M				Wegner, KM; Kalbe, M; Kurtz, J; Reusch, TBH; Milinski, M			Parasite selection for immunogenetic optimality	SCIENCE			English	Article							MHC; STICKLEBACKS		Max Planck Inst Limnol, Dept Evolutionary Ecol, D-24306 Plon, Germany	Max Planck Society	Wegner, KM (corresponding author), Max Planck Inst Limnol, Dept Evolutionary Ecol, August Thienemann Str 2, D-24306 Plon, Germany.	wegner@mpil-ploen.mpg.de	Reusch, Thorsten B.H./G-4141-2011; Reusch, Thorsten B. H./B-9311-2019; Wegner, Mathias/B-6674-2009; Kurtz, Joachim/A-9678-2008; Wegner, K. Mathias/P-1149-2015	Kurtz, Joachim/0000-0002-7258-459X; Wegner, K. Mathias/0000-0002-2410-8898; Reusch, Thorsten B. H./0000-0002-8961-4337				Bernatchez L, 2003, J EVOLUTION BIOL, V16, P363, DOI 10.1046/j.1420-9101.2003.00531.x; DEBOER RJ, 1993, P ROY SOC B-BIOL SCI, V252, P171, DOI 10.1098/rspb.1993.0062; Kalbe M, 2002, J FISH BIOL, V60, P1529, DOI [10.1111/j.1095-8649.2002.tb02445.x, 10.1006/jfbi.2002.2013]; NOWAK MA, 1992, P NATL ACAD SCI USA, V89, P10896, DOI 10.1073/pnas.89.22.10896; Penn DJ, 2002, P NATL ACAD SCI USA, V99, P11260, DOI 10.1073/pnas.162006499; Reusch TBH, 2001, NATURE, V414, P300, DOI 10.1038/35104547; VIDOVIC D, 1988, NATURE, V336, P222, DOI 10.1038/336222a0; Wegner KM, 2003, J EVOLUTION BIOL, V16, P224, DOI 10.1046/j.1420-9101.2003.00519.x; Wootton R.J., 1976, BIOL STICKLEBACKS	9	238	241	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1343	1343		10.1126/science.1088293	http://dx.doi.org/10.1126/science.1088293			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958352				2022-12-24	WOS:000185116400029
J	Crown, J				Crown, J			Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?	LANCET			English	Editorial Material							RANDOMIZED-TRIAL		St Vincents Univ Hosp, Dublin 4, Ireland	University College Dublin; Saint Vincent's University Hospital	Crown, J (corresponding author), St Vincents Univ Hosp, Dublin 4, Ireland.		Crown, John/AAL-3367-2020	Crown, John/0000-0002-3125-7613				Bergh J, 2000, LANCET, V356, P1384, DOI 10.1016/S0140-6736(00)02841-5; Bergh J, 2000, LANCET, V356, P2196; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; CROWN J, 1995, ANN ONCOL         S4, V6, pS21; CROWN J, 2003, P AN M AM SOC CLIN, V22, pA23; *EARL BREAST CANC, 1992, LANCET, V339, P1; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; HRYNIUK W, 1984, J CLIN ONCOL, V2, P81; Nabholtz JM PT, 2002, P AN M AM SOC CLIN, V21, p36a; NITZ UA, 2003, P AN M AM SOC CLIN, V22, pA832; NORTON L, 1988, CANCER RES, V48, P7067; RODENHUIS S, 2003, P ASCO, V22, pA6; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101	13	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					677	678		10.1016/S0140-6736(03)14242-0	http://dx.doi.org/10.1016/S0140-6736(03)14242-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957087				2022-12-24	WOS:000185034800005
J	Greenland, P; Knoll, MD; Stamler, J; Neaton, JD; Dyer, AR; Garside, DB; Wilson, PW				Greenland, P; Knoll, MD; Stamler, J; Neaton, JD; Dyer, AR; Garside, DB; Wilson, PW			Major risk factors as antecedents of fatal and nonfatal coronary heart disease events	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; CHOLESTEROL LEVELS; CURRENT KNOWLEDGE; FOLLOW-UP; MORTALITY; ASSOCIATION; PREDICTION; BURDEN	Context A frequently cited concept is that individual major risk factors for coronary heart disease (CHD) are absent in many patients (perhaps >50%) with CHD. However, prior studies have not systematically evaluated the extent to which CHD patients have previous exposure to at least 1 risk factor, including diabetes, cigarette smoking, or clinically elevated levels of cholesterol or blood pressure. Objective To determine the, frequency of exposure to major CHD risk factors. Design, Setting, and Participants Three prospective cohort studies were included: the Chicago Heart Association Detection Project in Industry, with a population sample of 35642 employed men and women aged 18 to 59 years; screenees for the Multiple Risk Factor Intervention Trial, including 347978 men aged 35 to 57 years; and a population-based sample of 3295 men and women aged 34 to 59 years from the Framingham Heart Study (FHS). Follow-up lasted 21 to 30 years across the studies. Main Outcome Measures Fatal CHD in all cohorts and nonfatal myocardial infarction (MI) in the FHS, compared by exposure to major CHD risk factors, defined as total cholesterol of at least 240 mg/dL (greater than or equal to6.22 mmol/L), systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, cigarette smoking, and diabetes. Participants were stratified by sex and age (18-39 vs 40-59 years). Results For fatal CHD (n=20995), exposure to at least 1 clinically elevated major risk factor ranged from 87% to 100%. Among those aged 40 to 59 years at baseline with fatal CHD (n=19263), exposure to at least 1 major risk factor ranged from 87% to 94%. For nonfatal MI, prior exposure was documented in 92% (95% Cl, 87%-96%) (n=167) of men aged 40 to 59 years at baseline and in 87% (95% Cl, 80%-94%) (n=94) of women in this age group. Conclusions Antecedent major CHD risk factor exposures were very common among those who developed CHD, emphasizing the importance of considering all major risk factors in determining CHD risk estimation and in attempting to prevent clinical CHD. These results challenge claims that CHD events commonly occur in persons without exposure to at least 1 major CHD risk factor.	Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; Boston Univ, Sch Med, Boston, MA 02118 USA	Northwestern University; Feinberg School of Medicine; University of Minnesota System; University of Minnesota Twin Cities; Boston University	Greenland, P (corresponding author), 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.	p-greenland@northwestern.edu	Greenland, Philip/ABD-5528-2021; Wilson, Peter W.F./J-2455-2016	Deloria Knoll, Maria/0000-0001-9041-2671	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068140, R01HL021010] Funding Source: NIH RePORTER	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; AGMON J, 1992, CIRCULATION, V86, P839; Barker MH, 1939, AM HEART J, V18, P95; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; Grundy SM, 1999, CIRCULATION, V100, P1481, DOI 10.1161/01.CIR.100.13.1481; Hennekens CH, 1998, CIRCULATION, V97, P1095, DOI 10.1161/01.CIR.97.11.1095; JOHNSON NL, 1969, DISCRETE DISTRIBUTIO, P58; Lefkowitz RJ, 2001, JAMA-J AM MED ASSOC, V285, P581, DOI 10.1001/jama.285.5.581; Magnus P, 2001, ARCH INTERN MED, V161, P2657, DOI 10.1001/archinte.161.22.2657; Mosca L, 2002, NEW ENGL J MED, V347, P1615, DOI 10.1056/NEJMe020127; Nelson N, 1944, J BIOL CHEM, V153, P375; *NIH, 1974, PUBL NIH, P1; Pasternak RC, 1996, J AM COLL CARDIOL, V27, P978, DOI 10.1016/0735-1097(96)87731-X; Ridker PM, 1999, ANN INTERN MED, V130, P933, DOI 10.7326/0003-4819-130-11-199906010-00018; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; ROSE G, 1982, BRIT MED J, V284, P1600, DOI 10.1136/bmj.284.6329.1600; ROSENMAN RH, 1974, MED CLIN N AM, V58, P269, DOI 10.1016/S0025-7125(16)32158-7; RUBINS HB, 1995, AM J CARDIOL, V75, P1196, DOI 10.1016/S0002-9149(99)80761-9; STAMLER J, 1975, J CHRON DIS, V28, P527, DOI 10.1016/0021-9681(75)90060-0; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; The Inter-Society Commission for Heart Disease Resources, 1970, CIRCULATION, V42, pA55; Vasan RS, 2002, CIRCULATION, V105, P48, DOI 10.1161/hc0102.101774; Wilson PWF, 1997, NEW ENGL J MED, V337, P516, DOI 10.1056/NEJM199708213370802; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Winkelmann BR, 2000, AM HEART J, V140, pS11, DOI 10.1067/mhj.2000.109636; Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488	29	700	738	2	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					891	897		10.1001/jama.290.7.891	http://dx.doi.org/10.1001/jama.290.7.891			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928465	Bronze			2022-12-24	WOS:000184828800025
J	Kwiterovich, PO; Vining, EPG; Pyzik, P; Skolasky, R; Freeman, JM				Kwiterovich, PO; Vining, EPG; Pyzik, P; Skolasky, R; Freeman, JM			Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; A-I; CHOLESTEROL; EFFICACY; DISEASE; HEALTH; ARTERY	Context Little prospective long-term information is available on the effect of a ketogenic diet on plasma lipoproteins in children with difficult-to-control seizures. Objective To determine the effect in children with intractable seizures of a high-fat ketogenic diet on plasma levels of the major apolipoprotein B (apoB)-containing lipoproteins, low-density lipoprotein (LDL) and very LDL (VLDL); and the major apolipoprotein A-I (apoA-I)-containing lipoprotein, high-density lipoprotein (HDL). Design, Setting, and Patients A 6-month prospective cohort study of 141 children (mean [SD] age, 5.2 [3.8] years for 70 boys and 6.1 [4.4] years for 71 girls) with difficult-to-treat seizures who were hospitalized for initiation of a high-fat ketogenic diet and followed up as outpatients. This cohort constituted a subgroup of the 371 patients accepted into the ketogenic diet program between 1994 and 2001. A subset of the cohort was also studied after 12 (n = 59) and 24 (n = 27) months. Intervention A ketogenic diet consisting of a high ratio of fat to carbohydrate and protein combined (4:1 [n = 102], 3.5:1 [n = 7], or 3:1 [n = 32]). After diet initiation, the calories and ratio were adjusted to maintain ideal body weight for height and maximal urinary ketosis for seizure control. Main Outcome Measures Differences at baseline and 6-month follow-up for levels of total, VLDL, LDL, HDL, and non-HDL cholesterol; triglycerides; total apoB; and apoA-I., Results At 6 months, the high-fat ketogenic diet significantly increased the mean plasma levels of total (58 mg/dL [1.50 mmol/L]), LDL (50 mg/dL (1.30 mmol/L]), VLDL (8 mg/dL [0.21 mmol/L]), and non-HDL cholesterol (63 mg/dL [1.63 mmol/L]) (P<.001 vs baseline for each); triglycerides (58 mg/dL [0.66 mmol/L]) (P<.001); and total apoB (49 mg/dL) (P<.001). Mean HDL cholesterol decreased significantly (P<.001), although apoA-I increased (4 mg/dL) (P =.23). Significant but less marked changes persisted in children observed after 12 and 24 months. Conclusions A high-fat ketogenic diet produced significant increases in the atherogenic apoB-containing lipoproteins and a decrease in the antiatherogenic HDL cholesterol. Further studies are necessary to determine if such a diet adversely affects endothelial vascular function and promotes inflammation and formation of atherosclerotic lesions.	Johns Hopkins Med Inst, Dept Neurol, Lipid Res Atherosclerosis Div, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Neurol, Pediat Epilepsy Ctr, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Kwiterovich, PO (corresponding author), Johns Hopkins Univ, Lipid Clin, Lipid Res Atherosclerosis Div, 550 N Broadway,Suite 308, Baltimore, MD 21205 USA.	pkwitero@jhmi.edu		Skolasky, Richard/0000-0002-2598-4427	NCRR NIH HHS [M01-RR-00052] Funding Source: Medline; NICHD NIH HHS [N01-HD-7-3268] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073268] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anderson JW, 2000, J AM COLL NUTR, V19, P578, DOI 10.1080/07315724.2000.10718955; BACHORIK PS, 1994, CLIN CHEM, V40, P1915; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Chesney D, 1999, CLIN PEDIATR, V38, P107, DOI 10.1177/000992289903800207; CORTNER JA, 1990, J PEDIATR-US, V116, P514, DOI 10.1016/S0022-3476(05)81595-1; de Jongh S, 2002, ATHEROSCLEROSIS, V163, P193, DOI 10.1016/S0021-9150(02)00003-5; DEKABAN AS, 1966, ARCH NEUROL-CHICAGO, V15, P177, DOI 10.1001/archneur.1966.00470140067009; DIGGLE PJ, 1994, OXFORD STAT SCI SERI, V13; *EXP PAN BLOOD CHO, 1992, PEDIATRICS, V89, P524; Freeman J. M., 2000, KETOGENIC DIET TREAT; Freeman JM, 1998, PEDIATRICS, V102, P1358, DOI 10.1542/peds.102.6.1358; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gilbert DL, 2000, J CHILD NEUROL, V15, P787, DOI 10.1177/088307380001501203; Hemingway C, 2001, PEDIATRICS, V108, P898, DOI 10.1542/peds.108.4.898; HUTTENLOCHER PR, 1976, PEDIATR RES, V10, P536, DOI 10.1203/00006450-197605000-00006; Katyal NG, 2000, CLIN PEDIATR, V39, P153, DOI 10.1177/000992280003900303; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; Kwiterovich PO, 2002, AM J CARDIOL, V90, p30I; Kwiterovich PO, 2002, AM J CARDIOL, V90, p1I, DOI 10.1016/S0002-9149(02)02796-0; Lefevre F, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e46; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; Rice JA, 1988, MATH STAT DATA ANAL; SCHWARTZ RM, 1989, DEV MED CHILD NEUROL, V31, P152; Schwartzkroin PA, 1999, EPILEPSY RES, V37, P171, DOI 10.1016/S0920-1211(99)00069-8; Sharman MJ, 2002, J NUTR, V132, P1879, DOI 10.1093/jn/132.7.1879; Shih WJ, 2000, CLIN CHEM, V46, P351; Srinivasan SR, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e29; SRINIVASAN SR, 1994, METABOLISM, V43, P1042, DOI 10.1016/0026-0495(94)90187-2; SRINIVASAN SR, 1995, CLIN CHEM, V41, P159; Stafstrom CE, 2000, NEUROLOGY, V54, P282, DOI 10.1212/WNL.54.2.282; Swink T D, 1997, Adv Pediatr, V44, P297; Urbina EM, 2002, AM J CARDIOL, V90, P953, DOI 10.1016/S0002-9149(02)02660-7; *US DEP HHS, 1980, PHS NIH PUBL; Vining EPG, 2002, DEV MED CHILD NEUROL, V44, P796, DOI 10.1017/S0012162201002961; Volek JS, 2000, J AM COLL NUTR, V19, P383, DOI 10.1080/07315724.2000.10718935; Willi SM, 1998, PEDIATRICS, V101, P61, DOI 10.1542/peds.101.1.61	38	190	201	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					912	920		10.1001/jama.290.7.912	http://dx.doi.org/10.1001/jama.290.7.912			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928468	Bronze			2022-12-24	WOS:000184828800028
J	Renesto, P; Crapoulet, N; Ogata, H; La Scola, B; Vestris, G; Claverie, JM; Raoult, D				Renesto, P; Crapoulet, N; Ogata, H; La Scola, B; Vestris, G; Claverie, JM; Raoult, D			Genome-based design of a cell-free culture medium for Tropheryma whipplei	LANCET			English	Article								Empirical approaches have guided the development of bacterial cultures. The availability of sequenced genomes now provides opportunities to define culture media for growth of fastidious pathogens with computer modelling of metabolic networks. A key issue the possibility of growing host-dependent bacteria in cell-free conditions. The sequenced Tropheryma whipplei genome was analysed to identify specific metabolic deficiencies. We used this information to design a comprehensive medium that allowed three established T whipplei strains from culture with human cells and one new strain from a clinical sample to grow axenically. Genomic information can, therefore, provide sufficient clues for designing axenic media for fastidious and uncultured pathogens.	CNRS, Fac Med, UMR 6020, Unite Rickettsies, F-13385 Marseille, France; Informat Genom & Struct, UPR 2589, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Raoult, D (corresponding author), CNRS, Fac Med, UMR 6020, Unite Rickettsies, 27 Blvd Jean Moulin, F-13385 Marseille, France.	Didier.Raoult@medecine.univ-mrs.fr	RAOULT, Didier/A-8434-2008; renesto, patricia/T-6446-2019; Claverie, Jean-Michel/AAG-4889-2019; Renesto, patricia/M-6105-2014; LA SCOLA, Bernard/P-6477-2016; Claverie, Jean Michel/Z-2183-2019	RAOULT, Didier/0000-0002-0633-5974; renesto, patricia/0000-0002-6749-7862; Claverie, Jean-Michel/0000-0003-1424-0315; LA SCOLA, Bernard/0000-0001-8006-7704; 				Bentley SD, 2003, LANCET, V361, P637, DOI 10.1016/S0140-6736(03)12597-4; Davey HM, 1996, MICROBIOL REV, V60, P641, DOI 10.1128/MMBR.60.4.641-696.1996; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; La Scola B, 2001, INT J SYST EVOL MICR, V51, P1471, DOI 10.1099/00207713-51-4-1471; RAOULT D, IN PRESS GENOME RES; Zengler K, 2002, P NATL ACAD SCI USA, V99, P15681, DOI 10.1073/pnas.252630999	6	142	147	3	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					447	449		10.1016/S0140-6736(03)14071-8	http://dx.doi.org/10.1016/S0140-6736(03)14071-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927433				2022-12-24	WOS:000184651100013
J	Pagliarini, RA; Xu, T				Pagliarini, RA; Xu, T			A genetic screen in Drosophila for metastatic behavior	SCIENCE			English	Article							E-CADHERIN; ECTOPIC EXPRESSION; CELL REARRANGEMENT; GROWTH; CANCER; DEATH; SUPPRESSORS; BAZOOKA; ENCODES; MOSAICS	A genetic screen was designed in Drosophila to interrogate its genome for mutations sufficient to cause noninvasive tumors of the eye disc to invade neighboring or distant tissues. We found that cooperation between oncogenic Ras(V12) expression and inactivation of any one of a number of genes affecting cell polarity leads to metastatic behavior, including basement membrane degradation, loss of E-cadherin expression, migration, invasion, and secondary tumor formation. Inactivation of these cell polarity genes cannot drive metastatic behavior alone or in combination with other tumor-initiating alterations. These findings suggest that the oncogenic background of tissues makes a distinct contribution toward metastatic development.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet,Boyer Ctr Mol Med, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet,Boyer Ctr Mol Med, 295 Congress Ave, New Haven, CT 06536 USA.	tian.xu@yale.edu			NCI NIH HHS [CA69408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Geneva JL, 2000, DEV BIOL, V221, P181, DOI 10.1006/dbio.2000.9671; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; HAY BA, 1994, DEVELOPMENT, V120, P2121; Ito K, 1997, DEVELOPMENT, V124, P761; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Karim FD, 1998, DEVELOPMENT, V125, P1; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pagliarini Raymond A, 2003, Methods Mol Biol, V223, P349; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Potter CJ, 2000, TRENDS GENET, V16, P33, DOI 10.1016/S0168-9525(99)01878-8; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; XU T, 1993, DEVELOPMENT, V117, P1223; XU TA, 1995, DEVELOPMENT, V121, P1053	34	432	441	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	2003	302	5648					1227	1231		10.1126/science.1088474	http://dx.doi.org/10.1126/science.1088474			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14551319				2022-12-24	WOS:000186544300059
J	Dickinson, D; Raynor, DKT				Dickinson, D; Raynor, DKT			Ask the patients - they may want to know more than you think	BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; MEDICINES		Consumation, Consumer Informat Design, London SW17 7QW, England; Univ Leeds, Pharm Practice & Med Management, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Dickinson, D (corresponding author), Consumation, Consumer Informat Design, 53 Hosack Rd, London SW17 7QW, England.		Sturchio, Jeffrey/GWZ-3472-2022					Berry DC, 1997, PSYCHOL HEALTH, V12, P467, DOI 10.1080/08870449708406723; Berry DC, 2002, LANCET, V359, P853, DOI 10.1016/S0140-6736(02)07923-0; Blenkinsopp A, 1998, BRIT MED J, V317, P413; Coulter A, 1999, BRIT MED J, V318, P318, DOI 10.1136/bmj.318.7179.318; Dickinson D, 2001, PATIENT EDUC COUNS, V43, P147, DOI 10.1016/S0738-3991(00)00156-7; RAYNOR DK, IN PRESS PATIENT ED	6	70	73	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					861	861		10.1136/bmj.327.7419.861-a	http://dx.doi.org/10.1136/bmj.327.7419.861-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732BP	14551106	Green Accepted, Green Published			2022-12-24	WOS:000185921200028
J	Clement, AM; Nguyen, MD; Roberts, EA; Garcia, ML; Boillee, S; Rule, M; McMahon, AP; Doucette, W; Siwek, D; Ferrante, RJ; Brown, RH; Julien, JP; Goldstein, LSB; Cleveland, DW				Clement, AM; Nguyen, MD; Roberts, EA; Garcia, ML; Boillee, S; Rule, M; McMahon, AP; Doucette, W; Siwek, D; Ferrante, RJ; Brown, RH; Julien, JP; Goldstein, LSB; Cleveland, DW			Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU/ZN SUPEROXIDE-DISMUTASE; TRANSGENIC MOUSE MODEL; DISEASE ONSET; FAMILIAL ALS; EXPRESSION; DEATH; DEGENERATION; PROGRESSION; MUTATIONS	The most common form of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease affecting adult motor neurons, is caused by dominant mutations in the ubiquitously expressed Cu-Zn superoxide dismutase (SOD1). In chimeric mice that are mixtures of normal and SOD1 mutant-expressing cells, toxicity to motor neurons is shown to require damage from mutant SOD1 acting within nonneuronal cells. Normal motor neurons in SOD1 mutant chimeras develop aspects of ALS pathology. Most important, nonneuronal cells that do not express mutant SOD1 delay degeneration and significantly extend survival of mutant-expressing motor neurons.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; McGill Univ, Montreal Gen Hosp, Hlth Care Ctr, Res Inst,Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Massachusetts Gen Hosp E, Day Neuromuscular Res Lab, Charlestown, MA 02139 USA; Boston Univ, Sch Med, Bedford VA Med Ctr, Dept Neurol,Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA; Boston Univ, Sch Med, Bedford VA Med Ctr, Dept Pathol,Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA; Boston Univ, Sch Med, Bedford VA Med Ctr, Dept Psychiat,Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; McGill University; Harvard University; Boston University; Geriatric Research Education & Clinical Center; Boston University; Geriatric Research Education & Clinical Center; Boston University; Geriatric Research Education & Clinical Center	Cleveland, DW (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dcleveland@ucsd.edu	Boillee, Severine/J-4027-2017; McMahon, Andrew P/ABE-7520-2020; Doucette, Wilder/S-2019-2016; Cleveland, Don/AAN-9783-2021	Doucette, Wilder/0000-0003-2249-0461; Cleveland, Don/0000-0002-1934-3682; BOILLEE, Severine/0000-0001-5518-9005	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031248, R01NS027036, R01NS037912, R37NS027036, P50NS031248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013846, P01AG012992] Funding Source: NIH RePORTER; NIA NIH HHS [AG 13846, AG 12992] Funding Source: Medline; NICHD NIH HHS [HD 30249] Funding Source: Medline; NINDS NIH HHS [R37 NS027036, NS 27036, NS 37912, NS 31248] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrus PK, 1998, J NEUROCHEM, V71, P2041; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bush AI, 2002, NAT NEUROSCI, V5, P919, DOI 10.1038/nn1002-919a; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Elliott JL, 2001, MOL BRAIN RES, V95, P172, DOI 10.1016/S0169-328X(01)00242-X; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Gong YH, 2000, J NEUROSCI, V20, P660, DOI 10.1523/JNEUROSCI.20-02-00660.2000; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hadjantonakis AK, 2001, HISTOCHEM CELL BIOL, V115, P49, DOI 10.1007/s004180000233; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Jaarsma D, 2001, ACTA NEUROPATHOL, V102, P293; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; JULIEN JP, 1990, J PHYSIOLOGY PARIS, V84, P50; KAWAMATA T, 1992, AM J PATHOL, V140, P691; Kriz J, 2002, NEUROBIOL DIS, V10, P268, DOI 10.1006/nbdi.2002.0487; LEIGH PN, 1991, BRAIN, V114, P775, DOI 10.1093/brain/114.2.775; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Nagy A, 1999, GENE TARGETING PRACT, P177; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Pramatarova A, 2001, J NEUROSCI, V21, P3369, DOI 10.1523/JNEUROSCI.21-10-03369.2001; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	35	844	884	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					113	117		10.1126/science.1086071	http://dx.doi.org/10.1126/science.1086071			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526083				2022-12-24	WOS:000185678500048
J	Lonart, G; Schoch, S; Kaeser, PS; Larkin, CJ; Sudhof, TC; Linden, DJ				Lonart, G; Schoch, S; Kaeser, PS; Larkin, CJ; Sudhof, TC; Linden, DJ			Phosphorylation of RIM1 alpha by PKA triggers presynaptic long-term potentiation at cerebellar parallel fiber synapses	CELL			English	Article							DEPENDENT PROTEIN-KINASE; CA3 PYRAMIDAL NEURONS; RAB3 EFFECTOR; ACTIVE ZONE; 2 FORMS; LTP; RIM; EXPRESSION; MECHANISMS; PLASTICITY	Presynaptic activation of protein kinase A (PKA) induces LTP in cerebellar parallel fiber synapses. Presynaptic LTP is known to require the active zone protein RIM1alpha, but the underlying induction mechanism remains unclear. We now show that PKA directly phosphorylates RIM1alpha at two sites. Using paired recordings from cultured cerebellar granule and Purkinje neurons, we demonstrate that LTP is absent in neurons from RIM1alpha KO mice but is rescued by presynaptic expression of RIM1alpha. Mutant RIM1alpha lacking the N-terminal phosphorylation site is unable to rescue LTP in RIM1alpha knockout neurons but selectively suppresses LTP in wild-type neurons. Our findings suggest that PKA-mediated phosphorylation of the active zone protein RIM1alpha at a single N-terminal site induces presynaptic LTP.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Eastern Virginia Med Sch, Dept Pathol & Anat, Norfolk, VA 23501 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Eastern Virginia Medical School; Johns Hopkins University	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	thomas.sudhof@utsouthwestern.edu; dlinden@jhmi.edu	Schoch, Susanne/F-7741-2012		NIMH NIH HHS [MH51106, MH01505, MH01590] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH051106, R29MH051106, R01MH051106] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Bear MF, 2001, SYNAPSES, P455; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; Castro-Alamancos MA, 1999, J NEUROSCI, V19, P9090, DOI 10.1523/JNEUROSCI.19-20-09090.1999; Chavis P, 1998, NEURON, V20, P773, DOI 10.1016/S0896-6273(00)81015-6; Coppola T, 2001, J BIOL CHEM, V276, P32756, DOI 10.1074/jbc.M100929200; Daly C, 1997, J NEUROSCI, V17, P2365; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HAMIYA H, 2002, J NEUROSCI, V22, P10524; Hansel C, 2001, NAT NEUROSCI, V4, P467, DOI 10.1038/87419; Hibino H, 2002, NEURON, V34, P411, DOI 10.1016/S0896-6273(02)00667-0; HIRANO T, 1991, SYNAPSE, V7, P321, DOI 10.1002/syn.890070408; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Kapur A, 2001, NEUROSCIENCE, V107, P59, DOI 10.1016/S0306-4522(01)00293-7; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; Lev-Ram V, 2002, P NATL ACAD SCI USA, V99, P8389, DOI 10.1073/pnas.122206399; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Linden DJ, 2001, P NATL ACAD SCI USA, V98, P14066, DOI 10.1073/pnas.241384598; Linden DJ, 1998, J NEUROPHYSIOL, V79, P3151, DOI 10.1152/jn.1998.79.6.3151; Linden DJ, 1997, NEURON, V18, P983, DOI 10.1016/S0896-6273(00)80337-2; Linden DJ, 1999, J NEUROSCI, V19, P10221; Lonart G, 1998, J NEUROSCI, V18, P634; Lonart G, 2002, TRENDS NEUROSCI, V25, P329, DOI 10.1016/S0166-2236(02)02193-8; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; LopezGarcia JC, 1996, P NATL ACAD SCI USA, V93, P4712, DOI 10.1073/pnas.93.10.4712; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; Medina JF, 2000, NAT NEUROSCI, V3, P1205, DOI 10.1038/81486; Medina JF, 2000, J NEUROSCI, V20, P5516, DOI 10.1523/JNEUROSCI.20-14-05516.2000; Mellor J, 2001, NAT NEUROSCI, V4, P125, DOI 10.1038/83941; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; REGEHR WG, 1991, NEURON, V7, P451, DOI 10.1016/0896-6273(91)90297-D; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; Salin PA, 1996, NEURON, V16, P797, DOI 10.1016/S0896-6273(00)80099-9; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; SHIBUKI K, 1992, NEUROREPORT, V3, P231, DOI 10.1097/00001756-199203000-00003; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spencer JP, 2002, NEUROSCI LETT, V329, P217, DOI 10.1016/S0304-3940(02)00659-6; SPILLANE DM, 1995, NEUROPHARMACOLOGY, V34, P1573, DOI 10.1016/0028-3908(95)00107-H; Storm DR, 1998, NEURON, V20, P1199, DOI 10.1016/S0896-6273(00)80500-0; Tong G, 1996, NEURON, V16, P1147, DOI 10.1016/S0896-6273(00)80141-5; Villacres EC, 1998, J NEUROSCI, V18, P3186; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2003, GENOMICS, V81, P126, DOI 10.1016/S0888-7543(02)00024-1; Wang Y, 2002, P NATL ACAD SCI USA, V99, P14464, DOI 10.1073/pnas.182532999; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; WHITTAKER VP, 1993, J NEUROCYTOL, V22, P735, DOI 10.1007/BF01181319; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; Zenisek D, 2000, NEURON, V25, P229, DOI 10.1016/S0896-6273(00)80885-5; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43889	64	174	184	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					49	60		10.1016/S0092-8674(03)00727-X	http://dx.doi.org/10.1016/S0092-8674(03)00727-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532002	Bronze			2022-12-24	WOS:000185815500008
J	Dillon, N				Dillon, N			Positions, please ...	NATURE			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Clin Sci Ctr,Gene Regulat & Chromatin Grp, London W12 0NN, England	Imperial College London	Dillon, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Clin Sci Ctr,Gene Regulat & Chromatin Grp, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.							Beurton P. J., 2000, CONCEPT GENE DEV EVO; Dillon N, 2000, BIOESSAYS, V22, P657, DOI 10.1002/1521-1878(200007)22:7<657::AID-BIES8>3.3.CO;2-U; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5	3	20	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					457	457		10.1038/425457a	http://dx.doi.org/10.1038/425457a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523423	Bronze			2022-12-24	WOS:000185648100023
J	Steed, PM; Tansey, MG; Zalevsky, J; Zhukovsky, EA; Desjarlais, JR; Szymkowski, DE; Abbott, C; Carmichael, D; Chan, C; Cherry, L; Cheung, P; Chirino, AJ; Chung, HH; Doberstein, SK; Eivazi, A; Filikov, AV; Gao, SX; Hubert, RS; Hwang, M; Hyun, L; Kashi, S; Kim, A; Kim, E; Kung, J; Martinez, SP; Muchhal, US; Nguyen, DHT; O'Brien, C; O'Keefe, D; Singer, K; Vafa, O; Vielmetter, J; Yoder, SC; Dahiyat, BI				Steed, PM; Tansey, MG; Zalevsky, J; Zhukovsky, EA; Desjarlais, JR; Szymkowski, DE; Abbott, C; Carmichael, D; Chan, C; Cherry, L; Cheung, P; Chirino, AJ; Chung, HH; Doberstein, SK; Eivazi, A; Filikov, AV; Gao, SX; Hubert, RS; Hwang, M; Hyun, L; Kashi, S; Kim, A; Kim, E; Kung, J; Martinez, SP; Muchhal, US; Nguyen, DHT; O'Brien, C; O'Keefe, D; Singer, K; Vafa, O; Vielmetter, J; Yoder, SC; Dahiyat, BI			Inactivation of TNF signaling by rationally designed dominant-negative TNF variants	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; MUTATIONAL ANALYSIS; THERAPY; INVOLVEMENT; TOXICITY	Tumor necrosis factor (TNF) is a key regulator of inflammatory responses and has been implicated in many pathological conditions. We used structure-based design to engineer variant TNF proteins that rapidly form heterotrimers with native TNF to give complexes that neither bind to nor stimulate signaling through TNF receptors. Thus, TNF is inactivated by sequestration. Dominant-negative TNFs represent a possible approach to anti-inflammatory biotherapeutics, and experiments in animal models show that the strategy can attenuate TNF-mediated pathology. Similar rational design could be used to engineer inhibitors of additional TNF superfamily cytokines as well as other multimeric ligands.	Xencor, Monrovia, CA 91016 USA		Dahiyat, BI (corresponding author), Xencor, 111 W Lemon Ave, Monrovia, CA 91016 USA.	baz@xencor.com	Zhukovsky, Eugene/Q-3218-2019	Szymkowski, David/0000-0002-8934-7902				AGGARWAL BB, 2000, CYTOKINE REFERENCE; Ameloot P, 2001, J BIOL CHEM, V276, P27098, DOI 10.1074/jbc.M104486200; Bendele AM, 2000, ARTHRITIS RHEUM-US, V43, P2648, DOI 10.1002/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M; Beutler B, 2001, IMMUNITY, V15, P5, DOI 10.1016/S1074-7613(01)00176-5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROUCKAERT P, 1992, LYMPHOKINE CYTOK RES, V11, P193; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Filikov AV, 2002, PROTEIN SCI, V11, P1452, DOI 10.1110/ps.3500102; Goldbach-Mansky R, 2003, ANNU REV MED, V54, P197, DOI 10.1146/annurev.med.54.101601.152342; Hayes RJ, 2002, P NATL ACAD SCI USA, V99, P15926, DOI 10.1073/pnas.212627499; HISHINUMA I, 1990, HEPATOLOGY, V12, P1187, DOI 10.1002/hep.1840120518; Horiuchi T, 1999, ENDOCR J, V46, P643, DOI 10.1507/endocrj.46.643; Li YP, 2001, BIOL PHARM BULL, V24, P666, DOI 10.1248/bpb.24.666; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo P, 2002, PROTEIN SCI, V11, P1218, DOI 10.1110/ps.4580102; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; Sakaguchi S, 2000, INT J IMMUNOPHARMACO, V22, P935, DOI 10.1016/S0192-0561(00)00056-4; SREEKRISHNA K, 1989, BIOCHEMISTRY-US, V28, P4117, DOI 10.1021/bi00435a074; Steiner G, 1999, RHEUMATOLOGY, V38, P202, DOI 10.1093/rheumatology/38.3.202; Ulfgren AK, 2000, ARTHRITIS RHEUM, V43, P2391, DOI 10.1002/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F; Ware CF, 2000, J EXP MED, V192, pF35, DOI 10.1084/jem.192.11.F35; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	27	176	201	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1895	1898		10.1126/science.1081297	http://dx.doi.org/10.1126/science.1081297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512626				2022-12-24	WOS:000185536700048
J	Semmann, D; Krambeck, HJR; Milinski, M				Semmann, D; Krambeck, HJR; Milinski, M			Volunteering leads to rock-paper-scissors dynamics in a public goods game	NATURE			English	Article							SIZABLE GROUPS; EVOLUTION; COOPERATION; COMMONS; RECIPROCITY; PUNISHMENT; TRAGEDY; HUMANS	Collective efforts are a trademark of both insect and human societies(1). They are achieved through relatedness in the former(2) and unknown mechanisms in the latter. The problem of achieving cooperation among non-kin has been described as the 'tragedy of the commons', prophesying the inescapable collapse of many human enterprises(3,4). In public goods experiments, initial cooperation usually drops quickly to almost zero(5). It can be maintained by the opportunity to punish defectors(6) or the need to maintain good reputation(7). Both schemes require that defectors are identified. Theorists propose that a simple but effective mechanism operates under full anonymity. With optional participation in the public goods game, 'loners' (players who do not join the group), defectors and cooperators will coexist through rock-paper-scissors dynamics(8,9). Here we show experimentally that volunteering generates these dynamics in public goods games and that manipulating initial conditions can produce each predicted direction. If, by manipulating displayed decisions, it is pretended that defectors have the highest frequency, loners soon become most frequent, as do cooperators after loners and defectors after cooperators. On average, cooperation is perpetuated at a substantial level.	Max Planck Inst Limnol, Dept Evolutionary Ecol, D-24306 Plon, Germany	Max Planck Society	Milinski, M (corresponding author), Max Planck Inst Limnol, Dept Evolutionary Ecol, D-24306 Plon, Germany.							AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; BERKES F, 1989, NATURE, V340, P91, DOI 10.1038/340091a0; BOLTON GE, 2001, WHATS REPUTATION IND; BOYD R, 1992, ETHOL SOCIOBIOL, V13, P171, DOI 10.1016/0162-3095(92)90032-Y; BOYD R, 1988, J THEOR BIOL, V132, P337, DOI 10.1016/S0022-5193(88)80219-4; Colman AM., 1995, GAME THEORY ITS APPL; DAWES RM, 1980, ANNU REV PSYCHOL, V31, P169, DOI 10.1146/annurev.ps.31.020180.001125; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 2003, NATURE, V422, P137, DOI 10.1038/nature01474; Fehr E, 2000, AM ECON REV, V90, P980, DOI 10.1257/aer.90.4.980; Gintis H, 2000, J THEOR BIOL, V206, P169, DOI 10.1006/jtbi.2000.2111; Gintis H., 2000, GAME THEORY EVOLVING; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hardin G, 1998, SCIENCE, V280, P682, DOI 10.1126/science.280.5364.682; Hauert C, 2002, J THEOR BIOL, V218, P187, DOI 10.1006/jtbi.2002.3067; Hauert C, 2002, SCIENCE, V296, P1129, DOI 10.1126/science.1070582; Ledyard JO, 1995, HDB EXPT EC, P111, DOI DOI 10.3987/CONTENTS-12-85-7; MAGURRAN AE, 1987, PROC R SOC SER B-BIO, V229, P439, DOI 10.1098/rspb.1987.0004; Michor F, 2002, NATURE, V419, P677, DOI 10.1038/419677a; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; Ostrom E., 1999, GOVERNING COMMONS; Ridley Matt, 1996, ORIGINS VIRTUE; SCHELLING TC, 1973, J CONFLICT RESOLUT, V17, P381, DOI 10.1177/002200277301700302; SEINEN I, 2001, T120010031 TINB I; SOBER E, 1999, OTHER EVOLUTION PSYC; Sugden R, 1986, EC RIGHTS COOPERATIO; Trivers R., 1985, SOCIAL EVOLUTION; Wedekind C, 2000, SCIENCE, V288, P850, DOI 10.1126/science.288.5467.850	30	259	264	4	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					390	393		10.1038/nature01986	http://dx.doi.org/10.1038/nature01986			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	724TG	14508487				2022-12-24	WOS:000185502300039
J	Chalder, T; Goodman, R; Wessely, S; Hotopf, M; Meltzer, H				Chalder, T; Goodman, R; Wessely, S; Hotopf, M; Meltzer, H			Epidemiology of chronic fatigue syndrome and self reported myalgic encephalomyelitis in 5-15 year olds: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Guys Kings & St Thomass Sch Med, Dept Psychol Med, London SE5 8AZ, England; Inst Psychiat, Dept Child & Adolescent Psychiat, London SE5 8AF, England; Off Natl Stat, London SW1V 2QQ, England	University of London; King's College London; University of London; King's College London	Chalder, T (corresponding author), Guys Kings & St Thomass Sch Med, Dept Psychol Med, London SE5 8AZ, England.		Chalder, Trudie/A-5717-2011; Hotopf, Matthew/E-4971-2010; Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929; Hotopf, Matthew/0000-0002-3980-4466; Chalder, Trudie/0000-0003-0775-1045; Goodman, Robert/0000-0001-5596-1667				Dobbins J.G., 1997, J CHRONIC FATIGUE SY, V3, P15, DOI DOI 10.1300/J092v03n02_03; Dowsett E. J., 1997, J CHRONIC FATIGUE SY, V3, P29, DOI DOI 10.1300/J092V03N02_; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Goldberg DP., 1972, DETECTION PSYCHIAT I; Goodman R, 2000, J CHILD PSYCHOL PSYC, V41, P645, DOI 10.1111/j.1469-7610.2000.tb02345.x; Jordan K. M., 2000, J CHRONIC FATIGUE SY, V6, P3; Meltzer H., 2000, MENTAL HLTH CHILDREN; Richards J., 1998, PSYCHIAT B, V22, P203; SPEIGHT A, 2000, ARCH DIS CHILD, V82, pG215	9	95	96	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 20	2003	327	7416					654	655		10.1136/bmj.327.7416.654	http://dx.doi.org/10.1136/bmj.327.7416.654			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500438	Bronze, Green Published			2022-12-24	WOS:000185463100022
J	Mair, W; Goymer, P; Pletcher, SD; Partridge, L				Mair, W; Goymer, P; Pletcher, SD; Partridge, L			Demography of dietary restriction and death in Drosophila	SCIENCE			English	Article							AGE-SPECIFIC MORTALITY; LIFE-SPAN; CALORIE RESTRICTION; OXIDATIVE STRESS; MELANOGASTER; LONGEVITY; MICE; RECEPTOR	Dietary restriction (DR) increases life-span in organisms from yeast to mammals, presumably by slowing the accumulation of aging-related damage. Here we show that in Drosophila, DR extends life-span entirely by reducing the short-term risk of death. Two days after the application of DR at any age for the first time, previously fully fed flies are no more likely to die than flies of the same age that have been subjected to long-term DR. DR of mammals may also reduce short-term risk of death, and hence DR instigated at any age could generate a full reversal of mortality.	UCL, Dept Biol, London WC1E 6BT, England; Univ London Imperial Coll Sci Technol & Med, Ctr Populat Biol, NERC, Ascot SL5 7PY, Berks, England	University of London; University College London; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Partridge, L (corresponding author), UCL, Dept Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.	l.partridge@ucl.ac.uk	Partridge, Linda/A-5501-2010; Partridge, Linda/E-7342-2015	Goymer, Patrick/0000-0002-2789-9373; Mair, William/0000-0002-0661-1342; Partridge, Linda/0000-0001-9615-0094	Biotechnology and Biological Sciences Research Council [SF19106] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Carey J. R., 2003, LONGEVITY BIOL DEMOG, DOI [10.1515/9780691224084, DOI 10.1515/9780691224084]; Carey JR, 1998, SCIENCE, V281, P996, DOI 10.1126/science.281.5379.996; Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; Good TP, 2001, J INSECT PHYSIOL, V47, P1467, DOI 10.1016/S0022-1910(01)00138-X; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Kealy RD, 2002, J AM VET MED ASSOC, V220, P1315, DOI 10.2460/javma.2002.220.1315; Kenyon C, 1996, CELL, V84, P501, DOI 10.1016/S0092-8674(00)81024-7; Lee E, 2013, STAT METHODS SURVIVA; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; MIQUEL J, 1976, MECH AGEING DEV, V5, P347, DOI 10.1016/0047-6374(76)90034-8; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; PARTRIDGE L, 1985, J INSECT PHYSIOL, V31, P393, DOI 10.1016/0022-1910(85)90084-8; Pearl R., 1928, RATE LIVING; Pletcher SD, 2000, J GERONTOL A-BIOL, V55, pB381, DOI 10.1093/gerona/55.8.B381; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; Richardson A., 1992, POTENTIAL NUTR MODUL, P177; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854	21	374	389	3	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1731	1733		10.1126/science.1086016	http://dx.doi.org/10.1126/science.1086016			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500985				2022-12-24	WOS:000185387700047
J	Staller, P; Sulitkova, J; Liszlwan, J; Moch, H; Oakeley, EJ; Krek, W				Staller, P; Sulitkova, J; Liszlwan, J; Moch, H; Oakeley, EJ; Krek, W			Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL	NATURE			English	Article							INDUCIBLE FACTOR-I; RENAL-CELL CARCINOMA; HYPOXIA; CANCER; GENES; METASTASIS; PROTEIN; GROWTH; PHOSPHORYLATION; FACTOR-1-ALPHA	Organ-specific metastasis is governed, in part, by interactions between chemokine receptors on cancer cells and matching chemokines in target organs. For example, malignant breast cancer cells express the chemokine receptor CXCR4 and commonly metastasize to organs that are an abundant source of the CXCR4-specific ligand stromal cell-derived factor-1alpha (ref. 1). It is still uncertain how an evolving tumour cell is reprogrammed to express CXCR4, thus implementing the tendency to metastasize to specific organs. Here we show that the von Hippel-Lindau tumour suppressor protein pVHL negatively regulates CXCR4 expression owing to its capacity to target hypoxia-inducible factor (HIF) for degradation under normoxic conditions. This process is suppressed under hypoxic conditions, resulting in HIF-dependent CXCR4 activation. An analysis of clear cell renal carcinoma that manifests mutation of the VHL gene in most cases revealed an association of strong CXCR4 expression with poor tumour-specific survival. These results suggest a mechanism for CXCR4 activation during tumour cell evolution and imply that VHL inactivation acquired by incipient tumour cells early in tumorigenesis confers not only a selective survival advantage but also the tendency to home to selected organs.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Univ Basel, Inst Pathol, CH-4031 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; University of Basel	Krek, W (corresponding author), ETH Honggerberg, Inst Cell Biol, HPM F 42, CH-8093 Zurich, Switzerland.							Aebersold DM, 2001, CANCER RES, V61, P2911; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Liotta LA, 2001, NATURE, V410, P24, DOI 10.1038/35065180; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Moch H, 2000, CANCER, V89, P604, DOI 10.1002/1097-0142(20000801)89:3<604::AID-CNCR16>3.3.CO;2-H; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; OBERLEY LW, 1982, SUPEROXIDE DISMUTASE, V1, P1; PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wiesener MS, 2001, CANCER RES, V61, P5215	30	712	754	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					307	311		10.1038/nature01874	http://dx.doi.org/10.1038/nature01874			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679920				2022-12-24	WOS:000185370900048
J	Adachi, M; Saito, H; Kobayashi, H; Horie, Y; Kato, S; Yoshioka, M; Ishii, H				Adachi, M; Saito, H; Kobayashi, H; Horie, Y; Kato, S; Yoshioka, M; Ishii, H			Hepatic injury in 12 patients taking the herbal weight loss aids Chaso or Onshido	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATOTOXICITY; SUPPLEMENTS; REMEDIES	Background: The Chinese herbal dietary supplements Chaso and Onshido are marketed for weight loss in Japan. The safety of these weight loss aids is unknown. Objective: To describe patients who developed liver injury while taking Chaso or Onshido. Design: Case series. Setting: Keio University Hospital, Tokyo, Japan, and other hospitals in Japan. Patients: 6 patients who took Chaso and 6 patients who took Onshido before presenting with liver injury. Measurements: Pathologic, clinical, and laboratory evaluations and chemical analysis of the herbal weight loss aids. Results: All 12 patients developed acute liver injury characterized by a marked increase in serum liver chemistry values (mean alanine aminotransferase level, 1978 U/L [range, 283 to 4074 U/L]) after ingesting these products. Two patients developed fulminant hepatic failure: 1 patient required liver transplantation, and the other patient died. N-nitroso-fenfluramine, a variant of the appetite-depressant drug fenfluramine, was present in these products. Conclusions: The use of the weight loss aids Chaso and Onshido may be associated with acute liver injury. N-nitroso-fenfluramine is a possible hepatotoxic ingredient.	Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Ishii, H (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.							Allison DB, 2001, CRIT REV FOOD SCI, V41, P1, DOI 10.1080/20014091091661; Barnes J, 1998, BRIT J CLIN PHARMACO, V45, P496, DOI 10.1046/j.1365-2125.1998.00715.x; Chitturi S, 2000, J GASTROEN HEPATOL, V15, P1093, DOI 10.1046/j.1440-1746.2000.02349.x; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; ELIASON BC, 1994, J FAM PRACTICE, V38, P287; Favreau JT, 2002, ANN INTERN MED, V136, P590, DOI 10.7326/0003-4819-136-8-200204160-00008; HANAWA N, 2003, ACTAZ HEPATOLOGICA J, V44, P21; Hasegawa R, 1998, CANCER LETT, V123, P185, DOI 10.1016/S0304-3835(97)00417-5; Hutchins GM, 2001, NEW ENGL J MED, V344, P1095; KATO Y, 1979, Gastroenterologia Japonica, V14, P216; Nadir A, 1996, AM J GASTROENTEROL, V91, P1436; Shaw D, 1997, DRUG SAFETY, V17, P342, DOI 10.2165/00002018-199717050-00006; Sheikh NM, 1997, ARCH INTERN MED, V157, P913, DOI 10.1001/archinte.157.8.913; Trey C, 1970, Prog Liver Dis, V3, P282; Zimmerman H J, 2000, Clin Liver Dis, V4, P73, DOI 10.1016/S1089-3261(05)70097-0	16	59	60	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					488	492		10.7326/0003-4819-139-6-200309160-00012	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679326				2022-12-24	WOS:000185324100005
J	Bais, HP; Vepachedu, R; Gilroy, S; Callaway, RM; Vivanco, JM				Bais, HP; Vepachedu, R; Gilroy, S; Callaway, RM; Vivanco, JM			Allelopathy and exotic plant invasion: From molecules and genes to species interactions	SCIENCE			English	Article							ROOT; NEIGHBORS	Here we present evidence that Centaurea maculosa (spotted knapweed), an invasive species in the western United States, displaces native plant species by exuding the phytotoxin (-)-catechin from its roots. Our results show inhibition of native species' growth and germination in field soils at natural concentrations of (-)- catechin. In susceptible species such as Arabidopsis thaliana, the allelo-chemical triggers a wave of reactive oxygen species (ROS) initiated at the root meristem, which leads to a Ca2+ signaling cascade triggering genome-wide changes in gene expression and, ultimately, death of the root system. Our results support a "novel weapons hypothesis" for invasive success.	Colorado State Univ, Dept Hort & Landscape Architecture, Cell & Mol Biol Program, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Hort & Landscape Architecture, Grad Degree Program Ecol, Ft Collins, CO 80523 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Univ Montana, Div Biol Sci, Missoula, MT 59812 USA	Colorado State University; Colorado State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Montana System; University of Montana	Vivanco, JM (corresponding author), Colorado State Univ, Dept Hort & Landscape Architecture, Cell & Mol Biol Program, Ft Collins, CO 80523 USA.	jvivanco@lamar.colostate.edu	Rechsteiner, Cynthia/C-5894-2011	Gilroy, Simon/0000-0001-9597-6839				Bais HP, 2002, PLANT PHYSIOL, V128, P1173, DOI 10.1104/pp.011019; Bais HP, 2001, IN VITRO CELL DEV-PL, V37, P730; BAIS HP, UNPUB; Callaway RM, 2000, SCIENCE, V290, P521, DOI 10.1126/science.290.5491.521; Callaway RM, 2002, TRENDS ECOL EVOL, V17, P104, DOI 10.1016/S0169-5347(01)02438-7; Fasano JM, 2001, PLANT CELL, V13, P907, DOI 10.1105/tpc.13.4.907; Gheldof N, 2002, J AGR FOOD CHEM, V50, P5870, DOI 10.1021/jf0256135; Goslee SC, 2001, ECOL MODEL, V139, P31, DOI 10.1016/S0304-3800(01)00231-9; Grant JJ, 2000, PLANT PHYSIOL, V124, P21, DOI 10.1104/pp.124.1.21; Jones DL, 1998, PLANTA, V206, P378, DOI 10.1007/s004250050413; KEANE S, 2002, TRENDS ECOL EVOL, V17, P170; Kennedy TA, 2002, NATURE, V417, P636, DOI 10.1038/nature00776; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Ridenour WM, 2001, OECOLOGIA, V126, P444, DOI 10.1007/s004420000533	14	780	1000	12	626	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1377	1380		10.1126/science.1083245	http://dx.doi.org/10.1126/science.1083245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958360				2022-12-24	WOS:000185116400041
J	Kiers, ET; Rousseau, RA; West, SA; Denison, RF				Kiers, ET; Rousseau, RA; West, SA; Denison, RF			Host sanctions and the legume-rhizobium mutualism	NATURE			English	Article							NITROGENASE ACTIVITY; ROOT-NODULES; EVOLUTION; STABILITY; PERMEABILITY; COMPETITION	Explaining mutualistic cooperation between species remains one of the greatest problems for evolutionary biology(1-4). Why do symbionts provide costly services to a host, indirectly benefiting competitors sharing the same individual host? Host monitoring of symbiont performance and the imposition of sanctions on 'cheats' could stabilize mutualism(5,6). Here we show that soybeans penalize rhizobia that fail to fix N-2 inside their root nodules. We prevented a normally mutualistic rhizobium strain from cooperating (fixing N-2) by replacing air with an N-2-free atmosphere (Ar:O-2). A series of experiments at three spatial scales (whole plants, half root systems and individual nodules) demonstrated that forcing non-cooperation (analogous to cheating) decreased the reproductive success of rhizobia by about 50%. Non-invasive monitoring implicated decreased O-2 supply as a possible mechanism for sanctions against cheating rhizobia. More generally, such sanctions by one or both partners may be important in stabilizing a wide range of mutualistic symbioses.	Univ Calif Davis, Davis, CA 95616 USA; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of California System; University of California Davis; University of Edinburgh	Denison, RF (corresponding author), Univ Calif Davis, 1 Shields Ave, Davis, CA 95616 USA.	rfdenison@ucdavis.edu	West, Stuart A/M-3608-2014; Toby, Kiers/H-4819-2017	West, Stuart A/0000-0003-2152-3153; Toby, Kiers/0000-0002-0597-1653				AMARGER N, 1981, SOIL BIOL BIOCHEM, V13, P475, DOI 10.1016/0038-0717(81)90037-7; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Burdon JJ, 1999, J APPL ECOL, V36, P398, DOI 10.1046/j.1365-2664.1999.00409.x; Crespi BJ, 2001, TRENDS ECOL EVOL, V16, P178, DOI 10.1016/S0169-5347(01)02115-2; DENISON RF, 1991, PLANT PHYSIOL, V96, P137, DOI 10.1104/pp.96.1.137; Denison RF, 2000, AM NAT, V156, P567, DOI 10.1086/316994; DENISON RF, 1995, PLANT PHYSIOL, V107, P1355, DOI 10.1104/pp.107.4.1355; Ferriere R, 2002, P ROY SOC B-BIOL SCI, V269, P773, DOI 10.1098/rspb.2001.1900; Frank S. A., 1998, FDN SOCIAL EVOLUTION, DOI DOI 10.1515/9780691206820; FRANK SA, 1995, NATURE, V377, P520, DOI 10.1038/377520a0; HAHN M, 1986, FEMS MICROBIOL LETT, V33, P143; HARTWIG U, 1987, ANN BOT-LONDON, V59, P285, DOI 10.1093/oxfordjournals.aob.a087317; Herre EA, 1999, TRENDS ECOL EVOL, V14, P49, DOI 10.1016/S0169-5347(98)01529-8; KIJNE JW, 1975, PHYSIOL PLANT PATHOL, V7, P17, DOI 10.1016/0048-4059(75)90055-7; KING BJ, 1991, PLANT PHYSIOL, V96, P376, DOI 10.1104/pp.96.2.376; Layzell D. B., 1989, Applications of continuous and steady-state methods to root biology., P1; LAYZELL DB, 1979, PLANT PHYSIOL, V64, P888, DOI 10.1104/pp.64.5.888; Lodwig EM, 2003, NATURE, V422, P722, DOI 10.1038/nature01527; PELLMYR O, 1994, NATURE, V372, P257, DOI 10.1038/372257a0; RASCHE ME, 1989, PLANT PHYSIOL, V91, P663, DOI 10.1104/pp.91.2.663; Ratnieks FLW, 2001, ANN ZOOL FENN, V38, P201; SEN D, 1980, PLANT SCI LETT, V18, P315, DOI 10.1016/0304-4211(80)90122-4; SHEEHY JE, 1983, ANN BOT-LONDON, V52, P565, DOI 10.1093/oxfordjournals.aob.a086611; SINGLETON PW, 1987, PLANT PHYSIOL, V83, P552, DOI 10.1104/pp.83.3.552; SINGLETON PW, 1983, CROP SCI, V23, P69, DOI 10.2135/cropsci1983.0011183X002300010019x; SPRENT JI, 1985, P ROY SOC EDINB B, V85, P215, DOI 10.1017/S0269727000004036; UDVARDI MK, 1993, SYMBIOSIS, V14, P87; West SA, 2002, J EVOLUTION BIOL, V15, P830, DOI 10.1046/j.1420-9101.2002.00441.x; West SA, 2002, P ROY SOC B-BIOL SCI, V269, P685, DOI 10.1098/rspb.2001.1878; Yu DW, 2001, BIOL J LINN SOC, V72, P529, DOI [10.1006/bijl.2000.0514, 10.1111/j.1095-8312.2001.tb01336.x]	30	619	643	5	415	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					78	81		10.1038/nature01931	http://dx.doi.org/10.1038/nature01931			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955144	Green Published			2022-12-24	WOS:000185089200041
J	Rothberg, MB; Bellantonio, S; Rose, DN				Rothberg, MB; Bellantonio, S; Rose, DN			Management of influenza in adults older than 65 years of age: Cost-effectiveness of rapid testing and antiviral therapy	ANNALS OF INTERNAL MEDICINE			English	Article							NEURAMINIDASE INHIBITOR OSELTAMIVIR; TREATING INFLUENZA; INHALED ZANAMIVIR; NURSING-HOME; EFFICACY; SAFETY; VACCINATION; AMANTADINE; IMPACT; PROPHYLAXIS	Background: Although antiviral therapy is cost-effective in adults, its cost-effectiveness in older adults has not been studied. Objective: To determine the cost-effectiveness of influenza testing and treatment strategies for older adults. Design: Cost-utility decision model. Data Sources: Clinical trials of antiviral drugs and epidemiologic data. Target Population: Noninstitutionalized adults older than 65 years of age with influenza-like illness. Time Horizon: Lifetime. Perspective: Societal. Interventions: Rapid diagnostic testing or empirical therapy with antiviral drugs. Outcome Measures: Cost per quality-adjusted life-year (QALY) saved. Results of Base-Case Analysis: Compared with no intervention, empirically treating an unvaccinated 75-year-old patient with amantadine increased life expectancy by 0.0014 QALY at a cost of $1.57, a cost-effectiveness ratio of $1129 per QALY saved. Compared with amantadine, rapid diagnostic testing followed by treatment with oseltamivir cost $5025 per QALY saved and empirical treatment with oseltamivir cost $10 296 per QALY saved. Testing and treatment strategies were less cost-effective if the patient was vaccinated, ranging from $2483 per QALY saved with amantadine to $70 300 per QALY saved with oseltamivir. Results of Sensitivity Analysis: The decision was sensitive to the probability of influenza, the efficacy of oseltamivir in preventing hospitalizations, and hospitalization and case-fatality rates. The decision was not sensitive to the probability or severity of medication side effects, the quality of life for influenza illness or hospitalization, the efficacy of antiviral therapy in shortening influenza illness, or the rapid diagnostic test characteristics. Conclusions: For unvaccinated or high-risk vaccinated patients during the influenza season, empirical oseltamivir treatment is cost-effective. For other patients, rapid diagnostic testing followed by treatment with oseltamivir is cost-effective. Empirical amantadine treatment offers a low-cost alternative if patients cannot afford oseltamivir.	Baystate Med Ctr, Div Gen Med & Geriatr, Springfield, MA 01199 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Baystate Medical Center; Tufts University	Rothberg, MB (corresponding author), Baystate Med Ctr, Div Gen Med & Geriatr, 759 Chestnut St, Springfield, MA 01199 USA.	Michael.Rothberg@bhs.org						[Anonymous], 1999, MED LETT DRUGS THER, V41, P121; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; Boivin G, 2000, CLIN INFECT DIS, V31, P1166, DOI 10.1086/317425; Bowles SK, 2002, J AM GERIATR SOC, V50, P608, DOI 10.1046/j.1532-5415.2002.50153.x; Bridges Carolyn B, 2002, MMWR Recomm Rep, V51, P1; *CDCP, 2002, REP SURV METH US CUR; Cox FM, 2000, AM J MANAG CARE, V6, P205; Crane M, 2001, Med Econ, V78, P50; CRANE M, 2001, MED ECON, V78, P55; DEMICHELI V, 2001, COCHRANE DB SYST REV; Diggory P, 2001, BRIT MED J, V322, P577, DOI 10.1136/bmj.322.7286.577; DOLIN R, 1982, NEW ENGL J MED, V307, P580, DOI 10.1056/NEJM198209023071002; *GLAX WELLC, 2001, REL ZAN INH PACK INS; Gold MR, 1996, COST EFFECTIVENESS H; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; Govaert TME, 1998, FAM PRACT, V15, P16, DOI 10.1093/fampra/15.1.16; Gravenstein S, 2002, CLIN INFECT DIS, V35, P729, DOI 10.1086/341246; Griffin AD, 2001, PHARMACOECONOMICS, V19, P293, DOI 10.2165/00019053-200119030-00007; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; Hayden FG, 1996, JAMA-J AM MED ASSOC, V275, P295, DOI 10.1001/jama.275.4.295; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; Jefferson T, 1999, PHARMACOECONOMICS, V16, P85, DOI 10.2165/00019053-199916001-00011; Kaiser L, 2000, ARCH INTERN MED, V160, P3234, DOI 10.1001/archinte.160.21.3234; Kerlikowske K, 1999, JAMA-J AM MED ASSOC, V282, P2156, DOI 10.1001/jama.282.22.2156; Keyser LA, 2000, ARCH INTERN MED, V160, P1485, DOI 10.1001/archinte.160.10.1485; Lalezari J, 2001, ARCH INTERN MED, V161, P212, DOI 10.1001/archinte.161.2.212; Lee PY, 2002, ANN INTERN MED, V137, P225, DOI 10.7326/0003-4819-137-4-200208200-00005; Libow LS, 1996, J AM GERIATR SOC, V44, P1153, DOI 10.1111/j.1532-5415.1996.tb01363.x; Matsumoto K, 1999, ANTIVIR THER, V4, P61; *MED EC, 2001, 2001 DRUG TOP RED BO; Monto AS, 1999, J ANTIMICROB CHEMOTH, V44, P23, DOI 10.1093/jac/44.suppl_2.23; Monto AS, 1999, J INFECT DIS, V180, P254, DOI 10.1086/314904; Muennig PA, 2001, CLIN INFECT DIS, V33, P1879, DOI 10.1086/324491; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1; Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; Simonsen L, 2000, J INFECT DIS, V181, P831, DOI 10.1086/315320; Smith KJ, 2002, AM J MED, V113, P300, DOI 10.1016/S0002-9343(02)01222-6; STANGE KC, 1991, J AM GERIATR SOC, V39, P700, DOI 10.1111/j.1532-5415.1991.tb03625.x; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; US Department of Labor Bureau of Labor Statistic, CONS PRIC IND ALL UR; Wenzel RP, 2000, JAMA-J AM MED ASSOC, V283, P1057, DOI 10.1001/jama.283.8.1057; Zambon M, 2001, ARCH INTERN MED, V161, P2116, DOI 10.1001/archinte.161.17.2116; 1999, MED LETT DRUGS THER, V41, P91	47	59	63	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				321	329		10.7326/0003-4819-139-5_Part_1-200309020-00007	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965940				2022-12-24	WOS:000185037500002
J	Snowdon, DA				Snowdon, DA			Healthy aging and dementia: Findings from the Nun Study	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				ALZHEIMERS-DISEASE; EARLY-LIFE; LINGUISTIC ABILITY; COGNITIVE FUNCTION	The Nun Study is a longitudinal study of 678 Catholic sisters 75 to 107 years of age who are members of the School Sisters of Notre Dame congregation. Data collected for this study include early and middle-life risk factors from the convent archives, annual cognitive and physical function evaluations during old age, and postmortem neuropathologic evaluations of the participants' brains. The case histories presented include a centenarian who was a model of healthy aging, a 92-year-old with dementia and clinically significant Alzheimer disease neuropathology and vascular lesions, a cognitively and physically intact centenarian with almost no neuropathology, and an 85-year-old with well-preserved cognitive and physical function despite a genetic predisposition to Alzheimer disease and an abundance of Alzheimer disease lesions. These case histories provide examples of how healthy aging and dementia relate to the degree of pathology present in the brain and the level of resistance to the clinical expression of the neuropathology.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	University of Kentucky	Snowdon, DA (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 320 Hlth Sci Bldg, Lexington, KY 40536 USA.	dsnowdon@nunstudy.mi8.com			NIA NIH HHS [R01AG09862, 5P50AG05144, K04AG00553] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K04AG000553, R01AG009862, P50AG005144] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Butler SM, 1996, J GERONTOL B-PSYCHOL, V51, pS201, DOI 10.1093/geronb/51B.4.S201; Danner DD, 2001, J PERS SOC PSYCHOL, V80, P804, DOI 10.1037/0022-3514.80.5.804; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; OHM TG, 1995, NEUROSCIENCE, V64, P209, DOI 10.1016/0306-4522(95)90397-P; Riley KP, 2002, ANN NEUROL, V51, P567, DOI 10.1002/ana.10161; Snowdon DA, 1997, GERONTOLOGIST, V37, P150, DOI 10.1093/geront/37.2.150; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Snowdon DA, 1999, 1ST INTERNATIONAL CONGRESS ON VASCULAR DEMENTIA, P19; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Snowdon DA, 2000, ANN NY ACAD SCI, V903, P34, DOI 10.1111/j.1749-6632.2000.tb06347.x; SNOWDON DA, 1999, PARADOXES LONGEVITY, P103, DOI DOI 10.1007/978-3-642-60100-2_9; Snowdon David, 2001, AGING GRACE WHAT NUN; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248	15	192	204	4	47	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			450	454		10.7326/0003-4819-139-5_Part_2-200309021-00014	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00014			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965975				2022-12-24	WOS:000185133800014
J	Harris, HH; Pickering, IJ; George, GN				Harris, HH; Pickering, IJ; George, GN			The chemical form of mercury in fish	SCIENCE			English	Article									SLAC, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	George, GN (corresponding author), Univ Saskatchewan, Dept Geol Sci, 114 Sci Pl, Saskatoon, SK S7N 5E2, Canada.		Pickering, Ingrid J/A-4547-2013; Harris, Hugh/A-4983-2008; George, Graham N/E-3290-2013	Pickering, Ingrid J/0000-0002-0936-2994; Harris, Hugh/0000-0002-3472-8628; George, Graham/0000-0002-0420-7493				Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; Goyer R., 2000, TOXICOLOGICAL EFFECT; Guallar E, 2002, NEW ENGL J MED, V347, P1747, DOI 10.1056/NEJMoa020157; Wagemann R, 1998, SCI TOTAL ENVIRON, V218, P19, DOI 10.1016/S0048-9697(98)00192-2	4	1141	1184	3	320	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1203	1203		10.1126/science.1085941	http://dx.doi.org/10.1126/science.1085941			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947190				2022-12-24	WOS:000185003500031
J	Bibby, TS; Mary, I; Nield, J; Partensky, F; Barber, J				Bibby, TS; Mary, I; Nield, J; Partensky, F; Barber, J			Low-light-adapted Prochlorococcus species possess specific antennae for each photosystem	NATURE			English	Article							CYANOBACTERIA/; PROKARYOTE; RESOLUTION; COMPLEXES; PHYLOGENY; PROTEINS; GENES; RING	Prochlorococcus, the most abundant genus of photosynthetic organisms(1), owes its remarkably large depth distribution in the oceans to the occurrence of distinct genotypes adapted to either low- or high-light niches(2,3). The pcb genes, encoding the major chlorophyll-binding, light-harvesting antenna proteins in this genus(4), are present in multiple copies in low- light strains but as a single copy in high-light strains(5). The basis of this differentiation, however, has remained obscure. Here we show that the moderate low- light-adapted strain Prochlorococcus sp. MIT 9313 has one iron-stress-induced pcb gene encoding an antenna protein serving photosystem I (PSI)-comparable to isiA genes from cyanobacteria(6,7) -and a constitutively expressed pcb gene encoding a photosystem II (PSII) antenna protein. By comparison, the very low- light-adapted strain SS120 has seven pcb genes encoding constitutive PSI and PSII antennae, plus one PSI iron-regulated pcb gene, whereas the high-light-adapted strain MED4 has only a constitutive PSII antenna. Thus, it seems that the adaptation of Prochlorococcus to low light environments has triggered a multiplication and specialization of Pcb proteins comparable to that found for Cab proteins in plants and green algae(8).	Univ London Imperial Coll Sci Technol & Med, Wolfson Labs, Dept Biol Sci, London SW7 2AZ, England; CNRS, Biol Stn, UMR 7127, F-29682 Roscoff, France; Univ Paris 06, F-29682 Roscoff, France	Imperial College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Barber, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Wolfson Labs, Dept Biol Sci, Biochem Bldg,S Kensington Campus, London SW7 2AZ, England.		Partensky, Frédéric/AAH-1170-2021; Bibby, Thomas/C-9159-2014; Partensky, Frédéric/B-9194-2018; Nield, Jon/C-5892-2013	Partensky, Frédéric/0000-0003-1274-4050; Partensky, Frédéric/0000-0003-1274-4050; Nield, Jon/0000-0001-9983-0239; Bibby, Thomas/0000-0003-1743-473X				Bhaya D, 2000, J BACTERIOL, V182, P5692, DOI 10.1128/JB.182.20.5692-5699.2000; Bibby TS, 2001, NATURE, V413, P590, DOI 10.1038/35098153; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; Boekema EJ, 2001, NATURE, V412, P745, DOI 10.1038/35089104; Garczarek L, 2001, PLANT MOL BIOL, V46, P683, DOI 10.1023/A:1011681726654; Green BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/annurev.arplant.47.1.685; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; LaRoche J, 1996, P NATL ACAD SCI USA, V93, P15244; MARY I, IN PRESS FEMS MICROB; Moore LR, 1999, LIMNOL OCEANOGR, V44, P628, DOI 10.4319/lo.1999.44.3.0628; Moore LR, 1998, NATURE, V393, P464, DOI 10.1038/30965; Partensky F, 1997, PHOTOSYNTH RES, V51, P209, DOI 10.1023/A:1005807408161; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; PARTENSKY F, IN PRESS ADV PHOTOSY; SIDLER W, 1994, MOL BIOL CYANOBACTER, V14, P139; Straus N.A., 1994, MOL BIOL CYANOBACTER, P731, DOI DOI 10.1007/978-94-011-0227-8_25; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/S0304-3991(81)80197-0; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004	20	127	156	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1051	1054		10.1038/nature01933	http://dx.doi.org/10.1038/nature01933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944966				2022-12-24	WOS:000184984200042
J	Culley, AI; Lang, AS; Suttle, CA				Culley, AI; Lang, AS; Suttle, CA			High diversity of unknown picorna-like viruses in the sea	NATURE			English	Article							MARINE VIRUSES; RNA; POLYMERASES; EVOLUTION; TAXONOMY; MOTIFS	Picorna-like viruses are a loosely defined group of positive-sense single-stranded RNA viruses that are major pathogens of animals, plants and insects. They include viruses that are of enormous economic and public-health concern and are responsible for animal diseases (such as poliomyelitis(1)), plant diseases (such as sharka(2)) and insect diseases (such as sacbrood(3)). Viruses from the six divergent families (the Picornaviridae, Caliciviridae, Comoviridae, Sequiviridae, Dicistroviridae and Potyviridae) that comprise the picorna-like virus superfamily(4) have the following features in common: a genome with a protein attached to the(5)' end and no overlapping open reading frames, all the RNAs are translated into a polyprotein before processing, and a conserved RNA-dependent RNA polymerase (RdRp) protein. Analyses of RdRp sequences from these viruses produce phylogenies that are congruent with established picorna-like virus family assignments(5-7); hence, this gene is an excellent molecular marker for examining the diversity of picorna-like viruses in nature. Here we report, on the basis of analysis of RdRp sequences amplified from marine virus communities, that a diverse array of picorna-like viruses exists in the ocean. All of the sequences amplified were divergent from known picorna-like viruses, and fell within four monophyletic groups that probably belong to at least two new families. Moreover, we show that an isolate belonging to one of these groups is a lytic pathogen of Heterosigma akashiwo, a toxic-bloom-forming alga responsible for severe economic losses to the finfish aquaculture industry, suggesting that picorna-like viruses are important pathogens of marine phytoplankton.	Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z4, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Suttle, CA (corresponding author), Univ British Columbia, Dept Bot, 1461-6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	csuttle@eos.ubc.ca	suttle, c/N-1144-2019; Suttle, Curtis A/C-3150-2008	suttle, c/0000-0002-0372-0033; Suttle, Curtis A/0000-0002-0372-0033; Lang, Andrew/0000-0002-4510-7683				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 2001, FIELDS VIROLOGY; BAILEY L, 1964, VIROLOGY, V23, P425, DOI 10.1016/0042-6822(64)90266-1; BERNARD J, 1995, VET RES, V26, P341; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Fuhrman JA, 1999, NATURE, V399, P541, DOI 10.1038/21119; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; Kingsley DH, 2002, APPL ENVIRON MICROB, V68, P3914, DOI 10.1128/AEM.68.8.3914-3918.2002; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Liljas L, 2002, ARCH VIROL, V147, P59, DOI 10.1007/s705-002-8303-1; Mann NH, 2003, FEMS MICROBIOL REV, V27, P17, DOI 10.1016/S0168-6445(03)00016-0; Mari J, 2002, J GEN VIROL, V83, P915, DOI 10.1099/0022-1317-83-4-915; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Short SM, 2002, APPL ENVIRON MICROB, V68, P1290, DOI 10.1128/AEM.68.3.1290-1296.2002; Smayda T.J., 1998, PHYSL ECOLOGY HARMFU, P113; SMITH AW, 1973, NATURE, V244, P108, DOI 10.1038/244108a0; Smith AW, 2000, VIRAL ECOLOGY, P447, DOI 10.1016/B978-012362675-2/50013-6; SUTTLE CA, 1991, APPL ENVIRON MICROB, V57, P721, DOI 10.1128/AEM.57.3.721-726.1991; Suttle CA, 2000, VIRAL ECOLOGY, P247, DOI 10.1016/B978-012362675-2/50007-0; SUTTLE CA, 1992, APPL ENVIRON MICROB, V58, P3721, DOI 10.1128/AEM.58.11.3721-3729.1992; Tai V, 2003, J PHYCOL, V39, P343, DOI 10.1046/j.1529-8817.2003.01162.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Van Bressem MF, 1999, DIS AQUAT ORGAN, V38, P53, DOI 10.3354/dao038053; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; Wilhelm SW, 1999, BIOSCIENCE, V49, P781, DOI 10.2307/1313569; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000; Zanotto PMD, 1996, J VIROL, V70, P6083, DOI 10.1128/JVI.70.9.6083-6096.1996; [No title captured]	30	149	156	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2003	424	6952					1054	1057		10.1038/nature01886	http://dx.doi.org/10.1038/nature01886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944967				2022-12-24	WOS:000184984200043
J	Mossessova, E; Bickford, LC; Goldberg, J				Mossessova, E; Bickford, LC; Goldberg, J			SNARE selectivity of the COPII coat	CELL			English	Article							N-TERMINAL DOMAIN; ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; TRANSPORT VESICLES; CRYSTAL-STRUCTURE; CARGO SELECTION; GOLGI-COMPLEX; YEAST; PROTEINS; ER	The COPII coat buds transport vesicles from the endoplasmic reticulum that incorporate cargo and SNARE molecules. Here, we show that recognition of the ER-Golgi SNAREs Bet1, Sed5, and Sec22 occurs through three binding sites on the Sec23/24 subcomplex of yeast COPII. The A site binds to the YNNSNPF motif of Sed5. The B site binds to Lxx-UM-E sequences present in both the Bet1 and Sed5 molecules, as well as to the DxE cargo-sorting signal. A third, spatially distinct site binds to Sec22. COPII selects the free v-SNARE form of Bet1 because the LxxLE sequence is sequestered in the four-helix bundle of the v-/t-SNARE complex. COPII favors Sed5 within the Sed5/Bos1/ Sec22 t-SNARE complex because t-SNARE assembly removes autoinhibitory contacts to expose the YNNSNPF motif. The COPII coat seems to be a specific conductor of the fusogenic forms of these SNAREs, suggesting how vesicle fusion specificity may be programmed during budding.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, 1275 York Ave, New York, NY 10021 USA.	jonathan@ximpact4.ski.mskcc.org						[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bracher A, 2002, EMBO J, V21, P6114, DOI 10.1093/emboj/cdf608; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Kiessling V, 2003, BIOPHYS J, V84, P408, DOI 10.1016/S0006-3495(03)74861-9; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Margittai M, 2003, BIOCHEMISTRY-US, V42, P4009, DOI 10.1021/bi027437z; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Munson M, 2000, NAT STRUCT BIOL, V7, P894; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thoma NH, 2000, BIOCHEMISTRY-US, V39, P12043, DOI 10.1021/bi000835m; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9	42	285	298	2	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2003	114	4					483	495		10.1016/S0092-8674(03)00608-1	http://dx.doi.org/10.1016/S0092-8674(03)00608-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941276	Bronze			2022-12-24	WOS:000184928800011
J	Thordarson, P; Bijsterveld, EJA; Rowan, AE; Nolte, RJM				Thordarson, P; Bijsterveld, EJA; Rowan, AE; Nolte, RJM			Epoxidation of polybutadiene by a topologically linked catalyst	NATURE			English	Article							DNA; ROTAXANE; METALLOPORPHYRINS; OXIDATION; MOTION	Nature has evolved complex enzyme architectures that facilitate the synthesis and manipulation of the biopolymers DNA and RNA, including enzymes capable of attaching to the biopolymer substrate and performing several rounds of catalysis before dissociating(1-5). Many of these 'processive' enzymes have a toroidal shape and completely enclose the biopolymer while moving along its chain, as exemplified by the DNA enzymes T4 DNA polymerase holoenzyme(6) and lambda-exonucleoase(7). The overall architecture of these systems resembles that of rotaxanes, in which a long molecule or polymer is threaded through a macrocycle. Here we describe a rotaxane that mimics the ability of processive enzymes to catalyse multiple rounds of reaction while the polymer substrate stays bound. The catalyst consists of a substrate binding cavity incorporating a manganese( III) porphyrin complex that oxidizes alkenes within the toroid cavity, provided a ligand has been attached to the outer face of the toroid to both activate the porphyrin complex and shield it from being able to oxidize alkenes outside the cavity. We find that when threaded onto a polybutadiene polymer strand, this catalyst epoxidizes the double bonds of the polymer, thereby acting as a simple analogue of the enzyme systems.	Univ Nijmegen, Dept Organ Chem, NSRIM, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Rowan, AE (corresponding author), Univ Nijmegen, Dept Organ Chem, NSRIM, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	rowan@sci.kun.nl	Thordarson, Pall/A-2138-2015; Nolte, Roeland/C-9930-2013; Rowan, Alan E/F-9702-2015	Thordarson, Pall/0000-0002-1200-8814; Nolte, Roeland/0000-0002-5612-7815; Rowan, Alan E/0000-0003-0728-3851				Ashton PR, 1998, J AM CHEM SOC, V120, P11190, DOI 10.1021/ja981889a; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; Brouwer AM, 2001, SCIENCE, V291, P2124, DOI 10.1126/science.1057886; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Davis AP, 1999, NATURE, V401, P120, DOI 10.1038/43576; Elemans JAAW, 2000, CHEM COMMUN, P2443, DOI 10.1039/b008567g; Elemans JAAW, 1999, J ORG CHEM, V64, P7009, DOI 10.1021/jo990112c; FARRINGT.JA, 1969, J CHEM SOC CHEM COMM, P259, DOI 10.1039/c29690000259; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HARADA A, 1992, NATURE, V356, P325, DOI 10.1038/356325a0; HOLLIS BW, 1990, P NATL ACAD SCI USA, V87, P6009, DOI 10.1073/pnas.87.16.6009; Jimenez MC, 2000, ANGEW CHEM INT EDIT, V39, P3284, DOI 10.1002/1521-3773(20000915)39:18<3284::AID-ANIE3284>3.0.CO;2-7; Kool ET, 1998, ACCOUNTS CHEM RES, V31, P502, DOI 10.1021/ar9602462; Kool ET, 2000, ANGEW CHEM INT EDIT, V39, P990, DOI 10.1002/(SICI)1521-3773(20000317)39:6<990::AID-ANIE990>3.0.CO;2-0; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; LIN SM, 1993, NUCLEASES; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; Perkins TT, 2001, BIOPHYS J, V80, p349A; Rowan AE, 1998, CHEM COMMUN, P611, DOI 10.1039/a708373d; Sacco HC, 2001, J CHEM SOC PERK T 2, P181, DOI 10.1039/b006755p; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; Schalley CA, 2001, ACCOUNTS CHEM RES, V34, P465, DOI 10.1021/ar000179i; SHEN YX, 1994, J AM CHEM SOC, V116, P537, DOI 10.1021/ja00081a014; TORNARITIS MJ, 1992, POLYMER, V33, P1771, DOI 10.1016/0032-3861(92)91081-C; Trakselis MA, 2001, P NATL ACAD SCI USA, V98, P8368, DOI 10.1073/pnas.111006698; Tsuda Y, 1998, J MOL CATAL A-CHEM, V130, P285, DOI 10.1016/S1381-1169(97)00220-3	28	325	327	1	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					915	918		10.1038/nature01925	http://dx.doi.org/10.1038/nature01925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	713EH	12931181				2022-12-24	WOS:000184843600034
J	Ri-Li, G; Chase, PJ; Witkowski, S; Wyrick, BL; Stone, JA; Levine, BD; Babb, TG				Ri-Li, G; Chase, PJ; Witkowski, S; Wyrick, BL; Stone, JA; Levine, BD; Babb, TG			Obesity: Associations with acute mountain sickness	ANNALS OF INTERNAL MEDICINE			English	Article							RESEARCH ISSUES; HIGH-ALTITUDE; SLEEP-APNEA; EXERCISE	Background: Although few retrospective studies of high altitude have reported that obesity might be associated with the development of acute mountain sickness (AMS), this association has not been studied prospectively. Objective: To determine whether obesity is associated with the development of AMS. Design: Obese and nonobese men were compared at a simulated altitude of 3658 m (12000 ft). Setting: 24 hours in a hypobaric environmental chamber. Participants: 9 obese and 10 nonobese men. Measurements: Percentage body fat (by hydrostatic weighing), Lake Louise AMS score, and Sao(2) level (by pulse oximetry) were measured. Results: Average AMS scores increased more rapidly with time spent at simulated high altitudes for obese men than for nonobese men (P<0.001). The response of Sao(2) with exposure differed between nonobese and obese men. After 24 hours in the altitude chamber, seven obese men (78%) and four nonobese men (40%) had AMS scores of 4 or more. Conclusion: Obesity seems to be associated with the development of AMS, which may be partly related to greater nocturnal desaturation with altitude exposure.	Presbyterian Med Ctr, Inst Exercise & Environm Med, Dallas, TX 75231 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Qinghai Med Coll, Inst High Altitude Med, Xining, Qinghai, Peoples R China	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Qinghai University	Babb, TG (corresponding author), Presbyterian Med Ctr, Inst Exercise & Environm Med, 7232 Greenville Ave,Suite 435, Dallas, TX 75231 USA.		Chase, Paul/H-3462-2019	Chase, Paul/0000-0003-2127-0889				Ahmed Q, 1997, HUM PATHOL, V28, P264, DOI 10.1016/S0046-8177(97)90122-2; Becker HF, 1999, AM J RESP CRIT CARE, V159, P112, DOI 10.1164/ajrccm.159.1.9803037; Eichenberger U, 1996, AM J RESP CRIT CARE, V154, P1748, DOI 10.1164/ajrccm.154.6.8970365; Flegal KM, 1999, MED SCI SPORT EXER, V31, pS509, DOI 10.1097/00005768-199911001-00004; GE R, 1995, CHINESE J APPL PHYSL, V11, P205; GE RL, 1987, CHINESE J INT MED, V13, P115; GOLDSTEIN JL, 1992, EUR HEART J, V13, P34, DOI 10.1093/eurheartj/13.suppl_B.34; HACKETT PH, 2001, WILDERNESS MED, P1; Hill JO, 1999, MED SCI SPORT EXER, V31, pS515, DOI 10.1097/00005768-199911001-00005; HIRATA K, 1989, LANCET, V2, P1040; HONIGMAN B, 1993, ANN INTERN MED, V118, P587, DOI 10.7326/0003-4819-118-8-199304150-00003; KAYSER B, 1991, J WILDERNESS MED, V2, P110, DOI 10.1580/0953-9859-2.2.110; LUPIHERRERA E, 1980, CHEST, V78, P553, DOI 10.1378/chest.78.4.553; Maggiorini M, 1998, AVIAT SPACE ENVIR MD, V69, P1186; PACY PJ, 1986, SPORTS MED, V3, P89, DOI 10.2165/00007256-198603020-00002; Roach RC, 2000, J APPL PHYSIOL, V88, P581, DOI 10.1152/jappl.2000.88.2.581; Sutton J., 1992, HYPOXIA MOUNTAIN MED; WEST JB, 1986, J APPL PHYSIOL, V61, P280, DOI 10.1152/jappl.1986.61.1.280; WHITE DP, 1985, MED CLIN N AM, V69, P1205, DOI 10.1016/S0025-7125(16)30983-X	19	71	78	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2003	139	4					253	257		10.7326/0003-4819-139-4-200308190-00007	http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712JY	12965980				2022-12-24	WOS:000184795600003
J	Tagliabue, E; Agresti, R; Carcangiu, ML; Ghirelli, C; Morelli, D; Campiglio, M; Martel, M; Giovanazzi, R; Greco, M; Balsari, A; Menard, S				Tagliabue, E; Agresti, R; Carcangiu, ML; Ghirelli, C; Morelli, D; Campiglio, M; Martel, M; Giovanazzi, R; Greco, M; Balsari, A; Menard, S			Role of HER2 in wound-induced breast carcinoma proliferation	LANCET			English	Article							GROWTH-FACTOR; TUMOR RECURRENCE; CELLS; CANCER; MASTECTOMY; RESECTION; ANTIBODY; IMMUNOSUPPRESSION; PROGRESSION; IRRADIATION	Objective: Clinical and experimental data have suggested that surgical removal of primary tumours promotes the growth of metastatic lesions. We assessed the effect of surgery on proliferation of breast carcinomas, in particular those overexpressing HER2 oncoprotein. Methods: Proliferation of breast carcinoma cells was assessed by MIB-1 immunohistochemistry in sections of primary breast carcinomas and in residual tumour found in re-excision specimens, and in in-vitro cell lines by colorimetric assay. Epidermal growth factor (EGF)-like growth factors were measured by displacement of radiolabelled EGF from its receptor. Cellular damage was measured in terms of creatine phosphokinase level. Downmodulation of HER2 was investigated by cytoplasmic expression of anti-HER2 antibody and by inhibition with anti-HER2 antibody trastuzumab. Findings: Residual breast carcinomas that had been surgically removed within 48 days after first surgery showed a significant increase in proliferation if they were HER2-positive. Wound drainage fluid and postsurgical serum samples from patients stimulated in-vitro growth of HER2-overexpressing breast carcinoma cells. Removal of HER2 from the cell membrane led to a striking reduction of the induced proliferation. The amount of EGF-like growth factors in post-surgical serum samples, as well as the extent of drainage-fluid-induced proliferation, directly correlated with the amount of surgical damage assessed by creatine phosphokinase levels (r=0.77, p=0.002 and r=0.69, p=0.009, respectively). Treatment of HER2-positive tumour cells with trastuzumab before adding the growth stimulus abolished drainage-fluid-induced proliferation. Interpretation: HER2 overexpression by breast carcinoma cells has a role in postsurgery stimulation of growth of breast carcinoma cells.	Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Ist Nazl Tumori, Gen Surg Breast Unit B, I-20133 Milan, Italy; Ist Nazl Tumori, Pathol Unit, I-20133 Milan, Italy; Ist Nazl Tumori, Med Lab Unit, I-20133 Milan, Italy; Univ Milan, Inst Pathol, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan	Menard, S (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.	sylvie.menard@istitutotumori.mi.it	Tagliabue, Elda/B-9377-2017; Morelli, Daniele/I-4113-2017; balsari, andrea/M-5657-2016; menard, sylvie mm/C-7940-2011; Agresti, Roberto/AAB-6062-2019	Tagliabue, Elda/0000-0001-9877-2903; Morelli, Daniele/0000-0002-1823-3764; balsari, andrea/0000-0002-3250-2668; Agresti, Roberto/0000-0003-4700-1951				BAKER DG, 1989, SURGERY, V106, P525; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; COLE WH, 1985, J SURG ONCOL, V30, P139; Decker D, 1996, SURGERY, V119, P316, DOI 10.1016/S0039-6060(96)80118-8; DEMICHELI R, 1994, J NATL CANCER I, V86, P45; FISHER B, 1989, CANCER RES, V49, P1996; FISHER B, 1992, SEMIN SURG ONCOL, V8, P153; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Haffty BG, 2002, SEMIN RADIAT ONCOL, V12, P329, DOI 10.1053/srao.2002.35252; HANSBROUGH JF, 1984, AM J SURG, V148, P303, DOI 10.1016/0002-9610(84)90459-8; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hofer SOP, 1998, ARCH SURG-CHICAGO, V133, P383, DOI 10.1001/archsurg.133.4.383; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; IOZZO RV, 1995, LAB INVEST, V73, P157; KLAUKE R, 1993, EUR J CLIN CHEM CLIN, V31, P901; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Menard S, 2002, CLIN CANCER RES, V8, P520; MIZUTANI J, 1992, BRIT J CANCER, V65, P794, DOI 10.1038/bjc.1992.170; MORGENSTERN L, 1973, AM J SURG, V125, P29, DOI 10.1016/0002-9610(73)90005-6; PIZAO PE, 1992, BRIT J CANCER, V66, P660, DOI 10.1038/bjc.1992.333; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Rowley DR, 1998, CANCER METAST REV, V17, P411, DOI 10.1023/A:1006129420005; Schindel DT, 1997, J PEDIATR SURG, V32, P995, DOI 10.1016/S0022-3468(97)90385-7; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SIEWEKE MH, 1994, CRIT REV ONCOGENESIS, V5, P297, DOI 10.1615/CritRevOncog.v5.i2-3.90; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; WATSON DI, 1995, MED J AUSTRALIA, V163, P106, DOI 10.5694/j.1326-5377.1995.tb126131.x	32	119	122	2	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					527	533		10.1016/S0140-6736(03)14112-8	http://dx.doi.org/10.1016/S0140-6736(03)14112-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932384				2022-12-24	WOS:000184817600009
J	Kashefi, K; Lovley, DR				Kashefi, K; Lovley, DR			Extending the upper temperature limit for life	SCIENCE			English	Article							ELECTRON-ACCEPTOR; GEN. NOV.; FE(III)		Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Lovley, DR (corresponding author), Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.							Blochl E, 1997, EXTREMOPHILES, V1, P14; Daniel RM, 2000, CELL MOL LIFE SCI, V57, P250, DOI 10.1007/PL00000688; GOLD T, 1992, P NATL ACAD SCI USA, V89, P6045, DOI 10.1073/pnas.89.13.6045; Jannasch H.W., 1995, GEOPHYS MONOGR SER, V91, P273, DOI DOI 10.1029/GM091P0273; Kashefi K, 2002, APPL ENVIRON MICROB, V68, P1735, DOI 10.1128/AEM.68.4.1735-1742.2002; Kashefi K, 2002, INT J SYST EVOL MICR, V52, P719, DOI [10.1099/ijs.0.01953-0, 10.1099/00207713-52-3-719]; Lovley DR, 2000, ENVIRONMENTAL MICROBE-METAL INTERACTIONS, P3; Russell MJ, 2002, GEOCHEM NEWS, V113, P6; Vargas M, 1998, NATURE, V395, P65, DOI 10.1038/25720	9	442	488	8	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					934	934		10.1126/science.1086823	http://dx.doi.org/10.1126/science.1086823			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920290				2022-12-24	WOS:000184755900028
J	Sakaba, T; Neher, E				Sakaba, T; Neher, E			Direct modulation of synaptic vesicle priming by GABA(B) receptor activation at a glutamatergic synapse	NATURE			English	Article							PRESYNAPTIC CALCIUM CURRENT; TRANSMITTER RELEASE; BRAIN-STEM; G-PROTEINS; INHIBITION; CAMP; RAT; TRANSMISSION; CURRENTS; CALYX	Second messenger cascades involving G proteins(1,2) and calcium(3) are known to modulate neurotransmitter release(4,5). A prominent effect of such a cascade is the downmodulation of presynaptic calcium influx(6,7), which markedly reduces evoked neurotransmitter release(5,7,8). Here we show that G-protein-mediated signalling, such as through GABA (gamma-amino butyric acid) subtype B (GABA(B)) receptors, retards the recruitment of synaptic vesicles during sustained activity and after short-term depression. This retardation occurs through a lowering of cyclic AMP, which blocks the stimulatory effect of increased calcium concentration on vesicle recruitment. In this signalling pathway, cAMP (functioning through the cAMP-dependent guanine nucleotide exchange factor) and calcium/calmodulin cooperate to enhance vesicle priming. The differential modulation of the two forms of synaptic plasticity, presynaptic inhibition and calcium-dependent recovery from synaptic depression, is expected to have interesting consequences for the dynamic behaviour of neural networks.	Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	Max Planck Society	Neher, E (corresponding author), Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany.		Neher, Erwin/A-2109-2013	Sakaba, Takeshi/0000-0003-0688-7717				BARNESDAVIES M, 1995, J PHYSIOL-LONDON, V488, P387, DOI 10.1113/jphysiol.1995.sp020974; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Borst JGG, 1995, J PHYSIOL-LONDON, V489, P825, DOI 10.1113/jphysiol.1995.sp021095; Cuttle MF, 1998, J PHYSIOL-LONDON, V512, P723, DOI 10.1111/j.1469-7793.1998.723bd.x; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; Dittman JS, 1998, J NEUROSCI, V18, P6147; Dittman JS, 1996, J NEUROSCI, V16, P1623; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; FORSYTHE ID, 1994, J PHYSIOL-LONDON, V479, P381, DOI 10.1113/jphysiol.1994.sp020303; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; Isaacson JS, 1998, J NEUROPHYSIOL, V80, P1571, DOI 10.1152/jn.1998.80.3.1571; Kajikawa Y, 2001, P NATL ACAD SCI USA, V98, P8054, DOI 10.1073/pnas.141031298; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Sakaba T, 2003, J NEUROSCI, V23, P837; Sakaba T, 2001, NEURON, V32, P1119, DOI 10.1016/S0896-6273(01)00543-8; Sakaba T, 2001, P NATL ACAD SCI USA, V98, P331, DOI 10.1073/pnas.021541098; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; SILINSKY EM, 1984, J PHYSIOL-LONDON, V346, P243, DOI 10.1113/jphysiol.1984.sp015019; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Stevens CF, 1998, NEURON, V21, P415, DOI 10.1016/S0896-6273(00)80550-4; Takahashi T, 2000, SCIENCE, V289, P460, DOI 10.1126/science.289.5478.460; Takahashi T, 1998, J NEUROSCI, V18, P3138; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; Wu LG, 1997, TRENDS NEUROSCI, V20, P204, DOI 10.1016/S0166-2236(96)01015-6; Xu XZS, 1998, J BIOL CHEM, V273, P31297, DOI 10.1074/jbc.273.47.31297; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	30	184	191	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					775	778		10.1038/nature01859	http://dx.doi.org/10.1038/nature01859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917685				2022-12-24	WOS:000184733900040
J	Trompouki, E; Hatzivassiliou, E; Tsichritzis, T; Farmer, H; Ashworth, A; Mosialos, G				Trompouki, E; Hatzivassiliou, E; Tsichritzis, T; Farmer, H; Ashworth, A; Mosialos, G			CYLD is a deubiquitinating enzyme that negatively regulates NF-kappa B activation by TNFR family members	NATURE			English	Article							EPSTEIN-BARR-VIRUS; RECEPTOR-ASSOCIATED FACTOR-2; TRANSFORMING PROTEIN LMP1; ECTODERMAL DYSPLASIA; MEMBRANE-PROTEIN; COMPLEX; KINASE; TRAF2; IKK; IDENTIFICATION	Familial cylindromatosis is an autosomal dominant predisposition to tumours of skin appendages called cylindromas. Familial cylindromatosis is caused by mutations in a gene encoding the CYLD protein of previously unknown function(1). Here we show that CYLD is a deubiquitinating enzyme that negatively regulates activation of the transcription factor NF-kappaB by specific tumour-necrosis factor receptors (TNFRs). Loss of the deubiquitinating activity of CYLD correlates with tumorigenesis. CYLD inhibits activation of NF-kappaB by the TNFR family members CD40, XEDAR and EDAR in a manner that depends on the deubiquitinating activity of CYLD. Downregulation of CYLD by RNA-mediated interference augments both basal and CD40-mediated activation of NF-kappaB. The inhibition of NF-kappaB activation by CYLD is mediated, at least in part, by the deubiquitination and inactivation of TNFR-associated factor 2 (TRAF2) and, to a lesser extent, TRAF6. These results indicate that CYLD is a negative regulator of the cytokine-mediated activation of NF-kappaB that is required for appropriate cellular homeostasis of skin appendages.	Biomed Sci Res Ctr Alexander Fleming, Inst Immunol, Vari 16672, Greece; Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, Canc Res UK Gene Funct & Regulat Grp, London SW3 6JB, England	Alexander Fleming Biomedical Sciences Research Center; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Mosialos, G (corresponding author), Biomed Sci Res Ctr Alexander Fleming, Inst Immunol, 34 Alexander Fleming St, Vari 16672, Greece.		Trompouki, Eirini/AAX-9539-2020	Trompouki, Eirini/0000-0002-7242-8810				Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hatzivassiliou E, 1997, BIOCHEMISTRY-US, V36, P9221, DOI 10.1021/bi963145k; Hatzivassiliou E, 2002, FRONT BIOSCI, V7, pD319, DOI 10.2741/hatziva; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Yan MH, 2002, CURR BIOL, V12, P409, DOI 10.1016/S0960-9822(02)00687-5; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	27	758	788	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					793	796		10.1038/nature01803	http://dx.doi.org/10.1038/nature01803			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917689	Green Published			2022-12-24	WOS:000184733900044
J	Chen, LM; Friedman, RM; Roe, AW				Chen, LM; Friedman, RM; Roe, AW			Optical Imaging of a tactile illusion in area 3b of the primary somatosensory cortex	SCIENCE			English	Article							CUTANEOUS STIMULI; SQUIRREL-MONKEYS; PARIETAL CORTEX; BODY-SURFACE; POINT; SKIN; REPRESENTATIONS; ORGANIZATION; INTEGRATION; RESPONSES	In the tactile funneling illusion, the simultaneous presentation of brief stimuli at multiple points on the skin produces a single focal sensation at the center of the stimulus pattern even when no physical stimulus occurs at that site. Consistent with the funneling percept, we show with optical imaging in area 3b of the primary somatosensory cortex (SI) that simultaneous stimulation of two fingertips produces a single focal cortical activation between the single fingertip activation regions. Thus, in contrast to traditional views of the body map, topographic representation in the SI reflects the perceived rather than the physical location of peripheral stimulation.	Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06520 USA	Yale University; Yale University	Roe, AW (corresponding author), Vanderbilt Univ, Dept Psychol, 066 Wilson Hall,111 21st Ave S, Nashville, TN 37203 USA.		Chen, Li Min/C-3554-2011	Roe, Anna Wang/0000-0003-4146-9705				ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; Bonhoeffer Tobias, 1996, P55; Bringuier V, 1999, SCIENCE, V283, P695, DOI 10.1126/science.283.5402.695; Chen LM, 2001, J NEUROPHYSIOL, V86, P3011, DOI 10.1152/jn.2001.86.6.3011; GARDNER EP, 1981, J NEUROPHYSIOL, V46, P479, DOI 10.1152/jn.1981.46.3.479; GARDNER EP, 1972, J NEUROPHYSIOL, V35, P925, DOI 10.1152/jn.1972.35.6.925; GARDNER EP, 1972, J NEUROPHYSIOL, V35, P954, DOI 10.1152/jn.1972.35.6.954; GARDNER EP, 1980, J NEUROPHYSIOL, V43, P420, DOI 10.1152/jn.1980.43.2.420; Hashimoto I, 1999, NEUROREPORT, V10, P3201, DOI 10.1097/00001756-199910190-00014; IWAMURA Y, 1983, EXP BRAIN RES, V51, P315; Kapadia MK, 2000, J NEUROPHYSIOL, V84, P2048, DOI 10.1152/jn.2000.84.4.2048; MCKENNA TM, 1982, J NEUROPHYSIOL, V48, P289, DOI 10.1152/jn.1982.48.2.289; NELSON RJ, 1980, J COMP NEUROL, V192, P611, DOI 10.1002/cne.901920402; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; Ramsden BM, 2001, CEREB CORTEX, V11, P648, DOI 10.1093/cercor/11.7.648; SCHROEDER CE, 1995, J NEUROPHYSIOL, V74, P722, DOI 10.1152/jn.1995.74.2.722; SHERRICK CE, 1964, AM J PSYCHOL, V77, P42, DOI 10.2307/1419270; SUR M, 1982, J COMP NEUROL, V211, P177, DOI 10.1002/cne.902110207; Tommerdahl M, 1998, J NEUROPHYSIOL, V80, P3272, DOI 10.1152/jn.1998.80.6.3272; von Bekesy G, 1967, SENSORY INHIBITION	20	124	125	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					881	885		10.1126/science.1087846	http://dx.doi.org/10.1126/science.1087846			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14500850				2022-12-24	WOS:000186258000054
J	Guermonprez, P; Saveanu, L; Kleijmeer, M; Davoust, J; van Endert, P; Amigorena, S				Guermonprez, P; Saveanu, L; Kleijmeer, M; Davoust, J; van Endert, P; Amigorena, S			ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells	NATURE			English	Article							ANTIGEN PRESENTATION; MEMBRANE-PROTEINS; DEGRADATION; MOLECULES; TRANSPORT; COMPLEX; CYTOSOL	Induction of cytotoxic T-cell immunity requires the phagocytosis of pathogens, virus-infected or dead tumour cells by dendritic cells(1). Peptides derived from phagocytosed antigens are then presented to CD8(+) T lymphocytes on major histocompatibility complex (MHC) class I molecules, a process called "cross-presentation"(2,3). After phagocytosis, antigens are exported into the cytosol and degraded by the proteasome(4-6). The resulting peptides are thought to be translocated into the lumen of the endoplasmic reticulum (ER) by specific transporters associated with antigen presentation (TAP), and loaded onto MHC class I molecules by a complex "loading machinery" (which includes tapasin, calreticulin and Erp57)(7). Here we show that soon after or during formation, phagosomes fuse with the ER. After antigen export to the cytosol and degradation by the proteasome, peptides are translocated by TAP into the lumen of the same phagosomes, before loading on phagosomal MHC class I molecules. Therefore, cross-presentation in dendritic cells occurs in a specialized, self-sufficient, ER-phagosome mix compartment.	Inst Curie, INSERM, U520, F-75005 Paris, France; Inst Necker, INSERM, U580, F-75015 Paris, France; UMC Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Genethon, CNRS, UMR 8115, F-91002 Evry 02, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Utrecht University; Utrecht University Medical Center; Centre National de la Recherche Scientifique (CNRS)	Amigorena, S (corresponding author), Inst Curie, INSERM, U520, 26 Rue Ulm, F-75005 Paris, France.	sebastian.amigorena@curie.fr	SAVEANU, Loredana/Q-1241-2019; Guermonprez, Pierre/ABE-7718-2020; Davoust, Jean/ABB-6720-2020; van Endert, Peter/R-4606-2017; Saveanu, Loredana/K-6821-2017	SAVEANU, Loredana/0000-0003-3138-7968; Guermonprez, Pierre/0000-0001-5621-2262; van Endert, Peter/0000-0003-3782-0750; Davoust, Jean/0000-0002-3098-7665; Amigorena, Sebastian/0000-0001-8583-8416				Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Daniel S, 1997, J IMMUNOL, V159, P2350; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Lemonnier FA, 2002, VIRUS RES, V82, P87; Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Ramachandra L, 1998, J IMMUNOL METHODS, V213, P53, DOI 10.1016/S0022-1759(98)00017-9; RAPOSO G, 1997, HDB EXPT IMMUNOLOGY, P1; Reits E, 2003, IMMUNITY, V18, P97, DOI 10.1016/S1074-7613(02)00511-3; Rock KL, 2002, ADV IMMUNOL, V80, P1, DOI 10.1016/S0065-2776(02)80012-8; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3	22	589	613	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					397	402		10.1038/nature01911	http://dx.doi.org/10.1038/nature01911			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508489				2022-12-24	WOS:000185502300041
J	Little, J; Khoury, MJ				Little, J; Khoury, MJ			Mendelian randomisation: a new spin or real progress?	LANCET			English	Editorial Material							METHYLENETETRAHYDROFOLATE REDUCTASE MTHFR; POPULATION STRATIFICATION; LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; C677T POLYMORPHISM; ENZYME-ACTIVITY; HUMAN-GENOME; DISEASE; SUSCEPTIBILITY; HOMOCYSTEINE		Ctr Dis Control & Prevent, Off Genom & Dis Prevent, Atlanta, GA 30341 USA; Univ Aberdeen, Dept Med & Therapeut, Epidemiol Grp, Aberdeen, Scotland	Centers for Disease Control & Prevention - USA; University of Aberdeen	Little, J (corresponding author), Ctr Dis Control & Prevent, Off Genom & Dis Prevent, Atlanta, GA 30341 USA.		Little, Julian/AAR-6117-2020	Little, Julian/0000-0001-5026-5531				Andreassi MG, 2003, HUM GENET, V112, P171, DOI 10.1007/s00439-002-0859-3; Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777; Ardlie KG, 2002, AM J HUM GENET, V71, P304, DOI 10.1086/341719; Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Crott JW, 2001, CARCINOGENESIS, V22, P1019, DOI 10.1093/carcin/22.7.1019; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; KHOURY MJ, 1987, AM J EPIDEMIOL, V126, P561, DOI 10.1093/oxfordjournals.aje.a114695; Lievers KJA, 2001, J MOL MED-JMM, V79, P522, DOI 10.1007/s001090100253; Little J, 2003, AM J EPIDEMIOL, V157, P667, DOI 10.1093/aje/kwg048; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Nallamothu BK, 2000, ARCH INTERN MED, V160, P3406, DOI 10.1001/archinte.160.22.3406; NARAYANAN S, 2001, THESIS U ABERDEEN AB; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Rozen R, 1997, THROMB HAEMOSTASIS, V78, P523; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Strachan T., 2004, HUM MOL GENET, V3; Thomas DC, 2002, CANCER EPIDEM BIOMAR, V11, P505; van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825; Wacholder S, 2002, CANCER EPIDEM BIOMAR, V11, P513; Weisberg I, 1998, MOL GENET METAB, V64, P169, DOI 10.1006/mgme.1998.2714; 2003, LANCET, V361, P357	23	51	52	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					930	931		10.1016/S0140-6736(03)14396-6	http://dx.doi.org/10.1016/S0140-6736(03)14396-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511923				2022-12-24	WOS:000185489600004
J	Morris, CA; Avorn, J				Morris, CA; Avorn, J			Internet marketing of herbal products	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	19th International Conference on Pharmacoepidermiology/Annual Meeting of the International-Society-for-Pharmacoepidemiology	AUG   22, 2003	PHILADELPHIA, PENNSYLVANIA	Internat Soc Pharmacoepidemiol			DIETARY-SUPPLEMENTS; UNITED-STATES; HEALTH; MEDICINE; NEED; WEB	Context Passage of the Dietary Supplement Health and Education Act in 1994 restricted the Food and Drug Administration's control over dietary supplements, leading to enormous growth in their promotion. The Internet is often used by consumers as a source of information on such therapies. Objective To assess the information presented and indications claimed on the Internet for the 8 best-selling herbal products. Data Sources We searched the Internet using the 5 most commonly used search engines. For each, we entered the names of the 8 most widely used herbal supplements (ginkgo biloba, St John's wort, echinacea, ginseng, garlic, saw palmetto, kava kava, and valerian root). We analyzed the health content of all Web sites listed on the first page of the search results. Study Selection We analyzed all accessible, English-language Web sites that pertained to oral herbal supplements. A total of 522 Web sites were identified; of these, 443 sites met inclusion criteria for the analysis. Data Extraction The nature of the Web site (retail or nonretail), whether it was a sponsored link, and all references, indications, claims, and disclaimers were recorded. Two reviewers independently categorized medical claims as disease or nondisease according to Food and Drug Administration criteria. Data Synthesis Among 443 Web sites, 338 (76%) were retail sites either selling product or directly linked to a vendor. A total of 273 (81%) of the 338 retail Web sites made 1 or more health claims; of these, 149 (55%) claimed to treat, prevent, diagnose, or cure specific diseases. More than half (153/292; 52%) of sites with a health claim omitted the standard federal disclaimer. Nonretail sites were more likely than retail sites to include literature references, although only 52 (12%) of the 443 Web sites provided referenced information without a link to a distributor or vendor. Conclusions Consumers maybe misled, by vendors' claims that herbal products can treat, prevent, diagnose, or cure specific diseases, despite regulations prohibiting such statements. Physicians should be aware of this widespread and easily accessible information. More effective regulation is required to put this class of therapeutics on the same evidence-based footing as other medicinal products.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Morris, CA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.							Blendon RJ, 2001, ARCH INTERN MED, V161, P805, DOI 10.1001/archinte.161.6.805; Bonakdar RA, 2002, FAM MED, V34, P522; CHALLENER C, 2002, CHEM MARKET REP 0617, pFR11; Drazen JM, 2003, NEW ENGL J MED, V348, P777, DOI 10.1056/NEJMp030021; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fontanarosa PB, 2003, JAMA-J AM MED ASSOC, V289, P1568, DOI 10.1001/jama.289.12.1568; *FOOD DRUG ADM, CONS ADV KAV DIET SU; *FOOD DRUG ADM, FDA ADV DIET SUPPL M; Fox S., 2002, VITAL DECISIONS INTE; *GEN ACC OFF, 2002, 83177 GEN ACC OFF; JELLIN JM, 2002, PHARM LETT PRESCRIBE; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Lipman MM, 2003, NEW ENGL J MED, V348, P1498; Marcus DM, 2002, NEW ENGL J MED, V347, P2073, DOI 10.1056/NEJMsb022858; Palmer ME, 2003, LANCET, V361, P101, DOI 10.1016/S0140-6736(03)12227-1; Slater MD, 2002, JAMA-J AM MED ASSOC, V288, P316, DOI 10.1001/jama.288.3.316; SULLIVAN D, 2002, JUPITER MEDIA METRIX; Troger U, 1998, BMJ-BRIT MED J, V317, P1069, DOI 10.1136/bmj.317.7165.1069; *US DEP COMM, 2002, NAT ONL AM AR EXP TH; Waxman H, COMMUNICATION; Wilson P, 2002, BMJ-BRIT MED J, V324, P598, DOI 10.1136/bmj.324.7337.598; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604; 2002, NUTR BUSINESS J  MAY, P1; 2001, FED REG, V65, P56035	25	172	178	0	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1505	1509		10.1001/jama.290.11.1505	http://dx.doi.org/10.1001/jama.290.11.1505			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129992				2022-12-24	WOS:000185329000034
J	Richter, J; Hatz, C; Haussinger, D				Richter, J; Hatz, C; Haussinger, D			Ultrasound in tropical and parasitic diseases	LANCET			English	Review							SCHISTOSOMIASIS-MANSONI; ECHINOCOCCOSIS; EVOLUTION	Context Migration and worldwide travel mean that western clinicians and radiologists more and more face imported tropical diseases. Diseases with unclear signs and symptoms are likely to be investigated with ultrasound Many tropical diseases have particular ultrasonographic features that are not familiar to the examiner and which may lead to further unnecessary or even harmful diagnostic investigations. In developing countries, ultrasound machines are becoming more widely distributed and are fairly cheap. Portable devices allow field use of ultrasound for population studies and individual diagnosis of tropical diseases Starting point Recently, WHO introduced a standardised classification of ultrasonographic images of cystic echinococcosis (Acta Trop 2003; 85: 253-61), to obtain comparable results in patients worldwide and to link disease status with each morphological type of echinococcosis cyst. WHO also defined guidelines for the puncture, aspiration, injection of ethanol, and re-aspiration of such cysts. Ultrasound allows diagnosis of schistosomiasis-induced periportal fibrosis and bladder abnormalities. Liver abscesses can be differentiated from other focal lesions such as cysts or neoplasms. For amoebic abscesses, invasive procedures are usually not required. In doubtful cases ultrasound-guided puncture can give adequate material for microscopy and culture. Helminths (eg, ascaris), flukes, and filariae can be seen directly with ultrasound. Filaria-induced damage also includes hypoechogenic splenic foci and ultrasonographic abnormalities due to tropical hypereosinophilia. Where next? Classification of cysts and procedures that are less invasive than conventional surgery are being developed further for cystic echinococcosis. Novel methods are needed for the assessment of polycystic and alveolar echinococcosis. Ultrasound protocols for schistosomiasis are being evaluated for interobserver reliability, relation to clinical disease status, and power to predict complications. A WHO expert-group is also developing a standardised protocol for Asian schistosomiasis. International consensus on an algorithm for managing amoebic liver abscesses,is needed.	Univ Dusseldorf, Univ Clin, Clin Gastroenterol Hepatol & Infect Dis, D-4000 Dusseldorf, Germany; Swiss Trop Inst, CH-4002 Basel, Switzerland	Heinrich Heine University Dusseldorf; University of Basel; Swiss Tropical & Public Health Institute	Richter, J (corresponding author), Univ Dusseldorf, Klin Gastroenterol Hepatol & Infektiol, Tropenmed Ambulanz, D-40225 Dusseldorf, Germany.							ACQUATELLA H, 1983, CIRCULATION, V67, P1219, DOI 10.1161/01.CIR.67.6.1219; AMARAL F, 1994, AM J TROP MED HYG, V50, P753, DOI 10.4269/ajtmh.1994.50.753; Bartholomot B, 2002, AM J TROP MED HYG, V66, P23, DOI 10.4269/ajtmh.2002.66.23; Brunetti E, 2001, LANCET, V358, P1464, DOI 10.1016/S0140-6736(01)06518-7; Burchard GD, 1996, CLIN INFECT DIS, V23, P979, DOI 10.1093/clinids/23.5.979; CERRI GG, 1984, RADIOLOGY, V153, P777, DOI 10.1148/radiology.153.3.6387793; DAlessandro A, 1997, ACTA TROP, V67, P43, DOI 10.1016/S0001-706X(97)00048-X; Hatz CF, 1998, AM J TROP MED HYG, V59, P775, DOI 10.4269/ajtmh.1998.59.775; King CH, 2003, TROP MED INT HEALTH, V8, P109, DOI 10.1046/j.1365-3156.2003.00994.x; LEICHSENRING M, 1990, AM J TROP MED HYG, V43, P380, DOI 10.4269/ajtmh.1990.43.380; Macpherson CNL, 2003, ACTA TROP, V85, P253, DOI 10.1016/S0001-706X(02)00213-9; MUELLER PR, 1985, RADIOLOGY, V155, P627, DOI 10.1148/radiology.155.3.3890001; Niamey Working Group, 2000, ULTR SCHIST PRACT GU; Richter J, 1999, TROP MED INT HEALTH, V4, P774, DOI 10.1046/j.1365-3156.1999.00482.x; *WHO, 1995, MAN DIAGN ULTR; *WHO, 1998, WHO TECH REP SER, V875; WHO Informal Working Group on Echinococcosis (WHO-IGWE), 2001, PAIR PUNCT ASP INJ R	17	64	65	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 13	2003	362	9387					900	902		10.1016/S0140-6736(03)14334-6	http://dx.doi.org/10.1016/S0140-6736(03)14334-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RH	13678978				2022-12-24	WOS:000185329400023
J	Ekstrom, AD; Kahana, MJ; Caplan, JB; Fields, TA; Isham, EA; Newman, EL; Fried, I				Ekstrom, AD; Kahana, MJ; Caplan, JB; Fields, TA; Isham, EA; Newman, EL; Fried, I			Cellular networks underlying human spatial navigation	NATURE			English	Article							HUMAN HIPPOCAMPUS; HEAD DIRECTION; SINGLE-NEURON; CELLS; RESPONSES	Place cells of the rodent hippocampus constitute one of the most striking examples of a correlation between neuronal activity and complex behaviour in mammals(1,2). These cells increase their firing rates when the animal traverses specific regions of its surroundings, providing a context-dependent map of the environment(3-5). Neuroimaging studies implicate the hippocampus and the parahippocampal region in human navigation(6-8). However, these regions also respond selectively to visual stimuli(9-13). It thus remains unclear whether rodent place coding has a homologue in humans or whether human navigation is driven by a different, visually based neural mechanism. We directly recorded from 317 neurons in the human medial temporal and frontal lobes while subjects explored and navigated a virtual town. Here we present evidence for a neural code of human spatial navigation based on cells that respond at specific spatial locations and cells that respond to views of landmarks. The former are present primarily in the hippocampus, and the latter in the parahippocampal region. Cells throughout the frontal and temporal lobes responded to the subjects' navigational goals and to conjunctions of place, goal and view.	Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA; Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Tel Aviv Med Ctr, Funct Neurosurg Unit, IL-69978 Tel Aviv, Israel	Brandeis University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Kahana, MJ (corresponding author), Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA.	kahana@brandeis.edu; ifried@mednet.ucla.edu	Ekstrom, Arne/A-1329-2013	Newman, Ehren/0000-0001-7006-4112; Ekstrom, Arne/0000-0002-6812-2368				Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Aguirre GK, 1998, NEURON, V21, P373, DOI 10.1016/S0896-6273(00)80546-2; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Cameron KA, 2001, NEURON, V30, P289, DOI 10.1016/S0896-6273(01)00280-X; Caplan JB, 2003, J NEUROSCI, V23, P4726; Epstein R, 2003, NEURON, V37, P865, DOI 10.1016/S0896-6273(03)00117-X; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; Frank LM, 2000, NEURON, V27, P169, DOI 10.1016/S0896-6273(00)00018-0; Fried I, 1999, J NEUROSURG, V91, P697, DOI 10.3171/jns.1999.91.4.0697; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; Georges-Francois P, 1999, CEREB CORTEX, V9, P197, DOI 10.1093/cercor/9.3.197; Kreiman G, 2000, NAT NEUROSCI, V3, P946, DOI 10.1038/78868; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; MARKUS EJ, 1995, J NEUROSCI, V15, P7079; Matsumura N, 1999, J NEUROSCI, V19, P2381; MULLER RU, 1987, J NEUROSCI, V7, P1951; MULLER RU, 1987, J NEUROSCI, V7, P1935; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Ojemann GA, 2002, NAT NEUROSCI, V5, P64, DOI 10.1038/nn785; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1978, EXP BRAIN RES, V31, P573; QUIRK GJ, 1992, J NEUROSCI, V12, P1945; Robertson RG, 1999, HIPPOCAMPUS, V9, P206, DOI 10.1002/(SICI)1098-1063(1999)9:3<206::AID-HIPO2>3.3.CO;2-8; Skaggs W., 1993, ADV NEURAL INFORM PR, V5, P1030; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; Witter M., 2002, PARAHIPPOCAMPAL REGI, P3, DOI DOI 10.1093/ACPROF:OSO/9780198509172.001.0001	27	806	831	5	153	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					184	187		10.1038/nature01964	http://dx.doi.org/10.1038/nature01964			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968182				2022-12-24	WOS:000185236000044
J	Fu, J; Gaetani, S; Oveisi, F; Lo Verme, J; Serrano, A; de Fonseca, FR; Rosengarth, A; Luecke, H; Di Giacomo, B; Tarzia, G; Piomelli, D				Fu, J; Gaetani, S; Oveisi, F; Lo Verme, J; Serrano, A; de Fonseca, FR; Rosengarth, A; Luecke, H; Di Giacomo, B; Tarzia, G; Piomelli, D			Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha	NATURE			English	Article							FATTY-ACIDS; GAMMA ACTIVATORS; GENE-EXPRESSION; NITRIC-OXIDE; MICE; RAT; EICOSANOIDS; TRANSPORT; LIGANDS; PROTEIN	Oleylethanolamide (OEA) is a naturally occurring lipid that regulates satiety and body weight(1,2). Although structurally related to the endogenous cannabinoid anandamide, OEA does not bind to cannabinoid receptors and its molecular targets have not been defined. Here we show that OEA binds with high affinity to the peroxisome-proliferator-activated receptor-alpha (PPAR-alpha), a nuclear receptor that regulates several aspects of lipid metabolism. Administration of OEA produces satiety and reduces body weight gain in wild-type mice, but not in mice deficient in PPAR-alpha. Two distinct PPAR-alpha agonists have similar effects that are also contingent on PPAR-alpha expression, whereas potent and selective agonists for PPAR-gamma and PPAR-beta/delta are ineffective. In the small intestine of wild-type but not PPAR-alpha-null mice, OEA regulates the expression of several PPAR-alpha target genes: it initiates the transcription of proteins involved in lipid metabolism and represses inducible nitric oxide synthase, an enzyme that may contribute to feeding stimulation. Our results, which show that OEA induces satiety by activating PPAR-alpha, identify an unexpected role for this nuclear receptor in regulating behaviour, and raise possibilities for the treatment of eating disorders.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Fdn Hosp Carlos Haya, Malaga, Spain; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Urbino, Inst Med Chem, I-61029 Urbino, Italy	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Urbino	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.		Fu, Jin/A-3510-2012; DE FONSECA, FERNANDO RODRIGUEZ/E-9767-2012; Gaetani, Silvana/D-3455-2009; Luecke, Hartmut/F-4712-2012	Luecke, Hartmut/0000-0002-4938-0775; Serrano, Antonia/0000-0002-8017-9754				Akiyama TE, 2001, J BIOL CHEM, V276, P39088, DOI 10.1074/jbc.M107073200; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Best JD, 2001, EXPERT OPIN INV DRUG, V10, P1901; BROWN PJ, 2000, Patent No. 32; Butler A A, 2001, Trends Genet, V17, pS50, DOI 10.1016/S0168-9525(01)02481-7; CHANG AY, 1983, DIABETES, V32, P830, DOI 10.2337/diabetes.32.9.830; CHAO EYH, 2001, Patent No. 83; Chaput E, 2000, BIOCHEM BIOPH RES CO, V271, P445, DOI 10.1006/bbrc.2000.2647; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CLEARY MP, 1987, ATHEROSCLEROSIS, V66, P107, DOI 10.1016/0021-9150(87)90185-7; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gaetani S, 2003, NEUROPSYCHOPHARMACOL, V28, P1311, DOI 10.1038/sj.npp.1300166; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Gregoire FM, 2002, AM J PHYSIOL-ENDOC M, V282, pE703, DOI 10.1152/ajpendo.00072.2001; Janero DR, 2001, NUTRITION, V17, P896, DOI 10.1016/S0899-9007(01)00647-5; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; STICKERKRONGRAD A, 1996, LIFE SCI, V58, pPL9; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	30	838	906	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					90	93		10.1038/nature01921	http://dx.doi.org/10.1038/nature01921			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955147				2022-12-24	WOS:000185089200044
J	Askari, AT; Unzek, S; Popovic, ZB; Goldman, CK; Forudi, F; Kiedrowski, M; Rovner, A; Ellis, SG; Thomas, JD; DiCorleto, PE; Topol, EJ; Penn, MS				Askari, AT; Unzek, S; Popovic, ZB; Goldman, CK; Forudi, F; Kiedrowski, M; Rovner, A; Ellis, SG; Thomas, JD; DiCorleto, PE; Topol, EJ; Penn, MS			Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy	LANCET			English	Article							MYOCARDIAL-INFARCTION; PROGENITOR CELLS; HEART FUNCTION; TRANSPLANTATION; MOBILIZATION; SDF-1; NEOVASCULARIZATION; RECRUITMENT; MIGRATION; REQUIRES	Background Myocardial regeneration via stem-cell mobilisation at the time of myocardial infarction is known to occur, although the mechanism for stem-cell homing to infarcted tissue subsequently and whether this approach can be used for treatment of ischaemic cardiomyopathy are unknown. We investigated these issues in a Lewis rat model (ligation of the left anterior descending artery) of ischaemic cardiomyopathy. Methods We studied the effects of stem-cell mobilisation by use of granulocyte colony-stimulating factor (filgrastim) with or without transplantation of syngeneic cells. Shortening fraction and myocardial strain by tissue doppler imaging were quantified by echocardiography. Findings Stem-cell mobilisation with filgrastim alone did not lead to engraftment of bone-marrow-derived cells. Stromal-cell-derived factor 1 (SDF-1), required for stem-cell homing to bone marrow, was upregulated immediately after myocardial infarction and downregulated within 7 days. 8 weeks after myocardial infarction, transplantation into the peri-infarct zone of syngeneic cardiac fibroblasts stably transfected to express SDF-1 induced homing of CD117-positive stem cells to injured myocardium after filgrastim administration (control vs SDF-1-expressing cardiac fibroblasts mean 7.2 [SD 3.4] vs 33.2 [6.0] cells/mm(2), n=4 per group, p<0.02) resulting in greater left-ventricular mass (1.24 [0.29] vs 1.57 [0.27] g) and better cardiac function (shortening fraction 9.2 [4.9] vs 17.2 [4.2]%, n=8 per group, p<0.05). Interpretation These findings show that SDF-1 is sufficient to induce therapeutic stem-cell homing to injured myocardium and suggest a strategy for directed stem-cell engraftment into injured tissues. Our findings also indicate that therapeutic strategies focused on stem-cell mobilisation for regeneration of myocardial tissue must be initiated within days of myocardial infarction unless signalling for stem-cell homing is re-established.	Cleveland Clin Fdn, Dept Cardiovasc Med, Expt Anim Lab, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Stem Cell & Regenerat Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Penn, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, Expt Anim Lab, NC10, Cleveland, OH 44195 USA.	pennm@ccf.org		Topol, Eric/0000-0002-1478-4729; popovic, zoran/0000-0001-5692-2299				Askari AT, 2003, J EXP MED, V197, P615, DOI 10.1084/jem.20021426; Behfar A, 2002, FASEB J, V16, P1558, DOI 10.1096/fj.02-0072com; Collins KA, 2001, AM J PHYSIOL-HEART C, V280, pH1954, DOI 10.1152/ajpheart.2001.280.5.H1954; Doitsidou M, 2002, CELL, V111, P647, DOI 10.1016/S0092-8674(02)01135-2; Etzion S, 2001, J MOL CELL CARDIOL, V33, P1321, DOI 10.1006/jmcc.2000.1391; FIRSTENBERG MS, 2000, CURR SURG, V57, P466, DOI DOI 10.1016/S0149-7944(00)00296-8; Greenberg NL, 2002, CIRCULATION, V105, P99, DOI 10.1161/hc0102.101396; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Liesveld JL, 2001, J HEMATOTH STEM CELL, V10, P643, DOI 10.1089/152581601753193850; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Penn MS, 2002, PROG CARDIOVASC DIS, V45, P21, DOI 10.1053/pcad.2002.123466; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; ROBBINS MA, 1998, MANAGEMENT END STAGE, P3; Sakai T, 1999, J THORAC CARDIOV SUR, V118, P715, DOI 10.1016/S0022-5223(99)70018-8; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Tomita S, 2002, J THORAC CARDIOV SUR, V123, P1132, DOI 10.1067/mtc.2002.120716; Topol EJ, 2001, LANCET, V357, P1905; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Yong K, 1999, BRIT J HAEMATOL, V107, P441, DOI 10.1046/j.1365-2141.1999.01714.x; Yoo KJ, 2002, YONSEI MED J, V43, P296, DOI 10.3349/ymj.2002.43.3.296; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	30	1034	1138	0	70	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	2003	362	9385					697	703		10.1016/S0140-6736(03)14232-8	http://dx.doi.org/10.1016/S0140-6736(03)14232-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957092				2022-12-24	WOS:000185034800010
J	Tsuda, M; Sasaoka, Y; Kiso, M; Abe, K; Haraguchi, S; Kobayashi, S; Saga, Y				Tsuda, M; Sasaoka, Y; Kiso, M; Abe, K; Haraguchi, S; Kobayashi, S; Saga, Y			Conserved role of nanos proteins in germ cell development	SCIENCE			English	Article							DROSOPHILA; MOUSE; GENERATION; PUMILIO; EMBRYOS; GENES	In Drosophila, maternally supplied Nanos functions in the migration of primordial germ cells (PGCs) into the gonad; in mice, zygotic genes are involved instead. We report the cloning and the functional analyses of nanos2 and nanos3 in mice. These genes are differentially expressed in mouse PGCs. nanos2 is predominantly expressed in male germ cells, and the elimination of this gene results in a complete loss of spermatogonia. However, nanos3 is found in migrating PGCs, and the elimination of this factor results in the complete loss of germ cells in both sexes. Hence, although mice and flies differ in their mechanisms for germ cell specification, there seems to be conserved function for nanos proteins among invertebrates and vertebrates.	SOKENDAI, Natl Inst Genet, Div Mammalian Dev, Shizuoka 4118540, Japan; Japan Sci & Technol Corp, CREST, Minato Ku, Tokyo 1050011, Japan; RIKEN, Bioresource Ctr, Tsukuba, Ibaraki 3050074, Japan; Shiga Univ Med Sci, Dept Microbiol, Otsu, Shiga 5202192, Japan; Okazaki Natl Res Inst, Natl Inst Basic Biol, Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan	Graduate University for Advanced Studies - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Japan Science & Technology Agency (JST); RIKEN; Shiga University of Medical Science; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okazaki Institute for Integrative Bioscience (OIIB)	Saga, Y (corresponding author), SOKENDAI, Natl Inst Genet, Div Mammalian Dev, Yata 1111, Shizuoka 4118540, Japan.	ysaga@lab.nig.ac.jp						Abe K, 1996, DEV BIOL, V180, P468, DOI 10.1006/dbio.1996.0320; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; Forbes A, 1998, DEVELOPMENT, V125, P679; Haraguchi S, 2003, MECH DEVELOP, V120, P721, DOI 10.1016/S0925-4773(03)00043-1; Jaruzelska J, 2003, DEV GENES EVOL, V213, P120, DOI 10.1007/s00427-003-0303-2; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; Koprunner M, 2001, GENE DEV, V15, P2877; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Mochizuki K, 2000, DEV GENES EVOL, V210, P591, DOI 10.1007/s004270000105; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; Pilon M, 1997, DEVELOPMENT, V124, P1771; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Subramaniam K, 1999, DEVELOPMENT, V126, P4861; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; Ying Y, 2000, MOL ENDOCRINOL, V14, P1053, DOI 10.1210/me.14.7.1053	15	439	473	1	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1239	1241		10.1126/science.1085222	http://dx.doi.org/10.1126/science.1085222			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947200				2022-12-24	WOS:000185003500043
J	Lee, PN; Callaerts, P; de Couet, HG; Martindale, MQ				Lee, PN; Callaerts, P; de Couet, HG; Martindale, MQ			Cephalopod Hox genes and the origin of morphological novelties	NATURE			English	Article							SQUID EUPRYMNA-SCOLOPES; B-LIKE GENE; EXPRESSION; EVOLUTION; SHELL; BRAIN; ORGAN	Cephalopods are a diverse group of highly derived molluscs, including nautiluses, squids, octopuses and cuttlefish. Evolution of the cephalopod body plan from a monoplacophoran-like ancestor(1) entailed the origin of several key morphological innovations contributing to their impressive evolutionary success(2). Recruitment of regulatory genes(3), or even pre-existing regulatory networks(4), may be a common genetic mechanism for generating new structures. Hox genes encode a family of transcriptional regulatory proteins with a highly conserved role in axial patterning in bilaterians(5); however, examples highlighting the importance of Hox gene recruitment for new developmental functions are also known(6,7). Here we examined developmental expression patterns for eight out of nine Hox genes(8) in the Hawaiian bobtail squid Euprymna scolopes, by whole-mount in situ hybridization. Our data show that Hox orthologues have been recruited multiple times and in many ways in the origin of new cephalopod structures. The manner in which these genes have been co-opted during cephalopod evolution provides insight to the nature of the molecular mechanisms driving morphological change in the Lophotrochozoa, a clade exhibiting the greatest diversity of body plans in the Metazoa.	Univ Hawaii Manoa, Dept Zool, Honolulu, HI 96822 USA; Univ Hawaii, Kewalo Marine Lab, Pacific Biomed Res Ctr, Honolulu, HI 96813 USA; Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Houston System; University of Houston	de Couet, HG (corresponding author), Univ Hawaii Manoa, Dept Zool, 2538 McCarthy Mall, Honolulu, HI 96822 USA.		de Couet, Heinz/J-9522-2012; Callaerts, Patrick/I-8118-2013	de Couet, Heinz/0000-0002-0307-2881; Callaerts, Patrick/0000-0003-4530-4561				Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; Brusca R., 2003, INVERTEBRATES; Budelrnann B, 1995, NERVOUS SYSTEM INVER, P115; BURKE AC, 1995, DEVELOPMENT, V121, P333; Callaerts P, 2002, P NATL ACAD SCI USA, V99, P2088, DOI 10.1073/pnas.042683899; Carroll S. B., 2001, DNA DIVERSITY MOL GE; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; Hartmann B, 2003, MECH DEVELOP, V120, P177, DOI 10.1016/S0925-4773(02)00456-2; HINMAN VF, IN PRESS EVOL DEV; HOLLAND CH, 1987, J GEOL SOC LONDON, V144, P1, DOI 10.1144/gsjgs.144.1.0001; House M., 1988, CEPHALOPODS PRESENT, P1; Keys DN, 1999, SCIENCE, V283, P532, DOI 10.1126/science.283.5401.532; Kulakova MA, 2002, MECH DEVELOP, V115, P177, DOI 10.1016/S0925-4773(02)00113-2; Lowe CJ, 1997, NATURE, V389, P718, DOI 10.1038/39580; MCFALLNGAI M, 1990, BIOL BULL, V179, P332, DOI 10.2307/1542325; Moshel SM, 1998, DEV GENES EVOL, V208, P135, DOI 10.1007/s004270050164; Nederbragt AJ, 2002, DEV BIOL, V246, P341, DOI 10.1006/dbio.2002.0653; Nogi T, 2001, DEV GROWTH DIFFER, V43, P177; RUNNEGAR B, 1974, SCIENCE, V186, P311, DOI 10.1126/science.186.4161.311; Seaver EC, 2001, DEV BIOL, V236, P195, DOI 10.1006/dbio.2001.0309; Shigeno S, 2001, J COMP NEUROL, V437, P449, DOI 10.1002/cne.1295; Shigeno S, 2001, ZOOL SCI, V18, P527, DOI 10.2108/zsj.18.527; SUNDERMANN G, 1990, ZOOMORPHOLOGY, V109, P343, DOI 10.1007/BF00803575; Telford MJ, 2000, CURR BIOL, V10, P349, DOI 10.1016/S0960-9822(00)00387-0; von Boletzky S, 1970, C. r. hebd. Seanc. Acad. Sci., Paris, V270D, P2182; VONBOLETSKY S, 1994, MCGRAWHILL YB SCI TE, P73; VONBOLETZKY S, 1988, CEPHALOPODS PRESENT, P167; Wanninger A, 2001, EVOL DEV, V3, P312, DOI 10.1046/j.1525-142X.2001.01034.x; YOUNG JZ, 1972, PHILOS T R SOC B, V263, P409, DOI 10.1098/rstb.1972.0005; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262	30	137	139	3	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1061	1065		10.1038/nature01872	http://dx.doi.org/10.1038/nature01872			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944969				2022-12-24	WOS:000184984200045
J	Kaplan, CD; Laprade, L; Winston, F				Kaplan, CD; Laprade, L; Winston, F			Transcription elongation factors repress transcription initiation from cryptic sites	SCIENCE			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; CHROMATIN-STRUCTURE; CELL-CYCLE; IN-VIVO; SPT6; YEAST; GENES; DROSOPHILA; MUTATIONS	Previous studies have suggested that transcription elongation results in changes in chromatin structure. Here we present studies of Saccharomyces cerevisiae Spt6, a conserved protein implicated in both transcription elongation and chromatin structure. Our results show that, surprisingly, an spt6 mutant permits aberrant transcription initiation from within coding regions. Furthermore, transcribed chromatin in the spt6 mutant is hypersensitive to micrococcal nuclease, and this hypersensitivity is suppressed by mutational inactivation of RNA polymerase II. These results suggest that Spt6 plays a critical role in maintaining normal chromatin structure during transcription elongation, thereby repressing transcription initiation from cryptic promoters. Other elongation and chromatin factors, including Spt16 and histone H3, appear to contribute to this control.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Winston, F (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.	winston@rascal.med.harvard.edu	Kaplan, Craig/AAO-4500-2021	Kaplan, Craig/0000-0002-7518-695X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032967, R37GM032967] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32967] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2002, MOL CELL, V9, P451, DOI 10.1016/S1097-2765(02)00487-2; Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Andrulis ED, 2002, NATURE, V420, P837, DOI 10.1038/nature01181; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; CLARKADAMS CD, 1987, MOL CELL BIOL, V7, P679, DOI 10.1128/MCB.7.2.679; DENIS CL, 1984, GENETICS, V108, P833; DOLLARD C, 1994, MOL CELL BIOL, V14, P5223, DOI 10.1128/MCB.14.8.5223; Formosa T, 2002, GENETICS, V162, P1557; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1987, CELL, V48, P589, DOI 10.1016/0092-8674(87)90237-6; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hartzog GA, 2002, BBA-GENE STRUCT EXPR, V1577, P276, DOI 10.1016/S0167-4781(02)00458-X; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; KAPLAN CD, UNPUB; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Lindstrom DL, 2001, GENETICS, V159, P487; MALONE EA, 1991, MOL CELL BIOL, V11, P5710, DOI 10.1128/MCB.11.11.5710; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NATSOULIS G, 1994, GENETICS, V136, P93; NEIGEBORN L, 1987, MOL CELL BIOL, V7, P672, DOI 10.1128/MCB.7.2.672; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NORRIS D, 1988, SCIENCE, V242, P759, DOI 10.1126/science.2847314; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; PRELICH G, 1993, GENETICS, V135, P665; SWANSON MS, 1992, GENETICS, V132, P325; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; Winkler M, 2000, J VIROL, V74, P8053, DOI 10.1128/JVI.74.17.8053-8064.2000; WINSTON F, 1984, GENETICS, V107, P179	32	444	452	3	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2003	301	5636					1096	1099		10.1126/science.1087374	http://dx.doi.org/10.1126/science.1087374			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934008				2022-12-24	WOS:000184872400040
J	Lo, B; Chou, V; Cedars, MI; Gates, E; Taylor, RN; Wagner, RM; Wolf, L; Yamamoto, KR				Lo, B; Chou, V; Cedars, MI; Gates, E; Taylor, RN; Wagner, RM; Wolf, L; Yamamoto, KR			Consent from donors for embryo and stem cell research	SCIENCE			English	Editorial Material							ATTITUDES		Univ Calif San Francisco, Program Med Eth, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Human Subjects Protect Program, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lo, B (corresponding author), Univ Calif San Francisco, Program Med Eth, Sch Med, San Francisco, CA 94143 USA.	bernie@medicine.ucsf.edu		Wolf, Leslie/0000-0002-4660-8383				*ABCNEWS COM, 2001, PUBL BACKS STEM CELL; American Society for Reproductive Medicine, 2002, Fertil Steril, V77, pS2; *CAN I HLTH RES AD, 2002, HUM PLUR STEM CELL R; *CIHR, 2003, HUM STEM CELL RES OP; *COMM EUR COMM, 2003, REP HUM EMBR STEM CE; Ethics Comm, 2002, FERTIL STERIL, V78, P957; Feinberg J., 1988, HARMLESS WRONGDOING; *HL, 2002, REP SEL COMM STEM CE; *HUM FERT EMBR AUT, 2001, COD PRACT; Kalfoglou AL, 2000, FERTIL STERIL, V74, P660, DOI 10.1016/S0015-0282(00)01489-8; Kimbrell Andrew, 1997, HUMAN BODY SHOP CLON; McMahon CA, 2003, HUM REPROD, V18, P871, DOI 10.1093/humrep/deg167; *NAT BIOETH ADV CO, 1999, ETH ISS STEM CELL RE; National Bioethics Advisory Commission, 1999, RES INV HUM BIOL MAT; National Institute of Health, 1994, REP HUM EMBR RES PAN; *NY STAT TASK FORC, 1998, ASS REPR TECHN REC P; Radin Margaret J., 1996, CONTESTED COMMODITIE; Robertson JA., 1994, CHILDREN CHOICE FREE; *VA COMM U CTR PUB, 2002, VCU LIF SCI SURV; 2000, FED REG, V65, P51975	20	21	21	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2003	301	5635					921	921		10.1126/science.1087038	http://dx.doi.org/10.1126/science.1087038			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920284				2022-12-24	WOS:000184755900021
J	Pockley, AG				Pockley, AG			Heat shock proteins as regulators of the immune response	LANCET			English	Review							T-CELL RESPONSES; RECEPTOR-MEDIATED ENDOCYTOSIS; TYPE-16 E7-EXPRESSING TUMOR; JUVENILE CHRONIC ARTHRITIS; SMOOTH-MUSCLE CELLS; STRESS PROTEINS; MOLECULAR CHAPERONES; CUTTING EDGE; HUMAN HEAT-SHOCK-PROTEIN-60; MYCOBACTERIUM-TUBERCULOSIS	Until recently, heat shock proteins (also known as heat stress proteins) have mostly been regarded as intracellular molecules that mediate a range of essential housekeeping and cytoprotective functions. However, interest in their role as intercellular signalling molecules has been fuelled by the observations that these molecules can be released and re present in the extracellular environment under physiological conditions. They can elicit cytokine production by, and adhesion molecule expression of, a range of cell types, and they can deliver maturation signals and peptides to antigen presenting cells through receptor-mediated interactions. These functions suggest that heat shock proteins could be immunoregulatory agents with potent and widely-applicable therapeutic uses. Furthermore, the induction of self heat shock protein immune reactivity can attenuate autoimmunity and delay transplant rejection, and heat shock proteins derived from tumours and pathogens can elicit specific, protective immunity. This review will focus on this rapidly evolving area of heat shock protein biology.	Univ Sheffield, No Gen Hosp, Ctr Clin Sci, Div Clin Sci N,Immunobiol Res Grp, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital; University of Sheffield	Pockley, AG (corresponding author), Univ Sheffield, No Gen Hosp, Ctr Clin Sci, Div Clin Sci N,Immunobiol Res Grp, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.	g.pockley@sheffield.ac.uk	Pockley, Alan G/I-4704-2015; Xia, Xianfeng/F-9169-2011	Pockley, Alan G/0000-0001-9593-6431; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL069726] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69726] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KM, 2000, IMMUNOL LETT, V74, P35, DOI 10.1016/S0165-2478(00)00246-7; ANDERTON SM, 1995, J EXP MED, V181, P943, DOI 10.1084/jem.181.3.943; ANDERTON SM, 1996, STRESS PROTEINS MED, P73; Anthony LSD, 1999, VACCINE, V17, P373, DOI 10.1016/S0264-410X(98)00199-6; Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Bassan M, 1998, NEUROSCI LETT, V250, P37, DOI 10.1016/S0304-3940(98)00428-5; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Berwin B, 2002, J IMMUNOL, V168, P4282, DOI 10.4049/jimmunol.168.9.4282; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Binder RJ, 2001, J IMMUNOL, V166, P4968, DOI 10.4049/jimmunol.166.8.4968; Birk OS, 1999, P NATL ACAD SCI USA, V96, P5159, DOI 10.1073/pnas.96.9.5159; BLACHERE NE, 1993, J IMMUNOTHER, V14, P352, DOI 10.1097/00002371-199311000-00016; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Chandawarkar RY, 1999, J EXP MED, V189, P1437, DOI 10.1084/jem.189.9.1437; CHILD DF, 1993, J ROY SOC MED, V86, P217; CHILD DF, 1995, DIABETIC MED, V12, P595, DOI 10.1111/j.1464-5491.1995.tb00548.x; CHOUCHANE L, 1994, J INFECT DIS, V169, P253, DOI 10.1093/infdis/169.2.253; Chu NR, 2000, CELL STRESS CHAPERON, V5, P401, DOI 10.1379/1466-1268(2000)005<0401:IOAHPT>2.0.CO;2; Chu NR, 2000, CLIN EXP IMMUNOL, V121, P216, DOI 10.1046/j.1365-2249.2000.01293.x; Ciupitu AMT, 2002, CANCER IMMUNOL IMMUN, V51, P163, DOI 10.1007/s00262-002-0263-9; Ciupitu AMT, 1998, J EXP MED, V187, P685, DOI 10.1084/jem.187.5.685; COHEN IR, 1996, STRESS PROTEINS MED, P93; DEGRAEFFMEEDER ER, 1995, J CLIN INVEST, V95, P934, DOI 10.1172/JCI117801; DEGRAEFFMEEDER ER, 1991, LANCET, V337, P1368, DOI 10.1016/0140-6736(91)93057-G; DONATI YRA, 1990, BIOCHEM PHARMACOL, V40, P2571, DOI 10.1016/0006-2952(90)90573-4; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; FINCATO G, 1991, BLOOD, V77, P579; Galdiero M, 1997, INFECT IMMUN, V65, P699, DOI 10.1128/IAI.65.2.699-707.1997; Gaston JSH, 2002, CLIN EXP IMMUNOL, V127, P1, DOI 10.1046/j.1365-2249.2002.01759.x; GASTON JSH, 1990, J EXP MED, V171, P831, DOI 10.1084/jem.171.3.831; GEORGOPOULOS C, 1993, IMMUNOL TODAY, V14, P373, DOI 10.1016/0167-5699(93)90135-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Habich C, 2002, J IMMUNOL, V168, P569, DOI 10.4049/jimmunol.168.2.569; Heikema A, 1997, IMMUNOL LETT, V57, P69, DOI 10.1016/S0165-2478(97)00048-5; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Hoshino K, 1999, J IMMUNOL, V162, P3749; Janetzki S, 2000, INT J CANCER, V88, P232, DOI 10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kingston AE, 1996, CLIN EXP IMMUNOL, V103, P77, DOI 10.1046/j.1365-2249.1996.929628.x; KIRBY AC, 1995, J CLIN INVEST, V96, P1185, DOI 10.1172/JCI118150; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Lamb J R, 1989, Int Immunol, V1, P191, DOI 10.1093/intimm/1.2.191; LATHANGUE NB, 1988, EXP CELL RES, V178, P169; Lewthwaite J, 2002, CELL STRESS CHAPERON, V7, P130, DOI 10.1379/1466-1268(2002)007<0130:RLCBNC>2.0.CO;2; Lewthwaite J, 2002, CIRCULATION, V106, P196, DOI 10.1161/01.CIR.0000021121.26290.2C; Lewthwaite JC, 2001, INFECT IMMUN, V69, P7349, DOI 10.1128/IAI.69.12.7349-7355.2001; Liao DF, 2000, J BIOL CHEM, V275, P189, DOI 10.1074/jbc.275.1.189; Macht LM, 2000, IMMUNOLOGY, V99, P208, DOI 10.1046/j.1365-2567.2000.00966.x; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; Meghji S, 1997, J EXP MED, V186, P1241, DOI 10.1084/jem.186.8.1241; Mizzen L, 1998, BIOTHERAPY, V10, P173, DOI 10.1007/BF02678295; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MUNK ME, 1989, J IMMUNOL, V143, P2844; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; Nollen EAA, 2002, J CELL SCI, V115, P2809; NOVER I, 1991, HEAT SHOCK RESPONSE; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Paul AGA, 2000, J IMMUNOL, V165, P7270, DOI 10.4049/jimmunol.165.12.7270; PEETERMANS WE, 1994, SCAND J IMMUNOL, V39, P613, DOI 10.1111/j.1365-3083.1994.tb03421.x; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pockley AG, 2002, J HYPERTENS, V20, P1815, DOI 10.1097/00004872-200209000-00027; Pockley AG, 1999, CELL STRESS CHAPERON, V4, P29, DOI 10.1054/csac.1998.0121; Pockley AG, 1998, IMMUNOL INVEST, V27, P367, DOI 10.3109/08820139809022710; Pockley AG, 2000, HYPERTENSION, V36, P303, DOI 10.1161/01.HYP.36.2.303; Ramage JM, 1999, J IMMUNOL, V162, P704; RANFORD JC, 2000, EXP REV MOL MED; Rea IM, 2001, EXP GERONTOL, V36, P341, DOI 10.1016/S0531-5565(00)00215-1; Reddi K, 1998, J BONE MINER RES, V13, P1260, DOI 10.1359/jbmr.1998.13.8.1260; RES PCM, 1988, LANCET, V2, P478, DOI 10.1016/S0140-6736(88)90123-7; RETZLAFF C, 1994, INFECT IMMUN, V62, P5689, DOI 10.1128/IAI.62.12.5689-5693.1994; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; Robert J, 2001, EUR J IMMUNOL, V31, P186, DOI 10.1002/1521-4141(200101)31:1<186::AID-IMMU186>3.0.CO;2-D; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1994, CURR OPIN IMMUNOL, V6, P728, DOI 10.1016/0952-7915(94)90076-0; STINISSEN P, 1995, J IMMUNOL, V154, P4883; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Suzue K, 1996, J IMMUNOL, V156, P873; Tanaka S, 1999, J IMMUNOL, V163, P5560; THOMPSON SJ, 1990, EUR J IMMUNOL, V20, P2479, DOI 10.1002/eji.1830201118; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; TUN RYM, 1994, DIABETIC MED, V11, P66, DOI 10.1111/j.1464-5491.1994.tb00232.x; UDONO H, 1994, J IMMUNOL, V152, P5398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; van Eden W, 2000, DRUG DISCOV TODAY, V5, P115, DOI 10.1016/S1359-6446(99)01464-6; van Eden W, 1998, IMMUNOL TODAY, V19, P303, DOI 10.1016/S0167-5699(98)01283-3; VANDENBROEK MF, 1989, J EXP MED, V170, P449, DOI 10.1084/jem.170.2.449; VanRoon J, 1996, FASEB J, V10, P1801; vanRoon JAG, 1997, J CLIN INVEST, V100, P459, DOI 10.1172/JCI119553; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Wang XY, 2001, J IMMUNOL, V166, P490, DOI 10.4049/jimmunol.166.1.490; WELCH WJ, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0593-56; Wendling U, 2000, J IMMUNOL, V164, P2711, DOI 10.4049/jimmunol.164.5.2711; Wright BH, 2000, HEART VESSELS, V15, P18, DOI 10.1007/s003800070043; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cb.11.110195.002301; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P4588, DOI 10.1073/pnas.89.10.4588; Xu QB, 2000, CIRCULATION, V102, P14, DOI 10.1161/01.CIR.102.1.14; Yoshida N, 2001, NATURE, V411, P44, DOI 10.1038/35075148; YOUNG D, 1993, PHILOS T ROY SOC B, V339, P363, DOI 10.1098/rstb.1993.0035; YOUNG RA, 1990, ANNU REV IMMUNOL, V8, P401, DOI 10.1146/annurev.immunol.8.1.401; ZUO J, 1994, MOL CELL BIOL, V14, P7447	119	527	566	3	47	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					469	476		10.1016/S0140-6736(03)14075-5	http://dx.doi.org/10.1016/S0140-6736(03)14075-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927437				2022-12-24	WOS:000184651100025
J	Mazumder, B; Sampath, P; Seshadri, V; Maitra, RK; DiCorleto, PE; Fox, PL				Mazumder, B; Sampath, P; Seshadri, V; Maitra, RK; DiCorleto, PE; Fox, PL			Regulated release of L13a from the 60S ribosomal subunit as a mechanism of transcript-specific translational control	CELL			English	Article							BINDING-PROTEIN; MESSENGER-RNAS; TYROSINE PHOSPHORYLATION; TRANSPLANTATION ANTIGEN; GAMMA-INTERFERON; CERULOPLASMIN; YEAST; EXPRESSION; COMPLEX; GENE	Transcript-specific translational control is generally directed by binding of trans-acting proteins to structural elements in the untranslated region (UTR) of the target mRNA. Here, we elucidate a translational silencing mechanism involving regulated release of an integral ribosomal protein and subsequent binding to its target mRNA. Human ribosomal protein L13a was identified as a candidate interferon-Gamma-Activated Inhibitor of Translation (GAIT) of ceruloplasmin (Cp) mRNA by a genetic screen for Cp 3' -UTR binding proteins. In vitro activity of L13a was shown by inhibition of target mRNA translation by recombinant protein. In response to interferon-gamma in vivo, the entire cellular pool of L13a was phosphorylated and released from the 60S ribosomal subunit. Released L13a specifically bound the 3'-UTR GAIT element of Cp mRNA and silenced translation. We propose a model in which the ribosome functions not only as a protein synthesis machine, but also as a depot for regulatory proteins that modulate translation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Virus Core Facil, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Biol, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University	Fox, PL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	foxp@ccf.org		Mazumder, Barsanjit/0000-0003-3069-7833	NHLBI NIH HHS [HL67725, HL29582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582, R01HL067725] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnold RJ, 1999, J BIOL CHEM, V274, P37035, DOI 10.1074/jbc.274.52.37035; Ballesta JPG, 1999, FEMS MICROBIOL REV, V23, P537, DOI 10.1111/j.1574-6976.1999.tb00412.x; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Bielli P, 2002, CELL MOL LIFE SCI, V59, P1413, DOI 10.1007/s00018-002-8519-2; CAMPOS F, 1990, BIOCHIM BIOPHYS ACTA, V1087, P142, DOI 10.1016/0167-4781(90)90198-B; CHAN YL, 1994, J BIOL CHEM, V269, P5589; Diaz JJ, 2002, J CHROMATOGR B, V771, P237, DOI 10.1016/S1570-0232(02)00038-7; Dominski Z, 2002, MOL CELL BIOL, V22, P6648, DOI 10.1128/MCB.22.18.6648-6660.2002; Ehrenwald E, 1996, J CLIN INVEST, V97, P884, DOI 10.1172/JCI118491; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FLEMING RE, 1991, AM J PHYSIOL, V260, pL68, DOI 10.1152/ajplung.1991.260.2.L68; Gebauer F, 2003, MOL CELL, V11, P1397, DOI 10.1016/S1097-2765(03)00176-X; Gitlin JD, 1998, PEDIATR RES, V44, P271, DOI 10.1203/00006450-199809000-00001; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kirkpatrick P, 2002, NAT REV DRUG DISCOV, V1, P99, DOI 10.1038/nrd738; KLEBANOFF SJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P302, DOI 10.1016/0003-9861(92)90522-X; Kritzik MR, 2000, J ENDOCRINOL, V165, P67, DOI 10.1677/joe.0.1650067; Law LMJ, 2003, J VIROL, V77, P1764, DOI 10.1128/JVI.77.3.1764-1771.2003; Lee SW, 2002, P NATL ACAD SCI USA, V99, P5942, DOI 10.1073/pnas.082119899; LHOEST J, 1984, EUR J BIOCHEM, V141, P585, DOI 10.1111/j.1432-1033.1984.tb08233.x; Li J, 2001, J IMMUNOL, V166, P432, DOI 10.4049/jimmunol.166.1.432; Li JX, 2002, NATURE, V418, P793, DOI 10.1038/nature00936; MADEN BEH, 1968, J MOL BIOL, V35, P333, DOI 10.1016/S0022-2836(68)80028-2; Martin F, 1997, EMBO J, V16, P769, DOI 10.1093/emboj/16.4.769; MARZOUKI A, 1990, BIOCHIM BIOPHYS ACTA, V1048, P238, DOI 10.1016/0167-4781(90)90062-7; MASSE T, 1990, MOL GEN GENET, V220, P377, DOI 10.1007/BF00391742; Mauro VP, 2002, P NATL ACAD SCI USA, V99, P12031, DOI 10.1073/pnas.192442499; Mazumder B, 1997, J IMMUNOL, V159, P1938; Mazumder B, 1999, MOL CELL BIOL, V19, P6898; Mazumder B, 2001, MOL CELL BIOL, V21, P6440, DOI 10.1128/MCB.21.19.6440-6449.2001; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Mezzetti A, 1999, ARTERIOSCL THROM VAS, V19, P2659, DOI 10.1161/01.ATV.19.11.2659; Moore PB, 2003, ANNU REV BIOCHEM, V72, P813, DOI 10.1146/annurev.biochem.72.110601.135450; Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OSAKI S, 1966, J BIOL CHEM, V241, P2746; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; PRICE SR, 1992, GENOMICS, V14, P959, DOI 10.1016/S0888-7543(05)80117-X; REMACHA M, 1995, MOL CELL BIOL, V15, P4754; SAENZROBLES MT, 1988, EUR J BIOCHEM, V177, P531, DOI 10.1111/j.1432-1033.1988.tb14405.x; SALONEN JT, 1991, BRIT MED J, V302, P756, DOI 10.1136/bmj.302.6779.756; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Serganov A, 2003, EMBO J, V22, P1898, DOI 10.1093/emboj/cdg170; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; Siomi MC, 2002, MOL CELL BIOL, V22, P8438, DOI 10.1128/MCB.22.24.8438-8447.2002; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Vilardell J, 2000, MOL CELL, V5, P761, DOI 10.1016/S1097-2765(00)80255-5; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; WOOL IG, 1996, TRANSLATIONAL CONTRO, P481; WORMINGTON M, 1991, METHOD CELL BIOL, V36, P167; Yoo JY, 1999, GENE, V229, P215, DOI 10.1016/S0378-1119(98)00604-0; Zalfa F, 2003, CELL, V112, P317, DOI 10.1016/S0092-8674(03)00079-5; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1; Zhang YY, 2003, EMBO J, V22, P1801, DOI 10.1093/emboj/cdg171	62	246	263	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					187	198		10.1016/S0092-8674(03)00773-6	http://dx.doi.org/10.1016/S0092-8674(03)00773-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567916	Green Submitted, Bronze			2022-12-24	WOS:000186039200010
J	Sawaya, GF; McConnell, KJ; Kulasingam, SL; Lawson, HW; Kerlikowske, K; Melnikow, J; Lee, NC; Gildengorin, G; Myers, ER; Washington, AE				Sawaya, GF; McConnell, KJ; Kulasingam, SL; Lawson, HW; Kerlikowske, K; Melnikow, J; Lee, NC; Gildengorin, G; Myers, ER; Washington, AE			Risk of cervical cancer associated with extending the interval between cervical-cancer screenings	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; PAPILLOMAVIRUS INFECTION; RANDOMIZED TRIAL; COSTA-RICA; WOMEN; ABNORMALITIES; CYTOLOGY; GUIDELINES; MANAGEMENT; NEOPLASIA	BACKGROUND: Although contemporary guidelines suggest that the intervals between Papanicolaou tests can be extended to three years among low-risk women with previous negative tests, the excess risk of cervical cancer associated with less frequent than annual screening is uncertain. METHODS: We determined the prevalence of biopsy-proven cervical neoplasia among 938,576 women younger than 65 years of age, stratified according to the number of previous consecutive negative Papanicolaou tests. Using a Markov model that estimates the rate at which dysplasia will progress to cancer, we estimated the risk of cancer within three years after one or more negative Papanicolaou tests, as well as the number of additional Papanicolaou tests and colposcopic examinations that would be required to avert one case of cancer given a particular interval between screenings. RESULTS: Among 31,728 women 30 to 64 years of age who had had three or more consecutive negative tests, the prevalence of biopsy-proven cervical intraepithelial neoplasia of grade 2 was 0.028 percent and the prevalence of grade 3 neoplasia was 0.019 percent; none of the women had invasive cervical cancer. According to our model, the estimated risk of cancer with annual Papanicolaou tests for three years was 2 in 100,000 among women 30 to 44 years of age, 1 in 100,000 among women 45 to 59 years of age, and 1 in 100,000 among women 60 to 64 years of age; these risks would be 5 in 100,000, 2 in 100,000, and 1 in 100,000, respectively, if screening were performed once three years after the last negative test. To avert one additional case of cancer by screening 100,000 women annually for three years rather than once three years after the last negative test, an average of 69,665 additional Papanicolaou tests and 3861 colposcopic examinations would be needed in women 30 to 44 years of age and an average of 209,324 additional Papanicolaou tests and 11,502 colposcopic examinations in women 45 to 59 years of age. CONCLUSIONS: As compared with annual screening for three years, screening performed once three years after the last negative test in women 30 to 64 years of age who have had three or more consecutive negative Papanicolaou tests is associated with an average excess risk of cervical cancer of approximately 3 in 100,000.	Dept Vet Affairs, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94121 USA; Dept Vet Affairs, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA; Dept Vet Affairs, Dept Med, San Francisco, CA 94121 USA; Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Oregon Hlth Sci Univ, Dept Emergency Med Publ Hlth & Prevent Med, Portland, OR 97201 USA; Duke Univ, Dept Obstet & Gynecol, Durham, NC 27710 USA; Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA; Univ Calif Davis, Dept Family & Community Med, Sacramento, CA 95817 USA	University of California System; University of California San Francisco; Oregon Health & Science University; Duke University; Centers for Disease Control & Prevention - USA; University of California System; University of California Davis	Sawaya, GF (corresponding author), Dept Vet Affairs, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94121 USA.			Kulasingam, Shalini/0000-0002-0932-9166	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS007373] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA074973] Funding Source: NIH RePORTER; AHRQ HHS [HS07373] Funding Source: Medline; NCI NIH HHS [K08 CA 74973-02] Funding Source: Medline; PHS HHS [282-98-0026] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AG HLTH CAR POL R, 1999, AHCPR PUBL; BEARMAN DM, 1987, OBSTET GYNECOL, V69, P660; Belinson J, 2002, GYNECOL ONCOL, V84, P355, DOI 10.1006/gyno.2001.6554; CHAN PG, IN PRESS OBSTET GYNE; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; DEVESA SS, 1989, CANCER, V64, P2184, DOI 10.1002/1097-0142(19891115)64:10<2184::AID-CNCR2820641034>3.0.CO;2-8; Duggan MA, 1998, EUR J GYNAECOL ONCOL, V19, P338; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; FAHS MC, 1992, ANN INTERN MED, V117, P520, DOI 10.7326/0003-4819-117-6-520; FINK DJ, 1988, CA-CANCER J CLIN, V38, P127, DOI 10.3322/canjclin.38.2.127; FLEISS JL, 1981, STATISTICAL METHODS, P64; Freeman-Wang T, 2001, BRIT J OBSTET GYNAEC, V108, P482, DOI 10.1016/S0306-5456(00)00121-2; Henson R M, 1996, J Public Health Manag Pract, V2, P36; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252; Hutchinson ML, 1999, CANCER CYTOPATHOL, V87, P48, DOI 10.1002/(SICI)1097-0142(19990425)87:2&lt;48::AID-CNCR2&gt;3.0.CO;2-D; JANERICH DT, 1995, AM J PUBLIC HEALTH, V85, P791, DOI 10.2105/AJPH.85.6.791; Kulasingam SL, 2002, JAMA-J AM MED ASSOC, V288, P1749, DOI 10.1001/jama.288.14.1749; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; Lawson HW, 1998, OBSTET GYNECOL, V92, P745, DOI 10.1016/S0029-7844(98)00257-9; Melnikow J, 1998, OBSTET GYNECOL, V92, P727, DOI 10.1016/S0029-7844(98)00245-2; Munoz N, 1996, SEX TRANSM DIS, V23, P504, DOI 10.1097/00007435-199611000-00012; Myers ER, 2000, OBSTET GYNECOL, V96, P645, DOI 10.1016/S0029-7844(00)00979-0; Myers ER, 2000, AM J EPIDEMIOL, V151, P1158, DOI 10.1093/oxfordjournals.aje.a010166; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; National Institutes of Health, 1996, CERV CANC NIH CONS S; PAYNE N, 2000, LIQUID BASED CYTOLOG; PRETORIUS R, 1991, GYNECOL ONCOL, V42, P48, DOI 10.1016/0090-8258(91)90229-X; *PREV SERV TASK FO, 2003, CERV CANC SCREEN; Ries LAG, 2003, SEER CANC STAT REV 1; Saslow D, 2002, CA-CANCER J CLIN, V52, P342, DOI 10.3322/canjclin.52.6.342; Sawaya GF, 2001, NEW ENGL J MED, V344, P1603, DOI 10.1056/NEJM200105243442107; Sawaya GF, 1999, OBSTET GYNECOL, V94, P307, DOI 10.1016/S0029-7844(99)00289-6; Sawaya GF, 2000, ANN INTERN MED, V133, P942, DOI 10.7326/0003-4819-133-12-200012190-00009; Sawaya GF, 2000, OBSTET GYNECOL, V96, P219, DOI 10.1016/S0029-7844(00)00882-6; Schiffman M, 2000, JAMA-J AM MED ASSOC, V283, P87, DOI 10.1001/jama.283.1.87; Schwartz PE, 1996, AM J OBSTET GYNECOL, V175, P1105, DOI 10.1016/S0002-9378(96)70012-1; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Stenkvist B, 1996, J Med Screen, V3, P204; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Swan J, 2003, CANCER, V97, P1528, DOI 10.1002/cncr.11208; SYRJANEN K, 1992, OBSTET GYNECOL, V79, P675; VANOORTMARSSEN GJ, 1991, BRIT J CANCER, V64, P559, DOI 10.1038/bjc.1991.350; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120; Wright TC, 2003, NEW ENGL J MED, V348, P489, DOI 10.1056/NEJMp020178	45	86	107	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1501	1509		10.1056/NEJMoa035419	http://dx.doi.org/10.1056/NEJMoa035419			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561792				2022-12-24	WOS:000185916400004
J	Ho, DG; Gao, RM; Celaje, J; Chung, HY; Selke, M				Ho, DG; Gao, RM; Celaje, J; Chung, HY; Selke, M			Phosphadioxirane: A peroxide from an ortho-substituted arylphosphine and singlet dioxygen	SCIENCE			English	Article							OXYGEN; SULFIDES; PHOSPHINES; CHEMISTRY; MECHANISM	We prepared the primary adduct for the reaction of singlet dioxygen (O-1(2)) with an arylphosphine by using the sterically hindered arylphosphine tris(omethoxyphenyl) phosphine. The resulting phosphadioxirane has a dioxygen molecule triangularly bound to the phosphorus atom. Olefin trapping experiments show that the phosphadioxirane can undergo nonradical oxygen atom-transfer reactions. Under protic conditions, two different intermediates are formed during the reaction of singlet dioxygen with tris(o-methoxyphenyl) phosphine, namely, the corresponding hydroperoxy arylphosphine and a hydroxy phosphorane. Experiments with other arylphosphines possessing different electronic and steric properties demonstrate that the relative stability of the tris(o-methoxyphenyl) phosphadioxirane is due to both steric and electronic effects.	Calif State Univ Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90032 USA	California State University System; California State University Los Angeles	Selke, M (corresponding author), Calif State Univ Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90032 USA.	mselke@calstatela.edu			NIGMS NIH HHS [GM 64104, GM 08101] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM064104] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], COMMUNICATION; BOLDUC PR, 1974, J ORG CHEM, V39, P3178; Clennan EL, 2001, ACCOUNTS CHEM RES, V34, P875, DOI 10.1021/ar0100879; EAPEN KC, 1980, J FLUORINE CHEM, V15, P239, DOI 10.1016/S0022-1139(00)82580-4; Gao RM, 2001, ORG LETT, V3, P3719, DOI 10.1021/ol010195v; GORENSTEINDG, 1984, PHOSPHORUS 31 NMR PR, P14; GU CL, 1981, J AM CHEM SOC, V103, P5949, DOI 10.1021/ja00409a073; Jensen F, 1998, J AM CHEM SOC, V120, P4439, DOI 10.1021/ja973782d; LIANG JJ, 1983, J AM CHEM SOC, V105, P4717, DOI 10.1021/ja00352a033; NAHM K, 1993, J AM CHEM SOC, V115, P4879, DOI 10.1021/ja00064a057; NAHM K, 1989, J AM CHEM SOC, V111, P909; Reynolds MS, 1996, INORG CHEM, V35, P2378, DOI 10.1021/ic951212d; TSUJI S, 1993, J ORG CHEM, V58, P5055, DOI 10.1021/jo00071a012; VONITZSTEIN M, 1983, J CHEM SOC CHEM COMM, V164	14	58	59	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					259	262		10.1126/science.1089145	http://dx.doi.org/10.1126/science.1089145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	730HT	14551430				2022-12-24	WOS:000185825900034
J	Bloom, J; Amador, V; Bartolini, F; DeMartino, G; Pagano, M				Bloom, J; Amador, V; Bartolini, F; DeMartino, G; Pagano, M			Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation	CELL			English	Article							S-PHASE; IN-VIVO; UBIQUITINATION; PROTEIN; PROGRESSION; RESIDUE; CYCLIN; P53; INHIBITOR; P21(CIP1)	We examined the mechanism responsible for the degradation of p21, a negative regulator of the cell division cycle. We found that p21 proteolysis requires functional ubiquitin and Nedd8 systems. Ubiquitinylated forms of p21 and p21(K0), a p21 mutant missing all lysines, are detected in vivo and in vitro, showing that the presence of lysines is dispensable for p21 ubiquitinylation. Instead, the free amino group of the N-terminal methionine of p21 is a site for ubiquitinylation in vivo. Although wild-type p21 is more abundantly ubiquitinylated than p21(K0) mutant due to the presence of internal lysine residues, their rates of proteolysis are indistinguishable. These results demonstrate that proteasomal degradation of p21 is regulated by the ubiquitin pathway and suggest that the site of the ubiquitin chain is critical in making p21 a competent substrate for the proteasome.	NYU, Inst Canc, New York, NY 10016 USA; NYU, Sch Med, New York, NY 10016 USA; Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	New York University; New York University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pagano, M (corresponding author), NYU, Inst Canc, 550 1St Ave, New York, NY 10016 USA.			pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [R01CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Fukuchi K, 2002, BIOCHEM BIOPH RES CO, V293, P120, DOI 10.1016/S0006-291X(02)00198-5; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; NISHIMOTO T, 1980, SOMAT CELL GENET, V6, P465, DOI 10.1007/BF01539150; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367	25	263	271	1	17	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					71	82		10.1016/S0092-8674(03)00755-4	http://dx.doi.org/10.1016/S0092-8674(03)00755-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532004	Bronze			2022-12-24	WOS:000185815500010
J	Englund, C; Loren, CE; Grabbe, C; Varshney, GK; Deleuil, F; Hallberg, B; Palmer, RH				Englund, C; Loren, CE; Grabbe, C; Varshney, GK; Deleuil, F; Hallberg, B; Palmer, RH			Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion	NATURE			English	Article							NON-HODGKINS-LYMPHOMA; DROSOPHILA-MELANOGASTER; GENE; EMBRYOGENESIS	The Drosophila melanogaster gene Anaplastic lymphoma kinase (Alk) is homologous to mammalian Alk, a member of the Alk/Ltk family of receptor tyrosine kinases (RTKs)(1). We have previously shown that the Drosophila Alk RTK is crucial for visceral mesoderm development during early embryogenesis(2). Notably, observed Alk visceral mesoderm defects are highly reminiscent of the phenotype reported for the secreted molecule Jelly belly (Jeb)(3). Here we show that Drosophila Alk is the receptor for Jeb in the developing visceral mesoderm, and that Jeb binding stimulates an Alk-driven, extracellular signal-regulated kinase-mediated signalling pathway, which results in the expression of the downstream gene duf (also known as kirre)(4,5)-needed for muscle fusion. This new signal transduction pathway drives specification of the muscle founder cells, and the regulation of Duf expression by the Drosophila Alk RTK explains the visceral-mesoderm-specific muscle fusion defects observed in both Alk and jeb mutant animals.	Umea Univ, Umea Ctr Mol Pathogenesis, S-90187 Umea, Sweden; Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden	Umea University; Umea University	Palmer, RH (corresponding author), Umea Univ, Umea Ctr Mol Pathogenesis, S-90187 Umea, Sweden.	Ruth.Palmer@ucmp.umu.se	Varshney, Gaurav/L-5261-2014	Varshney, Gaurav K./0000-0002-0429-1904				BATE M, 1990, DEVELOPMENT, V110, P791; Baylies MK, 2001, CURR OPIN GENET DEV, V11, P431, DOI 10.1016/S0959-437X(00)00214-8; Campos-Ortega J, 1997, EMBRYONIC DEV DROSOP; CARMENA A, 1995, GENE DEV, V9, P2373, DOI 10.1101/gad.9.19.2373; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Dworak HA, 2002, BIOESSAYS, V24, P591, DOI 10.1002/bies.10115; Fujioka H, 2002, CHEM IMMUNOL, V80, P1; Gabay L, 1997, DEVELOPMENT, V124, P3535; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Klapper R, 2002, MECH DEVELOP, V110, P85, DOI 10.1016/S0925-4773(01)00567-6; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Loren CE, 2003, EMBO REP, V4, P781, DOI 10.1038/sj.embor.embor897; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Palmer RH, 1999, J BIOL CHEM, V274, P35621, DOI 10.1074/jbc.274.50.35621; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Ruiz-Gomez M, 2000, CELL, V102, P189, DOI 10.1016/S0092-8674(00)00024-6; San Martin B, 2001, DEVELOPMENT, V128, P3331; Strunkelnberg M, 2001, DEVELOPMENT, V128, P4229; Weiss JB, 2001, CELL, V107, P387, DOI 10.1016/S0092-8674(01)00540-2	23	121	122	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					512	516		10.1038/nature01950	http://dx.doi.org/10.1038/nature01950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523447				2022-12-24	WOS:000185648100045
J	Staal, M; Meysman, FJR; Stal, LJ				Staal, M; Meysman, FJR; Stal, LJ			Temperature excludes N-2-fixing heterocystous cyanobacteria in the tropical oceans	NATURE			English	Article							NITROGEN-FIXATION; N-2 FIXATION; BALTIC SEA; PHOTOSYNTHESIS; TRICHODESMIUM; OXYGEN	Whereas the non-heterocystous cyanobacteria Trichodesmium spp. are the dominant N-2-fixing organisms in the tropical oceans(1), heterocystous species dominate N-2 fixation in freshwater lakes and brackish environments such as the Baltic Sea(2). So far no satisfactory explanation for the absence of heterocystous cyanobacteria in the pelagic of the tropical oceans has been given, even though heterocysts would seem to represent an ideal strategy for protecting nitrogenase from being inactivated by O-2, thereby enabling cyanobacteria to fix N-2 and to perform photosynthesis simultaneously. Trichodesmium is capable of N-2 fixation, apparently without needing to differentiate heterocysts(3). Here we show that differences in the temperature dependence of O-2 flux, respiration and N-2 fixation activity explain how Trichodesmium performs better than heterocystous species at higher temperatures. Our results also explain why Trichodesmium is not successful in temperate or cold seas. The absence of heterocystous cyanobacteria in the pelagic zone of temperate and cold seas, however, requires another explanation.	NIOO KNAW, Dept Marine Microbiol, NL-4400 AC Yerseke, Netherlands; NIOO KNAW, Dept Ecosyst Studies, NL-4400 AC Yerseke, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW)	Staal, M (corresponding author), NIOO KNAW, Dept Marine Microbiol, POB 140, NL-4400 AC Yerseke, Netherlands.		Stal, Lucas J/B-3334-2011; Meysman, Filip JR/C-9585-2009	Meysman, Filip JR/0000-0001-5334-7655				Bergman B, 1997, FEMS MICROBIOL REV, V19, P139, DOI 10.1016/S0168-6445(96)00028-9; Berman-Frank I, 2001, LIMNOL OCEANOGR, V46, P1249, DOI 10.4319/lo.2001.46.6.1249; Berman-Frank I, 2001, SCIENCE, V294, P1534, DOI 10.1126/science.1064082; Carpenter EJ, 2001, PHYCOLOGIA, V40, P105; Chen YB, 1996, J PHYCOL, V32, P916, DOI 10.1111/j.0022-3646.1996.00916.x; DAVISON IR, 1991, J PHYCOL, V27, P2, DOI 10.1111/j.0022-3646.1991.00002.x; Hoffmann L, 1999, EUR J PHYCOL, V34, P371; KANA TM, 1993, LIMNOL OCEANOGR, V38, P18, DOI 10.4319/lo.1993.38.1.0018; KANGATHARALINGAM N, 1991, J PHYCOL, V27, P680, DOI 10.1111/j.0022-3646.1991.00680.x; Karl D, 2002, BIOGEOCHEMISTRY, V57, P47, DOI 10.1023/A:1015798105851; Laamanen MJ, 1997, J PLANKTON RES, V19, P1385, DOI 10.1093/plankt/19.10.1385; MURRY MA, 1989, ARCH MICROBIOL, V151, P469, DOI 10.1007/BF00454860; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sanudo-Wilhelmy SA, 2001, NATURE, V411, P66, DOI 10.1038/35075041; Staal M, 2001, ENVIRON MICROBIOL, V3, P343, DOI 10.1046/j.1462-2920.2001.00201.x; Staal M, 2002, APPL ENVIRON MICROB, V68, P4679, DOI 10.1128/AEM.68.9.4679-4683.2002; Stal LJ, 2000, EUR J PHYCOL, V35, P97, DOI 10.1080/09670260010001735681; TALLING J. F., 1957, NEW PHYTOL, V56, P29, DOI 10.1111/j.1469-8137.1957.tb07447.x; WALSBY A E, 1985, Proceedings of the Royal Society of London Series B Biological Sciences, V226, P345, DOI 10.1098/rspb.1985.0099; Wolk C.P., 1994, MOL BIOL CYANOBACTER, P770	20	123	130	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					504	507		10.1038/nature01999	http://dx.doi.org/10.1038/nature01999			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523445				2022-12-24	WOS:000185648100043
J	Ouyang, Z; Takats, Z; Blake, TA; Gologan, B; Guymon, AJ; Wiseman, JM; Oliver, JC; Davisson, VJ; Cooks, RG				Ouyang, Z; Takats, Z; Blake, TA; Gologan, B; Guymon, AJ; Wiseman, JM; Oliver, JC; Davisson, VJ; Cooks, RG			Preparing protein microarrays by soft-landing of mass-selected ions	SCIENCE			English	Article							POLYATOMIC IONS; FABRICATION; DEPOSITION	Intact, multiply protonated proteins of particular mass and charge were selected from ionized protein mixtures and gently landed at different positions on a surface to form a microarray. An array of cytochrome c, lysozyme, insulin, and apomyoglobin was generated, and the deposited proteins showed electrospray ionization mass spectra that matched those of the authentic compounds. Deposited lysozyme and trypsin retained their biological activity. Multiply charged ions of protein kinase A catalytic subunit and hexokinase were also soft-landed into glycerol-based liquid surfaces. These soft-landed kinases phosphorylated LRRASLG oligopeptide and D-fructose, respectively.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Cooks, RG (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.	cooks@purdue.edu	Cockshutt, Naomi/AAJ-2721-2020; Cooks, R Graham/G-1051-2015	Cooks, R Graham/0000-0002-9581-9603; Blake, Thomas/0000-0001-8536-9998				Bromann K, 1996, SCIENCE, V274, P956, DOI 10.1126/science.274.5289.956; Feng BB, 1999, J AM CHEM SOC, V121, P8961, DOI 10.1021/ja9923888; FRANCHETTI V, 1977, INT J MASS SPECTROM, V23, P29, DOI 10.1016/0020-7381(77)80004-1; Fuerstenau SD, 2001, ANGEW CHEM INT EDIT, V40, P542, DOI 10.1002/1521-3773(20010202)40:3<541::AID-ANIE541>3.0.CO;2-K; Geiger RJ, 1999, INT J MASS SPECTROM, V182, P415, DOI 10.1016/S1387-3806(98)14262-8; Jones VW, 1998, ANAL CHEM, V70, P1233, DOI 10.1021/ac971125y; Laurell T, 1999, J MICROMECH MICROENG, V9, P369, DOI 10.1088/0960-1317/9/4/314; LEE JC, 1981, J BIOL CHEM, V256, P7193; Luo H, 1998, INT J MASS SPECTROM, V174, P193, DOI 10.1016/S0168-1176(97)00302-9; MacBeath G, 2000, SCIENCE, V289, P1760; Martin BD, 1998, LANGMUIR, V14, P3971, DOI 10.1021/la9713311; Miller SA, 1997, SCIENCE, V275, P1447, DOI 10.1126/science.275.5305.1447; Mooney JF, 1996, P NATL ACAD SCI USA, V93, P12287, DOI 10.1073/pnas.93.22.12287; Morozov VN, 1999, ANAL CHEM, V71, P3110, DOI 10.1021/ac981412h; Pan P, 2003, ANAL CHEM, V75, P1491, DOI 10.1021/ac020637w; Roda A, 2000, BIOTECHNIQUES, V28, P492, DOI 10.2144/00283st07; Rowe CA, 1999, ANAL CHEM, V71, P433, DOI 10.1021/ac980798t; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schwartz JC, 2002, J AM SOC MASS SPECTR, V13, P659, DOI 10.1016/S1044-0305(02)00384-7; Siuzdak G, 1999, J MASS SPECTROM, V34, P1087, DOI 10.1002/(SICI)1096-9888(199910)34:10<1087::AID-JMS872>3.0.CO;2-A; Zhu H, 2003, CURR OPIN CHEM BIOL, V7, P55, DOI 10.1016/S1367-5931(02)00005-4	21	219	226	2	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1351	1354		10.1126/science.1088776	http://dx.doi.org/10.1126/science.1088776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12920304				2022-12-24	WOS:000185116400032
J	Diehr, P; Patrick, DL				Diehr, P; Patrick, DL			Trajectories of health for older adults over time: Accounting fully for death	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				SELF-RATED HEALTH; PATTERNS; TRIAL; INDEX; LIFE	The process of healthy aging can best be described by plotting the trajectory of health-related variables over time. Unfortunately, graphs including data only from survivors may be misleading because they may confuse patterns of mortality with patterns of change in health. Two approaches for creating graphs that account for death in such situations are 1) to incorporate a category or value for death into the longitudinal health variable and 2) to measure time in years before death or some other event. The first approach has been applied to self-rated health (excellent to poor) and the 36-Item Short-Form Health Survey (SF-36). It allows for flexible and interpretable analyses and may be appropriate for other variables as well. The second approach also accounts fully for death, but the questions it can address are limited. Both approaches are useful and should be used at a minimum for supporting analyses in longitudinal studies in which persons die during observation.	Univ Washington, Dept Biostat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Diehr, P (corresponding author), Univ Washington, Dept Biostat, Box 357232, Seattle, WA 98195 USA.	pdiehr@u.washington.edu	Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085084, N01HC085081, N01HC015103, N01HC085082, N01HC085083, N01HC085085, N01HC035129, N01HC085080, N01HC085086, N01HC085079] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85081, N01-HC-85082, N01-HC-85080, N01-HC-85083, N01-HC-85079, N01-HC-85086, N01-HC-85084, N01-HC-35129, N01 HC-15103, N01-HC-85085] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOZZETTE SA, 1995, JAMA-J AM MED ASSOC, V273, P295, DOI 10.1001/jama.273.4.295; DIEHR P, 1995, MED CARE, V33, pAS164; Diehr P, 1998, J CLIN EPIDEMIOL, V51, P343, DOI 10.1016/S0895-4356(97)00298-9; Diehr P, 2002, J CLIN EPIDEMIOL, V55, P269, DOI 10.1016/S0895-4356(01)00462-0; Diehr P, 2001, QUAL LIFE RES, V10, P431, DOI 10.1023/A:1012566130639; Diehr P, 2001, MED CARE, V39, P670, DOI 10.1097/00005650-200107000-00004; Diehr P, 2001, J AM GERIATR SOC, V49, P36, DOI 10.1046/j.1532-5415.2001.49007.x; DIEHR P, 2003, IN PRESS MED CARE; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; JOHNSON LL, 2002, THESIS U WASHINGTON; KAPLAN RM, 1979, MED CARE, V17, P501, DOI 10.1097/00005650-197905000-00005; LONGSTRETH WT, 1993, NEUROLOGY, V43, P2534, DOI 10.1212/WNL.43.12.2534; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Shock N.W., 1984, NORMAL HUMAN AGING B	16	38	38	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			416	420		10.7326/0003-4819-139-5_Part_2-200309021-00007	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965968				2022-12-24	WOS:000185133800007
J	Trembleau, L; Rebek, J				Trembleau, L; Rebek, J			Helical conformation of alkanes in a hydrophobic cavitand	SCIENCE			English	Article							MOLECULAR RECOGNITION; COMPLEXATION	Alkanes adopt extended conformations in solution that minimize steric interactions and maximize surface area. Folding can reduce the amount of hydrophobic surface exposed to solvent, but sterically unfavorable gauche interactions result. However, we found that the alkyl chains of two common surfactants in aqueous solution adopt helical conformations when bound within a synthetic receptor. The receptor recognizes the helical alkane better than the extended conformation, even though 2 to 3 kilocalories per mole of strain is introduced. The proper filling of space and burial of hydrophobic surface drive the molecular recognition between the receptor and the coiled alkane.	Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Rebek, J (corresponding author), Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jrebek@scripps.edu		Trembleau, Laurent/0000-0001-6376-9077	NIGMS NIH HHS [GM 27932] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027932, R01GM027932] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atwood JL, 2002, J AM CHEM SOC, V124, P10646, DOI 10.1021/ja027191l; Atwood JL, 2003, CHEM COMMUN, P940, DOI 10.1039/b301511d; ATWOOD JL, 1995, SUPRAMOL CHEM, V5, P105, DOI 10.1080/10610279508029481; BLOKZIJL W, 1993, ANGEW CHEM INT EDIT, V32, P1545, DOI 10.1002/anie.199315451; Casnati A, 2003, ACCOUNTS CHEM RES, V36, P246, DOI 10.1021/ar0200798; GOODLING K, 1994, J CHEM EDUC, V71, pA8, DOI 10.1021/ed071pA8; Haino T, 2000, CHEM-EUR J, V6, P3797, DOI 10.1002/1521-3765(20001016)6:20<3797::AID-CHEM3797>3.0.CO;2-1; Hof F, 2003, ANGEW CHEM INT EDIT, V42, P3150, DOI 10.1002/anie.200351174; LEHN JM, 1995, SUPRAMOL CHEM, V5, P97, DOI 10.1080/10610279508029480; MCDONALD DQ, 1992, TETRAHEDRON LETT, V33, P7743, DOI 10.1016/0040-4039(93)88034-G; Mecozzi S, 1998, CHEM-EUR J, V4, P1016, DOI 10.1002/(SICI)1521-3765(19980615)4:6<1016::AID-CHEM1016>3.0.CO;2-B; Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NISHIO M, 1998, CH PI INTERACTION; PETERSON BR, 1995, TETRAHEDRON, V51, P401, DOI 10.1016/0040-4020(94)00905-A; Rekharsky MV, 1998, CHEM REV, V98, P1875, DOI 10.1021/cr970015o; Rudkevich DM, 1998, J AM CHEM SOC, V120, P12216, DOI 10.1021/ja982970g; SCHNEIDER HJ, 1987, J ORG CHEM, V52, P1613, DOI 10.1021/jo00384a046; SONCINI P, 1992, J ORG CHEM, V57, P4608, DOI 10.1021/jo00043a015; STAFFORD RE, 1989, BIOCHEMISTRY-US, V28, P5113, DOI 10.1021/bi00438a031; TURRO NJ, 1978, J AM CHEM SOC, V100, P5951, DOI 10.1021/ja00486a062; VANSTAM J, 1994, J CHEM EDUC, V75, P93; [No title captured]	23	191	192	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1219	1220		10.1126/science.1086644	http://dx.doi.org/10.1126/science.1086644			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947192				2022-12-24	WOS:000185003500035
J	Eichinger, S; Minar, E; Bialonczyk, C; Hirschl, M; Quehenberger, P; Schneider, B; Weltermann, A; Wagner, O; Kyrle, PA				Eichinger, S; Minar, E; Bialonczyk, C; Hirschl, M; Quehenberger, P; Schneider, B; Weltermann, A; Wagner, O; Kyrle, PA			D-dimer levels and risk of recurrent venous thromboembolism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL ANTICOAGULANT-THERAPY; DEEP-VEIN THROMBOSIS; FACTOR-V-LEIDEN; PROTHROMBIN GENE; HETEROZYGOUS CARRIERS; FIRST EPISODE; MUTATION; THROMBOPHILIA	Context Widespread screening of patients with venous thromboembolism (VTE) for thrombophilic risk factors has become common clinical practice. Because of the increasing number of risk factors, assessing the risk of recurrence in an individual patient is intricate; therefore, a laboratory method that measures multifactorial thrombophilia is required. Objective To prospectively study the relationship between the risk of recurrent VTE and D-dimer, a global marker of coagulation activation and fibrinolysis. Design, Setting, and Participants Prospective cohort study of 610 patients older than 18 years who were treated with oral anticoagulants for at least 3 months with a first spontaneous VTE, in whom D-dimer levels were measured shortly after discontinuation of oral anticoagulation. The study was conducted at the Department of Internal Medicine I, University Hospital, Vienna, Austria. Patients entered the study at time of discontinuation of oral anticoagulants and were observed at 3-month intervals during the first year and every 6 months thereafter from July 1992 to October 2002. Main Outcome Measure Objectively documented symptomatic recurrent VTE. Results A total of 79 (13%) of 610 patients had recurrent VTE with a mean observation time of 38 months. Patients with recurrence had significantly higher D-dimer levels compared with those without recurrence (553 ng/mL vs 427 ng/mL, P=.01). Compared with patients with D-dimer levels of 750 ng/mL or higher, the relative risk (RR) of recurrence was 0.6 (95% confidence interval [CI], 0.3-1.4),0.6 (95% CI, 0.3-1.2), and 0.3 (95% CI, 0.1-0.6) in patients with D-dimer levels of 500 to 749 ng/mL, 250 to 499 ng/mL, and less than 250 ng/mL, respectively. The cumulative probability of recurrent VTE at 2 years was 3.7% (95% CI, 0.9%-6.5%) among patients with D-dimer levels of less than 250 ng/mL compared with 11.5% (95% CI, 8.0%-15.0%) among patients with higher levels (P=.001). Patients with D-dimer levels of less than 250 ng/mL had a 60% lower RR of recurrence compared with patients with higher levels (RR, 0.4; 95% CI, 0.2-0.8). Conclusion Patients with a first spontaneous VTE and a D-dimer level of less than 250 ng/mL after withdrawal of oral anticoagulation have a low risk of VTE recurrence.	Univ Vienna, Dept Internal Med 1, A-1090 Vienna, Austria; Univ Vienna, Ludwig Boltzmann Inst, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med 2, A-1090 Vienna, Austria; Univ Vienna, Clin Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria; Univ Vienna, Inst Med Stat, A-1090 Vienna, Austria; Wilhelminenspital Stadt Wien, Vienna, Austria; Hanuschkrankenhaus, Vienna, Austria	University of Vienna; Ludwig Boltzmann Institute; University of Vienna; University of Vienna; University of Vienna; University of Vienna; Wilhelminenspital; WGKK - Hanusch Hospital	Eichinger, S (corresponding author), Univ Vienna, Dept Internal Med 1, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	sabine.eichinger@akh-wien.ac.at						Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302; Andreescu ACM, 2002, THROMB HAEMOSTASIS, V87, P47, DOI 10.1055/s-0037-1612942; Bauer KA, 2001, ANN INTERN MED, V135, P367, DOI 10.7326/0003-4819-135-5-200109040-00013; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Cushman M, 2003, BLOOD, V101, P1243, DOI 10.1182/blood-2002-05-1416; De Stefano V, 1999, NEW ENGL J MED, V341, P801, DOI 10.1056/NEJM199909093411104; De Stefano V, 2001, BRIT J HAEMATOL, V113, P630, DOI 10.1046/j.1365-2141.2001.02827.x; Eichinger S, 1999, THROMB HAEMOSTASIS, V81, P14; Eichinger S, 1998, THROMB HAEMOSTASIS, V80, P566; Eichinger S, 2002, ARCH INTERN MED, V162, P2357, DOI 10.1001/archinte.162.20.2357; Hirsh J, 2002, BLOOD, V99, P3102, DOI 10.1182/blood.V99.9.3102; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747; Kyrle PA, 2000, NEW ENGL J MED, V343, P457, DOI 10.1056/NEJM200008173430702; Lindmarker P, 1999, THROMB HAEMOSTASIS, V81, P684; Mannucci PM, 2002, THROMB HAEMOSTASIS, V88, P1; Margaglione M, 1999, THROMB HAEMOSTASIS, V82, P1583; Martinelli I, 2001, THROMB HAEMOSTASIS, V86, P395; Palareti G, 2002, THROMB HAEMOSTASIS, V87, P7; Pinede L, 2001, CIRCULATION, V103, P2453; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501	24	254	261	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1071	1074		10.1001/jama.290.8.1071	http://dx.doi.org/10.1001/jama.290.8.1071			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941680	Bronze			2022-12-24	WOS:000184958900026
J	Wang, TJ; Massaro, JM; Levy, D; Vasan, RS; Wolf, PA; D'Agostino, RB; Larson, MG; Kannel, WB; Benjamin, EJ				Wang, TJ; Massaro, JM; Levy, D; Vasan, RS; Wolf, PA; D'Agostino, RB; Larson, MG; Kannel, WB; Benjamin, EJ			A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community - The Framingham Heart Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR HYPERTROPHY; ISCHEMIC-STROKE; ANTICOAGULATION; MANAGEMENT; DISEASE; ASPIRIN; THROMBOEMBOLISM; PREVALENCE; VALIDATION; PREVENTION	Context Prior risk stratification schemes for atrial fibrillation (AF) have been based on randomized trial cohorts or Medicare administrative databases, have included patients with established AF, and have focused on stroke as the principal outcome. Objective To derive risk scores for stroke alone and stroke or death in community-based individuals with new-onset AF. Design, Setting, and Participants Prospective, community-based, observational cohort in Framingham, Mass. We identified 868 participants with new-onset AF, 705 of whom were not treated with warfarin at baseline. Risk scores for stroke (ischemic or hemorrhagic) and stroke or death were developed with censoring when warfarin initiation occurred during follow-up. Event rates were examined in low-risk individuals, as defined by the risk score and 4 previously published risk schemes. Main Outcome Measures Stroke and the combination of stroke or death. Results During a mean follow-up of 4.0 years free of warfarin use, stroke alone occurred in 83 participants and stroke or death occurred in 382 participants. A risk score for stroke was derived that included the following risk predictors: advancing age, female sex, increasing systolic blood pressure, prior stroke or transient ischemic attack, and diabetes. With the risk score, 14.3% of the cohort had a predicted 5-year stroke rate less than or equal to7.5% (average annual rate less than or equal to1.5%), and 30.6% of the cohort had a predicted 5-year stroke rate less than or equal to10% (average annual rate less than or equal to2%). Actual stroke rates in these low-risk groups were 1.1 and 1.5 per 100 person-years, respectively. Previous risk schemes classified 6.4% to 17.3% of subjects as low risk, with actual stroke rates of 0.9 to 2.3 per 100 person-years. A risk score for stroke or death is also presented. Conclusion These risk scores can be used to estimate the absolute risk of an adverse event in individuals with AF, which may be helpful in counseling patients and making treatment decisions.	Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Cardiol, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Epidemiol, Boston, MA 02215 USA; Boston Univ, Dept Math, Boston, MA 02215 USA; NHLBI, Bethesda, MD 20892 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Div Cardiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Prevent Med, Boston, MA 02118 USA	Framingham Heart Study; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Boston University	Benjamin, EJ (corresponding author), Framingham Heart Dis Epidemiol Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	emelia@fram.nhlbi.nih.gov	Benjamin, Emelia/E-7103-2011; Levy, Daniel/ABF-6873-2021; Ramachandran, Vasan/Y-2527-2019; Levy, Daniel/ABB-2752-2021	Benjamin, Emelia/0000-0003-4076-2336; Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Larson, Martin/0000-0002-9631-1254; Massaro, Joseph/0000-0002-2682-4812; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL074077, K24HL004334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [K23 HL074077-01, 1K24-HL-04334, N01-HC-25195] Funding Source: Medline; NINDS NIH HHS [5R01-NS-17950] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		*AM HEART ASS, 2002, HEART DIS STROK STAT; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; [Anonymous], 1994, ARCH INTERN MED, V154, P2254; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Biblo LA, 2001, AM J CARDIOL, V87, P346, DOI 10.1016/S0002-9149(00)01374-6; CABIN HS, 1990, AM J CARDIOL, V65, P1112, DOI 10.1016/0002-9149(90)90323-S; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Evans A, 2001, ARCH INTERN MED, V161, P1443, DOI 10.1001/archinte.161.11.1443; Ezekowitz M, 1998, ARCH INTERN MED, V158, P1316; Feinberg WM, 1999, J GEN INTERN MED, V14, P56, DOI 10.1046/j.1525-1497.1999.00281.x; Feinberg WM, 1999, THROMB HAEMOSTASIS, V82, P100, DOI 10.1055/s-0037-1614636; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Gerdts E, 2002, HYPERTENSION, V39, P739, DOI 10.1161/hy0302.105683; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 1999, ANN INTERN MED, V131, P688, DOI 10.7326/0003-4819-131-9-199911020-00010; Hart RG, 2000, J AM COLL CARDIOL, V35, P183, DOI 10.1016/S0735-1097(99)00489-1; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Kalra L, 1999, STROKE, V30, P1218, DOI 10.1161/01.STR.30.6.1218; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; Kearon C, 1997, NEW ENGL J MED, V336, P1506, DOI 10.1056/NEJM199705223362107; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Morrow DA, 2000, CIRCULATION, V102, P2031, DOI 10.1161/01.CIR.102.17.2031; Nam BH, 2000, THESIS BOSTON U BOST; NOVELLO P, 1993, ITAL J NEUROL SCI, V14, P571, DOI 10.1007/BF02339217; ONUNDARSON PT, 1987, EUR HEART J, V8, P521; Pearce LA, 2000, AM J MED, V109, P45, DOI 10.1016/S0002-9343(00)00440-X; Seidl K, 1998, AM J CARDIOL, V82, P580, DOI 10.1016/S0002-9149(98)00419-6; *STROK PREV ATR FI, 1992, ANN INTERN MED, V116, P71; SULLIVAN LM, IN PRESS STAT MED; van Walraven C, 2003, ARCH INTERN MED, V163, P936, DOI 10.1001/archinte.163.8.936; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; Wood KA, 1997, AM J CARDIOL, V79, P1043, DOI 10.1016/S0002-9149(97)00044-1	44	585	614	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1049	1056		10.1001/jama.290.8.1049	http://dx.doi.org/10.1001/jama.290.8.1049			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941677	Bronze			2022-12-24	WOS:000184958900023
J	Gebert, B; Fischer, W; Weiss, E; Hoffmann, R; Haas, R				Gebert, B; Fischer, W; Weiss, E; Hoffmann, R; Haas, R			Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation	SCIENCE			English	Article							GASTRIC EPITHELIAL-CELLS; PROTEIN; ABSENCE; TOXIN; GENE; CAGA; TRANSLOCATION; COLONIZATION; EXPRESSION; INFECTION	Helicobacter pylori (Hp) vacuolating cytotoxin VacA induces cellular vacuolation in epithelial cells. We found that VacA could efficiently block proliferation of T cells by inducing a G(1)/S cell cycle arrest. It interfered with the T cell receptor/interleukin-2 (IL-2) signaling pathway at the level of the Ca2+-calmodulin-dependent phosphatase calcineurin. Nuclear translocation of nuclear factor of activated T cells (NFAT), a transcription factor acting as a global regulator of immune response genes, was abrogated, resulting in downregulation of IL-2 transcription. VacA partially mimicked the activity of the immunosuppressive drug FK506 by possibly inducing a local immune suppression, explaining the extraordinary chronicity of Hp infections.	LMU Munchen, Max Von Pettenkofer Inst Hyg & Med Microbiol, Munich, Germany	University of Munich	Haas, R (corresponding author), LMU Munchen, Max Von Pettenkofer Inst Hyg & Med Microbiol, Munich, Germany.		Hoffmann, Reinhard/I-8748-2018	Hoffmann, Reinhard/0000-0003-1514-1183				ARNIEVA MR, 2003, SCIENCE, V300, P1430; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Blaser MJ, 1996, SCI AM, V274, P104, DOI 10.1038/scientificamerican0296-104; Boulton IC, 2002, NAT IMMUNOL, V3, P229, DOI 10.1038/ni769; Ermak TH, 1998, J EXP MED, V188, P2277, DOI 10.1084/jem.188.12.2277; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kim HP, 2002, EMBO J, V21, P3051, DOI 10.1093/emboj/cdf321; KNIPP U, 1994, FEMS IMMUNOL MED MIC, V8, P157, DOI 10.1111/j.1574-695X.1994.tb00438.x; Krauss-Etschmann S, 2003, CLIN DIAGN LAB IMMUN, V10, P22, DOI 10.1128/CDLI.10.1.22-29.2003; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Lucas B, 2001, INFECT IMMUN, V69, P1714, DOI 10.1128/IAI.69.3.1714-1721.2001; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Molinari M, 1998, J EXP MED, V187, P135, DOI 10.1084/jem.187.1.135; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Odenbreit S, 2001, CELL MICROBIOL, V3, P21, DOI 10.1046/j.1462-5822.2001.00088.x; RYFFEL B, 1995, IMMUNOPHARMACOLOGY, V30, P199, DOI 10.1016/0162-3109(95)00023-M; Salama NR, 2001, INFECT IMMUN, V69, P730, DOI 10.1128/IAI.69.2.730-736.2001; Shirin H, 1999, CANCER RES, V59, P2277; Whitehouse CA, 1998, INFECT IMMUN, V66, P1934, DOI 10.1128/IAI.66.5.1934-1940.1998; Yoshida T, 1999, J IMMUNOL, V163, P3295	25	407	427	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1099	1102		10.1126/science.1086871	http://dx.doi.org/10.1126/science.1086871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934009				2022-12-24	WOS:000184872400041
J	Tsuda, M; Shigemoto-Mogami, Y; Koizumi, S; Mizokoshi, A; Kohsaka, S; Salter, MW; Inoue, K				Tsuda, M; Shigemoto-Mogami, Y; Koizumi, S; Mizokoshi, A; Kohsaka, S; Salter, MW; Inoue, K			P2X(4) receptors induced in spinal microglia gate tactile allodynia after nerve injury	NATURE			English	Article							DORSAL HORN NEURONS; ATP P-2X RECEPTORS; SYNAPTIC TRANSMISSION; BRAIN; CORD; RAT; PAIN; INVOLVEMENT; CYTOKINES; RELEASE	Pain after nerve damage is an expression of pathological operation of the nervous system 1,2, one hallmark of which is tactile allodynia-pain hypersensitivity evoked by innocuous stimuli. Effective therapy for this pain is lacking, and the underlying mechanisms are poorly understood. Here we report that pharmacological blockade of spinal P2X(4) receptors (P2X(4)Rs)(3-7), a subtype of ionotropic ATP receptor(8), reversed tactile allodynia caused by peripheral nerve injury without affecting acute pain behaviours in naive animals. After nerve injury, P2X(4)R expression increased strikingly in the ipsilateral spinal cord, and P2X(4)Rs were induced in hyperactive microglia but not in neurons or astrocytes. Intraspinal administration of P2X(4)R antisense oligodeoxynucleotide decreased the induction of P2X(4)Rs and suppressed tactile allodynia after nerve injury. Conversely, intraspinal administration of microglia in which P2X(4)Rs had been induced and stimulated, produced tactile allodynia in naive rats. Taken together, our results demonstrate that activation of P2X(4)Rs in hyperactive microglia is necessary for tactile allodynia after nerve injury and is sufficient to produce tactile allodynia in normal animals. Thus, blocking P2X(4)Rs in microglia might be a new therapeutic strategy for pain induced by nerve injury.	Natl Inst Hlth Sci, Div Biosignaling, Setagaya Ku, Tokyo 1588501, Japan; Hosp Sick Children, Programme Brain & Behav, Toronto, ON M5G 1X8, Canada; Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 1588501, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Higashi Ku, Fukuoka 8128582, Japan; Natl Inst Neurosci, Dept Neurochem, Tokyo 1878502, Japan	National Institute of Health Sciences - Japan; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National Institute of Health Sciences - Japan; Kyushu University; National Center for Neurology & Psychiatry - Japan	Inoue, K (corresponding author), Natl Inst Hlth Sci, Div Biosignaling, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.		Koizumi, Schuichi/E-8568-2010; Tsuda, Makoto/AAE-7256-2020	Koizumi, Schuichi/0000-0001-6184-3106; 				Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; Bardoni R, 1997, J NEUROSCI, V17, P5297; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Fam SR, 2000, J NEUROSCI, V20, P2800; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306-4522(00)00110-X; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Khakh BS, 2001, PHARMACOL REV, V53, P107; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; Li P, 1998, J NEUROPHYSIOL, V80, P3356, DOI 10.1152/jn.1998.80.6.3356; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; NAKAJIMA K, 1992, J NEUROCHEM, V58, P1401, DOI 10.1111/j.1471-4159.1992.tb11356.x; Nakatsuka T, 2001, J NEUROSCI, V21, P6522, DOI 10.1523/JNEUROSCI.21-17-06522.2001; SAWYNOK J, 1993, BRAIN RES, V610, P32, DOI 10.1016/0006-8993(93)91213-C; Seguela P, 1996, J NEUROSCI, V16, P448; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Tsuda M, 1999, BRIT J PHARMACOL, V128, P1497, DOI 10.1038/sj.bjp.0702960; Tsuda M, 1999, BRIT J PHARMACOL, V127, P449, DOI 10.1038/sj.bjp.0702582; Virginio C, 1998, MOL PHARMACOL, V53, P969; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wang CZ, 1996, BIOCHEM BIOPH RES CO, V220, P196, DOI 10.1006/bbrc.1996.0380; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Zheng JH, 2000, NEUROSCI LETT, V278, P41, DOI 10.1016/S0304-3940(99)00896-4	28	1131	1242	5	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					778	783		10.1038/nature01786	http://dx.doi.org/10.1038/nature01786			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917686				2022-12-24	WOS:000184733900041
J	Zhou, Q; Renard, JP; Le Friec, G; Brochard, V; Beaujean, N; Cherifi, Y; Fraichard, A; Cozzi, J				Zhou, Q; Renard, JP; Le Friec, G; Brochard, V; Beaujean, N; Cherifi, Y; Fraichard, A; Cozzi, J			Generation of fertile cloned rats by regulating oocyte activation	SCIENCE			English	Article									INRA, Dev Biol & Reprod Unit, Jouy En Josas, France; Chinese Acad Sci, Inst Zool, Beijing, Peoples R China; GenOway, Lyon, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Chinese Academy of Sciences; Institute of Zoology, CAS	Renard, JP (corresponding author), INRA, Dev Biol & Reprod Unit, Jouy En Josas, France.		Beaujean, Nathalie/C-9883-2011	Beaujean, Nathalie/0000-0003-0188-9190				Hirabayashi M, 2003, CLONING STEM CELLS, V5, P35, DOI 10.1089/153623003321512148; Jabob H. J., 2002, NATURE REV GENET, V3, P33; Josefsberg LBY, 2000, BIOL REPROD, V62, P1270, DOI 10.1095/biolreprod62.5.1270; Zan YH, 2003, NAT BIOTECHNOL, V21, P645, DOI 10.1038/nbt830; ZERNICKAGOETZ M, 1991, MOL REPROD DEV, V28, P169, DOI 10.1002/mrd.1080280210	5	300	378	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1179	1179		10.1126/science.1088313	http://dx.doi.org/10.1126/science.1088313			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14512506	Green Submitted			2022-12-24	WOS:000186544300044
J	Hacein-Bey-Abina, S; Von Kalle, C; Schmidt, M; McCcormack, MP; Wulffraat, N; Leboulch, P; Lim, A; Osborne, CS; Pawliuk, R; Morillon, E; Sorensen, R; Forster, A; Fraser, P; Cohen, JI; de Saint Basile, G; Alexander, I; Wintergerst, U; Frebourg, T; Aurias, A; Stoppa-Lyonnet, D; Romana, S; Radford-Weiss, I; Gross, F; Valensi, F; Delabesse, E; Macintyre, E; Sigaux, F; Soulier, J; Leiva, LE; Wissler, M; Prinz, C; Rabbitts, TH; Le Deist, F; Fischer, A; Cavazzana-Calvo, M				Hacein-Bey-Abina, S; Von Kalle, C; Schmidt, M; McCcormack, MP; Wulffraat, N; Leboulch, P; Lim, A; Osborne, CS; Pawliuk, R; Morillon, E; Sorensen, R; Forster, A; Fraser, P; Cohen, JI; de Saint Basile, G; Alexander, I; Wintergerst, U; Frebourg, T; Aurias, A; Stoppa-Lyonnet, D; Romana, S; Radford-Weiss, I; Gross, F; Valensi, F; Delabesse, E; Macintyre, E; Sigaux, F; Soulier, J; Leiva, LE; Wissler, M; Prinz, C; Rabbitts, TH; Le Deist, F; Fischer, A; Cavazzana-Calvo, M			LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; NONHUMAN-PRIMATES; TRANSGENIC MICE; PROTEIN RBTN2; HUMAN GENOME; GAMMA-CHAIN; LEUKEMIA; TRANSLOCATIONS; LYMPHOCYTES; DELTA	We have previously shown correction of X-linked severe combined immunodeficiency [SCID-X1, also known as gamma chain (gammac) deficiency] in 9 out of 10 patients by retrovirus-mediated gammac gene transfer into autologous CD34 bone marrow cells. However, almost 3 years after gene therapy, uncontrolled exponential clonal proliferation of mature T cells (with gammadelta+ or alphabeta+ T cell receptors) has occurred in the two youngest patients. Both patients' clones showed retrovirus vector integration in proximity to the LMO2 proto-oncogene promoter, leading to aberrant transcription and expression of LMO2. Thus, retrovirus vector insertion can trigger deregulated premalignant cell proliferation with unexpected frequency, most likely driven by retrovirus enhancer activity on the LMO2 gene promoter.	INSERM, U429, F-75743 Paris 15, France; Assistance Publ Hop Paris, Dept Biotherapie, F-75743 Paris, France; Univ Paris 05, Lab Cytogenet, F-75743 Paris 15, France; Univ Paris 05, Lab Cent Hematol, F-75743 Paris 15, France; Univ Paris 05, CNRS, Unite Rech Associee 1461, F-75743 Paris 15, France; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75743 Paris 15, France; Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Med Ctr Utrecht, Wilhelmina Kinderziekenhuis, Utrecht, Netherlands; Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; INSERM, U277, F-75730 Paris, France; Babraham Inst, Lab Chromatin & Gene Express, Dev Genet Programme, Cambridge CB2 4AT, England; Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70112 USA; Childrens Hosp, New Orleans, LA 70112 USA; NIAID, Med Virol Sect, Clin Invest Lab, Bethesda, MD 20892 USA; Childrens Hosp Westmead, Sydney, NSW 2145, Australia; Univ & Childrens Hosp, D-80337 Munich, Germany; CHU, Serv Genet, F-76183 Rouen, France; Fac Med & Pharm, INSERM 9906, Equipe Mixte, F-76183 Rouen, France; Inst Curie, INSERM, U434, Paris 15, France; Inst Curie, Dept Oncol Genet, Paris 15, France; Hop St Louis, INSERM, U462, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Freiburg; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; MRC Laboratory Molecular Biology; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Children's Hospital of New Orleans; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Sydney; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fischer, A (corresponding author), INSERM, U429, F-75743 Paris 15, France.		Frebourg, Thierry/AAK-8390-2020; Wilson, Matthew H/K-3193-2013; DELABESSE, Eric/I-5221-2016; Osborne, Cameron/N-1398-2017; Fraser, Peter/B-7549-2009; de Saint Basile, Genevieve/G-9731-2017; Rabbitts, Terence/D-6262-2016	DELABESSE, Eric/0000-0002-0928-0753; Osborne, Cameron/0000-0003-4126-2499; de Saint Basile, Genevieve/0000-0002-1913-5269; Fraser, Peter/0000-0002-0041-1227; Wintergerst, Uwe/0000-0002-0785-0337; McCormack, Matthew/0000-0003-1536-5611; Romana, Serge Pierrick/0000-0003-3435-239X; Rabbitts, Terence/0000-0002-4982-2609; Macintyre-Davi, Elizabeth Anne/0000-0003-0520-0493; Alexander, Ian E/0000-0002-6213-5627	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000430, ZIAAI000430] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; AURIAS A, UNPUB; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Dechanet J, 1999, J CLIN INVEST, V103, P1437, DOI 10.1172/JCI5409; DONAHUE RE, 1992, J EXP MED, V176, P1125, DOI 10.1084/jem.176.4.1125; FISCH P, 1992, ONCOGENE, V7, P2389; Freitas AA, 2000, ANNU REV IMMUNOL, V18, P83, DOI 10.1146/annurev.immunol.18.1.83; GARCIA IS, 1991, ONCOGENE, V6, P577; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; HaceinBey S, 1996, BLOOD, V87, P3108, DOI 10.1182/blood.V87.8.3108.bloodjournal8783108; Kamps WA, 1999, BLOOD, V94, P1226; Lafarge X, 2001, J INFECT DIS, V184, P533, DOI 10.1086/322843; Lantz O, 2000, NAT IMMUNOL, V1, P54, DOI 10.1038/76917; LARSON RC, 1994, ONCOGENE, V9, P3675; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Lim A, 2002, J IMMUNOL METHODS, V261, P177, DOI 10.1016/S0022-1759(02)00004-2; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; NEALE GAM, 1995, BLOOD, V86, P3060; Neale Geoffrey A. M., 1997, Leukemia (Basingstoke), V11, P289; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PRINTZ M, 1995, GENE THER, V2, P143; Rabbitts TH, 2001, ONCOGENE, V20, P5763, DOI 10.1038/sj.onc.1204597; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Schmidt M. K., UNPUB; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Song X, 2002, P NATL ACAD SCI USA, V99, P6269, DOI 10.1073/pnas.092112199; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANIN EF, 1994, J VIROL, V68, P4241, DOI 10.1128/JVI.68.7.4241-4250.1994; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; [No title captured]	38	2657	2827	3	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					415	419		10.1126/science.1088547	http://dx.doi.org/10.1126/science.1088547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564000				2022-12-24	WOS:000185963200033
J	O'Riordan, M; Moors, MA; Portnoy, DA				O'Riordan, M; Moors, MA; Portnoy, DA			Listeria intracellular growth and virulence require host-derived lipoic acid	SCIENCE			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; ESCHERICHIA-COLI; LIPB GENES; MONOCYTOGENES; PROTEIN; IDENTIFICATION; ANTIOXIDANT; METABOLISM; SECRETION; BIOLOGY	Listeria monocytogenes is a Gram-positive intracytosolic pathogen that causes severe disease in pregnant and immunocompromised individuals. We found that L. monocytogenes lacking the lipoate protein ligase LplA1 was defective for growth specifically in the host cytosol and was less virulent in animals by a factor of 300. A major target for LplA1, the E2 subunit of pyruvate dehydrogenase (PDH), lacked a critical lipoyl modi. cation when the DeltalplA1 strain was grown intracellularly, which suggests that abortive growth was due to loss of PDH function. Thus, the use of host-derived lipoic acid may be a critical process for in vivo replication of bacterial pathogens.	Univ Calif Berkeley, Sch Publ Hlth, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Wake Forest University; Wake Forest Baptist Medical Center	O'Riordan, M (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.		O'Riordan, Mary/D-8227-2011	O'Riordan, Mary/0000-0001-6014-4637	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029619, R01AI029619, R01AI027655] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI029619, R01 AI027655, R01 AI27655, AI29619] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; CAMILLI A, 1989, P NATL ACAD SCI USA, V86, P5522, DOI 10.1073/pnas.86.14.5522; Chico-Calero I, 2002, P NATL ACAD SCI USA, V99, P431, DOI 10.1073/pnas.012363899; Dacheux D, 2002, INFECT IMMUN, V70, P3973, DOI 10.1128/IAI.70.7.3973-3977.2002; DUBENSKY T, COMMUNICATION; Gao HC, 2002, J BACTERIOL, V184, P2780, DOI 10.1128/JB.184.10.2780-2788.2002; Glaser P, 2001, SCIENCE, V294, P849; Lenz LL, 2002, MOL MICROBIOL, V45, P1043, DOI 10.1046/j.1365-2958.2002.03072.x; Lissens W, 2000, HUM MUTAT, V15, P209, DOI 10.1002/(SICI)1098-1004(200003)15:3<209::AID-HUMU1>3.0.CO;2-K; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; MORRIS TW, 1995, J BACTERIOL, V177, P1; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; O'Riordan M, 2002, TRENDS MICROBIOL, V10, P361, DOI 10.1016/S0966-842X(02)02401-0; ORIORDAN M, UNPUB; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Portnoy DA, 2002, J CELL BIOL, V158, P409, DOI 10.1083/jcb.200205009; PREMARATNE RJ, 1991, APPL ENVIRON MICROB, V57, P3046, DOI 10.1128/AEM.57.10.3046-3048.1991; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; Stein A, 2000, J BACTERIOL, V182, P2119, DOI 10.1128/JB.182.8.2119-2124.2000	22	101	128	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					462	464		10.1126/science.1088170	http://dx.doi.org/10.1126/science.1088170			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564012				2022-12-24	WOS:000185963200048
J	Ansley, SJ; Badano, JL; Blacque, OE; Hill, J; Hoskins, BE; Leitch, CC; Kim, JC; Ross, AJ; Eichers, ER; Teslovich, TM; Mah, AK; Johnsen, RC; Cavender, JC; Lewis, RA; Leroux, MR; Beales, PL; Katsanis, N				Ansley, SJ; Badano, JL; Blacque, OE; Hill, J; Hoskins, BE; Leitch, CC; Kim, JC; Ross, AJ; Eichers, ER; Teslovich, TM; Mah, AK; Johnsen, RC; Cavender, JC; Lewis, RA; Leroux, MR; Beales, PL; Katsanis, N			Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome	NATURE			English	Article							HUMAN OBESITY SYNDROME; C-ELEGANS; INTRAFLAGELLAR TRANSPORT; TRIALLELIC INHERITANCE; KIDNEY-DISEASE; PROTEIN; CILIA; GENE; IDENTIFICATION; MUTATIONS	Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder characterized primarily by retinal dystrophy, obesity, polydactyly, renal malformations and learning disabilities. Although five BBS genes have been cloned(1-6), the molecular basis of this syndrome remains elusive. Here we show that BBS is probably caused by a defect at the basal body of ciliated cells. We have cloned a new BBS gene, BBS8, which encodes a protein with a prokaryotic domain, pilF, involved in pilus formation and twitching mobility. In one family, a homozygous null BBS8 mutation leads to BBS with randomization of left-right body axis symmetry, a known defect of the nodal cilium. We have also found that BBS8 localizes specifically to ciliated structures, such as the connecting cilium of the retina and columnar epithelial cells in the lung. In cells, BBS8 localizes to centrosomes and basal bodies and interacts with PCM1, a protein probably involved in ciliogenesis. Finally, we demonstrate that all available Caenorhabditis elegans BBS homologues are expressed exclusively in ciliated neurons, and contain regulatory elements for RFX, a transcription factor that modulates the expression of genes associated with ciliogenesis and intraflagellar transport.	Johns Hopkins Univ, Inst Med Genet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; UCL, Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; King Khalid Eye Specialist Hosp, Riyadh 11462, Saudi Arabia	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Simon Fraser University; University of London; University College London; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; King Khaled Eye Specialist Hospital	Katsanis, N (corresponding author), Johns Hopkins Univ, Inst Med Genet, Baltimore, MD 21287 USA.	katsanis@jhmi.edu	Katsanis, Nicholas/E-1837-2012; Beales, Philip L/C-7367-2009; Blacque, Oliver/AAL-8860-2021	Blacque, Oliver/0000-0003-1598-2695; Katsanis, Nicholas/0000-0002-2480-0171; Badano, Jose/0000-0002-0706-8652				Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Badano JL, 2003, AM J HUM GENET, V72, P650, DOI 10.1086/368204; Beales PL, 1999, J MED GENET, V36, P437; Beales PL, 2003, AM J HUM GENET, V72, P1187, DOI 10.1086/375178; BRENNER S, 1974, GENETICS, V77, P71; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Fujiwara M, 1999, DEVELOPMENT, V126, P4839; Haycraft CJ, 2001, DEVELOPMENT, V128, P1493; Hobert O, 2002, BIOTECHNIQUES, V32, P728, DOI 10.2144/02324bm01; Hou XY, 2002, J CLIN INVEST, V109, P533, DOI 10.1172/JC1200214099; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Katsanis N, 2002, AM J HUM GENET, V71, P22, DOI 10.1086/341031; Katsanis N, 2000, NAT GENET, V26, P67, DOI 10.1038/79201; Kubo A, 1999, J CELL BIOL, V147, P969, DOI 10.1083/jcb.147.5.969; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; MAURER L, 1987, J BACTERIOL, V169, P640, DOI 10.1128/jb.169.2.640-645.1987; Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105; Morgan D, 2002, HUM MOL GENET, V11, P3345, DOI 10.1093/hmg/11.26.3345; Mykytyn K, 2002, NAT GENET, V31, P435, DOI 10.1038/ng935; Mykytyn K, 2001, NAT GENET, V28, P188, DOI 10.1038/88925; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nishimura DY, 2001, HUM MOL GENET, V10, P865, DOI 10.1093/hmg/10.8.865; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Pazour GJ, 2002, J CELL BIOL, V157, P103, DOI 10.1083/jcb.200107108; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Slavotinek AM, 2000, NAT GENET, V26, P15, DOI 10.1038/79116; Swoboda P, 2000, MOL CELL, V5, P411, DOI 10.1016/S1097-2765(00)80436-0; Watanabe D, 2003, DEVELOPMENT, V130, P1725, DOI 10.1242/dev.00407	29	496	527	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					628	633		10.1038/nature02030	http://dx.doi.org/10.1038/nature02030			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14520415				2022-12-24	WOS:000185801000040
J	Hurlstone, AFL; Haramis, APG; Wienholds, E; Begthel, H; Korving, J; van Eeden, F; Cuppen, E; Zivkovic, D; Plasterk, RHA; Clevers, H				Hurlstone, AFL; Haramis, APG; Wienholds, E; Begthel, H; Korving, J; van Eeden, F; Cuppen, E; Zivkovic, D; Plasterk, RHA; Clevers, H			The Wnt/beta-catenin pathway regulates cardiac valve formation	NATURE			English	Article							BETA-CATENIN; COLORECTAL-CANCER; CUSHION FORMATION; ZEBRAFISH; GENE; TRANSFORMATION; APC; SPECIFICATION; PHENOTYPE; MUTATION	Truncation of the tumour suppressor adenomatous polyposis coli (Apc) constitutively activates the Wnt/beta-catenin signalling pathway(1). Apc has a role in development: for example, embryos of mice with truncated Apc do not complete gastrulation(2). To understand this role more fully, we examined the effect of truncated Apc on zebrafish development. Here we show that, in contrast to mice, zebrafish do complete gastrulation. However, mutant hearts fail to loop and form excessive endocardial cushions. Conversely, overexpression of Apc or Dickkopf 1 (Dkk1), a secreted Wnt inhibitor(3), blocks cushion formation. In wild-type hearts, nuclear beta-catenin, the hallmark of activated canonical Wnt signalling(4), accumulates only in valve-forming cells, where it can activate a Tcf reporter. In mutant hearts, all cells display nuclear beta-catenin and Tcf reporter activity, while valve markers are markedly upregulated. Concomitantly, proliferation and epithelial-mesenchymal transition, normally restricted to endocardial cushions, occur throughout the endocardium. Our findings identify a novel role for Wnt/beta-catenin signalling in determining endocardial cell fate.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Clevers, H (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		Cuppen, Edwin/H-2389-2016; Van Eeden, Freek/E-6198-2010; Cuppen, Edwin/F-5696-2011	Cuppen, Edwin/0000-0002-0400-9542; Cuppen, Edwin/0000-0002-0400-9542; Hurlstone, Adam/0000-0001-5260-9457				Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Colbert T, 2001, PLANT PHYSIOL, V126, P480, DOI 10.1104/pp.126.2.480; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Hacker U, 1997, DEVELOPMENT, V124, P3565; Hashimoto H, 2000, DEV BIOL, V217, P138, DOI 10.1006/dbio.1999.9537; Heisenberg CP, 2001, GENE DEV, V15, P1427, DOI 10.1101/gad.194301; IWAMOTO R, 2003, P NATL ACAD SCI; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim RY, 2001, DEV BIOL, V235, P449, DOI 10.1006/dbio.2001.0284; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Lickert H, 2002, DEV CELL, V3, P171, DOI 10.1016/S1534-5807(02)00206-X; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; Tzahor E, 2001, GENE DEV, V15, P255, DOI 10.1101/gad.871501; van de Water S, 2001, DEVELOPMENT, V128, P3877; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Westerfield M, 1995, ZEBRAFISH BOOK; Wienholds E, 2002, SCIENCE, V297, P99, DOI 10.1126/science.1071762; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8	24	315	333	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					633	637		10.1038/nature02028	http://dx.doi.org/10.1038/nature02028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534590				2022-12-24	WOS:000185801000041
J	Verschure, PFMJ; Voegtlin, T; Douglas, RJ				Verschure, PFMJ; Voegtlin, T; Douglas, RJ			Environmentally mediated synergy between perception and behaviour in mobile robots	NATURE			English	Article							PLASTICITY; CORTEX	The notion that behaviour influences perception seems self-evident, but the mechanism of their interaction is not known. Perception and behaviour are usually considered to be separate processes. In this view, perceptual learning constructs compact representations of sensory events, reflecting their statistical properties(1,2), independently of behavioural relevance(3,4). Behavioural learning(5,6), however, forms associations between perception and action, organized by reinforcement(7,8), without regard for the construction of perception. It is generally assumed that the interaction between these two processes is internal to the agent, and can be explained solely in terms of the neuronal substrate(9). Here we show, instead, that perception and behaviour can interact synergistically via the environment. Using simulated and real mobile robots, we demonstrate that perceptual learning directly supports behavioural learning and so promotes a progressive structuring of behaviour. This structuring leads to a systematic bias in input sampling, which directly affects the organization of the perceptual system. This external, environmentally mediated feedback matches the perceptual system to the emerging behavioural structure, so that the behaviour is stabilized.	Univ Swiss Fed Inst Technol ETH Zurich, Inst Neuroinformat, CH-8057 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Verschure, PFMJ (corresponding author), Univ Swiss Fed Inst Technol ETH Zurich, Inst Neuroinformat, CH-8057 Zurich, Switzerland.		verschure, paul/E-1677-2011; Verschure, Paul/AAR-2340-2021	Verschure, Paul/0000-0003-3643-9544				Arkin R. C., 1998, BEHAV BASED ROBOTICS; Bell AJ, 1999, PHILOS T ROY SOC B, V354, P2013, DOI 10.1098/rstb.1999.0540; CLANCEY WJ, 1996, SITUATED COGNITION H; Goldstone RL, 1998, ANNU REV PSYCHOL, V49, P585, DOI 10.1146/annurev.psych.49.1.585; Houde JF, 2002, J COGNITIVE NEUROSCI, V14, P1125, DOI 10.1162/089892902760807140; Kalman R.E., 1960, T ASME J BASIC ENG, V82, P35, DOI [DOI 10.1115/1.3662552, 10.1115/1.3662552]; LAVOND DG, 1993, ANNU REV PSYCHOL, V44, P317, DOI 10.1146/annurev.ps.44.020193.001533; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; Mackintosh N. J., 1974, PSYCHOL ANIMAL LEARN; Massaro DW, 1997, PERCEIVING TALKING F; MCFARLAND D, 1993, INTELLIGENT BEHAV AN; Mehta MR, 1997, P NATL ACAD SCI USA, V94, P8918, DOI 10.1073/pnas.94.16.8918; MONDADA F, 1993, EXPT ROBOTICS, V3, P501; Olshausen BA, 1996, NATURE, V381, P607, DOI 10.1038/381607a0; Rao RPN, 1999, NAT NEUROSCI, V2, P79, DOI 10.1038/4580; Rescorla RA, 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; Sanchez-Montanes MA, 2000, NEURAL COMPUT, V12, P519, DOI 10.1162/089976600300015682; Scheier C, 1999, UNDERSTANDING INTELL; Schultz W, 2000, ANNU REV NEUROSCI, V23, P473, DOI 10.1146/annurev.neuro.23.1.473; Squire LR., 1999, MEMORY MIND MOL; Sur M, 2001, NAT REV NEUROSCI, V2, P251, DOI 10.1038/35067562; Sutton Richard S., 1998, REINFORCEMENT LEARNI; Thorndike E, 1898, PSYCHOL REV SER MO S, V2, P1, DOI [DOI 10.1037/H0092987, DOI 10.1037/0003-066X.53.10.1125]; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; Verschure P. F. M. J., 1992, Robotics and Autonomous Systems, V9, P181, DOI 10.1016/0921-8890(92)90054-3; VERSCHURE PFM, 1992, ANIMALS ANIMATS, P210; Verschure PFMJ, 2003, COGNITIVE SCI, V27, P561, DOI 10.1016/S0364-0213(03)00034-X; Verschure PFMJ, 1998, NEURAL NETWORKS, V11, P1531, DOI 10.1016/S0893-6080(98)00029-X	28	138	139	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					620	624		10.1038/nature02024	http://dx.doi.org/10.1038/nature02024			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	729XU	14534588				2022-12-24	WOS:000185801000038
J	Chen, Y; Deng, LB; Maeno-Hikichi, Y; Lai, MZ; Chang, SH; Chen, G; Zhang, JF				Chen, Y; Deng, LB; Maeno-Hikichi, Y; Lai, MZ; Chang, SH; Chen, G; Zhang, JF			Formation of an endophilin-Ca2+ channel complex is critical for clathrin-mediated synaptic vesicle endocytosis	CELL			English	Article							NEURONAL CA2+ CHANNELS; NEUROTRANSMITTER RELEASE; NEUROMUSCULAR-JUNCTION; HIPPOCAMPAL SYNAPSES; PROTEIN-INTERACTION; SH3 DOMAIN; CELL; EXOCYTOSIS; SRC; SYNAPTOTAGMIN	A tight balance between synaptic vesicle exocytosis and endocytosis is fundamental to maintaining synaptic structure and function. Calcium influx through voltage-gated Ca2+ channels is crucial in regulating synaptic vesicle exocytosis. However, much less is known about how Ca2+ regulates vesicle endocytosis or how the endocytic machinery becomes enriched at the nerve terminal. We report here a direct interaction between voltage-gated Ca2+ channels and endophilin, a key regulator of clathrin-mediated synaptic vesicle endocytosis. Formation of the endophlin-Ca2+ channel complex is Ca2+ dependent. The primary Ca2+ binding domain resides within endophilin and regulates both endophilin-Ca2+ channel and endophilin-dynamin complexes. Introduction into hippocampal neurons of a dominant-negative endophilin construct, which constitutively binds to Ca2+ channels, significantly reduces endocytosis-mediated uptake of FM 4-64 dye without abolishing exocytosis. These results suggest an important role for Ca2+ channels in coordinating synaptic vesicle recycling by directly coupling to both exocytotic and endocytic machineries.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Zhang, JF (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.		Chen, Yuan/D-1462-2011	Chen, Yuan/0000-0002-9412-4623; Chen JNU, Gong/0000-0002-1857-3670	NINDS NIH HHS [NS39355] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039355] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BETZ WJ, 1993, J PHYSIOL-LONDON, V460, P287, DOI 10.1113/jphysiol.1993.sp019472; Beutner D, 2001, NEURON, V29, P681, DOI 10.1016/S0896-6273(01)00243-4; BROCARD JB, 1993, NEURON, V11, P751, DOI 10.1016/0896-6273(93)90084-5; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; Griesinger CB, 2002, J NEUROSCI, V22, P3939, DOI 10.1523/JNEUROSCI.22-10-03939.2002; Guichet A, 2002, EMBO J, V21, P1661, DOI 10.1093/emboj/21.7.1661; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; Higgins MK, 2002, TRENDS BIOCHEM SCI, V27, P257, DOI 10.1016/S0968-0004(02)02089-3; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Huttner WB, 2002, TRENDS CELL BIOL, V12, P155, DOI 10.1016/S0962-8924(02)02252-3; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Kuromi H, 2002, NEURON, V35, P333, DOI 10.1016/S0896-6273(02)00777-8; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Maeno-Hikichi Y, 2003, NAT NEUROSCI, V6, P468, DOI 10.1038/nn1041; Mayer BJ, 2001, J CELL SCI, V114, P1253; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; Neves G, 2001, P NATL ACAD SCI USA, V98, P15282, DOI 10.1073/pnas.261311698; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; Sankaranarayanan S, 2001, NAT NEUROSCI, V4, P129, DOI 10.1038/83949; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Teng HB, 2000, J NEUROSCI, V20, P7986; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Yoshihara M, 2003, CURR OPIN NEUROBIOL, V13, P315, DOI 10.1016/S0959-4388(03)00063-1; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	54	91	95	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					37	48		10.1016/S0092-8674(03)00726-8	http://dx.doi.org/10.1016/S0092-8674(03)00726-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532001	Bronze			2022-12-24	WOS:000185815500007
J	Friedrich, R; Panizzi, P; Fuentes-Prior, P; Richter, K; Verhamme, I; Anderson, PJ; Kawabata, SI; Huber, R; Bode, W; Bock, PE				Friedrich, R; Panizzi, P; Fuentes-Prior, P; Richter, K; Verhamme, I; Anderson, PJ; Kawabata, SI; Huber, R; Bode, W; Bock, PE			Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation	NATURE			English	Article							BINDING-PROTEIN; STREPTOCOCCUS-AGALACTIAE; STAPHYLOCOCCUS-AUREUS; CRYSTAL-STRUCTURE; GENOME SEQUENCE; THROMBIN; STREPTOKINASE; PROTHROMBIN; PLASMINOGEN; FIBRONECTIN	Many bacterial pathogens secrete proteins that activate host trypsinogen-like enzyme precursors, most notably the proenzymes of the blood coagulation and fibrinolysis systems(1,2). Staphylococcus aureus, an important human pathogen implicated in sepsis and endocarditis(3), secretes the cofactor staphylocoagulase, which activates prothrombin, without the usual proteolytic cleavages, to directly initiate blood clotting(4,5). Here we present the 2.2 Angstrom crystal structures of human alpha-thrombin and prethrombin-2 bound to a fully active staphylocoagulase variant. The cofactor consists of two domains, each with three-helix bundles; this is a novel fold that is distinct from known serine proteinase activators, particularly the streptococcal plasminogen activator streptokinase(6). The staphylocoagulase fold is conserved in other bacterial plasma-protein-binding factors and extracellular-matrix-binding factors(7-9). Kinetic studies confirm the importance of isoleucine 1 and valine 2 at the amino terminus of staphylocoagulase for zymogen activation. In addition to making contacts with the 148 loop and (pro)exosite I of pre-thrombin-2, staphylocoagulase inserts its N-terminal peptide into the activation pocket of bound prethrombin-2, allosterically inducing functional catalytic machinery. These investigations demonstrate unambiguously the validity of the zymogen-activation mechanism known as 'molecular sexuality'(10).	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Tech Univ Munich, Lehrstuhl Biotechnol, D-85747 Garching, Germany; Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan	Max Planck Society; Vanderbilt University; Technical University of Munich; Kyushu University	Bode, W (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany.		Richter, Klaus/A-2673-2010; Panizzi, Peter/A-6072-2019	Richter, Klaus/0000-0002-8952-9642; Panizzi, Peter/0000-0003-0141-8807; Fuentes-Prior, Pablo/0000-0002-6618-3204	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL094533] Funding Source: NIH RePORTER; NHLBI NIH HHS [R00 HL094533] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Bjerketorp J, 2002, MICROBIOL-SGM, V148, P2037, DOI 10.1099/00221287-148-7-2037; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Boxrud PD, 2001, J BIOL CHEM, V276, P26084, DOI 10.1074/jbc.M101966200; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; CHEUNG AI, 1995, INFECT IMMUN, V63, P1914, DOI 10.1128/IAI.63.5.1914-1920.1995; Glaser P, 2002, MOL MICROBIOL, V45, P1499, DOI 10.1046/j.1365-2958.2002.03126.x; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; KAWABATA SI, 1987, J PROTEIN CHEM, V6, P17; Khan AR, 1998, PROTEIN SCI, V7, P815; Lahteenmaki K, 2001, FEMS MICROBIOL REV, V25, P531, DOI 10.1111/j.1574-6976.2001.tb00590.x; Mylonakis E, 2001, NEW ENGL J MED, V345, P1318, DOI 10.1056/NEJMra010082; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; TAGER M, 1965, ANN NY ACAD SCI, V128, P92, DOI 10.1111/j.1749-6632.1965.tb11632.x; Tettelin H, 2002, P NATL ACAD SCI USA, V99, P12391, DOI 10.1073/pnas.182380799; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662	25	194	214	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					535	539		10.1038/nature01962	http://dx.doi.org/10.1038/nature01962			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523451				2022-12-24	WOS:000185648100050
J	Liu, QH; Rand, TA; Kalidas, S; Du, FH; Kim, HE; Smith, DP; Wang, XD				Liu, QH; Rand, TA; Kalidas, S; Du, FH; Kim, HE; Smith, DP; Wang, XD			R2D2, a bridge between the initiation and effector steps of the Drosophila RNAi pathway	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; GENETIC INTERFERENCE; MESSENGER-RNA; C-ELEGANS; REQUIREMENTS	The RNA interference (RNAi) pathway is initiated by processing long double-stranded RNA into small interfering RNA (siRNA). The siRNA-generating enzyme was puriFIed from Drosophila S2 cells and consists of two stoichiometric subunits: Dicer-2 (DCR-2) and a previously unknown protein that we named R2D2. R2D2 is homologous to the Caenorhabditis elegans RNAi protein RDE-4. Association with R2D2 does not affect the enzymatic activity of DCR-2. Rather, the DCR-2/R2D2 complex, but not DCR-2 alone, binds to siRNA and enhances sequence-specific messenger RNA degradation mediated by the RNA-initiated silencing complex(RISC). These results indicate that R2D2 bridges the initiation and effector steps of the Drosophila RNAi pathway by facilitating siRNA passage from Dicer to RISC.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, XD (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA.		Kim, Hyun-Eui/GOV-5988-2022	Kim, Hyun-Eui/0000-0003-1495-1993; Wang, Xiaodong/0000-0001-9885-356X; Smith, Dean/0000-0002-4271-0436	NIDCD NIH HHS [DC02539] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002539] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; KALIDAS S, UNPUB; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zenobi, UNPUB	16	536	585	5	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1921	1925		10.1126/science.1088710	http://dx.doi.org/10.1126/science.1088710			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512631				2022-12-24	WOS:000185536700055
J	Kim, M; Carman, CV; Springer, TA				Kim, M; Carman, CV; Springer, TA			Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins	SCIENCE			English	Article							INSIDE-OUT ACTIVATION; ALPHA-SUBUNIT; AFFINITY; TAILS; LFA-1; FLOW; ALPHA-IIB-BETA-3; ADHESIVENESS; CHEMOKINES; REVEALS	Although critical for development, immunity, wound healing, and metastasis, integrins represent one of the few classes of plasma membrane receptors for which the basic signaling mechanism remains a mystery. We investigated cytoplasmic conformational changes in the integrin LFA-1 (alpha(L)beta(2)) in living cells by measuring fluorescence resonance energy transfer between cyan fluorescent protein - fused and yellow fluorescent protein - fused alpha(L) and beta(2) cytoplasmic domains. In the resting state these domains were close to each other, but underwent significant spatial separation upon either intracellular activation of integrin adhesiveness (inside-out signaling) or ligand binding (outside-in signaling). Thus, bidirectional integrin signaling is accomplished by coupling extracellular conformational changes to an unclasping and separation of the alpha and beta cytoplasmic domains, a distinctive mechanism for transmitting information across the plasma membrane.	Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu	Carman, Christopher V./AAX-8995-2020; Carman, Christopher/L-8108-2016	Carman, Christopher V./0000-0001-7358-2548; Carman, Christopher/0000-0001-7358-2548	NCI NIH HHS [CA31798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031798, R37CA031798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Liu SC, 2000, J CELL SCI, V113, P3563; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Ulmer TS, 2001, BIOCHEMISTRY-US, V40, P7498, DOI 10.1021/bi010338l; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Weljie AM, 2002, P NATL ACAD SCI USA, V99, P5878, DOI 10.1073/pnas.092515799; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	31	611	631	3	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1720	1725		10.1126/science.1084174	http://dx.doi.org/10.1126/science.1084174			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500982				2022-12-24	WOS:000185387700044
J	Palatnik, JF; Allen, E; Wu, XL; Schommer, C; Schwab, R; Carrington, JC; Weigel, D				Palatnik, JF; Allen, E; Wu, XL; Schommer, C; Schwab, R; Carrington, JC; Weigel, D			Control of leaf morphogenesis by microRNAs	NATURE			English	Article							VIRAL SUPPRESSOR; DICER HOMOLOG; C-ELEGANS; RNA; ARABIDOPSIS; GENE; DROSOPHILA; PLANTS; EMBRYO; PREDICTION	Plants with altered microRNA metabolism have pleiotropic developmental defects, but direct evidence for microRNAs regulating specific aspects of plant morphogenesis has been lacking. In a genetic screen, we identified the JAW locus, which produces a microRNA that can guide messenger RNA cleavage of several TCP genes controlling leaf development. MicroRNA-guided cleavage of TCP4 mRNA is necessary to prevent aberrant activity of the TCP4 gene expressed from its native promoter. In addition, overexpression of wild-type and microRNA-resistant TCP variants demonstrates that mRNA cleavage is largely sufficient to restrict TCP function to its normal domain of activity. TCP genes with microRNA target sequences are found in a wide range of species, indicating that microRNA-mediated control of leaf morphogenesis is conserved in plants with very different leaf forms.	Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Oregon State Univ, Ctr Gene Res & Biotechnol, Corvallis, OR 97331 USA; Oregon State Univ, Dept Bot & Plant Pathol, Corvallis, OR 97331 USA	Max Planck Society; Salk Institute; Oregon State University; Oregon State University	Weigel, D (corresponding author), Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany.		Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/C-1418-2008; Schommer, Carla/AAV-7958-2021; Carrington, James C/A-4656-2012; Schwab, Rebecca/I-9352-2012	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Carrington, James C/0000-0003-3572-129X; Schwab, Rebecca/0000-0001-9933-9669; Allen, Edwards/0000-0002-8318-6319; Palatnik, Javier/0000-0001-7996-5224				Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; CHEN X, 2003, SCIENCE         0731; Citerne HL, 2003, PLANT PHYSIOL, V131, P1042, DOI 10.1104/pp.102.016311; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Golden TA, 2002, PLANT PHYSIOL, V130, P808, DOI 10.1104/pp.003491; Hadfi K, 1998, DEVELOPMENT, V125, P879; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Kawasaki H, 2003, NATURE, V423, P838, DOI 10.1038/nature01730; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; McConnell JR, 2001, NATURE, V411, P709, DOI 10.1038/35079635; Nath U, 2003, SCIENCE, V299, P1404, DOI 10.1126/science.1079354; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Plasterk RHA, 2002, SCIENCE, V296, P1263, DOI 10.1126/science.1072148; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SWOFFORD DL, 1993, GEN PHYSL, V102, pA9; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; Weigel D., 2002, ARABIDOPSIS LAB MANU; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xie ZX, 2003, CURR BIOL, V13, P784, DOI 10.1016/S0960-9822(03)00281-1; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	40	1291	1490	21	278	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					257	263		10.1038/nature01958	http://dx.doi.org/10.1038/nature01958			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	12931144				2022-12-24	WOS:000185370900035
J	Mallam, KM; Metcalf, BS; Kirkby, J; Voss, LD; Wilkin, TJ				Mallam, KM; Metcalf, BS; Kirkby, J; Voss, LD; Wilkin, TJ			Contribution of timetabled physical education to total physical activity in primary school children: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							ACTIVITY MONITOR		Derriford Hosp, Peninsula Med Sch, Dept Endocrinol & Metab, Plymouth PL6 8DH, Devon, England	Derriford Hospital; University of Plymouth	Wilkin, TJ (corresponding author), Derriford Hosp, Peninsula Med Sch, Dept Endocrinol & Metab, Plymouth PL6 8DH, Devon, England.							Ekelund U, 2001, MED SCI SPORT EXER, V33, P275; Metcalf BS, 2002, MED SCI SPORT EXER, V34, P1533, DOI 10.1097/00005768-200209000-00022; MURPHY MJ, IN PRESS PEDIATRICS; Rowe N, 2000, YOUNG PEOPLE SPORT N	4	84	84	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					592	593		10.1136/bmj.327.7415.592	http://dx.doi.org/10.1136/bmj.327.7415.592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969924	Green Published, Bronze			2022-12-24	WOS:000185358700020
J	Arpigny, C; Jehin, E; Manfroid, J; Hutsemekers, D; Schulz, R; Stuwe, JA; Zucconi, JM; Ilyin, I				Arpigny, C; Jehin, E; Manfroid, J; Hutsemekers, D; Schulz, R; Stuwe, JA; Zucconi, JM; Ilyin, I			Anomalous nitrogen isotope ratio in comets	SCIENCE			English	Article							ABUNDANCE RATIO; PRESOLAR GRAINS; INTERSTELLAR; NUCLEOSYNTHESIS; PHOTOLYSIS; CHEMISTRY; ORIGIN; CN	High-resolution spectra of the CN B-2 Sigma(+)- X-2 Sigma(+) (0,0) band at 390 nanometers yield isotopic ratios for comets C/ 1995 O1 (Hale-Bopp) and C/ 2000 WM1 (LINEAR) as follows: 165 +/- 40 and 115 +/- 20 for C-12/C-13, 140 +/- 35 and 140 +/- 30 for N-14/N-15. Our N isotopic measurements are lower than the terrestrial N-14/N-15 = 272 and the ratio for Hale-Bopp from measurements of HCN, the presumed parent species of CN. This isotopic anomaly suggests the existence of other parent(s) of CN, with an even lower N isotopic ratio. Organic compounds like those found in interplanetary dust particles are good candidates.	Inst Astrophys & Geophys, B-4000 Liege, Belgium; European So Observ, Santiago 19, Chile; European Space Technol Ctr, European Space Agcy, RSSD, NL-2200 AG Noordwijk, Netherlands; Leiden Observ, NL-2300 RA Leiden, Netherlands; Observ Besancon, F-25010 Besancon, France; Univ Oulu, Astron Div, FIN-90014 Oulu, Finland	European Southern Observatory; European Space Agency; Leiden University; Leiden University - Excl LUMC; University of Oulu	Arpigny, C (corresponding author), Inst Astrophys & Geophys, Sart Tilman,Batiment B5c, B-4000 Liege, Belgium.	Claude.Arpigny@ulg.ac.be						AHEARN MF, 1986, NATURE, V324, P649, DOI 10.1038/324649a0; ALEON J, IN PRESS GEOCHIM COS; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; ARPIGNY C, 2000, B AM ASTRON SOC, V32, P1074; BERNSTEIN MP, 1995, ASTROPHYS J, V454, P327, DOI 10.1086/176485; Bernstein MP, 2002, ASTROPHYS J, V576, P1115, DOI 10.1086/341863; Charnley SB, 2002, ASTROPHYS J, V569, pL133, DOI 10.1086/340484; Chin YN, 1999, ASTROPHYS J, V512, pL143, DOI 10.1086/311875; Clayton DD, 1997, ASTROPHYS J, V486, P824, DOI 10.1086/304545; Cochran AL, 2002, ICARUS, V157, P297, DOI 10.1006/icar.2002.6850; Cochran AL, 2000, ICARUS, V146, P583, DOI 10.1006/icar.2000.6413; DAHMEN G, 1995, ASTRON ASTROPHYS, V295, P194; Dekker H, 2000, P SOC PHOTO-OPT INS, V4008, P534, DOI 10.1117/12.395512; FLOSS C, 2003, LUNAR PLANET SCI, V34, P1234; Hashizume K, 2000, SCIENCE, V290, P1142, DOI 10.1126/science.290.5494.1142; Henkel C, 1999, ESO ASTROPHY SYMP, P103; Hoppe P, 1997, ASTROPHYS J, V487, pL101, DOI 10.1086/310869; Ikeda M, 2002, ASTROPHYS J, V575, P250, DOI 10.1086/341287; Jessberger EK, 1999, SPACE SCI REV, V90, P91, DOI 10.1023/A:1005233727874; Jessberger EK, 2001, ASTR AST LI, P253; Jewitt DC, 1997, SCIENCE, V278, P90, DOI 10.1126/science.278.5335.90; Kallenbach R, 1998, ASTROPHYS J, V507, pL185, DOI 10.1086/311702; KELLER LP, 1998, LUNAR PLANET SCI, V28, P1811; KLAVETTER JJ, 2000, ICARUS, V146, P583; KLEINE M, 1995, ASTROPHYS J, V439, P1021, DOI 10.1086/175239; Lucas R, 1998, ASTRON ASTROPHYS, V337, P246; Meier R, 1999, SPACE SCI REV, V90, P33, DOI 10.1023/A:1005269208310; Messenger S, 2000, NATURE, V404, P968, DOI 10.1038/35010053; Mostefaoui S, 2002, EARTH PLANET SC LETT, V204, P89, DOI 10.1016/S0012-821X(02)00964-0; Owen T, 2001, ASTROPHYS J, V553, pL77, DOI 10.1086/320501; Rauer H, 2003, ASTRON ASTROPHYS, V397, P1109, DOI 10.1051/0004-6361:20021550; RETTIG TW, 1992, ASTROPHYS J, V393, P398; Terzieva R, 2000, MON NOT R ASTRON SOC, V317, P563, DOI 10.1046/j.1365-8711.2000.03618.x; Woodney LM, 2002, ICARUS, V157, P193, DOI 10.1006/icar.2001.6798; Wyckoff S, 2000, ASTROPHYS J, V535, P991, DOI 10.1086/308863; Zinner E, 1998, ANNU REV EARTH PL SC, V26, P147, DOI 10.1146/annurev.earth.26.1.147; Ziurys LM, 1999, ASTROPHYS J, V527, pL67, DOI 10.1086/312388; ZUCCONI JM, 1985, ASTRON ASTROPHYS, V150, P180	38	85	85	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1522	1524		10.1126/science.1086711	http://dx.doi.org/10.1126/science.1086711			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970562				2022-12-24	WOS:000185255300046
J	Hoffmeister, KM; Josefsson, EC; Isaac, NA; Clausen, H; Hartwig, JH; Stossel, TP				Hoffmeister, KM; Josefsson, EC; Isaac, NA; Clausen, H; Hartwig, JH; Stossel, TP			Glycosylation restores survival of chilled blood platelets	SCIENCE			English	Article							GLYCOPROTEIN IB-ALPHA; CARBOHYDRATE MOIETY; COLLAGEN ADHESION; RECEPTOR; ERYTHROCYTES; GLYCOCALICIN; COMPLEX; CLONING	Cooling of blood platelets clusters the von Willebrand factor receptor complex. Macrophage alpha(M)beta(2) integrins bind to the GPIbalpha subunit of the clustered complex, resulting in rapid clearance of transfused, cooled platelets. This precludes refrigeration of platelets for transfusion, but the current practice of room temperature storage has major drawbacks. We document that alpha(M)beta(2) is a lectin that recognizes exposed beta-N-acetylglucosamine residues of N-linked glycans on GPIbalpha. Enzymatic galactosylation of chilled platelets blocks alpha(M)beta(2) recognition, prolonging the circulation of functional cooled platelets. Platelet-associated galactosyltransferase produces efficient galactosylation when uridine diphosphate - galactose is added, affording a potentially simple method for storing platelets in the cold.	Harvard Univ, Sch Med, Dept Med, Div Hematol, Boston, MA 02115 USA; Univ Gothenburg, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden; Univ Copenhagen, Sch Dent, Dept Oral Diag, Copenhagen, Denmark; Zymequest Inc, Beverly, MA 01915 USA	Harvard University; Harvard Medical School; University of Gothenburg; University of Copenhagen	Hoffmeister, KM (corresponding author), Harvard Univ, Sch Med, Dept Med, Div Hematol, Boston, MA 02115 USA.	khoffmeister@rics.bwh.harvard.edu	clausen, henrik/AAD-8016-2021	Clausen, Henrik/0000-0002-0915-5055; Josefsson, Emma/0000-0001-6478-5204	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019429, R01HL019429, P01HL056949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19429, HL56949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARTHUR PG, 1991, J PEDIATR GASTR NUTR, V13, P260, DOI 10.1097/00005176-199110000-00004; BARBER AJ, 1971, BIOCHIM BIOPHYS ACTA, V252, P533, DOI 10.1016/0304-4165(71)90156-5; BECKER GA, 1973, TRANSFUSION, V13, P61, DOI 10.1111/j.1537-2995.1973.tb05442.x; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; BERRY GT, 1995, LANCET, V346, P1073, DOI 10.1016/S0140-6736(95)91745-4; Blajchman MA, 2001, TRANSFUS APHER SCI, V24, P245, DOI 10.1016/S1473-0502(01)00063-5; Ellies LG, 2002, P NATL ACAD SCI USA, V99, P10042, DOI 10.1073/pnas.142005099; Fotinopoulou A, 2003, BIOTECHNOL APPL BIOC, V37, P1, DOI 10.1042/BA20020023; Hoffmeister KM, 2003, CELL, V112, P87, DOI 10.1016/S0092-8674(02)01253-9; HOPPER KE, 1986, BLOOD, V68, P167; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JAMIESON GA, 1971, NATURE-NEW BIOL, V234, P5, DOI 10.1038/newbio234005a0; KORREL SAM, 1988, FEBS LETT, V228, P321, DOI 10.1016/0014-5793(88)80024-3; Kuehnert MJ, 2001, TRANSFUSION, V41, P1493, DOI 10.1046/j.1537-2995.2001.41121493.x; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MCCULLOUGH J, 2003, BLOOD PRINCIPLES PRA, P2011; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; *NAT BLOOD DAT RES, 2001, COMPR REP BLOOD COLL, P3; Park EI, 2003, J BIOL CHEM, V278, P4597, DOI 10.1074/jbc.M210612200; RENDU F, 1984, THROMB RES, V36, P447, DOI 10.1016/0049-3848(84)90301-3; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; ROSS GD, 1985, J IMMUNOL, V134, P3307; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Thornton BP, 1996, J IMMUNOL, V156, P1235; TSUJI T, 1987, J BIOCHEM-TOKYO, V101, P241, DOI 10.1093/oxfordjournals.jbchem.a121897; TSUJI T, 1983, J BIOL CHEM, V258, P6335; VAYSSE J, 1986, P NATL ACAD SCI USA, V83, P1339, DOI 10.1073/pnas.83.5.1339; WARD C, 1996, BIOCHEMISTRY-US, V28, P8326	30	190	207	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1531	1534		10.1126/science.1085322	http://dx.doi.org/10.1126/science.1085322			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970565				2022-12-24	WOS:000185255300049
J	Zagotta, WN; Olivier, NB; Black, KD; Young, EC; Olson, R; Gouaux, E				Zagotta, WN; Olivier, NB; Black, KD; Young, EC; Olson, R; Gouaux, E			Structural basis for modulation and agonist specificity of HCN pacemaker channels	NATURE			English	Article							NUCLEOTIDE-GATED CHANNELS; CAMP MODULATION; MOLECULAR-MECHANISM; BINDING DOMAIN; PROTEIN-KINASE; STOICHIOMETRY; ACTIVATION; DEPENDENCE; SUBUNIT; K+	The family of hyperpolarization-activated, cyclic nucleotide-modulated (HCN) channels are crucial for a range of electrical signalling, including cardiac and neuronal pacemaker activity, setting resting membrane electrical properties and dendritic integration(1). These nonselective cation channels, underlying the I-f, I-h and I-q currents of heart and nerve cells, are activated by membrane hyperpolarization and modulated by the binding of cyclic nucleotides such as cAMP and cGMP(2). The cAMP-mediated enhancement of channel activity is largely responsible for the increase in heart rate caused by beta-adrenergic agonists(3). Here we have investigated the mechanism underlying this modulation by studying a carboxy-terminal fragment of HCN2 containing the cyclic nucleotide-binding domain (CNBD) and the C-linker region that connects the CNBD to the pore. X-ray crystallographic structures of this C-terminal fragment bound to cAMP or cGMP, together with equilibrium sedimentation analysis, identify a tetramerization domain and the mechanism for cyclic nucleotide specificity, and suggest a model for ligand-dependent channel modulation. On the basis of amino acid sequence similarity to HCN channels, the cyclic nucleotide-gated, and eag- and KAT1-related families of channels are probably related to HCN channels in structure and mechanism.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Seattle, WA 98195 USA; Columbia Univ, Howard Hughes Med Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Columbia University; Howard Hughes Medical Institute	Gouaux, E (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 650 W 168th St, New York, NY 10032 USA.	zagotta@u.washington.edu; jeg52@columbia.edu	Gouaux, Eric/Y-4370-2019	Gouaux, Eric/0000-0002-8549-2360; Young, Edgar C./0000-0002-8453-088X	NEI NIH HHS [R01 EY010329, R01 EY010329-10] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010329] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Guerrero SA, 2001, APPL MICROBIOL BIOT, V56, P718, DOI 10.1007/s002530100690; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Johnson JP, 2001, NATURE, V412, P917, DOI 10.1038/35091089; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KUMAR VD, 1992, BIOCHEMISTRY-US, V31, P4643, DOI 10.1021/bi00134a015; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Matulef K, 1999, NEURON, V24, P443, DOI 10.1016/S0896-6273(00)80857-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Rothberg BS, 2002, J GEN PHYSIOL, V119, P83, DOI 10.1085/jgp.119.1.83; Shin KS, 2001, J GEN PHYSIOL, V117, P91, DOI 10.1085/jgp.117.2.91; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Ulens C, 2003, BIOPHYS J, V84, p137A; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Wang J, 2001, J GEN PHYSIOL, V118, P237, DOI 10.1085/jgp.118.3.237; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	30	458	476	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					200	205		10.1038/nature01922	http://dx.doi.org/10.1038/nature01922			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968185				2022-12-24	WOS:000185236000048
J	Schirmer, EC; Florens, L; Guan, TL; Yates, JR; Gerace, L				Schirmer, EC; Florens, L; Guan, TL; Yates, JR; Gerace, L			Nuclear membrane proteins with potential disease links found by subtractive proteomics	SCIENCE			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; PORE COMPLEX; IDENTIFICATION TECHNOLOGY; GENE; ENVELOPE; LAMINA	To comprehensively identify integral membrane proteins of the nuclear envelope (NE), we prepared separately NEs and organelles known to cofractionate with them from liver. Proteins detected by multidimensional protein identification technology in the cofractionating organelles were subtracted from the NE data set. In addition to all 13 known NE integral proteins, 67 uncharacterized open reading frames with predicted membrane-spanning regions were identified. All of the eight proteins tested targeted to the NE, indicating that there are substantially more integral proteins of the NE than previously thought. Furthermore, 23 of these mapped within chromosome regions linked to a variety of dystrophies.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Yates, JR (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.			Schirmer, Eric/0000-0003-2635-1338; Florens, Laurence/0000-0002-9310-6650	NCRR NIH HHS [RR11823] Funding Source: Medline; NIGMS NIH HHS [GM28521, F32 GM19085] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019085, R01GM028521] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apel ED, 2000, J BIOL CHEM, V275, P31986, DOI 10.1074/jbc.M004775200; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; De Sandre-Giovannoli A, 2002, AM J HUM GENET, V70, P726, DOI 10.1086/339274; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Kitaguchi T, 2001, NEUROMUSCULAR DISORD, V11, P542, DOI 10.1016/S0960-8966(01)00207-3; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; Satow R, 2002, BIOCHEM BIOPH RES CO, V295, P85, DOI 10.1016/S0006-291X(02)00641-1; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7; Zhang QP, 2001, J CELL SCI, V114, P4485; [No title captured]	21	491	529	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1380	1382		10.1126/science.1088176	http://dx.doi.org/10.1126/science.1088176			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958361				2022-12-24	WOS:000185116400042
J	McDermott, R; Tulip, F; Schmidt, B; Sinha, A				McDermott, R; Tulip, F; Schmidt, B; Sinha, A			Sustaining better diabetes care in remote indigenous Australian communities	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Problem Inhabitants of Torres Strait Islands have the highest prevalence of diabetes in Australia and many preventable complications. In 1999, a one year randomised cluster trial showed improved diabetes care processes and reduced admissions to hospital when local indigenous health workers used registers, recall and reminder systems, and basic diabetes care plans, supported by a specialist outreach service. This study looked at whether those improvements were sustained two years after the end of the trial. Design Three year follow up clinical audit of 21 primary healthcare centres, and review of admissions to hospital in the previous 12 months. Background and setting Remote indigenous communities in far north east Australia, population about 9600, including 921 people with diabetes. Key measures for improvement Number of people on registers, care processes (regular measures of weight, blood pressure, haemoglobin A(1c), urinary protein concentration, and concentrations of serum lipids and creatinine), appropriate clinical interventions (drug treatment and vaccinations), and intermediate patient outcome measures (weight, blood pressure, and glycaemic control). Admissions to hospital. Strategies for change Audit and feedback to clinicians and managers; provision of clinical guidelines and a clear management structure; workshops and training. Effects of change The number of people on registers increased from 555 in 1999 to 921 in 2002. Most care processes and clinical interventions improved. The proportion of people with good glycaemic control (haemoglobin A(1c), less than or equal to 7%) increased from 18% to 25% in line with increased use of insulin (from 7% to 16%). The proportion of those with well controlled hypertension (<140/90) increased from 40% to 64%. The proportion admitted to hospital with a diabetes related condition fell from 25% to 20%. Mean weight increased from 87 kg to 91 kg. Lessons learnt In remote settings, appropriate management structures and clinical support for people with diabetes can lead to improvements in care processes, control of blood pressure, and preventable complications that result in admission to hospital. Control of weight and glycaemia are more difficult and requires more active community engagement. Priorities now include increasing the availability and affordability of good food, achieving weight loss, and increasing appropriate use of hypoglycaemic agents, including insulin.	Queensland Hlth, Trop Publ Hlth Unit, Cairns, Qld 4870, Australia; James Cook Univ N Queensland, Townsville, Qld 4811, Australia; Queensland Hlth, Cairns Diabet Ctr, Cairns, Qld 4870, Australia	Queensland Health; James Cook University; Queensland Health	McDermott, R (corresponding author), Queensland Hlth, Trop Publ Hlth Unit, Cairns, Qld 4870, Australia.	robyn_mcdermott@health.qld.gov.au	McDermott, Robyn A/C-5824-2008					Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P965; Leonard D, 1995, AUST J PUBLIC HEALTH, V19, P589; Leonard D, 2002, AUST NZ J PUBL HEAL, V26, P144, DOI 10.1111/j.1467-842X.2002.tb00907.x; McDermott RA, 2001, MED J AUSTRALIA, V174, P497, DOI 10.5694/j.1326-5377.2001.tb143397.x; *QUEENSL HLTH, 2002, CHRON DIS STRAT IMPL, V1, P76; *QUEENSL HLTH, 2000, HLTH FOOD ACC BASK; *TORR STRAIT NO PE, 1996, MER ZAG DIAB OUR WOR	7	63	66	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2003	327	7412					428	430		10.1136/bmj.327.7412.428	http://dx.doi.org/10.1136/bmj.327.7412.428			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715YY	12933731	Green Published, Green Accepted			2022-12-24	WOS:000185003100021
J	Sucena, E; Delon, I; Jones, I; Payre, F; Stern, DL				Sucena, E; Delon, I; Jones, I; Payre, F; Stern, DL			Regulatory evolution of shavenbaby/ovo underlies multiple cases of morphological parallelism	NATURE			English	Article							WINGLESS; EPIDERMIS	Cases of convergent evolution that involve changes in the same developmental pathway, called parallelism, provide evidence that a limited number of developmental changes are available to evolve a particular phenotype(1). To our knowledge, in no case are the genetic changes underlying morphological convergence understood. However, morphological convergence is not generally assumed to imply developmental parallelism(2). Here we investigate a case of convergence of larval morphology in insects and show that the loss of particular trichomes, observed in one species of the Drosophila melanogaster species group, has independently evolved multiple times in the distantly related D. virilis species group(3). We present genetic and gene expression data showing that regulatory changes of the shavenbaby/ovo (svb/ovo) gene underlie all independent cases of this morphological convergence. Our results indicate that some developmental regulators might preferentially accumulate evolutionary changes and that morphological parallelism might therefore be more common than previously appreciated.	Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Ctr Dev Biol, F-31062 Toulouse 4, France; Vanguard High Sch, New York, NY 10021 USA	Princeton University	Stern, DL (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	dstern@princeton.edu	Sucena, Élio/ABF-6684-2020; Sucena, Élio/M-1753-2015	Sucena, Élio/0000-0001-8810-870X; Sucena, Élio/0000-0001-8810-870X; Stern, David/0000-0002-1847-6483; PAYRE, Francois/0000-0002-8144-6711	NIGMS NIH HHS [R01 GM063622] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063622] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bokor P, 1996, DEVELOPMENT, V122, P1083; Darwin C., 1859, ORIGIN SPECIES MEANS; DICKINSON WJ, 1993, EVOLUTION, V47, P1396, DOI [10.2307/2410155, 10.1111/j.1558-5646.1993.tb02162.x]; Endler J.A., 1986, Monographs in Population Biology, pviii; FFRENCHCONSTANT RH, 1994, INSECT BIOCHEM MOLEC, V24, P335, DOI 10.1016/0965-1748(94)90026-4; Hatini V, 2000, GENE DEV, V14, P1364; Hodin J, 2000, J EXP ZOOL, V288, P1; HSU TC, 1951, THESIS U TEXAS; KUHN DT, 1992, DROSOPHILA INFORMATI, V71, P218; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Spicer GS, 2002, ANN ENTOMOL SOC AM, V95, P156, DOI 10.1603/0013-8746(2002)095[0156:MPOTDV]2.0.CO;2; STEWART CB, 1987, COLD SPRING HARB SYM, V52, P891, DOI 10.1101/SQB.1987.052.01.097; Sucena E, 2000, P NATL ACAD SCI USA, V97, P4530, DOI 10.1073/pnas.97.9.4530; Throckmorton L.H., 1982, Genetics and Biology of Drosophila, V3b, P227; Wittkopp PJ, 2003, P NATL ACAD SCI USA, V100, P1808, DOI 10.1073/pnas.0336368100; Wittkopp PJ, 2002, CURR BIOL, V12, P1547, DOI 10.1016/S0960-9822(02)01113-2; Wray GA, 1998, CURR OPIN GENET DEV, V8, P675, DOI 10.1016/S0959-437X(98)80036-1	17	168	174	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					935	938		10.1038/nature01768	http://dx.doi.org/10.1038/nature01768			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931187				2022-12-24	WOS:000184843600040
J	de la Hoya, M; Fernandez, JM; Tosar, A; Godino, J; de Abajo, AS; Vidart, JA; Perez-Segura, P; Diaz-Rubio, E; Caldes, T				de la Hoya, M; Fernandez, JM; Tosar, A; Godino, J; de Abajo, AS; Vidart, JA; Perez-Segura, P; Diaz-Rubio, E; Caldes, T			Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-CHROMOSOME; INACTIVATION	Context Defects in X-chromosome inactivation distort sex ratio in mice. The BRCA1 gene is also involved in X-chromosome inactivation, suggesting the possibility that some sex-ratio distortion may be associated with BRCA1-related human cancer syndromes. Objective To determine whether BRCA1 mutations are associated with distortion of the sex ratio of births in families with breast cancer, ovarian cancer, or both. Design and Setting Analysis of germline mutations in participants from Spain who had been screened for BRCA between 1998 and 2002. Participants Sixty-eight families with at least 3 breast cancer cases or ovarian cancer cases, or both types of cancer in 2 generations (germline mutations: BRCA1, n = 17; BRCA2, n = 15; and BRCA unrelated, n = 36). An average of 4 relatives per family were tested for the corresponding BRCA mutation. Main Outcome Measure Male and female births registered in breast and/or ovarian pedigrees tested for the presence of BRCA1 and BRCA2 germline mutations. Results Of BRCA1-related breast and/or ovarian cancer pedigrees, there was a 2-fold excess of female births (218 female vs 109 male births). Of BRCA2-related or BRCA-unrelated breast and/or ovarian cancer pedigrees, there was not an excess of female births (1175 fernale/150 male and 344 female/315 male, respectively). Of 327 BRCA1 births, 218 (67%) were female births compared with 54% among BRCA2 pedigrees 0 75/327; P<.001) and 52% among BRCA-unrelated pedigrees (344/659; P<.001). Female births increased in the offspring of BRCA1 carriers compared with BRCA2 carriers (67% vs 52%; P=.004). Conclusion In these families with breast and/or ovarian cancer, mutations in BRCA1 but not BRCA2 were associated with a sex ratio skewed against male births.	Hosp Clin San Carlos, Mol Oncol Lab, Mol Oncol Unit, Madrid 28040, Spain; Hosp Clin San Carlos, Dept Gynecol, Madrid 28040, Spain; Hosp Clin San Carlos, Dept Clin Oncol, Madrid 28040, Spain	Hospital Clinico San Carlos; Hospital Clinico San Carlos; Hospital Clinico San Carlos	Caldes, T (corresponding author), Hosp Clin San Carlos, Mol Oncol Lab, Mol Oncol Unit, Martin Lagos S-N, Madrid 28040, Spain.		Godino, Javier/M-3753-2018; de la Hoya, MIguel/Z-2911-2019	Godino, Javier/0000-0002-5653-2722; de la Hoya, Miguel/0000-0002-8113-1410; Diaz-Rubio, Eduardo/0000-0003-2792-5348				Buller RE, 1999, JNCI-J NATL CANCER I, V91, P339, DOI 10.1093/jnci/91.4.339; de la Hoya M, 2002, INT J CANCER, V97, P466, DOI 10.1002/ijc.1627; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Lee JT, 2002, NAT GENET, V32, P195, DOI 10.1038/ng939; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3	5	27	28	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					929	931		10.1001/jama.290.7.929	http://dx.doi.org/10.1001/jama.290.7.929			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928470	Bronze			2022-12-24	WOS:000184828800030
J	Alvarez-Dolado, M; Pardal, R; Garcia-Vardugo, JM; Fike, JR; Lee, HO; Pfeffer, K; Lois, C; Morrison, SJ; Alvarez-Buylla, A				Alvarez-Dolado, M; Pardal, R; Garcia-Vardugo, JM; Fike, JR; Lee, HO; Pfeffer, K; Lois, C; Morrison, SJ; Alvarez-Buylla, A			Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes	NATURE			English	Article							STEM-CELLS; MONOCLONAL-ANTIBODIES; IN-VIVO; MICE; DNA; DIFFERENTIATION; PLASTICITY; MICROGLIA; ANTIGENS; BRAIN	Recent studies have suggested that bone marrow cells possess a broad differentiation potential, being able to form new liver cells, cardiomyocytes and neurons(1,2). Several groups have attributed this apparent plasticity to 'transdifferentiation'(3-5). Others, however, have suggested that cell fusion could explain these results(6-9). Using a simple method based on Cre/lox recombination to detect cell fusion events, we demonstrate that bone-marrow-derived cells (BMDCs) fuse spontaneously with neural progenitors in vitro. Furthermore, bone marrow transplantation demonstrates that BMDCs fuse in vivo with hepatocytes in liver, Purkinje neurons in the brain and cardiac muscle in the heart, resulting in the formation of multinucleated cells. No evidence of transdifferentiation without fusion was observed in these tissues. These observations provide the first in vivo evidence for cell fusion of BMDCs with neurons and cardiomyocytes, raising the possibility that cell fusion may contribute to the development or maintenance of these key cell types.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Michigan, Dept Internal Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Valencia, Inst Cavanilles, E-46100 Valencia, Spain; Univ Dusseldorf, Inst Med Microbiol, D-40225 Dusseldorf, Germany; MIT, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Valencia; Heinrich Heine University Dusseldorf; Massachusetts Institute of Technology (MIT)	Alvarez-Buylla, A (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.		Morrison, Sean/ABD-5326-2021; Alvarez-Dolado, Manuel/C-2706-2017; García-Verdugo, José Manuel/L-8421-2017; IBIS, FISIOPATOLOGIA/O-9510-2015; Pardal, Ricardo/C-4370-2015	Alvarez-Dolado, Manuel/0000-0002-0655-8289; García-Verdugo, José Manuel/0000-0001-9872-6499; Pardal, Ricardo/0000-0003-1085-0714; Morrison, Sean/0000-0003-1587-8329; Alvarez-Buylla, Arturo/0000-0003-4426-8925; Pfeffer, Klaus/0000-0002-5652-6330				Anderson JM, 2000, CURR OPIN HEMATOL, V7, P40, DOI 10.1097/00062752-200001000-00008; ARIAS IM, 2001, LIVER BIOL PATHOBIOL; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LAPHAM LW, 1968, SCIENCE, V159, P310, DOI 10.1126/science.159.3812.310; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; MARES V, 1973, BRAIN RES, V53, P273, DOI 10.1016/0006-8993(73)90214-X; Morrison SJ, 2001, CURR BIOL, V11, pR7, DOI 10.1016/S0960-9822(00)00033-6; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PALAY LP, 1974, CEREBELLAR CORTEX, P15; PIPER HM, 1989, ISOLATED ADULT CARDI; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Spector D. L., 1998, CELLS LAB MANUAL; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; VANEWIJK W, 1981, J IMMUNOL, V127, P2594; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Weiss S, 1996, J NEUROSCI, V16, P7599; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	30	1250	1351	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					968	973		10.1038/nature02069	http://dx.doi.org/10.1038/nature02069			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14555960	Green Published			2022-12-24	WOS:000186230600043
J	Flum, DR; Cheadle, A; Prela, C; Dellinger, EP; Chan, L				Flum, DR; Cheadle, A; Prela, C; Dellinger, EP; Chan, L			Bile duct injury during cholecystectomy and survival in medicare beneficiaries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BENIGN BILIARY STRICTURES; QUALITY-OF-LIFE; LAPAROSCOPIC CHOLECYSTECTOMY; INTRAOPERATIVE CHOLANGIOGRAPHY; TRACT INJURY; MANAGEMENT; SURGERY; COMPLICATIONS; HEPATICOJEJUNOSTOMY; ANASTOMOSIS	Context Common bile duct (CBD) injury during cholecystectomy is a significant source of patient morbidity, but its impact on survival is unclear. Objective To demonstrate the relation between CBD injury and survival and to identify the factors associated with improved survival among Medicare beneficiaries. Design, Setting, and Patients Retrospective study using Medicare National Claims History Part B data(January 1, 1992, through December 31, 1999) linked to death records and to the American Medical Association's (AMA's) Physician Masterfile. Records with a procedure code for cholecystectomy were reviewed and those with an additional procedure code for repair of the CBD within 365 days were defined as having a CBD injury. Main Outcome Measure Survival after cholecystectomy, controlling for patient (sex, age, comorbidity index, disease severity) and surgeon (procedure year, case order, surgeon specialty) characteristics. Results Of the 1570361 patients identified as having had a cholecystectomy (62.9% women), 7911 patients (0.5%) had CBD injuries. The entire population had a mean (SD) age of 71.4 (10.2) years. Thirty-three percent of all patients died within the 9.2-year follow-up period (median survival, 5.6 years; interquartile range, 3.2-7.4 years), with 55.2% of patients without and 19.5% with a CBD injury remained alive. The adjusted hazard ratio (HR) for death during the follow-up period was significantly higher (2.79; 95% confidence interval [Cl]; 2.71-2.88) for patients with a CBD injury than those without CBD injury. The hazard significantly increased with advancing age and comorbidities and decreased with the experience of the repairing surgeon. The adjusted hazard of death during the follow-up period was 11% greater (HR, 1.11; 95% Cl, 1.02-1.20) if the repairing surgeon was the same as the injuring surgeon. Conclusions The association between CBD injury during cholecystectomy and survival among Medicare beneficiaries is stronger than suggested by previous reports. Referring patients with CBD injuries to surgeons or institutions with greater experience in CBD repair may represent a system-level opportunity to improve outcome.	Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Ctr Med & Med Serv, Div Clin Stand & Qual, Seattle, WA USA; Univ Washington, Robert Wood Johnson Clin Scholars Program, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Flum, DR (corresponding author), Univ Washington, Dept Surg, BB 431,1959 NE Pacific St,Box 356410, Seattle, WA 98195 USA.	daveflum@u.washington.edu	Flum, David/GPX-7976-2022					Al-Ghnaniem R, 2002, BRIT J SURG, V89, P1118, DOI 10.1046/j.1365-2168.2002.02182.x; Bauer T W, 1998, J Gastrointest Surg, V2, P61, DOI 10.1016/S1091-255X(98)80104-2; Boerma D, 2001, ANN SURG, V234, P750, DOI 10.1097/00000658-200112000-00006; Buanes T, 1998, SURG ENDOSC-ULTRAS, V12, P852, DOI 10.1007/s004649900728; Carroll BJ, 1998, SURG ENDOSC-ULTRAS, V12, P310, DOI 10.1007/s004649900660; Chaudhary A, 2002, DIGEST SURG, V19, P22, DOI 10.1159/000052001; Csendes A, 2001, WORLD J SURG, V25, P1346, DOI 10.1007/s00268-001-0121-5; CSENDES A, 1992, HEPATO-GASTROENTEROL, V39, P333; DAVIDS PHP, 1993, ANN SURG, V217, P237, DOI 10.1097/00000658-199303000-00004; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DEZIEL DJ, 1993, AM J SURG, V165, P9, DOI 10.1016/S0002-9610(05)80397-6; Flum DR, 2003, JAMA-J AM MED ASSOC, V289, P1639, DOI 10.1001/jama.289.13.1639; Gigot JF, 1997, SURG ENDOSC-ULTRAS, V11, P1171, DOI 10.1007/s004649900563; Gouma DJ, 2002, BRIT J SURG, V89, P385, DOI 10.1046/j.0007-1323.2002.02051.x; INNES JT, 1988, AM SURGEON, V54, P27; Johnson SR, 2000, SURGERY, V128, P668, DOI 10.1067/msy.2000.108422; Kern KA, 1997, ARCH SURG-CHICAGO, V132, P392; KERN KA, 1994, AM J SURG, V168, P217, DOI 10.1016/S0002-9610(05)80189-8; Krahenbuhl L, 2001, WORLD J SURG, V25, P1325; Lillemoe KD, 2000, ANN SURG, V232, P430, DOI 10.1097/00000658-200009000-00015; Ludwig K, 2002, SURG ENDOSC, V16, P1098, DOI 10.1007/s00464-001-9183-6; MACAULAY FX, 1967, SCIENCE, V157, P1261, DOI 10.1126/science.157.3794.1261-b; MacFadyen BV, 1998, SURG ENDOSC-ULTRAS, V12, P315, DOI 10.1007/s004649900661; Mathisen O, 2002, SCAND J GASTROENTERO, V37, P476, DOI 10.1080/003655202317316123; Mirza DF, 1997, BRIT J SURG, V84, P786, DOI 10.1002/bjs.1800840614; Nealon WH, 1996, ANN SURG, V223, P639, DOI 10.1097/00000658-199606000-00002; PELLEGRINI CA, 1984, AM J SURG, V147, P175, DOI 10.1016/0002-9610(84)90054-0; PITT HA, 1989, ANN SURG, V210, P417, DOI 10.1097/00000658-198910000-00001; Russell JC, 1996, ARCH SURG-CHICAGO, V131, P382; Slater K, 2002, ANZ J SURG, V72, P83, DOI 10.1046/j.1445-2197.2002.02315.x; STEWART L, 1995, ARCH SURG-CHICAGO, V130, P1123; Targarona EM, 1998, SURG ENDOSC-ULTRAS, V12, P322, DOI 10.1007/s004649900662; Tocchi A, 2000, ARCH SURG-CHICAGO, V135, P153, DOI 10.1001/archsurg.135.2.153; Topal B, 1999, SURG ENDOSC, V13, P53, DOI 10.1007/s004649900897; Tsatis KG, 2003, SURG ENDOSC, V17, P31, DOI 10.1007/s00464-001-9230-3; Walsh R M, 1998, J Gastrointest Surg, V2, P458, DOI 10.1016/S1091-255X(98)80037-1; WOODS MS, 1994, AM J SURG, V167, P27, DOI 10.1016/0002-9610(94)90050-7; Z'graggen K, 1998, SURG ENDOSC-ULTRAS, V12, P1303, DOI 10.1007/s004649900846	38	317	352	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2003	290	16					2168	2173		10.1001/jama.290.16.2168	http://dx.doi.org/10.1001/jama.290.16.2168			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CB	14570952	Bronze			2022-12-24	WOS:000186036700026
J	Dickinson, D; Raynor, DKT; Kennedy, JG; Bonaccorso, S; Sturchio, JL				Dickinson, D; Raynor, DKT; Kennedy, JG; Bonaccorso, S; Sturchio, JL			What information do patients need about medicines?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Consumation, Consumer Informat Design, London SW17 7QW, England; Univ Leeds, Pharm Practice & Med Management Grp, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Dickinson, D (corresponding author), Consumation, Consumer Informat Design, 53 Hosack Rd, London SW17 7QW, England.		Sturchio, Jeffrey/GWZ-3472-2022						0	70	73	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					861	861		10.1136/bmj.327.7419.861-a	http://dx.doi.org/10.1136/bmj.327.7419.861-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551106	Green Accepted, Green Published			2022-12-24	WOS:000185921200029
J	Gent, JF; Triche, EW; Holford, TR; Belanger, K; Bracken, MB; Beckett, WS; Leaderer, BP				Gent, JF; Triche, EW; Holford, TR; Belanger, K; Bracken, MB; Beckett, WS; Leaderer, BP			Association of low-level ozone and fine particles with respiratory symptoms in children with asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFRICAN-AMERICAN CHILDREN; AIR-POLLUTION; MEDICATION USE; AMBIENT OZONE; 1ST YEAR; PARTICULATE; EXPOSURE; SUMMER; HEALTH; LIFE	Context Exposure to ozone and particulate matter of 2.5 mum or less (PM2.5) in air at levels above current US Environmental Protection Agency (EPA) standards is a risk factor for respiratory symptoms in children with asthma. Objective To examine simultaneous effects of ozone and PM2.5 at levels below EPA standards on daily respiratory symptoms and rescue medication use among children with asthma. Design, Setting, and Participants Daily respiratory symptoms and medication use were examined prospectively for 271 children younger than 12 years with physician-diagnosed, active asthma residing in southern New England. Exposure to ambient concentrations of ozone and PM2.5 from April 1 through September 30, 2001, was assessed using ozone (peak 1-hour and 8-hour) and 24-hour PM2.5. Logistic regression analyses using generalized estimating equations were performed separately for maintenance medication users (n=130) and nonusers (n=141). Associations between pollutants (adjusted for temperature, controlling for same- and previous-day levels) and respiratory symptoms and use of rescue medication were evaluated. Main Outcome Measures Respiratory symptoms and rescue medication use recorded on calendars by subjects' mothers. Results Mean (SD) levels were 59 (19) ppb (1-hour average) and 51 (16) ppb (8-hour average) for ozone and 13 (8) mug/m(3) for PM2.5. In copollutant models, ozone level but not PM2.5 was significantly associated with respiratory symptoms and rescue medication use among children using maintenance medication; a 50-ppb increase in 1-hour ozone was associated with increased likelihood of wheeze (by 35%) and chest tightness (by 47%). The highest levels of ozone (1-hour or 8-hour averages) were associated with increased shortness of breath and rescue medication use. No significant, exposure-dependent associations were observed for any outcome by any pollutant among children who did not use maintenance medication. Conclusion Asthmatic children using maintenance medication are particularly vulnerable to ozone, controlling for exposure to fine particles, at levels below EPA standards.	Yale Univ, Ctr Perinatal Pediat & Environm Epidemiol, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY USA	Yale University; University of Rochester	Gent, JF (corresponding author), Yale Univ, Ctr Perinatal Pediat & Environm Epidemiol, Sch Med, Dept Epidemiol & Publ Hlth, 1 Church St,6th Floor, New Haven, CT 06510 USA.	janneane.gent@yale.edu	Triche, Elizabeth/I-4986-2014		NIEHS NIH HHS [ES05410, ES07456, ES11013, ES01247] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007456, P30ES001247, R01ES011013] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allison P. D., 1999, LOGISTIC REGRESSION; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; *COMM MASS DEP ENV, 2000, AIR QUAL REP; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.2307/3434265; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781, DOI 10.1289/ehp.021100781; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105, DOI 10.1164/ajrccm.155.6.9196122; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Hanania NA, 1998, CHEST, V114, P752, DOI 10.1378/chest.114.3.752; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198, DOI 10.1016/S0091-6749(99)70013-8; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Mortimer KM, 2000, AM J RESP CRIT CARE, V162, P1838, DOI 10.1164/ajrccm.162.5.9908113; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; OSTRO BD, 1995, INHAL TOXICOL, V7, P711, DOI 10.3109/08958379509014475; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.2307/3433341; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368, DOI 10.1080/00039899709602213; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300, DOI 10.1164/ajrccm.154.2.8756798; *SAS I INC, 2001, SAS VERS 8; SILVERMAN F, 1979, ENVIRON HEALTH PERSP, V29, P131, DOI 10.2307/3429055; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313, DOI 10.1164/ajrccm/137.2.313; *STAT CONN DEP ENV, 1999, ANN AIR QUAL SUMM; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654, DOI 10.1164/ajrccm.155.2.9032209; Ulmer C, 1997, PEDIATR PULM, V23, P344, DOI 10.1002/(SICI)1099-0496(199705)23:5<344::AID-PPUL6>3.3.CO;2-4; *US EPA, 1996, EPA600AP93004AC US E	24	324	334	1	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1859	1867		10.1001/jama.290.14.1859	http://dx.doi.org/10.1001/jama.290.14.1859			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729CB	14532314				2022-12-24	WOS:000185752600026
J	Grzybowski, M; Clements, EA; Parsons, L; Welch, R; Tintinalli, AT; Ross, MA; Zalenski, RJ				Grzybowski, M; Clements, EA; Parsons, L; Welch, R; Tintinalli, AT; Ross, MA; Zalenski, RJ			Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy - A propensity analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; PRIMARY ANGIOPLASTY; NATIONAL REGISTRY; RANDOMIZED TRIALS; ACUTE MI; SCORES; ANGIOGRAPHY; VOLUME	Context There are no definitive recommendations for the management of acute myocardial infarction (AMI) in patients with ST-segment elevation who have contraindications to thrombolytic therapy. It is not clear whether, and the extent to which, immediate mechanical reperfusion (IMR) reduces in-hospital mortality in this population. Objective To determine whether IMR (defined as percutaneous coronary intervention or coronary artery bypass graft surgery) is associated with a mortality benefit in patients with acute ST-segment elevation AMI who are eligible for IMR but have contraindications to thrombolytic therapy. Design, Setting, and Patients From June 1994 to January 2003, the National Registry of Myocardial Infarction 2, 3, and 4 enrolled 1799704 patients with AMI. A total of 19917 patients with acute ST-segment elevation were eligible for IMR but had thrombolytic contraindications after excluding patients who were transferred in from or out to other facilities, patients who received intracoronary thrombolytics, and those who received no medications within 24 hours of arrival. Main Outcome Measure In-hospital mortality. Results Of the 19917 patients, 4705 patients (23.6%) received IMR and 5173 patients (25.9%) died. In-hospital mortality rates in the IMR and non-IMR treated groups in the unadjusted analysis were 11.1%, representing 521 of 4705 patients, and 30.6%, representing 4652 of 15212 patients, respectively, for a risk reduction of 63.7% (odds ratio [OR], 0.28; 95% confidence interval [CI], 0.26-0.31). In a further analysis using a propensity matching score to reduce the effects of bias, 3905 patients who received IMR remained at lower risk for in-hospital mortality than 3905 matched patients (10.9% vs 20.1%, respectively, for a risk reduction of 45.8%; OR, 0.48; 95% Cl, 0.43-0.55). Following a second logistic model applied to the matched groups to adjust for residual differences, a significant treatment effect persisted (OR, 0.64; 95% Cl, 0.56-0.75). Conclusions In this population, IMR was associated with a reduced risk of in-hospital mortality after appropriate adjustments. Of those we studied who were eligible for IMR, 15212 patients (76.4%) did not receive it. These results suggest that using IMR in patients with acute ST-segment elevation AMI and contrainclications to thrombolytics should be strongly considered.	Wayne State Univ, Sch Med, Dept Emergency Med, Ctr Healthcare Effectiveness, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Med, Div Cardiol, Detroit, MI 48201 USA; Spectrum Hlth Hosp, Dept Pharm, Grand Rapids, MI USA; Ovat Res Grp, Chicago, IL USA; William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA; John D Dingell Vet Affairs Hosp, Dept Med, Sect Urgent Care, Detroit, MI USA	Wayne State University; Wayne State University; Beaumont Health	Grzybowski, M (corresponding author), Wayne State Univ, Sch Med, Dept Emergency Med, Ctr Healthcare Effectiveness, UHC 6-G,4201 St Antoine, Detroit, MI 48201 USA.							Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P1943, DOI 10.1001/jama.287.15.1943; Barron HV, 2000, AM J CARDIOL, V85, P294, DOI 10.1016/S0002-9149(99)00735-3; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Canto JG, 2000, NEW ENGL J MED, V342, P1573, DOI 10.1056/NEJM200005253422106; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; Grines CL, 2002, J AM COLL CARDIOL, V39, P1713, DOI 10.1016/S0735-1097(02)01870-3; HIMBERT D, 1993, AM J CARDIOL, V71, P377, DOI 10.1016/0002-9149(93)90435-F; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Magid DJ, 2000, JAMA-J AM MED ASSOC, V284, P3131, DOI 10.1001/jama.284.24.3131; McCullough PA, 1998, J AM COLL CARDIOL, V32, P596, DOI 10.1016/S0735-1097(98)00284-8; Moon JCC, 2002, INT J CARDIOL, V85, P199, DOI 10.1016/S0167-5273(02)00183-3; MOSES LE, 1995, MED CARE, V33, pAS8; Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8; Parsons, 2001, P 26 ANN SAS US GROU; Peterson ED, 2003, J AM COLL CARDIOL, V42, P45, DOI 10.1016/S0735-1097(03)00514-X; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; Stone GW, 1996, CATHETER CARDIO DIAG, V39, P333, DOI 10.1002/(SICI)1097-0304(199612)39:4<333::AID-CCD1>3.0.CO;2-E; Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2; Zahn R, 1999, CATHETER CARDIO INTE, V46, P127, DOI 10.1002/(SICI)1522-726X(199902)46:2<127::AID-CCD2>3.3.CO;2-7	26	79	82	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1891	1898		10.1001/jama.290.14.1891	http://dx.doi.org/10.1001/jama.290.14.1891			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729CB	14532318	Bronze			2022-12-24	WOS:000185752600030
J	He, WZ; Cowin, P; Stokes, DL				He, WZ; Cowin, P; Stokes, DL			Untangling desmosomal knots with electron tomography	SCIENCE			English	Article							CELL-CELL ADHESION; PEMPHIGUS-VULGARIS ANTIGEN; E-CADHERIN; MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; BINDING; IDENTIFICATION; SUPERFAMILY; ACTIN	Cell adhesion by adherens junctions and desmosomes relies on interactions between cadherin molecules. However, the molecular interfaces that de. ne molecular specificity and that mediate adhesion remain controversial. We used electron tomography of plastic sections from neonatal mouse skin to visualize the organization of desmosomes in situ. The resulting three-dimensional maps reveal individual cadherin molecules forming discrete groups and interacting through their tips. Fitting of an x-ray crystal structure for C-cadherin to these maps is consistent with a flexible intermolecular interface mediated by an exchange of amino-terminal tryptophans. This flexibility suggests a novel mechanism for generating both cis and trans interactions and for propagating these adhesive interactions along the junction.	NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; New York Struct Biol Ctr, New York, NY 10027 USA	New York University; New York University	Stokes, DL (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, 540 1st Ave, New York, NY 10016 USA.	stokes@saturn.med.nyu.edu		Cowin, Pamela/0000-0002-1827-1154	NIGMS NIH HHS [R01 GM47429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Angst BD, 2001, J CELL SCI, V114, P629; Baumeister W, 2002, CURR OPIN STRUC BIOL, V12, P679, DOI 10.1016/S0959-440X(02)00378-0; Birchmeier C, 1996, ACTA ANAT, V156, P217; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; DEROSIER DJ, 1980, NATURE, V287, P291, DOI 10.1038/287291a0; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; GEIGER B, 1990, CELL DIFFER DEV, V32, P343, DOI 10.1016/0922-3371(90)90049-3; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hatsell S, 2001, NAT CELL BIOL, V3, pE270, DOI 10.1038/ncb1201-e270; Huber O, 1999, J CELL SCI, V112, P4415; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; LELOUP R, 1979, BIOL CELLULAIRE, V34, P137; McDonald K, 1999, METH MOL B, V117, P77; McEwen BF, 2001, J HISTOCHEM CYTOCHEM, V49, P553, DOI 10.1177/002215540104900502; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, MECH DEVELOP, V33, P49, DOI 10.1016/0925-4773(90)90134-8; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; ROH JY, 1995, J CELL BIOL, V128, P939, DOI 10.1083/jcb.128.5.939; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHAPIRO L, 1995, P NATL ACAD SCI USA, V92, P6793, DOI 10.1073/pnas.92.15.6793; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Taylor KA, 1999, CELL, V99, P421, DOI 10.1016/S0092-8674(00)81528-7; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WAGNER G, 1995, SCIENCE, V267, P342, DOI 10.1126/science.7824932; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	46	192	195	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					109	113		10.1126/science.1086957	http://dx.doi.org/10.1126/science.1086957			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526082				2022-12-24	WOS:000185678500047
J	Tadokoro, S; Shattil, SJ; Eto, K; Tai, V; Liddington, RC; de Pereda, JM; Ginsberg, MH; Calderwood, DA				Tadokoro, S; Shattil, SJ; Eto, K; Tai, V; Liddington, RC; de Pereda, JM; Ginsberg, MH; Calderwood, DA			Talin binding to integrin beta tails: A final common step in integrin activation	SCIENCE			English	Article							AFFINITY MODULATION; CYTOPLASMIC DOMAIN; ALPHA(IIB)BETA(3); LIGAND; CELLS; IIIA; IIB	Control of integrin affinity for ligands (integrin activation) is essential for normal cell adhesion, migration, and assembly of an extracellular matrix. Integrin activation is usually mediated through the integrin beta subunit cytoplasmic tail and can be regulated by many different biochemical signaling pathways. We report that specific binding of the cytoskeletal protein talin to integrin beta subunit cytoplasmic tails leads to the conformational rearrangements of integrin extracellular domains that increase their affinity. Thus, regulated binding of talin to integrin beta tails is a final common element of cellular signaling cascades that control integrin activation.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Burnham Inst, Program Cell Adhes, La Jolla, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	ginsberg@scripps.edu	de Pereda, Jose M/F-1733-2010; de Pereda, Jose M/AAE-5226-2022; Calderwood, David A/AAC-6954-2019	de Pereda, Jose M/0000-0002-8912-6739; de Pereda, Jose M/0000-0002-8912-6739; Calderwood, David A/0000-0002-0791-4142				Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Eto K, 2002, P NATL ACAD SCI USA, V99, P12819, DOI 10.1073/pnas.202380099; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TAPLEY P, 1989, ONCOGENE, V4, P325; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200	23	945	969	5	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					103	106		10.1126/science.1086652	http://dx.doi.org/10.1126/science.1086652			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526080				2022-12-24	WOS:000185678500045
J	Dueber, JE; Yeh, BJ; Chak, K; Lim, WA				Dueber, JE; Yeh, BJ; Chak, K; Lim, WA			Reprogramming control of an allosteric signaling switch through modular recombination	SCIENCE			English	Article							WASP-FAMILY PROTEINS; ARP2/3 COMPLEX; SH3 DOMAINS; N-WASP; ACTIVATION; BINDING; SYSTEMS; CDC42	Many eukaryotic signaling proteins are composed of simple modular binding domains, yet they can display sophisticated behaviors such as allosteric gating and multi-input signal integration, properties essential for complex cellular circuits. To understand how such behavior can emerge from combinations of simple domains, we engineered variants of the actin regulatory protein N-WASP (neuronal Wiskott-Aldrich syndrome protein) in which the "output" domain of N-WASP was recombined with heterologous autoinhibitory "input" domains. Synthetic switch proteins were created with diverse gating behaviors in response to nonphysiological inputs. Thus, this type of modular framework can facilitate the evolution or engineering of cellular signaling circuits.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biol Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Chem & Chem Biol Grad Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	wlim@itsa.ucsf.edu						Buck M, 2001, BIOCHEMISTRY-US, V40, P14115, DOI 10.1021/bi0157215; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lim WA, 2002, CURR OPIN STRUC BIOL, V12, P61, DOI 10.1016/S0959-440X(02)00290-7; Mayer BJ, 2001, J CELL SCI, V114, P1253; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; Mullins RD, 2000, METHOD ENZYMOL, V325, P214; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Pawson T, 2000, GENE DEV, V14, P1027; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zalevsky J, 2001, CURR BIOL, V11, P1903, DOI 10.1016/S0960-9822(01)00603-0; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8	18	231	240	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1904	1908		10.1126/science.1085945	http://dx.doi.org/10.1126/science.1085945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512628				2022-12-24	WOS:000185536700050
J	Strack, B; Calistri, A; Craig, S; Popova, E; Gottlinger, HG				Strack, B; Calistri, A; Craig, S; Popova, E; Gottlinger, HG			AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding	CELL			English	Article							LATE ASSEMBLY DOMAIN; ROUS-SARCOMA-VIRUS; GAG PROTEIN; MULTIVESICULAR-BODY; SACCHAROMYCES-CEREVISIAE; PARTICLE-PRODUCTION; TERMINAL DOMAIN; ESCRT-I; UBIQUITIN; TSG101	HIV-1 and other retroviruses exit infected cells by budding from the plasma membrane, a process requiring membrane fission. The primary late assembly (L) domain in the p6 region of HIV-1 Gag mediates the detachment of the virion by recruiting host Tsg101, a component of the class E vacuolar protein sorting (Vps) machinery. We now show that HIV Gag p6 contains a second region involved in L domain function that binds AIP1, a homolog of the yeast class E Vps protein Bro1. Further, AIP1 interacts with Tsg101 and homologs of a subunit of the yeast class E Vps protein complex ESCRT-III. AIP1 also binds to the L domain in EIAV p9, and this binding correlates perfectly with L domain function. These observations identify AIP1 as a component of the viral budding machinery, which serves to link a distinct region in the L domain of HIV-1 p6 and EIAV p9 to ESCRT-III.	Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Gottlinger, HG (corresponding author), Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA.			Calistri, Arianna/0000-0002-6881-7936; Gottlinger, Heinrich/0000-0003-4124-5824; Popova, Elena/0000-0001-8470-8994	NIAID NIH HHS [AI29873] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029873, R01AI029873] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; Accola MA, 1999, J VIROL, V73, P9992, DOI 10.1128/JVI.73.12.9992-9999.1999; Alexander L, 2000, J VIROL, V74, P4361, DOI 10.1128/JVI.74.9.4361-4376.2000; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Borsetti A, 1998, J VIROL, V72, P9313, DOI 10.1128/JVI.72.11.9313-9317.1998; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; Forsberg H, 2001, GENETICS, V158, P973; Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Howard TL, 2001, J CELL SCI, V114, P2395; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Le Blanc I, 2002, J VIROL, V76, P10024, DOI 10.1128/JVI.76.19.10024-10029.2002; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; Puffer BA, 1997, J VIROL, V71, P6541, DOI 10.1128/JVI.71.9.6541-6546.1997; Springael JY, 2002, FEBS LETT, V517, P103, DOI 10.1016/S0014-5793(02)02586-3; Strack B, 2002, J VIROL, V76, P5472, DOI 10.1128/JVI.76.11.5472-5479.2002; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Vincent O, 2003, MOL CELL BIOL, V23, P1647, DOI 10.1128/MCB.23.5.1647-1655.2003; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vogt VM, 2000, P NATL ACAD SCI USA, V97, P12945, DOI 10.1073/pnas.97.24.12945; WILLS JW, 1994, J VIROL, V68, P6605, DOI 10.1128/JVI.68.10.6605-6618.1994; Xiang Y, 1996, J VIROL, V70, P5695, DOI 10.1128/JVI.70.8.5695-5700.1996; Yasuda J, 1998, J VIROL, V72, P4095, DOI 10.1128/JVI.72.5.4095-4103.1998; Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700; Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000	40	634	650	2	17	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 19	2003	114	6					689	699		10.1016/S0092-8674(03)00653-6	http://dx.doi.org/10.1016/S0092-8674(03)00653-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505569	Bronze			2022-12-24	WOS:000185464000007
J	Kaufman, AJ; Xiao, SH				Kaufman, AJ; Xiao, SH			High CO2 levels in the Proterozoic atmosphere estimated from analyses of individual microfossils	NATURE			English	Article							CARBON ISOTOPIC COMPOSITION; GROWTH-RATE	Solar luminosity on the early Earth was significantly lower than today. Therefore, solar luminosity models suggest that, in the atmosphere of the early Earth, the concentration of greenhouse gases such as carbon dioxide and methane must have been much higher(1,2). However, empirical estimates of Proterozoic levels of atmospheric carbon dioxide concentrations have not hitherto been available. Here we present ion microprobe analyses of the carbon isotopes in individual organic-walled microfossils extracted from a Proterozoic (similar to1.4-gigayear-old) shale in North China. Calculated magnitudes of the carbon isotope fractionation in these large, morphologically complex microfossils suggest elevated levels of carbon dioxide in the ancient atmosphere-between 10 and 200 times the present atmospheric level. Our results indicate that carbon dioxide was an important greenhouse gas during periods of lower solar luminosity, probably dominating over methane after the atmosphere and hydrosphere became pervasively oxygenated between 2 and 2.2 gigayears ago.	Univ Maryland, Dept Geol, College Pk, MD 20742 USA; Tulane Univ, Dept Earth & Environm Sci, New Orleans, LA 70118 USA	University System of Maryland; University of Maryland College Park; Tulane University	Kaufman, AJ (corresponding author), Univ Maryland, Dept Geol, College Pk, MD 20742 USA.	kaufman@geol.umd.edu; xiao@vt.edu	Xiao, Shuhai/A-2190-2009	Xiao, Shuhai/0000-0003-4655-2663				Bidigare RR, 1999, GLOBAL BIOGEOCHEM CY, V13, P251, DOI 10.1029/1998GB900011; Brasier MD, 1998, GEOLOGY, V26, P555, DOI 10.1130/0091-7613(1998)026<0555:ABYOES>2.3.CO;2; Cristy SS, 2000, PRACT SPECTROSC SERI, V23, P159; Farquhar J, 1999, EARTH PLANET SC LETT, V171, P607, DOI 10.1016/S0012-821X(99)00177-6; GROTZINGER JP, 1993, J GEOL, V101, P235, DOI 10.1086/648218; Habicht KS, 2002, SCIENCE, V298, P2372, DOI 10.1126/science.1078265; Hayes JM, 1999, CHEM GEOL, V161, P103, DOI 10.1016/S0009-2541(99)00083-2; Holland H. D., 1994, EARLY LIFE EARTH, V84, P237; House CH, 2000, GEOLOGY, V28, P707, DOI 10.1130/0091-7613(2000)28<707:CICOIP>2.0.CO;2; Javaux EJ, 2001, NATURE, V412, P66, DOI 10.1038/35083562; Karhu JA, 1996, GEOLOGY, V24, P867, DOI 10.1130/0091-7613(1996)024<0867:CIATRO>2.3.CO;2; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; KNOLL AH, 1984, J PALEONTOL, V58, P131; Laws EA, 1997, LIMNOL OCEANOGR, V42, P1552, DOI 10.4319/lo.1997.42.7.1552; LAWS EA, 1995, GEOCHIM COSMOCHIM AC, V59, P1131, DOI 10.1016/0016-7037(95)00030-4; Pavlov AA, 2003, GEOLOGY, V31, P87, DOI 10.1130/0091-7613(2003)031<0087:MRPA>2.0.CO;2; Popp BN, 1998, GEOCHIM COSMOCHIM AC, V62, P69, DOI 10.1016/S0016-7037(97)00333-5; RYE R, 1995, NATURE, V378, P603, DOI 10.1038/378603a0; Schulz HN, 1999, SCIENCE, V284, P493, DOI 10.1126/science.284.5413.493; SHIVELY JM, 1991, VARIATIONS AUTOTROPH, P1; Ueno Y, 2001, INT GEOL REV, V43, P196, DOI 10.1080/00206810109465008; Xiao SH, 1997, PRECAMBRIAN RES, V84, P197, DOI 10.1016/S0301-9268(97)00029-6	22	124	137	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2003	425	6955					279	282		10.1038/nature01902	http://dx.doi.org/10.1038/nature01902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679912				2022-12-24	WOS:000185370900040
J	Sheppard, CRC				Sheppard, CRC			Predicted recurrences of mass coral mortality in the Indian Ocean	NATURE			English	Article							REEFS; RECOVERY; FUTURE; EVENT	In 1998, more than 90% of shallow corals were killed on most Indian Ocean reefs(1). High sea surface temperature (SST) was a primary cause(2,3), acting directly or by interacting with other factors(3-7). Mean SSTs have been forecast to rise above the 1998 values in a few decades(2,3); however, forecast SSTs rarely flow seamlessly from historical data, or may show erroneous seasonal oscillations, precluding an accurate prediction of when lethal SSTs will recur. Differential acclimation by corals in different places complicates this further(3,7,8). Here I scale forecast SSTs at 33 Indian Ocean sites where most shallow corals died in 1998 (ref. 1) to identify geographical patterns in the timing of probable repeat occurrences. Reefs located 10-15degrees south will be affected every 5 years by 2010-2025. North and south from this, dates recede in a pattern not directly related to present SSTs; paradoxically, some of the warmest sites may be affected last. Temperatures lethal to corals vary in this region by 6degreesC, and acclimation of a modest 2degreesC by corals could prolong their survival by nearly 100 years.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Sheppard, CRC (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.			sheppard, charles/0000-0002-2579-5124				CESAR HSJ, 2000, EC CORAL REEFS, P244; Cubasch U., 2001, PROJECTIONS FUTURE C, P525; Douglas AE, 2003, MAR POLLUT BULL, V46, P385, DOI 10.1016/S0025-326X(03)00037-7; Gates RD, 1999, AM ZOOL, V39, P30; Harrison P.L., 1990, CORAL REEFS, V25, P133; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; LINDEN O, 2002, CORAL REEF DEGRADATI, P284; McAvaney BJ, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P471; McClanahan TR, 2000, MAR POLLUT BULL, V40, P587, DOI 10.1016/S0025-326X(00)00064-3; Nakamura T, 2001, MAR ECOL PROG SER, V212, P301, DOI 10.3354/meps212301; Pittock AB, 1999, AM ZOOL, V39, P10; RAYNER NA, IN PRESS J GEOPHYS R; Riegl B, 2002, MAR BIOL, V140, P29, DOI 10.1007/s002270100676; Sheppard C, 2002, MAR POLLUT BULL, V44, P303, DOI 10.1016/S0025-326X(02)00059-0; Sheppard C, 2001, MAR POLLUT BULL, V42, P1199, DOI 10.1016/S0025-326X(01)00238-7; Sheppard Charles, 2002, Aquatic Ecosystem Health & Management, V5, P395, DOI 10.1080/14634980290002020; SHEPPARD CRC, 1988, J NAT HIST, V22, P263, DOI 10.1080/00222938800770201; Sheppard CRC, 2002, AMBIO, V31, P40, DOI 10.1639/0044-7447(2002)031[0040:EVROCR]2.0.CO;2; SHEPPARD CRC, 1991, FAUNA SAUDI ARABIA, V12, P7; Spencer T, 2000, MAR POLLUT BULL, V40, P569, DOI 10.1016/S0025-326X(00)00026-6; Turner J., 2000, CORAL REEF DEGRADATI, P94; Veron J. E., 2000, CORALS WORLD, V1-3; Wilkinson C, 1999, AMBIO, V28, P188; WILKINSON C, 2000, SEAS MILLENNIUM ENV, V3, P43	24	272	287	6	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					294	297		10.1038/nature01987	http://dx.doi.org/10.1038/nature01987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679917				2022-12-24	WOS:000185370900045
J	Buchner, DA; Trudeau, M; Meisler, MH				Buchner, DA; Trudeau, M; Meisler, MH			SCNM1, a putative RNA splicing factor that modifies disease severity in mice	SCIENCE			English	Article							SODIUM-CHANNEL SCN8A; MOUSE; MUTATION; GENES; IDENTIFICATION; NA(V)1.6; PROTEINS; ALLELES; ABSENCE; SNRNP	The severity of many inherited disorders is influenced by genetic background. We describe a modifier interaction in C57BL/6J mice that converts a chronic movement disorder into a lethal neurological disease. The primary mutation (med(J)) changes a splice donor site of the sodium channel gene Scn8a (Na(v) 1.6). The modifier mutation is characteristic of strain C57BL/6J and introduces a nonsense codon into sodium channel modifier 1 (SCNM1), a zinc finger protein and a putative splice factor. An internally deleted SCNM1 protein is also predicted as a result of exon skipping associated with disruption of a consensus exonic splicing enhancer. The effect of the modifier mutation is to reduce the abundance of correctly spliced sodium channel transcripts below the threshold for survival. Our finding that genetic variation in a putative RNA splicing factor influences disease susceptibility in mice raises the possibility that a similar mechanism modifies the severity of human inherited disorders.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Meisler, MH (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.	meislerm@umich.edu		Buchner, David/0000-0003-3920-4871	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024872, T32GM007544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000011] Funding Source: NIH RePORTER; NHGRI NIH HHS [T32 HG00040] Funding Source: Medline; NIDCD NIH HHS [T32 DC00011] Funding Source: Medline; NIGMS NIH HHS [GM24872, T32 GM07544] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1931, INBORN FACTORS DIS E; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; BUCHNER DA, IN PRESS GENOMICS; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; Caldwell JH, 2000, P NATL ACAD SCI USA, V97, P5616, DOI 10.1073/pnas.090034797; Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Clark TA, 2002, SCIENCE, V296, P907, DOI 10.1126/science.1069415; Cryns K, 2002, GENOME RES, V12, P613, DOI 10.1101/gr.218402; Du HS, 2002, NATURE, V419, P86, DOI 10.1038/nature00947; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; Haywood MEK, 2000, ARTHRITIS RHEUM, V43, P349, DOI 10.1002/1529-0131(200002)43:2<349::AID-ANR14>3.0.CO;2-M; Kearney JA, 2002, HUM MOL GENET, V11, P2765, DOI 10.1093/hmg/11.22.2765; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Meisler MH, 2001, NEUROSCIENTIST, V7, P136, DOI 10.1177/107385840100700208; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; Nadeau JH, 2003, CURR OPIN GENET DEV, V13, P290, DOI 10.1016/S0959-437X(03)00061-3; Nesic D, 2001, MOL CELL BIOL, V21, P6406, DOI 10.1128/MCB.21.19.6406-6417.2001; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Slavotinek A, 2003, HUM MOL GENET, V12, pR45, DOI 10.1093/hmg/ddg099; Sprunger LK, 1999, HUM MOL GENET, V8, P471, DOI 10.1093/hmg/8.3.471; Stoilov P, 2002, DNA CELL BIOL, V21, P803, DOI 10.1089/104454902320908450; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tarantino LM, 1998, ALCOHOL CLIN EXP RES, V22, P1099	29	95	100	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					967	969		10.1126/science.1086187	http://dx.doi.org/10.1126/science.1086187			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920299				2022-12-24	WOS:000184755900040
J	Brennan, M; Penn, MS; Van Lente, F; Nambi, V; Shishehbor, MH; Aviles, RJ; Goormastic, M; Pepoy, ML; McErlean, ES; Topol, EJ; Nissen, SE; Hazen, SL				Brennan, M; Penn, MS; Van Lente, F; Nambi, V; Shishehbor, MH; Aviles, RJ; Goormastic, M; Pepoy, ML; McErlean, ES; Topol, EJ; Nissen, SE; Hazen, SL			Prognostic value of myeloperoxidase in patients with chest pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE CORONARY SYNDROMES; UNSTABLE ANGINA-PECTORIS; C-REACTIVE PROTEIN; TROPONIN-I; INFLAMMATION; ATHEROSCLEROSIS; NEUTROPHIL; INHIBITOR; LESIONS; SERUM	BACKGROUND: Inflammation is linked to adverse outcomes in acute coronary syndromes. Myeloperoxidase, an abundant leukocyte enzyme, is elevated in culprit lesions that have fissured or ruptured in patients with sudden death from cardiac causes. Numerous lines of evidence suggest mechanistic links between myeloperoxidase and both inflammation and cardiovascular disease. METHODS: We assessed the value of plasma levels of myeloperoxidase as a predictor of the risk of cardiovascular events in 604 sequential patients presenting to the emergency department with chest pain. RESULTS: Initial plasma myeloperoxidase levels predicted the risk of myocardial infarction, even in patients who are negative for troponin T (<0.1 ng per milliliter) at base line (P<0.001). Myeloperoxidase levels at presentation also predicted the risk of major adverse cardiac events (myocardial infarction, the need for revascularization, or death) within 30 days and 6 months after presentation (P<0.001). In patients without evidence of myocardial necrosis (defined as those who were negative for troponin T), the base-line myeloperoxidase levels independently predicted the risk of major adverse coronary events at 30 days (unadjusted 2nd, 3rd, and 4th quartile odds ratios, 2.2 [95 percent confidence interval, 1.1 to 4.6], 4.2 [95 percent confidence interval, 2.1 to 8.4], and 4.1 [95 percent confidence interval, 2.0 to 8.4], respectively) and at 6 months. CONCLUSIONS: A single initial measurement of plasma myeloperoxidase independently predicts the early risk of myocardial infarction, as well as the risk of major adverse cardiac events in the ensuing 30-day and 6-month periods. Myeloperoxidase levels, in contrast to troponin T, creatine kinase MB isoform, and C-reactive protein levels, identified patients at risk for cardiac events in the absence of myocardial necrosis, highlighting its potential usefulness for risk stratification among patients who present with chest pain.	Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Clin Pathol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Internal Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Hazen, SL (corresponding author), Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, 9500 Euclid Ave,NC10, Cleveland, OH 44195 USA.	hazens@ccf.org	Hazen, Stanley L/ABD-5845-2021	Topol, Eric/0000-0002-1478-4729	NATIONAL CANCER INSTITUTE [F32CA096348] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061878, R01HL062526, R01HL070621] Funding Source: NIH RePORTER; NCI NIH HHS [CA96348] Funding Source: Medline; NCRR NIH HHS [M01 RR018390] Funding Source: Medline; NHLBI NIH HHS [HL61878, HL62526, HL70621] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Agner K., 1972, STRUCTURE FUNCTION O, P329; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Biasucci L M, 2001, Ital Heart J, V2, P164; Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; deServi S, 1996, AM J CARDIOL, V78, P564, DOI 10.1016/S0002-9149(96)00367-0; DINERMAN JL, 1990, J AM COLL CARDIOL, V15, P1559, DOI 10.1016/0735-1097(90)92826-N; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; McErlean ES, 2000, AM J CARDIOL, V85, P421, DOI 10.1016/S0002-9149(99)00766-3; Naruko T, 2002, CIRCULATION, V106, P2894, DOI 10.1161/01.CIR.0000042674.89762.20; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Sabatine MS, 2002, CIRCULATION, V105, P1760, DOI 10.1161/01.CIR.0000015464.18023.0A; Schmitt D, 1999, BIOCHEMISTRY-US, V38, P16904, DOI 10.1021/bi991623w; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Shabani F, 1998, FREE RADICAL RES, V28, P115, DOI 10.3109/10715769809065797; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	25	798	882	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1595	1604		10.1056/NEJMoa035003	http://dx.doi.org/10.1056/NEJMoa035003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573731	Bronze			2022-12-24	WOS:000186088400004
J	Strom, BL; Schinnar, R; Apter, AJ; Margolis, DJ; Lautenbach, E; Hennessy, S; Bilker, WB; Pettitt, D				Strom, BL; Schinnar, R; Apter, AJ; Margolis, DJ; Lautenbach, E; Hennessy, S; Bilker, WB; Pettitt, D			Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK FACTOR; SELECTION; DATABASE; ALLERGY; SENSITIVITY; PREVALENCE; VALIDATION; CELECOXIB; PROFILE; ATOPY	BACKGROUND: The safety of sulfonamide nonantibiotics is unclear in patients with prior allergic reactions to sulfonamide antibiotics. METHODS: We conducted a retrospective cohort study using the General Practice Research Database in the United Kingdom, examining the risk of allergic reactions within 30 days after the receipt of a sulfonamide nonantibiotic. Patients with evidence of prior hypersensitivity after the receipt of a sulfonamide antibiotic were compared with those without such evidence. Similar analyses were also performed with the use of penicillins instead of sulfonamides, to determine whether any risk was specific to sulfonamide cross-reactivity. RESULTS: Of 969 patients with an allergic reaction after a sulfonamide antibiotic, 96 (9.9 percent) had an allergic reaction after subsequently receiving a sulfonamide nonantibiotic. Of 19,257 who had no allergic reaction after a sulfonamide antibiotic, 315 (1.6 percent) had an allergic reaction after receiving a sulfonamide nonantibiotic (adjusted odds ratio, 2.8; 95 percent confidence interval, 2.1 to 3.7). However, the risk of allergic reactions was even greater after the receipt of a penicillin among patients with a prior hypersensitivity reaction to a sulfonamide antibiotic, as compared with patients with no such history (adjusted odds ratio, 3.9; 95 percent confidence interval, 3.5 to 4.3). Furthermore, among those with a prior hypersensitivity reaction after the receipt of a sulfonamide antibiotic, the risk of an allergic reaction after the subsequent receipt of a sulfonamide nonantibiotic was lower than the risk of an allergic reaction after the subsequent receipt of a penicillin (adjusted odds ratio, 0.7; 95 percent confidence interval, 0.5 to 0.9). Finally, the risk of an allergic reaction after the receipt of a sulfonamide nonantibiotic was lower among patients with a history of hypersensitivity to sulfonamide antibiotics than among patients with a history of hypersensitivity to penicillins (adjusted odds ratio, 0.6; 95 percent confidence interval, 0.5 to 0.8). CONCLUSIONS: There is an association between hypersensitivity after the receipt of sulfonamide antibiotics and a subsequent allergic reaction after the receipt of a sulfonamide nonantibiotic, but this association appears to be due to a predisposition to allergic reactions rather than to cross-reactivity with sulfonamide-based drugs.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA; Pfizer, Dept Outcomes Res, New York, NY USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pfizer	Strom, BL (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, 824 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.		Bilker, Warren/AAS-3515-2021					ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358; BRETZA JA, 1982, WISC MED J, V81, P21; Cribb AE, 1996, ADVERSE DRUG REACT T, V15, P9; Demoly P, 2001, CURR OPIN ALLERGY CL, V1, P305, DOI 10.1097/01.all.0000011031.16814.e0; DITTO AM, 2002, PATTERSONS ALLERGIC, P295; ENRIGHT T, 1989, ANN ALLERGY, V62, P302; Garcia Rodriguez L A, 2000, PHARMACOEPIDEM DR S, P375; GREENBERGER PA, 2002, PATTERSONS ALLERGIC, P335; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; HANSBROUGH JR, 1987, J ALLERGY CLIN IMMUN, V80, P538, DOI 10.1016/0091-6749(87)90004-2; HOIGNE R, 1993, MONOGR ALLERGY, V31, P147; Holtzer CD, 1998, PHARMACOTHERAPY, V18, P831; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; Hosoya T, 2000, Radiat Med, V18, P39; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Knowles S, 2001, DRUG SAFETY, V24, P239, DOI 10.2165/00002018-200124040-00001; LANDOR M, 1993, ANN ALLERGY, V70, P196; Lawrenson R, 2000, BRIT J CLIN PHARMACO, V49, P591, DOI 10.1046/j.1365-2125.2000.00199.x; Lewis JD, 2002, PHARMACOEPIDEM DR S, V11, P211, DOI 10.1002/pds.698; LIEBERMAN P, 1997, ALLERGIC DIS DIAGNOS, P289; LIS Y, 1995, J CLIN EPIDEMIOL, V48, P431, DOI 10.1016/0895-4356(94)00137-F; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Margolis DJ, 2002, J AM ACAD DERMATOL, V46, P381, DOI 10.1067/mjd.2002.121739; Margolis DJ, 2002, ANN EPIDEMIOL, V12, P321, DOI 10.1016/S1047-2797(01)00255-1; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Park J, 2000, Can J Clin Pharmacol, V7, P38; Pastorello EA, 1998, ALLERGY, V53, P880, DOI 10.1111/j.1398-9995.1998.tb03995.x; Patterson R, 1999, CLIN THER, V21, P2065, DOI 10.1016/S0149-2918(00)87238-0; ROBINS JM, 1986, AM J EPIDEMIOL, V123, P392, DOI 10.1093/oxfordjournals.aje.a114254; RYTEL MW, 1963, JAMA-J AM MED ASSOC, V186, P894; Sanchez-Borges N, 2000, ANN ALLERG ASTHMA IM, V84, P101, DOI 10.1016/S1081-1206(10)62748-2; *SAS I, 2000, SAS VERS 8 0; SMITH JW, 1966, NEW ENGL J MED, V274, P998, DOI 10.1056/NEJM196605052741804	35	212	216	0	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1628	U9		10.1056/NEJMoa022963	http://dx.doi.org/10.1056/NEJMoa022963			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573734				2022-12-24	WOS:000186088400007
J	Bogan, JS; Hendon, N; McKee, AE; Tsao, TS; Lodish, HF				Bogan, JS; Hendon, N; McKee, AE; Tsao, TS; Lodish, HF			Functional cloning of TUG as a regulator of GLUT4 glucose transporter trafficking	NATURE			English	Article							3T3-L1 ADIPOCYTES; INSULIN; PROTEINS; CELLS; COMPARTMENTS; INTERACTS; MEMBRANE; DOMAIN; GENE; P47	Insulin stimulates glucose uptake in fat and muscle by mobilizing the GLUT4 glucose transporter. GLUT4 is sequestered intracellularly in the absence of insulin, and is redistributed to the plasma membrane within minutes of insulin stimulation(1,2). But the trafficking mechanisms that control GLUT4 sequestration have remained elusive. Here we describe a functional screen to identify proteins that modulate GLUT4 distribution, and identify TUG as a putative tether, containing a UBX domain, for GLUT4. In truncated form, TUG acts in a dominant-negative manner to inhibit insulin-stimulated GLUT4 redistribution in Chinese hamster ovary cells and 3T3-L1 adipocytes. Full-length TUG forms a complex specifically with GLUT4; in 3T3-L1 adipocytes, this complex is present in unstimulated cells and is largely disassembled by insulin. Endogenous TUG is localized with the insulin-mobilizable pool of GLUT4 in unstimulated 3T3-L1 adipocytes, and is not mobilized to the plasma membrane by insulin. Distinct regions of TUG are required to bind GLUT4 and to retain GLUT4 intracellularly in transfected, non-adipose cells. Our data suggest that TUG traps endocytosed GLUT4 and tethers it intracellularly, and that insulin mobilizes this pool of retained GLUT4 by releasing this tether.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Bogan, JS (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,Box 208020, New Haven, CT 06520 USA.		Bogan, Jonathan S/A-1575-2010	Bogan, Jonathan S/0000-0001-6463-8466; Tsao, Tsu-Shuen/0000-0002-1041-9687				Becker K, 1997, FEBS LETT, V412, P102, DOI 10.1016/S0014-5793(97)00758-8; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074; Lalioti VS, 2002, J BIOL CHEM, V277, P19783, DOI 10.1074/jbc.M110294200; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Perera HKI, 2003, MOL BIOL CELL, V14, P2946, DOI 10.1091/mbc.E02-11-0722; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Wright DA, 1996, J BIOL CHEM, V271, P31037, DOI 10.1074/jbc.271.49.31037; Yuan XM, 2001, J MOL BIOL, V311, P255, DOI 10.1006/jmbi.2001.4864	22	143	148	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					727	733		10.1038/nature01989	http://dx.doi.org/10.1038/nature01989			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562105				2022-12-24	WOS:000185924500044
J	Pui, CH; Sandlund, JT; Pei, DQ; Rivera, GK; Howard, SC; Ribeiro, RC; Rubnitz, JE; Razzouk, BI; Hudson, MM; Cheng, C; Raimondi, SC; Behm, FG; Downing, JR; Relling, MV; Evans, WE				Pui, CH; Sandlund, JT; Pei, DQ; Rivera, GK; Howard, SC; Ribeiro, RC; Rubnitz, JE; Razzouk, BI; Hudson, MM; Cheng, C; Raimondi, SC; Behm, FG; Downing, JR; Relling, MV; Evans, WE			Results of therapy for acute lymphoblastic leukemia in black and white children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CENTRAL-NERVOUS-SYSTEM; CANCER SURVIVAL; RACIAL-DIFFERENCES; CHILDHOOD-CANCER; LUMBAR PUNCTURE; TRIALS; RISK; INTENSIFICATION; DIAGNOSIS	Context Treatment results for acute lymphoblastic leukemia (ALL) clearly have improved over the past decade, but black children have not fared as well as white children in large national trials. Objective To compare the clinical outcomes of therapy for black and white children with ALL treated at a single institution. Design, Setting, and Patients A retrospective analysis of 412 children and adolescents (68 black, 338 white, and 6 other race) with newly diagnosed ALL who were treated consecutively at a pediatric cancer center in Memphis, Tenn. Patients were enrolled from December 1991 to July 1998 in successive Total Therapy studies regardless of race, ethnicity, or ability to pay and received risk-directed therapy according to stringent criteria. Interventions All patients received the same intensive, remission-induction therapy followed by 120 weeks of risk-assigned postremission therapy that included reinduction treatment, pulses of high-dose methotrexate, and early intensification of intrathecal chemotherapy. Main Outcome Measures Event-free and overall survival rates for black and white children were estimated by the method of Kaplan and Meier and compared with the Mantel-Haenszel test and by Cox proportional hazards regression analysis, adjusting for known prognostic factors. Results The 68 black children were significantly more likely than the 338 white children to have higher-risk prognostic features, including an initial leukocyte count greater than 100 X 10(3)/muL, a T-cell immunophenotype, and the t(1;19) chromosomal translocation with E2A-PBX1 fusion, and were less likely to have hyperdiploid blast cells, a favorable prognostic factor in childhood ALL. However, the clinical outcomes for these 2 cohorts were not significantly different: 5-year event-free and overall survival rates were 80.7% (95% confidence interval [CI], 70.3%-91.1%) and 86.2% (95% Cl, 77.2%-95.2%) for black children vs 79.4% (95% CI, 74.7%-84.1%) and 85.0% (95% Cl, 80.9%-89.1%) for white children. Ten-year results also were comparable, but the Cls were wide because of the small numbers of patients who had been followed up for 10 years or more. The lack of a racial effect on the long-term outcome of therapy was still apparent in a multivariate Cox regression analysis, adjusting for sex, age, presenting leukocyte count, leukemic cell DNA index, immunophenotype, and central nervous system status. Conclusion With equal access to effective antileukemic therapy, black and white children with ALL can expect the same high rate of cure.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Pui, CH (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	ching-hon.pui@stjude.org	Howard, Scott C/K-3401-2013; Pui, Ching-Hon/N-8076-2018; Relling, Mary/N-5032-2018; Evans, William E./C-2069-2012; Downing, James R./N-8102-2018; Hudson, Melissa M/N-4441-2018; Cheng, Cheng/N-8075-2018; Raimondi, Susana C/N-8166-2018	Howard, Scott C/0000-0003-2244-1686; Pui, Ching-Hon/0000-0003-0303-5658; Evans, William E./0000-0002-9333-5322; Hudson, Melissa M/0000-0001-6984-2407; Razzouk, Bassem/0000-0003-0536-6135	NATIONAL CANCER INSTITUTE [P30CA021765, R37CA036401, R01CA051001, R01CA078224, R29CA051001, R01CA036401] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51001, CA-36401, CA-21765, CA-78224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agresti A., 1996, INTRO CATEGORICAL DA; Bach PB, 2002, JAMA-J AM MED ASSOC, V287, P2106, DOI 10.1001/jama.287.16.2106; Bhatia S, 2002, BLOOD, V100, P1957, DOI 10.1182/blood-2002-02-0395; Clarke M, 2003, J CLIN ONCOL, V21, P1798, DOI 10.1200/JCO.2003.08.047; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; FALLETTA JM, 1984, PROG CANCER RES THER, V27, P191; Gajjar A, 2000, BLOOD, V96, P3381; Gaynon PS, 2000, LEUKEMIA, V14, P2223, DOI 10.1038/sj.leu.2401939; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Gustafsson G, 2000, LEUKEMIA, V14, P2267, DOI 10.1038/sj.leu.2401961; HOWARD J, 1992, CANCER, V69, P2349, DOI 10.1002/1097-0142(19920501)69:9&lt;2349::AID-CNCR2820690925&gt;3.0.CO;2-7; Howard SC, 2002, JAMA-J AM MED ASSOC, V288, P2001, DOI 10.1001/jama.288.16.2001; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P169; KALWINSKY DK, 1985, LEUKEMIA RES, V9, P817, DOI 10.1016/0145-2126(85)90300-5; MAHMOUD HH, 1993, NEW ENGL J MED, V329, P314, DOI 10.1056/NEJM199307293290504; Maloney KW, 2000, LEUKEMIA, V14, P2276, DOI 10.1038/sj.leu.2401965; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Matherly LH, 1997, BLOOD, V90, P578, DOI 10.1182/blood.V90.2.578.578_578_589; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; PINKEL D, 1993, LEUKEMIA, V7, pS146; Pollock BH, 2000, J CLIN ONCOL, V18, P813, DOI 10.1200/JCO.2000.18.4.813; Pui CH, 2000, LEUKEMIA, V14, P2286, DOI 10.1038/sj.leu.2401938; PUI CH, 1988, J CLIN ONCOL, V6, P56, DOI 10.1200/JCO.1988.6.1.56; PUI CH, 1995, JAMA-J AM MED ASSOC, V273, P633, DOI 10.1001/jama.273.8.633; Pui CH, 2003, J CLIN ONCOL, V21, P179, DOI 10.1200/JCO.2003.10.032; PUI CH, 1992, LEUKEMIA, V6, P150; PUI CH, 1986, BLOOD, V67, P1688; Pui CH, 2003, NEW ENGL J MED, V349, P640, DOI 10.1056/NEJMoa035091; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; Pui CH, 2000, BRIT J HAEMATOL, V109, P13, DOI 10.1046/j.1365-2141.2000.01843.x; Pui CH, 1998, BLOOD, V92, P411, DOI 10.1182/blood.V92.2.411.414k34_411_415; PUI CH, IN PRESS N ENGL J ME; RAGLAND KE, 1991, AM J EPIDEMIOL, V133, P672; REAMAN GH, 1984, PROG CANCER RES THER, V27, P163; Relling MV, 2003, BLOOD, V101, P3862, DOI 10.1182/blood-2002-08-2405; Ries L. A. G., 1999, SEER CANC STAT REV 1; RIES LA, 1999, PUBLICATION NIH; SATHER H, 1984, PROG CANCER RES THER, V27, P179; Schrappe M, 2000, LEUKEMIA, V14, P2205, DOI 10.1038/sj.leu.2401973; WALTERS TR, 1972, CANCER, V29, P210, DOI 10.1002/1097-0142(197201)29:1<210::AID-CNCR2820290131>3.0.CO;2-U; Wilson JF, 2001, NAT GENET, V29, P265, DOI 10.1038/ng761	43	130	134	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2001	2007		10.1001/jama.290.15.2001	http://dx.doi.org/10.1001/jama.290.15.2001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CX	14559953				2022-12-24	WOS:000185924200023
J	McIntire, JJ; Umetsu, SE; Macaubas, C; Hoyte, EG; Cinnioglu, C; Cavalli-Sforza, LL; Barsh, GS; Hallmayer, JF; Underhill, PA; Risch, NJ; Freeman, GJ; DeKruyff, RH; Umetsu, DT				McIntire, JJ; Umetsu, SE; Macaubas, C; Hoyte, EG; Cinnioglu, C; Cavalli-Sforza, LL; Barsh, GS; Hallmayer, JF; Underhill, PA; Risch, NJ; Freeman, GJ; DeKruyff, RH; Umetsu, DT			Hepatitis A virus link to atopic disease	NATURE			English	Editorial Material							HAY-FEVER; INFECTION; MARKERS		Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Stanford University; Stanford University; Stanford University; Harvard University; Dana-Farber Cancer Institute	McIntire, JJ (corresponding author), Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA.		Jones, Jennifer/C-8691-2015; Freeman, Gordon/AAC-5380-2019	Jones, Jennifer/0000-0002-9488-7719; Freeman, Gordon/0000-0002-7210-5616				Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bower WA, 2000, J INFECT DIS, V182, P12, DOI 10.1086/315701; Feigelstock D, 1998, J VIROL, V72, P6621, DOI 10.1128/JVI.72.8.6621-6628.1998; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Silberstein E, 2003, J VIROL, V77, P8765, DOI 10.1128/JVI.77.16.8765-8774.2003; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259	10	166	185	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					576	576		10.1038/425576a	http://dx.doi.org/10.1038/425576a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534576				2022-12-24	WOS:000185801000026
J	Houde, M; Bertholet, S; Gagnon, E; Brunet, S; Goyette, G; Laplante, A; Princiotta, MF; Thibault, P; Sacks, D; Desjardins, M				Houde, M; Bertholet, S; Gagnon, E; Brunet, S; Goyette, G; Laplante, A; Princiotta, MF; Thibault, P; Sacks, D; Desjardins, M			Phagosomes are competent organelles for antigen cross-presentation	NATURE			English	Article							MHC CLASS-I; CD8(+) T-CELLS; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; COMPLEX; PHAGOCYTOSIS; ACTIVATION; PATHWAY; CYTOSOL; LOCALIZATION	The ability to process microbial antigens and present them at the surface of cells is an important aspect of our innate ability to clear infections. It is generally accepted that antigens in the cytoplasm are loaded in the endoplasmic reticulum and presented at the cell surface on major histocompatibility complex (MHC) class I molecules, whereas peptides present in endo/phagocytic compartments are presented on MHC class II molecules(1,2). Despite the apparent segregation of the class I and class II pathways, antigens from intracellular pathogens including mycobacteria, Escherichia coli, Salmonella typhimurium, Brucella abortus and Leishmania, have been shown to elicit an MHCclass-I-dependent CD8(+) T-cell response(3-7), a process referred to as cross-presentation(2). The cellular mechanisms allowing the cross-presentation pathway are poorly understood. Here we show that phagosomes display the elements and properties needed to be self-sufficient for the cross-presentation of exogenous antigens, a newly ascribed function linked to phagocytosis mediated by the endoplasmic reticulum.	Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3C 3J7, Canada; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Caprion Pharmaceut Inc, Montreal, PQ H45 2C8, Canada	Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Desjardins, M (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, CP6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.			Thibault, Pierre/0000-0001-5993-0331; Goyette, Guillaume/0000-0003-3277-568X; Desjardins, Michel/0000-0002-5684-5980	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000658, Z01AI000658, Z01AI000494, ZIAAI000494] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belkaid Y, 2002, J IMMUNOL, V168, P3992, DOI 10.4049/jimmunol.168.8.3992; Brooks P, 2000, BIOCHEM J, V352, P611, DOI 10.1042/0264-6021:3520611; Canaday DH, 1999, J IMMUNOL, V162, P372; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; Heath WR, 2001, NAT REV IMMUNOL, V1, P126, DOI 10.1038/35100512; KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Lennon-Dumenil AM, 2002, J EXP MED, V196, P529, DOI 10.1084/jem.20020327; MacAry PA, 2001, P NATL ACAD SCI USA, V98, P3982, DOI 10.1073/pnas.071477498; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Muno D, 2000, FEBS LETT, V478, P178, DOI 10.1016/S0014-5793(00)01849-4; OLIVEIRA SC, 1995, EUR J IMMUNOL, V25, P2551, DOI 10.1002/eji.1830250922; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Ramachandra L, 1999, J IMMUNOL, V162, P3263; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; Tirosh B, 2003, J BIOL CHEM, V278, P6664, DOI 10.1074/jbc.M210158200; Turner J, 1996, IMMUNOLOGY, V87, P339, DOI 10.1046/j.1365-2567.1996.512590.x; Watts C, 2001, SEMIN IMMUNOL, V13, P373; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	27	564	582	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					402	406		10.1038/nature01912	http://dx.doi.org/10.1038/nature01912			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508490				2022-12-24	WOS:000185502300042
J	Berkley, S				Berkley, S			Thorny issues in the ethics of AIDS vaccine trials	LANCET			English	Editorial Material									IAVI, New York, NY 10013 USA	International AIDS Vaccine Initiative	Berkley, S (corresponding author), IAVI, New York, NY 10013 USA.							*IAVI, 2001, NEW ACC PAR PUBL SEC; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916	2	23	24	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					992	992		10.1016/S0140-6736(03)14371-1	http://dx.doi.org/10.1016/S0140-6736(03)14371-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724LT	14513850				2022-12-24	WOS:000185489600024
J	Chen, EH; Pryce, BA; Tzeng, JA; Gonzalez, GA; Olson, EN				Chen, EH; Pryce, BA; Tzeng, JA; Gonzalez, GA; Olson, EN			Control of myoblast fusion by a guanine nucleotide exchange factor, loner, and its effector ARF6	CELL			English	Article							ADP-RIBOSYLATION FACTOR; DROSOPHILA EMBRYOGENESIS; ACTIN CYTOSKELETON; TRANSCRIPTION FACTOR; MUSCLE DEVELOPMENT; GENETIC-ANALYSIS; ROLLING-PEBBLES; PROTEIN; MEMBRANE; MYOGENESIS	Myoblast fusion is essential for the formation and regeneration of skeletal muscle. In a genetic screen for regulators of muscle development in Drosophila, we discovered a gene encoding a guanine nucleotide exchange factor, called loner, which is required for myoblast fusion. Loner localizes to subcellular sites of fusion and acts downstream of cell surface fusion receptors by recruiting the small GTPase ARF6 and stimulating guanine nucleotide exchange. Accordingly, a dominant-negative ARF6 disrupts myoblast fusion in Drosophila embryos and in mammalian myoblasts in culture, mimicking the fusion defects caused by loss of Loner. Loner and ARF6, which also control the proper membrane localization of another small GTPase, Rac, are key components of a cellular apparatus required for myoblast fusion and muscle development. In muscle cells, this fusigenic mechanism is coupled to fusion receptors; in other fusion-competent cell types it may be triggered by different upstream signals.	Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Biol Mol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.							Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Artero RD, 2001, DEVELOPMENT, V128, P4251; Bate Michael, 1993, P1013; Baylies MK, 2001, CURR OPIN GENET DEV, V11, P431, DOI 10.1016/S0959-437X(00)00214-8; Baylies MK, 1998, CELL, V93, P921, DOI 10.1016/S0092-8674(00)81198-8; Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Bour BA, 2000, GENE DEV, V14, P1498; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen EH, 2001, DEV CELL, V1, P705, DOI 10.1016/S1534-5807(01)00084-3; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Doberstein SK, 1997, J CELL BIOL, V136, P1249, DOI 10.1083/jcb.136.6.1249; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Dworak HA, 2002, BIOESSAYS, V24, P591, DOI 10.1002/bies.10115; Dworak HA, 2001, DEVELOPMENT, V128, P4265; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frasch M, 2000, CELL, V102, P127, DOI 10.1016/S0092-8674(00)00016-7; Frasch M, 1999, CURR OPIN GENET DEV, V9, P522, DOI 10.1016/S0959-437X(99)00014-3; Fuerstenberg S, 1998, DEV BIOL, V201, P66, DOI 10.1006/dbio.1998.8944; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; Hakeda-Suzuki S, 2002, NATURE, V416, P438, DOI 10.1038/416438a; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Keller CA, 1997, DEV BIOL, V181, P197, DOI 10.1006/dbio.1996.8434; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; KNUDSEN KA, 1992, MEMBRANE FUSION, P601; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Menon SD, 2001, DEV CELL, V1, P691, DOI 10.1016/S1534-5807(01)00075-2; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Paululat A, 1999, MECH DEVELOP, V83, P17, DOI 10.1016/S0925-4773(99)00029-5; Radhakrishna H, 1999, J CELL SCI, V112, P855; Rau A, 2001, DEVELOPMENT, V128, P5061; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Ruiz-Gomez M, 2000, CELL, V102, P189, DOI 10.1016/S0092-8674(00)00024-6; RuizGomez M, 1997, DEVELOPMENT, V124, P3407; Rusconi JC, 1998, MECH DEVELOP, V79, P39, DOI 10.1016/S0925-4773(98)00170-1; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Someya A, 2001, P NATL ACAD SCI USA, V98, P2413, DOI 10.1073/pnas.051634798; Strunkelnberg M, 2001, DEVELOPMENT, V128, P4229; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Taylor MV, 2002, CURR BIOL, V12, pR224, DOI 10.1016/S0960-9822(02)00757-1; WAKELAM MJO, 1985, BIOCHEM J, V228, P1	61	128	132	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 19	2003	114	6					751	762		10.1016/S0092-8674(03)00720-7	http://dx.doi.org/10.1016/S0092-8674(03)00720-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505574	Bronze			2022-12-24	WOS:000185464000012
J	Ouzounov, DG; Ahmad, FR; Muller, D; Venkataraman, N; Gallagher, MT; Thomas, MG; Silcox, J; Koch, KW; Gaeta, AL				Ouzounov, DG; Ahmad, FR; Muller, D; Venkataraman, N; Gallagher, MT; Thomas, MG; Silcox, J; Koch, KW; Gaeta, AL			Generation of megawatt optical solitons in hollow-core photonic band-gap fibers	SCIENCE			English	Article							FEMTOSECOND LASER-PULSES; SELF-FREQUENCY SHIFT; ANOMALOUS-DISPERSION; MICROSTRUCTURED FIBERS; CRYSTAL FIBERS; AIR; GUIDANCE; NM	The measured dispersion of a low-loss, hollow-core photonic band-gap fiber is anomalous throughout most of the transmission band, and its variation with wavelength is large compared with that of a conventional step-index fiber. For an air-filled fiber, femtosecond self-frequency-shifted fundamental solitons with peak powers greater than 2 megawatts can be supported. For Xe-filled fibers, nonfrequency-shifted temporal solitons with peak powers greater than 5.5 megawatts can be generated, representing an increase in the power that can be propagated in an optical fiber of two orders of magnitude. The results demonstrate a unique capability to deliver high-power pulses in a single spatial mode over distances exceeding 200 meters.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; Corning Inc, Corning, NY 14831 USA	Cornell University; Corning Inc; State University of New York (SUNY) System; SUNY Community College	Gaeta, AL (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.	a.gaeta@cornell.edu	Muller, David/A-7745-2010; Gaeta, Alexander/AAE-2095-2019	Muller, David/0000-0003-4129-0473; 	NCI NIH HHS [R44CA88391-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA088391] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MJ, 1981, INTRO OPTICAL WAVEGU, P245; AGRAWAL GP, 2001, NONLINEAR FIBER OPTI, P120; Allan DC, 2001, NATO SCI SER II-MATH, V563, P305; Atherton BW, 1998, P SOC PHOTO-OPT INS, V3269, P22, DOI 10.1117/12.580605; Benabid F, 2002, SCIENCE, V298, P399, DOI 10.1126/science.1076408; Cregan RF, 1999, SCIENCE, V285, P1537, DOI 10.1126/science.285.5433.1537; DIANOV EM, 1985, JETP LETT+, V41, P294; GORDON JP, 1986, OPT LETT, V11, P662, DOI 10.1364/OL.11.000662; HASEGAWA A, 1973, APPL PHYS LETT, V23, P142, DOI 10.1063/1.1654836; JACKSON JD, 1975, CLASSICAL ELECTRODYN, P343; Knight JC, 2000, IEEE PHOTONIC TECH L, V12, P807, DOI 10.1109/68.853507; Knight JC, 1998, SCIENCE, V282, P1476, DOI 10.1126/science.282.5393.1476; MITSCHKE FM, 1986, OPT LETT, V11, P659, DOI 10.1364/OL.11.000659; MOLLENAUER LF, 1980, PHYS REV LETT, V45, P1095, DOI 10.1103/PhysRevLett.45.1095; Nibbering ETJ, 1997, J OPT SOC AM B, V14, P650, DOI 10.1364/JOSAB.14.000650; Ouzounov D, 2002, OPT COMMUN, V205, P227, DOI 10.1016/S0030-4018(02)01359-7; Ouzounov D, 2001, OPT COMMUN, V192, P219, DOI 10.1016/S0030-4018(01)01185-3; Ouzounov DG, 2002, OPT LETT, V27, P1513, DOI 10.1364/OL.27.001513; Price JHV, 2002, J OPT SOC AM B, V19, P1286, DOI 10.1364/JOSAB.19.001286; Ranka JK, 2000, OPT LETT, V25, P796, DOI 10.1364/OL.25.000796; Ranka JK, 2000, OPT LETT, V25, P25, DOI 10.1364/OL.25.000025; RANKA JK, 1997, OPT LETT, V22, P1934; Smith CM, 2003, NATURE, V424, P657, DOI 10.1038/nature01849; VENKATARAMAN N, 2002, EUR C OPT COMM; Wadsworth WJ, 2000, ELECTRON LETT, V36, P53, DOI 10.1049/el:20000134; Washburn BR, 2001, ELECTRON LETT, V37, P1510, DOI 10.1049/el:20011047	26	416	440	1	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1702	1704		10.1126/science.1088387	http://dx.doi.org/10.1126/science.1088387			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500976				2022-12-24	WOS:000185387700038
J	Miller, MW; Williams, ES				Miller, MW; Williams, ES			Horizontal prion transmission in mule deer	NATURE			English	Editorial Material							CHRONIC WASTING DISEASE; ODOCOILEUS-HEMIONUS; SCRAPIE; SHEEP; EPIDEMIOLOGY		Wildlife Res Ctr, Colorado Div, Ft Collins, CO 80526 USA; Univ Wyoming, Dept Vet Sci, Laramie, WY 82070 USA	University of Wyoming	Miller, MW (corresponding author), Wildlife Res Ctr, Colorado Div, Ft Collins, CO 80526 USA.							HADLOW WJ, 1982, J INFECT DIS, V146, P657, DOI 10.1093/infdis/146.5.657; Hoinville LJ, 1996, REV SCI TECH OIE, V15, P827, DOI 10.20506/rst.15.3.959; Hourrigan J., 1979, Slow transmissible diseases of the nervous system. Volume 1., P331; MCFADYEAN J, 1918, J COMP PATHOL THER, V31, P102; Miller MW, 2000, J WILDLIFE DIS, V36, P676, DOI 10.7589/0090-3558-36.4.676; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Redman CA, 2002, EPIDEMIOL INFECT, V128, P513, DOI 10.1017/S0950268802007008; Sigurdson CJ, 1999, J GEN VIROL, V80, P2757, DOI 10.1099/0022-1317-80-10-2757; Spraker TR, 2002, VET PATHOL, V39, P110, DOI 10.1354/vp.39-1-110; Williams E.S., 1992, Revue Scientifique et Technique Office International des Epizooties, V11, P551; Williams ES, 2002, REV SCI TECH OIE, V21, P305, DOI 10.20506/rst.21.2.1340; Woolhouse MEJ, 1998, P ROY SOC B-BIOL SCI, V265, P1205, DOI 10.1098/rspb.1998.0421	12	221	225	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					35	36		10.1038/425035a	http://dx.doi.org/10.1038/425035a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955129				2022-12-24	WOS:000185089200026
J	Gottfried, JA; O'Doherty, J; Dolan, RJ				Gottfried, JA; O'Doherty, J; Dolan, RJ			Encoding predictive reward value in human amygdala and orbitofrontal cortex	SCIENCE			English	Article							SENSORY-SPECIFIC SATIETY; PREFRONTAL CORTEX; ACTIVATION; LESIONS; REINFORCEMENT; MOTIVATION; RESPONSES; NEURONS; HUNGER; FMRI	Adaptive behavior is optimized in organisms that maintain flexible representations of the value of sensory-predictive cues. To identify central representations of predictive reward value in humans, we used reinforcer devaluation while measuring neural activity with functional magnetic resonance imaging. We presented two arbitrary visual stimuli, both before and after olfactory devaluation, in a paradigm of appetitive conditioning. In amygdala and orbitofrontal cortex, responses evoked by a predictive target stimulus were decreased after devaluation, whereas responses to the nondevalued stimulus were maintained. Thus, differential activity in amygdala and orbitofrontal cortex encodes the current value of reward representations accessible to predictive cues.	Wellcome Dept Imaging Neurosci, Funct Imaging Lab, London WC1N 3BG, England	University of London; University College London	Gottfried, JA (corresponding author), Wellcome Dept Imaging Neurosci, Funct Imaging Lab, 12 Queen Sq, London WC1N 3BG, England.		O'Doherty, John P/F-1204-2013	Dolan, Ray/0000-0001-9356-761X				Balleine BW, 2000, J NEUROSCI, V20, P8954; Baxter MG, 2000, J NEUROSCI, V20, P4311; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Buchel C, 1998, NEURON, V20, P947, DOI 10.1016/S0896-6273(00)80476-6; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; Critchley HD, 1996, J NEUROPHYSIOL, V75, P1673, DOI 10.1152/jn.1996.75.4.1673; Critchley HD, 2002, NEURON, V33, P653, DOI 10.1016/S0896-6273(02)00588-3; Dayan P, 2002, NEURON, V36, P285, DOI 10.1016/S0896-6273(02)00963-7; Dickinson A., 2002, STEVENS HDB EXPT PSY, V3; Gallagher M, 1999, J NEUROSCI, V19, P6610; Gottfried JA, 2002, J NEUROSCI, V22, P10829; Gottfried JA, 2002, J NEUROSCI, V22, P10819; Hatfield T, 1996, J NEUROSCI, V16, P5256; Ikeda M, 2002, J NEUROL NEUROSUR PS, V73, P371, DOI 10.1136/jnnp.73.4.371; LaBar KS, 2001, BEHAV NEUROSCI, V115, P493, DOI 10.1037//0735-7044.115.2.493; LaBar KS, 1998, NEURON, V20, P937, DOI 10.1016/S0896-6273(00)80475-4; Malkova L, 1997, J NEUROSCI, V17, P6011; Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1; O'Doherty J, 2000, NEUROREPORT, V11, P893, DOI 10.1097/00001756-200003200-00046; O'Doherty JP, 2002, NEURON, V33, P815, DOI 10.1016/S0896-6273(02)00603-7; ROLLS BJ, 1981, PHYSIOL BEHAV, V27, P137, DOI 10.1016/0031-9384(81)90310-3; Rolls ET, 1996, J NEUROPHYSIOL, V75, P1970, DOI 10.1152/jn.1996.75.5.1970; SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P733, DOI 10.1152/jn.1995.74.2.733; Schoenbaum G, 1999, J NEUROSCI, V19, P1876; Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272; Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720; Small DM, 1999, NEUROREPORT, V10, P7, DOI 10.1097/00001756-199901180-00002; TERZIAN H, 1955, NEUROLOGY, V5, P373, DOI 10.1212/WNL.5.6.373	28	840	847	1	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1104	1107		10.1126/science.1087919	http://dx.doi.org/10.1126/science.1087919			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934011	Green Submitted			2022-12-24	WOS:000184872400043
J	Harvey, KF; Pfleger, CM; Hariharan, IK				Harvey, KF; Pfleger, CM; Hariharan, IK			The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis	CELL			English	Article							PROTEIN-KINASE; REGULATING APOPTOSIS; TNF SUPERFAMILY; IMAGINAL DISC; JNK PATHWAY; DEGRADATION; REAPER; DIAP1; GENE; GRIM	Establishing and maintaining homeostasis is critical to the well-being of an organism and is determined by the balance of cell proliferation and death. Two genes that function together to regulate growth, proliferation, and apoptosis in Drosophila are warts (wts), encoding a serine/threonine kinase, and salvador (sav), encoding a WW domain containing Wts-interacting protein. However, the mechanisms by which sav and wts regulate growth and apoptosis are not well understood. Here, we describe mutations in hippo (hpo), which encodes a protein kinase most related to mammalian Mst1 and Mst2. Like wts and sav, hpo mutations result in increased tissue growth and impaired apoptosis characterized by elevated levels of the cell cycle regulator cyclin E and apoptosis inhibitor DIAP1. Hpo, Sav, and Wts interact physically and functionally, and regulate DIAP1 levels, likely by Hpo-mediated phosphorylation and subsequent degradation. Thus, Hpo links Sav and Wts to a key regulator of apoptosis.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Hariharan, IK (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.		Harvey, Kieran/AAD-5268-2022	Harvey, Kieran/0000-0001-7845-369X	NCI NIH HHS [CA95281] Funding Source: Medline; NIGMS NIH HHS [GM61672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger J, 2001, NAT GENET, V29, P475, DOI 10.1038/ng773; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lisi S, 2000, GENETICS, V154, P669; Marygold SJ, 2002, CURR BIOL, V12, pR785, DOI 10.1016/S0960-9822(02)01294-0; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Richardson H, 2002, J IMMUNOL METHODS, V265, P21, DOI 10.1016/S0022-1759(02)00068-6; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Suzanne M, 2001, DEV BIOL, V237, P282, DOI 10.1006/dbio.2001.0384; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P668; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	40	726	757	1	69	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					457	467		10.1016/S0092-8674(03)00557-9	http://dx.doi.org/10.1016/S0092-8674(03)00557-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941274	Bronze			2022-12-24	WOS:000184928800009
J	Chien, P; DePace, AH; Collins, SR; Weissman, JS				Chien, P; DePace, AH; Collins, SR; Weissman, JS			Generation of prion transmission barriers by mutational control of amyloid conformations	NATURE			English	Article							STRUCTURAL BASIS; SUP35 PROTEIN; IN-VITRO; YEAST; PSI+; DIVERSITY; DISEASES; STRAINS; VARIANT; PSI(+)	Self-propagating beta-sheet-rich protein aggregates are implicated in a wide range of protein-misfolding phenomena, including amyloid diseases and prion-based inheritance(1). Two properties have emerged as common features of amyloids. Amyloid formation is ubiquitous: many unrelated proteins form such aggregates and even a single polypeptide can misfold into multiple forms(2-6) - a process that is thought to underlie prion strain variation(7). Despite this promiscuity, amyloid propagation can be highly sequence specific: amyloid fibres often fail to catalyse the aggregation of other amyloidogenic proteins(8,9). In prions, this specificity leads to barriers that limit transmission between species(7,8,10-12). Using the yeast prion [PSI+](13), we show in vitro that point mutations in Sup35p, the protein determinant of [PSI+], alter the range of 'infectious' conformations, which in turn changes amyloid seeding specificity. We generate a new transmission barrier in vivo by using these mutations to specifically disfavour subsets of prion strains. The ability of mutations to alter the conformations of amyloid states without preventing amyloid formation altogether provides a general mechanism for the generation of prion transmission barriers and may help to explain how mutations alter toxicity in conformational diseases.	Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA.	jsw1@itsa.ucsf.edu		Collins, Sean/0000-0002-4276-5840; Weissman, Jonathan/0000-0003-2445-670X				Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; Bartz JC, 2000, J VIROL, V74, P5542, DOI 10.1128/JVI.74.12.5542-5547.2000; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baxa U, 2002, P NATL ACAD SCI USA, V99, P5253, DOI 10.1073/pnas.082097899; Chernoff YO, 2000, MOL MICROBIOL, V35, P865, DOI 10.1046/j.1365-2958.2000.01761.x; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 1996, GENETICS, V144, P1375; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; King CY, 2001, J MOL BIOL, V307, P1247, DOI 10.1006/jmbi.2001.4542; Kochneva-Pervukhova NV, 2001, YEAST, V18, P489, DOI 10.1002/yea.700; Kushnirov VV, 2000, EMBO J, V19, P324, DOI 10.1093/emboj/19.3.324; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Mastrianni JA, 2001, NEUROLOGY, V57, P2198, DOI 10.1212/WNL.57.12.2198; Nakayashiki T, 2001, MOL CELL, V7, P1121, DOI 10.1016/S1097-2765(01)00259-3; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Post K, 2000, ARCH VIROL, P265; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	29	85	86	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					948	951		10.1038/nature01894	http://dx.doi.org/10.1038/nature01894			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931190				2022-12-24	WOS:000184843600043
J	Gompel, N; Carroll, SB				Gompel, N; Carroll, SB			Genetic mechanisms and constraints governing the evolution of correlated traits in drosophilid flies	NATURE			English	Article							CONVERGENT PHENOTYPES; ADULT ABDOMEN; MELANOGASTER; PHYLOGENY; PROTEINS; PATTERN; PANNIER	Some morphological traits differ greatly between related species, but it is not clear whether diversity evolves through changes in the same genes and whether similar, independent (that is, convergent) changes occur by the same mechanism(1,2). Pigmentation in fruitflies presents an attractive opportunity to explore these issues because pigmentation patterns are diverse, similar patterns have arisen in independent clades, and numerous genes governing their formation have been identified(3-5) in Drosophila melanogaster. Here we show that both evolutionary diversification and convergence can be due to evolution at the same locus, by comparing abdominal pigmentation and trichome patterns and the expression of Bric-a-brac2 (Bab2), which regulates both traits in D. melanogaster(3,6), in 13 species representing the major clades (7,8) of the subfamily Drosophilinae. Modifications of Bab2 expression are frequently correlated with diverse pigmentation and trichome patterns that evolved independently in multiple lineages. In a few species, Bab2 expression is not correlated with changes in pigmentation but is correlated with a conserved pattern of trichomes, indicating that this locus can be circumvented to evolve new patterns when a correlated trait is under different constraints.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, 1525 Linden Dr, Madison, WI 53706 USA.	sbcarrol@facstaff.wisc.edu		Gompel, Nicolas/0000-0003-3358-7963				Abzhanov A, 2000, DEVELOPMENT, V127, P2239; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; AYALA FJ, 1965, EVOLUTION, V19, P538, DOI 10.1111/j.1558-5646.1965.tb03329.x; BOCK IR, 1972, STUDIES GENETICS, P1, DOI DOI 10.1590/S0085-56262014000400004; Calleja M, 2000, DEVELOPMENT, V127, P3971; Couderc JL, 2002, DEVELOPMENT, V129, P2419; GRIMALDI DA, 1990, B AM MUS NAT HIST, P1; Kopp A, 2000, NATURE, V408, P553, DOI 10.1038/35046017; Kopp A, 1999, DEVELOPMENT, V126, P3495; Kopp A, 2003, GENETICS, V163, P771; Kopp A, 1997, DEVELOPMENT, V124, P3715; Kwiatowski J, 1999, MOL PHYLOGENET EVOL, V13, P319, DOI 10.1006/mpev.1999.0657; Lachaise D, 2000, P ROY SOC B-BIOL SCI, V267, P1487, DOI 10.1098/rspb.2000.1169; Llopart A, 2002, EVOLUTION, V56, P2262; Maddison WP, 2000, MACCLADE 4 ANAL PHYL; MADHAVAN MM, 1980, J EMBRYOL EXP MORPH, V60, P1; Majerus M. E. N, 1994, LADYBIRDS; Majerus MEN, 1998, MELANISM EVOLUTION A; Remsen J, 2002, MOL PHYLOGENET EVOL, V24, P249, DOI 10.1016/S1055-7903(02)00226-9; Schutt C, 2000, DEVELOPMENT, V127, P667; SMITH JM, 1985, Q REV BIOL, V60, P265, DOI 10.1086/414425; Wittkopp PJ, 2003, P NATL ACAD SCI USA, V100, P1808, DOI 10.1073/pnas.0336368100; Wittkopp PJ, 2002, DEVELOPMENT, V129, P1849; Wray GA, 2002, BRAIN BEHAV EVOLUT, V59, P327, DOI 10.1159/000063566; Wulbeck C, 2002, DEVELOPMENT, V129, P3861	25	98	104	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					931	935		10.1038/nature01787	http://dx.doi.org/10.1038/nature01787			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931186				2022-12-24	WOS:000184843600039
J	Allsop, DJ; West, SA				Allsop, DJ; West, SA			Changing sex at the same relative body size - Similar forces may select for gender switching across taxa in all animals with this facility	NATURE			English	Editorial Material							AGE		Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Allsop, DJ (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Kings Bldg,W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	david.allsop@ed.ac.uk	West, Stuart A/M-3608-2014	West, Stuart A/0000-0003-2152-3153				Allsop DJ, 2003, J EVOLUTION BIOL, V16, P921, DOI 10.1046/j.1420-9101.2003.00590.x; CHARNOV E L, 1982; Charnov EL, 2000, EVOL ECOL RES, V2, P1067; Charnov Eric L., 1993, P1; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Frank S. A., 1998, FDN SOCIAL EVOLUTION, DOI DOI 10.1515/9780691206820; Gemmill AW, 1999, J EVOLUTION BIOL, V12, P1148, DOI 10.1046/j.1420-9101.1999.00117.x; Harvey P.H., 1991, COMP METHOD EVOLUTIO; LEIGH EG, 1976, P NATL ACAD SCI USA, V73, P3655, DOI DOI 10.1111/J.1420-9101.2006.01156.X; WEST PA, 1985, J ROY SOC HEALTH, V1, P15	10	53	55	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					783	784		10.1038/425783a	http://dx.doi.org/10.1038/425783a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574399	Green Submitted			2022-12-24	WOS:000186118500032
J	Ashton, CM; Souchek, J; Petersen, NJ; Menke, TJ; Collins, TC; Kizer, KW; Wright, SM; Wray, NP				Ashton, CM; Souchek, J; Petersen, NJ; Menke, TJ; Collins, TC; Kizer, KW; Wright, SM; Wray, NP			Hospital use and survival among Veterans Affairs beneficiaries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE SYSTEM; QUALITY; VA; ADMISSIONS; OUTCOMES; IMPACT; RATES	BACKGROUND: Initiatives to reduce hospital care were part of the reorganization of the Department of Veterans Affairs (VA) medical care system undertaken in the mid-1990s. We examined changes in the use of VA health services and survival from 1994 through 1998 among VA beneficiaries with serious chronic diseases. We postulated that if access to hospital care was reduced too much, or if decreased hospital use was not offset by improvements in ambulatory care, urgent care visits would increase or survival rates would fall. METHODS: We tracked changes in risk-adjusted VA bed-day rates, rates of medical visits, rates of visits for testing and consultation, and rates of urgent care visits per patient-year among VA beneficiaries in nine disease cohorts (a total of 342,300 beneficiaries). Trends in non-VA hospital use by VA beneficiaries 65 years of age or older who were enrolled in fee-for-service Medicare were also studied. VA and Medicare vital-status data were used to calculate one-year survival rates. RESULTS: From 1994 through 1998, VA bed-day rates fell by 50 percent, rates of medical-clinic visits and visits for testing and consultation increased moderately, and rates of urgent care visits fell by 35 percent. The sharp decline in the use of VA hospitals was not compensated for by increases in the use of Medicare-reimbursed non-VA hospital care by veterans eligible for both VA care and Medicare, and the use of non-VA hospitals actually declined in four cohorts. The survival rates were essentially unchanged over the study period. CONCLUSIONS: The marked decline in VA hospital use from 1994 through 1998 did not curtail access to needed services and was not associated with serious consequences for chronically ill VA beneficiaries.	Vet Affairs Med Ctr, Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Vet Hlth Adm Headquarters, Washington, DC USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ashton, CM (corresponding author), Vet Affairs Med Ctr, Ctr Qual Care & Utilizat Studies, 152,2002 Holcombe Blvd, Houston, TX 77030 USA.	carol.ashton@med.va.gov						Ashton CM, 1999, NEW ENGL J MED, V340, P32, DOI 10.1056/NEJM199901073400106; ASHTON CM, 1994, MED CARE, V32, P447, DOI 10.1097/00005650-199405000-00004; BLUMENTHAL D, 1995, HEALTH SERV RES, V30, P253; BOOTH BM, 1991, MED CARE, V29, pAS40; COX DR, 1972, J R STAT SOC B, V34, P187; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; Forrest CB, 1996, J FAM PRACTICE, V43, P40; GARG R, 1995, JAMA-J AM MED ASSOC, V274, P462; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; GRAVES EJ, 1997, VITAL HLTH STAT 13, V128; Iglehart JK, 1996, NEW ENGL J MED, V335, P1407, DOI 10.1056/NEJM199610313351821; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; Kizer KW, 1999, AM J MED QUAL, V14, P3, DOI 10.1177/106286069901400103; Kizer KW, 1997, HOSP HEALTH SERV ADM, V42, P283; Kizer KW, 2001, HLTH INFORMAT SER, P79; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; Menke TJ, 1998, MED CARE, V36, P1126, DOI 10.1097/00005650-199808000-00003; MILLER MG, 1994, JAMA-J AM MED ASSOC, V271, P1493, DOI 10.1001/jama.271.19.1493; NAJI S, 1994, BRIT MED J, V308, P1208; *NAT CTR HLTH STAT, 2002, PROV TABL BIRTHS MAR, V47; Page WF, 1996, ANN EPIDEMIOL, V6, P102, DOI 10.1016/1047-2797(95)00126-3; POPOVIC JR, 2000, VITAL HLTH STAT 13, V148; Smith CB, 1996, MED CARE, V34, P85, DOI 10.1097/00005650-199601000-00007; SNEDECOR GW, 1980, STATISTICAL METHODS, P288; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; *VET HLTH ADM OFF, 1997, VET EQ RES ALL SYST; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Wilson NJ, 1997, HEALTH AFFAIR, V16, P200, DOI 10.1377/hlthaff.16.4.200; Wray NP, 1999, HEALTH SERV RES, V34, P777; Wray NP, 1997, MED CARE, V35, P768, DOI 10.1097/00005650-199708000-00003; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	31	75	76	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1637	1646		10.1056/NEJMsa003299	http://dx.doi.org/10.1056/NEJMsa003299			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	734ZT	14573736				2022-12-24	WOS:000186088400010
J	Seminara, SB; Messager, S; Chatzidaki, EE; Thresher, RR; Acierno, JS; Shagoury, JK; Bo-Abbas, Y; Kuohung, W; Schwinof, KM; Hendrick, AG; Zahn, D; Dixon, J; Kaiser, UB; Slaugenhaupt, SA; Gusella, JF; O'Rahilly, S; Carlton, MBL; Crowley, WF; Aparicio, SAJR; Colledge, WH				Seminara, SB; Messager, S; Chatzidaki, EE; Thresher, RR; Acierno, JS; Shagoury, JK; Bo-Abbas, Y; Kuohung, W; Schwinof, KM; Hendrick, AG; Zahn, D; Dixon, J; Kaiser, UB; Slaugenhaupt, SA; Gusella, JF; O'Rahilly, S; Carlton, MBL; Crowley, WF; Aparicio, SAJR; Colledge, WH			The GPR54 gene as a regulator of puberty	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GONADOTROPIN-RELEASING-HORMONE; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; METASTASIS-SUPPRESSOR GENE; PROTEIN-COUPLED RECEPTOR; LUTEINIZING-HORMONE; KALLMANNS-SYNDROME; MENSTRUAL-CYCLE; GNRH RECEPTOR; KISS-1; MEN	BACKGROUND: Puberty, a complex biologic process involving sexual development, accelerated linear growth, and adrenal maturation, is initiated when gonadotropin-releasing hormone begins to be secreted by the hypothalamus. We conducted studies in humans and mice to identify the genetic factors that determine the onset of puberty. METHODS: We used complementary genetic approaches in humans and in mice. A consanguineous family with members who lacked pubertal development (idiopathic hypogonadotropic hypogonadism) was examined for mutations in a candidate gene, GPR54, which encodes a G protein-coupled receptor. Functional differences between wild-type and mutant GPR54 were examined in vitro. In parallel, a Gpr54-deficient mouse model was created and phenotyped. Responsiveness to exogenous gonadotropin-releasing hormone was assessed in both the humans and the mice. RESULTS: Affected patients in the index pedigree were homozygous for an L148S mutation in GPR54, and an unrelated proband with idiopathic hypogonadotropic hypogonadism was determined to have two separate mutations, R331X and X399R. The in vitro transfection of COS-7 cells with mutant constructs demonstrated a significantly decreased accumulation of inositol phosphate. The patient carrying the compound heterozygous mutations (R331X and X399R) had attenuated secretion of endogenous gonadotropin-releasing hormone and a left-shifted dose-response curve for gonadotropin-releasing hormone as compared with six patients who had idiopathic hypogonadotropic hypogonadism without GPR54 mutations. The Gpr54-deficient mice had isolated hypogonadotropic hypogonadism (small testes in male mice and a delay in vaginal opening and an absence of follicular maturation in female mice), but they showed responsiveness to both exogenous gonadotropins and gonadotropin-releasing hormone and had normal levels of gonadotropin-releasing hormone in the hypothalamus. CONCLUSIONS: Mutations in GPR54, a G protein-coupled receptor gene, cause autosomal recessive idiopathic hypogonadotropic hypogonadism in humans and mice, suggesting that this receptor is essential for normal gonadotropin-releasing hormone physiology and for puberty.	Paradigm Therapeut, Cambridge CB4 0WA, England; Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Human Genet Res, Mol Neurogenet Unit, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Inst Human Genet, Boston, MA USA; Univ Cambridge, Dept Physiol, Cambridge, England; Univ Cambridge, Dept Oncol, Cambridge, England; Univ Cambridge, Dept Clin Biochem, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2QQ, England; Kuwait Univ, Fac Med, Al Jabriyah, Kuwait	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Kuwait University	Colledge, WH (corresponding author), Paradigm Therapeut, 214 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0WA, England.		Oka, Yoshitaka/C-9670-2010; Colledge, William/X-4976-2019; O'Rahilly, Stephen/ABF-6509-2020	Oka, Yoshitaka/0000-0002-3482-3051; Colledge, William/0000-0002-9603-4429; O'Rahilly, Stephen/0000-0003-2199-4449; Acierno, James/0000-0002-5301-4970; Hendrick, Alan/0000-0002-8604-0462; Aparicio, Samuel/0000-0002-0487-9599; Kuohung, Wendy/0000-0003-1764-2264	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028138, R01HD015788, T32HD040135, R01HD043341] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM061354] Funding Source: NIH RePORTER; NCRR NIH HHS [3M01 RR01066-22S2] Funding Source: Medline; NICHD NIH HHS [U54 HD029164, 5R01 HD15788-17, T32 HD40135, R01 HD043341, U54 HD28138-13, U54 HD028138, R01 HD015788] Funding Source: Medline; NIGMS NIH HHS [GM61354] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acierno JS, 2003, J CLIN ENDOCR METAB, V88, P2947, DOI 10.1210/jc.2003-030423; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Bedecarrats GY, 2003, J CLIN ENDOCR METAB, V88, P834, DOI 10.1210/jc.2002-020806; Bo-Abbas Y, 2003, J CLIN ENDOCR METAB, V88, P2730, DOI 10.1210/jc.2002-021948; CAMERON JL, 1985, BIOL REPROD, V33, P147, DOI 10.1095/biolreprod33.1.147; CARATY A, 1995, ENDOCRINOLOGY, V136, P3452, DOI 10.1210/en.136.8.3452; COLLINS TJ, 1981, NEUROBIOL AGING, V2, P125, DOI 10.1016/0197-4580(81)90010-5; CROWLEY WF, 1980, J CLIN ENDOCR METAB, V51, P173, DOI 10.1210/jcem-51-1-173; de Roux N, 2003, P NATL ACAD SCI USA, V100, P10972, DOI 10.1073/pnas.1834399100; FILICORI M, 1986, J CLIN ENDOCR METAB, V62, P1136, DOI 10.1210/jcem-62-6-1136; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; HOFFMAN AR, 1982, NEW ENGL J MED, V307, P1237, DOI 10.1056/NEJM198211113072003; Horikoshi Y, 2003, J CLIN ENDOCR METAB, V88, P914, DOI 10.1210/jc.2002-021235; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.m104847200; Lee DK, 1999, FEBS LETT, V446, P103, DOI 10.1016/S0014-5793(99)00009-5; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; LEE JH, 1997, J NATL CANCER I, V89, P1549; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEGOUIS R, 1993, P NATL ACAD SCI USA, V90, P2461, DOI 10.1073/pnas.90.6.2461; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; MCDOWELL IFW, 1982, J ENDOCRINOL, V95, P331, DOI 10.1677/joe.0.0950331; MCDOWELL IFW, 1982, J ENDOCRINOL, V95, P321, DOI 10.1677/joe.0.0950321; Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; SANTEN RJ, 1973, J CLIN INVEST, V52, P2617, DOI 10.1172/JCI107454; SANTORO N, 1986, ENDOCR REV, V7, P11, DOI 10.1210/edrv-7-1-11; Seminara SB, 1998, ENDOCR REV, V19, P521, DOI 10.1210/er.19.5.521; SPRATT DI, 1987, J CLIN ENDOCR METAB, V64, P283, DOI 10.1210/jcem-64-2-283; SPRATT DI, 1988, AM J PHYSIOL, V254, pE658, DOI 10.1152/ajpendo.1988.254.5.E658; *UCSC, 2002, UCSC GEN BROWS; van Hoof A, 2002, SCIENCE, V295, P2262, DOI 10.1126/science.1067272; WHITCOMB RW, 1990, J CLIN ENDOCR METAB, V70, P3, DOI 10.1210/jcem-70-1-3; WIEMANN JN, 1989, ENDOCRINOLOGY, V124, P1760, DOI 10.1210/endo-124-4-1760	37	1859	1937	5	106	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1614	U8		10.1056/NEJMoa035322	http://dx.doi.org/10.1056/NEJMoa035322			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573733				2022-12-24	WOS:000186088400006
J	Hemingway, H; Shipley, M; Britton, A; Page, M; Macfarlane, P; Marmot, M				Hemingway, H; Shipley, M; Britton, A; Page, M; Macfarlane, P; Marmot, M			Prognosis of angina with and without a diagnosis: 11 year follow up in the Whitehall II prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							ABNORMALITIES; MORTALITY; SYMPTOMS	Objective To investigate the prognosis of angina among people with and without diagnosis by a doctor and an abnormal cardiovascular test result. Design Prospective cohort study with a median follow up of 11 years. Setting 20 civil service departments originally located in London. Participants 10 308 civil servants aged 35-55 years at baseline. Main outcome measures Recurrent reports of angina; quality of life (SF-36 physical functioning); non-fatal myocardial infarction; death from any cause (n = 344). Results 1158 (11.4%) participants developed angina, and 813 (70%) had no evidence of diagnosis by a doctor at the time of the initial report. Participants without a diagnosis had an increased risk of impaired physical functioning (age and sex adjusted odds ratio of 2.36 (95% confidence interval 1.91 to 2.90)) compared with those who had neither angina nor myocardial infarction throughout follow up. Among reported cases of angina without a diagnosis, the 15.5% with an abnormality on a study electrocardiogram had an increased risk of death (hazard ratio 2.37 (1.16 to 4.87)). These effects were similar in magnitude to those in participants with a diagnosis of angina. Conclusion Undiagnosed angina was common and had an adverse impact on prognosis comparable to that of diagnosed angina, particularly among people with electrocardiographic abnormalities. Efforts to improve prognosis among people with angina should take account of this submerged clinical iceberg.	UCL, Sch Med, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, London WC1E 6BT, England; Univ Glasgow, Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland	University of London; University College London; UCL Medical School; Royal Infirmary of Edinburgh; University of Glasgow	Hemingway, H (corresponding author), UCL, Sch Med, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, London WC1E 6BT, England.	h.hemingway@public-health.ucl.ac.uk	Hemingway, Harry/C-1219-2009; Marmot, M G/Y-3920-2019; Greiver, Michelle/N-8764-2015	Hemingway, Harry/0000-0003-2279-0624; Marmot, M G/0000-0002-2431-6419; Greiver, Michelle/0000-0001-8957-0285	AHRQ HHS [5 R01 HS06516] Funding Source: Medline; Medical Research Council [G19/35, G8802774, G0100222] Funding Source: Medline; NHLBI NIH HHS [2R01 HL36310] Funding Source: Medline; NIA NIH HHS [R01 AG13196-02] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013196] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Daviglus ML, 1999, JAMA-J AM MED ASSOC, V281, P530, DOI 10.1001/jama.281.6.530; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Gardner K, 1999, BRIT MED J, V319, P418, DOI 10.1136/bmj.319.7207.418; Gibbons RJ, 2003, CIRCULATION, V107, P149, DOI 10.1161/01.CIR.0000047041.66447.29; Hemingway H, 2000, J EPIDEMIOL COMMUN H, V54, P510, DOI 10.1136/jech.54.7.510; Lampe FC, 1999, J CLIN EPIDEMIOL, V52, P73, DOI 10.1016/S0895-4356(98)00146-2; Lampe FC, 2001, AM J EPIDEMIOL, V153, P1173, DOI 10.1093/aje/153.12.1173; LAST JM, 1963, LANCET, P28; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MCCORMICK A, 1995, MORBIDITY STAT GEN P; Rose G, 1982, CARDIOVASCULAR SURVE; Stafford M, 1998, J EPIDEMIOL COMMUN H, V52, P353, DOI 10.1136/jech.52.6.353; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583	13	47	50	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 18	2003	327	7420					895	898		10.1136/bmj.327.7420.895	http://dx.doi.org/10.1136/bmj.327.7420.895			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563744	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000186072100016
J	Ueshima, R; Asami, T				Ueshima, R; Asami, T			Single-gene speciation by left-right reversal - A land-snail species of polyphyletic origin results from chirality constraints on mating.	NATURE			English	Editorial Material							SYMPATRIC SPECIATION; PARTULA-SUTURALIS; POLYMORPHISM; EVOLUTION; COIL		Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan; Shinshu Univ, Dept Biol, Matsumoto, Nagano 3608621, Japan; Japan Sci & Technol, PRESTO, Kawaguchi 3320012, Japan	University of Tokyo; Shinshu University; Japan Science & Technology Agency (JST)	Ueshima, R (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan.	asami99@gipac.shinshu-u.ac.jp						Asami T, 1998, AM NAT, V152, P225, DOI 10.1086/286163; Dobzhansky T., 1937, GENETICS ORIGIN SPEC; FREEMAN G, 1982, ROUX ARCH DEV BIOL, V191, P69, DOI 10.1007/BF00848443; GITTENBERGER E, 1988, EVOLUTION, V42, P826, DOI 10.1111/j.1558-5646.1988.tb02502.x; Harrison RG, 1998, ENDLESS FORMS, P19; JOHNSON MS, 1990, EVOLUTION, V44, P459, DOI 10.1111/j.1558-5646.1990.tb05215.x; JOHNSON MS, 1982, HEREDITY, V49, P145, DOI 10.1038/hdy.1982.80; LIPTON CS, 1979, MALACOLOGIA, V19, P129; Muller H., 1942, BIOL S, V6, P71; ORR HA, 1991, EVOLUTION, V45, P764, DOI 10.1111/j.1558-5646.1991.tb04345.x; VANHATENBURG FHO, 1996, HEREDITY, V76, P278; VERMEIJ GJ, 1975, NATURE, V254, P419, DOI 10.1038/254419a0	12	130	138	2	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	2003	425	6959					679	679		10.1038/425679a	http://dx.doi.org/10.1038/425679a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562091	Bronze			2022-12-24	WOS:000185924500029
J	Lewin, MR; Bouyer, DH; Walker, DH; Musher, DM				Lewin, MR; Bouyer, DH; Walker, DH; Musher, DM			Rickettsia sibirica infection in members of scientific expeditions to northern Asia	LANCET			English	Article							INNER-MONGOLIA	The risk of acquiring North Asian tick typhus (infection by Rickettsia sibirica) during travel to regions of Asia where this disease is endemic is unknown. We investigated prospectively 13 paleontologists on expedition to Mongolia. Four paleontologists had acute illness characterised by fever, rash, headache, and lymphadenoparthy. All had IgM and IgG antibodies to R sibirica. Paleontologists with no illness and people who went on expeditions in other parts of the world did not have antibodies to R sibirica. Only two of the four infected persons were aware of tick bites. Travellers to regions endemic for R sibirica are at risk of contracting North Asian tick typhus even in the absence of recognised tick-bites.	Univ Calif San Francisco, Fresno, CA USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA	University of California System; University of California San Francisco; University of California San Francisco at Fresno; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine	Lewin, MR (corresponding author), Dept Emergency Med, Room 275,445 S Cedar Ave, Fresno, CA 93702 USA.	aplysia99@yahoo.com		Lewin, Matthew/0000-0003-4480-9891				ANTONOV NI, 1936, DALNEVOST MED ZH, V5, P77; Lankester T, 1997, LANCET, V349, P656, DOI 10.1016/S0140-6736(05)61613-3; LIU QH, 1990, ANN NY ACAD SCI, V590, P237, DOI 10.1111/j.1749-6632.1990.tb42225.x; LIU QH, 1995, EPIDEMIOL INFECT, V115, P177, DOI 10.1017/S0950268800058246; Lyskovtsev MM, 1968, MISCELLANEOUS PUBLIC, V6, P42	5	18	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1201	1202		10.1016/S0140-6736(03)14515-1	http://dx.doi.org/10.1016/S0140-6736(03)14515-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568744				2022-12-24	WOS:000185924100014
J	Mukhopadhyay, S; Kim, BS; Chipman, PR; Rossmann, MG; Kuhn, RJ				Mukhopadhyay, S; Kim, BS; Chipman, PR; Rossmann, MG; Kuhn, RJ			Structure of West Nile virus	SCIENCE			English	Article							ENVELOPE GLYCOPROTEIN; DENGUE VIRUS; ENCEPHALITIS		Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kuhn, RJ (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	kuhnr@purdue.edu	Kuhn, Richard/AAR-2722-2021	Kuhn, Richard/0000-0003-4148-1026; Chipman, Paul/0000-0003-3652-4087	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI045976] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 45976] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beasley DWC, 2002, J VIROL, V76, P13097, DOI 10.1128/JVI.76.24.13097-13100.2002; Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0	6	284	307	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					248	248		10.1126/science.1089316	http://dx.doi.org/10.1126/science.1089316			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551429				2022-12-24	WOS:000185825900031
J	Wai, SN; Lindmark, B; Soderblom, T; Takade, A; Westermark, M; Oscarsson, J; Jass, J; Richter-Dahlfors, A; Mizunoe, Y; Uhlin, BE				Wai, SN; Lindmark, B; Soderblom, T; Takade, A; Westermark, M; Oscarsson, J; Jass, J; Richter-Dahlfors, A; Mizunoe, Y; Uhlin, BE			Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial ClyA cytotoxin	CELL			English	Article							HEAT-LABILE ENTEROTOXIN; OUTER-MEMBRANE VESICLES; ESCHERICHIA-COLI; SECRETORY PATHWAY; PROTEIN SECRETION; CRYSTAL-STRUCTURE; HEMOLYSIN-E; IN-VITRO; SHEA; EXPRESSION	The ClyA protein is a pore-forming cytotoxin expressed by Escherichia coli and some other enterobacteria. It confers cytotoxic activity toward mammalian cells, but it has remained unknown how ClyA is surface exposed and exported from bacterial cells. Outer-membrane vesicles (OMVs) released from the bacteria were shown to contain ClyA protein. ClyA formed oligomeric pore assemblies in the OMVs, and the cytotoxic activity toward mammalian cells was considerably higher than that of ClyA protein purified from the bacterial periplasm. The redox status of ClyA correlated with its ability to form the oligomeric pore assemblies. In bacterial cells with a defective periplasmic disulphide oxidoreductase system, the ClyA protein was phenotypically expressed in a constitutive manner. The results define a vesicle-mediated transport mechanism in bacteria, and our findings show that the localization of proteins to OMVs directly may contribute to the activation and delivery of pathogenic effector proteins.	Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Kyushu Univ, Fac Med Sci, Dept Bacteriol, Fukuoka 8128582, Japan	Umea University; Karolinska Institutet; Kyushu University	Wai, SN (corresponding author), Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden.	sun.nyunt.wai@molbiol.umu.se	Jass, Jana/D-1617-2013; Uhlin, Bernt Eric/AAO-6292-2021	Jass, Jana/0000-0001-7957-0310; Uhlin, Bernt Eric/0000-0002-2991-8072; Richter-Dahlfors, Agneta/0000-0002-5479-7591; Wai, Sun Nyunt/0000-0003-4793-4671				AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; Atkins A, 2000, J BIOL CHEM, V275, P41150, DOI 10.1074/jbc.M005420200; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Chen LY, 1996, J BIOL CHEM, V271, P2703, DOI 10.1074/jbc.271.5.2703; Christie PJ, 2000, TRENDS MICROBIOL, V8, P354, DOI 10.1016/S0966-842X(00)01792-3; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; del Castillo FJ, 2001, FEMS MICROBIOL LETT, V204, P281, DOI 10.1016/S0378-1097(01)00413-X; delCastillo FJ, 1997, MOL MICROBIOL, V25, P107, DOI 10.1046/j.1365-2958.1997.4391813.x; Fiocca R, 1999, J PATHOL, V188, P220, DOI 10.1002/(SICI)1096-9896(199906)188:2<220::AID-PATH307>3.0.CO;2-C; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Green J, 1997, MICROBIOL-SGM, V143, P3785, DOI 10.1099/00221287-143-12-3785; Henderson IR, 2000, TRENDS MICROBIOL, V8, P529, DOI 10.1016/S0966-842X(00)01853-9; HENNING U, 1979, ANAL BIOCHEM, V97, P153, DOI 10.1016/0003-2697(79)90339-7; Horstman AL, 2000, J BIOL CHEM, V275, P12489, DOI 10.1074/jbc.275.17.12489; Horstman AL, 2002, J BIOL CHEM, V277, P32538, DOI 10.1074/jbc.M203740200; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kadokura H, 2000, P NATL ACAD SCI USA, V97, P10884, DOI 10.1073/pnas.97.20.10884; Kadurugamuwa JL, 1998, ANTIMICROB AGENTS CH, V42, P1476, DOI 10.1128/AAC.42.6.1476; Kato S, 2002, MICROB PATHOGENESIS, V32, P1, DOI 10.1006/mpat.2001.0474; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai XH, 2000, INFECT IMMUN, V68, P4363, DOI 10.1128/IAI.68.7.4363-4367.2000; LARSSON S, 1986, AM J PHYSIOL, V251, pC455, DOI 10.1152/ajpcell.1986.251.3.C455; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; Oscarsson J, 2002, INFECT IMMUN, V70, P5759, DOI 10.1128/IAI.70.10.5759-5769.2002; Oscarsson J, 2002, INT J MED MICROBIOL, V291, P625, DOI 10.1078/1438-4221-00176; Oscarsson J, 1999, MOL MICROBIOL, V32, P1226, DOI 10.1046/j.1365-2958.1999.01435.x; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Sandkvist M, 2001, MOL MICROBIOL, V40, P271, DOI 10.1046/j.1365-2958.2001.02403.x; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Tauschek M, 2002, P NATL ACAD SCI USA, V99, P7066, DOI 10.1073/pnas.092152899; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; UHLIN BE, 1994, J CELL BIOCH S A, V18, P71; WAI SN, 1995, MICROBIOL IMMUNOL, V39, P451, DOI 10.1111/j.1348-0421.1995.tb02228.x; Wai SN, 2003, J BACTERIOL, V185, P5491, DOI 10.1128/JB.185.18.5491-5499.2003; Wai SN, 1998, APPL ENVIRON MICROB, V64, P3648; Wallace AJ, 2000, CELL, V100, P265, DOI 10.1016/S0092-8674(00)81564-0; Westermark M, 2000, J BACTERIOL, V182, P6347, DOI 10.1128/JB.182.22.6347-6357.2000; WHITTAM TS, 1988, J INFECT DIS, V157, P1124, DOI 10.1093/infdis/157.6.1124; Xia Y, 2000, EMBO J, V19, P1450, DOI 10.1093/emboj/19.7.1450	48	350	365	6	49	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					25	35		10.1016/S0092-8674(03)00754-2	http://dx.doi.org/10.1016/S0092-8674(03)00754-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532000	Bronze			2022-12-24	WOS:000185815500006
J	Fischle, W; Wang, YM; Allis, CD				Fischle, W; Wang, YM; Allis, CD			Binary switches and modification cassettes in histone biology and beyond	NATURE			English	Article							POSITION-EFFECT VARIEGATION; MAMMALIAN-CELLS; LYSINE METHYLATION; MOLECULAR-BASIS; H3; HP1; CHROMATIN; PHOSPHORYLATION; CORE; IDENTIFICATION	An immense number of post-translational modifications on histone proteins have been described and additional sites of modification are still being uncovered. Whereas many direct and indirect connections between certain histone modifications and distinct biological phenomena have now been established, concepts for comprehending the extreme density and variety of these covalent modifications are lacking. Here, we formally introduce localized 'binary switches' and 'modification cassettes' as new concepts in histone biology, elucidating mechanisms that might govern the biological readout of distinct modification patterns. Specifically, our hypotheses provide missing models for the dynamic readout of stable histone modifications and offer explanations for several long-standing questions embedded in the literature. Our ideas might also apply to non-histone proteins and are open to direct experimental examination.	Rockefeller Univ, Lab Chromat Biol, New York, NY 10021 USA	Rockefeller University	Allis, CD (corresponding author), Rockefeller Univ, Lab Chromat Biol, 1230 York Ave, New York, NY 10021 USA.			Wang, Yanming/0000-0002-0710-043X				Appella E, 2000, PATHOL BIOL, V48, P227; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Baarends WM, 1999, DEV BIOL, V207, P322, DOI 10.1006/dbio.1998.9155; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; DAVIE JR, 1991, BIOCHEM CELL BIOL, V69, P66, DOI 10.1139/o91-009; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; FUJITAKI JM, 1981, BIOCHEMISTRY-US, V20, P3658, DOI 10.1021/bi00515a055; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; KELLUM R, 1995, J CELL SCI, V108, P1407; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Li YH, 2003, DEVELOPMENT, V130, P1817, DOI 10.1242/dev.00405; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Park JH, 2002, NAT GENET, V32, P273, DOI 10.1038/ng982; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thompson JS, 2003, GENETICS, V163, P447; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; Zhang KL, 2002, ANAL BIOCHEM, V306, P259, DOI 10.1006/abio.2002.5719; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	38	522	535	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					475	479		10.1038/nature02017	http://dx.doi.org/10.1038/nature02017			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523437				2022-12-24	WOS:000185648100035
J	Yanagisawa, S; Yoo, SD; Sheen, J				Yanagisawa, S; Yoo, SD; Sheen, J			Differential regulation of EIN3 stability by glucose and ethylene signalling in plants	NATURE			English	Article							INDUCIBLE GENE-EXPRESSION; PROTEASOME PATHWAY; RESPONSE PATHWAY; ABSCISIC-ACID; ARABIDOPSIS; PROTEIN; LIGHT; TRANSDUCTION; MAIZE; ETHYLENE-INSENSITIVE3	Glucose is a global regulator of growth and metabolism that is evolutionarily conserved from unicellular microorganisms to multicellular animals and plants(1). In photosynthetic plants, glucose shows hormone-like activities and modulates many essential processes, including embryogenesis, germination, seedling development, vegetative growth, reproduction and senescence(2,3). Genetic and phenotypic analyses of Arabidopsis mutants with glucose-insensitive (gin) and glucose-oversensitive (glo) phenotypes have identified an unexpected antagonistic interaction between glucose and the plant stress hormone ethylene. The ethylene-insensitive etr1 and ein2 mutants have glo phenotypes, whereas the constitutive ethylene signalling mutant ctr1 is allelic to gin4 (refs 4, 5). The precise molecular mechanisms underlying the complex signalling network that governs plant growth and development in response to nutrients and plant hormones are mostly unknown. Here we show that glucose enhances the degradation of ETHYLENE-INSENSITIVE3 (EIN3), a key transcriptional regulator in ethylene signalling(6,7), through the plant glucose sensor hexokinase(8). Ethylene, by contrast, enhances the stability of EIN3. The ein3 mutant has a glo phenotype, and overexpression of EIN3 in transgenic Arabidopsis decreases glucose sensitivity.	Okayama Univ, Bioresources Res Inst, Kurashiki, Okayama 7100046, Japan; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Genet,Dept Mol Biol, Boston, MA 02114 USA	Okayama University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Yanagisawa, S (corresponding author), Okayama Univ, Bioresources Res Inst, Chuo 2-20-1, Kurashiki, Okayama 7100046, Japan.	yanagi-s@rib.okayama-u.ac.jp						Alonso JM, 1999, SCIENCE, V284, P2148, DOI 10.1126/science.284.5423.2148; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chang CC, 1999, PLANT CELL, V11, P911, DOI 10.1105/tpc.11.5.911; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; Cheng WH, 2002, PLANT CELL, V14, P2723, DOI 10.1105/tpc.006494; Fujimoto SY, 2000, PLANT CELL, V12, P393, DOI 10.1105/tpc.12.3.393; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; He JX, 2002, P NATL ACAD SCI USA, V99, P10185, DOI 10.1073/pnas.152342599; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; JANG JC, 1994, PLANT CELL, V6, P1665, DOI 10.1105/tpc.6.11.1665; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kosugi S, 2000, NUCLEIC ACIDS RES, V28, P960, DOI 10.1093/nar/28.4.960; Kovtun Y, 1998, NATURE, V395, P716, DOI 10.1038/27240; Lopez-Molina L, 2001, P NATL ACAD SCI USA, V98, P4782, DOI 10.1073/pnas.081594298; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; SHEEN J, 1993, EMBO J, V12, P3497, DOI 10.1002/j.1460-2075.1993.tb06024.x; SHEEN JY, 1986, EMBO J, V5, P3417, DOI 10.1002/j.1460-2075.1986.tb04663.x; Silverstone AL, 2001, PLANT CELL, V13, P1555, DOI 10.1105/tpc.13.7.1555; Smeekens S, 2000, ANNU REV PLANT PHYS, V51, P49, DOI 10.1146/annurev.arplant.51.1.49; Solano R, 1998, GENE DEV, V12, P3703, DOI 10.1101/gad.12.23.3703; Vierstra RD, 2003, TRENDS PLANT SCI, V8, P135, DOI 10.1016/S1360-1385(03)00014-1; Wang KLC, 2002, PLANT CELL, V14, pS131, DOI 10.1105/tpc.001768; Yanagisawa S, 1998, PLANT CELL, V10, P75, DOI 10.1105/tpc.10.1.75; Zhou L, 1998, P NATL ACAD SCI USA, V95, P10294, DOI 10.1073/pnas.95.17.10294; Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x	30	377	413	4	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					521	525		10.1038/nature01984	http://dx.doi.org/10.1038/nature01984			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523448				2022-12-24	WOS:000185648100047
J	Nathoo, S; Serghides, L; Kain, KC				Nathoo, S; Serghides, L; Kain, KC			Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes	LANCET			English	Article							MALARIA	In response to the HIV/AIDS pandemic, antiretroviral treatment is currently being implemented in sub-Saharan Africa, where malaria and HIV-1 co-infections are highly prevalent. The effectiveness and tolerability of antiretrovirals in patients with malaria and HIV-1 co-infection have not been investigated. Antiretrovirals decrease CD36 surface concentrations in vivo, which might impair receptor function and affect parasite-host interactions. Thus, we investigated the effects of these drugs on CD36-mediated cytoadherence and non-opsonic phagocytosis of Plasmodium falciparum parasitised erythrocytes in vitro. The protease-inhibitor class of antiretrovirals particularly impairs CD36-mediated cytoadherence and non-opsonic phagocytosis of parasitised erythrocytes by human macrophages. Such treatment might therefore contribute to altered malaria disease outcomes in co-infected patients.	Toronto Gen Hosp, Trop Dis Unit, Div Infect Dis, Dept Med,Univ Hlth Network, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Kain, KC (corresponding author), Toronto Gen Hosp, Trop Dis Unit, Div Infect Dis, Dept Med,Univ Hlth Network, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	kevin.kain@uhn.on.ca	Serghides, Lena/C-7968-2018	Serghides, Lena/0000-0002-2817-6134; Kain, Kevin/0000-0001-6068-1272				Aitman TJ, 2000, NATURE, V405, P1015, DOI 10.1038/35016636; Corbett EL, 2002, LANCET, V359, P2177, DOI 10.1016/S0140-6736(02)09095-5; Rogerson SJ, 1999, AM J TROP MED HYG, V61, P467, DOI 10.4269/ajtmh.1999.61.467; Serghides L, 2001, J IMMUNOL, V166, P6742, DOI 10.4049/jimmunol.166.11.6742; Serghides L, 2002, AIDS, V16, P353, DOI 10.1097/00002030-200202150-00006	5	51	52	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1039	1041		10.1016/S0140-6736(03)14414-5	http://dx.doi.org/10.1016/S0140-6736(03)14414-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522535				2022-12-24	WOS:000185564600012
J	Kamal, A; Thao, L; Sensintaffar, J; Zhang, L; Boehm, MF; Fritz, LC; Burrows, FJ				Kamal, A; Thao, L; Sensintaffar, J; Zhang, L; Boehm, MF; Fritz, LC; Burrows, FJ			A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors	NATURE			English	Article							HEAT-SHOCK PROTEINS; ATP BINDING; GELDANAMYCIN; CHAPERONE; DEGRADATION; EXPRESSION; DESTABILIZATION; HYDROLYSIS; CAPACITOR; RECEPTOR	Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signalling proteins, including HER-2/ErbB2, Akt, Raf-1, Bcr-Abl and mutated p53(1-7). Hsp90 inhibitors bind to Hsp90, and induce the proteasomal degradation of Hsp90 client proteins(6,8-11). Although Hsp90 is highly expressed in most cells, Hsp90 inhibitors selectively kill cancer cells compared to normal cells, and the Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG) is currently in phase I clinical trials(12,13). However, the molecular basis of the tumour selectivity of Hsp90 inhibitors is unknown. Here we report that Hsp90 derived from tumour cells has a 100-fold higher binding affinity for 17-AAG than does Hsp90 from normal cells. Tumour Hsp90 is present entirely in multi-chaperone complexes with high ATPase activity, whereas Hsp90 from normal tissues is in a latent, uncomplexed state. In vitro reconstitution of chaperone complexes with Hsp90 resulted in increased binding affinity to 17-AAG, and increased ATPase activity. These results suggest that tumour cells contain Hsp90 complexes in an activated, high-affinity conformation that facilitates malignant progression, and that may represent a unique target for cancer therapeutics.	Conforma Therapeut Corp, San Diego, CA 92121 USA		Burrows, FJ (corresponding author), Conforma Therapeut Corp, 9393 Towne Ctr dr,Suite 240, San Diego, CA 92121 USA.	fburrows@conformacorp.com						An WG, 2000, CELL GROWTH DIFFER, V11, P355; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Chiosis G, 2003, MOL CANCER THER, V2, P123; Chiosis G, 2001, CHEM BIOL, V8, P289, DOI 10.1016/S1074-5521(01)00015-1; EGORIN MJ, 1999, P AM ASSOC CANC RES, V40, P3409; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; GRESS TM, 1994, CANCER RES, V54, P547; Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; MILLER P, 1994, CANCER RES, V54, P2724; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHUH S, 1985, J BIOL CHEM, V260, P4292; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Solit DB, 2002, CLIN CANCER RES, V8, P986; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Workman P, 2003, MOL CANCER THER, V2, P131; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yano M, 1996, JPN J CANCER RES, V87, P908, DOI 10.1111/j.1349-7006.1996.tb02119.x	32	1123	1190	12	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					407	410		10.1038/nature01913	http://dx.doi.org/10.1038/nature01913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508491				2022-12-24	WOS:000185502300043
J	Davidson, AJ; Ernst, P; Wang, Y; Dekens, MPS; Kingsley, PD; Palis, J; Korsmeyer, SJ; Daley, GQ; Zon, LI				Davidson, AJ; Ernst, P; Wang, Y; Dekens, MPS; Kingsley, PD; Palis, J; Korsmeyer, SJ; Daley, GQ; Zon, LI			cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes	NATURE			English	Article							HOMEOBOX GENE; HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA; CAUDAL HOMOLOG; TAIL FORMATION; STEM-CELL; EXPRESSION; MICE; DROSOPHILA; EXPANSION	Organogenesis is dependent on the formation of distinct cell types within the embryo. Important to this process are the hox genes, which are believed to confer positional identities to cells along the anteroposterior axis(1-3). Here, we have identified the caudal-related gene cdx4 as the locus mutated in kugelig (kgg), a zebrafish mutant with an early defect in haematopoiesis that is associated with abnormal anteroposterior patterning and aberrant hox gene expression. The blood deficiency in kgg embryos can be rescued by overexpressing hoxb7a or hoxa9a but not hoxb8a, indicating that the haematopoietic defect results from perturbations in specific hox genes. Furthermore, the haematopoietic defect in kgg mutants is not rescued by scl overexpression, suggesting that cdx4 and hox genes act to make the posterior mesoderm competent for blood development. Overexpression of cdx4 during zebrafish development or in mouse embryonic stem cells induces blood formation and alters hox gene expression. Taken together, these findings demonstrate that cdx4 regulates hox genes and is necessary for the specification of haematopoietic cell fate during vertebrate embryogenesis.	Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02115 USA; Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Max Planck Inst Entwicklungsbiol, Genet Abt, D-72076 Tubingen, Germany; Univ Rochester, Dept Pediat, Ctr Human Genet & Mol Pediat Dis, Rochester, NY 14642 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Max Planck Society; University of Rochester	Zon, LI (corresponding author), Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02115 USA.			wang, Yuan/0000-0002-0939-1269; Palis, James/0000-0001-7324-1049; Ernst, Patricia/0000-0001-7638-2939; Dekens, Marcus P.S./0000-0003-1689-3491				Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Bjornsson JM, 2003, MOL CELL BIOL, V23, P3872, DOI 10.1128/MCB.23.11.3872-3883.2003; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Charite J, 1998, DEVELOPMENT, V125, P4349; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Chen F, 1998, MECH DEVELOP, V77, P49, DOI 10.1016/S0925-4773(98)00126-9; Edgar LG, 2001, DEV BIOL, V229, P71, DOI 10.1006/dbio.2000.9977; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; Hunter CP, 1999, DEVELOPMENT, V126, P805; JOLY JS, 1992, DIFFERENTIATION, V50, P75, DOI 10.1111/j.1432-0436.1992.tb00488.x; Kappen C, 2000, AM J HEMATOL, V65, P111, DOI 10.1002/1096-8652(200010)65:2<111::AID-AJH4>3.0.CO;2-Z; Katsuyama Y, 1999, DEV BIOL, V213, P257, DOI 10.1006/dbio.1999.9403; Kingsley PD, 2001, DEV GROWTH DIFFER, V43, P133; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Tamai Y, 1999, CANCER RES, V59, P2965; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; van den Akker E, 2002, DEVELOPMENT, V129, P2181	30	197	213	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					300	306		10.1038/nature01973	http://dx.doi.org/10.1038/nature01973			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679919				2022-12-24	WOS:000185370900047
J	Wilson, JF				Wilson, JF			How cloning could change medicine	ANNALS OF INTERNAL MEDICINE			English	Article													Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136					0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					535	538		10.7326/0003-4819-139-6-200309160-00036	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00036			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679343				2022-12-24	WOS:000185324100026
J	Lassen, A; Hallas, J; de Muckadell, OBS				Lassen, A; Hallas, J; de Muckadell, OBS			Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		Odense Univ Hosp, Dept Med Gastroenterol, DK-5000 Odense, Denmark; Odense Univ Hosp, Dept Internal Med, DK-5000 Odense, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital	Lassen, A (corresponding author), Odense Univ Hosp, Dept Med Gastroenterol, DK-5000 Odense, Denmark.		Lassen, Annmarie/AAA-5816-2019	Lassen, Annmarie/0000-0003-4942-6152; Hallas, Jesper/0000-0002-8097-8708; Schaffalitzky de Muckadell, Ove B/0000-0003-1969-2329				De Boer WA, 2001, GUT, V48, P567, DOI 10.1136/gut.48.4.567; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; Gaist D, 1997, DAN MED BULL, V44, P445; Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x; McColl KEL, 2000, AM J GASTROENTEROL, V95, P101	5	10	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					603	603		10.1136/bmj.327.7415.603	http://dx.doi.org/10.1136/bmj.327.7415.603			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969930	Green Published, Bronze			2022-12-24	WOS:000185358700026
J	Tkachev, D; Mimmack, ML; Ryan, MM; Wayland, M; Freeman, T; Jones, PB; Starkey, M; Webster, MJ; Yolken, RH; Bahn, S				Tkachev, D; Mimmack, ML; Ryan, MM; Wayland, M; Freeman, T; Jones, PB; Starkey, M; Webster, MJ; Yolken, RH; Bahn, S			Oligodendrocyte dysfunction in schizophrenia and bipolar disorder	LANCET			English	Article							GENE-EXPRESSION; PSYCHIATRIC-DISORDERS; UP-REGULATION; TARGET GENES; BRAIN; MYELIN; MICROARRAY; SUSCEPTIBILITY; PATHOLOGY; PROTEINS	Background Results of array studies have suggested abnormalities in expression of lipid and myelin-related genes in schizophrenia. Here, we investigated oligodendrocyte-specific and myelination-associated gene expression in schizophrenia and bipolar affective disorder. Methods We used samples from the Stanley brain collection, consisting of 15 schizophrenia, 15 bipolar affective disorder, and 15 control brains. Indexing-based differential display PCR was done to screen for differences in gene expression in schizophrenia patients versus controls. Results were cross-validated with quantitative PCR,, which was also used to investigate expression profiles of 16 other oligodendrocyte and myelin genes in schizophrenia and bipolar disorder. These genes were further investigated with an ongoing microarray analysis. Findings Results of differential display and quantitative PCR analysis showed a reduction of key oligodendrocyte-related and myelin-related genes in schizophrenia and bipolar patients; expression changes for both disorders showed a high degree of overlap. Microarray results of the same genes investigated by quantitative PCR correlated well overall. Interpretation Schizophrenia and bipolar brains showed downregulation of key oligodendrocyte and myelination genes, including transcription factors that regulate these genes, compared with control brains. These results lend support to and extend observations from other microarray investigations. Our study also showed similar expression changes to the schizophrenia group in bipolar brains, which thus lends support to the notion that the disorders share common causative and pathophysiological pathways.	Babraham Inst, Dept Neurobiol, Cambridge, England; UK Human Genome Mapping Project Resource Ctr, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England; Uniformed Serv Univ Hlth Sci, Dept Psychiat, Stanley Lab Brain Res, Bethesda, MD 20814 USA; Johns Hopkins Univ, Sch Med, Stanley Div Dev Neurovirol, Baltimore, MD USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Uniformed Services University of the Health Sciences - USA; Johns Hopkins University	Bahn, S (corresponding author), Univ Cambridge, Dept Psychiat, Cambridge CB2 2QQ, England.		Wayland, Matthew/V-6751-2019; yolken, robert/AAW-2556-2021	Wayland, Matthew/0000-0002-8095-858X; Jones, Peter Brian/0000-0002-0387-880X				Bahn S, 2002, LANCET, V359, P310, DOI 10.1016/S0140-6736(02)07497-4; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; BENES FM, 1986, ARCH GEN PSYCHIAT, V43, P31; Bertolino A, 2001, BIOL PSYCHIAT, V49, P39, DOI 10.1016/S0006-3223(00)00997-5; Bertolino A, 1998, BIOL PSYCHIAT, V43, P641, DOI 10.1016/S0006-3223(97)00555-6; Buchsbaum MS, 1998, NEUROREPORT, V9, P425, DOI 10.1097/00001756-199802160-00013; Colantuoni C, 2001, NEUROBIOL DIS, V8, P847, DOI 10.1006/nbdi.2001.0428; CONNOR JR, 1994, DEV NEUROSCI-BASEL, V16, P233, DOI 10.1159/000112115; Erikson KM, 1997, J NUTR, V127, P2030, DOI 10.1093/jn/127.10.2030; Foong J, 2000, J NEUROL NEUROSUR PS, V68, P70, DOI 10.1136/jnnp.68.1.70; Garbern JY, 2002, BRAIN, V125, P551, DOI 10.1093/brain/awf043; GOTTESMAN II, 1987, SCHIZOPHRENIA BULL, V13, P23, DOI 10.1093/schbul/13.1.23; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Hata R, 2001, BIOCHEM BIOPH RES CO, V284, P310, DOI 10.1006/bbrc.2001.4968; Ho L, 2001, NEUROSCI LETT, V298, P191, DOI 10.1016/S0304-3940(00)01753-5; Hof PR, 2002, NEUROCHEM RES, V27, P1193, DOI 10.1023/A:1020981510759; Horrobin DF, 1999, PROSTAG LEUKOTR ESS, V60, P141, DOI 10.1054/plef.1999.0027; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lim KO, 1999, ARCH GEN PSYCHIAT, V56, P367, DOI 10.1001/archpsyc.56.4.367; Lu QR, 2001, P NATL ACAD SCI USA, V98, P10851, DOI 10.1073/pnas.181340798; Marcus J, 2002, J CELL BIOL, V156, P567, DOI 10.1083/jcb.200111047; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Mayfield RD, 2002, J NEUROCHEM, V81, P802, DOI 10.1046/j.1471-4159.2002.00860.x; Maziade M, 1997, AM J MED GENET, V74, P311, DOI 10.1002/(SICI)1096-8628(19970531)74:3<311::AID-AJMG13>3.3.CO;2-C; Mimmack ML, 2002, P NATL ACAD SCI USA, V99, P4680, DOI 10.1073/pnas.032069099; Pongrac J, 2002, NEUROCHEM RES, V27, P1049, DOI 10.1023/A:1020904821237; Snider JV, 2001, DRUG DISCOV TODAY, V6, P1062, DOI 10.1016/S1359-6446(01)01988-2; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Torrey EF, 2000, SCHIZOPHR RES, V44, P151, DOI 10.1016/S0920-9964(99)00192-9; Uranova N, 2001, BRAIN RES BULL, V55, P597, DOI 10.1016/S0361-9230(01)00528-7; Whitney LW, 1999, ANN NEUROL, V46, P425; Wood JN, 2000, J PAIN, V1, P19, DOI 10.1054/jpai.2000.9807a; Wurmbach E, 2001, J BIOL CHEM, V276, P47195, DOI 10.1074/jbc.M108716200; Yool DA, 2000, HUM MOL GENET, V9, P987, DOI 10.1093/hmg/9.6.987; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	36	722	751	1	36	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 6	2003	362	9386					798	805		10.1016/S0140-6736(03)14289-4	http://dx.doi.org/10.1016/S0140-6736(03)14289-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DN	13678875				2022-12-24	WOS:000185188500014
J	Chen, W; ten Berge, D; Brown, J; Ahn, S; Hu, LA; Miller, WE; Caron, MG; Barak, LS; Nusse, R; Lefkowitz, RJ				Chen, W; ten Berge, D; Brown, J; Ahn, S; Hu, LA; Miller, WE; Caron, MG; Barak, LS; Nusse, R; Lefkowitz, RJ			Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4	SCIENCE			English	Article							COUPLED RECEPTOR KINASES; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; PROTEINS; ACTIVATION; SIGNALS; ADAPTER	Wnt proteins, regulators of development in many organisms, bind to seven transmembrane-spanning (7TMS) receptors called frizzleds, thereby recruiting the cytoplasmic molecule dishevelled (Dvl) to the plasma membrane. Frizzled-mediated endocytosis of Wg (a Drosophila Wnt protein) and lysosomal degradation may regulate the formation of morphogen gradients. Endocytosis of Frizzled 4 (Fz4) in human embryonic kidney 293 cells was dependent on added Wnt5A protein and was accomplished by the multifunctional adaptor protein beta-arrestin 2 (betaarr2), which was recruited to Fz4 by binding to phosphorylated Dvl2. These findings provide a previously unrecognized mechanism for receptor recruitment of beta-arrestin and demonstrate that Dvl plays an important role in the endocytosis of frizzled, as well as in promoting signaling.	Stanford Univ, Sch Med, Beckman Ctr, Dept Dev Biol,Howard Hughes Med Inst, Stanford, CA 94305 USA; Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA	Howard Hughes Medical Institute; Stanford University; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Nusse, R (corresponding author), Stanford Univ, Sch Med, Beckman Ctr, Dept Dev Biol,Howard Hughes Med Inst, Stanford, CA 94305 USA.		Lefkowitz, Robert/AAW-2649-2021; Berge, Derk ten/ABF-2591-2020; Berge, Derk ten/C-1967-2012	Berge, Derk ten/0000-0002-5863-0860; Chen, Wei/0000-0002-9934-4000	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037, R01HL061365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16037, HL 61365] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Chen W, 2001, P NATL ACAD SCI USA, V98, P14889, DOI 10.1073/pnas.211572798; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Dubois L, 2001, CELL, V105, P613, DOI 10.1016/S0092-8674(01)00375-0; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	22	259	270	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1391	1394		10.1126/science.1082808	http://dx.doi.org/10.1126/science.1082808			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958364				2022-12-24	WOS:000185116400045
J	Bloss, TA; Witze, ES; Rothman, JH				Bloss, TA; Witze, ES; Rothman, JH			Suppression of CED-3-independent apoptosis by mitochondrial beta NAC in Caenorhabditis elegans	NATURE			English	Article							PROGRAMMED CELL-DEATH; C-ELEGANS; IDENTIFICATION	To ensure cell survival, it is essential that the ubiquitous proapoptotic machinery is kept quiescent. As death is irreversible, cells must continually integrate developmental information with regulatory inputs to control the switch between repressing and activating apoptosis. Inappropriate activation or suppression of apoptosis can lead to degenerative pathologies(1) or tumorigenesis(2), respectively. Here we report that Caenorhabditis elegans inhibitor of cell death-1 (ICD-1) is necessary and sufficient to prevent apoptosis. Loss of ICD-1 leads to inappropriate apoptosis in developing and differentiated cells in various tissues. Although this apoptosis requires CED-4, it occurs independently of CED-3-the caspase essential for developmental apoptosis(3) showing that these core pro-apoptotic proteins have separable roles. Overexpressing ICD-1 inhibits the apoptosis of cells that are normally programmed to die. ICD-1 is the beta-subunit of the nascent polypeptide-associated complex (bNAC) and contains a putative caspase-cleavage site and caspase recruitment domain. It localizes primarily to mitochondria, underscoring the role of mitochondria in coordinating apoptosis(4). Human bNAC is a caspase substrate that is rapidly eliminated in dying cells(5,6), suggesting that ICD-1 apoptosis-suppressing activity may be inactivated by caspases.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Rothman, JH (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.							Brockstedt E, 1999, J PROTEIN CHEM, V18, P225, DOI 10.1023/A:1020636308270; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; HALL D, 1995, CAENORHABDITIS ELEGA, P396; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hersh BM, 2002, P NATL ACAD SCI USA, V99, P4355, DOI 10.1073/pnas.062065399; Hodgkin J, 1997, C ELEGANS, P881; Kamath C, 2001, MASSIVE COMP, V2, P1; Ledwich D, 2000, METHOD ENZYMOL, V322, P76; LEWIS JA, 1995, CAENORHABDITIS ELEGA, P4; Liu QA, 1999, ANN NY ACAD SCI, V887, P92, DOI 10.1111/j.1749-6632.1999.tb07925.x; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; MILLER DM, 1995, CAENORHABDITIS ELEGA, P365; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Rospert S, 2002, CELL MOL LIFE SCI, V59, P1632, DOI 10.1007/PL00012490; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Seshagiri S, 1998, FEBS LETT, V428, P71, DOI 10.1016/S0014-5793(98)00493-1; Shaham S, 1998, J BIOL CHEM, V273, P35109, DOI 10.1074/jbc.273.52.35109; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; Vaughn DE, 1999, J MOL BIOL, V293, P439, DOI 10.1006/jmbi.1999.3177; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Xu KL, 2001, NEURON, V31, P957, DOI 10.1016/S0896-6273(01)00432-9; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	29	86	105	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1066	1071		10.1038/nature01920	http://dx.doi.org/10.1038/nature01920			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944970				2022-12-24	WOS:000184984200046
J	Bourlat, SJ; Nielsen, C; Lockyer, AE; Littlewood, DTJ; Telford, MJ				Bourlat, SJ; Nielsen, C; Lockyer, AE; Littlewood, DTJ; Telford, MJ			Xenoturbella is a deuterostome that eats molluscs	NATURE			English	Article							PHYLUM UNCERTAIN; BOCKI; PLATYHELMINTHES; FLATWORMS; SEQUENCE; SUPPORT	Xenoturbella bocki, first described in 1949 (ref. 1), is a delicate, ciliated, marine worm with a simple body plan: it lacks a through gut, organized gonads, excretory structures and coelomic cavities. Its nervous system is a diffuse nerve net with no brain. Xenoturbella's affinities have long been obscure and it was initially linked to turbellarian flatworms(1). Subsequent authors considered it variously as related to hemichordates and echinoderms owing to similarities of nerve net and epidermal ultrastructure (2,3), to acoelomorph flatworms based on body plan and ciliary ultrastructure(4-6) (also shared by hemichordates(7)), or as among the most primitive of Bilateria(8). In 1997 two papers seemed to solve this uncertainty: molecular phylogenetic analyses(9) placed Xenoturbella within the bivalve molluscs, and eggs and larvae resembling those of bivalves were found within specimens of Xenoturbella(10,11). This molluscan origin implies that all bivalve characters are lost during a radical metamorphosis into the adult Xenoturbella. Here, using data from three genes, we show that the samples in these studies were contaminated by bivalve embryos eaten by Xenoturbella and that Xenoturbella is in fact a deuterostome related to hemichordates and echinoderms.	Univ Cambridge, Dept Zool, Museum Zool, Cambridge CB2 3EJ, England; Univ Copenhagen, Zool Museum, DK-2100 Copenhagen, Denmark; Nat Hist Museum, Dept Zool, London SW7 5BD, England	University of Cambridge; University of Copenhagen; Natural History Museum London	Telford, MJ (corresponding author), Univ Cambridge, Dept Zool, Museum Zool, Downing St, Cambridge CB2 3EJ, England.		Bourlat, Sarah/AAR-2251-2020; Littlewood, Tim/B-5230-2008; Bourlat, Sarah/A-5232-2009; Nielsen, Claus/A-4794-2013; Telford, Maximilian J/B-7178-2008; Lockyer, Anne/AAO-4327-2021	Littlewood, Tim/0000-0002-2718-4001; Bourlat, Sarah/0000-0003-0218-0298; Telford, Maximilian J/0000-0002-3749-5620; Lockyer, Anne/0000-0002-3498-2423; Nielsen, Claus/0000-0001-6898-7655				Castresana J, 1998, P NATL ACAD SCI USA, V95, P3703, DOI 10.1073/pnas.95.7.3703; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Ehlers U, 1997, ZOOMORPHOLOGY, V117, P71; FRANZEN A, 1987, ZOOL SCR, V16, P9, DOI 10.1111/j.1463-6409.1987.tb00046.x; Gee H., 1996, BACKBONE VIEWS ORIGI; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Israelsson O, 1999, P ROY SOC B-BIOL SCI, V266, P835, DOI 10.1098/rspb.1999.0713; Israelsson O, 1997, NATURE, V390, P32, DOI 10.1038/36246; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Lundin K, 1998, ZOOL SCR, V27, P263, DOI 10.1111/j.1463-6409.1998.tb00440.x; Lundin K, 2001, BELG J ZOOL, V131, P153; Maddison WP, 2000, MACCLADE 4 ANAL PHYL; Noren M, 1997, NATURE, V390, P31, DOI 10.1038/36242; PARDOS F, 1988, ACTA ZOOL-STOCKHOLM, V69, P1, DOI 10.1111/j.1463-6395.1988.tb00895.x; PEDERSEN KJ, 1986, ACTA ZOOL-STOCKHOLM, V67, P103, DOI 10.1111/j.1463-6395.1986.tb00854.x; REISINGER ERICH, 1960, ZEITSCHR WISS ZOOL, V164, P188; Swofford DL, 1998, PHYLOGENETIC ANAL US; Telford MJ, 2003, P ROY SOC B-BIOL SCI, V270, P1077, DOI 10.1098/rspb.2003.2342; Telford MJ, 2000, P NATL ACAD SCI USA, V97, P11359, DOI 10.1073/pnas.97.21.11359; Westblad E., 1949, ARK ZOOL, V1, P3	21	128	131	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					925	928		10.1038/nature01851	http://dx.doi.org/10.1038/nature01851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931184				2022-12-24	WOS:000184843600037
J	Sugiura, R; Kita, A; Shimizu, Y; Shuntoh, H; Sio, SO; Kuno, T				Sugiura, R; Kita, A; Shimizu, Y; Shuntoh, H; Sio, SO; Kuno, T			Feedback regulation of MAPK signalling by an RNA-binding protein	NATURE			English	Article							FISSION YEAST; KH-DOMAIN; IN-VIVO; KINASE; PHOSPHATASE; PATHWAYS; ENCODES; STRESS; POMBE	Mitogen-activated protein kinases (MAPKs) are evolutionarily conserved enzymes that convert extracellular signals into various outputs such as cell growth, differentiation and cell death(1-4). MAPK phosphatases selectively inactivate MAPKs by dephosphorylating critical phosphothreonine and phosphotyrosine residues(5,6). The transcriptional induction of MAPK phosphatase expression by various stimuli, including MAPK activation, has been well documented as a negative-feedback mechanism of MAPK signalling(7,8). Here we show that Rnc1, a novel K-homology-type RNA-binding protein in fission yeast, binds and stabilizes Pmp1 messenger RNA(9), the MAPK phosphatase for Pmk1 (refs 10, 11). Rnc1 therefore acts as a negative regulator of Pmk1 signalling. Notably, Pmk1 phosphorylates Rnc1, causing enhancement of the RNA-binding activity of Rnc1. Thus, Rnc1 is a component of a new negative-feedback loop that regulates the Pmk1 pathway through its binding to Pmp1 mRNA. Our findings-the post-transcriptional mRNA stabilization of a MAPK phosphatase mediated by an RNA-binding protein-provide an additional regulatory mechanism for fine-tuning of MAPK signalling pathways.	Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Mol Pharmacol & Pharmacogenom, Kobe, Hyogo 6500017, Japan; Kobe Univ, Sch Med, Fac Hlth Sci, Suma Ku, Kobe, Hyogo 6540142, Japan	Kobe University; Kobe University	Sugiura, R (corresponding author), Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Mol Pharmacol & Pharmacogenom, Kobe, Hyogo 6500017, Japan.							Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOHRER K, 1988, NUCLEIC ACIDS RES, V6, P9457; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Loewith R, 2000, J CELL SCI, V113, P153; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; RODRIGUEZ PL, 1994, BIOTECHNIQUES, V17, P702; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Sugiura R, 1999, NATURE, V399, P479, DOI 10.1038/20951; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Toda T, 1996, MOL CELL BIOL, V16, P6752; YOSHIDA T, 1994, J CELL SCI, V107, P1725; ZaitsevskayaCarter T, 1997, EMBO J, V16, P1318, DOI 10.1093/emboj/16.6.1318	24	57	61	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					961	965		10.1038/nature01907	http://dx.doi.org/10.1038/nature01907			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931193				2022-12-24	WOS:000184843600046
J	KewalRamani, VN; Coffin, JM				KewalRamani, VN; Coffin, JM			Weapons of mutational destruction	SCIENCE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL VIF PROTEIN; REVERSE TRANSCRIPTION; G->A HYPERMUTATION; HIV-1 VIRIONS; TYPE-1 VIF; SOR GENE; DNA; REPLICATION; INFECTION		NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA; Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tufts University	KewalRamani, VN (corresponding author), NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA.		KewalRamani, Vineet/V-5084-2019		NATIONAL CANCER INSTITUTE [ZIABC010487, Z01BC010487] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gaddis NC, 2003, J VIROL, V77, P5810, DOI 10.1128/JVI.77.10.5810-5820.2003; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Gunther S, 1997, VIROLOGY, V235, P104, DOI 10.1006/viro.1997.8676; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Klarmann GJ, 2003, J BIOL CHEM, V278, P7902, DOI 10.1074/jbc.M207223200; Korth MJ, 2000, CURR TOP MICROBIOL, V242, P197; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Ochsenbauer C, 1997, J GEN VIROL, V78, P627, DOI 10.1099/0022-1317-78-3-627; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Vartanian JP, 2002, J GEN VIROL, V83, P801, DOI 10.1099/0022-1317-83-4-801; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WAINHOBSON S, 1995, VIROLOGY, V209, P297, DOI 10.1006/viro.1995.1261; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	29	29	31	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					923	925		10.1126/science.1088965	http://dx.doi.org/10.1126/science.1088965			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920286	Green Published			2022-12-24	WOS:000184755900023
J	Bala, ADS; Spitzer, MW; Takahashi, TT				Bala, ADS; Spitzer, MW; Takahashi, TT			Prediction of auditory spatial acuity from neural images on the owl's auditory space map	NATURE			English	Article							INTERAURAL TIME DIFFERENCE; SOUND-LOCALIZATION; SINGLE NEURONS; BARN OWL; PSYCHOPHYSICAL PERFORMANCE; PERCEPTUAL DECISION; RECEPTIVE-FIELDS; MACAQUE MONKEY; VISUAL-MOTION; DISCRIMINATION	The owl can discriminate changes in the location of sound sources as small as 3degrees and can aim its head to within 2degrees of a source(1,2). Atypical neuron in its midbrain space map has a spatial receptive field that spans 40degrees- a width that is many times the behavioural threshold(3). Here we have quantitatively examined the relationship between neuronal activity and perceptual acuity in the auditory space map in the barn owl midbrain. By analysing changes in firing rate resulting from small changes of stimulus azimuth, we show that most neurons can reliably signal changes in source location that are smaller than the behavioural threshold. Each source is represented in the space map by a focus of activity in a population of neurons. Displacement of the source causes the pattern of activity in this population to change. We show that this change predicts the owl's ability to detect a change in source location.	Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	University of Oregon	Bala, ADS (corresponding author), Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.		Bala, Avinash/B-7923-2013	Bala, Avinash/0000-0002-8531-5110				AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; [Anonymous], 1998, NEURAL NETWORKS BRAI; Bala ADS, 2000, J COMP PHYSIOL A, V186, P425, DOI 10.1007/s003590050442; BALDI P, 1988, BIOL CYBERN, V59, P313, DOI 10.1007/BF00332921; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; Bell CC, 2001, CURR OPIN NEUROBIOL, V11, P481, DOI 10.1016/S0959-4388(00)00238-5; Britten KH, 1999, J NEUROSCI, V19, P5074; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; COLBURN HS, 1973, J ACOUST SOC AM, V54, P1458, DOI 10.1121/1.1914445; Eurich CW, 1997, BIOL CYBERN, V76, P357, DOI 10.1007/s004220050349; FAREL PB, 1976, J NEUROPHYSIOL, V39, P661, DOI 10.1152/jn.1976.39.4.661; Fitzpatrick DC, 1997, NATURE, V388, P871, DOI 10.1038/42246; FUJITA I, 1991, J NEUROSCI, V11, P722; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Gold JI, 2000, NATURE, V404, P390, DOI 10.1038/35006062; HALL JL, 1965, J ACOUST SOC AM, V37, P813; Kandel E R, 1976, Cold Spring Harb Symp Quant Biol, V40, P465; Keller CH, 1998, HEARING RES, V118, P13, DOI 10.1016/S0378-5955(98)00014-8; KNUDSEN EI, 1977, SCIENCE, V198, P1278, DOI 10.1126/science.929202; KNUDSEN EI, 1979, J COMP PHYSIOL, V133, P13, DOI 10.1007/BF00663106; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; O'Reilly RC, 2002, TRENDS COGN SCI, V6, P505, DOI 10.1016/S1364-6613(02)02005-3; Recanzone GH, 2000, J NEUROPHYSIOL, V83, P2723, DOI 10.1152/jn.2000.83.5.2723; ROLLS ET, 1989, EUR J NEUROSCI, V1, P53, DOI 10.1111/j.1460-9568.1989.tb00774.x; SAKITT B, 1973, NATURE, V241, P133, DOI 10.1038/241133a0; Shackleton TM, 2003, J NEUROSCI, V23, P716, DOI 10.1523/JNEUROSCI.23-02-00716.2003; Shadlen MN, 1996, J NEUROSCI, V16, P1486; Siebert WM., 1968, RECOGNIZING PATTERNS, V104, P602; SOKOLOV EN, 1963, ANNU REV PHYSIOL, V25, P545, DOI 10.1146/annurev.ph.25.030163.002553; ZOHARY E, 1994, NATURE, V370, P140, DOI 10.1038/370140a0	30	76	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					771	774		10.1038/nature01835	http://dx.doi.org/10.1038/nature01835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917684				2022-12-24	WOS:000184733900039
J	Papa, FR; Zhang, C; Shokat, K; Walter, P				Papa, FR; Zhang, C; Shokat, K; Walter, P			Bypassing a kinase activity with an ATP-competitive drug	SCIENCE			English	Article							UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; RNASE-L; TRANSMEMBRANE PROTEIN; TYROSINE KINASES; NUCLEUS; IRE1P; ER; PHOSPHORYLATION; DIMERIZATION	Unfolded proteins in the endoplasmic reticulum cause trans-autophosphorylation of the bifunctional transmembrane kinase Ire1, which induces its endoribonuclease activity. The endoribonuclease initiates nonconventional splicing of HAC1 messenger RNA to trigger the unfolded-protein response (UPR). We explored the role of Ire1's kinase domain by sensitizing it through site-directed mutagenesis to the ATP-competitive inhibitor 1NM-PP1. Paradoxically, rather than being inhibited by 1NM-PP1, drug-sensitized Ire1 mutants required 1NM-PP1 as a cofactor for activation. In the presence of 1NM-PP1, drug-sensitized Ire1 bypassed mutations that inactivate its kinase activity and induced a full UPR. Thus, rather than through phosphorylation per se, a conformational change in the kinase domain triggered by occupancy of the active site with a ligand leads to activation of all known downstream functions.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Papa, FR (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.		Longo, Kenneth A/A-5631-2010	Papa, Feroz/0000-0002-3684-9108	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032384, R01GM032384] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44009] Funding Source: Medline; NIGMS NIH HHS [GM32384] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; Carroll AS, 2001, P NATL ACAD SCI USA, V98, P12578, DOI 10.1073/pnas.211195798; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dong BH, 1999, NUCLEIC ACIDS RES, V27, P439, DOI 10.1093/nar/27.2.439; Dong BH, 2001, RNA, V7, P361, DOI 10.1017/S1355838201002230; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; MORI K, 1993, CELL, V74, P743; Naik S, 1998, NUCLEIC ACIDS RES, V26, P1522, DOI 10.1093/nar/26.6.1522; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Schuit F, 1999, J BIOL CHEM, V274, P32803, DOI 10.1074/jbc.274.46.32803; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, J CELL SCI, V113, P3697; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Weiss EL, 2000, NAT CELL BIOL, V2, P677, DOI 10.1038/35036300	29	195	205	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 28	2003	302	5650					1533	1537		10.1126/science.1090031	http://dx.doi.org/10.1126/science.1090031			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	747JV	14564015				2022-12-24	WOS:000186802200033
J	Huxter, J; Burgess, N; O'Keefe, J				Huxter, J; Burgess, N; O'Keefe, J			Independent rate and temporal coding in hippocampal pyramidal cells	NATURE			English	Article							THETA-PHASE PRECESSION; PLACE CELLS; NEURONAL-ACTIVITY; OSCILLATIONS; MEMORY; EXPERIENCE; EXPANSION; SEQUENCES; DYNAMICS; POSITION	In the brain, hippocampal pyramidal cells use temporal(1) as well as rate(2) coding to signal spatial aspects of the animal's environment or behaviour. The temporal code takes the form of a phase relationship to the concurrent cycle of the hippocampal electroencephalogram theta rhythm(1). These two codes could each represent a different variable(3,4). However, this requires the rate and phase to vary independently, in contrast to recent suggestions(5,6) that they are tightly coupled, both reflecting the amplitude of the cell's input. Here we show that the time of firing and firing rate are dissociable, and can represent two independent variables: respectively the animal's location within the place field, and its speed of movement through the field. Independent encoding of location together with actions and stimuli occurring there may help to explain the dual roles of the hippocampus in spatial and episodic memory(7,8), or may indicate a more general role of the hippocampus in relational/declarative memory(9,10).	UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; UCL, Inst Cognit Neurosci, London WC1E 6BT, England	University of London; University College London; University of London; University College London	O'Keefe, J (corresponding author), UCL, Dept Anat & Dev Biol, Gower St, London WC1E 6BT, England.	j.okeefe@ucl.ac.uk	Burgess, Neil/B-2420-2009	Burgess, Neil/0000-0003-0646-6584	MRC [G117/433] Funding Source: UKRI; Medical Research Council [G117/433, G0501672(76328), G0501672] Funding Source: Medline; Wellcome Trust [071248] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BURGESS N, 1994, NEURAL NETWORKS, V7, P1065, DOI 10.1016/S0893-6080(05)80159-5; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Eichenbaum HE, 2001, CONDITIONING CONSCIO; Ekstrom AD, 2001, NEURON, V31, P631, DOI 10.1016/S0896-6273(01)00401-9; Harris KD, 2002, NATURE, V417, P738, DOI 10.1038/nature00808; Hirase H, 1999, EUR J NEUROSCI, V11, P4373, DOI 10.1046/j.1460-9568.1999.00853.x; Jensen O, 1996, LEARN MEMORY, V3, P279, DOI 10.1101/lm.3.2-3.279; Jensen O, 2000, J NEUROPHYSIOL, V83, P2602, DOI 10.1152/jn.2000.83.5.2602; Kahana MJ, 1999, NATURE, V399, P781, DOI 10.1038/21645; Kamondi A, 1998, HIPPOCAMPUS, V8, P244, DOI 10.1002/(SICI)1098-1063(1998)8:3<244::AID-HIPO7>3.0.CO;2-J; Lengyel M, 2003, HIPPOCAMPUS, V13, P700, DOI 10.1002/hipo.10116; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; Mehta MR, 2002, NATURE, V417, P741, DOI 10.1038/nature00807; Mehta MR, 1997, P NATL ACAD SCI USA, V94, P8918, DOI 10.1073/pnas.94.16.8918; Moita MAP, 2003, NEURON, V37, P485, DOI 10.1016/S0896-6273(03)00033-3; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKeefe J, 1996, NATURE, V381, P425, DOI 10.1038/381425a0; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; OKeefe J, 1991, BRAIN SPACE, P273, DOI DOI 10.1016/j.neuron.2015.06.011; Pike FG, 2000, J PHYSIOL-LONDON, V529, P205, DOI 10.1111/j.1469-7793.2000.00205.x; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Tsodyks MV, 1996, HIPPOCAMPUS, V6, P271, DOI 10.1002/(SICI)1098-1063(1996)6:3<271::AID-HIPO5>3.3.CO;2-Q; Wallenstein GV, 1997, J NEUROPHYSIOL, V78, P393, DOI 10.1152/jn.1997.78.1.393; WIENER SI, 1989, J NEUROSCI, V9, P2737; Wood ER, 1999, NATURE, V397, P613, DOI 10.1038/17605; Yamaguchi Y, 2002, J NEUROPHYSIOL, V87, P2629, DOI 10.1152/jn.2002.87.6.2629	30	417	427	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					828	832		10.1038/nature02058	http://dx.doi.org/10.1038/nature02058			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574410	Green Accepted			2022-12-24	WOS:000186118500043
J	Couzin, J				Couzin, J			Aging research - Is long life in the blood?	SCIENCE			English	News Item																			0	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					373	+						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14563979				2022-12-24	WOS:000185963200006
J	Finney, SJ; Zekveld, C; Elia, A; Evans, TW				Finney, SJ; Zekveld, C; Elia, A; Evans, TW			Glucose control and mortality in critically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	99th International Conference of the American-Thoracic-Society	MAY, 2003	SEATTLE, WASHINGTON	Amer Thorac Soc			ACUTE MYOCARDIAL-INFARCTION; INTENSIVE INSULIN THERAPY; ADMISSION PLASMA-GLUCOSE; INDEPENDENT RISK-FACTOR; DIABETIC-PATIENTS; HYPERGLYCEMIA; INFUSION; TRIAL; MODULATION; FAILURE	Context Hyperglycemia is common in critically ill patients, even in those without diabetes mellitus. Aggressive glycemic control may reduce mortality in this population. However, the relationship between mortality, the control of hyperglycemia, and the administration of exogenous insulin is unclear. Objective To determine whether blood glucose level or quantity of insulin administered is associated with reduced mortality in critically ill patients. Design, Setting, and Patients Single-center, prospective, observational study of 531 patients (median age, 64 years) newly admitted over the first 6 months of 2002 to an adult intensive care unit (ICU) in a UK national referral center for cardiorespiratory surgery and medicine. Main Outcome Measures The primary end point was intensive care unit (ICU) mortality. Secondary end points were hospital mortality, ICU and hospital length of stay, and predicted threshold glucose level associated with risk of death.. Results Of 531 patients admitted to the ICU, 523 underwent analysis of their glycemic control. Twenty-four-hour control of blood glucose levels was variable. Rates of ICU and hospital mortality were 5.2% and 5.7%, respectively; median lengths of stay were 1.8 (interquartile range, 0.9-3.7) days and 6 (interquartile range, 4.5-8.3) days, respectively. Multivariable logistic regression demonstrated that increased administration of insulin was positively and significantly associated with ICU mortality (odds ratio, 1.02 [95% confidence interval, 1.01-1.04] at a prevailing glucose level of 111-144 mg/dL [6.1-8.0 mmol/L] for a 1-IU/d increase), suggesting that mortality benefits are attributable to glycemic control rather than increased administration of insulin. Also, the regression models suggest that a mortality benefit accrues below a predicted threshold glucose level of 144 to 200 mg/dL (8.0-11.1 mmol/L), with a speculative upper limit of 145 mg/dL (8.0 mmol/L) for the target blood glucose level. Conclusions increased insulin administration is positively associated with death in the ICU regardless of the prevailing blood glucose level. Thus, control of glucose levels rather than of absolute levels of exogenous insulin appear to account for the mortality benefit associated with intensive insulin therapy demonstrated by others.	Royal Brompton Hosp, Adult Intens Care Unit, London SW3 6LY, England; Royal Brompton Hosp, Dept Occupat & Environm Med, London SW3 6LY, England; Royal Brompton Hosp, Dept Biomed Engn, London SW3 6LY, England	Royal Brompton Hospital; Royal Brompton Hospital; Royal Brompton Hospital	Evans, TW (corresponding author), Royal Brompton Hosp, Adult Intens Care Unit, Sydney St, London SW3 6LY, England.		Finney, Simon/A-2168-2012	Finney, Simon/0000-0001-8219-1952				Annane D, 2003, CRIT CARE MED, V31, P634, DOI 10.1097/01.CCM.0000045569.14948.F2; British Association for Parenteral and Enteral Nutrition, 1996, STAND GUID NUTR SUPP; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; *DEP HLTH, 2000, HOSP ACT STAT; Dhatariya K, 2003, JAMA-J AM MED ASSOC, V289, P1244, DOI 10.1001/jama.289.10.1244-a; Diaz R, 1998, CIRCULATION, V98, P2227, DOI 10.1161/01.CIR.98.21.2227; Evans TW, 2001, NEW ENGL J MED, V345, P1417, DOI 10.1056/NEJM200111083451910; Furnary AP, 1999, ANN THORAC SURG, V67, P352, DOI 10.1016/S0003-4975(99)00014-4; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; McManus LM, 2001, J LEUKOCYTE BIOL, V70, P395; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; Montori VM, 2002, JAMA-J AM MED ASSOC, V288, P2167, DOI 10.1001/jama.288.17.2167; Norhammar AM, 1999, DIABETES CARE, V22, P1827, DOI 10.2337/diacare.22.11.1827; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wass CT, 1996, MAYO CLIN PROC, V71, P801; Zindrou D, 2001, DIABETES CARE, V24, P1634, DOI 10.2337/diacare.24.9.1634	23	688	730	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2041	2047		10.1001/jama.290.15.2041	http://dx.doi.org/10.1001/jama.290.15.2041			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CX	14559958	Bronze			2022-12-24	WOS:000185924200028
J	Deng, YB; Ren, XY; Yang, L; Lin, YH; Wu, XW				Deng, YB; Ren, XY; Yang, L; Lin, YH; Wu, XW			A JNK-dependent pathway is required for TNF alpha-induced apoptosis	CELL			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAY; INDUCED CELL-DEATH; CYTOCHROME-C; CASPASE ACTIVATION; MITOCHONDRIA; INDUCTION; INHIBITION; PROMOTES; PROTEIN	Tumor necrosis factor (TNFalpha) receptor signaling can simultaneously activate caspase 8, the transcription factor, NF-KB and the kinase, JNK. While activation of caspase 8 is required for TNFalpha-induced apoptosis, and induction of NF-KB inhibits cell death, the precise function of JNK activation in TNFa signaling is not clearly understood. Here, we report that TNFalpha-mediated caspase 8 cleavage and apoptosis require a sequential pathway involving JNK, Bid, and Smac/DIABLO. Activation of JNK induces caspase 8-independent cleavage of Bid at a distinct site to generate the Bid cleavage product jBid. Translocation of jBid to mitochondria leads to preferential release of Smac/DIABLO, but not cytochrome c. The released Smac/DIABLO then disrupts the TRAF2-cIAP1 complex. We propose that the JNK pathway described here is required to relieve the inhibition imposed by TRAF2-cIAP1 on caspase 8 activation and induction of apoptosis. Further, our findings define a mechanism for crosstalk between intrinsic and extrinsic cell death pathways.	Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Wu, XW (corresponding author), Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.		ren, xianyan/J-3165-2018	Deng, Yibin/0000-0001-5711-3565				Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LUO ZG, 1996, CELL, V94, P481; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; VAN AD, 1996, SCIENCE, V274, P787; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XD, 2001, GENE DEV, V15, P2922; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	44	474	494	1	34	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					61	70		10.1016/S0092-8674(03)00757-8	http://dx.doi.org/10.1016/S0092-8674(03)00757-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532003	Bronze			2022-12-24	WOS:000185815500009
J	Kim, D; Park, D; Choi, S; Lee, S; Sun, M; Kim, C; Shin, HS				Kim, D; Park, D; Choi, S; Lee, S; Sun, M; Kim, C; Shin, HS			Thalamic control of visceral nociception mediated by T-type Ca2+ channels	SCIENCE			English	Article							THALAMOCORTICAL RELAY; CALCIUM CHANNELS; DORSAL COLUMN; SPINAL-CORD; NEURONS; BURST; RESPONSES; PATHWAY; NUCLEUS; RATS	Sensations from viscera, like fullness, easily become painful if the stimulus persists. Mice lacking alpha1GT-typeCa(2+) channels show hyperalgesia to visceral pain. Thalamic infusion of a T-type blocker induced similar hyperalgesia in wild-type mice. In response to visceral pain, the ventroposterolateral thalamic neurons evoked a surge of single spikes, which then slowly decayed as T type-dependent burst spikes gradually increased. In alpha1G-deficient neurons, the single-spike response persisted without burst spikes. These results indicate that T-type Ca2+ channels underlie an antinociceptive mechanism operating in the thalamus and support the idea that burst. ring plays a critical role in sensory gating in the thalamus.	Korea Inst Sci & Technol, Natl Creat Res Initiat Ctr Calcium & Learning, Seoul 136791, South Korea	Korea Institute of Science & Technology (KIST)	Shin, HS (corresponding author), Korea Inst Sci & Technol, Natl Creat Res Initiat Ctr Calcium & Learning, Seoul 136791, South Korea.	shin@kist.re.kr	Kim, Daesoo/C-1625-2011	Kim, Daesoo/0000-0001-9915-1463				AlChaer ED, 1996, J NEUROPHYSIOL, V76, P2661, DOI 10.1152/jn.1996.76.4.2661; BAL T, 1993, J PHYSIOL-LONDON, V468, P669, DOI 10.1113/jphysiol.1993.sp019794; Clozel JP, 1997, J HYPERTENS, V15, pS17, DOI 10.1097/00004872-199715055-00004; CRUNELLI V, 1989, J PHYSIOL-LONDON, V413, P543, DOI 10.1113/jphysiol.1989.sp017668; Dogrul A, 1998, GEN PHARMACOL-VASC S, V30, P613, DOI 10.1016/S0306-3623(97)00335-2; GUIDO W, 1992, J NEUROPHYSIOL, V68, P2199, DOI 10.1152/jn.1992.68.6.2199; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P205, DOI 10.1113/jphysiol.1984.sp015153; Jeanmonod D, 1996, BRAIN, V119, P363, DOI 10.1093/brain/119.2.363; Kim D, 2001, NEURON, V31, P35, DOI 10.1016/S0896-6273(01)00343-9; Le Masson G, 2002, NATURE, V417, P854, DOI 10.1038/nature00825; Llinas R, 2001, ANN NY ACAD SCI, V929, P166; LLINAS R, 1982, NATURE, V297, P406, DOI 10.1038/297406a0; Matthews EA, 2001, EUR J PHARMACOL, V415, P141, DOI 10.1016/S0014-2999(01)00812-3; MCCORMICK DA, 1990, NEUROSCIENCE, V39, P103, DOI 10.1016/0306-4522(90)90225-S; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Mogil JS, 1999, PAIN, V80, P67, DOI 10.1016/S0304-3959(98)00197-3; Montero VM, 1999, NEUROSCIENCE, V91, P805, DOI 10.1016/S0306-4522(98)00632-0; SEYBOLD VS, 1995, CAN J PHYSIOL PHARM, V73, P1007, DOI 10.1139/y95-141; Sherman SM, 2001, TRENDS NEUROSCI, V24, P122, DOI 10.1016/S0166-2236(00)01714-8; Sherman SM, 2001, NAT NEUROSCI, V4, P344, DOI 10.1038/85973; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; STERIADE M, 1984, BRAIN RES REV, V8, P1, DOI 10.1016/0165-0173(84)90017-1; Steriade M, 2001, NAT NEUROSCI, V4, P671, DOI 10.1038/89434; Steriade M., 1997, THALAMUS; Talley EM, 1999, J NEUROSCI, V19, P1895; Todorovic SM, 2002, BRAIN RES, V951, P336, DOI 10.1016/S0006-8993(02)03350-4; Todorovic SM, 2001, NEURON, V31, P75, DOI 10.1016/S0896-6273(01)00338-5; Willis WD, 1999, P NATL ACAD SCI USA, V96, P7675, DOI 10.1073/pnas.96.14.7675	29	189	199	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					117	119		10.1126/science.1088886	http://dx.doi.org/10.1126/science.1088886			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526084				2022-12-24	WOS:000185678500049
J	Alon, U				Alon, U			Biological networks: The tinkerer as an engineer	SCIENCE			English	Editorial Material							TRANSCRIPTIONAL REGULATION; GENE-REGULATION; ROBUSTNESS; MOTIFS; ORGANIZATION; EVOLUTION	This viewpoint comments on recent advances in understanding the design principles of biological networks. It highlights the surprising discovery of "good-engineering" principles in biochemical circuitry that evolved by random tinkering.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Alon, U (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	urialon@weizmann.ac.il						Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; Arkin A, 1997, SCIENCE, V277, P1275, DOI 10.1126/science.277.5330.1275; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BRAY D, 1990, J THEOR BIOL, V143, P215, DOI 10.1016/S0022-5193(05)80268-1; Conant GC, 2003, NAT GENET, V34, P264, DOI 10.1038/ng1181; Csete ME, 2002, SCIENCE, V295, P1664, DOI 10.1126/science.1069981; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eldar A, 2002, NATURE, V419, P304, DOI 10.1038/nature01061; Fell D., 1997, UNDERSTANDING CONTRO; Gardner TS, 2003, SCIENCE, V301, P102, DOI 10.1126/science.1081900; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; KACSER H, 1973, S SOC EXP BIOL, V32, P65; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lipson H, 2002, EVOLUTION, V56, P1549, DOI 10.1111/j.0014-3820.2002.tb01466.x; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; MYERS CR, 2003, CONDMAT0305575; Rao CV, 2001, ANNU REV BIOMED ENG, V3, P391, DOI 10.1146/annurev.bioeng.3.1.391; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Ronen M, 2002, P NATL ACAD SCI USA, V99, P10555, DOI 10.1073/pnas.152046799; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; Savageau M, 1976, BIOCH SYSTEMS ANAL S; SAVAGEAU MA, 1971, NATURE, V229, P542, DOI 10.1038/229542a0; Setty Y, 2003, P NATL ACAD SCI USA, V100, P7702, DOI 10.1073/pnas.1230759100; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WAGNER A, 2003, SCI STKE, pPE41; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896	34	410	429	5	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1866	1867		10.1126/science.1089072	http://dx.doi.org/10.1126/science.1089072			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512615				2022-12-24	WOS:000185536700037
J	Pealer, LN; Marfin, AA; Petersen, LR; Lanciotti, RS; Page, PL; Stramer, SL; Stobierski, MG; Signs, K; Newman, B; Kapoor, H; Goodman, JL; Chamberland, ME				Pealer, LN; Marfin, AA; Petersen, LR; Lanciotti, RS; Page, PL; Stramer, SL; Stobierski, MG; Signs, K; Newman, B; Kapoor, H; Goodman, JL; Chamberland, ME		W Nile Virus Transmission Investig	Transmission of West Nile virus through blood transfusion in the United States in 2002	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; ENCEPHALITIS; EPIDEMIC; INFECTION; RISK	BACKGROUND: During the 2002 West Nile virus epidemic in the United States, patients were identified whose West Nile virus illness was temporally associated with the receipt of transfused blood and blood components. METHODS: Patients with laboratory evidence of recent West Nile virus infection within four weeks after receipt of a blood component from a donor with viremia were considered to have a confirmed transfusion-related infection. We interviewed the donors of these components, asking them whether they had had symptoms compatible with the presence of a viral illness before or after their donation; blood specimens retained from the time of donation and collected at follow-up were tested for West Nile virus. RESULTS: Twenty-three patients were confirmed to have acquired West Nile virus through transfused leukoreduced and nonleukoreduced red cells, platelets, or fresh-frozen plasma. Of the 23 recipients, 10 (43 percent) were immunocompromised owing to transplantation or cancer and 8 (35 percent) were at least 70 years of age. Immunocompromised recipients tended to have longer incubation periods than nonimmunocompromised recipients and infected persons in mosquito-borne community outbreaks. Sixteen donors with evidence of viremia at donation were linked to the 23 infected recipients; of these donors, 9 reported viral symptoms before or after donation, 5 were asymptomatic, and 2 were lost to follow-up. Fever, new rash, and painful eyes were independently associated with being an implicated donor with viremia rather than a donor without viremia. All 16 donors were negative for West Nile virus-specific IgM antibody at donation. CONCLUSIONS: Transfused red cells, platelets, and fresh-frozen plasma can transmit West Nile virus. Screening of potential donors with the use of nucleic acid-based assays for West Nile virus may reduce this risk.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; CDC, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA; Amer Red Cross, Blood Serv, Biomed Headquarters, Washington, DC 20006 USA; Amer Red Cross, Blood Serv, Sci Support Off, Gaithersburg, MD USA; Michigan Dept Community Hlth, Bur Labs, Lansing, MI USA; Amer Red Cross, Blood Serv, Detroit, MI USA; US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; American Red Cross; American Red Cross; MDHHS - Michigan Department of Health & Human Services; American Red Cross; US Food & Drug Administration (FDA)	Pealer, LN (corresponding author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, 1600 Clifton Rd,D-18, Atlanta, GA 30333 USA.			Basile, Alison Jane/0000-0002-5646-1557				[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P833; [Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P790; Biggerstaff BJ, 2002, TRANSFUSION, V42, P1019, DOI 10.1046/j.1537-2995.2002.00167.x; Campbell GL, 2002, LANCET INFECT DIS, V2, P519, DOI 10.1016/S1473-3099(02)00368-7; *CDCP, 2003, EP EP W NIL VIR US R; Chamberland ME, 2002, CLIN INFECT DIS, V34, P797, DOI 10.1086/338787; *FOOD DRUG ADM, 2003, GUID IND REV REC ASS; Harrington T, 2003, TRANSFUSION, V43, P1018, DOI 10.1046/j.1537-2995.2003.00481.x; Huang CN, 2002, EMERG INFECT DIS, V8, P1367, DOI 10.3201/eid0812.020532; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Lanciotti RS, 2000, J CLIN MICROBIOL, V38, P4066, DOI 10.1128/JCM.38.11.4066-4071.2000; Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000; Mostashari F, 2001, LANCET, V358, P261, DOI 10.1016/S0140-6736(01)05480-0; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Petersen LR, 2002, ANN INTERN MED, V137, P173, DOI 10.7326/0003-4819-137-3-200208060-00009; Roehrig JT, 2002, CURR TOP MICROBIOL, V267, P223; SOUTHAM CM, 1954, AM J TROP MED HYG, V3, P19, DOI 10.4269/ajtmh.1954.3.19; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; 2003, MMWR MORB MORTAL WKL, V52, P769; 2001, MMWR MORB MORTAL WKL, V50, P37; 2002, MMWR MORB MORTAL WKL, V51, P1129; 2000, MMWR MORB MORTAL WKL, V50, P101; 2002, MMWR MORB MORTAL WKL, V51, P929	23	434	464	0	19	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2003	349	13					1236	1245		10.1056/NEJMoa030969	http://dx.doi.org/10.1056/NEJMoa030969			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LJ	14500806				2022-12-24	WOS:000185488800006
J	Gaucher, EA; Thomson, JM; Burgan, MF; Benner, SA				Gaucher, EA; Thomson, JM; Burgan, MF; Benner, SA			Inferring the palaeoenvironment of ancient bacteria on the basis of resurrected proteins	NATURE			English	Article							ELONGATION-FACTOR TU; COMMON ANCESTOR; EVOLUTION; THERMOSTABILITY; RIBONUCLEASE; DIVERSITY; SEQUENCES; LIFE	Features of the physical environment surrounding an ancestral organism can be inferred by reconstructing sequences(1-9) of ancient proteins made by those organisms, resurrecting these proteins in the laboratory, and measuring their properties. Here, we resurrect candidate sequences for elongation factors of the Tu family (EF-Tu) found at ancient nodes in the bacterial evolutionary tree, and measure their activities as a function of temperature. The ancient EF-Tu proteins have temperature optima of 55-65degreesC. This value seems to be robust with respect to uncertainties in the ancestral reconstruction. This suggests that the ancient bacteria that hosted these particular genes were thermophiles, and neither hyperthermophiles nor mesophiles. This conclusion can be compared and contrasted with inferences drawn from an analysis of the lengths of branches in trees joining proteins from contemporary bacteria(10), the distribution of thermophily in derived bacterial lineages(11), the inferred G+C content of ancient ribosomal RNA(12), and the geological record combined with assumptions concerning molecular clocks(13). The study illustrates the use of experimental palaeobiochemistry and assumptions about deep phylogenetic relationships between bacteria to explore the character of ancient life.	Univ Florida, NASA, Astrobiol Inst, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32611 USA; Univ Florida, Dept Chem, Gainesville, FL 32611 USA	National Aeronautics & Space Administration (NASA); State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Gaucher, EA (corresponding author), Univ Florida, NASA, Astrobiol Inst, Gainesville, FL 32611 USA.		Gaucher, Eric/I-7313-2013	Green, Michelle/0000-0002-6055-4342				Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; ARAI KI, 1972, J BIOL CHEM, V247, P7029; Benner SA, 2002, SCIENCE, V296, P864, DOI 10.1126/science.1069863; Brochier C, 2002, NATURE, V417, P244, DOI 10.1038/417244a; Cavalier-Smith T, 2002, INT J SYST EVOL MICR, V52, P7, DOI 10.1099/00207713-52-1-7; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; Chang BSW, 2002, MOL BIOL EVOL, V19, P1483, DOI 10.1093/oxfordjournals.molbev.a004211; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Galtier N, 1999, SCIENCE, V283, P220, DOI 10.1126/science.283.5399.220; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Gaucher EA, 2001, P NATL ACAD SCI USA, V98, P548, DOI 10.1073/pnas.98.2.548; Golding GB, 1998, MOL BIOL EVOL, V15, P355, DOI 10.1093/oxfordjournals.molbev.a025932; Gromiha MM, 1999, BIOPHYS CHEM, V82, P51, DOI 10.1016/S0301-4622(99)00103-9; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; Miyazaki J, 2001, J BIOCHEM-TOKYO, V129, P777, DOI 10.1093/oxfordjournals.jbchem.a002919; NOCK S, 1995, EUR J BIOCHEM, V234, P132, DOI 10.1111/j.1432-1033.1995.00132.x; PAULING L, 1963, ACTA CHEM SCAND, V17, pS9; Sanangelantoni AM, 1996, MICROBIOL-UK, V142, P2525, DOI 10.1099/00221287-142-9-2525; STACKHOUSE J, 1990, FEBS LETT, V262, P104, DOI 10.1016/0014-5793(90)80164-E; SWOFFORD DL, 2002, PAUP PHYLOGENETIC AN; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG Z, 1999, COMPUT APPL BIOSCI, V13, P555; YANG ZH, 1995, GENETICS, V141, P1641; Zhang JZ, 2002, P NATL ACAD SCI USA, V99, P5486, DOI 10.1073/pnas.072626199	30	180	188	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					285	288		10.1038/nature01977	http://dx.doi.org/10.1038/nature01977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679914				2022-12-24	WOS:000185370900042
J	McMahon, BJ; Hennessy, TW; Bensler, JM; Bruden, DL; Parkinson, AJ; Morris, JM; Reasonover, AL; Hurlburt, DA; Bruce, MG; Sacco, F; Butler, JC				McMahon, BJ; Hennessy, TW; Bensler, JM; Bruden, DL; Parkinson, AJ; Morris, JM; Reasonover, AL; Hurlburt, DA; Bruce, MG; Sacco, F; Butler, JC			The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections	ANNALS OF INTERNAL MEDICINE			English	Article							ANTIBIOTIC-RESISTANCE; METRONIDAZOLE RESISTANCE; TRIPLE THERAPIES; HIGH PREVALENCE; UNITED-STATES; RISK-FACTORS; CLARITHROMYCIN; ERADICATION; SUSCEPTIBILITY; POPULATION	Background: The relationship between previous antimicrobial treatments and infection with drug-resistant Helicobacter pylori is unknown. Objectives: To determine whether previous use of antimicrobial agents predicts subsequent antibiotic resistance of H. pylori and whether resistance affects treatment outcome. Design: Retrospective cohort analysis of adults recruited sequentially from a clinical practice. Setting: A referral hospital in Anchorage, Alaska. Patients: 125 adults infected with H. pylori. Measurements: Medical records were reviewed for antimicrobial agents prescribed in the 10 years before diagnosis with H. pylori infection. Antimicrobial susceptibility of H. pylori isolates obtained from endoscopic gastric biopsy was determined by using agar dilution, Cure was determined by using the urea breath test 2 months after antimicrobial treatment. Results: Among the 125 patients, 37 (30%) were found to have H. pylori isolates resistant to clarithromycin and 83 (66%) were found to have H. pylori isolates resistant to metronidazole. Resistance to clarithromycin was associated with previous use of any macrolide antibiotic (P < 0.001), and resistance to metronidazole was associated with previous use of metronidazole (P < 0.001). The odds of isolates being resistant to clarithromycin increased in relation to the number of courses of macrolides received (P < 0.001). Among 53 persons treated with clarithromycin-based regimens, treatment failed in 77% of those carrying clarithromycin-resistant H. pylori (10 of 13) and 13% of those with clarithromycin-susceptible strains (5 of 40) (relative risk, 6.2 [95% Cl, 1.9 to 37.1]; P < 0.001). Conclusions: Previous use of macrolides and metronidazole is associated with H. pylori resistant to these antimicrobial agents. Clarithromycin resistance is associated with a greater risk for failure with clarithromycin-based treatments.	CDCP, Arctic Invest Program, Natl Ctr Infect Dis, Anchorage, AK 99508 USA; Alaska Native Med Ctr, Anchorage, AK USA	Alaska Native Medical Center	McMahon, BJ (corresponding author), CDCP, Arctic Invest Program, Natl Ctr Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.	bdm9@cdc.gov						Alarcon T, 1999, INT J ANTIMICROB AG, V12, P19, DOI 10.1016/S0924-8579(99)00051-5; BANATVALA N, 1994, GUT, V35, P1562, DOI 10.1136/gut.35.11.1562; Bardhan PK, 1997, CLIN INFECT DIS, V25, P973, DOI 10.1086/516067; Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; Blaser MJ, 1997, J CLIN INVEST, V100, P759, DOI 10.1172/JCI119588; Blecker U, 1997, PEDIATR INFECT DIS J, V16, P391, DOI 10.1097/00006454-199704000-00011; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; CASELLA G, 1986, CAN J STAT, V14, P113, DOI 10.2307/3314658; Centers for Disease Control and Prevention (CDC), 2016, DEV WAT MAN PROGR RE; Dore MP, 2000, DIGEST DIS SCI, V45, P68, DOI 10.1023/A:1005457226341; Dowell SF, 1998, PEDIATRICS, V101, P163; Falk GW, 1997, CLEV CLIN J MED, V64, P187, DOI 10.3949/ccjm.64.4.187; Fraser AG, 1999, AUST NZ J MED, V29, P512, DOI 10.1111/j.1445-5994.1999.tb00752.x; Gonzales R, 2001, ANN INTERN MED, V134, P479, DOI 10.7326/0003-4819-134-6-200103200-00013; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; Greenberg PD, 1999, ARCH INTERN MED, V159, P2283, DOI 10.1001/archinte.159.19.2283; Hoshiya S, 2000, J GASTROENTEROL, V35, P10; Katelaris PH, 2002, GASTROENTEROLOGY, V123, P1763, DOI 10.1053/gast.2002.37051; Laine L, 2001, ANN INTERN MED, V134, P361, DOI 10.7326/0003-4819-134-5-200103060-00008; Lautenbach E, 2001, CLIN INFECT DIS, V32, P1162, DOI 10.1086/319757; Leach AJ, 1997, CLIN INFECT DIS, V24, P356, DOI 10.1093/clinids/24.3.356; Mandell Lionel A., 2000, Clinical Infectious Diseases, V31, P383, DOI 10.1086/313959; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; McColl K, 1998, NEW ENGL J MED, V339, P1869, DOI 10.1056/NEJM199812243392601; Megraud F, 1999, ANTIMICROB AGENTS CH, V43, P2747, DOI 10.1128/AAC.43.11.2747; Meyer JM, 2002, ANN INTERN MED, V136, P13, DOI 10.7326/0003-4819-136-1-200201010-00008; Miehlke S, 2001, Semin Gastrointest Dis, V12, P167; Miyaji H, 1997, ALIMENT PHARM THERAP, V11, P1131, DOI 10.1046/j.1365-2036.1997.00258.x; Moayyedi P, 2000, LANCET, V355, P1665, DOI 10.1016/S0140-6736(00)02236-4; Moayyedi P, 1998, J GASTROENTEROL, V33, P62; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Osato MS, 1999, INT J ANTIMICROB AG, V12, P341, DOI 10.1016/S0924-8579(99)00079-5; Osato MS, 2001, ARCH INTERN MED, V161, P1217, DOI 10.1001/archinte.161.9.1217; Parkinson AJ, 2000, CLIN DIAGN LAB IMMUN, V7, P885, DOI 10.1128/CDLI.7.6.885-888.2000; PETERSON WL, 1993, AM J GASTROENTEROL, V88, P1860; Pilotto A, 1999, ALIMENT PHARM THER, V13, P667; Pilotto A, 2000, DIGEST LIVER DIS, V32, P763, DOI 10.1016/S1590-8658(00)80352-7; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; RICHARD P, 1994, J INFECT DIS, V170, P377, DOI 10.1093/infdis/170.2.377; Rozynek E, 1997, EUR J CLIN MICROBIOL, V16, P943, DOI 10.1007/BF01700566; Taylor DE, 1998, CAN J GASTROENTEROL, V12, P295, DOI 10.1155/1998/672746; TYTGAT GNJ, 1990, GASTROENTEROL CLIN N, V19, P183; van der Hulst RWM, 1998, GUT, V42, P166, DOI 10.1136/gut.42.2.166; Wolle K, 1998, EUR J CLIN MICROBIOL, V17, P519, DOI 10.1007/BF01691138; Xia HHX, 1997, AM J GASTROENTEROL, V92, P1780; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65; 2000, PERFORMANCE STANDARD, V20, P1	49	143	151	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					463	469		10.7326/0003-4819-139-6-200309160-00008	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679322				2022-12-24	WOS:000185324100001
J	Schoofs, MWCJ; van der Klift, M; Hofman, A; de Laet, CEDH; Herings, RMC; Stijnen, T; Pols, HAP; Stricker, BHC				Schoofs, MWCJ; van der Klift, M; Hofman, A; de Laet, CEDH; Herings, RMC; Stijnen, T; Pols, HAP; Stricker, BHC			Thiazide diuretics and the risk for hip fracture	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MINERAL DENSITY; NORMAL POSTMENOPAUSAL WOMEN; OSTEOPOROTIC FRACTURES; CONTROLLED-TRIAL; LONG-TERM; ROTTERDAM; MEN; HYDROCHLOROTHIAZIDE; QUESTIONNAIRE; EPIDEMIOLOGY	Background: Since most hip fractures are related to osteoporosis, treating accelerated bone loss can be an important strategy to prevent hip fractures. Thiazides have been associated with reduced age-related bone loss by decreasing urinary calcium excretion. Objective: To examine the association between dose and duration of thiazide diuretic use and the risk for hip fracture and to study the consequences of discontinuing use. Design: Prospective population-based cohort study. Setting: The Rotterdam Study. Participants: 7891 individuals 55 years of age and older. Measurements: Hip fractures were reported by the general practitioners and verified by trained research assistants. Details of all dispensed drugs were available on a day-to-day basis. Exposure to thiazides was divided into 7 mutually exclusive categories: never use, current use for 1 to 42 days, current use for 43 to 365 days, current use for more than 365 days, discontinuation of use since 1 to 60 days, discontinuation of use since 61 to 120 days, and discontinuation of use since more than 120 days. Results: 281 hip fractures occurred. Relative to nonuse, current use of thiazides for more than 365 days was statistically significantly associated with a lower risk for hip fracture (hazard ratio, 0.46 [95% Cl, 0.21 to 0.96]). There was no clear dose dependency. This lower risk disappeared approximately 4 months after thiazide use was discontinued. Conclusions: Thiazide diuretics protect against hip fracture, but this protective effect disappears within 4 months after use is discontinued.	Erasmus Univ, Ctr Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Stricker, BHC (corresponding author), Erasmus Univ, Ctr Med, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Herings, Ron/AAE-4096-2021	Herings, Ron/0000-0002-2561-8734; De Laet, Chris/0000-0002-1951-2079				Adams JS, 1999, ANN INTERN MED, V130, P658, DOI 10.7326/0003-4819-130-8-199904200-00012; ADLANDDAVENPORT P, 1985, AM J OBSTET GYNECOL, V152, P630, DOI 10.1016/S0002-9378(85)80035-1; [Anonymous], 1992, INT STAT CLASS DIS R, V1-3; Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; Aubin R, 1996, KIDNEY INT, V50, P1476, DOI 10.1038/ki.1996.461; BURGER H, 1994, BONE MINER, V25, P1, DOI 10.1016/S0169-6009(08)80203-6; Burger H, 1998, AM J EPIDEMIOL, V147, P871, DOI 10.1093/oxfordjournals.aje.a009541; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; DUARTE CG, 1971, NEW ENGL J MED, V284, P828, DOI 10.1056/NEJM197104152841506; FELSON DT, 1991, JAMA-J AM MED ASSOC, V265, P370, DOI 10.1001/jama.265.3.370; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; HALE WE, 1984, NEW ENGL J MED, V310, P926; HEIDRICH FE, 1991, ANN INTERN MED, V115, P1, DOI 10.7326/0003-4819-115-1-1; Herings RMC, 1996, J CLIN EPIDEMIOL, V49, P115, DOI 10.1016/0895-4356(95)00552-8; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; LaCroix AZ, 2000, ANN INTERN MED, V133, P516, DOI 10.7326/0003-4819-133-7-200010030-00010; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; Lajeunesse D, 2000, J BONE MINER RES, V15, P894, DOI 10.1359/jbmr.2000.15.5.894; Meijer WT, 1998, ARTERIOSCL THROM VAS, V18, P185, DOI 10.1161/01.ATV.18.2.185; MELTON LJ, 1993, BONE, V14, pS1; MORTON DJ, 1994, AM J EPIDEMIOL, V139, P1107, DOI 10.1093/oxfordjournals.aje.a116954; Moser M, 1998, JAMA-J AM MED ASSOC, V279, P1813, DOI 10.1001/jama.279.22.1813; Onder G, 2001, J HUM HYPERTENS, V15, P291, DOI 10.1038/sj.jhh.1001176; PEH CA, 1993, J AM GERIATR SOC, V41, P513, DOI 10.1111/j.1532-5415.1993.tb01887.x; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; RASHIQ S, 1986, BRIT MED J, V292, P861, DOI 10.1136/bmj.292.6524.861; RAY WA, 1989, LANCET, V1, P687; Reid IR, 2000, AM J MED, V109, P362, DOI 10.1016/S0002-9343(00)00510-6; Savage PJ, 1998, ARCH INTERN MED, V158, P741, DOI 10.1001/archinte.158.7.741; Sigurdsson G, 2001, J INTERN MED, V250, P51, DOI 10.1046/j.1365-2796.2001.00850.x; TRANSBOL I, 1982, METABOLISM, V31, P383, DOI 10.1016/0026-0495(82)90115-9; Twisk J, 2002, J CLIN EPIDEMIOL, V55, P329, DOI 10.1016/S0895-4356(01)00476-0; VANDERKUY A, 2000, FARMACOTHERAPEUTISCH, P523; WASNICH RD, 1986, OBSTET GYNECOL, V67, P457; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; *WHO COLL CTR DRUG, 1993, AN THER CHEM IND; *WHO COLL CTR DRUG, 1992, AN THER CHEM IND INC; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	42	146	155	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					476	482		10.7326/0003-4819-139-6-200309160-00010	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679324	Green Published			2022-12-24	WOS:000185324100003
J	Sjolund, M; Wreiber, K; Andersson, DI; Blaser, MJ; Engstrand, L				Sjolund, M; Wreiber, K; Andersson, DI; Blaser, MJ; Engstrand, L			Long-term persistence of resistant enterococcus species after antibiotics to eradicate Helicobacter pylori	ANNALS OF INTERNAL MEDICINE			English	Article							GROUP-A STREPTOCOCCI; BIOLOGICAL COST; MACROLIDE RESISTANCE; DETERMINANTS; PCR	Background: Antibiotic treatment selects for resistance not only in the pathogen to which it is directed but also in the indigenous microflora. Objective: To determine whether a widely used regimen (clarithromycin, metronidazole, and omeprazole) for Helicobacter pylori eradication affects resistance development in enterococci. Design: Cohort study. Setting: Endoscopy units at 3 community hospitals in Sweden. Patients: 5 consecutive dyspeptic patients who were colonized with H. pylori, had endoscopy-confirmed duodenal ulcer, and received antibiotic treatment, and 5 consecutive controls with dyspepsia but no ulcer who did not receive treatment. Measurements: Fecal samples were obtained from patients and controls before, immediately after, 1 year after, and 3 years after treatment. From each patient and sample, enterococci were isolated and analyzed for DNA fingerprint, clarithromycin susceptibility, and presence of the erm(B) gene. Results: in treated patients, all enterococci isolated immediately after treatment showed high-level clarithromycin resistance due to erm(B). In 3 patients, resistant enterococci persisted for 1 to 3 years after treatment. No resistance developed among controls. Conclusion: A common H. pylori treatment selects for highly resistant enterococci that can persist for at least 3 years without further selection.	Swedish Inst Infect Dis Control, Dept Bacteriol, SE-17182 Solna, Sweden	Swedish Institute for Infectious Disease Control	Engstrand, L (corresponding author), Swedish Inst Infect Dis Control, Dept Bacteriol, SE-17182 Solna, Sweden.	lars.engstrand@smi.ki.se		Andersson, Dan/0000-0001-6640-2174	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM63270] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3; Bjorkholm B, 2001, P NATL ACAD SCI USA, V98, P14607, DOI 10.1073/pnas.241517298; Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; Cresti S, 2002, ANTIMICROB AGENTS CH, V46, P1816, DOI 10.1128/AAC.46.6.1816-1822.2002; Descheemaeker P, 1997, INT J SYST BACTERIOL, V47, P555, DOI 10.1099/00207713-47-2-555; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; KUIPERS EJ, 1995, ALIMENT PHARM THERAP, V9, P59; Levy SB, 2002, J ANTIMICROB CHEMOTH, V49, P25, DOI 10.1093/jac/49.1.25; Maiden MCJ, 1998, CLIN INFECT DIS, V27, pS12, DOI 10.1086/514917; Martinez JL, 2000, ANTIMICROB AGENTS CH, V44, P1771, DOI 10.1128/AAC.44.7.1771-1777.2000; Megraud F, 2000, GASTROENTEROL CLIN N, V29, P759, DOI 10.1016/S0889-8553(05)70145-X; Murray BE, 1999, P ASSOC AM PHYSICIAN, V111, P328, DOI 10.1046/j.1525-1381.1999.99241.x; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; Nagaev I, 2001, MOL MICROBIOL, V40, P433, DOI 10.1046/j.1365-2958.2001.02389.x; Portillo A, 2000, ANTIMICROB AGENTS CH, V44, P967, DOI 10.1128/AAC.44.4.967-971.2000; Sander P, 2002, ANTIMICROB AGENTS CH, V46, P1204, DOI 10.1128/AAC.46.5.1204-1211.2002; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; Shoemaker NB, 2001, APPL ENVIRON MICROB, V67, P561, DOI 10.1128/AEM.67.2.561-568.2001; Sutcliffe J, 1996, ANTIMICROB AGENTS CH, V40, P2562, DOI 10.1128/AAC.40.11.2562	20	109	124	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					483	487		10.7326/0003-4819-139-6-200309160-00011	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679325				2022-12-24	WOS:000185324100004
J	Coupland, C; Hippisley-Cox, J; Kendrick, D; Groom, L; Cross, E; Savelyich, B				Coupland, C; Hippisley-Cox, J; Kendrick, D; Groom, L; Cross, E; Savelyich, B			Severe traffic injuries to children, Trent, 1992-7: time trend analysis	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England	University of Nottingham	Coupland, C (corresponding author), Univ Nottingham, Div Primary Care, Nottingham NG7 2RD, England.		Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Kendrick, Denise/0000-0003-3603-6542; Coupland, Carol/0000-0002-2327-3306				Cryer PC, 2000, PUBLIC HEALTH, V114, P232; Hippisley-Cox J, 2002, BRIT MED J, V324, P1132, DOI 10.1136/bmj.324.7346.1132; *OFF NAT STAT, 2001, MORT STAT INJ POIS; THOMPSON DC, 1999, COCHRANE LIB; Towner E, 2001, Inj Prev, V7, P161, DOI 10.1136/ip.7.2.161	5	9	10	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					593	594		10.1136/bmj.327.7415.593	http://dx.doi.org/10.1136/bmj.327.7415.593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969925	Green Published, Bronze			2022-12-24	WOS:000185358700021
J	Clack, JA; Ahlberg, PE; Finney, SM; Alonso, PD; Robinson, J; Ketcham, RA				Clack, JA; Ahlberg, PE; Finney, SM; Alonso, PD; Robinson, J; Ketcham, RA			A uniquely specialized ear in a very early tetrapod	NATURE			English	Article							PHOLIDERPETON-SCUTIGERUM HUXLEY; EARLY EVOLUTION; COAL MEASURES; ACANTHOSTEGA; AMPHIBIANS; STAPES; FOSSIL	The Late Devonian genus Ichthyostega was for many decades the earliest known tetrapod, and the sole representative of a transitional form between a fish and a land vertebrate. However, despite being known since 1932 (ref. 1) from a large collection of specimens, its morphology remained enigmatic and not what was expected of a very primitive tetrapod(2). Its apparent specializations led it to be considered as a "blind offshoot"(3) or "side-branch"(4) off the tetrapod family tree, and recent cladistic analyses have disagreed about its exact phylogenetic position(5-8) within the tetrapod stem group. In particular, its braincase and ear region defied interpretation, such that conventional anatomical terms seemed inapplicable(4). Using new material collected in 1998 (ref. 9), preparation of earlier-collected material, and high-resolution computed tomography scanning, here we identify and interpret these problematic anatomical structures. They can now be seen to form part of a highly specialized ear, probably a hearing device for use in water. This represents a structurally and functionally unique modification of the tetrapod otic region, unlike anything seen in subsequent tetrapod evolution. The presence of deeply grooved gill bars as in its contemporary Acanthostega(10) suggest that Ichthyostega may have been more aquatically adapted than previously believed.	Univ Museum Zool, Cambridge CB2 3EJ, England; Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England; Univ Texas, Dept Geol Sci, High Resolut Xray CT Facil, Austin, TX 78712 USA	University of Cambridge; Natural History Museum London; University of Texas System; University of Texas Austin	Clack, JA (corresponding author), Univ Museum Zool, Downing St, Cambridge CB2 3EJ, England.	j.a.clack@zoo.cam.ac.uk	Ketcham, Richard/B-5431-2011; Ahlberg, Per/E-8086-2013; Domínguez Alonso, Patricio/C-2679-2013	Ketcham, Richard/0000-0002-2748-0409; Ahlberg, Per/0000-0001-9054-2900				Ahlberg PE, 1998, T ROY SOC EDIN-EARTH, V89, P11, DOI 10.1017/S0263593300002340; Ahlberg PE, 1996, NATURE, V381, P61, DOI 10.1038/381061a0; BERNACSEK GM, 1981, CAN J EARTH SCI, V18, P150, DOI 10.1139/e81-012; CLACK JA, 1987, PHILOS T ROY SOC B, V318, P1, DOI 10.1098/rstb.1987.0082; Clack JA, 1998, ZOOL J LINN SOC-LOND, V122, P61, DOI 10.1006/zjls.1997.0114; CLACK JA, 1983, ZOOL J LINN SOC-LOND, V79, P121, DOI 10.1111/j.1096-3642.1983.tb01163.x; Clack JA, 2002, J NEUROBIOL, V53, P251, DOI 10.1002/neu.10129; Clack JA, 2002, NATURE, V418, P72, DOI 10.1038/nature00824; Clack JA, 2000, GEOL SOC SPEC PUBL, V180, P557, DOI 10.1144/GSL.SP.2000.180.01.29; COATES MI, 1991, NATURE, V352, P234, DOI 10.1038/352234a0; Dominguez P, 2002, NATURE, V417, P841, DOI 10.1038/nature00805; HETHERINGTON TE, 1982, J EXP BIOL, V98, P49; Jarvik E., 1952, Meddelelser om Gronland, V114, P1; Jarvik E., 1980, BASIC STRUCTURE EVOL, V1; Jarvik Erik, 1996, Fossils and Strata, V40, P1; Ketcham RA, 2001, COMPUT GEOSCI-UK, V27, P381, DOI 10.1016/S0098-3004(00)00116-3; Laurin M, 1998, ANN SCI NAT ZOOL, V19, P1, DOI 10.1016/S0003-4339(98)80132-9; Ruta M, 2003, BIOL REV, V78, P251, DOI 10.1017/S1464793102006103; Save-Soderbergh G., 1932, Medd Grenland, V94 T, P1; SMITHSON TR, 1982, ZOOL J LINN SOC-LOND, V74, P93, DOI 10.1111/j.1096-3642.1982.tb01142.x; SMITHSON TR, 1982, ZOOL J LINN SOC-LOND, V76, P29, DOI 10.1111/j.1096-3642.1982.tb01955.x; Yan HY, 2000, J COMP PHYSIOL A, V186, P435, DOI 10.1007/s003590050443	22	80	82	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					65	69		10.1038/nature01904	http://dx.doi.org/10.1038/nature01904			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955140				2022-12-24	WOS:000185089200037
J	Guerin, PJ; Brasher, C; Baron, E; Mic, D; Grimont, F; Ryan, M; Aavitsland, P; Legros, D				Guerin, PJ; Brasher, C; Baron, E; Mic, D; Grimont, F; Ryan, M; Aavitsland, P; Legros, D			Shigella dysenteriae serotype 1 in west Africa: intervention strategy for an outbreak in Sierra Leone	LANCET			English	Article							FLUOROQUINOLONES	In November 1999, a Medecins Sans Frontieres team based in the southeastern part of Sierra Leone reported an increased number of cases of bloody diarrhoea. Shigella dysenteriae serotype 1 (Sd1) was isolated in the early cases. A total of 4218 cases of dysentery were reported in Kenema district from December, 1999, to March, 2000. The overall attack rate was 7-5%. The attack rate was higher among children younger than 5 years than in the rest of the population (11.2% vs 6.8%; relative risk=1.6; 95% CI 1.5-1.8). The case fatality was 3.1%, also higher for children younger than 5 years (6.1% vs 2.1%; relative risk=2.9; 95% CI 2.1-4-1]). Among 583 patients regarded at increased risk of death who were treated with ciprofloxacin in isolation centres, case fatality was 0.9%. A 5-day ciprofloxacin regimen, targeted to the most severe cases of bloody diarrhoea, was highly effective. This is the first time a large outbreak caused by Sd1 has been reported in west Africa.	Epictr, F-75011 Paris, France; Norwegian Inst Publ Hlth, Div Infect Dis Control, Oslo, Norway; Med Sans Frontieres, Paris, France; Inst Pasteur, Ctr Natl Reference Escherichia Coli & Shigella, Paris, France; WHO, Global Alert & Response Team, Dept Surveillance & Response, Communicable Dis Cluster, CH-1211 Geneva, Switzerland; European Programme Intervent Epidemiol Training, Paris, France	Norwegian Institute of Public Health (NIPH); Doctors Without Borders; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; World Health Organization	Guerin, PJ (corresponding author), Epictr, F-75011 Paris, France.		Guerin, Philippe/AAH-8873-2021; Brasher, Chris/Y-4488-2019	Brasher, Chris/0000-0003-1037-3604; Guerin, Philippe/0000-0002-6008-2963				Bethell DB, 1996, ARCH DIS CHILD, V74, P44, DOI 10.1136/adc.74.1.44; Hooper DC, 2000, CLIN INFECT DIS, V31, pS24, DOI 10.1086/314056; KEUSCH GT, 1998, BACTERIAL INFECT HUM, P631; Legros D, 1999, TROP MED INT HEALTH, V4, P428, DOI 10.1046/j.1365-3156.1999.00413.x; RIES AA, 1994, J INFECT DIS, V169, P1035, DOI 10.1093/infdis/169.5.1035	5	35	38	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					705	706		10.1016/S0140-6736(03)14227-4	http://dx.doi.org/10.1016/S0140-6736(03)14227-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957094				2022-12-24	WOS:000185034800012
J	Shao, F; Golstein, C; Ade, J; Stoutemyer, M; Dixon, JE; Innes, RW				Shao, F; Golstein, C; Ade, J; Stoutemyer, M; Dixon, JE; Innes, RW			Cleavage of Arabidopsis PBS1 by a bacterial type III effector	SCIENCE			English	Article							DISEASE RESISTANCE GENE; RICE BLAST RESISTANCE; PSEUDOMONAS-SYRINGAE; AVIRULENCE GENE; YERSINIA EFFECTOR; PROTEINS; KINASE; RIN4; VIRULENCE; PROTEASE	Plant disease-resistance (R) proteins are thought to function as receptors for ligands produced directly or indirectly by pathogen avirulence (Avr) proteins. The biochemical functions of most Avr proteins are unknown, and the mechanisms by which they activate R proteins have not been determined. In Arabidopsis, resistance to Pseudomonas syringae strains expressing AvrPphB requires RPS5, a member of the class of R proteins that have a predicted nucleotide-binding site and leucine-rich repeats, and PBS1, a protein kinase. AvrPphB was found to proteolytically cleave PBS1, and this cleavage was required for RPS5-mediated resistance, which indicates that AvrPphB is detected indirectly via its enzymatic activity.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	Indiana University System; Indiana University Bloomington; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Innes, RW (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.		Innes, Roger/A-5244-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046451, R29GM046451] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18849] Funding Source: Medline; NIGMS NIH HHS [GM46451] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold DL, 2001, MICROBIOL-SGM, V147, P1171, DOI 10.1099/00221287-147-5-1171; Axtell MJ, 2003, CELL, V112, P369, DOI 10.1016/S0092-8674(03)00036-9; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Deslandes L, 2003, P NATL ACAD SCI USA, V100, P8024, DOI 10.1073/pnas.1230660100; FLOR HH, 1955, PHYTOPATHOLOGY, V45, P680; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; Kim YJ, 2002, CELL, V109, P589, DOI 10.1016/S0092-8674(02)00743-2; Kjemtrup S, 2000, CURR OPIN MICROBIOL, V3, P73, DOI 10.1016/S1369-5274(99)00054-5; Kruger J, 2002, SCIENCE, V296, P744, DOI 10.1126/science.1069288; Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Orbach MJ, 2000, PLANT CELL, V12, P2019, DOI 10.1105/tpc.12.11.2019; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Puri N, 1997, MOL PLANT MICROBE IN, V10, P247, DOI 10.1094/MPMI.1997.10.2.247; Rossi M, 1998, P NATL ACAD SCI USA, V95, P9750, DOI 10.1073/pnas.95.17.9750; Shao F, 2002, CELL, V109, P575, DOI 10.1016/S0092-8674(02)00766-3; SHAO F, UNPUB; Swiderski MR, 2001, PLANT J, V26, P101, DOI 10.1046/j.1365-313x.2001.01014.x; Tampakaki AP, 2002, MOL PLANT MICROBE IN, V15, P292, DOI 10.1094/MPMI.2002.15.3.292; Tornero P, 2002, PLANT CELL, V14, P1005, DOI 10.1105/tpc.001032; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; Warren RF, 1998, PLANT CELL, V10, P1439, DOI 10.1105/tpc.10.9.1439; Warren RF, 1999, GENETICS, V152, P401; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	27	421	440	4	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1230	1233		10.1126/science.1085671	http://dx.doi.org/10.1126/science.1085671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947197				2022-12-24	WOS:000185003500040
J	Yanagisawa, K; Shyr, Y; Xu, BGJ; Massion, PP; Larsen, PH; White, BC; Roberts, JR; Edgerton, M; Gonzalez, A; Nadaf, S; Moore, JH; Caprioli, RM; Carbone, DP				Yanagisawa, K; Shyr, Y; Xu, BGJ; Massion, PP; Larsen, PH; White, BC; Roberts, JR; Edgerton, M; Gonzalez, A; Nadaf, S; Moore, JH; Caprioli, RM; Carbone, DP			Proteomic patterns of tumour subsets in non-small-cell lung cancer	LANCET			English	Article							IMAGING MASS-SPECTROMETRY; GENE-EXPRESSION; PROSTATE-CANCER; MESSENGER-RNA; BREAST-CANCER; PROTEINS; SERUM; SUMO; CLASSIFICATION; ADENOCARCINOMA	Background Proteomics-based approaches complement the genome initiatives and may be the next step in attempts to understand the biology of cancer. We used matrix-assisted laser desorption/ionisation mass spectrometry directly from 1-mm regions of single frozen tissue sections for profiling of protein expression from surgically resected tissues to classify lung tumours. Methods Proteomic spectra were obtained and aligned from 79 lung tumours and 14 normal lung tissues. We built a class-prediction model with the proteomic patterns in a training cohort of 42 lung tumours and eight normal lung samples, and assessed their statistical significance. We then applied this model to a blinded test cohort, including 37 lung tumours; and six normal lung samples, to estimate the misclassification rate. Findings We obtained more than 1600 protein peaks from histologically selected 1 mm diameter regions of single frozen sections from each tissue. Class-prediction models based on differentially expressed peaks enabled us to perfectly classify lung cancer histologies, distinguish primary tumours from metastases to the lung from other sites, and classify nodal involvement with 85% accuracy in the training cohort. This model nearly perfectly classified samples in the independent blinded test cohort. We also obtained a proteomic pattern comprised of 15 distinct mass spectrometry peaks that distinguished between patients with resected non-small-cell lung cancer who had poor prognosis (median survival 6 months, n=25) and those who had good prognosis (median survival 33 months, n=41, p<0.0001). Interpretation Proteomic patterns obtained directly from small amounts of fresh frozen lung-tumour tissue could be used to accurately classify and predict histological groups as well as nodal involvement and survival in resected non-small-cell lung cancer.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Div Hematol & Oncol,Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cardiovasc & Thorac Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Program Human Genet, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Carbone, DP (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Div Hematol & Oncol,Dept Med, 2200 Pierce Ave,685 Preston Res Bldg, Nashville, TN 37232 USA.		Moore, Jason H./AAV-9645-2021; Yanagisawa, Kiyoshi/I-7263-2014	Moore, Jason H./0000-0002-5015-1099; White, Bill/0000-0002-0684-5210	NCI NIH HHS [P50CA70907, CA 86243, 1P50CA90949] Funding Source: Medline; NIGMS NIH HHS [GM 58008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, R33CA086243, P50CA090949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam BL, 2002, CANCER RES, V62, P3609; Alarcon-Vargas D, 2002, CANCER BIOL THER, V1, P237, DOI 10.4161/cbt.74; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i; Carbone DP, 1997, SEMIN ONCOL, V24, P388; Chaurand P, 2002, CURR OPIN CHEM BIOL, V6, P676, DOI 10.1016/S1367-5931(02)00370-8; Chaurand P, 2001, PROTEOMICS, V1, P1320, DOI 10.1002/1615-9861(200110)1:10<1320::AID-PROT1320>3.3.CO;2-7; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Junker K, 2000, J CANCER RES CLIN, V126, P361, DOI 10.1007/PL00008483; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MINNA JD, 2001, HARRISONS PRINCIPLES, P562; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Paciucci R, 1996, FEBS LETT, V385, P72, DOI 10.1016/0014-5793(96)00352-3; Paweletz CP, 2001, DIS MARKERS, V17, P301, DOI 10.1155/2001/674959; Petricoin EF, 2002, J NATL CANCER I, V94, P1576; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; SHYR Y, 2003, TUMOR PROTEOMIC PATT; SHYR Y, 2003, PRACTICAL APPROACH M; Stoeckli M, 2001, NAT MED, V7, P493, DOI 10.1038/86573; TUKEY JW, 1993, CONTROL CLIN TRIALS, V14, P266, DOI 10.1016/0197-2456(93)90225-3; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wilkins MR, 1996, ELECTROPHORESIS, V17, P830, DOI 10.1002/elps.1150170504; Xu BGJ, 2002, J AM SOC MASS SPECTR, V13, P1292, DOI 10.1016/S1044-0305(02)00644-X	33	456	512	3	69	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					433	439		10.1016/S0140-6736(03)14068-8	http://dx.doi.org/10.1016/S0140-6736(03)14068-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927430				2022-12-24	WOS:000184651100010
J	Wilson, JF				Wilson, JF			Should doctors prescribe alcohol to adults?	ANNALS OF INTERNAL MEDICINE			English	News Item							CONSUMPTION; DRINKING; MORTALITY						Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Abramson JL, 2001, JAMA-J AM MED ASSOC, V285, P1971, DOI 10.1001/jama.285.15.1971; Ellison RC, 2002, ANN NY ACAD SCI, V957, P1, DOI 10.1111/j.1749-6632.2002.tb02900.x; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; Goldberg IJ, 2003, NEW ENGL J MED, V348, P163, DOI 10.1056/NEJMe020163; Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095; Nicolas JM, 2002, ANN INTERN MED, V136, P192, DOI 10.7326/0003-4819-136-3-200202050-00007; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401	7	5	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 21	2003	139	8					711	714		10.7326/0003-4819-139-8-200310210-00036	http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00036			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734DW	14568873				2022-12-24	WOS:000186040800022
J	Gu, Y; Filippi, MD; Cancelas, JA; Siefring, JE; Williams, EP; Jasti, AC; Harris, CE; Lee, AW; Prabhakar, R; Atkinson, SJ; Kwiatkowski, DJ; Williams, DA				Gu, Y; Filippi, MD; Cancelas, JA; Siefring, JE; Williams, EP; Jasti, AC; Harris, CE; Lee, AW; Prabhakar, R; Atkinson, SJ; Kwiatkowski, DJ; Williams, DA			Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases	SCIENCE			English	Article							RHO-GTPASES; MAST-CELLS; STEM-CELLS; T-CELLS; BINDING; GENE; EXPRESSION; ACTIVATION; DELETION; ADHESION	The Rho guanosine triphosphatases (GTPases) Rac1 and Rac2 are critical signaling regulators in mammalian cells. The deletion of both Rac1 and Rac2 murine alleles leads to a massive egress of hematopoietic stem/progenitor cells (HSC/Ps) into the blood from the marrow, whereas Rac1(-/-) but not Rac2(-/-) HSC/Ps fail to engraft in the bone marrow of irradiated recipient mice. In contrast, Rac2, but not Rac1, regulates superoxide production and directed migration in neutrophils, and in each cell type, the two GTPases play distinct roles in actin organization, cell survival, and proliferation. Thus, Rac1 and Rac2 regulate unique aspects of hematopoietic development and function.	Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Hoxworth Blood Ctr, Cincinnati, OH 45267 USA; Indiana Univ, Dept Med, Indianapolis, IN 46202 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Indiana University System; Indiana University-Purdue University Indianapolis; Harvard University; Brigham & Women's Hospital	Williams, DA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA.		Cancelas, Jose/AAR-9324-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062757] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK62757] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Gu Y, 2002, MOL CELL BIOL, V22, P7645, DOI 10.1128/MCB.22.21.7645-7657.2002; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOLL J, 1991, ONCOGENE, V6, P863; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Palacios R, 1996, P NATL ACAD SCI USA, V93, P5247, DOI 10.1073/pnas.93.11.5247; Papayannopoulou T, 1997, ACTA HAEMATOL-BASEL, V97, P97; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; SHIRSAT NV, 1990, ONCOGENE, V5, P769; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; VAN AL, 1997, GENE DEV, V11, P2295; van der Loo JCM, 1998, J CLIN INVEST, V102, P1051, DOI 10.1172/JCI3687; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898	25	396	417	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					445	449		10.1126/science.1088485	http://dx.doi.org/10.1126/science.1088485			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564009				2022-12-24	WOS:000185963200043
J	Bonaccorso, S; Sturchio, JL				Bonaccorso, S; Sturchio, JL			Perspectives from the pharmaceutical industry	BRITISH MEDICAL JOURNAL			English	Article									Merck & Co Inc, Mkt & Med Serv, Whitehouse Stn, NJ 08889 USA; Merck & Co Inc, External Affairs Europe Middle E & Africa, Whitehouse Stn, NJ 08889 USA	Merck & Company; Merck & Company	Bonaccorso, S (corresponding author), Merck & Co Inc, Mkt & Med Serv, 1 Merck Dr, Whitehouse Stn, NJ 08889 USA.							Bonaccorso SN, 2002, BRIT MED J, V324, P910, DOI 10.1136/bmj.324.7342.910; Calfee JE, 2002, J LAW ECON, V45, P673, DOI 10.1086/374704; Coulter A, 2003, EUROPEAN PATIENT FUT; *EUR FED PHARM IND, 2001, GUID INT WEB SIT AV; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; World Health Organization, 2003, ADHERENCE LONG TERM	6	14	14	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					863	864		10.1136/bmj.327.7419.863	http://dx.doi.org/10.1136/bmj.327.7419.863			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551109	Green Published			2022-12-24	WOS:000185921200031
J	Narayan, KMV; Boyle, JP; Thompson, TJ; Sorensen, SW; Williamson, DF				Narayan, KMV; Boyle, JP; Thompson, TJ; Sorensen, SW; Williamson, DF			Lifetime risk for diabetes mellitus in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; BREAST-CANCER; US; PREVALENCE; POPULATION; MORTALITY; PERSPECTIVE; IMPACT; ADULTS; BURDEN	Context Although diabetes mellitus is one of the most prevalent and costly chronic diseases in the United States, no estimates have been published of individuals' average lifetime risk of developing diabetes. Objective Toe stimate age-, sex-, and race/ethnicity-specific lifetime risk. of diabetes in the cohort born in 2000 in the United States. Design, Setting, and Participants Data from the National Health Interview Survey (1984-2000) were used to estimate age-, sex-, and race/ethnicity-specific prevalence and incidence in 2000. US Census Bureau data. and data from a previous study of diabetes as a cause of death were used to estimate age-, sex-, and race/ethnicity- specific mortality rates for diabetic and nondiabetic populations. Main Outcome Measures, Residual (remaining) lifetime risk of diabetes (from birth to 80, years in 1-year intervals), duration with diabetes, and life-years and quality-adjusted life-years lost from diabetes. Results the estimated lifetime risk of developing diabetes for individuals born in 2000 is 32.8% for males and 38.5% for females. Females have higher residual lifetime risks at all ages. The highest. estimated lifetime risk for diabetes is among Hispanics (males, 45.4% and females, 515%) Individuals diagnosed as having diabetes have large reductions in life expectancy. For example, we estimate that if an individual is diagnosed at age 40 years, men will lose 11.6 life-years and 18.6 quality-adjusted life-years and women will lose 14.3 life-years and 22.0 quality-adjusted life-years. Conclusions, For individuals born in the United States in 2000, the lifetime probability of being diagnosed with diabetes mellitus is substantial. Primary prevention of diabetes and its complications are important public health priorities.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Narayan, KMV (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, 4770 Buford Hwy NE,MSK-10, Atlanta, GA 30341 USA.							[Anonymous], 1995, DIABETES AM; Botman S, 2000, VITAL HLTH STAT, V2; Boyle JP, 2001, DIABETES CARE, V24, P1936, DOI 10.2337/diacare.24.11.1936; Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006; *BUR CENS, 2000, COMP ASS RES POP AG; Burke JP, 1999, ARCH INTERN MED, V159, P1450, DOI 10.1001/archinte.159.13.1450; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Clarke P, 2002, MED DECIS MAKING, V22, P340, DOI 10.1177/027298902400448902; Coffey JT, 2002, DIABETES CARE, V25, P2238, DOI 10.2337/diacare.25.12.2238; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; Davidson MB, 2002, DIABETES CARE, V25, P1, DOI 10.2337/diacare.25.1.1; *DEP HLTH HUM SERV, 1998, SUMM HLTH STAT US CH; Engelgau MM, 2000, DIABETES CARE, V23, P1563, DOI 10.2337/diacare.23.10.1563; Fagot-Campagna A, 2000, J PEDIATR-US, V136, P664, DOI 10.1067/mpd.2000.105141; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Gu K, 1998, DIABETES CARE, V21, P1138, DOI 10.2337/diacare.21.7.1138; HARRIS MI, 1995, NIH PUBLICATION, P1; HOEL PG, 1972, INTRO STOCHASTIC PRO; Honeycutt Amanda A, 2003, Health Care Manag Sci, V6, P155, DOI 10.1023/A:1024467522972; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Jagger C, 2003, J PUBLIC HEALTH MED, V25, P42, DOI 10.1093/pubmed/fdg009; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Leibson CL, 1997, AM J EPIDEMIOL, V146, P12, DOI 10.1093/oxfordjournals.aje.a009187; Lloyd-Jones DM, 1999, LANCET, V353, P89, DOI 10.1016/S0140-6736(98)10279-9; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Mokdad AH, 2001, DIABETES CARE, V24, P412, DOI 10.2337/diacare.24.2.412; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; NARAYAN KM, 2002, EPIDEMIOLOGY DIABETE; Narayan KMV, 2000, DIABETES CARE, V23, P1794, DOI 10.2337/diacare.23.12.1794; Narayan KMV, 2000, DIABETES RES CLIN PR, V50, pS77; *NAT CTR HLTH STAT, 2002, HLTH US; *NAT CTR HLTH STAT, 2000 NAT HLTH INT SU; *NAT CTR HLTH STAT, 1993, CD ROM SERIES, V10; O'Connor PJ, 1998, AM J MANAG CARE, V4, P335; Phillips KA, 1999, NEW ENGL J MED, V340, P141, DOI 10.1056/NEJM199901143400211; Ray NF, 1998, DIABETES CARE, V21, P296; Rothman K., 1998, MODERN EPIDEMIOLOGY; Sasieni PD, 1999, AM J EPIDEMIOL, V149, P869; Saydah SH, 2002, AM J EPIDEMIOL, V156, P714, DOI 10.1093/aje/kwf111; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Seshadri S, 1997, NEUROLOGY, V49, P1498, DOI 10.1212/WNL.49.6.1498; Tierney EF, 2001, AM J PUBLIC HEALTH, V91, P84, DOI 10.2105/AJPH.91.1.84; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003	44	1021	1045	0	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1884	1890		10.1001/jama.290.14.1884	http://dx.doi.org/10.1001/jama.290.14.1884			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729CB	14532317	Bronze			2022-12-24	WOS:000185752600029
J	Bellaby, P				Bellaby, P			Communication and miscommunication of risk: understanding UK parents' attitudes to combined MMR vaccination	BRITISH MEDICAL JOURNAL			English	Article							CREUTZFELDT-JAKOB-DISEASE; RUBELLA VACCINE; TREND ANALYSIS; MEASLES; MUMPS; IMMUNIZATION; CHILDREN; ENGLAND; AUTISM; POLICY	In this article on the public perception of risks Paul Bellaby considers three examples of risks to children in the UK-an insignificant risk (autism caused by MMR vaccine), a real but probably small risk (vCJD from BSE), and a real and demonstrably larger risk (injuries from road crashes) and contrasts the perceptions of the risks by parents.	Univ Salford, Inst Publ Hlth Res & Policy, Salford M5 4QA, Greater Manches, England	University of Salford	Bellaby, P (corresponding author), Univ Salford, Inst Publ Hlth Res & Policy, Salford M5 4QA, Greater Manches, England.							Adams J, 1998, INTERDISCIPL SCI REV, V23, P146; Bartlett DMC, 1998, CRIME LAW SOCIAL CH, V30, P237, DOI 10.1023/A:1008386621333; BEDFORD H, 2003, BMJ-BRIT MED J, V326, P718; BOBO JK, 1993, PEDIATRICS, V91, P308; Boulianne N, 2003, CAN J PUBLIC HEALTH, V94, P218, DOI 10.1007/BF03405070; Brown P, 2001, EMERG INFECT DIS, V7, P6, DOI 10.3201/eid0701.010102; Cousens S, 2003, STAT METHODS MED RES, V12, P235, DOI 10.1191/0962280203sm332ra; DiGuiseppi C, 1997, BRIT MED J, V314, P710, DOI 10.1136/bmj.314.7082.710; Durbach N, 2000, SOC HIST MED, V13, P45, DOI 10.1093/shm/13.1.45; Evans M, 2001, BRIT J GEN PRACT, V51, P904; Ghani AC, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-4; Hennock EP, 1998, SOC HIST MED, V11, P49, DOI 10.1093/shm/11.1.49; HILLMAN M, 1990, ONE FALSE MOVE STUDY; Huxley RR, 2000, BRIT J NUTR, V84, P247, DOI 10.1017/S0007114500001483; Kaye JA, 2001, BRIT MED J, V322, P460, DOI 10.1136/bmj.322.7284.460; Lutwick SM, 2000, PEDIATR CLIN N AM, V47, P427, DOI 10.1016/S0031-3955(05)70215-7; Marks L., 1996, METROPOLITAN MATERNI; Middleton E, 2003, BMJ-BRIT MED J, V326, P854, DOI 10.1136/bmj.326.7394.854; Mullany L, 2003, AM J MANAG CARE, V9, pS23; *OFF NAT STAT, 2003, ANN ABSTR STAT; Petrovic M, 2001, BRIT MED J, V322, P82, DOI 10.1136/bmj.322.7278.82; Ramsay ME, 2002, BRIT J GEN PRACT, V52, P912; *SCI MED CTR, 2002, MMR LEARN LESS; Szreter S., 1988, SOC HIST MED, V1, P1, DOI [10.1145/1073943.1073950, DOI 10.1145/1073943.1073950]; Taylor B, 2002, BRIT MED J, V324, P393, DOI 10.1136/bmj.324.7334.393; Vernon JG, 2003, BRIT J GEN PRACT, V53, P399; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; 2003, INDEPENDENT     0731, P16; 2003, INDEPENDENT     0731, P4	29	64	64	0	24	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2003	327	7417					725	728		10.1136/bmj.327.7417.725	http://dx.doi.org/10.1136/bmj.327.7417.725			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	728FZ	14512482	Green Published			2022-12-24	WOS:000185708300022
J	Jackson, H; Hubbard, R				Jackson, H; Hubbard, R			Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article									City Hosp Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital	Hubbard, R (corresponding author), City Hosp Nottingham, Div Epidemiol & Publ Hlth, Hucknall Rd, Nottingham NG5 1PB, England.							ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; British Medical Association, 2003, INV GEN PRACT NEW GE; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Nolan D, 1999, THORAX, V54, P468, DOI 10.1136/thx.54.5.468d; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	5	56	57	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 20	2003	327	7416					653	654		10.1136/bmj.327.7416.653	http://dx.doi.org/10.1136/bmj.327.7416.653			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500437	Bronze, Green Published			2022-12-24	WOS:000185463100021
J	Koekkoek, SKE; Hulscher, HC; Dortland, BR; Hensbroek, RA; Elgersma, Y; Ruigrok, TJH; De Zeeuw, CI				Koekkoek, SKE; Hulscher, HC; Dortland, BR; Hensbroek, RA; Elgersma, Y; Ruigrok, TJH; De Zeeuw, CI			Cerebellar LTD and learning-dependent timing of conditioned eyelid responses	SCIENCE			English	Article							LONG-TERM DEPRESSION; KINASE-C INHIBITOR; MUTANT MICE; VESTIBULOOCULAR REFLEX; EXPRESSION; ADAPTATION	Mammals can be trained to make a conditioned movement at a precise time, which is correlated to the interval between the conditioned stimulus and unconditioned stimulus during the learning. This learning-dependent timing has been shown to depend on an intact cerebellar cortex, but which cellular process is responsible for this form of learning remains to be demonstrated. Here, we show that protein kinase C-dependent long-term depression in Purkinje cells is necessary for learning-dependent timing of Pavlovian-conditioned eyeblink responses.	Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	De Zeeuw, CI (corresponding author), Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands.	c.dezeeuw@erasmusmc.nl	Elgersma, Ype/F-5164-2013	Elgersma, Ype/0000-0002-3758-1297				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Aizenman CD, 1998, NEURON, V21, P827, DOI 10.1016/S0896-6273(00)80598-X; BUONOMANO DV, 1994, NEURAL COMPUT, V6, P38, DOI 10.1162/neco.1994.6.1.38; De Zeeuw CI, 1998, NEURON, V20, P495, DOI 10.1016/S0896-6273(00)80990-3; Gao WC, 2003, J NEUROSCI, V23, P1859; Garcia KS, 1998, NEUROPHARMACOLOGY, V37, P471, DOI 10.1016/S0028-3908(98)00055-0; Garcia KS, 1999, J NEUROSCI, V19, P10940, DOI 10.1523/JNEUROSCI.19-24-10940.1999; Goossens J, 2001, J NEUROSCI, V21, P5813, DOI 10.1523/JNEUROSCI.21-15-05813.2001; Hansel C, 2000, NEURON, V26, P473, DOI 10.1016/S0896-6273(00)81179-4; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Kistler WM, 2003, CEREBELLUM, V2, P44, DOI 10.1080/14734220309426; Koekkoek SKE, 2002, J NEUROPHYSIOL, V88, P2124, DOI 10.1152/jn.2002.88.4.2124; Medina JF, 2002, NATURE, V416, P330, DOI 10.1038/416330a; Miyata M, 2001, EUR J NEUROSCI, V13, P1945, DOI 10.1046/j.0953-816x.2001.01570.x; PERRETT SP, 1993, J NEUROSCI, V13, P1708; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; van Alphen AM, 2002, EUR J NEUROSCI, V16, P486, DOI 10.1046/j.1460-9568.2002.02094.x; Yeo CH, 1998, TRENDS COGN SCI, V2, P322, DOI 10.1016/S1364-6613(98)01219-4	18	213	219	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1736	1739		10.1126/science.1088383	http://dx.doi.org/10.1126/science.1088383			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500987				2022-12-24	WOS:000185387700049
J	Thornton, JW; Need, E; Crews, D				Thornton, JW; Need, E; Crews, D			Resurrecting the ancestral steroid receptor: Ancient origin of estrogen signaling	SCIENCE			English	Article							REPRODUCTIVE-SYSTEM; OCTOPUS-VULGARIS; EVOLUTION; MECHANISMS; INDUCTION; BINDING; GENOME; FEMALE; GENE	Receptors for sex and adrenal steroid hormones are absent from fully sequenced invertebrate genomes and have not been recovered from other invertebrates. Here we report the isolation of an estrogen receptor ortholog from the mollusk Aplysia californica and the reconstruction, synthesis, and experimental characterization of functional domains of the ancestral protein from which all extant steroid receptors (SRs) evolved. Our findings indicate that SRs are extremely ancient and widespread, having diversified from a primordial gene before the origin of bilaterally symmetric animals, and that this ancient receptor had estrogen receptor - like functionality. This gene was lost in the lineage leading to arthropods and nematodes and became independent of hormone regulation in the Aplysia lineage.	Univ Oregon, Ctr Ecol & Evolutionary Biol, Eugene, OR 97403 USA; Univ Texas, Sect Integrat Biol, Austin, TX 78712 USA	University of Oregon; University of Texas System; University of Texas Austin	Thornton, JW (corresponding author), Univ Oregon, Ctr Ecol & Evolutionary Biol, Eugene, OR 97403 USA.	joet@uoregon.edu	Thornton, Joseph/GSN-4190-2022		PHS HHS [41770] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baker ME, 2003, BIOESSAYS, V25, P396, DOI 10.1002/bies.10252; Bentley P., 1998, COMP VERTEBRATE ENDO; Benton MJ, 2003, SCIENCE, V300, P1698, DOI 10.1126/science.1077795; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Di Cosmo A, 2002, MOL REPROD DEV, V61, P367, DOI 10.1002/mrd.10014; Di Cosmo A, 2001, J EXP ZOOL, V289, P33, DOI 10.1002/1097-010X(20010101/31)289:1<33::AID-JEZ4>3.0.CO;2-A; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; MAGLICH JM, 2001, GENOME BIOL, V2; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Oberdorster E, 2002, MAR ENVIRON RES, V54, P715, DOI 10.1016/S0141-1136(02)00118-6; Peterson KJ, 2001, EVOL DEV, V3, P170, DOI 10.1046/j.1525-142x.2001.003003170.x; Suzuki Y, 2002, P NATL ACAD SCI USA, V99, P16138, DOI 10.1073/pnas.212646199; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; *US EPA, 2003, END DISR SCREEN TEST; ZILLIACUS J, 1994, P NATL ACAD SCI USA, V91, P4175, DOI 10.1073/pnas.91.10.4175	19	484	507	4	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1714	1717		10.1126/science.1086185	http://dx.doi.org/10.1126/science.1086185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500980				2022-12-24	WOS:000185387700042
J	Cook, D; Rocker, G; Marshall, J; Sjokvist, P; Dodek, P; Griffith, L; Freitag, A; Varon, J; Bradley, C; Levy, M; Finfer, S; Hamielec, C; McMullin, J; Weaver, B; Walter, S; Guyatt, G				Cook, D; Rocker, G; Marshall, J; Sjokvist, P; Dodek, P; Griffith, L; Freitag, A; Varon, J; Bradley, C; Levy, M; Finfer, S; Hamielec, C; McMullin, J; Weaver, B; Walter, S; Guyatt, G		Level Care Study Investigators; Canadian Critical Care Trials Grp	Withdrawal of mechanical ventilation in anticipation of death in the intensive care unit	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENTS; CRITICALLY ILL; CARDIOPULMONARY-RESUSCITATION; DECISION-MAKING; SUPPORT; PHYSICIAN; PREFERENCES; END; DIRECTIVES; HOSPITALS	BACKGROUND: In critically ill patients who are receiving mechanical ventilation, the factors associated with physicians' decisions to withdraw ventilation in anticipation of death are unclear. The objective of this study was to examine the clinical determinants that were associated with the withdrawal of mechanical ventilation. METHODS: We studied adults who were receiving mechanical ventilation in 15 intensive care units, recording base-line physiological characteristics, daily Multiple Organ Dysfunction Scores, the patient's decision-making ability, the type of life support administered, the use of do-not-resuscitate orders, the physician's prediction of the patient's status, and the physician's perceptions of the patient's preferences about the use of life support. We examined the relation between these factors and withdrawal of mechanical ventilation, using Cox proportional-hazards regression analysis. RESULTS: Of 851 patients who were receiving mechanical ventilation, 539 (63.3 percent) were successfully weaned, 146 (17.2 percent) died while receiving mechanical ventilation, and 166 (19.5 percent) had mechanical ventilation withdrawn. The need for inotropes or vasopressors was associated with withdrawal of the ventilator (hazard ratio, 1.78; 95 percent confidence interval, 1.20 to 2.66; P=0.004), as were the physician's prediction that the patient's likelihood of survival in the intensive care unit was less than 10 percent (hazard ratio, 3.49; 95 percent confidence interval, 1.39 to 8.79; P=0.002), the physician's prediction that future cognitive function would be severely impaired (hazard ratio, 2.51; 95 percent confidence interval, 1.28 to 4.94; P=0.04), and the physician's perception that the patient did not want life support used (hazard ratio, 4.19; 95 percent confidence interval, 2.57 to 6.81; P<0.001). CONCLUSIONS: Rather than age or the severity of the illness and organ dysfunction, the strongest determinants of the withdrawal of ventilation in critically ill patients were the physician's perception that the patient preferred not to use life support, the physician's predictions of a low likelihood of survival in the intensive care unit and a high likelihood of poor cognitive function, and the use of inotropes or vasopressors.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Dalhousie Univ, Dept Med, Halifax, NS, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Huddinge Univ, Dept Anesthesia & Intens Care, Stockholm, Sweden; Univ British Columbia, Program Crit Care Med, Vancouver, BC V5Z 1M9, Canada; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Brown Univ, Dept Med, Providence, RI 02912 USA; Univ Sydney, Royal N Shore Hosp, Intens Therapy Unit, Sydney, NSW 2006, Australia; Toronto Hosp, Toronto, ON M5T 2S8, Canada; London Hlth Sci Ctr, London, ON, Canada; Hamilton Hlth Sci Ctr, Hamilton, ON, Canada	McMaster University; McMaster University; Dalhousie University; University of Toronto; University of British Columbia; Baylor College of Medicine; Brown University; Royal North Shore Hospital; University of Sydney; University of Toronto; University Toronto Affiliates; University Health Network Toronto; London Health Sciences Centre; McMaster University	Cook, D (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.		Varon, Joseph/R-5198-2019; Walter, Stephen/AAB-5548-2022; Varon, Joseph/T-9481-2019	Walter, Stephen/0000-0003-4157-8928; Finfer, Simon/0000-0002-2785-5864; Varon, Joseph/0000-0002-7622-9974				Asch DA, 1996, MED CARE, V34, P103, DOI 10.1097/00005650-199602000-00002; CHRISTAKIS NA, 1993, LANCET, V342, P642, DOI 10.1016/0140-6736(93)91759-F; CHRISTAKIS NA, 1995, J GEN INTERN MED, V10, P491, DOI 10.1007/BF02602399; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Cook DJ, 2001, LANCET, V358, P1941, DOI 10.1016/S0140-6736(01)06960-4; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; Esteban A, 2001, INTENS CARE MED, V27, P1744, DOI 10.1007/s00134-001-1111-7; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Hall RI, 2000, CHEST, V118, P1424, DOI 10.1378/chest.118.5.1424; Hamel Mary Beth, 1995, JAMA (Journal of the American Medical Association), V273, P1842, DOI 10.1001/jama.273.23.1842; JAYES RL, 1993, JAMA-J AM MED ASSOC, V270, P2213, DOI 10.1001/jama.270.18.2213; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Keenan SP, 1998, CRIT CARE MED, V26, P245, DOI 10.1097/00003246-199802000-00018; Keenan SP, 1997, CRIT CARE MED, V25, P1324, DOI 10.1097/00003246-199708000-00019; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANKEN PN, 1991, ANN INTERN MED, V115, P478; LEE DKP, 1994, JAMA-J AM MED ASSOC, V271, P1358, DOI 10.1001/jama.271.17.1358; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McLean RF, 2000, CRIT CARE MED, V28, P100, DOI 10.1097/00003246-200001000-00016; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; SLOMKA J, 1992, SOC SCI MED, V35, P251, DOI 10.1016/0277-9536(92)90021-H; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Smucker WD, 2000, MED DECIS MAKING, V20, P271, DOI 10.1177/0272989X0002000303; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; WOOD GG, 1995, CAN J ANAESTH, V42, P186, DOI 10.1007/BF03010673	36	298	304	0	19	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1123	1132		10.1056/NEJMoa030083	http://dx.doi.org/10.1056/NEJMoa030083			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679526	Bronze			2022-12-24	WOS:000185369700005
J	Manisty, C; Waxman, J				Manisty, C; Waxman, J			For and against - Doctors should not discuss resuscitation with terminally ill patients - For	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC-ARREST; CANCER		Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Canc Med, London W12 0NN, England	Imperial College London	Waxman, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Canc Med, Hammersmith Campus, London W12 0NN, England.		Manisty, Charlotte/AAN-3723-2021	Manisty, Charlotte/0000-0003-0245-7090				BMA Resuscitation Council UK and Royal College of Nursing, DEC REL CARD RES; Ewer MS, 2001, CANCER, V92, P1905, DOI 10.1002/1097-0142(20011001)92:7<1905::AID-CNCR1708>3.0.CO;2-6; Haidet P, 1998, AM J MED, V105, P222, DOI 10.1016/S0002-9343(98)00242-3; Varon J, 1998, RESUSCITATION, V36, P165, DOI 10.1016/S0300-9572(98)00015-X	4	20	21	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					614	615		10.1136/bmj.327.7415.614	http://dx.doi.org/10.1136/bmj.327.7415.614			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969934	Green Published			2022-12-24	WOS:000185358700030
J	Bunce, M; Worthy, TH; Ford, T; Hoppitt, W; Willerslev, E; Drummond, A; Cooper, A				Bunce, M; Worthy, TH; Ford, T; Hoppitt, W; Willerslev, E; Drummond, A; Cooper, A			Extreme reversed sexual size dimorphism in the extinct New Zealand moa Dinornis	NATURE			English	Article							DNA; SEQUENCES; EVOLUTION	The ratite moa(Aves; Dinornithiformes) were massive graviportal browsers weighing up to 250 kg (ref. 1) that dominated the New Zealand biota until their extinction approximately 500 yr ago. Despite an extensive Quaternary fossil record, moa taxonomy remains problematic(1-4) and currently 11 species are recognized. Three Dinornis species were found throughout New Zealand and differed markedly in size(1-2 m height at back) and mass (from similar to34 to 242 kg)(1). Surprisingly, ancient mitochondrial DNA sequences show that the three species were genetically indistinguishable within each island, but formed separate North and South Island clades. Here we show, using the first sex-linked nuclear sequences from an extinct species, that on each island the three morphological forms actually represent just one species, whose size varied markedly according to sex and habitat. The largest females in this example of extreme reversed sexual size dimorphism were about 280% the weight and 150% the height of the largest males, which is unprecedented among birds and terrestrial mammals. The combination of molecular and palaeontological data highlights the difficulties of analysing extinct groups, even those with detailed fossil records.	Univ Oxford, Dept Zool, Henry Wellcome Ancient Biomol Ctr, Oxford OX1 3PS, England; Palaeofaunal Surveys, Masterton, New Zealand; Univ Copenhagen, Inst Zool, Dept Evolutionary Biol, DK-2100 Copenhagen, Denmark; Univ Oxford, Dept Stat, Oxford OX1 3TG, England	University of Oxford; University of Copenhagen; University of Oxford	Cooper, A (corresponding author), Univ Oxford, Dept Zool, Henry Wellcome Ancient Biomol Ctr, S Parks Rd, Oxford OX1 3PS, England.	alan.cooper@zoo.ox.ac.uk	Drummond, Alexei J/A-3209-2010; Cooper, Alan/E-8171-2012; Hoppitt, William/A-8216-2008; Willerslev, Eske/A-9619-2011; Worthy, Trevor/B-3781-2012; Willerslev, Eske/AAA-5686-2019	Drummond, Alexei J/0000-0003-4454-2576; Cooper, Alan/0000-0002-7738-7851; Hoppitt, William/0000-0003-0815-5720; Willerslev, Eske/0000-0002-7081-6748; Worthy, Trevor/0000-0001-7047-4680; Bunce, Michael/0000-0002-0302-4206; Ford, Tom/0000-0002-1131-8335				Andersson Malte, 1994; Archey G., 1941, Bull Aukland Inst Mus, Vno. 1, P1; ATKINSON IAE, 1989, NEW ZEAL J ECOL, V12, P67; Barnes I, 2002, SCIENCE, V295, P2267, DOI 10.1126/science.1067814; BERTRAM B.C.R., 1979, P 17 INT ORN C S ALT, P890; Cooper A, 2000, SCIENCE, V289, P1139; Cooper A, 2001, NATURE, V409, P704, DOI 10.1038/35055536; CRACRAFT J, 1976, Paleobiology, V2, P166; Davies S.J.J.F., 2002, RATITES TINAMOUS; Drummond AJ, 2002, GENETICS, V161, P1307; Greenwood AD, 1999, MOL BIOL EVOL, V16, P1466, DOI 10.1093/oxfordjournals.molbev.a026058; HJELMQVIST L, 1995, FEBS LETT, V367, P306, DOI 10.1016/0014-5793(95)00554-M; Hutton FW, 1892, T P NZ I, V24, P93; Huynen L, 2002, MOL ECOL, V11, P851, DOI 10.1046/j.1365-294X.2002.01483.x; LEWIS KB, 1994, MAR GEOL, V116, P293, DOI 10.1016/0025-3227(94)90047-7; MARCHANG M, 1990, HDB AUSTR NZ ANTARCT; Oliver W. R. B., 1949, Dominion Mus. Bull. Wellington N.Z., V15, P1; Owen, 1879, MEMOIRS EXTINCT WING; Owen R, 1840, P ZOOL SOC LOND, VVII, P169, DOI [10.1080/00222934009496800, DOI 10.1080/00222934009496800]; Shetty S, 1999, CHROMOSOME RES, V7, P289, DOI 10.1023/A:1009278914829; SHINE R, 1989, Q REV BIOL, V64, P419, DOI 10.1086/416458; WORTHY T H, 1987, National Museum of New Zealand Records, V3, P59; WORTHY TH, 1994, NEW ZEAL J ZOOL, V21, P113, DOI 10.1080/03014223.1994.9517981; Worthy TH, 2002, LOST WORLD MOA	24	135	143	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					172	175		10.1038/nature01871	http://dx.doi.org/10.1038/nature01871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968178				2022-12-24	WOS:000185236000040
J	Vestergaard, P; Mosekilde, L				Vestergaard, P; Mosekilde, L			Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; FOLLOW-UP; RISK; MORBIDITY; SURVIVAL; TRIAL; DEATH	Objectives To assess the effects of surgery compared with conservative treatment (no surgery) for primary hyperparathyroidism. Design Cohort study. Setting Nationwide Danish cohort. Participants 3213 patients, mean age 61 (SD 16) years, with a diagnosis of primary hyperparathyroidism between 1980 and 1999. 1934 (60%) underwent surgery and 1279 (40%) were treated conservatively. Main outcome measures Occurrence of fractures, osteoporosis, kidney or urinary tract stones, acute myocardial infarction, angina pectoris, cardiac arrhythmias, arterial hypertension, heart failure, stroke, acute pancreatitis, stomach or duodenal ulcers, muscle pain, malignant diseases, psychiatric disorders, and mortality. Results At diagnosis of primary hyperparathyroidism, patients who subsequently underwent surgery had a lower prevalence of previous fracture (odds ratio 0.64, 95% confidence interval 0.51 to 0.80), acute myocardial infarction (0.59, 0.42 to 0.83), stroke (0.57, 0.37 to 0.88), psychiatric disorders (0.54, 0.31 to 0.94), and painful muscle disorders (0.44, 0.26 to 0.76), whereas kidney stones (2.49, 1.93 to 3.23) and acute pancreatitis (2.77, 1.33 to 5.76) were more prevalent. After diagnosis, the risks of fractures (hazards ratio 0.69, 0.56 to 0.84) and gastric ulcers (0.59, 0.41 to 0.84) were lower in patients treated surgically than those treated conservatively. Events involving kidney or urinary tact stones were more prevalent in patients treated surgically than patients treated conservatively (1.87, 1.30 to 2.68). Mortality was lower in patients treated surgically (0.65, 0.57 to 0.73). Conclusions Patients treated surgically for primary hyperparathyroidism have a lower prevalence of fractures and gastric ulcers than patients treated conservatively. The type of treatment had no effect on the occurrence of cardiovascular events.	Aarhus Univ Hosp, Aarhus Kommune Hosp, Dept Endocrinol & Metab C, DK-8000 Aarhus, Denmark	Aarhus University	Vestergaard, P (corresponding author), Aarhus Kommune Hosp, Osteoporosis Clin, Tage Hansens Gade 2, DK-8000 Aarhus C, Denmark.	p-vest@post4.tele.dk						Andersen TF, 1999, DAN MED BULL, V46, P263; Bilezikian JP, 2002, J BONE MINER RES, V17, pN2; *CAN BUR STAT, 1998, STAT YB 1998; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christiansen P, 1999, BONE, V25, P589, DOI 10.1016/S8756-3282(99)00207-0; DANIELS J, 1983, AM J MED, V75, P17, DOI 10.1016/0002-9343(83)91162-2; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; Hedback G, 1998, EUR J CLIN INVEST, V28, P271; HEDBACK G, 1991, WORLD J SURG, V15, P399, DOI 10.1007/BF01658740; Jurgensen H J, 1984, Ugeskr Laeger, V146, P3303; Leifsson BG, 1996, J CLIN ENDOCR METAB, V81, P2149, DOI 10.1210/jc.81.6.2149; MADSEN M, 1990, Ugeskrift for Laeger, V152, P308; Mollerup CL, 2002, BMJ-BRIT MED J, V325, P807, DOI 10.1136/bmj.325.7368.807; Mosbech J, 1995, Ugeskr Laeger, V157, P3741; PALMER M, 1987, SURGERY, V102, P1; PALOYAN D, 1982, AM SURGEON, V48, P366; Rao D, 2000, J BONE MINER RES, V15, pS164; ROBERTS WC, 1981, AM J MED, V71, P371, DOI 10.1016/0002-9343(81)90163-7; SANCHO JJ, 1992, WORLD J SURG, V16, P732, DOI 10.1007/BF02067371; Soreide JA, 1997, SURGERY, V122, P1117, DOI 10.1016/S0039-6060(97)90216-6; Stefenelli T, 1997, SURGERY, V121, P157, DOI 10.1016/S0039-6060(97)90285-3; Talpos GB, 2000, SURGERY, V128, P1013, DOI 10.1067/msy.2000.110844; Vestergaard P, 2000, BRIT MED J, V321, P598, DOI 10.1136/bmj.321.7261.598; Wermers RA, 1997, ANN INTERN MED, V126, P433, DOI 10.7326/0003-4819-126-6-199703150-00003	24	103	107	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2003	327	7414					530	533		10.1136/bmj.327.7414.530	http://dx.doi.org/10.1136/bmj.327.7414.530			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958111	Green Published, Bronze			2022-12-24	WOS:000185283700016
J	Gibbons, DL; Erk, I; Reilly, B; Navaza, J; Kielian, M; Rey, FA; Lepault, J				Gibbons, DL; Erk, I; Reilly, B; Navaza, J; Kielian, M; Rey, FA; Lepault, J			Visualization of the target-membrane-inserted fusion protein of Semliki Forest virus by combined electron microscopy and crystallography	CELL			English	Article							BORNE ENCEPHALITIS-VIRUS; CELL-CELL FUSION; INFLUENZA HEMAGGLUTININ; CHOLESTEROL DEPENDENCE; ENVELOPE GLYCOPROTEIN; CONFORMATIONAL-CHANGE; LOW-PH; BINDING; ENTRY; ACTIVATION	Semliki Forest virus enters cells by receptor-mediated endocytosis. The acidic environment of the endosome triggers a membrane fusion reaction that is mediated by the E1 glycoprotein. During fusion, E1 rearranges from an E1/E2 heterodimer to a highly stable, membrane-inserted E1 homotrimer (E1HT). In this study, we analyzed E1HT by a combination of electron cryomicroscopy, electron crystallography of negatively stained 2D crystals, and fitting of the available X-ray structure of the monomeric E1 ectodomain into the resulting 3D reconstruction. The visualized E1HT reveals that the ectodomain has reoriented vertically and inserted the distal tip of domain II into the lipid bilayer. Our data allow the visualization of a viral fusion protein inserted in its target membrane and demonstrate that insertion is a cooperative process, resulting in rings composed of five to six homotrimers.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; CNRS, INRA, UMR 2472 1157, F-91198 Gif Sur Yvette, France	Yeshiva University; Albert Einstein College of Medicine; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay	Kielian, M (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	kielian@aecom.yu.edu; mem-vms@gv.cnrs-gif.fr	Lepault, Jean/AAN-8859-2020; Rey, Felix/B-6497-2012	Rey, Felix/0000-0002-9953-7988; Kielian, Margaret/0000-0002-7395-4791	NCI NIH HHS [P30-CA13330] Funding Source: Medline; NIGMS NIH HHS [T32 GM07288, R01 GM52929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052929, T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn A, 2002, J VIROL, V76, P3267, DOI 10.1128/JVI.76.7.3267-3275.2002; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; Chatterjee PK, 2002, J VIROL, V76, P12712, DOI 10.1128/JVI.76.24.12712-12722.2002; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; GAROFF H, 1980, NATURE, V288, P236, DOI 10.1038/288236a0; Gaudin Y, 1996, J VIROL, V70, P7371, DOI 10.1128/JVI.70.11.7371-7378.1996; Gibbons DL, 2000, J VIROL, V74, P7772, DOI 10.1128/JVI.74.17.7772-7780.2000; Gibbons DL, 2002, J VIROL, V76, P1194, DOI 10.1128/JVI.76.3.1194-1205.2002; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; HARTER C, 1989, J BIOL CHEM, V264, P6459; HELENIUS A, 1977, J CELL BIOL, V75, P866, DOI 10.1083/jcb.75.3.866; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KAARIAINEN L, 1969, ANN MED EXP BIOL FEN, V47, P235; Kanaseki T, 1997, J CELL BIOL, V137, P1041, DOI 10.1083/jcb.137.5.1041; Kielian M, 1996, J CELL BIOL, V134, P863, DOI 10.1083/jcb.134.4.863; Kielian M, 2000, Subcell Biochem, V34, P409; KIELIAN M, 1985, J CELL BIOL, V101, P2284, DOI 10.1083/jcb.101.6.2284; KLIMJACK MR, 1994, J VIROL, V68, P6940, DOI 10.1128/JVI.68.11.6940-6946.1994; LEPAULT J, 1983, J MICROSC-OXFORD, V129, P89, DOI 10.1111/j.1365-2818.1983.tb04163.x; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; Markovic I, 2001, J CELL BIOL, V155, P833, DOI 10.1083/jcb.200103005; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Navaza J, 2002, ACTA CRYSTALLOGR D, V58, P1820, DOI 10.1107/S0907444902013707; Pletnev SV, 2001, CELL, V105, P127, DOI 10.1016/S0092-8674(01)00302-6; Plonsky I, 1996, J CELL BIOL, V135, P1831, DOI 10.1083/jcb.135.6.1831; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Roche S, 2002, VIROLOGY, V297, P128, DOI 10.1006/viro.2002.1429; SCHLESINGER S, 2001, FIELDS VIROLOGY, P895; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Stiasny K, 2001, J VIROL, V75, P7392, DOI 10.1128/JVI.75.16.7392-7398.2001; Vashishtha M, 1998, J CELL BIOL, V140, P91, DOI 10.1083/jcb.140.1.91; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Wengler G, 1999, VIROLOGY, V257, P472, DOI 10.1006/viro.1999.9661; WILSCHUT J, 1995, MOL MEMBR BIOL, V12, P143, DOI 10.3109/09687689509038510; Yeager M, 1999, Methods Enzymol, V294, P135; Zhang W, 2002, J VIROL, V76, P11645, DOI 10.1128/JVI.76.22.11645-11658.2002	45	92	92	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	2003	114	5					573	583		10.1016/S0092-8674(03)00683-4	http://dx.doi.org/10.1016/S0092-8674(03)00683-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678581	Bronze			2022-12-24	WOS:000185193100007
J	Rueness, EK; Stenseth, NC; O'Donoghue, M; Boutin, S; Ellegren, H; Jakobsen, KS				Rueness, EK; Stenseth, NC; O'Donoghue, M; Boutin, S; Ellegren, H; Jakobsen, KS			Ecological and genetic spatial structuring in the Canadian lynx	NATURE			English	Article							CLADISTIC-ANALYSIS; SNOWSHOE HARE; GEOGRAPHICAL-DISTRIBUTION; PHENOTYPIC ASSOCIATIONS; POPULATION-DYNAMICS; HAPLOTYPES; DISPERSAL; SPECIATION; PATTERNS; PROGRAM	The Canadian lynx, distributed all across the northern part of North America, is well known for its regular population cycles-cycles that have different underlying structures in different parts of Canada(1). Using both nuclear and mitochondrial DNA markers, we report here a close resemblance between the earlier observed spatial ecological structuring of the Canadian lynx(1) and its spatial genetic structuring. Specifically, we demonstrate that the Rocky Mountains represent a barrier to gene flow in western Canada, and, somewhat surprisingly, we detect the presence of a geographically invisible barrier south of Hudson Bay (coinciding with the separation between the ecological Continental and Atlantic regions(1)). No evidence for isolation in different glacial refugia within North America was found. We suggest that ecological factors underlying the spatial dynamic structuring also strongly influence the genetic structuring of the Canadian lynx.	Univ Oslo, Dept Biol, Ctr Ecol & Evolutionary Synth, N-0315 Oslo, Norway; Yukon Dept Environm, Fish & Wildlife Branch, Mayo, YT Y0B 1M0, Canada; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Uppsala Univ, Dept Evolutionary Biol, SE-75236 Uppsala, Sweden	University of Oslo; University of Alberta; Uppsala University	Stenseth, NC (corresponding author), Univ Oslo, Dept Biol, Ctr Ecol & Evolutionary Synth, POB 1031 Blindern, N-0315 Oslo, Norway.		Boutin, Stan A/A-2619-2014; Stenseth, Nils Chr./G-5212-2016	Boutin, Stan A/0000-0001-6317-038X; Stenseth, Nils Chr./0000-0002-1591-5399				Avise JC, 2000, PHYLOGEOGRAPHY HIST, DOI 10.2307/j.ctv1nzfgj7; Burton C, 2002, MOL ECOL, V11, P1689, DOI 10.1046/j.1365-294X.2002.01566.x; Clement M, 2000, MOL ECOL, V9, P1657, DOI 10.1046/j.1365-294x.2000.01020.x; Dawson A.G., 1992, ICE AGE EARTH LATE Q; Doebeli M, 2003, NATURE, V421, P259, DOI 10.1038/nature01274; Elton C, 1942, J ANIM ECOL, V11, P215, DOI 10.2307/1358; Fedorov VB, 2002, P ROY SOC B-BIOL SCI, V269, P2071, DOI 10.1098/rspb.2002.2126; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; Hewitt GM, 1996, BIOL J LINN SOC, V58, P247, DOI 10.1111/j.1095-8312.1996.tb01434.x; JANCZEWSKI DN, 1995, MOL BIOL EVOL, V12, P690; Krebs C.J., 2001, ECOSYSTEM DYNAMICS B; KREBS CJ, 1995, SCIENCE, V269, P1112, DOI 10.1126/science.269.5227.1112; Kurten B., 1980, PLEISTOCENE MAMMALS; Menotti-Raymond M, 1999, GENOMICS, V57, P9, DOI 10.1006/geno.1999.5743; Mowat G, 1998, CAN FIELD NAT, V112, P32; Mowat Garth, 2000, P265; Poole KG, 1997, J WILDLIFE MANAGE, V61, P497, DOI 10.2307/3802607; Posada D, 2000, MOL ECOL, V9, P487, DOI 10.1046/j.1365-294x.2000.00887.x; Ranta E, 1997, ECOGRAPHY, V20, P454, DOI 10.1111/j.1600-0587.1997.tb00412.x; RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573; ROGERS AR, 1995, EVOLUTION, V49, P608, DOI 10.1111/j.1558-5646.1995.tb02297.x; Schneider S., 2000, ARLEQUIN SOFTWARE PO; Schwartz MK, 2002, NATURE, V415, P520, DOI 10.1038/415520a; Slough BG, 1996, J WILDLIFE MANAGE, V60, P946, DOI 10.2307/3802397; Stenseth NC, 1999, SCIENCE, V285, P1071, DOI 10.1126/science.285.5430.1071; Stenseth NC, 1997, P NATL ACAD SCI USA, V94, P5147, DOI 10.1073/pnas.94.10.5147; Stenseth NC, 1998, P NATL ACAD SCI USA, V95, P15430, DOI 10.1073/pnas.95.26.15430; TEMPLETON AR, 1995, GENETICS, V140, P767; TEMPLETON AR, 1992, GENETICS, V132, P619; TEMPLETON AR, 1993, GENETICS, V134, P659	30	91	97	2	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					69	72		10.1038/nature01942	http://dx.doi.org/10.1038/nature01942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955141				2022-12-24	WOS:000185089200038
J	Spath, GF; Lye, LF; Segawa, H; Sacks, DL; Turco, SJ; Beverley, SM				Spath, GF; Lye, LF; Segawa, H; Sacks, DL; Turco, SJ; Beverley, SM			Persistence without pathology in phosphoglycan-deficient Leishmania major	SCIENCE			English	Article							MURINE CUTANEOUS LEISHMANIASIS; LATENT LEISHMANIASIS; VIRULENCE FACTOR; LIPOPHOSPHOGLYCAN; MICE; PARASITES; HOST; PROMASTIGOTES; REACTIVATION; IMMUNITY	Leishmania infections involve an acute phase of replication within macrophages, typically associated with pathology. After recovery parasites persist for long periods, which can lead to severe disease upon reactivation. Unlike the role of host factors, parasite factors affecting persistence are poorly understood. Leishmania major lacking phosphoglycans (lpg2(-)) were unable to survive in sand flies and macrophages, but retained the ability to persist indefinitely in the mammalian host without inducing disease. The L. major lpg2(-) thus provides a platform for probing parasite factors implicated in persistence and its role in disease and immunity.	Washington Univ, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; NIAID, Parasit Dis Lab, Bethesda, MD 20892 USA	Washington University (WUSTL); University of Kentucky; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Beverley, SM (corresponding author), Washington Univ, Dept Mol Microbiol, St Louis, MO 63110 USA.		Späth, Gerald/B-1393-2014	Beverley, Stephen/0000-0001-5319-0811; Spaeth, Gerald/0000-0002-0256-2029	NIAID NIH HHS [AI31078] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000256, ZIAAI000256, R01AI031078] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AEBISCHER T, 1993, INFECT IMMUN, V61, P220, DOI 10.1128/IAI.61.1.220-226.1993; Alexander J, 1998, J IMMUNOL, V161, P6794; Alvar J, 1997, CLIN MICROBIOL REV, V10, P298, DOI 10.1128/CMR.10.2.298; Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; Bogdan C, 1998, INT J PARASITOL, V28, P121, DOI 10.1016/S0020-7519(97)00169-0; Bogdan C, 2000, J EXP MED, V191, P2121, DOI 10.1084/jem.191.12.2121; Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; GREEN PJ, 1994, MOL BIOCHEM PARASIT, V66, P319, DOI 10.1016/0166-6851(94)90158-9; Ilg T, 1999, BIOCHEM SOC T, V27, P518; Ilg T, 2001, J BIOL CHEM, V276, P4988, DOI 10.1074/jbc.M008030200; Ilgoutz SC, 2001, INT J PARASITOL, V31, P899, DOI 10.1016/S0020-7519(01)00197-7; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MOODY SF, 1993, J BIOL CHEM, V268, P18457; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; Piedrafita D, 1999, EUR J IMMUNOL, V29, P235, DOI 10.1002/(SICI)1521-4141(199901)29:01&lt;235::AID-IMMU235&gt;3.0.CO;2-S; Rittig MG, 2000, PARASITOL TODAY, V16, P292, DOI 10.1016/S0169-4758(00)01692-6; Sacks DL, 2000, P NATL ACAD SCI USA, V97, P406, DOI 10.1073/pnas.97.1.406; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656; Stenger S, 1996, J EXP MED, V183, P1501, DOI 10.1084/jem.183.4.1501; TITUS RG, 1991, EUR J IMMUNOL, V21, P559, DOI 10.1002/eji.1830210305; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; UZONNA J, UNPUB; Uzonna JE, 2001, J IMMUNOL, V167, P6967, DOI 10.4049/jimmunol.167.12.6967	30	135	143	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1241	1243		10.1126/science.1087499	http://dx.doi.org/10.1126/science.1087499			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947201				2022-12-24	WOS:000185003500044
J	Sullivan, MB; Waterbury, JB; Chisholm, SW				Sullivan, MB; Waterbury, JB; Chisholm, SW			Cyanophages infecting the oceanic cyanobacterium Prochlorococcus	NATURE			English	Article							MARINE SYNECHOCOCCUS; SARGASSO SEA; DIVERSITY; ABUNDANCE; BACTERIOPHAGE; ECOTYPES; ECOLOGY; VIRUSES; WH7803; PHAGES	Prochlorococcus is the numerically dominant phototroph in the tropical and subtropical oceans, accounting for half of the photosynthetic biomass in some areas(1,2). Here we report the isolation of cyanophages that infect Prochlorococcus, and show that although some are host-strain-specific, others cross-infect with closely related marine Synechococcus as well as between high-light-and low-light-adapted Prochlorococcus isolates, suggesting a mechanism for horizontal gene transfer. Highlight-adapted Prochlorococcus hosts yielded Podoviridae exclusively, which were extremely host-specific, whereas low-light-adapted Prochlorococcus and all strains of Synechococcus yielded primarily Myoviridae, which has a broad host range. Finally, both Prochlorococcus and Synechococcus strain-specific cyanophage titres were low (< 10(3) ml(-1)) in stratified oligotrophic waters even where total cyanobacterial abundances were high (> 10(5) cells ml(-1)). These low titres in areas of high total host cell abundance seem to be a feature of open ocean ecosystems. We hypothesize that gradients in cyanobacterial population diversity, growth rates, and/or the incidence of lysogeny underlie these trends.	MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; MIT, Woods Hole Oceanog Inst, Joint Program Biol Oceanog, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution; Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution	Chisholm, SW (corresponding author), MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA.		Sullivan, Matthew B/H-3256-2011	Sullivan, Matthew B/0000-0003-4040-9831; Chisholm, Sallie/0000-0003-1480-2445				Bohannan BJM, 2000, ECOL LETT, V3, P362, DOI 10.1046/j.1461-0248.2000.00161.x; Cavender-Bares KK, 2001, DEEP-SEA RES PT I, V48, P2373, DOI 10.1016/S0967-0637(01)00027-9; Fuller NJ, 2003, APPL ENVIRON MICROB, V69, P2430, DOI 10.1128/AEM.69.5.2430-2443.2003; Hendrix RW, 1999, P NATL ACAD SCI USA, V96, P2192, DOI 10.1073/pnas.96.5.2192; Liu HB, 1997, AQUAT MICROB ECOL, V12, P39, DOI 10.3354/ame012039; Lu J, 2001, APPL ENVIRON MICROB, V67, P3285, DOI 10.1128/AEM.67.7.3285-3290.2001; Mann EL, 2002, LIMNOL OCEANOGR, V47, P976, DOI 10.4319/lo.2002.47.4.0976; Moore LR, 1999, LIMNOL OCEANOGR, V44, P628, DOI 10.4319/lo.1999.44.3.0628; Moore LR, 1998, NATURE, V393, P464, DOI 10.1038/30965; Murphy FA, 1995, VIRUS TAXONOMY CLASS; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Palenik B, 2003, NATURE, V424, P1037, DOI 10.1038/nature01943; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; Rocap G, 2002, APPL ENVIRON MICROB, V68, P1180, DOI 10.1128/AEM.68.3.1180-1191.2002; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Rohwer F, 2000, LIMNOL OCEANOGR, V45, P408, DOI 10.4319/lo.2000.45.2.0408; Scanlan DJ, 2002, FEMS MICROBIOL ECOL, V40, P1, DOI 10.1111/j.1574-6941.2002.tb00930.x; Steward GF, 1996, MAR ECOL PROG SER, V131, P287, DOI 10.3354/meps131287; Suttle C.A., 2000, ECOLOGY CYANOBACTERI, P563, DOI DOI 10.1007/0-306-46855-7_20; SUTTLE CA, 1994, APPL ENVIRON MICROB, V60, P3167, DOI 10.1128/AEM.60.9.3167-3174.1994; SUTTLE CA, 1993, MAR ECOL PROG SER, V92, P99, DOI 10.3354/meps092099; Thingstad TF, 2000, LIMNOL OCEANOGR, V45, P1320, DOI 10.4319/lo.2000.45.6.1320; Urbach E, 1998, LIMNOL OCEANOGR, V43, P1615, DOI 10.4319/lo.1998.43.7.1615; WATERBURY JB, 1993, APPL ENVIRON MICROB, V59, P3393, DOI 10.1128/AEM.59.10.3393-3399.1993; Waterbury JB, 1986, CAN B FISH AQUAT SCI, V214, P71; Wichels A, 1998, APPL ENVIRON MICROB, V64, P4128; Wilson WH, 1996, J PHYCOL, V32, P506, DOI 10.1111/j.0022-3646.1996.00506.x; WILSON WH, 1993, APPL ENVIRON MICROB, V59, P3736, DOI 10.1128/AEM.59.11.3736-3743.1993; Woese CR, 2000, P NATL ACAD SCI USA, V97, P8392, DOI 10.1073/pnas.97.15.8392	29	384	412	3	103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1047	1051		10.1038/nature01929	http://dx.doi.org/10.1038/nature01929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944965				2022-12-24	WOS:000184984200041
J	Bandfield, JL; Glotch, TD; Christensen, PR				Bandfield, JL; Glotch, TD; Christensen, PR			Spectroscopic identification of carbonate minerals in the martian dust	SCIENCE			English	Article							THERMAL EMISSION; MARS; SPECTROMETER; SOIL; SURFACES; SPECTRA; CLIMATE; CLAYS	Thermal infrared spectra of the martian surface indicate the presence of small concentrations (similar to2 to 5 weight %) of carbonates, specifically dominated by magnesite (MgCO3). The carbonates are widely distributed in the martian dust, and there is no indication of a concentrated source. The presence of small concentrations of carbonate minerals in the surface dust and in martian meteorites can sequester several bars of atmospheric carbon dioxide and may have been an important sink for a thicker carbon dioxide atmosphere in the martian past.	Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Bandfield, JL (corresponding author), Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA.		Glotch, Timothy/B-6829-2008	Bandfield, Joshua/0000-0003-3571-3716				Bandfield JL, 2000, SCIENCE, V287, P1626, DOI 10.1126/science.287.5458.1626; Bandfield JL, 2003, ICARUS, V161, P47, DOI 10.1016/S0019-1035(02)00025-8; BANDFIELD JL, 2002, J GEOPHYS RES; BANIN A, 1979, J MOL EVOL, V14, P133, DOI 10.1007/BF01732373; BETTS BH, 1995, J GEOPHYS RES-PLANET, V100, P5285, DOI 10.1029/95JE00226; BLANEY DL, 1989, J GEOPHYS RES-SOLID, V94, P10159, DOI 10.1029/JB094iB08p10159; BOOTH MC, 1978, J GEOPHYS RES, V83, P1809, DOI 10.1029/JB083iB04p01809; CALVIN WM, 1994, J GEOPHYS RES-PLANET, V99, P14659, DOI 10.1029/94JE01090; Christensen PR, 2001, J GEOPHYS RES-PLANET, V106, P23823, DOI 10.1029/2000JE001370; Fanale F.P., 1992, MARS, P1135; FANALE FP, 1982, ICARUS, V50, P381, DOI 10.1016/0019-1035(82)90131-2; Farmer V. C., 1974, INFRARED SPECTRA MIN; Gaffey S.J., 1993, REMOTE GEOCHEMICAL A, P43; GOODING JL, 1978, ICARUS, V33, P483, DOI 10.1016/0019-1035(78)90186-0; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; HUGUENIN RL, 1974, J GEOPHYS RES, V79, P3895, DOI 10.1029/JB079i026p03895; JAKOSKY BM, 1990, GEOPHYS RES LETT, V17, P985, DOI 10.1029/GL017i007p00985; KAHN R, 1985, ICARUS, V62, P175, DOI 10.1016/0019-1035(85)90116-2; Lane MD, 1997, J GEOPHYS RES-PLANET, V102, P25581, DOI 10.1029/97JE02046; Lellouch E, 2000, PLANET SPACE SCI, V48, P1393, DOI 10.1016/S0032-0633(00)00118-5; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P14595, DOI 10.1029/JB095iB09p14595; RUFF SW, 2002, EOS S, V83, P1059; RUFF SW, 2002, J GEOPHYS RES; Salisbury J.W., 1991, INFRARED 2 1 25 MUM; SALISBURY JW, 1989, J GEOPHYS RES-SOLID, V94, P9192, DOI 10.1029/JB094iB07p09192; SETTLE M, 1979, J GEOPHYS RES, V84, P8343, DOI 10.1029/JB084iB14p08343; TOON OB, 1980, ICARUS, V44, P552, DOI 10.1016/0019-1035(80)90130-X; Wagner C, 1996, ICARUS, V123, P256, DOI 10.1006/icar.1996.0156	29	256	262	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1084	1087		10.1126/science.1088054	http://dx.doi.org/10.1126/science.1088054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934004				2022-12-24	WOS:000184872400036
J	Wu, S; Huang, JB; Dong, JX; Pan, DJ				Wu, S; Huang, JB; Dong, JX; Pan, DJ			hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts	CELL			English	Article							TUMOR SUPPRESSORS; IMAGINAL DISC; CYCLIN-E; DROSOPHILA; GROWTH; SIZE; ACTIVATION; MOSAICS; DEATH; SHAPE	The coordination between cell proliferation and cell death is essential to maintain homeostasis within multicellular organisms. The mechanisms underlying this regulation are yet to be completely understood. Here, we report the identification of hippo (hpo) as a gene that regulates both cell proliferation and cell death in Drosophila. hpo encodes a Ste-20 family protein kinase that binds to and phosphorylates the tumor suppressor protein Salvador (Sav), which is known to interact with the Warts (Wts) protein kinase. Loss of hpo results in elevated transcription of the cell cycle regulator cyclin E and the cell-death inhibitor diap1, leading to increased proliferation and reduced apoptosis. Further, we show that hpo, sav, and wts define a pathway that regulates diap1 at the transcriptional level. A human homolog of hpo completely rescues the overgrowth phenotype of Drosophila hpo mutants, suggesting that hpo might play a conserved role for growth control in mammals.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pan, DJ (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Wu, Shian/0000-0003-4990-6594	NIGMS NIH HHS [GM62323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chen B, 1998, GENETICS, V149, P157; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Glantschnig H, 2002, J BIOL CHEM, V277, P42987, DOI 10.1074/jbc.M208538200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; Johnston LA, 2002, BIOESSAYS, V24, P54, DOI 10.1002/bies.10021; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Wolff Tanya, 1993, P1277; XU TA, 1995, DEVELOPMENT, V121, P1053; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	30	804	844	5	76	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					445	456		10.1016/S0092-8674(03)00549-X	http://dx.doi.org/10.1016/S0092-8674(03)00549-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941273	Bronze			2022-12-24	WOS:000184928800008
J	Khot, UN; Jia, G; Moliterno, DJ; Lincoff, AM; Khot, MB; Harrington, RA; Topol, EJ				Khot, UN; Jia, G; Moliterno, DJ; Lincoff, AM; Khot, MB; Harrington, RA; Topol, EJ			Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes - The enduring value of Killip classification	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; PLATELET GLYCOPROTEIN IIB/IIIA; ACUTE ISCHEMIC SYNDROMES; UNSTABLE ANGINA; RISK STRATIFICATION; SEGMENT ELEVATION; DOPPLER-ECHOCARDIOGRAPHY; CARDIAC AUSCULTATION; CARDIOGENIC-SHOCK; EJECTION FRACTION	Context In acute myocardial infarction, the presence and severity of heart failure at the time of initial presentation have been formally categorized by the Killip classification. Although well studied in ST-elevation myocardial infarction, the prognostic importance of Killip classification in non-ST-elevation acute coronary syndromes is not well established. Objectives To determine the prognostic importance of physical examination for heart failure analyzed according to Killip classification in non-ST-elevation acute coronary syndromes and to understand its predictive value relative to other variables. Design, Setting, and Patients From April 2001 to September 2003, We analyzed information from 26090 patients with non-ST-elevation acute coronary syndromes enrolled in the GUSTO IIb, PURSUIT, PARAGON A, and PARAGON B trials. Demographic information was categorized by Killip class. Killip classes III and IV were combined into 1 category. Multivariate Cox proportional hazard models were developed to determine the prognostic importance of Killip classification in comparison with other variables. Main Outcome Measure Association between Killip classification and all-cause mortality at 30 days and 6 months. Results Patients in Killip class II (n =2513) and III/IV (n =390) were older than those in Killip class I (n =23 187), with higher rates of diabetes, prior myocardial infarction, ST depression, and elevated cardiac enzymes (all P<.001). Higher Killip class was associated with higher mortality at 30 days (2.8% in Killip class I vs 8.8% in class II vs 14.4% in class III/IV; P<.001) and 6 months (5.0% vs 14.7% vs 23.0%, respectively; P<.001). Patients with Killip class II, III, or IV constituted 11% of the overall population but accounted for approximately 30% of the deaths at both time points. In multivariate analysis, Killip class III/IV was the most powerful predictor of mortality at 30 days (hazard ratio [HR], 2.35; 95% confidence interval [CI], 1.69-3.26; P<.001) and 6 months (HR, 2.12; 95% Cl, 1.63-2.75; P<.001). Killip class 11 was predictive of mortality at 30 days (HR, 1.73; 95% Cl, 1.44-2.09; P<.001) and 6 months (HR, 1.52; 95% Cl, 1.31-1.76; P<.001). Five factors-age, Killip classification, heart rate, systolic blood pressure, and ST depression-provided more than 70% of the prognostic information for 30-day and 6-month mortality. Conclusions Killip classification is a powerful independent predictor of all-cause mortality in patients with non-ST-elevation acute coronary syndromes. Age, Killip classification, heart rate, systolic blood pressure, and ST depression should receive particular attention in the initial assessment of these patients.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Duke Clin Res Inst, Durham, NC USA	Cleveland Clinic Foundation; Duke University	Khot, UN (corresponding author), Indiana Heart Phys, 112 N 17th Ave,Suite 300, Beech Grove, IN 46107 USA.			Topol, Eric/0000-0002-1478-4729				Alexander JH, 2000, JAMA-J AM MED ASSOC, V283, P347, DOI 10.1001/jama.283.3.347; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Armstrong PW, 1998, CIRCULATION, V98, P1860, DOI 10.1161/01.CIR.98.18.1860; Bazzino O, 1999, AM HEART J, V137, P322, DOI 10.1053/hj.1999.v137.93029; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Braunwald E, 1994, UNSTABLE ANGINA DIAG; BROWN KA, 1991, J AM COLL CARDIOL, V17, P1053, DOI 10.1016/0735-1097(91)90829-X; CHATTERJEE K, 2002, TXB CARDIOVASCULAR M, P273; COL NF, 1994, AM J CARDIOL, V73, P149, DOI 10.1016/0002-9149(94)90206-2; Collinson J, 2000, EUR HEART J, V21, P1450, DOI 10.1053/euhj.1999.1995; Coronado BE, 1997, J AM COLL CARDIOL, V29, P1490, DOI 10.1016/S0735-1097(97)00077-6; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; de Sa EL, 2002, MEDICINE, V81, P434, DOI 10.1097/00005792-200211000-00004; DeGeare VS, 2001, AM J CARDIOL, V87, P1035, DOI 10.1016/S0002-9149(01)01457-6; Diderholm E, 2002, AM HEART J, V143, P760, DOI 10.1067/mhj.2002.121733; Drazner MH, 2001, NEW ENGL J MED, V345, P574, DOI 10.1056/NEJMoa010641; Gigli G, 2002, Eur J Echocardiogr, V3, P59, DOI 10.1053/euje.2001.0119; Harrington RA, 2002, CIRCULATION, V105, P316; Holmes DR, 1999, CIRCULATION, V100, P2067, DOI 10.1161/01.CIR.100.20.2067; JAFFE WM, 1988, CIRCULATION, V78, P267, DOI 10.1161/01.CIR.78.2.267; Katz DA, 1996, JAMA-J AM MED ASSOC, V276, P1568; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; LAUNBJERG J, 1992, CARDIOLOGY, V80, P375, DOI 10.1159/000175028; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Mangione S, 1999, AM J RESP CRIT CARE, V159, P1119, DOI 10.1164/ajrccm.159.4.9806083; Mangione S, 1997, JAMA-J AM MED ASSOC, V278, P717, DOI 10.1001/jama.278.9.717; Moller JE, 2001, J AM SOC ECHOCARDIOG, V14, P757, DOI 10.1067/mje.2001.113367; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; Neskovic AN, 1999, AM HEART J, V137, P361, DOI 10.1053/hj.1999.v137.89744; NICOD P, 1988, AM J CARDIOL, V61, P1165, DOI 10.1016/0002-9149(88)91148-4; Roe MT, 2000, CIRCULATION, V102, P1101, DOI 10.1161/01.CIR.102.10.1101; Rott D, 1997, AM J CARDIOL, V80, P859, DOI 10.1016/S0002-9149(97)00536-5; Savonitto S, 2002, J AM COLL CARDIOL, V39, P22, DOI 10.1016/S0735-1097(01)01706-5; Schneiderman H, 2001, AM J MED, V110, P233, DOI 10.1016/S0002-9343(00)00736-1; Seres L, 1999, AM J CARDIOL, V84, P963, DOI 10.1016/S0002-9149(99)00481-6; Solomon DH, 2001, J AM COLL CARDIOL, V38, P969, DOI 10.1016/S0735-1097(01)01503-0; Tavel ME, 1996, CIRCULATION, V93, P1250, DOI 10.1161/01.CIR.93.6.1250; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; Topol EJ, 1996, NEW ENGL J MED, V335, P775; WARNOWICZ MA, 1983, CIRCULATION, V67, P330, DOI 10.1161/01.CIR.67.2.330	41	154	165	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	2003	290	16					2174	2181		10.1001/jama.290.16.2174	http://dx.doi.org/10.1001/jama.290.16.2174			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CB	14570953	Bronze			2022-12-24	WOS:000186036700027
J	Vasan, RS; Sullivan, LM; D'Agostino, RB; Roubenoff, R; Harris, T; Sawyer, DB; Levy, D; Wilson, PWF				Vasan, RS; Sullivan, LM; D'Agostino, RB; Roubenoff, R; Harris, T; Sawyer, DB; Levy, D; Wilson, PWF			Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: The Framingham Heart Study	ANNALS OF INTERNAL MEDICINE			English	Article							DILATED CARDIOMYOPATHY; BODY-COMPOSITION; TRANSGENIC MICE; OLDER WOMEN; WALL STRESS; HYPERTROPHY; HORMONE; OVEREXPRESSION; DISEASE; EPIDEMIOLOGY	Background: several experimental investigations have emphasized the favorable effects of insulin-like growth factor I (IGF-1) on left ventricular remodeling, partly through its antiapoptotic effects. Cross-sectional clinical studies have reported that low serum IGF-I levels in patients with heart failure correlate with cachexia and severity of ventricular dysfunction. it is unclear whether low serum IGF-I is a risk factor for heart failure. Objective: To prospectively study the association between serum IGF-I level and the incidence of congestive heart failure. Design: Community-based, prospective cohort study. Setting: Framingham, Massachusetts. Participants: 717 elderly individuals (mean age, 78.4 years; 67% women) who did not have myocardial infarction and congestive heart failure at baseline. Measurement: Incidence of a first episode of congestive heart failure on follow-up. Results: During follow-up (mean, 5.2 years), 56 participants (35 women) developed congestive heart failure. In multivarlable Cox regression models adjusting for established risk factors at baseline, there was a 27% decrease in risk for heart failure for every 1 standard. deviation increment in log IGF-I. Individuals with serum IGF-I level at or above the median value (140 mug/L) had half the risk for heart failure (hazard ratio, 0.49 [95% Cl, 0.26 to 0.92]) of those with serum IGF-I levels below the median. These comparisons were maintained in analyses adjusting for the occurrence of a myocardial infarction on follow-up. Conclusions: In our prospective, community-based investigation, serum IGF-I level was inversely related to the risk for congestive heart failure in elderly people without a previous myocardial infarction. Additional investigations are warranted to confirm these findings.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Boston Univ, Boston, MA 02215 USA; Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; NHLBI, Bethesda, MD 20892 USA; NIA, Bethesda, MD 20892 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Tufts University; United States Department of Agriculture (USDA); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Vasan, RS (corresponding author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.		Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Ramachandran, Vasan/Y-2527-2019; Wilson, Peter W.F./J-2455-2016	Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Roubenoff, Ronenn/0000-0002-3959-3179; Sullivan, Lisa/0000-0003-0726-7149	NHLBI NIH HHS [1K24 HL04334, N01-HC-25195] Funding Source: Medline; NIA NIH HHS [AG15797] Funding Source: Medline; NIDDK NIH HHS [DK02120] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG015797] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBLER GR, 1993, CARDIOVASC RES, V27, P1368, DOI 10.1093/cvr/27.7.1368; Anker SD, 2001, J AM COLL CARDIOL, V38, P443, DOI 10.1016/S0735-1097(01)01385-7; Anversa P, 1996, CARDIOVASC RES, V32, P484, DOI 10.1016/S0008-6363(96)00036-3; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Benbassat CA, 1997, J CLIN ENDOCR METAB, V82, P1484, DOI 10.1210/jc.82.5.1484; Bruch C, 2002, AM HEART J, V144, P538, DOI 10.1067/mhj.2002.123572; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; Cappola AR, 2001, J CLIN ENDOCR METAB, V86, P4139, DOI 10.1210/jc.86.9.4139; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Cox D. R., 1984, ANAL SURVIVAL DATA; Cupples LA, 1987, FRAMINGHAM STUDY EPI; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Donath MY, 1998, J CLIN ENDOCR METAB, V83, P3177, DOI 10.1210/jc.83.9.3177; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; GoodmanGruen D, 1997, AM J EPIDEMIOL, V145, P970, DOI 10.1093/oxfordjournals.aje.a009065; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Harris TB, 1997, J AM GERIATR SOC, V45, P133, DOI 10.1111/j.1532-5415.1997.tb04497.x; HINTZ RL, 1988, HORM METAB RES, V20, P344, DOI 10.1055/s-2007-1010832; Juul A, 2002, CIRCULATION, V106, P939, DOI 10.1161/01.CIR.0000027563.44593.CC; Khan AS, 2002, CARDIOVASC RES, V54, P25, DOI 10.1016/S0008-6363(01)00533-8; Lee WL, 1999, ENDOCRINOLOGY, V140, P4831, DOI 10.1210/en.140.10.4831; Leri A, 1999, CIRC RES, V84, P752; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; McMurray JJ, 2000, HEART, V83, P596, DOI 10.1136/heart.83.5.596; Mosterd A, 1997, EUR J EPIDEMIOL, V13, P491; Niebauer J, 1998, J AM COLL CARDIOL, V32, P393, DOI 10.1016/S0735-1097(98)00226-5; Osterziel KJ, 1998, LANCET, V351, P1233, DOI 10.1016/S0140-6736(97)11329-0; Parkhouse WS, 2000, MECH AGEING DEV, V113, P75, DOI 10.1016/S0047-6374(99)00103-7; Redaelli G, 1998, CIRC RES, V82, P594, DOI 10.1161/01.RES.82.5.594; Ren J, 1999, J MOL CELL CARDIOL, V31, P2049, DOI 10.1006/jmcc.1999.1036; Serneri GGN, 1999, CIRC RES, V85, P57; Tai BC, 2001, STAT MED, V20, P661, DOI 10.1002/sim.711; Vasan RS, 2003, CIRCULATION, V107, P1486, DOI 10.1161/01.CIR.0000057810.48709.F6; Vecchione C, 2001, HYPERTENSION, V37, P1480, DOI 10.1161/01.HYP.37.6.1480; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Wang PH, 2001, CIRC RES, V88, P552, DOI 10.1161/01.RES.88.6.552; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75	38	218	226	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 21	2003	139	8					642	648		10.7326/0003-4819-139-8-200310210-00007	http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734DW	14568852				2022-12-24	WOS:000186040800002
J	Wilcken, NRC; Stockler, MTR				Wilcken, NRC; Stockler, MTR			Fulvestrant: spreading the word, but not too thinly	LANCET			English	Editorial Material							ADVANCED BREAST-CANCER; POSTMENOPAUSAL WOMEN; ANASTROZOLE		Westmead Hosp, NSW Breast Canc Inst, Sydney, NSW, Australia; Westmead Hosp, Dept Med Oncol, Sydney, NSW, Australia; NHMRC Clin Trials Ctr, Sydney, NSW, Australia; Sydney Canc Ctr, RPA & Concord Hosp, Sydney, NSW, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; University of Sydney	Wilcken, NRC (corresponding author), Westmead Hosp, NSW Breast Canc Inst, Sydney, NSW, Australia.	nicholasw@westgate.wh.usyd.edu.au	Stockler, Martin R/N-3859-2016	Stockler, Martin R/0000-0003-3793-8724				[Anonymous], 1988, LANCET, V2, P349; *ASTR, 2002, FASL FULV INJ HORM T; Fletcher RH, 2003, LANCET, V361, P10, DOI 10.1016/S0140-6736(03)12185-X; Howell A, 2002, J CLIN ONCOL, V20, P3396, DOI 10.1200/JCO.2002.10.057; Mauriac L, 2003, EUR J CANCER, V39, P1228, DOI 10.1016/S0959-8049(03)00199-0; Osborne CK, 2002, J CLIN ONCOL, V20, P3386, DOI 10.1200/JCO.2002.10.058; STOCKLER M, 1993, MED J AUSTRALIA, V159, P291, DOI 10.5694/j.1326-5377.1993.tb137859.x; Tannock IF, 1996, J NATL CANCER I, V88, P206, DOI 10.1093/jnci/88.3-4.206	8	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2003	362	9392					1254	1254		10.1016/S0140-6736(03)14616-8	http://dx.doi.org/10.1016/S0140-6736(03)14616-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575967				2022-12-24	WOS:000186036900006
J	Colavita, A; Tessier-Lavigne, M				Colavita, A; Tessier-Lavigne, M			A neurexin-related protein, BAM-2, terminates axonal branches in C-elegans	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; NEURONS	Neuronal axons connect to multiple target cells through the formation of collateral branches, but the mechanisms that regulate this process are largely unknown. We show that BAM-2, a neurexin-related transmembrane protein, is required for development of VC motoneuron branches in the worm Caenorhabditis elegans. Expression analysis and ectopic expression experiments suggest that BAM-2 functions as a branch termination cue and reveal a mechanism for selective control of branches that sprout off a primary axon.	Stanford Univ, Howard Hughes Med Inst, Dept Biol Sci, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Tessier-Lavigne, M (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	marctl@gene.com		Colavita, Antonio/0000-0001-9391-5282				Acebes A, 2000, TRENDS NEUROSCI, V23, P557, DOI 10.1016/S0166-2236(00)01646-5; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; LI C, 1990, NEURON, V4, P681, DOI 10.1016/0896-6273(90)90195-L; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; OLSEN PT, COMMUNICATION; PELES E, COMMUNICATION; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Soussi-Yanicostas N, 2002, CELL, V109, P217, DOI 10.1016/S0092-8674(02)00713-4; TAKAO I, 2002, GENE EXPR PATTERNS, V2, P235; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Waggoner LE, 1998, NEURON, V21, P203, DOI 10.1016/S0896-6273(00)80527-9; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; WEINSHENKER D, 1995, J NEUROSCI, V15, P6975; Yates PA, 2001, J NEUROSCI, V21, P8548, DOI 10.1523/JNEUROSCI.21-21-08548.2001	18	24	35	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					293	296		10.1126/science.1089163	http://dx.doi.org/10.1126/science.1089163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551437				2022-12-24	WOS:000185825900044
J	Whitfield, CW; Cziko, AM; Robinson, GE				Whitfield, CW; Cziko, AM; Robinson, GE			Gene expression profiles in the brain predict behavior in individual honey bees	SCIENCE			English	Article							MICROARRAYS; GENOMICS	We show that the age-related transition by adult honey bees from hive work to foraging is associated with changes in messenger RNA abundance in the brain for 39% of similar to5500 genes tested. This result, discovered using a highly replicated experimental design involving 72 microarrays, demonstrates more extensive genomic plasticity in the adult brain than has yet been shown. Experimental manipulations that uncouple behavior and age revealed that messenger RNA changes were primarily associated with behavior. Individual brain messenger RNA profiles correctly predicted the behavior of 57 out of 60 bees, indicating a robust association between brain gene expression in the individual and naturally occurring behavioral plasticity.	Univ Illinois, Dept Entomol, 320 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA; Univ Illinois, Neurosci Program, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Robinson, GE (corresponding author), Univ Illinois, Dept Entomol, 320 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.	generobi@life.uiuc.edu						Alcock J., 2001, ANIMAL BEHAV EVOLUTI, V7th ed.; Becker JB, 1992, BEHAV ENDOCRINOLOGY; Ben-Shahar Y, 2002, SCIENCE, V296, P741, DOI 10.1126/science.1069911; Brett M, 2002, NAT REV NEUROSCI, V3, P243, DOI 10.1038/nrn756; CASH AC, UNPUB; Cavallaro S, 2002, NEUROCHEM RES, V27, P1201, DOI 10.1023/A:1020933627597; Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Dubnau J, 2003, CURR BIOL, V13, P286, DOI 10.1016/S0960-9822(03)00064-2; Etter PD, 2002, BIOESSAYS, V24, P494, DOI 10.1002/bies.10109; Gibson G, 2002, MOL ECOL, V11, P17, DOI 10.1046/j.0962-1083.2001.01425.x; Greenspan RJ, 1997, CURR OPIN NEUROBIOL, V7, P805, DOI 10.1016/S0959-4388(97)80139-0; Hofmann HA, 2000, J NEUROSCI, V20, P4740, DOI 10.1523/JNEUROSCI.20-12-04740.2000; Korol DL, 1998, AM J CLIN NUTR, V67, p764S, DOI 10.1093/ajcn/67.4.764S; Kucharski R, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-2-research0007; Mong JA, 2003, P NATL ACAD SCI USA, V100, P318, DOI 10.1073/pnas.262663799; Oster G.F., 1978, Monographs in Population Biology, pi; Robinson GE, 2002, AM NAT, V160, pS160, DOI 10.1086/342901; Robinson GE, 2002, GENES BRAIN BEHAV, V1, P197, DOI 10.1034/j.1601-183X.2002.10401.x; Slonim DK, 2002, NAT GENET, V32, P502, DOI 10.1038/ng1033; Sun MK, 2002, TRENDS PHARMACOL SCI, V23, P83, DOI 10.1016/S0165-6147(02)01899-0; Toma DP, 2002, NAT GENET, V31, P349, DOI 10.1038/ng893; Townsend JP, 2002, GENOME BIOL, V3; Wahlsten D, 2003, J NEUROBIOL, V54, P283, DOI 10.1002/neu.10173; Whitfield CW, 2002, GENOME RES, V12, P555, DOI 10.1101/gr.5302; Winston M.L., 1991, BIOL HONEY BEE; 2003, NATURE NEUROSCI, V6, P647	27	445	468	1	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					296	299		10.1126/science.1086807	http://dx.doi.org/10.1126/science.1086807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551438				2022-12-24	WOS:000185825900045
J	Kozlova, T; Thummel, CS				Kozlova, T; Thummel, CS			Essential roles for ecdysone signaling during Drosophila mid-embryonic development	SCIENCE			English	Article							GERM-BAND RETRACTION; RETINOID-X-RECEPTOR; MORPHOGENESIS; MELANOGASTER; ISOFORMS; TISSUE; METAMORPHOSIS; ULTRASPIRACLE; EMBRYOGENESIS; ECDYSTEROIDS	Although functions for the steroid hormone ecdysone during Drosophila metamorphosis have been well established, roles for the embryonic ecdysone pulse remain poorly understood. We show that the EcR-USP ecdysone receptor is first activated in the extraembryonic amnioserosa, implicating this tissue as a source of active ecdysteroids in the early embryo. Ecdysone signaling is required for germ band retraction and head involution, morphogenetic movements that shape the first instar larva. This mechanism for coordinating morphogenesis during Drosophila embryonic development parallels the role of ecdysone during metamorphosis. It also provides an intriguing parallel with the role of mammalian extraembryonic tissues as a critical source of steroid hormones during embryonic development.	Univ Utah, Sch Med, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Kozlova, T (corresponding author), Univ S Florida, Dept Biol, 4202 E Fowler Ave, Tampa, FL 33620 USA.							Antoniewski C, 1996, MOL CELL BIOL, V16, P2977; Bender M, 1997, CELL, V91, P777, DOI 10.1016/S0092-8674(00)80466-3; BOWNES M, 1988, P NATL ACAD SCI USA, V85, P1554, DOI 10.1073/pnas.85.5.1554; Buszczak M, 1999, DEVELOPMENT, V126, P4581; Chavez VM, 2000, DEVELOPMENT, V127, P4115; Cherbas L, 2003, DEVELOPMENT, V130, P271, DOI 10.1242/dev.00205; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; D'Avino PP, 2000, DEV BIOL, V220, P211, DOI 10.1006/dbio.2000.9650; Frank LH, 1996, DEVELOPMENT, V122, P1343; GAREN A, 1977, P NATL ACAD SCI USA, V74, P5099, DOI 10.1073/pnas.74.11.5099; Ghbeish N, 2001, P NATL ACAD SCI USA, V98, P3867, DOI 10.1073/pnas.061437798; Hoffmann J.A., 1985, P435; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; Kozlova T, 2002, DEVELOPMENT, V129, P1739; Lamka ML, 1999, DEV BIOL, V214, P102, DOI 10.1006/dbio.1999.9409; MAROY P, 1988, J INSECT PHYSIOL, V34, P633, DOI 10.1016/0022-1910(88)90071-6; ORO AE, 1992, DEVELOPMENT, V115, P449; PERRIMON N, 1985, GENETICS, V111, P23; Riddiford LM, 2001, VITAM HORM, V60, P1; ROOTE CE, 1995, DEV BIOL, V169, P322, DOI 10.1006/dbio.1995.1147; Schock F, 2003, GENE DEV, V17, P597, DOI 10.1101/gad.1068403; Schock F, 2002, DEV BIOL, V248, P29, DOI 10.1006/dbio.2002.0698; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; VONKALM L, 1995, BIOESSAYS, V17, P693, DOI 10.1002/bies.950170806; WARD RE, IN PRESS GENETICS; Warren JT, 2002, P NATL ACAD SCI USA, V99, P11043, DOI 10.1073/pnas.162375799; Yip MLR, 1997, DEVELOPMENT, V124, P2129	27	123	125	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1911	1914		10.1126/science.1087419	http://dx.doi.org/10.1126/science.1087419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	12958367				2022-12-24	WOS:000185536700052
J	Garcia-Garcia, MJ; Anderson, KV				Garcia-Garcia, MJ; Anderson, KV			Essential role of glycosaminoglycans in Fgf signaling during mouse gastrulation	CELL			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; UDP-GLUCOSE DEHYDROGENASE; ENDOTHELIAL-CELL PRECURSORS; ANTERIOR PRIMITIVE ENDODERM; SURFACE PROTEOGLYCAN; TARGETED DISRUPTION; MOLECULAR-CLONING; GROWTH-FACTORS; GENE ENCODES; TOUT-VELU	In vitro studies have suggested that proteoglycans facilitate signaling by mammalian growth factors, but genetic evidence supporting this role has been lacking. Here, we characterize the ENU-induced mutation lazy mesoderm (Izme), which disrupts the single mouse gene encoding UDP-glucose dehydrogenase (Ugdh), an enzyme required for the synthesis of the glycosaminoglycan (GAG) side chains of proteoglycans. lzme mutants arrest during gastrulation with defects in migration of mesoderm and endoderm, a phenotype similar to that of mutants in the fibroblast growth factor (Fgf) pathway. Analysis of the expression of molecular markers indicates that Fgf signaling is blocked in lzme mutant embryos. In contrast, signaling by the growth factors Nodal and Wnt3, which are also essential during mouse gastrulation, appears to be normal in lzme embryos. The results demonstrate that proteoglycans are required during mouse gastrulation specifically to promote Fgf signaling.	Sloan Kettering Inst, Dev Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Anderson, KV (corresponding author), Sloan Kettering Inst, Dev Biol Program, 1275 York Ave, New York, NY 10021 USA.	k-anderson@ski.mskcc.org		Anderson, Kathryn/0000-0003-1657-2161	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD035455, R37HD035455] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD035455] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35455] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Baeg GH, 2001, DEVELOPMENT, V128, P87; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bellosta P, 2001, MOL CELL BIOL, V21, P5946, DOI 10.1128/MCB.21.17.5946-5957.2001; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Binari RC, 1997, DEVELOPMENT, V124, P2623; Brennan J, 2001, NATURE, V411, P965, DOI 10.1038/35082103; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Chapman DL, 1998, NATURE, V391, P695, DOI 10.1038/35624; Chiao E, 2002, DEV BIOL, V243, P185, DOI 10.1006/dbio.2001.0554; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAMJANOV I, 1986, DEV BIOL, V116, P194, DOI 10.1016/0012-1606(86)90056-4; DasGupta R, 1999, DEVELOPMENT, V126, P4557; De Cat B, 2001, SEMIN CELL DEV BIOL, V12, P117, DOI 10.1006/scdb.2000.0240; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Furukawa K, 2002, BBA-GEN SUBJECTS, V1573, P377, DOI 10.1016/S0304-4165(02)00406-3; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; HOGAN BLM, 1994, DEVELOPMENT, P53; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kasarskis A, 1998, P NATL ACAD SCI USA, V95, P7485, DOI 10.1073/pnas.95.13.7485; Kelly RG, 2001, DEV CELL, V1, P435, DOI 10.1016/S1534-5807(01)00040-5; Li YF, 1997, MATRIX BIOL, V16, P49, DOI 10.1016/S0945-053X(97)90071-8; Lin XH, 1999, DEVELOPMENT, V126, P3715; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; MAKOVER A, 1989, DIFFERENTIATION, V40, P17, DOI 10.1111/j.1432-0436.1989.tb00809.x; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Minowada G, 1999, DEVELOPMENT, V126, P4465; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; Ornitz DM, 2001, GENOME BIOL, V2; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Saga Y, 1999, DEVELOPMENT, V126, P3437; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; Sun X, 1999, GENE DEV, V13, P1834, DOI 10.1101/gad.13.14.1834; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Wang YL, 2000, GENOMICS, V66, P333, DOI 10.1006/geno.2000.6221; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032	69	96	97	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					727	737		10.1016/S0092-8674(03)00715-3	http://dx.doi.org/10.1016/S0092-8674(03)00715-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505572	Bronze			2022-12-24	WOS:000185464000010
J	Feinberg, EH; Hunter, CP				Feinberg, EH; Hunter, CP			Transport of dsRNA into cells by the transmembrane protein SID-1	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; C-ELEGANS; CAENORHABDITIS-ELEGANS; GENETIC INTERFERENCE; IDENTIFICATION; RECEPTOR; RDE-1	RNA interference (RNAi) spreads systemically in plants and nematodes to silence gene expression distant from the site of initiation. We previously identified a gene, sid-1, essential for systemic but not cell-autonomous RNAi in Caenorhabditis elegans. Here, we demonstrate that SID-1 is a multispan transmembrane protein that sensitizes Drosophila cells to soaking RNAi with a potency that is dependent on double-stranded RNA ( dsRNA) length. Further analyses revealed that SID-1 enables passive cellular uptake of dsRNA. These data indicate that systemic RNAi in C. elegans involves SID-1-mediated intercellular transport of dsRNA.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Hunter, CP (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069891] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM069891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FEINBERG EH, UNPUB; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Han K, 2001, MOL CELLS, V12, P267; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Shibuya A, 2000, NAT IMMUNOL, V1, P441, DOI 10.1038/80886; SILHAVY TJ, 1985, MICROBIOL REV, V49, P398, DOI 10.1128/MMBR.49.4.398-418.1985; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Worby C A, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.95.pl1	21	387	421	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1545	1547		10.1126/science.1087117	http://dx.doi.org/10.1126/science.1087117			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970568				2022-12-24	WOS:000185255300053
J	Chen, W; Kirkbride, KC; How, T; Nelson, CD; Mo, JY; Frederick, JP; Wang, XF; Lefkowitz, RJ; Blobe, GC				Chen, W; Kirkbride, KC; How, T; Nelson, CD; Mo, JY; Frederick, JP; Wang, XF; Lefkowitz, RJ; Blobe, GC			beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling	SCIENCE			English	Article							GROWTH-FACTOR-BETA; PROTEIN-COUPLED RECEPTORS; INTERNALIZATION; ARRESTIN; EXPRESSION; MODULATION; TRANSDUCTION; MECHANISM; DISTINCT; KINASES	beta-Arrestins bind to activated seven transmembrane-spanning (7TMS) receptors (G protein-coupled receptors) after the receptors are phosphorylated by G protein-coupled receptor kinases (GRKs), thereby regulating their signaling and internalization. Here, we demonstrate an unexpected and analogous role of beta-arrestin 2 (betaarr2) for the single transmembrane-spanning type III transforming growth factor-beta (TGF-beta) receptor (TbetaRIII, also referred to as betaglycan). Binding of betaarr2 to TbetaRIII was also triggered by phosphorylation of the receptor on its cytoplasmic domain (likely at threonine 841). However, such phosphorylation was mediated by the type II TGF-beta receptor (TbetaRII), which is itself a kinase, rather than by a GRK. Association with betaarr2 led to internalization of both receptors and down-regulation of TGF-beta signaling. Thus, the regulatory actions of beta-arrestins are broader than previously appreciated, extending to the TGF-beta receptor family as well.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med & Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; Chen, Wei/0000-0002-9934-4000	NATIONAL CANCER INSTITUTE [R01CA075368, K22CA091816] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NCI NIH HHS [CA 91816, CA 75368] Funding Source: Medline; NHLBI NIH HHS [HL 16037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Chen W., UNPUB; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ehrlich M, 2001, J CELL SCI, V114, P1777; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; Luttrell LM, 2002, J CELL SCI, V115, P455; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; SIPES NJ, 1990, MOL CARCINOGEN, V3, P12, DOI 10.1002/mc.2940030106; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Yao DY, 2002, MOL BIOL CELL, V13, P4001, DOI 10.1091/mbc.02-07-0104; Zwaagstra JC, 1999, EXP CELL RES, V252, P352, DOI 10.1006/excr.1999.4640; Zwaagstra JC, 2001, J BIOL CHEM, V276, P27237, DOI 10.1074/jbc.M100033200	25	215	233	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1394	1397		10.1126/science.1083195	http://dx.doi.org/10.1126/science.1083195			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958365				2022-12-24	WOS:000185116400046
J	Nishimoto, S; Kawane, K; Watanabe-Fukunaga, R; Fukuyama, H; Ohsawa, Y; Uchiyama, Y; Hashida, N; Ohguro, N; Tano, Y; Morimoto, T; Fukuda, Y; Nagata, S				Nishimoto, S; Kawane, K; Watanabe-Fukunaga, R; Fukuyama, H; Ohsawa, Y; Uchiyama, Y; Hashida, N; Ohguro, N; Tano, Y; Morimoto, T; Fukuda, Y; Nagata, S			Nuclear cataract caused by a lack of DNA degradation in the mouse eye lens	NATURE			English	Article							DIFFERENTIATION; APOPTOSIS; DEOXYRIBONUCLEASE; EXPRESSION; DENUCLEATION; TRANSMISSION; PROTEINS; CELLS; ALPHA	The eye lens is composed of fibre cells, which develop from the epithelial cells on the anterior surface of the lens(1-3). Differentiation into a lens fibre cell is accompanied by changes in cell shape, the expression of crystallins(4) and the degradation of cellular organelles(5,6). The loss of organelles is believed to ensure the transparency of the lens, but the molecular mechanism behind this process is not known. Here we show that DLAD ('DNase II-like acid DNase'(7), also called DNase IIbeta(8)) is expressed in human and murine lens cells, and that mice deficient in the DLAD gene are incapable of degrading DNA during lens cell differentiation-the undigested DNA accumulates in the fibre cells. The DLAD(-/-) mice develop cataracts of the nucleus lentis, and their response to light on electroretinograms is severely reduced. These results indicate that DLAD is responsible for the degradation of nuclear DNA during lens cell differentiation, and that if DNA is left undigested in the lens, it causes cataracts of the nucleus lentis, blocking the light path.	Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Cell Biol & Neurosci, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Physiol & Biosignaling, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Integrated Biol Labs, Genet Lab, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Nagata, S (corresponding author), Trans Gen Inc, Prod Dept, Kumamoto 8612202, Japan.		Fukuyama, Hidehiro/AAY-6256-2021; Fukuyama, Hidehiro/N-5276-2018; , nhashida/ABI-4299-2020; Nagata, Shigekazu/AAG-3203-2019	Fukuyama, Hidehiro/0000-0002-6457-0630; Fukuyama, Hidehiro/0000-0002-6457-0630; Nagata, Shigekazu/0000-0001-9758-8426; Kawane, Kohki/0000-0003-1125-9483				Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; Bassnett S, 2002, EXP EYE RES, V74, P1, DOI 10.1006/exer.2001.1111; Bernardi G., 1971, HYDROLYSIS, P271; CHAUDUN E, 1994, J CELL PHYSIOL, V158, P354, DOI 10.1002/jcp.1041580218; Dahm R, 1998, EUR J CELL BIOL, V75, P237, DOI 10.1016/S0171-9335(98)80118-0; Ezaki J, 1996, J NEUROCHEM, V67, P1677, DOI 10.1046/j.1471-4159.1996.67041677.x; Fleming TP, 1998, INVEST OPHTH VIS SCI, V39, P1387; GRAINGER RM, 1992, EYE, V6, P117, DOI 10.1038/eye.1992.26; IMOTO Y, IN PRESS JPN J OPHTH; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Kawane K, 2001, SCIENCE, V292, P1546, DOI 10.1126/science.292.5521.1546; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Krieser RJ, 2002, CELL DEATH DIFFER, V9, P956, DOI 10.1038/sj.cdd.4401056; Krieser RJ, 2001, GENE, V269, P205, DOI 10.1016/S0378-1119(01)00434-6; KUWABARA T, 1974, INVEST OPHTH VISUAL, V13, P973; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2; McAvoy JW, 1999, EYE, V13, P425, DOI 10.1038/eye.1999.117; McIlroy D, 2000, GENE DEV, V14, P549; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Shiokawa D, 1999, NUCLEIC ACIDS RES, V27, P4083, DOI 10.1093/nar/27.20.4083; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; VRENSEN GFJM, 1991, EXP EYE RES, V52, P647, DOI 10.1016/0014-4835(91)90017-9; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Wride MA, 1998, EXP EYE RES, V66, P371, DOI 10.1006/exer.1997.0440	29	153	159	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1071	1074		10.1038/nature01895	http://dx.doi.org/10.1038/nature01895			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944971				2022-12-24	WOS:000184984200047
J	Miller, EA; Beilharz, TH; Malkus, PN; Lee, MCS; Hamamoto, S; Orci, L; Schekman, R				Miller, EA; Beilharz, TH; Malkus, PN; Lee, MCS; Hamamoto, S; Orci, L; Schekman, R			Multiple cargo binding sites on the COPII subunit Sec24p ensure capture of diverse membrane proteins into transport vesicles	CELL			English	Article							ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; SELECTIVE EXPORT; CYTOPLASMIC TAIL; STRUCTURAL BASIS; GOLGI-COMPLEX; ER EXPORT; COAT; YEAST; SIGNAL	We have characterized the mechanisms of cargo selection into ER-derived vesicles by the COPII subunit Sec24p. We identified a site on Sec24p that recognizes the v-SNARE Bet1p and show that packaging of a number of cargo molecules is disrupted when mutations are introduced at this site. Surprisingly, cargo proteins affected by these mutations did not share a single common sorting signal, nor were proteins sharing a putative class of signal affected to the same degree. We show that the same site is conserved as a cargo-interaction domain on the Sec24p homolog Lst1p, which only packages a subset of the cargoes recognized by Sec24p. Finally, we identified an additional mutation that defines another cargo binding domain on Sec24p, which specifically interacts with the SNARE Sec22p. Together, our data support a model whereby Sec24p proteins contain multiple independent cargo binding domains that allow for recognition of a diverse set of sorting signals.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva, Switzerland	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	Schekman, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Beilharz, Traude/O-5457-2019; Beilharz, Traude/I-1438-2014	Beilharz, Traude/0000-0002-8942-9502; Beilharz, Traude/0000-0002-8942-9502; Lee, Marcus/0000-0002-4973-0915; Miller, Elizabeth/0000-0002-1033-8369				Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Aridor M, 2002, TRAFFIC, V3, P537, DOI 10.1034/j.1600-0854.2002.30804.x; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Belden WJ, 2001, J BIOL CHEM, V276, P43040, DOI 10.1074/jbc.M108113200; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Kurihara T, 2000, MOL BIOL CELL, V11, P983, DOI 10.1091/mbc.11.3.983; Malkus P, 2002, J CELL BIOL, V159, P915, DOI 10.1083/jcb.200208074; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nakamura N, 1998, MOL BIOL CELL, V9, P3493, DOI 10.1091/mbc.9.12.3493; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2002, J CELL SCI, V115, P619; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 2001, TRAFFIC, V2, P105, DOI 10.1034/j.1600-0854.2001.020205.x; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Sato K, 2002, MOL BIOL CELL, V13, P2518, DOI 10.1091/mbc.E02-01-0027; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Shimoni Y, 2000, J CELL BIOL, V151, P973, DOI 10.1083/jcb.151.5.973; SIKORSKI RS, 1989, GENETICS, V122, P19; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Stockklausner C, 2001, FEBS LETT, V493, P129, DOI 10.1016/S0014-5793(01)02286-4; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124	39	386	394	1	21	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					497	509		10.1016/S0092-8674(03)00609-3	http://dx.doi.org/10.1016/S0092-8674(03)00609-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941277	Bronze			2022-12-24	WOS:000184928800012
J	Iwashita, T; Kruger, GM; Pardal, R; Kiel, MJ; Morrison, SJ				Iwashita, T; Kruger, GM; Pardal, R; Kiel, MJ; Morrison, SJ			Hirschsprung disease is linked to defects in neural crest stem cell function	SCIENCE			English	Article							ENTERIC NERVOUS-SYSTEM; MICE LACKING GDNF; TYROSINE KINASE; SELF-RENEWAL; IN-VITRO; C-RET; KIDNEY; DIFFERENTIATION; GFR-ALPHA-1; EXPRESSION	Genes associated with Hirschsprung disease, a failure to form enteric ganglia in the hindgut, were highly up-regulated in gut neural crest stem cells relative to whole-fetus RNA. One of these genes, the glial cell line-derived neurotrophic factor (GDNF) receptor Ret, was necessary for neural crest stem cell migration in the gut. GDNF promoted the migration of neural crest stem cells in culture but did not affect their survival or proliferation. Gene expression pro. ling, combined with reverse genetics and analyses of stem cell function, suggests that Hirschsprung disease is caused by defects in neural crest stem cell function.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Morrison, SJ (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Morrison, Sean/ABD-5326-2021; Crane, Genevieve M/AAK-9224-2020; Pardal, Ricardo/C-4370-2015; IBIS, FISIOPATOLOGIA/O-9510-2015	Crane, Genevieve M/0000-0001-9274-0214; Pardal, Ricardo/0000-0003-1085-0714; Morrison, Sean/0000-0003-1587-8329	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD040760] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557, P30AR048310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, P30DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040750] Funding Source: NIH RePORTER; NCI NIH HHS [CA46592] Funding Source: Medline; NIAMS NIH HHS [P60-AR20557, P30 AR48310] Funding Source: Medline; NICHD NIH HHS [R21 HD40760-02] Funding Source: Medline; NIDDK NIH HHS [DK58771, NIH5P60-DK20572] Funding Source: Medline; NINDS NIH HHS [R01 NS040750, R01 NS40750-01, R01 NS040750-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson DJ, 2001, NEURON, V30, P19, DOI 10.1016/S0896-6273(01)00260-4; Bixby S, 2002, NEURON, V35, P643, DOI 10.1016/S0896-6273(02)00825-5; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Chalazonitis A, 1998, DEV BIOL, V204, P385, DOI 10.1006/dbio.1998.9090; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Eketjall S, 2002, HUM MOL GENET, V11, P325, DOI 10.1093/hmg/11.3.325; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Gabriel SB, 2002, NAT GENET, V31, P89, DOI 10.1038/ng868; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; Heuckeroth RO, 1998, DEV BIOL, V200, P116, DOI 10.1006/dbio.1998.8955; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Morrison SJ, 2000, J NEUROSCI, V20, P7370; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Natarajan D, 2002, DEVELOPMENT, V129, P5151; Newgreen D, 2002, PEDIATR DEVEL PATHOL, V5, P224, DOI 10.1007/s10024-001-0142-y; Park IK, 2002, BLOOD, V99, P488, DOI 10.1182/blood.V99.2.488; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Shinohara T, 1999, P NATL ACAD SCI USA, V96, P5504, DOI 10.1073/pnas.96.10.5504; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Young HM, 2001, DEV BIOL, V229, P503, DOI 10.1006/dbio.2000.0100	37	162	174	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					972	976		10.1126/science.1085649	http://dx.doi.org/10.1126/science.1085649			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920301	Green Accepted			2022-12-24	WOS:000184755900042
J	Varaldi, J; Fouillet, P; Ravallec, M; Lopez-Ferber, M; Bouletreau, M; Fleury, F				Varaldi, J; Fouillet, P; Ravallec, M; Lopez-Ferber, M; Bouletreau, M; Fleury, F			Infectious behavior in a parasitoid	SCIENCE			English	Article							SUPERPARASITISM		Univ Lyon 1, Lab Biometrie & Biol Evolut, CNRS, UMR 5558, F-69622 Villeurbanne, France; Univ Montpellier 2, INRA, Lab Pathol Comparee, CNRS,UMR 5087, F-30380 St Christol Les Ales, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; Centre National de la Recherche Scientifique (CNRS); INRAE; Universite de Montpellier	Varaldi, J (corresponding author), Univ Lyon 1, Lab Biometrie & Biol Evolut, CNRS, UMR 5558, 43 Bld 11 Novembre 1918, F-69622 Villeurbanne, France.	varaldi@biomserv.univ-lyon1.fr	Lopez-Ferber, Miguel/F-5465-2012	Lopez-Ferber, Miguel/0000-0002-3850-1703; varaldi, julien/0000-0002-2100-1542				Allemand R, 2002, ANN SOC ENTOMOL FR, V38, P319, DOI 10.1080/00379271.2002.10697346; Poulin R, 1995, INT J PARASITOL, V25, P1371, DOI 10.1016/0020-7519(95)00100-X; VANALPHEN JJM, 1990, ANNU REV ENTOMOL, V35, P59, DOI 10.1146/annurev.en.35.010190.000423; Vinson SB, 1998, J INSECT PHYSIOL, V44, P703, DOI 10.1016/S0022-1910(98)00003-1	4	62	65	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 12	2003	302	5652					1930	1930		10.1126/science.1088798	http://dx.doi.org/10.1126/science.1088798			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	752NL	14564013				2022-12-24	WOS:000187174000050
J	Baumgart, T; Hess, ST; Webb, WW				Baumgart, T; Hess, ST; Webb, WW			Imaging coexisting fluid domains in biomembrane models coupling curvature and line tension	NATURE			English	Article							GIANT PHOSPHOLIPID-VESICLES; INTRAMEMBRANE DOMAINS; MEMBRANES; SHAPE; FISSION; TRANSITIONS; MONOLAYERS; DYNAMICS	Lipid bilayer membranes - ubiquitous in biological systems and closely associated with cell function - exhibit rich shape-transition behaviour, including bud formation(1) and vesicle fission(2). Membranes formed from multiple lipid components can laterally separate into coexisting liquid phases, or domains, with distinct compositions. This process, which may resemble raft formation in cell membranes, has been directly observed in giant unilamellar vesicles(3,4). Detailed theoretical frameworks(5-11) link the elasticity of domains and their boundary properties to the shape adopted by membranes and the formation of particular domain patterns, but it has been difficult to experimentally probe and validate these theories. Here we show that high-resolution fluorescence imaging using two dyes preferentially labelling different fluid phases directly provides a correlation between domain composition and local membrane curvature. Using freely suspended membranes of giant unilamellar vesicles, we are able to optically resolve curvature and line tension interactions of circular, stripe and ring domains. We observe long-range domain ordering in the form of locally parallel stripes and hexagonal arrays of circular domains, curvature-dependent domain sorting, and membrane fission into separate vesicles at domain boundaries. By analysing our observations using available membrane theory, we are able to provide experimental estimates of boundary tension between fluid bilayer domains.	Cornell Univ, Ithaca, NY 14853 USA; NICHHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Webb, WW (corresponding author), Cornell Univ, Ithaca, NY 14853 USA.		Webb, Watt W./B-5905-2011					ANDELMAN D, 1992, EUROPHYS LETT, V19, P57, DOI 10.1209/0295-5075/19/1/010; ANDELMAN D, 1987, J CHEM PHYS, V86, P3673, DOI 10.1063/1.451970; BARZIV R, 1994, PHYS REV LETT, V73, P1392, DOI 10.1103/PhysRevLett.73.1392; BENVEGNU DJ, 1992, J PHYS CHEM-US, V96, P6820, DOI 10.1021/j100195a053; Chen CM, 1997, PHYS REV LETT, V79, P1579, DOI 10.1103/PhysRevLett.79.1579; Debregeas G, 1998, SCIENCE, V279, P1704, DOI 10.1126/science.279.5357.1704; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; DOBEREINER HG, 1993, BIOPHYS J, V65, P1396; DUWE HP, 1990, PHYSICA A, V163, P410, DOI 10.1016/0378-4371(90)90349-W; HELFRICH W, 1984, NUOVO CIMENTO D, V3, P137, DOI 10.1007/BF02452208; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; Huttner WB, 2001, CURR OPIN CELL BIOL, V13, P478, DOI 10.1016/S0955-0674(00)00239-8; JENKINS JT, 1977, J MATH BIOL, V4, P149, DOI 10.1007/BF00275981; Jiang Y, 2000, PHYS REV E, V61, pR57, DOI 10.1103/PhysRevE.61.R57; Julicher F, 1996, PHYS REV E, V53, P2670, DOI 10.1103/PhysRevE.53.2670; KAS J, 1991, BIOPHYS J, V60, P825, DOI 10.1016/S0006-3495(91)82117-8; Kumar PBS, 2001, PHYS REV LETT, V86, P3911, DOI 10.1103/PhysRevLett.86.3911; LEIBLER S, 1987, J PHYS-PARIS, V48, P2013, DOI 10.1051/jphys:0198700480110201300; LIPOWSKY R, 1992, J PHYS II, V2, P1825, DOI 10.1051/jp2:1992238; Lipowsky R, 2003, J PHYS-CONDENS MAT, V15, pS31, DOI 10.1088/0953-8984/15/1/304; Mathivet L, 1996, BIOPHYS J, V70, P1112, DOI 10.1016/S0006-3495(96)79693-5; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/jphys:019840045090145700; SEIFERT U, 1993, PHYS REV LETT, V70, P1335, DOI 10.1103/PhysRevLett.70.1335; SEUL M, 1995, SCIENCE, V267, P476, DOI 10.1126/science.267.5197.476; Veatch SL, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.268101; Wintz W, 1996, EUROPHYS LETT, V33, P403, DOI 10.1209/epl/i1996-00353-8	29	1230	1254	7	325	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					821	824		10.1038/nature02013	http://dx.doi.org/10.1038/nature02013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574408				2022-12-24	WOS:000186118500041
J	Lee, S; Sowa, ME; Watanabe, YH; Sigler, PB; Chiu, W; Yoshida, M; Tsai, FTF				Lee, S; Sowa, ME; Watanabe, YH; Sigler, PB; Chiu, W; Yoshida, M; Tsai, FTF			The structure of clpB: A molecular chaperone that rescues proteins from an aggregated state	CELL			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; HSP100 CHAPERONE; LEUCINE-ZIPPER; BINDING; ATPASE; DNAK; TRANSLOCATION; SOFTWARE; SYSTEM	Molecular chaperones assist protein folding by facilitating their "forward" folding and preventing aggregation. However, once aggregates have formed, these chaperones cannot facilitate protein disaggregation. Bacterial ClpB and its eukaryotic homolog Hsp104 are essential proteins of the heat-shock response, which have the remarkable capacity to rescue stress-damaged proteins from an aggregated state. We have determined the structure of Thermus thermophilus ClpB (TClpB) using a combination of X-ray crystallography and cryo-electron microscopy (cryo-EM). Our single-particle reconstruction shows that TClpB forms a two-tiered hexameric ring. The ClpB/Hsp104-linker consists of an 85 Angstrom long and mobile coiled coil that is located on the outside of the hexamer. Our mutagenesis and biochemical data show that both the relative position and motion of this coiled coil are critical for chaperone function. Taken together, we propose a mechanism by which an ATP-driven conformational change is coupled to a large coiled-coil motion, which is indispensable for protein disaggregation.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06511 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA	Baylor College of Medicine; Tokyo Institute of Technology; Yale University; Howard Hughes Medical Institute; Yale University	Tsai, FTF (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	ftsai@bcm.tmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002250] Funding Source: NIH RePORTER; NCRR NIH HHS [P41RR02250] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Clarke AK, 2000, J BACTERIOL, V182, P7092, DOI 10.1128/JB.182.24.7092-7096.2000; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Jiang W, 2001, J MOL BIOL, V308, P1033, DOI 10.1006/jmbi.2001.4633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1991, MOL REPLACEMENT, P91; Kim KI, 2000, J MOL BIOL, V303, P655, DOI 10.1006/jmbi.2000.4165; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li JZ, 2003, STRUCTURE, V11, P323, DOI 10.1016/S0969-2126(03)00030-3; Li JZ, 2002, J MOL BIOL, V318, P1127, DOI 10.1016/S0022-2836(02)00188-2; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK SK, 1993, J BIOL CHEM, V268, P20170; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Stiggall D L, 1979, Methods Enzymol, V55, P308; Tek V, 2002, PROTEIN SCI, V11, P1192, DOI 10.1110/ps.4860102; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	53	349	356	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					229	240		10.1016/S0092-8674(03)00807-9	http://dx.doi.org/10.1016/S0092-8674(03)00807-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567920	Bronze			2022-12-24	WOS:000186039200014
J	Walmsley, MJ; Ooi, SKT; Reynolds, LF; Smith, SH; Ruf, S; Mathiot, A; Vanes, L; Williams, DA; Cancro, MP; Tybulewicz, VLJ				Walmsley, MJ; Ooi, SKT; Reynolds, LF; Smith, SH; Ruf, S; Mathiot, A; Vanes, L; Williams, DA; Cancro, MP; Tybulewicz, VLJ			Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling	SCIENCE			English	Article							RECEPTOR RESPONSES; B-1 CELLS; BAFF-R; ACTIVATION; EXPRESSION; SELECTION; KINASE	The Rac1 guanosine triphosphatase (GTPase) has been implicated in multiple cellular functions, including actin dynamics, proliferation, apoptosis, adhesion, and migration resulting from signaling by multiple receptors, including the B cell antigen receptor (BCR). We used conditional gene targeting to generate mice with specific Rac1 deficiency in the B cell lineage. In the absence of both Rac1 and the highly related Rac2, B cell development was almost completely blocked. Both GTPases were required to transduce BCR signals leading to proliferation, survival and upregulation of BAFF-R, a receptor for BAFF, a key survival molecule required for B cell development and maintenance.	Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	MRC National Institute for Medical Research; University of Pennsylvania; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Tybulewicz, VLJ (corresponding author), Natl Inst Med Res, Div Immune Cell Biol, Ridgeway,Mill Hill, London NW7 1AA, England.	vtybule@nimr.mrc.ac.uk		Tybulewicz, Victor/0000-0003-2439-0798; Cancro, Michael/0000-0002-8659-3227; Ooi, Steen/0000-0003-4198-9014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062757] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI054488] Funding Source: Medline; NIDDK NIH HHS [R01 DK62757] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amanna IJ, 2003, J IMMUNOL, V170, P4593, DOI 10.4049/jimmunol.170.9.4593; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Grill B, 2002, BLOOD, V100, P3183, DOI 10.1182/blood-2002-01-0154; Hayakawa K, 2000, CURR OPIN IMMUNOL, V12, P346, DOI 10.1016/S0952-7915(00)00098-4; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Lentz VM, 1998, J IMMUNOL, V160, P3743; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Nosaka Y, 2001, BIOCHEM BIOPH RES CO, V285, P675, DOI 10.1006/bbrc.2001.5222; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Smith SH, 2003, J IMMUNOL, V170, P5820, DOI 10.4049/jimmunol.170.12.5820; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Su TT, 2002, J IMMUNOL, V168, P2101, DOI 10.4049/jimmunol.168.5.2101; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; WALMSLEY MJ, UNPUB; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	26	208	211	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	2003	302	5644					459	462		10.1126/science.1089709	http://dx.doi.org/10.1126/science.1089709			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564011				2022-12-24	WOS:000185963200047
J	Scholefield, JH; Moss, S				Scholefield, JH; Moss, S			Screening sigmoidoscopy for colorectal cancer	LANCET			English	Editorial Material							DEBATE; COSTS		Univ Nottingham Hosp, Div GI Surg, Nottingham NG7 2UH, England; Canc Screening Evaluat Unit, Surrey, England	University of Nottingham	Scholefield, JH (corresponding author), Univ Nottingham Hosp, Div GI Surg, Nottingham NG7 2UH, England.	john.scholefield@nottingham.ac.uk						Atkin WS, 2002, LANCET, V359, P1291, DOI 10.1016/s0140-6736(02)08268-5; Atkin WS, 2003, GUT, V52, P321, DOI 10.1136/gut.52.3.321; Cronin KA, 1998, J NATL CANCER I, V90, P498, DOI 10.1093/jnci/90.7.498; Hardcastle JD, 1996, LANCET, V348, P1472, DOI 10.1016/S0140-6736(96)03386-7; Lund JN, 2001, GUT, V49, P91, DOI 10.1136/gut.49.1.91; Macafee DAL, 2003, GUT, V52, P323, DOI 10.1136/gut.52.3.323; MILBURN A, 2002, BRIT CANC C LOND NOV; Newcomb PA, 2003, J NATL CANCER I, V95, P622, DOI 10.1093/jnci/95.8.622; Rex DK, 2000, AM J GASTROENTEROL, V95, P868, DOI 10.1111/j.1572-0241.2000.02059.x; Schoen RE, 2003, JAMA-J AM MED ASSOC, V290, P41, DOI 10.1001/jama.290.1.41; Steele RJC, 2001, J MED SCREEN, V8, P197, DOI 10.1136/jms.8.4.197; WHYNES DK, 1992, J EPIDEMIOL COMMUN H, V46, P577, DOI 10.1136/jech.46.6.577	12	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1167	1168		10.1016/S0140-6736(03)14553-9	http://dx.doi.org/10.1016/S0140-6736(03)14553-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568733				2022-12-24	WOS:000185924100003
J	Jepson, PD; Arbelo, M; Deaville, R; Patterson, IAP; Castro, P; Baker, JR; Degollada, E; Ross, HM; Herraez, P; Pocknell, AM; Rodriguez, F; Howie, FE; Espinosa, A; Reid, RJ; Jaber, JR; Martin, V; Cunningham, AA; Fernandez, A				Jepson, PD; Arbelo, M; Deaville, R; Patterson, IAP; Castro, P; Baker, JR; Degollada, E; Ross, HM; Herraez, P; Pocknell, AM; Rodriguez, F; Howie, FE; Espinosa, A; Reid, RJ; Jaber, JR; Martin, V; Cunningham, AA; Fernandez, A			Gas-bubble lesions in stranded cetaceans - Was sonar responsible for a spate of whale deaths after an Atlantic military exercise?	NATURE			English	Editorial Material							COLLAPSE; GROWTH		Zool Soc London, Inst Zool, London NW1 4RY, England; Univ Las Palmas de Gran Canaria, Sch Vet, Inst Anim Hlth, Histol & Pathol Unit, Las Palmas Gran Canaria, Spain; SAC Vet Sci Div Inverness, Wildlife Unit, Inverness IV2 4JZ, Scotland; Univ Liverpool, Dept Vet Pathol, Wirral CH64 7TE, Merseyside, England; SAC Vet Sci Div Edinburgh, Penicuik EH26 0QE, Midlothian, Scotland	Zoological Society of London; Universidad de Las Palmas de Gran Canaria; Scottish Agricultural College; University of Liverpool; Scottish Agricultural College	Jepson, PD (corresponding author), Zool Soc London, Inst Zool, Regents Pk, London NW1 4RY, England.		Castro, Pedro Luis/ABF-6635-2021; Cunningham, Andrew A/E-7536-2010; Jepson, Paul D/G-1840-2013; Fernandez, Antonio/G-3448-2015; Langhamer, Olivia/J-3425-2012; Arbelo, Manuel/D-6789-2013; Rodriguez Guisado, Francisco/L-6874-2014	Fernandez, Antonio/0000-0001-5281-0521; Arbelo, Manuel/0000-0002-1623-5010; Rodriguez Guisado, Francisco/0000-0002-4968-5333; Castro, Pedro Luis/0000-0002-0395-899X; Herraez, Pedro/0000-0001-9316-2882				Crum LA, 1996, J ACOUST SOC AM, V99, P2898, DOI 10.1121/1.414859; FALKE KJ, 1985, SCIENCE, V229, P556, DOI 10.1126/science.4023700; Francis T. J. R., 2003, BENNETT ELLIOTTS PHY, P530; Frantzis A, 1998, NATURE, V392, P29, DOI 10.1038/32068; HARRISON R. J., 1956, PROC ZOOL SOC LONDON, V126, P205; Houser DS, 2001, J THEOR BIOL, V213, P183, DOI 10.1006/jtbi.2001.2415; Knight B., 1996, FORENSIC PATHOLOGY, V2nd ed.; Ponganis P. J., 2003, BENNETT ELLIOTTS PHY, P211; RIDGWAY SH, 1982, SCIENCE, V216, P651, DOI 10.1126/science.216.4546.651; RIDGWAY SH, 1979, SCIENCE, V206, P1182, DOI 10.1126/science.505001; SIMMONDS MP, 1991, NATURE, V351, P448, DOI 10.1038/351448a0; *USN, 2001, JOINT INT REP BAH MA	12	305	324	8	209	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					575	576		10.1038/425575a	http://dx.doi.org/10.1038/425575a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534575				2022-12-24	WOS:000185801000025
J	Stelfox, HT; Bates, DW; Redelmeier, DA				Stelfox, HT; Bates, DW; Redelmeier, DA			Safety of patients isolated for infection control	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; ADVERSE; EVENTS; STOP; CARE	Context Hospital infection control policies that use patient isolation prevent nosocomial transmission of infectious diseases, but may inadvertently lead to patient neglect and errors. Objective To examine the quality of medical care received by patients isolated for infection control. Design, Setting, and Patients We identified consecutive adults who were isolated for methicillin-resistant Staphylococcus aureus colonization or infection at 2 large North American teaching hospitals: a general cohort (patients admitted with all diagnoses between January 1, 1999, and January 1, 2000; n = 78); and a disease-specific cohort (patients admitted with a diagnosis of congestive heart failure between January 1, 1999, and July 1, 2002; n = 72). Two matched controls were selected for each isolated patient (n = 156 general cohort controls and n = 144 disease-specific cohort controls). Main Outcome Measures Quality-of-care measures encompassing processes, outcomes, and satisfaction. Adjustments for study cohort and patient demographic, hospital, and clinical characteristics were conducted using multivariable regression. Results Isolated and control patients generally had similar baseline characteristics; however, isolated patients were twice as likely as control patients to experience adverse events during their hospitalization (31 vs 15 adverse events per 1000 days; P<.001). This difference in adverse events reflected preventable events (20 vs 3 adverse events per 1000 days; P<.001) as opposed to nonpreventable events (11 vs 12 adverse events per 1000 days; P=.98). Isolated patients were also more likely to formally complain to the hospital about their care than control patients (8% vs 1%; P<.001), to have their vital signs not recorded as ordered (51% vs 31%; P<.001), and more likely to have days with no physician progress note (26% vs 13%; P<.001). No differences in hospital mortality were observed for the 2 groups (17% vs 10%; P=16). Conclusion Compared with controls, patients isolated for infection control precautions experience more preventable adverse events, express greater dissatisfaction with their treatment, and have less documented care.	Brigham & Womens Hosp, Div Gen Med, Boston, MA 02120 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02120 USA; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Clin Epidemiol Unit, Toronto, ON, Canada; Harvard Univ, Grad Sch Arts & Sci, Cambridge, MA 02138 USA; Partners HealthCare Syst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Harvard University; Partners Healthcare System	Stelfox, HT (corresponding author), Brigham & Womens Hosp, Div Gen Med, 1620 Tremont St, Boston, MA 02120 USA.	stelfox@fas.harvard.edu		Stelfox, Henry/0000-0003-1231-1490	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS011534] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Brown L H, 1997, Prehosp Emerg Care, V1, P145, DOI 10.1080/10903129708958808; Burke JP, 2003, NEW ENGL J MED, V348, P651, DOI 10.1056/NEJMhpr020557; Centers for Disease Control and Prevention, SEV AC RESP SYNDR SA; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Garner Julia S., 1996, Infection Control and Hospital Epidemiology, V17, P53; Gawande AA, 2003, NEW ENGL J MED, V348, P229, DOI 10.1056/NEJMsa021721; Harvard Medical Practice study, 1990, PAT DOCT LAW STUD ME, VI; HICKSON G, 1997, LAW CONTEMP PROBL, V27, P8; Hickson GB, 2002, JAMA-J AM MED ASSOC, V287, P2951, DOI 10.1001/jama.287.22.2951; HIGGINS L, 2001, J GEN INTERN MED S1, V16, P200; Kirkland KB, 1999, LANCET, V354, P1177, DOI 10.1016/S0140-6736(99)04196-3; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Knowles H E, 1993, Nurs Times, V89, P53; Kohn LT, 2000, ERR IS HUMAN BUILDIN; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Krumholz HM, 2000, CIRCULATION, V101, pE122, DOI 10.1161/01.CIR.101.12.e122; Krumholz HM, 2000, CIRCULATION, V101, P1483; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Montecalvo MA, 1999, ANN INTERN MED, V131, P269, DOI 10.7326/0003-4819-131-4-199908170-00006; Nettleman M D, 1994, Clin Perform Qual Health Care, V2, P67; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; Ostrowsky BE, 2001, NEW ENGL J MED, V344, P1427, DOI 10.1056/NEJM200105103441903; Peel RK, 1997, BRIT MED J, V315, P58; Perrow C., 1984, NORMAL ACCIDENTS LIV; Pichert J W, 1999, Jt Comm J Qual Improv, V25, P288; Reason J., 1997, MANAGING RISK ORG AC; Reason J., 1990, HUMAN ERROR; Rosenberg AL, 2000, CHEST, V118, P492, DOI 10.1378/chest.118.2.492; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; Sobie J M, 2000, J Emerg Nurs, V26, P549, DOI 10.1067/men.2000.110891; Teare EL, 1997, BRIT MED J, V314, P665, DOI 10.1136/bmj.314.7081.665; WEICK KE, 1987, CALIF MANAGE REV, V29, P112, DOI 10.2307/41165243; World Health Organization, HOSP INF CONTR GUID; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	36	405	406	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1899	1905		10.1001/jama.290.14.1899	http://dx.doi.org/10.1001/jama.290.14.1899			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	729CB	14532319	Bronze			2022-12-24	WOS:000185752600031
J	Miller, RF; Cloutier, R; Turner, S				Miller, RF; Cloutier, R; Turner, S			The oldest articulated chondrichthyan from the Early Devonian period	NATURE			English	Article							BRAINCASE; INTERRELATIONSHIPS; EVOLUTION; SHARKS	Chondrichthyans (including living sharks, skates, rays and chimaeras) have a fossil record of scales and dermal denticles perhaps dating back to the Late Ordovician period, about 455 million years ago(1,2). Their fossil tooth record extends to the earliest Devonian period, almost 418 million years ago(3), whereas the oldest known articulated shark remains date from the Early Devonian period(4), about 394 million years ago(5). Here we report the discovery of an articulated shark that is almost 409 million years old 5 from the Early Devonian (early Emsian) period of New Brunswick, Canada. The specimen, identified as Doliodus problematicus (Woodward)(6), sheds light on the earliest chondrichthyans and their interrelationships with basal jawed vertebrates. This species has been truly problematic(7). Previously known only from isolated teeth(2,6,8), it has been identified as an acanthodian and a chondrichthyan. This specimen is the oldest shark showing the tooth families in situ, and preserves one of the oldest chondrichthyan braincases. More notably, it shows the presence of paired pectoral fin-spines, previously unknown in cartilaginous fishes.	New Brunswick Museum, Steinhammer Palaeontol Lab, St John, NB E2K 1E5, Canada; Univ Quebec, Lab Biol Evolut, Rimouski, PQ G5L 3A1, Canada; Monash Univ, Sch Geosci, Clayton, Vic 3088, Australia; Queensland Museum, Brisbane, Qld 4101, Australia	University of Quebec; Monash University; Queensland Museum	Miller, RF (corresponding author), New Brunswick Museum, Steinhammer Palaeontol Lab, St John, NB E2K 1E5, Canada.		Turner, Susan/AAS-6992-2021	Turner, Susan/0000-0003-2308-158X; Cloutier, Richard/0000-0001-5780-3304				[Anonymous], 1988, SHARKS ORDER CARCHAR; Blieck Alain, 2000, Courier Forschungsinstitut Senckenberg, V223, P223; Coates MI, 2001, SYST ASSOC SPEC VOL, V61, P241; Coates MI, 1998, T ROY SOC EDIN-EARTH, V89, P63, DOI 10.1017/S026359330000701X; Denison R., 1979, Handbook of Paleoichthyology, V5, P1; DINELEY DL, 1968, CAN J EARTH SCI, V5, P945, DOI DOI 10.1139/E68-091; Forey P.L., 1992, Bulletin of the British Museum (Natural History) Geology, V48, P25; Gensel P, 1984, PLANT LIFE DEVONIAN; Heidtke Ulrich H.J., 2001, Mainzer Geowissenschaftliche Mitteilungen, V30, P105; Janvier P., 1986, Bulletin de l'Institut Francais d'Etudes Andines, V15, P73; Janvier P., 1996, EARLY VERTEBRATES; KEPPIE JD, 1999, GEOLOGICAL SOC AM SP, V336, P267; Long John A., 1995, Records of the Western Australian Museum, V17, P287; Mader H., 1986, GOTTINGER ARB GEOL P, V28, P1; MAISEY J G, 1986, Cladistics, V2, P201, DOI 10.1111/j.1096-0031.1986.tb00462.x; Maisey JG, 2001, J VERTEBR PALEONTOL, V21, P702, DOI 10.1671/0272-4634(2001)021[0702:APCBFT]2.0.CO;2; Maisey JG, 2001, SYST ASSOC SPEC VOL, V61, P263; REIF WE, 1982, EVOL BIOL, V15, P287; Shear WA, 1996, NATURE, V384, P555, DOI 10.1038/384555a0; Smith MM, 2001, SYST ASSOC SPEC VOL, V61, P223; Traquair RH, 1893, GEOLOGICAL MAGAZINE, V10, P145; Tucker RD, 1998, EARTH PLANET SC LETT, V158, P175, DOI 10.1016/S0012-821X(98)00050-8; TURNER S, RECENT ADV ORIGIN EA; WHITEAVES JF, 1881, CANADIAN NATURALIST, V10, P93; Williams G.L., 1985, LEXICON CANADIAN STR, VVI; Woodward A.S., 1892, GEOL MAG, P1, DOI [10.1017/S0016756800188533, DOI 10.1017/S0016756800188533]; YOUNG GC, 1982, PALAEONTOLOGY, V25, P817; Zangerl R., 1981, Handbook of Paleoichthyology, V3, P1; Zhu M, 2001, SYST ASSOC SPEC VOL, V61, P289; Zhu M, 1999, NATURE, V397, P607, DOI 10.1038/17594	30	119	126	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2003	425	6957					501	504		10.1038/nature02001	http://dx.doi.org/10.1038/nature02001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523444				2022-12-24	WOS:000185648100042
J	Murray, CJL; Shengelia, B; Gupta, N; Moussavi, S; Tandon, A; Thieren, M				Murray, CJL; Shengelia, B; Gupta, N; Moussavi, S; Tandon, A; Thieren, M			Validity of reported vaccination coverage in 45 countries	LANCET			English	Article							SAMPLE SELECTION BIAS; CHILD VACCINATION; MOTHERS REPORTS; ACCURACY	Background Monitoring and assessment of coverage rates in national health programmes is becoming increasingly important, We aimed to assess the accuracy of officially reported coverage rates of vaccination with diphtheria-tetanus-pertussis vaccine (DTP3), which is commonly used to monitor child health interventions. Methods We compared officially reported national data for DTP3 coverage with those from the household Demographic and Health Surveys (DHS) in 45 countries between :1990 and 2000. We adjusted survey data to reflect the number of valid vaccinations (ie, those administered in accordance with the schedule recommended by WHO) using a probit model with sample selection. The model predicted the probability of valid vaccinations for children, including those without documented vaccinations, after correcting for bias from differences between the children with and without documented information on vaccination. We then assessed the extent of survey bias and differences between officially reported data and those from DHS estimates. Findings Our results suggest that officially reported DTP3 coverage is higher than that reported from household surveys. This size of the difference increases with the rate of reported coverage of DTP3. Results of time-trend analysis show that changes in reported coverage are not correlated with changes reported from household surveys. Interpretation Although reported data might be the most widely available information for assessment of vaccination coverage, their validity for measuring changes in coverage over time is highly questionable. Household surveys can be used to validate data collected by service providers. Strategies for measurement of the coverage of all health interventions should be grounded in careful assessments of the validity of data derived from various sources.	WHO, Dept Hlth Serv Provis Evidence & Informat Policy, CH-1211 Geneva 27, Switzerland	World Health Organization	Shengelia, B (corresponding author), WHO, Dept Hlth Serv Provis Evidence & Informat Policy, CH-1211 Geneva 27, Switzerland.	shengeliab@who.int		Gupta, Neeru/0000-0002-3806-4435				Angelillo IF, 1999, B WORLD HEALTH ORGAN, V77, P224; BENNETT P, 1992, HEALTH EDUC RES, V7, P341, DOI 10.1093/her/7.3.341; BERK RA, 1983, AM SOCIOL REV, V48, P386, DOI 10.2307/2095230; Bhattacharya N, 1990, Indian J Public Health, V34, P220; Boerma J, 1994, DHS METHODOLOGICAL R; BORGDORFF MW, 1988, J TROP MED HYG, V91, P35; BROWN J, 2002, MEASURE EVALUATION W; Brugha R, 2002, LANCET, V359, P435, DOI 10.1016/S0140-6736(02)07607-9; CUTTS FT, 1993, B WORLD HEALTH ORGAN, V71, P633; GAREABALLAH ET, 1989, B WORLD HEALTH ORGAN, V67, P669; George K, 1990, Indian J Pediatr, V57, P588, DOI 10.1007/BF02726779; Guerin N, 1998, VACCINE, V16, pS81, DOI 10.1016/S0264-410X(98)00304-1; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; Langsten R, 1998, SOC SCI MED, V46, P1205, DOI 10.1016/S0277-9536(97)10049-1; *LATH CONS, 2001, IMM DAT QUAL AUD EV; LEWIS T, 1988, AM J DIS CHILD, V142, P283, DOI 10.1001/archpedi.1988.02150030053018; *MACR INT, 1996, SAMPL MAN DHS 3 BAS; *ORC MACR, 2001, MOD A QUEST MEASURE; Ramakrishnan R, 1999, Indian Pediatr, V36, P881; Singh R, 1976, Indian J Pediatr, V43, P118, DOI 10.1007/BF02749242; Suarez L, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e3; *UNICEF, ROUT IMM EST IMM COV; VALADEZ JJ, 1992, AM J PUBLIC HEALTH, V82, P120, DOI 10.2105/AJPH.82.1.120; VANDEVEN WPMM, 1981, J ECONOMETRICS, V17, P229, DOI 10.1016/0304-4076(81)90028-2; *WHO, 1999, WHOVB9906 DEP VACC B; *WHO, 1991, WHOEPIMLM9110 EXP PR; *WHO, 1996, WHOGPVGEN9503 GLOB P; *WHO, 2000, WHOVB0032 DEP VACC B; Wittet S, 2000, VACCINE, V19, P385, DOI 10.1016/S0264-410X(00)00196-1	29	154	161	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 27	2003	362	9389					1022	1027		10.1016/S0140-6736(03)14411-X	http://dx.doi.org/10.1016/S0140-6736(03)14411-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	725WD	14522532				2022-12-24	WOS:000185564600009
J	Allan, RS; Smith, CM; Belz, GT; van Lint, AL; Wakim, LM; Heath, WR; Carbone, FR				Allan, RS; Smith, CM; Belz, GT; van Lint, AL; Wakim, LM; Heath, WR; Carbone, FR			Epidermal viral immunity induced by CD8 alpha(+) dendritic cells but not by Langerhans cells	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS-1; TUMOR-NECROSIS-FACTOR; DRAINING LYMPH-NODE; SURFACE PHENOTYPE; STEADY-STATE; MOUSE; SKIN; ANTIGEN; SPLEEN; INFECTION	The classical paradigm for dendritic cell function derives from the study of Langerhans cells, which predominate within skin epidermis. After an encounter with foreign agents, Langerhans cells are thought to migrate to draining lymph nodes, where they initiate T cell priming. Contrary to this, we show here that infection of murine epidermis by herpes simplex virus did not result in the priming of virus-specific cytotoxic T lymphocytes by Langerhans cells. Rather, the priming response required a distinct CD8alpha(+) dendritic cell subset. Thus, the traditional view of Langerhans cells in epidermal immunity needs to be revisited to accommodate a requirement for other dendritic cells in this response.	Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia; Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Cooperat Res Vaccine Technol, Melbourne, Vic 3050, Australia	University of Melbourne; Walter & Eliza Hall Institute; Walter & Eliza Hall Institute	Heath, WR (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia.		Carbone, Francis/ABF-2141-2020; Belz, Gabrielle T/C-9350-2013	Belz, Gabrielle T/0000-0002-9660-9587; Heath, William/0000-0001-9670-259X; Wakim, Linda/0000-0003-1752-9579; Allan, Rhys/0000-0003-0906-2980				ALLAN RJ, UNPUB; Austyn JM, 1996, J EXP MED, V183, P1287, DOI 10.1084/jem.183.4.1287; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Coles RM, 2002, J IMMUNOL, V168, P834, DOI 10.4049/jimmunol.168.2.834; CUMBERBATCH M, 1995, IMMUNOLOGY, V84, P31; Hemmi H, 2001, INT IMMUNOL, V13, P695, DOI 10.1093/intimm/13.5.695; Henri S, 2001, J IMMUNOL, V167, P741, DOI 10.4049/jimmunol.167.2.741; HOEFSMIT ECM, 1982, IMMUNOBIOLOGY, V161, P255, DOI 10.1016/S0171-2985(82)80081-8; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; MAURER D, 2001, DENDRITIC CELLS, V2, pCH5; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; MOLL H, 1993, EUR J IMMUNOL, V23, P1595, DOI 10.1002/eji.1830230730; Mueller SN, 2002, IMMUNOL CELL BIOL, V80, P156, DOI 10.1046/j.1440-1711.2002.01071.x; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; O'Keeffe M, 2002, J EXP MED, V196, P1307, DOI 10.1084/jem.20021031; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROMANI N, 1989, J EXP MED, V169, P1169, DOI 10.1084/jem.169.3.1169; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; SILBERBERGSINAKIN I, 1976, CELL IMMUNOL, V25, P137, DOI 10.1016/0008-8749(76)90105-2; Smith CM, 2003, J IMMUNOL, V170, P4437, DOI 10.4049/jimmunol.170.9.4437; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; VREMEC D, 1992, J EXP MED, V176, P47, DOI 10.1084/jem.176.1.47; Zhao XY, 2003, J EXP MED, V197, P153, DOI 10.1084/jem.20021109	24	464	474	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1925	1928		10.1126/science.1087576	http://dx.doi.org/10.1126/science.1087576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512632				2022-12-24	WOS:000185536700056
J	Tedford, RH; Harington, CR				Tedford, RH; Harington, CR			An Arctic mammal fauna from the Early Pliocene of North America	NATURE			English	Article								A peat deposit on Ellesmere Island(1), Nunavut, Canada, allows a unique glimpse of the Early Pliocene terrestrial biota north of the Arctic Circle. The peat accumulated in a beaver pond surrounded by boreal larch forest near regional tree line(2) in coastal hills close to the Arctic Ocean. The ecological affinities of the plant and beetle remains(3) contained in the peat indicate that winter temperatures on Ellesmere Island were nearly 15degreesC higher and summer temperatures 10degreesC higher than they are today. Here we show that the mammalian remains buried in the peat represent mainly taxa of Eurasiatic zoogeographic and phyletic affinities, including the first North American occurrence of a meline badger (Arctomeles). This deposit contains direct evidence of the composition of an Early Pliocene (4-5 million years ago) arctic mammalian fauna during an active period of interchange between Asia and North America.	Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA; Canadian Museum Nat Paleobiol, Ottawa, ON K1P 6P4, Canada	American Museum of Natural History (AMNH)	Tedford, RH (corresponding author), Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA.	tedford@amnh.org						BJORK PR, 1970, T AM PHILOS SOC, V60, P3, DOI 10.2307/1006119; Dompierre H., 1997, Journal of Vertebrate Paleontology, V17, p43A; Dowsett H. J., 1999, 99535 US GEOL SURV; Elias SA, 2002, CAN J EARTH SCI, V39, P911, DOI 10.1139/E01-096; FYLES JG, 1989, CURR RES GEOL SURV C, V89, P101; Harington C.R., 2001, MERIDIAN         FAL, P11; Hulbert RC, 1999, PALAEONTOLOGY, V42, P1017; Hutchison JH, 2002, CAN J EARTH SCI, V39, P439, DOI 10.1139/E01-078; Lindsay E, 2002, J VERTEBR PALEONTOL, V22, P429, DOI 10.1671/0272-4634(2002)022[0429:ROTHBB]2.0.CO;2; MATTHEWS JV, 1990, ARCTIC, V43, P364; PETTER G, 1971, Mammalia, V35, P567, DOI 10.1515/mamm.1971.35.4.567; ROSHCHIN AD, 1949, T ODESKOGO GOSUD U, V60, P97; Rybczynski N., 1997, Journal of Vertebrate Paleontology, V17, p72A; SHER AV, 1986, PALAEONTOGRAPHICA IT, V74, P77; Shi N, 1994, STRIAE, V36, P1; Stach J., 1951, Acta Geologica Polonica, V2, P129; Tedford R.H., 1991, Journal of Vertebrate Paleontology, V11, P519; Teilhard de Chardin P., 1945, I GEOBIOL PEKING, V12, P1; VIRET J, 1934, TRAV LAB GEOL FS LYO, V2, P7; Zakrzewski R. J., 2001, Journal of Vertebrate Paleontology, V21, p116A	20	64	67	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					388	390		10.1038/nature01892	http://dx.doi.org/10.1038/nature01892			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508486				2022-12-24	WOS:000185502300038
J	Buljevac, D; Hop, WCJ; Reedeker, W; Janssens, ACJW; van der Meche, FGA; van Doorn, PA; Hintzen, RQ				Buljevac, D; Hop, WCJ; Reedeker, W; Janssens, ACJW; van der Meche, FGA; van Doorn, PA; Hintzen, RQ			Self reported stressful life events and exacerbations in multiple sclerosis: prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSYCHOLOGICAL STRESS; EMOTIONAL-STRESS; DISEASE; MS; INFECTIONS; MODELS	Objective To study the relation between self reported stressful life events not related to multiple sclerosis and the occurrence of exacerbations in relapsing-remitting multiple sclerosis. Design Longitudinal, prospective cohort study. Setting Outpatient clinic of a department of neurology in the Netherlands. Participants Patients aged 18-55 with relapsing-remitting multiple sclerosis who could walk with a cane or better (score of 0-6.0 on the expanded disability status scale) and had had at least two exacerbations in 24 months before inclusion in the study. Patients with other serious conditions were excluded. Main outcome measure The risk of increased disease activity as measured by the occurrence of exacerbations after weeks with stressful events. Results Seventy out of 73 included patients (96%) reported at least one stressful event. In total, 457 stressful life events were reported that were not related to multiple sclerosis. Average follow up time was 1.4 years. Throughout the study, 134 exacerbations occurred in 56 patients and 136 infections occurred in 57 patients. Cox regression. analysis with time dependent variables showed that the occurrence of stress was associated with a doubling of the exacerbation rate (relative risk 2.2, 95% confidence interval 1.2 to 4.0, P = 0.014) during the subsequent four weeks. Infections were associated with a threefold increase in the risk of exacerbation, but this effect was found to be independent of experienced stress. Conclusion Stressful events were associated with increased exacerbations in relapsing-remitting multiple sclerosis. This association was independent of die triggering effect of infections on exacerbations of multiple sclerosis.	Erasmus MC, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Med Psychol & Psychotherapy, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Hintzen, RQ (corresponding author), Erasmus MC, Dept Neurol, Postbox 2040, NL-3000 CA Rotterdam, Netherlands.	rhintzen@xs4all.nl	janssens, cecile c/L-1075-2015	Janssens, A Cecile/0000-0002-6153-4976				Antel JP, 1999, J NEUROIMMUNOL, V100, P181, DOI 10.1016/S0165-5728(99)00186-1; Buljevac D, 2002, BRAIN, V125, P952, DOI 10.1093/brain/awf098; Charnley J, 1979, LOW FRICTION ARTHROP, P157; CHELMICKASCHORR E, 1994, ANN NEUROL, V36, pS29, DOI 10.1002/ana.410360710; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; COX DR, 1972, J R STAT SOC B, V34, P187; Franklin GM, 1988, J NEUROL REHABIL, V2, P7; Goodin DS, 1999, NEUROLOGY, V52, P1737, DOI 10.1212/WNL.52.9.1737; GRANT I, 1989, J NEUROL NEUROSUR PS, V52, P8, DOI 10.1136/jnnp.52.1.8; Jafarian-Tehrani M, 1999, J NEUROIMMUNOL, V100, P13, DOI 10.1016/S0165-5728(99)00207-6; JANSSENS ACJ, 2003, IN PRESS ACTA NEUROL; Kroencke DC, 1999, MULT SCLER J, V5, P89, DOI 10.1177/135245859900500204; Mohr DC, 2000, NEUROLOGY, V55, P55, DOI 10.1212/WNL.55.1.55; NISIPEANU P, 1993, NEUROLOGY, V43, P1311, DOI 10.1212/WNL.43.7.1311; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; RABINS PV, 1986, BRAIN, V109, P585, DOI 10.1093/brain/109.4.585; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; Schwartz CE, 1999, BEHAV MED, V25, P110, DOI 10.1080/08964289909596740; SHERIDAN JF, 1994, CLIN MICROBIOL REV, V7, P200, DOI 10.1128/CMR.7.2.200-212.1994; SIBLEY WA, 1985, LANCET, V1, P1313; SIBLEY WA, 1997, MULTIPLE SCLEROSIS C, P141; Sternberg EM, 2001, J ENDOCRINOL, V169, P429, DOI 10.1677/joe.0.1690429; WARREN S, 1982, J CHRON DIS, V35, P821, DOI 10.1016/0021-9681(82)90047-9; WARREN S, 1991, J PSYCHOSOM RES, V35, P37, DOI 10.1016/0022-3999(91)90005-9	25	100	101	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2003	327	7416					646	+		10.1136/bmj.327.7416.646	http://dx.doi.org/10.1136/bmj.327.7416.646			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724AC	14500435	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000185463100015
J	Wu, WJ; Tu, S; Cerione, RA				Wu, WJ; Tu, S; Cerione, RA			Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation	CELL			English	Article							TYROSINE KINASE; BINDING PARTNERS; GROWTH; RHO; RAC; REGULATOR; GTPASES; FAMILY; ENDOCYTOSIS; PROTEINS	Cdc42 is a Ras-related protein that has been implicated in the control of normal cell growth, and when improperly regulated, in cellular transformation and invasiveness. A variety of extracellular stimuli, including epidermal growth factor (EGF), activate Cdc42. Here, we show that activation of Cdc42 protects the EGF receptor from the negative regulatory activity of the c-CbI ubiquitin ligase. Activated Cdc42 binds to p85Cool-1 (for cloned-out-of-library)/beta-Pix (for Pak-interactive exchange factor), a protein that directly associates with c-CbI. This inhibits the binding of CbI by the EGF receptor and thus prevents CbI from catalyzing receptor ubiquitination. The role played by Cdc42 in regulating the timing of EGIF receptor-CbI interactions is underscored by the fact that constitutively active Cdc42(F28L), by persistently blocking the binding of CbI to these receptors, leads to their aberrant accumulation and sustained EGF-stimulated ERK activation, thus resulting in cellular transformation.	Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu		Tu, S. Sean/0000-0003-0391-8186	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47458, GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Flanders JA, 2003, FEBS LETT, V550, P119, DOI 10.1016/S0014-5793(03)00853-6; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PAVELIC K, 1993, ANTICANCER RES, V13, P1133; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Tu S, 2001, J BIOL CHEM, V276, P19656, DOI 10.1074/jbc.M009838200; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WHITEHEAD IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P11; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	34	156	159	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					715	725		10.1016/S0092-8674(03)00688-3	http://dx.doi.org/10.1016/S0092-8674(03)00688-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505571	Bronze			2022-12-24	WOS:000185464000009
J	Wellman, CH; Osterloff, PL; Mohiuddin, U				Wellman, CH; Osterloff, PL; Mohiuddin, U			Fragments of the earliest land plants	NATURE			English	Article							WELSH BORDERLAND; SPORE MASSES; MICROFOSSIL RECORD; VASCULAR PLANTS; SPORANGIA; ULTRASTRUCTURE; ORDOVICIAN; BRYOPHYTES; ECOSYSTEMS; TETRADS	The earliest fossil evidence for land plants comes from microscopic dispersed spores(1-3). These microfossils are abundant and widely distributed in sediments, and the earliest generally accepted reports are from rocks of mid-Ordovician age (Llanvirn, 475 million years ago)(4). Although distribution, morphology and ultrastructure of the spores indicate that they are derived from terrestrial plants, possibly early relatives of the bryophytes, this interpretation remains controversial 5 as there is little in the way of direct evidence for the parent plants. An additional complicating factor is that there is a significant hiatus between the appearance of the first dispersed spores and fossils of relatively complete land plants (megafossils)(6): spores predate the earliest megafossils (Late Silurian, 425 million year ago) by some 50 million years(7). Here we report the description of spore-containing plant fragments from Ordovician rocks of Oman. These fossils provide direct evidence for the nature of the spore-producing plants. They confirm that the earliest spores developed in large numbers within sporangia, providing strong evidence that they are the fossilized remains of bona fide land plants. Furthermore, analysis of spore wall ultrastructure supports liverwort affinities.	Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Petr Dev Oman LLC, Muscat 113, Oman	University of Sheffield	Wellman, CH (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Alfred Denny Bldg,Western Bank, Sheffield S10 2TN, S Yorkshire, England.							BANKS HP, 1975, REV PALAEOBOT PALYNO, V20, P13, DOI 10.1016/0034-6667(75)90004-4; Brown R.C., 1990, MICROSPORES EVOLUTIO, P55; Droste H.H., 1997, GEOARABIA, V2, P419; Edwards D, 1999, BOT J LINN SOC, V130, P111, DOI 10.1006/bojl.1998.0243; EDWARDS D, 1995, NATURE, V374, P635, DOI 10.1038/374635a0; Edwards D, 1996, REV PALAEOBOT PALYNO, V90, P159, DOI 10.1016/0034-6667(95)00081-X; EDWARDS D, 1980, NATURE, V287, P41, DOI 10.1038/287041a0; EDWARDS D, 1995, NATURE, V377, P329, DOI 10.1038/377329a0; Edwards D., 2001, PLANTS INVADE LAND E, P3; Graham L, 1993, ORIGIN LAND PLANTS; GRAY J, 1971, SCIENCE, V173, P918, DOI 10.1126/science.173.4000.918; GRAY J, 1985, PHILOS T ROY SOC B, V309, P167, DOI 10.1098/rstb.1985.0077; Kenrick P, 2000, PHILOS T R SOC B, V355, P847, DOI 10.1098/rstb.2000.0619; Kenrick P, 1997, ORIGIN EARLY DIVERSI; Kroken SB, 1996, AM J BOT, V83, P1241, DOI 10.2307/2446108; MOHIUDDIN U, THESIS U SHEFFIELD; Nickrent DL, 2000, MOL BIOL EVOL, V17, P1885, DOI 10.1093/oxfordjournals.molbev.a026290; Pacini E, 1990, MICROSPORES EVOLUTIO, P213, DOI DOI 10.1016/B978-0-12-103458-0.50014-6; Qiu YL, 2000, J PHYCOL, V36, P799, DOI 10.1046/j.1529-8817.2000.03653.x; Richardson J. B., 1988, SUBSURFACE PALYNOSTR, P89; Steemans P, 1999, GEOBIOS-LYON, V32, P341, DOI 10.1016/S0016-6995(99)80048-5; Strother PK, 1996, GEOLOGY, V24, P55, DOI 10.1130/0091-7613(1996)024<0055:NEFLPF>2.3.CO;2; Taylor WA, 2002, REV PALAEOBOT PALYNO, V119, P325, DOI 10.1016/S0034-6667(01)00136-1; TAYLOR WA, 1995, NATURE, V373, P391, DOI 10.1038/373391b0; Wellman CH, 2000, PHILOS T R SOC B, V355, P717, DOI 10.1098/rstb.2000.0612; Wellman CH, 1998, PHILOS T ROY SOC B, V353, P1983, DOI 10.1098/rstb.1998.0349; Wellman CH, 1998, BOT J LINN SOC, V127, P117, DOI 10.1111/j.1095-8339.1998.tb02092.x	27	385	413	0	170	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					282	285		10.1038/nature01884	http://dx.doi.org/10.1038/nature01884			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679913	Green Accepted			2022-12-24	WOS:000185370900041
J	Hennessy, S; Bilker, WB; Zhou, L; Weber, AL; Brensinger, C; Wang, YL; Strom, BL				Hennessy, S; Bilker, WB; Zhou, L; Weber, AL; Brensinger, C; Wang, YL; Strom, BL			Retrospective drug utilization review, prescribing errors, and clinical outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICARE BENEFICIARIES; INTERVENTION; DATABASES; DISEASE	Context Retrospective drug utilization review is required of all state Medicaid programs and is performed by most private-sector prescription programs. However, it has not been shown to improve clinical outcomes or reduce the rate of potential prescribing errors, known as "exceptions." Objective To look for an effect of retrospective drug utilization review on the rate of exceptions and of clinical outcomes in patients with an exception. Design, Setting, and Participants Longitudinal ecologic study of the rate of exceptions, controlling for preintervention trends and calendar time; and a cohort study of all-cause and cause-specific hospitalizations in patients with an exception, controlling for potential individual-level confounders in 6 Medicaid programs using the same software in the mid-1990s. Main Outcome Measures The rate of exceptions was examined as a function of retrospective drug utilization review implementation. In addition, before-after comparisons were made of the incidence of all-cause and cause-specific hospitalization in patients with exceptions. Results We found no reduction in the rate of exceptions coincident with retrospective drug utilization review implementation (rate increase, 0.064 exceptions per 1000 prescriptions per month; 95% confidence interval [CI], -0.006 to 0.133). We also found no effect of retrospective drug utilization review on the incidence of all-cause hospitalization (odds ratio, 0.99; 95% Cl, 0.98-1.00) or cause-specific hospitalization. These results persisted in multiple subgroup analyses. Study states intervened using physician alerts in between 1% and 25% of exceptions. Conclusions We were unable to identify an effect of retrospective drug utilization review on the rate of exceptions or on clinical outcomes. Given the lack of evidence for effectiveness, and suggestions from previous research of possible harm, policy-makers should consider withdrawing the legislative mandate for retrospective drug utilization review.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Hennessy, S (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, 803 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.		Bilker, Warren/AAS-3515-2021		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG000987, R01AG014601] Funding Source: NIH RePORTER; AHRQ HHS [U18-HS10399] Funding Source: Medline; NIA NIH HHS [1K23AG000987, 1R01 AG14601] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*ABT ASS INC, 1998, EV DRUG US REV DEM P; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Carson JL, 2000, PHARMACOEPIDEM DR S, P307; CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Coleman CI, 2003, AM J HEALTH-SYST PH, V60, P1142, DOI 10.1093/ajhp/60.11.1142; Hennessey S, 2000, PHARMACOEPIDEM DR S, P505; Hennessy S, 2003, PHARMACOEPIDEM DR S, V12, P103, DOI 10.1002/pds.765; JAY DE, 1991, MED CAL THERAPEUTIC; Kleinbaum DG, 1998, APPL REGRESSION ANAL; Krumholz HM, 1998, J AM COLL CARDIOL, V31, P957, DOI 10.1016/S0735-1097(98)00106-5; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Raiford DS, 1996, EPIDEMIOLOGY, V7, P101, DOI 10.1097/00001648-199601000-00018; Ray WA, 1997, ANN INTERN MED, V127, P712, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00055; Smith DH, 1998, MED CARE, V36, P1013, DOI 10.1097/00005650-199807000-00008; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; STROM BL, 1995, AM J MED, V99, P282, DOI 10.1016/S0002-9343(99)80161-2; STROM BL, 1990, EPIDEMIOL REV, V12, P87, DOI 10.1093/oxfordjournals.epirev.a036064; Strom BL, 1997, ARCH INTERN MED, V157, P2626, DOI 10.1001/archinte.157.22.2626; *US CTR MED MED SE, MED DUALL EL POP; *US CTR MED MED SE, MED ENR BEN SEL FISC; West SL, 2000, PHARMACOEPIDEMIOLOGY, V3rd edn, P661; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; ZIMMERMAN DR, 1994, INQUIRY-J HEALTH CAR, V31, P89; 1969, FINAL REPORT TASK FO	27	38	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1494	1499		10.1001/jama.290.11.1494	http://dx.doi.org/10.1001/jama.290.11.1494			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129990				2022-12-24	WOS:000185329000032
J	Huynen, L; Millar, CD; Scofield, RP; Lambert, DM				Huynen, L; Millar, CD; Scofield, RP; Lambert, DM			Nuclear DNA sequences detect species limits in ancient moa	NATURE			English	Article							MITOCHONDRIAL-DNA; GENOME SEQUENCES; SEX; BIRDS; GENE	Ancient DNA studies have typically used multi-copy mitochondrial DNA sequences(1,2). This is largely because single-locus nuclear genes have been difficult to recover from sub-fossil material(3), restricting the scope of ancient DNA research. Here, we have isolated single-locus nuclear DNA markers to assign the sex of 115 extinct moa and, in combination with a mitochondrial DNA phylogeny, tested competing hypotheses about the specific status of moa taxa. Moa were large ratite birds that showed extreme size variation both within and among species(4). For some taxa, this large variation was hypothesized to represent sexual dimorphism, while for others it was argued to reflect the existence of different species(5). Our results show that moa were characterized by extreme reverse sexual dimorphism and as a result we have been able to clarify the number of moa species. For example, we show that the three recognized 'species' of Dinornis comprised only two monophyletic groups and that two of these 'species' comprised individuals of one sex only. This study also illustrates that single-locus nuclear DNA sequences can be consistently recovered from ancient material.	Univ Auckland, Sch Biol Sci, Allan Wilson Ctr Mol Ecol & Evolut, Auckland 1, New Zealand; Canterbury Museum, Christchurch 8001, New Zealand	Massey University; University of Auckland	Lambert, DM (corresponding author), Massey Univ, Inst Mol Biosci, Allan Wilson Ctr Mol Ecol & Evolut, Private Bag 102 904, Palmerston North, New Zealand.	D.M.Lambert@massey.ac.nz	Scofield, R. Paul/A-4271-2011	Scofield, R. Paul/0000-0002-7510-6980; Lambert, David/0000-0002-5821-3637				ANDERSON AJ, 1989, PRODIGIIOUS BIRDS MO; ANSARI HA, 1988, CYTOGENET CELL GENET, V47, P185, DOI 10.1159/000132545; Asfaw B, 2002, NATURE, V416, P317, DOI 10.1038/416317a; Clinton M, 1999, CELL MOL LIFE SCI, V55, P876, DOI 10.1007/s000180050341; Cooper A, 1998, CURR OPIN BIOTECH, V9, P49, DOI 10.1016/S0958-1669(98)80083-9; Cooper A, 2001, NATURE, V409, P704, DOI 10.1038/35055536; Cooper Alan, 1997, P345, DOI 10.1016/B978-012498315-1/50019-4; Cracraft J., 1976, Smithsonian Contributions to Paleobiology, VNo. 27, P189; Ellegren H, 1996, P ROY SOC B-BIOL SCI, V263, P1635, DOI 10.1098/rspb.1996.0239; GRIFFITHS R, 1995, NATURE, V375, P454, DOI 10.1038/375454a0; Griffiths R, 1998, MOL ECOL, V7, P1071, DOI 10.1046/j.1365-294x.1998.00389.x; Haddrath O, 2001, P ROY SOC B-BIOL SCI, V268, P939, DOI 10.1098/rspb.2001.1587; HERMANN B, 1993, ANCIENNT DNA; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; Hofreiter M, 2001, NAT REV GENET, V2, P353, DOI 10.1038/35072071; Holdaway RN, 2000, SCIENCE, V287, P2250, DOI 10.1126/science.287.5461.2250; Huynen L, 2002, MOL ECOL, V11, P851, DOI 10.1046/j.1365-294X.2002.01483.x; Lambert DM, 2002, SCIENCE, V295, P2270, DOI 10.1126/science.1068105; Leonard JA, 2002, SCIENCE, V298, P1613, DOI 10.1126/science.1076980; Owen R., 1839, P ZOOL SOC LOND, V7, P169; PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2; Polack J. S., 1838, NZ BEING NARRATIVE T, V1; PRANGE HD, 1979, AM NAT, V113, P103, DOI 10.1086/283367; Sambrook JFE, 1989, MOL CLONING LAB MANU; Swofford DL, 2002, PAUP PHYLOGENETIC AN; Taberlet P, 1999, BIOL J LINN SOC, V68, P41, DOI 10.1111/j.1095-8312.1999.tb01157.x; Taberlet P, 1996, NUCLEIC ACIDS RES, V24, P3189, DOI 10.1093/nar/24.16.3189; Wiens JJ, 2002, SYST BIOL, V51, P69, DOI 10.1080/106351502753475880; Worthy T.H., 1988, NATL MUSEUM NZ MISCE, V17, P1; Worthy TH., 2002, LOST WORLD MOA PREHI	30	96	100	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					175	178		10.1038/nature01838	http://dx.doi.org/10.1038/nature01838			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968179				2022-12-24	WOS:000185236000041
J	Theise, ND; Wilmut, I				Theise, ND; Wilmut, I			Flexible arrangement	NATURE			English	Editorial Material									Beth Israel Med Ctr, Div Digest Dis, New York, NY 10003 USA; Roslin Inst, Roslin Bioctr, Roslin EH25 9PS, Midlothian, Scotland	Harvard University; Beth Israel Deaconess Medical Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Theise, ND (corresponding author), Beth Israel Med Ctr, Div Digest Dis, New York, NY 10003 USA.							Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Cavaleri F, 2003, CELL, V113, P551, DOI 10.1016/S0092-8674(03)00394-5; Theise ND, 2002, LEUKEMIA, V16, P542, DOI 10.1038/sj.leu.2402445; Wilmut I, 2002, NATURE, V419, P583, DOI 10.1038/nature01079	4	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					21	21		10.1038/425021a	http://dx.doi.org/10.1038/425021a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955119	Bronze			2022-12-24	WOS:000185089200018
J	Chiovato, L; Latrofa, F; Braverman, LE; Pacini, F; Capezzone, M; Masserini, L; Grasso, L; Pinchera, A				Chiovato, L; Latrofa, F; Braverman, LE; Pacini, F; Capezzone, M; Masserini, L; Grasso, L; Pinchera, A			Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens	ANNALS OF INTERNAL MEDICINE			English	Article							GRAVES-DISEASE; ANTITHYROGLOBULIN ANTIBODIES; SURGICAL-TREATMENT; TSH RECEPTOR; AUTOANTIBODIES; THYROGLOBULIN; CARCINOMA; CANCER	Background: The development of antibodies to thyroid peroxidase, thyroglobulin, and thyroid-stimulating hormone (TSH) receptor is a main feature of autoimmune thyroid diseases. Objective: To investigate whether complete removal of thyroid antigens results in the abatement of humoral thyroid autoimmunity. Design: Retrospective chart review study of patients treated and monitored with a standard prospective protocol. Setting: University hospital in Pisa, Italy, between 1976 and 1994. Patients: 182 patients with differentiated thyroid carcinoma and serum antibodies to thyroid peroxidase, thyroglobulin, or TSH receptor due to coexistent clinical Hashimoto thyroiditis, Graves disease, or focal autoimmune thyroiditis. Intervention: Total thyroidectomy and radioiodine treatment to ablate residual or metastatic thyroid tissue. Regular follow-up with iodine-131 whole-body scanning and serum thyroglobulin measurement. Mean follow-up (+/-SD) was 10.1 +/- 4.1 years (range, 4 to 20 years). Measurements: Serum antibodies to thyroid peroxidase, thyroglobulin, and TSH receptor. Results: Thyroid peroxidase, thyroglobulin, and TSH-receptor antibodies progressively disappeared after the initial treatment. The median disappearance time was 6.3 years for thyroid peroxidase antibodies and 3.0 years for thyroglobulin antibodies. There was a statistically significant correlation between the disappearance of thyroid tissue and that of thyroid antibodies. The coexistence of Hashimoto thyroiditis or Graves disease with thyroid cancer did not modify the pattern of disappearance of thyroid antibody compared with patients with focal autoimmune thyroiditis. Conclusions: Complete ablation of thyroid tissue with its antigenic components results in the disappearance of antibodies to all major thyroid antigens, thus supporting the concept that continued antibody production depends on the persistence of autoantigen in the body.	Univ Pisa, Osped Cisanello, Dipartimento Endocrinol & Metab Ortopedia & Traum, I-56124 Pisa, Italy; Boston Univ, Sch Med, Boston, MA 02118 USA	University of Pisa; Boston University	Pinchera, A (corresponding author), Univ Pisa, Osped Cisanello, Dipartimento Endocrinol & Metab Ortopedia & Traum, Via Paradisa 2, I-56124 Pisa, Italy.	a.pinchera@endoc.med.unipi.it	Capezzone, Marco/AAD-1776-2022; Capezzone, Marco/AAA-3137-2022; Capezzone, Marco/AAL-2308-2020; Chiovato, Luca/K-6617-2016; chiovato, luca/AAC-9003-2019	Capezzone, Marco/0000-0001-8624-5831; Chiovato, Luca/0000-0001-7457-7353; MASSERINI, LUCIO/0000-0002-9661-9953; Latrofa, Francesco/0000-0003-0297-5904; Braverman, Lewis/0000-0003-1263-1099				DEBRUIN TWA, 1988, CLIN EXP IMMUNOL, V72, P481; Fatemi S., 2000, Endocrine Journal, V47, P108; HAYASHI Y, 1985, J CLIN ENDOCR METAB, V61, P1172, DOI 10.1210/jcem-61-6-1172; Larbre H, 2000, ANN ENDOCRINOL-PARIS, V61, P422; Marcocci C, 2000, THYROID, V8, P414; MARIOTTI S, 1984, J CLIN ENDOCR METAB, V58, P18, DOI 10.1210/jcem-58-1-18; MCLACHLAN SM, 1983, CLIN EXP IMMUNOL, V52, P620; Miccoli P, 1996, SURGERY, V120, P1020, DOI 10.1016/S0039-6060(96)80049-3; MORI Y, 1992, WORLD J SURG, V16, P647, DOI 10.1007/BF02067345; PACINI F, 1988, ACTA ENDOCRINOL-COP, V119, P373, DOI 10.1530/acta.0.1190373; Park Y. J., 2000, Endocrine Journal, V47, P108; PINCHERA A, 1969, J CLIN ENDOCR METAB, V29, P231, DOI 10.1210/jcem-29-2-231; Roeher HD, 1996, SURGERY, V120, P1024; RUBELLO D, 1992, J NUCL MED, V33, P1478; Spencer CA, 1998, J CLIN ENDOCR METAB, V83, P1121, DOI 10.1210/jc.83.4.1121; TENG CS, 1980, J CLIN ENDOCR METAB, V50, P1005, DOI 10.1210/jcem-50-6-1005; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; WINSA B, 1995, EUR J ENDOCRINOL, V132, P406, DOI 10.1530/eje.0.1320406	18	226	241	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				346	351		10.7326/0003-4819-139-5_Part_1-200309020-00010	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965943				2022-12-24	WOS:000185037500005
J	Lerman, R				Lerman, R			Death rituals	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									William Beaumont Hosp, Imaging Ctr, Royal Oak, MI 48073 USA	Beaumont Health	Lerman, R (corresponding author), William Beaumont Hosp, Imaging Ctr, 3601 W 13 Mile Rd, Royal Oak, MI 48073 USA.	rlerman@beaumont.edu							0	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				384	384		10.7326/0003-4819-139-5_Part_1-200309020-00016	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965949				2022-12-24	WOS:000185037500011
J	Wang, CT; Lu, JC; Bai, JH; Chang, PY; Martin, TFJ; Chapman, ER; Jackson, MB				Wang, CT; Lu, JC; Bai, JH; Chang, PY; Martin, TFJ; Chapman, ER; Jackson, MB			Different domains of synaptotagmin control the choice between kiss-and-run and full fusion	NATURE			English	Article							ADRENAL CHROMAFFIN CELLS; CA2+ BINDING; HIPPOCAMPAL SYNAPSES; PC12 CELLS; EXOCYTOSIS; IV; KINETICS; MECHANISM; SECRETION; SENSOR	Exocytosis-the release of the contents of a vesicle-proceeds by two mechanisms(1-6). Full fusion occurs when the vesicle and plasma membranes merge. Alternatively, in what is termed kiss-and-run, vesicles can release transmitter during transient contacts with the plasma membrane. Little is known at the molecular level about how the choice between these two pathways is regulated. Here we report amperometric recordings of catecholamine efflux through individual fusion pores. Transfection with synaptotagmin (Syt) IV increased the frequency and duration of kiss-and-run events, but left their amplitude unchanged. Endogenous Syt IV, induced by forskolin treatment, had a similar effect. Full fusion was inhibited by mutation of a Ca2+ ligand in the C(2)A domain of Syt I; kiss-and-run was inhibited by mutation of a homologous Ca2+ ligand in the C2B domain of Syt IV. The Ca2+ sensitivity for full fusion was 5-fold higher with Syt I than Syt IV, but for kiss-and-run the Ca2+ sensitivities differed by a factor of only two. Syt thus regulates the choice between full fusion and kiss-and-run, with Ca2+ binding to the C(2)A and C2B domains playing an important role in this choice.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Dept Comparat Biosci, Endocrinol Reprod Physiol Program, Madison, WI 53706 USA; Univ Wisconsin, Biophys Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, MB (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.		Wang, Chih-Tien/GRE-8232-2022; Lu, Juu-Chin/ABB-3198-2020	Wang, Chih-Tien/0000-0001-7639-7508; Lu, Juu-Chin/0000-0001-8523-6992; Chapman, Edwin/0000-0001-9787-8140				Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; ALVAREZ DT, 1993, NATURE, V363, P554, DOI DOI 10.1038/363554A0; Bai JH, 2002, P NATL ACAD SCI USA, V99, P1665, DOI 10.1073/pnas.032541099; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Chow Robert H., 1995, P245; COLQUHOUN D, 1982, PHILOS T ROY SOC B, V300, P1, DOI 10.1098/rstb.1982.0156; CORMACK B, 1994, CURRENT PROTOCOLS MO; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Eaton BA, 2000, J NEUROSCI, V20, P7334; Ferguson GD, 2001, MOL NEUROBIOL, V23, P173; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; JACKSON MB, 1992, METHOD ENZYMOL, V207, P729; Klenchin VA, 1998, METHODS, V16, P204, DOI 10.1006/meth.1998.0668; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Schneider SW, 2001, J MEMBRANE BIOL, V181, P67; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Stevens CF, 2000, P NATL ACAD SCI USA, V97, P12828, DOI 10.1073/pnas.230438697; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002	28	170	174	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					943	947		10.1038/nature01857	http://dx.doi.org/10.1038/nature01857			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931189				2022-12-24	WOS:000184843600042
J	Harmon, LJ; Schulte, JA; Larson, A; Losos, JB				Harmon, LJ; Schulte, JA; Larson, A; Losos, JB			Tempo and mode of evolutionary radiation in iguanian lizards	SCIENCE			English	Article							PHYLOGENETIC-RELATIONSHIPS; MOLECULAR PHYLOGENIES; ANOLIS LIZARDS; DIVERSITY; PATTERNS; DIVERSIFICATION; DISPARITY; STATES	Identification of general properties of evolutionary radiations has been hindered by the lack of a general statistical and phylogenetic approach applicable across diverse taxa. We present a comparative analytical framework for examining phylogenetic patterns of diversification and morphological disparity with data from four iguanian-lizard taxa that exhibit substantially different patterns of evolution. Taxa whose diversification occurred disproportionately early in their evolutionary history partition more of their morphological disparity among, rather than within, subclades. This inverse relationship between timing of diversification and morphological disparity within subclades may be a general feature that transcends the historically contingent properties of different evolutionary radiations.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Harmon, LJ (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.	harmon@biology.wustl.edu	Harmon, Luke/A-8225-2012	Harmon, Luke/0000-0002-4985-5750				Ciampaglio CN, 2001, PALEOBIOLOGY, V27, P695, DOI 10.1666/0094-8373(2001)027<0695:DCIMOP>2.0.CO;2; Conway-Morris S., 1998, CRUCIBLE CREATION; Cunningham CW, 1998, TRENDS ECOL EVOL, V13, P361, DOI 10.1016/S0169-5347(98)01382-2; Etheridge Richard, 1995, American Museum Novitates, V3142, P1; Foote M, 1997, ANNU REV ECOL SYST, V28, P129, DOI 10.1146/annurev.ecolsys.28.1.129; FOOTE M, 1993, PALEOBIOLOGY, V19, P185, DOI 10.1017/S0094837300015864; Fortey RA, 1996, BIOL J LINN SOC, V57, P13, DOI 10.1006/bijl.1995.0002; GARLAND T, 1993, SYST BIOL, V42, P265, DOI 10.2307/2992464; Givnish T.J., 1997, MOL EVOLUTION ADAPTI; Gould SJ, 2002, STRUCTURE EVOLUTIONA; Jackman TR, 1999, SYST BIOL, V48, P254, DOI 10.1080/106351599260283; LOSOS JB, 1994, ANNU REV ECOL SYST, V25, P467, DOI 10.1146/annurev.es.25.110194.002343; Losos JB, 2002, AM NAT, V160, P147, DOI 10.1086/341557; Melville J, 2001, J EXP ZOOL, V291, P339, DOI 10.1002/jez.1133; NEE S, 1992, P NATL ACAD SCI USA, V89, P8322, DOI 10.1073/pnas.89.17.8322; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Pianka E.R., 1986, ECOLOGY NATURAL HIST; Pybus OG, 2000, P ROY SOC B-BIOL SCI, V267, P2267, DOI 10.1098/rspb.2000.1278; Ruber L, 2001, J EVOLUTION BIOL, V14, P325, DOI 10.1046/j.1420-9101.2001.00269.x; Schluter D, 1997, EVOLUTION, V51, P1699, DOI 10.1111/j.1558-5646.1997.tb05095.x; Schluter D, 2000, ECOLOGY ADAPTIVE RAD; Schulte JA, 2000, BIOL J LINN SOC, V69, P75, DOI 10.1006/bijl.1999.0346; SCHULTE JA, 2001, THESIS WASHINGTON U; Simpson GG, 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; SITES JW, 1992, B AM MUS NAT HIST, P1; SMITH DC, 1981, ECOLOGY, V62, P679, DOI 10.2307/1937736; Wagner PJ, 1995, PALEOBIOLOGY, V21, P410, DOI 10.1017/S0094837300013464; Wills M. A., 2001, FOSSILS PHYLOGENY FO, P55	28	505	519	2	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					961	964		10.1126/science.1084786	http://dx.doi.org/10.1126/science.1084786			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920297				2022-12-24	WOS:000184755900038
J	Berman, DM; Karhadkar, SS; Maitra, A; de Oca, RM; Gerstenblith, MR; Briggs, K; Parker, AR; Shimada, Y; Eshleman, JR; Watkins, DN; Beachy, PA				Berman, DM; Karhadkar, SS; Maitra, A; de Oca, RM; Gerstenblith, MR; Briggs, K; Parker, AR; Shimada, Y; Eshleman, JR; Watkins, DN; Beachy, PA			Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours	NATURE			English	Article							INHIBITION; PATHWAY; CANCER; MOUSE; MEDULLOBLASTOMA; CARCINOGENESIS; CYCLOPAMINE; MODULATION; SIGNALS	Activation of the Hedgehog (Hh) signalling pathway by sporadic mutations or in familial conditions such as Gorlin's syndrome is associated with tumorigenesis in skin, the cerebellum and skeletal muscle(1,2). Here we show that a wide range of digestive tract tumours, including most of those originating in the oesophagus, stomach, biliary tract and pancreas, but not in the colon, display increased Hh pathway activity, which is suppressible by cyclopamine, a Hh pathway antagonist. Cyclopamine also suppresses cell growth in vitro and causes durable regression of xenograft tumours in vivo. Unlike in Gorlin's syndrome tumours, pathway activity and cell growth in these digestive tract tumours are driven by endogenous expression of Hh ligands, as indicated by the presence of Sonic hedgehog and Indian hedgehog transcripts, by the pathway- and growth-inhibitory activity of a Hh-neutralizing antibody, and by the dramatic growth-stimulatory activity of exogenously added Hh ligand. Our results identify a group of common lethal malignancies in which Hh pathway activity, essential for tumour growth, is activated not by mutation but by ligand expression.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; Kyoto Univ, Dept Surg, Kyoto 6068507, Japan	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Kyoto University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.		Karhadkar, Sunil/Y-9235-2019; Watkins, David N/I-6113-2013	Karhadkar, Sunil/0000-0001-7943-0203; berman, david/0000-0001-5985-3698				Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chen XX, 2001, CARCINOGENESIS, V22, P1119, DOI 10.1093/carcin/22.8.1119; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hebrok M, 2003, MECH DEVELOP, V120, P45, DOI 10.1016/S0925-4773(02)00331-3; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Lowenfels AB, 2002, HEMATOL ONCOL CLIN N, V16, P1, DOI 10.1016/S0889-8588(01)00003-X; Peek RM, 2002, J GASTROENTEROL, V37, P10, DOI 10.1007/BF02990093; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; Wang LC, 2000, J INVEST DERMATOL, V114, P901, DOI 10.1046/j.1523-1747.2000.00951.x; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385	23	1056	1168	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					846	851		10.1038/nature01972	http://dx.doi.org/10.1038/nature01972			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14520411				2022-12-24	WOS:000186118500047
J	Schwartz, E; Parise, M; Kozarsky, P; Cetron, M				Schwartz, E; Parise, M; Kozarsky, P; Cetron, M			Delayed onset of malaria - Implications for chemoprophylaxis in travelers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; PLACEBO-CONTROLLED TRIAL; UNITED-STATES TROOPS; DOUBLE-BLIND; ATOVAQUONE-PROGUANIL; VIVAX MALARIA; NONIMMUNE TRAVELERS; PYRIMETHAMINE-SULFADOXINE; CHLOROQUINE-PROGUANIL; AMERICAN TRAVELERS	BACKGROUND: Most antimalarial agents used by travelers act on the parasite's blood stage and therefore do not prevent late-onset illness, particularly that due to species that cause relapsing malaria. We examined the magnitude of this problem among Israeli and American travelers. METHODS: We examined malaria surveillance data from Israel and the United States to determine the traveler's destination, the infecting species, the type of chemoprophylaxis used, and the incubation period. RESULTS: In Israel, from 1994 through 1999, there were 300 cases of malaria among returning travelers in which one species of plasmodium could be identified. In 134 of these cases (44.7 percent), the illness developed more than two months after the traveler's return; nearly all of these cases were due to infection with Plasmodium vivax or P. ovale. In 108 of the 134 cases (80.6 percent), the patient had used an antimalarial regimen according to national guidelines. In the United States, from 1992 through 1998, there were 2822 cases of malaria among travelers in which the cause could be evaluated. Late illness developed in 987 (35.0 percent) of these travelers. The infection was due to P. vivax in 811 travelers, P. ovale in 66, P. falciparum in 59, and P. malariae in 51; 614 (62.2 percent) of those with late-onset illness had appropriately taken an effective antimalarial agent. CONCLUSIONS: In more than one third of malaria-infected travelers, the illness developed more than two months after their return. Most of these late-onset illnesses are not prevented by the commonly used and effective blood schizonticides. Agents that act on the liver phase of malaria parasites are needed for more effective prevention of malaria in travelers.	Chaim Sheba Med Ctr, Ctr Geog Med, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Med, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; CDCP, Malaria Epidemiol Branch, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA; CDCP, Surveillance & Epidemiol Branch, Div Global Migrat & Quarantine, Natl Ctr Infect Dis, Atlanta, GA USA; US PHS, US Dept HHS, Atlanta, GA USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA USA	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; United States Public Health Service; Emory University	Schwartz, E (corresponding author), Chaim Sheba Med Ctr, Ctr Geog Med, IL-52621 Tel Hashomer, Israel.							ALVING AS, 1952, JAMA-J AM MED ASSOC, V149, P1558, DOI 10.1001/jama.1952.72930340017010; Anabwani G, 1999, PEDIATR INFECT DIS J, V18, P456, DOI 10.1097/00006454-199905000-00011; Baird JK, 2001, CLIN INFECT DIS, V33, P1990, DOI 10.1086/324085; Baudon D, 1999, T ROY SOC TROP MED H, V93, P302, DOI 10.1016/S0035-9203(99)90030-5; Berman JD, 2001, T ROY SOC TROP MED H, V95, P429, DOI 10.1016/S0035-9203(01)90206-8; Brueckner RP, 1998, AM J TROP MED HYG, V58, P645, DOI 10.4269/ajtmh.1998.58.645; Bustos DG, 1999, J INFECT DIS, V179, P1587, DOI 10.1086/314770; *CDCP, 2001, HLTH INF INT TRAV 20; Croft A, 1997, BRIT MED J, V315, P1412, DOI 10.1136/bmj.315.7120.1412; Croft AMJ, 1996, LANCET, V347, P326, DOI 10.1016/S0140-6736(96)90500-0; deAlencar FEC, 1997, J INFECT DIS, V175, P1544, DOI 10.1086/516497; FRYAUFF DJ, 1995, LANCET, V346, P1190, DOI 10.1016/S0140-6736(95)92898-7; HATTON CSR, 1986, LANCET, V1, P411; HENNEQUIN C, 1994, ARCH INTERN MED, V154, P2360, DOI 10.1001/archinte.154.20.2360; Hogh B, 2000, LANCET, V356, P1888, DOI 10.1016/S0140-6736(00)03260-8; Lacy MD, 2002, CLIN INFECT DIS, V35, pE92, DOI 10.1086/343750; Lell B, 2000, LANCET, V355, P2041, DOI 10.1016/S0140-6736(00)02352-7; Lell B, 1998, LANCET, V351, P709, DOI 10.1016/S0140-6736(97)09222-2; Ling J, 2002, CLIN INFECT DIS, V35, P825, DOI 10.1086/342578; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; Looareesuwan S, 1999, T ROY SOC TROP MED H, V93, P637, DOI 10.1016/S0035-9203(99)90079-2; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P526, DOI 10.4269/ajtmh.1999.60.526; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; Mulenga M, 1999, CLIN THER, V21, P841, DOI 10.1016/S0149-2918(99)80006-X; NEFTEL KA, 1986, BRIT MED J, V292, P721, DOI 10.1136/bmj.292.6522.721; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; Overbosch D, 2001, CLIN INFECT DIS, V33, P1015, DOI 10.1086/322694; PHILLIPSHOWARD PA, 1986, BRIT MED J, V293, P932, DOI 10.1136/bmj.293.6552.932; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; Sabchareon A, 1998, T ROY SOC TROP MED H, V92, P201, DOI 10.1016/S0035-9203(98)90749-0; SANCHEZ JL, 1993, LANCET, V341, P1021, DOI 10.1016/0140-6736(93)91107-W; Schwartz E, 1998, CLIN INFECT DIS, V26, P1089, DOI 10.1086/520279; Schwartz E, 1999, CLIN INFECT DIS, V29, P1502, DOI 10.1086/313527; Shanks GD, 1999, J TRAVEL MED, V6, pS21; Shanks GD, 1998, CLIN INFECT DIS, V27, P494, DOI 10.1086/514710; Shapiro TA, 1999, AM J TROP MED HYG, V60, P831, DOI 10.4269/ajtmh.1999.60.831; Soto J, 1998, ANN INTERN MED, V129, P241, DOI 10.7326/0003-4819-129-3-199808010-00013; STEFFEN R, 1990, B WORLD HEALTH ORGAN, V68, P313; Sukwa TY, 1999, AM J TROP MED HYG, V60, P521, DOI 10.4269/ajtmh.1999.60.521; Taylor WRJ, 1999, CLIN INFECT DIS, V28, P74, DOI 10.1086/515071; Wallace MR, 1996, AM J MED, V100, P49, DOI 10.1016/S0002-9343(96)90011-X; *WHO, 2000, INT TRAV HLTH VACC R	43	116	120	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	2003	349	16					1510	1516		10.1056/NEJMoa021592	http://dx.doi.org/10.1056/NEJMoa021592			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	731ZM	14561793				2022-12-24	WOS:000185916400005
J	Taylor, GK; Nudds, RL; Thomas, ALR				Taylor, GK; Nudds, RL; Thomas, ALR			Flying and swimming animals cruise at a Strouhal number tuned for high power efficiency	NATURE			English	Article							LOCUSTA-MIGRATORIA L; OSCILLATING FOILS; INTERMITTENT FLIGHT; WINGBEAT FREQUENCY; NEUROMUSCULAR CONTROL; FLAPPING FLIGHT; NATURAL FLIGHT; WIDE-RANGE; KINEMATICS; PROPULSION	Dimensionless numbers are important in biomechanics because their constancy can imply dynamic similarity between systems, despite possible differences in medium or scale(1). A dimensionless parameter that describes the tail or wing kinematics of swimming and flying animals is the Strouhal number(1), St = fA/U, which divides stroke frequency (f) and amplitude (A) by forward speed (U)(2-8). St is known to govern a well-defined series of vortex growth and shedding regimes for airfoils undergoing pitching and heaving motions(6,8). Propulsive efficiency is high over a narrow range of St and usually peaks within the interval 0.2 < St < 0.4 (refs 3-8). Because natural selection is likely to tune animals for high propulsive efficiency, we expect it to constrain the range of St that animals use. This seems to be true for dolphins(2-5), sharks(3-5) and bony fish(3-5), which swim at 0.2 < St < 0.4. Here we show that birds, bats and insects also converge on the same narrow range of St, but only when cruising. Tuning cruise kinematics to optimize St therefore seems to be a general principle of oscillatory lift-based propulsion.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Taylor, GK (corresponding author), Univ Oxford, Dept Zool, Tinbergen Bldg,S Parks Rd, Oxford OX1 3PS, England.		Taylor, Graham/A-5041-2010; tay, wee beng/B-1095-2010; Usoh, Chigozie/H-5517-2011					Alexander RM., 2003, PRINCIPLES ANIMAL LO; Anderson JM, 1998, J FLUID MECH, V360, P41, DOI 10.1017/S0022112097008392; BAKER PS, 1981, J COMP PHYSIOL, V141, P233, DOI 10.1007/BF01342669; BAKER PS, 1979, J COMP PHYSIOL, V131, P79, DOI 10.1007/BF00613086; Bandyopadhyay PR, 2000, J FLUID ENG-T ASME, V122, P219, DOI 10.1115/1.483274; Bullen RD, 2002, J EXP BIOL, V205, P2615; DUDLEY R, 1990, J COMP PHYSIOL A, V167, P145; GOPALKRISHNAN R, 1994, J FLUID MECH, V274, P1, DOI 10.1017/S0022112094002016; Huang RF, 2001, J FLUID MECH, V441, P265, DOI 10.1017/S002211200100489X; Motani R, 2002, NATURE, V415, P309, DOI 10.1038/415309a; PENNYCUICK CJ, 1989, J EXP BIOL, V142, P1; Pennycuick CJ, 2001, J EXP BIOL, V204, P3283; PENNYCUICK CJ, 1990, J EXP BIOL, V150, P171; Pennycuick CJ, 1996, J EXP BIOL, V199, P1613; RAYNER JMV, 1987, CURRENT ORNITHOLOGY, V5, P1; Read DA, 2003, J FLUID STRUCT, V17, P163, DOI 10.1016/S0889-9746(02)00115-9; ROHR JJ, 1998, 1769 SPAC NAV WARF S; SCHOLEY KD, 1983, THESIS U BRISTOL; Tobalske BW, 1996, AUK, V113, P151, DOI 10.2307/4088943; Tobalske BW, 1999, J EXP BIOL, V202, P1725; Tobalske BW, 1996, J EXP BIOL, V199, P263; TOBALSKE BW, 1995, J EXP BIOL, V198, P1259; TOBALSKE BW, 1994, J EXP BIOL, V187, P1; TRIANTAFYLLOU GS, 1993, J FLUID STRUCT, V7, P205, DOI 10.1006/jfls.1993.1012; Triantafyllou MS, 2000, ANNU REV FLUID MECH, V32, P33, DOI 10.1146/annurev.fluid.32.1.33; TRIANTAFYLLOU MS, 1991, PHYS FLUIDS A-FLUID, V3, P2835, DOI 10.1063/1.858173; VIDELER JJ, 1988, J EXP BIOL, V134, P185; Wang ZJ, 2000, J FLUID MECH, V410, P323, DOI 10.1017/S0022112099008071; WITHERS PC, 1977, J EXP BIOL, V70, P13; Wolfgang MJ, 1999, J EXP BIOL, V202, P2303	30	566	579	10	211	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					707	711		10.1038/nature02000	http://dx.doi.org/10.1038/nature02000			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562101				2022-12-24	WOS:000185924500039
J	Heath, I				Heath, I			A wolf in sheep's clothing: a critical look at the ethics of drug taking	BRITISH MEDICAL JOURNAL			English	Article							CONCORDANCE; WOMEN	In 1997 a report of a working party of the Royal Pharmaceutical Society of Great Britain acknowledged that prescribing is "a technically difficult, and morally complex, problem" and that compliance is an ethically dubious aspiration.(1) The report proposed the use of a new term-concordance-which was intended to describe the creation, during the process of prescribing, of an agreement that respected the beliefs and wishes of the patient.(2) The intention of the working party was to foster a distinct change in culture in the relation between prescribing and drug taking and between patient and prescriber. The intention was honourable, but the initiative seems to be foundering.	Caversham Grp Practice, London NW5 2UP, England		Heath, I (corresponding author), Caversham Grp Practice, Kentish Town, London NW5 2UP, England.							Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Bashir A, 2001, INT J PHARM PRACT S, V9, pR78; Butler CC, 2001, J ANTIMICROB CHEMOTH, V48, P435, DOI 10.1093/jac/48.3.435; Carter S, 2003, QUESTION CHOICE COMP; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; DONALDSON MR, 1992, ALL ER, V4, P649; Dowell J, 2002, BRIT J GEN PRACT, V52, P24; Hodgkin P, 1996, BRIT MED J, V313, P1568, DOI 10.1136/bmj.313.7072.1568; Marinker M, 2003, BRIT MED J, V326, P348, DOI 10.1136/bmj.326.7385.348; METCALFE D, 1986, J ROY COLL GEN PRACT, V36, P349; POLLOCK AM, 2003, BRIT MED J, V377, P571; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; Royal Pharmaceutical Society of Great Britain, 1997, COMPL CONC ACH SHAR; Thornton H, 2003, BMJ-BRIT MED J, V327, P101, DOI 10.1136/bmj.327.7406.101; Tuckett D., 1985, M EXPERTS APPROACH S; ZBIGNIEW H, 1983, REPORT BESIEGED CITY	16	23	23	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					856	858		10.1136/bmj.327.7419.856	http://dx.doi.org/10.1136/bmj.327.7419.856			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551104	Green Published			2022-12-24	WOS:000185921200026
J	Eisenberger, NI; Lieberman, MD; Williams, KD				Eisenberger, NI; Lieberman, MD; Williams, KD			Does rejection hurt? An fMRI study of social exclusion	SCIENCE			English	Article							ANTERIOR CINGULATE CORTEX; BRAIN ACTIVITY; PAIN; CONNECTIONS; ACTIVATION; RESPONSES; MONKEYS; NETWORK	A neuroimaging study examined the neural correlates of social exclusion and tested the hypothesis that the brain bases of social pain are similar to those of physical pain. Participants were scanned while playing a virtual ball-tossing game in which they were ultimately excluded. Paralleling results from physical pain studies, the anterior cingulate cortex (ACC) was more active during exclusion than during inclusion and correlated positively with self-reported distress. Right ventral prefrontal cortex (RVPFC) was active during exclusion and correlated negatively with self-reported distress. ACC changes mediated the RVPFC-distress correlation, suggesting that RVPFC regulates the distress of social exclusion by disrupting ACC activity.	Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia	University of California System; University of California Los Angeles; Macquarie University	Eisenberger, NI (corresponding author), Univ Calif Los Angeles, Dept Psychol, Franz Hall, Los Angeles, CA 90095 USA.	neisenbe@ucla.edu	Williams, Kipling D/B-2620-2012; Lieberman, Matthew/ABD-8197-2020; Tudusciuc, Oana/C-1339-2011; Li, Chong/F-4265-2015	Lieberman, Matthew/0000-0002-4447-7359; 	NIMH NIH HHS [R21MH66709-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH066709] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brown JL, 2003, PSYCHOSOM MED, V65, P276, DOI 10.1097/01.PSY.0000030388.62434.46; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Carter CS, 2000, P NATL ACAD SCI USA, V97, P1944, DOI 10.1073/pnas.97.4.1944; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; FOLTZ EL, 1962, J NEUROSURG, V19, P89, DOI 10.3171/jns.1962.19.2.0089; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Hariri AR, 2000, NEUROREPORT, V11, P43, DOI 10.1097/00001756-200001170-00009; Kimbrell TA, 1999, BIOL PSYCHIAT, V46, P454, DOI 10.1016/S0006-3223(99)00103-1; Leary M.R., 2001, HURT FEELINGS NEGLEC; LIEBERMAN ML, UNPUB; Lorberbaum JP, 1999, DEPRESS ANXIETY, V10, P99, DOI 10.1002/(SICI)1520-6394(1999)10:3<99::AID-DA2>3.0.CO;2-#; MACLEAN PD, 1988, BRAIN RES, V450, P111, DOI 10.1016/0006-8993(88)91550-8; MURPHY MR, 1981, SCIENCE, V213, P459, DOI 10.1126/science.7244642; Nelson EE, 1998, NEUROSCI BIOBEHAV R, V22, P437, DOI 10.1016/S0149-7634(97)00052-3; PANKSEPP J, 1998, AFFECTIVE NEUROSCIEC; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Sawamoto N, 2000, J NEUROSCI, V20, P7438; Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720; Williams KD, 2000, J PERS SOC PSYCHOL, V79, P748, DOI 10.1037/0022-3514.79.5.748; ZADRO L, IN PRESS RESPONDING; Zhang YQ, 1997, PAIN, V72, P127, DOI 10.1016/S0304-3959(97)00025-0	23	2170	2227	13	482	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					290	292		10.1126/science.1089134	http://dx.doi.org/10.1126/science.1089134			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	730HT	14551436				2022-12-24	WOS:000185825900043
J	Fitzgerald, DW; Pape, JW; Wasserheit, JN; Counts, GW; Corey, L				Fitzgerald, DW; Pape, JW; Wasserheit, JN; Counts, GW; Corey, L			Provision of treatment in HIV-1 vaccine trials in developing countries	LANCET			English	Editorial Material							AIDS		HVTN, Seattle, WA 98109 USA		Fitzgerald, DW (corresponding author), HVTN, Seattle, WA 98109 USA.							Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; *CIOMS, 2002, INT ETH GUID BIOM RE; UNAIDS and WHO, 2000, ETH CONS HIV PREV VA; World Health Organization, 2002, SCAL ANT THER RES LT	5	26	29	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					993	994		10.1016/S0140-6736(03)14372-3	http://dx.doi.org/10.1016/S0140-6736(03)14372-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724LT	14513852				2022-12-24	WOS:000185489600025
J	Heckenberger, MJ; Kuikuro, A; Kuikuro, UT; Russell, JC; Schmidt, M; Fausto, C; Franchetto, B				Heckenberger, MJ; Kuikuro, A; Kuikuro, UT; Russell, JC; Schmidt, M; Fausto, C; Franchetto, B			Amazonia 1492: Pristine forest or cultural parkland?	SCIENCE			English	Article							LANDSCAPE; SCALE	Archaeology and indigenous history of Native Amazonian peoples in the Upper Xingu region of Brazil reveal unexpectedly complex regional settlement patterns and large-scale transformations of local landscapes over the past millennium. Mapping and excavation of archaeological structures document pronounced human-induced alteration of the forest cover, particularly in relation to large, dense late-prehistoric settlements ( circa 1200 to 1600 A. D.). The findings contribute to debates on human carrying capacity, population size and settlement patterns, anthropogenic impacts on the environment, and the importance of indigenous knowledge, as well as contributing to the pride of place of the native peoples in this part of the Amazon.	Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA; Univ Florida, Land Use & Environm Change Inst, Gainesville, FL 32611 USA; Univ Florida, Dept Geog, Gainesville, FL 32611 USA; Associacao Indigena kuikuro Alto Xingu, Parque Indigena Xingu, Mato Grosso, Brazil; Univ Fed Rio de Janeiro, Museu nacl, Dept Anthropol, BR-20940040 Rio De Janeiro, Brazil	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Universidade Federal do Rio de Janeiro	Heckenberger, MJ (corresponding author), Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA.	mheckenb@anthro.ufl.edu	Fausto, Carlos/I-4550-2013	Fausto, Carlos/0000-0002-0617-6643				Balee W., 1989, Advances in Economic Botany, V7, P1; CARNEIRO R, 1957, SUBSISTENCE SOCIAL S; Carneiro R., 1984, ADAPTIVE RESPONSES N, P65, DOI [10.1016/B978-0-12-321250-4.50007-5, DOI 10.1016/B978-0-12-321250-4.50007-5]; Denevan W.M., 1992, J STEWARD ANTHR SOC, V20, P153; Denevan William M., 2001, CULTIVATED LANDSCAPE; DENEVAN WM, 1992, ANN ASSOC AM GEOGR, V82, P369, DOI 10.1111/j.1467-8306.1992.tb01965.x; Erickson CL, 2000, NATURE, V408, P190, DOI 10.1038/35041555; HECKENBERGER M, 2001, COMP ARAWAK HIST RET, P99; HECKENBERGER M, 2001, OS POVOS INDIGENAS A, P77; Heckenberger MJ, 1998, ANTIQUITY, V72, P633, DOI 10.1017/S0003598X00087056; Heckenberger MJ, 1999, LAT AM ANTIQ, V10, P353, DOI 10.2307/971962; Lathrap DW, 1970, UPPER AMAZON; Mann CC, 2000, SCIENCE, V287, P786, DOI 10.1126/science.287.5454.786; MANN CC, 2002, ATLANTIC MONTHLY MAR, P41; METRAUX A, 1948, B BUR AM ETHNOL, V143, P349; Peterson J.B., 2001, UNKNOWN AMAZON CULTU, P86; Roosevelt AC., 1999, ARCHEOLOGICAL PAPERS, V9, P2, DOI DOI 10.1525/AP3A.1999.9.1.13; Smith N.J.H., 1995, AMAZONIA RESILIENCY; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; TAMBIAH S, 1985, RITUAL PERFORMANCE T; Woods W.I., 1999, YB C LAT AM GEOGR, V25, P7; 2002, AM BROADCASTING 0919; 2002, BRIT BROADCASTI 1219	23	310	332	3	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1710	1714		10.1126/science.1086112	http://dx.doi.org/10.1126/science.1086112			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500979				2022-12-24	WOS:000185387700041
J	Yuan, JP; Kiselyov, K; Shin, DM; Chen, J; Shcheynikov, N; Kang, SH; Dehoff, MH; Schwarz, MK; Seeburg, PH; Muallem, S; Worley, PF				Yuan, JP; Kiselyov, K; Shin, DM; Chen, J; Shcheynikov, N; Kang, SH; Dehoff, MH; Schwarz, MK; Seeburg, PH; Muallem, S; Worley, PF			Homer binds TRPC family channels and is required for gating of TRPC1 by IP3 receptors	CELL			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; OPERATED HTRP3 CHANNELS; PROLINE-RICH MOTIF; EVH1 DOMAIN; PROTEINS; CELLS; CALCIUM; COMPLEX; ASSOCIATION	Receptor signaling at the plasma membrane often releases calcium from intracellular stores. For example, inositol triphosphate (IP3) produced by receptor-coupled phospholipase C activates an intracellular store calcium channel, the IP3R. Conversely, stores can induce extracellular calcium to enter the cell through plasma membrane channels, too. How this "reverse" coupling works was unclear, but store IP(3)Rs were proposed to bind and regulate plasma membrane TRIP cation channels. Here, we demonstrate that the adaptor protein, termed Homer, facilitates a physical association between TRPC1 and the IP3R that is required for the TRP channel to respond to signals. The TRPC1-Homer-IP3R complex is dynamic and its disassembly parallels TRPC1 channel activation. Homer's action depends on its ability to crosslink and is blocked by the dominant-negative immediate early gene form, H1a. Since H1a is transcriptionally regulated by cellular activity, this mechanism can affect both short and long-term regulation of TRPC1 function.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Yonsei Univ, Dept Oral Biol, Brain Korea 21 Project Med Sci, Seoul 120752, South Korea; Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yonsei University; Max Planck Society	Worley, PF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	shmuel.muallem@utsouthwestern.edu; pworley@jhmi.edu		Shin, Dong Min/0000-0001-6042-0435; Kiselyov, Kirill/0000-0001-6683-2895				Baltensperger H, 1997, J BIOL CHEM, V272, P10151; Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; FAGNI L, 2002, SCI STKE; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Irie K, 2002, J MOL BIOL, V318, P1117, DOI 10.1016/S0022-2836(02)00170-5; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Klingelhofer J, 2003, ONCOGENE, V22, P1181, DOI 10.1038/sj.onc.1206245; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C., 2001, SCI STKE; Nucifora FC, 1996, MOL BIOL CELL, V7, P949, DOI 10.1091/mbc.7.6.949; Putney JW, 2001, NATURE, V410, P648, DOI 10.1038/35070704; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Shin DM, 2003, J CELL BIOL, V162, P293, DOI 10.1083/jcb.200210109; Soloviev MM, 2000, EUR J BIOCHEM, V267, P634, DOI 10.1046/j.1432-1327.2000.01078.x; Soloviev MM, 2000, J MOL BIOL, V295, P1185; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Vaca L, 2002, J BIOL CHEM, V277, P42178, DOI 10.1074/jbc.M204531200; Vazdarjanova A, 2002, J NEUROSCI, V22, P10067; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Vennekens R, 2002, CELL CALCIUM, V31, P253, DOI 10.1016/S0143-4160(02)00055-6; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8	33	398	416	1	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					777	789		10.1016/S0092-8674(03)00716-5	http://dx.doi.org/10.1016/S0092-8674(03)00716-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505576	Bronze			2022-12-24	WOS:000185464000014
J	Sinclair, ARE; Mduma, S; Brashares, JS				Sinclair, ARE; Mduma, S; Brashares, JS			Patterns of predation in a diverse predator-prey system	NATURE			English	Article							TROPHIC CASCADES; BOTTOM-UP; FOOD WEBS; TOP-DOWN; COMPETITION; COMMUNITY; HETEROGENEITY; ECOSYSTEM	There are many cases where animal populations are affected by predators and resources in terrestrial ecosystems(1-3),but the factors that determine when one or the other predominates remain poorly understood(4-5). Here we show, using 40 years of data from the highly diverse mammal community of the Serengeti ecosystem, East Africa, that the primary cause of mortality for adults of a particular species is determined by two factors-the species diversity of both the predators and prey and the body size of that prey species relative to other prey and predators. Small ungulates in Serengeti are exposed to more predators, owing to opportunistic predation, than are larger ungulates; they also suffer greater predation rates, and experience strong predation pressure. A threshold occurs at prey body sizes of similar to150 kg, above which ungulate species have few natural predators and exhibit food limitation. Thus, biodiversity allows both predation (top-down) and resource limitation (bottom-up) to act simultaneously to affect herbivore populations. This result may apply generally in systems where there is a diversity of predators and prey.	Univ British Columbia, Ctr Biodivers Res, Vancouver, BC V6T 1Z4, Canada; Tanzania Wildlife Res Inst, Arusha, Tanzania	University of British Columbia	Sinclair, ARE (corresponding author), Univ British Columbia, Ctr Biodivers Res, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.							[Anonymous], 1999, WALKERS MAMMALS WORL; Bertram B. C. B., 1979, SERENGETI DYNAMICS E, P221; BRASHARES JS, IN PRESS MAMMALS AFR; BROTEN M, 1995, SERENGETI, V2, P169; Cochran W. G., 1963, SAMPLING TECHNIQUES, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; Dunne JA, 2002, ECOL LETT, V5, P558, DOI 10.1046/j.1461-0248.2002.00354.x; Dyer LA, 2003, ECOL LETT, V6, P60, DOI 10.1046/j.1461-0248.2003.00398.x; Dyer LA, 1999, P NATL ACAD SCI USA, V96, P5072, DOI 10.1073/pnas.96.9.5072; ELLIOTT JP, 1977, CAN J ZOOL, V55, P1811, DOI 10.1139/z77-235; HAIRSTON NG, 1960, AM NAT, V94, P421, DOI 10.1086/282146; Hofer H., 1995, SERENGETI, P332, DOI DOI 10.1186/1471-2148-9-253; HUNTER MD, 1992, ECOLOGY, V73, P724; JOLLY G M, 1969, East African Agricultural and Forestry Journal, V34, P46; Kruuk H., 1972, SPOTTED HYENA STUDY; LAMPRECHT J, 1978, Z SAUGETIERKD, V43, P210; Mduma SAR, 1999, J ANIM ECOL, V68, P1101, DOI 10.1046/j.1365-2656.1999.00352.x; MDUMA SAR, 1995, SERENGETI, V2, P220; Persson L, 1999, OIKOS, V85, P385, DOI 10.2307/3546688; Polis GA, 1999, OIKOS, V86, P3, DOI 10.2307/3546565; Post E, 1999, NATURE, V401, P905, DOI 10.1038/44814; Schaller G. B., 1972, SERENGETI LION STUDY; Scheel, 1995, SERENGETI; Schoener TW, 1996, NATURE, V381, P691, DOI 10.1038/381691a0; Sinclair A. R. E., 1979, SERENGETI DYNAMICS E, P82; Sinclair A.R.E., 1979, SERENGETI DYNAMICS E; Sinclair ARE, 2000, OIKOS, V89, P313, DOI 10.1034/j.1600-0706.2000.890213.x; SINCLAIR ARE, 1985, J ANIM ECOL, V54, P899, DOI 10.2307/4386; SINCLAIR ARE, 1995, SERENGETI, V2, P194; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; [No title captured]	30	525	536	4	314	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					288	290		10.1038/nature01934	http://dx.doi.org/10.1038/nature01934			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679915				2022-12-24	WOS:000185370900043
J	Higginson, I				Higginson, I			For and against - Doctors should not discuss resuscitation with terminally ill patients - Against	BRITISH MEDICAL JOURNAL			English	Article							CARE; PHYSICIANS; LIFE; COMMUNICATION; PREFERENCES; CANCER; END		Kings Coll London, Weston Educ Ctr, Dept Palliat Care & Policy, London SE5 9RJ, England	University of London; King's College London	Higginson, I (corresponding author), Kings Coll London, Weston Educ Ctr, Dept Palliat Care & Policy, London SE5 9RJ, England.	irene.higginson@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				Davies E, 2003, SUPPORT CARE CANCER, V11, P21, DOI 10.1007/s00520-002-0392-x; Edmonds P, 2003, CLIN MED, V3, P149, DOI 10.7861/clinmedicine.3-2-149; Fallowfield LJ, 2002, PALLIATIVE MED, V16, P297, DOI 10.1191/0269216302pm575oa; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; GYSELS M, 2003, IMPROVING SUPPORTIVE; Koffman J, 2001, PALLIATIVE MED, V15, P337, DOI 10.1191/026921601678320322; MURRAY E, 2001, BRIT MED J, V323, P496; *NAT CANC RES I, 2002, STRAT AN 2002 OV CAN; Perron NJ, 2002, SWISS MED WKLY, V132, P562; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Teno JM, 1998, J GEN INTERN MED, V13, P439, DOI 10.1046/j.1525-1497.1998.00132.x	12	12	13	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					615	616		10.1136/bmj.327.7415.615	http://dx.doi.org/10.1136/bmj.327.7415.615			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969935	Green Published			2022-12-24	WOS:000185358700031
J	Sorenson, MD; Sefc, KM; Payne, RB				Sorenson, MD; Sefc, KM; Payne, RB			Speciation by host switch in brood parasitic indigobirds	NATURE			English	Article							VIDUA-CHALYBEATA; SYMPATRIC SPECIATION; SPECIES ASSOCIATIONS; GENETIC-EVIDENCE; COMMON CUCKOO; SONG MIMICRY; FINCHES; ORIGIN; DIFFERENTIATION; COEVOLUTION	A growing body of empirical and theoretical work supports the plausibility of sympatric speciation(1-3), but there remain few examples in which all the essential components of the process are well understood. The African indigobirds Vidua spp. are host-specific brood parasites. Indigobird nestlings are reared along with host young, and mimic the mouth markings of their respective hosts(4-6). As adults, male indigobirds mimic host song(4-7), whereas females use these songs to choose both their mates and the nests they parasitize(8). These behavioural mechanisms promote the cohesion of indigobird populations associated with a given host species, and provide a mechanism for reproductive isolation after a new host is colonized. Here we show that all indigobird species are similar genetically, but are significantly differentiated in both mitochondrial haplotype and nuclear allele frequencies. These data support a model of recent sympatric speciation. In contrast to the cuckoo Cuculus canorus, in which only female lineages are faithful to specific hosts(9,10), host switches have led to speciation in indigobirds because both males and females imprint on their hosts(8,11).	Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Michigan, Museum Zool, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA	Boston University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Sorenson, MD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.		Sorenson, Michael/D-8065-2011	Sorenson, Michael/0000-0001-5375-2917; Sefc, Kristina/0000-0001-8108-8339				Avise JC, 2000, PHYLOGEOGRAPHY HIST, DOI 10.2307/j.ctv1nzfgj7; Balloux F, 2002, MOL ECOL, V11, P155, DOI 10.1046/j.0962-1083.2001.01436.x; Berlocher SH, 2002, ANNU REV ENTOMOL, V47, P773, DOI 10.1146/annurev.ento.47.091201.145312; de Queiroz K, 1998, ENDLESS FORMS, P57; Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521; Edwards SV, 2000, EVOLUTION, V54, P1839; Gibbs HL, 2000, NATURE, V407, P183, DOI 10.1038/35025058; Goodman SJ, 1997, MOL ECOL, V6, P881, DOI 10.1046/j.1365-294X.1997.00260.x; Hedrick PW, 1999, EVOLUTION, V53, P313, DOI [10.2307/2640768, 10.1111/j.1558-5646.1999.tb03767.x]; Klein NK, 1998, EVOLUTION, V52, P566, DOI 10.1111/j.1558-5646.1998.tb01655.x; LOTEM A, 1995, ANIM BEHAV, V49, P1185, DOI 10.1006/anbe.1995.0152; Marchetti K, 1998, SCIENCE, V282, P471, DOI 10.1126/science.282.5388.471; Nicolai J., 1964, Zeitschrift fuer Tierpsychologie, V21, P129; Payne R.B., 1982, Miscellaneous Publications Museum of Zoology University of Michigan, V162, P1; Payne R. B., 1973, ORNITHOL MONOGR, V11, P1; Payne RB, 2000, ANIM BEHAV, V59, P69, DOI 10.1006/anbe.1999.1283; Payne RB, 1998, ANIM BEHAV, V55, P1537, DOI 10.1006/anbe.1997.0701; Payne RB, 2002, IBIS, V144, P373, DOI 10.1046/j.1474-919X.2002.00065.x; Payne RB, 2001, ANIM BEHAV, V62, P473, DOI 10.1006/anbe.2001.1773; PAYNE RB, 1994, IBIS, V136, P291, DOI 10.1111/j.1474-919X.1994.tb01098.x; Payne Robert B., 1996, Bulletin of the African Bird Club, V3, P14; SANDERSON MJ, 2003, R8S VERSION 1 60 AN; Schneider S., 2000, ARLEQUIN SOFTWARE PO, V2, P2496; Sefc KM, 2001, MOL ECOL NOTES, V1, P252, DOI 10.1046/j.1471-8278.2001.00095.x; SLATKIN M, 1987, SCIENCE, V236, P787, DOI 10.1126/science.3576198; Sorenson MD, 2002, INTEGR COMP BIOL, V42, P388, DOI 10.1093/icb/42.2.388; Sorenson MD, 2001, EVOLUTION, V55, P2550; SWOFFORD DL, 2002, PAUP PHYLOGENETIC AN; Via S, 2001, TRENDS ECOL EVOL, V16, P381, DOI 10.1016/S0169-5347(01)02188-7; [No title captured]	30	180	190	0	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					928	931		10.1038/nature01863	http://dx.doi.org/10.1038/nature01863			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931185	Green Published			2022-12-24	WOS:000184843600038
J	Hay, P				Hay, P			Commentary: Putting the research into practice	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Adelaide, Royal Adelaide Hosp, Dept Psychiat, Adelaide, SA 5001, Australia	Royal Adelaide Hospital; University of Adelaide	Hay, P (corresponding author), Univ Adelaide, Royal Adelaide Hosp, Dept Psychiat, Adelaide, SA 5001, Australia.	phillipa.hay@adelaide.edu.au		Hay, Phillipa/0000-0003-0296-6856				American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; [Anonymous], 2000, Am J Psychiatry, V157, P1; [Anonymous], 1992, Arch Gen Psychiatry, V49, P139; Cooper P. J., 1995, BULIMIA NERVOSA BING; Fairburn CG, 2003, LANCET, V361, P407, DOI 10.1016/S0140-6736(03)12378-1; Fairburn CG, 1996, AM J PSYCHIAT, V153, P386; Hay P, 2003, INT J EAT DISORDER, V33, P434, DOI 10.1002/eat.10162; Hay P. J., 1998, PRIMARY CARE COMMUN, V4, P95; HAY PJ, 2003, CLIN EVIDENCE, P1388	9	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 16	2003	327	7411					381	381		10.1136/bmj.327.7411.381	http://dx.doi.org/10.1136/bmj.327.7411.381			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919993	Green Published			2022-12-24	WOS:000184864200023
J	Chin, JW; Cropp, TA; Anderson, JC; Mukherji, M; Zhang, ZW; Schultz, PG				Chin, JW; Cropp, TA; Anderson, JC; Mukherji, M; Zhang, ZW; Schultz, PG			An expanded eukaryotic genetic code	SCIENCE			English	Article							SITE-SPECIFIC INCORPORATION; TRANSFER-RNA-SYNTHETASE; TYROSINE TRANSFER-RNA; UNNATURAL AMINO-ACIDS; PHOTO-CROSS-LINKING; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PROTEIN-STRUCTURE; REVERSE 2-HYBRID; YEAST	We describe a general and rapid route for the addition of unnatural amino acids to the genetic code of Saccharomyces cerevisiae. Five amino acids have been incorporated into proteins efficiently and with high fidelity in response to the nonsense codon TAG. The side chains of these amino acids contain a keto group, which can be uniquely modified in vitro and in vivo with a wide range of chemical probes and reagents; a heavy atom-containing amino acid for structural studies; and photocrosslinkers for cellular studies of protein interactions. This methodology not only removes the constraints imposed by the genetic code on our ability to manipulate protein structure and function in yeast, it provides a gateway to the systematic expansion of the genetic codes of multicellular eukaryotes.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Biol Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Schultz, PG (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062159] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 62159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER DG, 1982, FEBS LETT, V150, P419, DOI 10.1016/0014-5793(82)80781-3; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; Burke D., 2000, METHODS YEAST GENETI; Chin JW, 2003, CHEM BIOL, V10, P511, DOI 10.1016/S1074-5521(03)00123-6; Chin JW, 2002, P NATL ACAD SCI USA, V99, P11020, DOI 10.1073/pnas.172226299; Chin JW, 2002, J AM CHEM SOC, V124, P9026, DOI 10.1021/ja027007w; Chin JW, 2002, CHEMBIOCHEM, V3, P1135, DOI 10.1002/1439-7633(20021104)3:11<1135::AID-CBIC1135>3.0.CO;2-M; Corey E.J., 1995, LOGIC CHEM SYNTHESIS; CORNISH VW, 1995, ANGEW CHEM INT EDIT, V34, P621, DOI 10.1002/anie.199506211; Cornish VW, 1996, J AM CHEM SOC, V118, P8150, DOI 10.1021/ja961216x; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; Dougherty DA, 2000, CURR OPIN CHEM BIOL, V4, P645, DOI 10.1016/S1367-5931(00)00148-4; EDWARDS H, 1990, MOL CELL BIOL, V10, P1633, DOI 10.1128/MCB.10.4.1633; EDWARDS H, 1991, P NATL ACAD SCI USA, V88, P1153, DOI 10.1073/pnas.88.4.1153; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; Furter R, 1998, PROTEIN SCI, V7, P419; GOODMAN HM, 1968, NATURE, V217, P1019, DOI 10.1038/2171019a0; Hughes Timothy R, 2002, Funct Integr Genomics, V2, P199, DOI 10.1007/s10142-002-0059-1; JACKSON DY, 1994, SCIENCE, V266, P243, DOI 10.1126/science.7939659; Kirshenbaum K, 2002, CHEMBIOCHEM, V3, P235, DOI 10.1002/1439-7633(20020301)3:2/3<235::AID-CBIC235>3.0.CO;2-7; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; Liu DR, 1999, P NATL ACAD SCI USA, V96, P4780, DOI 10.1073/pnas.96.9.4780; MENDEL D, 1995, ANNU REV BIOPH BIOM, V24, P435, DOI 10.1146/annurev.biophys.24.1.435; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Sakamoto K, 2002, NUCLEIC ACIDS RES, V30, P4692, DOI 10.1093/nar/gkf589; Srinivasan G, 2002, SCIENCE, V296, P1459, DOI 10.1126/science.1069588; TREZEGUET V, 1991, MOL CELL BIOL, V11, P2744, DOI 10.1128/MCB.11.5.2744; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; Wang L, 2003, P NATL ACAD SCI USA, V100, P56, DOI 10.1073/pnas.0234824100; Wang L, 2002, CHEM COMMUN, P1, DOI 10.1039/b108185n; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; ZHANG Z, 2003, BIOCHEMISTRY-US, V42, pL375; Zhang ZW, 2002, ANGEW CHEM INT EDIT, V41, P2840, DOI 10.1002/1521-3773(20020802)41:15<2840::AID-ANIE2840>3.0.CO;2-#; [No title captured]	41	606	749	9	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					964	967		10.1126/science.1084772	http://dx.doi.org/10.1126/science.1084772			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920298				2022-12-24	WOS:000184755900039
J	Whitney, D; Goltz, HC; Thomas, CG; Gati, JS; Menon, RS; Goodale, MA				Whitney, D; Goltz, HC; Thomas, CG; Gati, JS; Menon, RS; Goodale, MA			Flexible retinotopy: Motion-dependent position coding in the visual cortex	SCIENCE			English	Article							PERCEIVED POSITION; STRIATE CORTEX; ATTENTION; REPRESENTATION; PERCEPTION; FIELD; OBJECTS; MONKEYS; NEURONS; HUMANS	Although the visual cortex is organized retinotopically, it is not clear whether the cortical representation of position necessarily reflects perceived position. Using functional magnetic resonance imaging (fMRI), we show that the retinotopic representation of a stationary object in the cortex was systematically shifted when visual motion was present in the scene. Whereas the object could appear shifted in the direction of the visual motion, the representation of the object in the visual cortex was always shifted in the opposite direction. The results show that the representation of position in the primary visual cortex, as revealed by fMRI, can be dissociated from perceived location.	Univ Western Ontario, Dept Psychol, London, ON N6A 5C2, Canada; John P Robarts Res Inst, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Whitney, D (corresponding author), Univ Western Ontario, Dept Psychol, London, ON N6A 5C2, Canada.		Menon, Ravi/ABA-8654-2020; Goodale, Melvyn A/M-5907-2013; Menon, Ravi S/K-5500-2013; Gati, Joseph S/K-5476-2013	Menon, Ravi/0000-0002-7916-0263; Goodale, Melvyn A/0000-0001-6748-0561; Menon, Ravi S/0000-0002-7916-0263; Thomas, Christopher/0000-0002-5209-8797; Goltz, Herbert/0000-0002-6496-754X	NATIONAL EYE INSTITUTE [F32EY013899] Funding Source: NIH RePORTER; NEI NIH HHS [F32 EY013899-01, F32 EY013899, F32 EY013899-03, F32 EY013899-02] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BATTAGLINI PP, 1993, ARCH ITAL BIOL, V131, P303; Berry MJ, 1999, NATURE, V398, P334, DOI 10.1038/18678; BEX PJ, 1995, VISION RES, V35, P2539, DOI 10.1016/0042-6989(95)00060-D; Brefczynski JA, 1999, NAT NEUROSCI, V2, P370, DOI 10.1038/7280; BURR D, 1980, NATURE, V284, P164, DOI 10.1038/284164a0; CAVANAGH P, 1992, SCIENCE, V257, P1563, DOI 10.1126/science.1523411; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; DEVALOIS RL, 1991, VISION RES, V31, P1619, DOI 10.1016/0042-6989(91)90138-U; Fu YX, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-20-j0003.2001; Georgeson MA, 2002, P ROY SOC B-BIOL SCI, V269, P1429, DOI 10.1098/rspb.2002.2029; Kirschfeld K, 1999, VISION RES, V39, P3702, DOI 10.1016/S0042-6989(99)00089-9; LAMME VAF, 1993, NATURE, V363, P541, DOI 10.1038/363541a0; Musseler J, 1998, PERCEPT PSYCHOPHYS, V60, P683, DOI 10.3758/BF03206055; Nishida S, 1999, NATURE, V397, P610, DOI 10.1038/17600; RAMACHAN.VS, 1974, PERCEPTION, V3, P97, DOI 10.1068/p030097; RAMACHANDRAN VS, 1990, PERCEPTION, V19, P611, DOI 10.1068/p190611; Reppas JB, 1997, NATURE, V388, P175, DOI 10.1038/40633; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Snowden RJ, 1998, CURR BIOL, V8, P1343, DOI 10.1016/S0960-9822(07)00567-2; Somers DC, 1999, P NATL ACAD SCI USA, V96, P1663, DOI 10.1073/pnas.96.4.1663; Stasheff SF, 2002, J NEUROPHYSIOL, V88, P1026, DOI 10.1152/jn.2002.88.2.1026; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981; Tootell RBH, 1998, NEURON, V21, P1409, DOI 10.1016/S0896-6273(00)80659-5; Tootell RBH, 1998, P NATL ACAD SCI USA, V95, P811, DOI 10.1073/pnas.95.3.811; Verstraten FAJ, 2000, VISION RES, V40, P3651, DOI 10.1016/S0042-6989(00)00213-3; VIRSU V, 1979, EXP BRAIN RES, V37, P475; Whitaker D, 1999, VISION RES, V39, P2999, DOI 10.1016/S0042-6989(99)00010-3; Whitney D, 2000, NAT NEUROSCI, V3, P954, DOI 10.1038/78878; WILSON JR, 1976, J NEUROPHYSIOL, V39, P512, DOI 10.1152/jn.1976.39.3.512	29	98	98	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 31	2003	302	5646					878	881		10.1126/science.1087839	http://dx.doi.org/10.1126/science.1087839			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737XQ	14500849	Green Accepted			2022-12-24	WOS:000186258000053
J	Hypponen, E; Smith, GD; Power, C				Hypponen, E; Smith, GD; Power, C			Effects of grandmothers' smoking in pregnancy on birth weight: intergenerational cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY REVASCULARIZATION; FOLLOW-UP; ANGINA; WHITEHALL; ABNORMALITIES; TRANSMISSION; ASSOCIATION; VARIABILITY; MANAGEMENT; GUIDELINE	Objective To investigate the influences on birth weight of maternal smoking during pregnancy across generations. Design Intergenerational cohort study. Participants Members of the 1958 birth cohort and their offspring and mothers. Setting England, Scotland, and Wales. Main outcome measure Birth weight. Results Information on grandmothers' smoking during pregnancy was available for 9028 singleton offspring of 4302 female cohort members. Assuming heritable transmission through the intergenerational birth weight association, grandmothers' smoking was predicted to result in a 34 g reduction (95% confidence interval - 41 g to - 28 g) in the birth weight of grandchildren. Random effects models showed a negative association between grandmothers' smoking and birth weight of grandchildren (Beta regression coefficient - 24 g, - 50 g to 3 g), but this effect was eliminated after adjustment for maternal smoking (0 g, - 26 g to 26 g). No association was evident among if the offspring of non-smoking mothers G 105; 14 17 g to 46 g), and after adjustment for maternal birth weight and height and body mass index as adults, grandmothers' smoking was positively associated with the birth weight of grandchildren (45 g, 10 g to 80 g). Conclusion Deficits in mothers' birth weight attributable to their mother smoking was not evident in the grandchildren.	Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of London; University College London; University of Bristol	Hypponen, E (corresponding author), Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.	e.hypponen@ich.ucl.ac.uk	Hypponen, Elina/B-2596-2014; Davey Smith, George/A-7407-2013	Hypponen, Elina/0000-0003-3670-9399; Davey Smith, George/0000-0002-1407-8314				Butler N.R., 1963, PERINATAL MORTALITY; BUTLER NR, 1969, PERINATAL PROBLEMS; CLARKE KW, 1994, BRIT HEART J, V71, P38; *CTR LONG STUD I E, 1994, SN3148 CTR LONG STUD; Daviglus ML, 1999, JAMA-J AM MED ASSOC, V281, P530, DOI 10.1001/jama.281.6.530; *DEP HLTH, 2000, NAT SERV RAM COR HEA; Eccles M, 2001, FAM PRACT, V18, P217, DOI 10.1093/fampra/18.2.217; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; FERRI E, 1993, LIFE 33 5 FOLLOW UP; FERRI E, 1993, LIFE 33 5 FOLLOW NAT; FOGELMAN KR, 1988, BRIT MED J, V297, P1233, DOI 10.1136/bmj.297.6658.1233; Gardner K, 1999, BRIT MED J, V319, P418, DOI 10.1136/bmj.319.7207.418; Gibbons RJ, 2003, CIRCULATION, V107, P149, DOI 10.1161/01.CIR.0000047041.66447.29; Hemingway H, 2000, J EPIDEMIOL COMMUN H, V54, P510, DOI 10.1136/jech.54.7.510; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; Hennessy E, 1998, PAEDIATR PERINAT EP, V12, P45, DOI 10.1046/j.1365-3016.1998.0120s1045.x; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Lake JK, 1997, ARCH DIS CHILD, V77, P376, DOI 10.1136/adc.77.5.376; Lampe FC, 1999, J CLIN EPIDEMIOL, V52, P73, DOI 10.1016/S0895-4356(98)00146-2; Lampe FC, 2001, AM J EPIDEMIOL, V153, P1173, DOI 10.1093/aje/153.12.1173; LAST JM, 1963, LANCET, V2, P28; LUMEY LH, 1994, INT J EPIDEMIOL, V23, P1006, DOI 10.1093/ije/23.5.1006; Macfarlane PW, 1996, J ELECTROCARDIOL, V29, P29, DOI 10.1016/S0022-0736(96)80016-1; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Martin RM, 2002, HEART, V88, P627, DOI 10.1136/heart.88.6.627; MCCORMICK A, 1995, MORBIDITY STAT GEN P; OUNSTED M, 1986, ANN HUM BIOL, V13, P143, DOI 10.1080/03014468600008281; Pocock SJ, 2000, J AM COLL CARDIOL, V35, P907, DOI 10.1016/S0735-1097(99)00637-3; Power C, 2002, INT J EPIDEMIOL, V31, P413, DOI 10.1093/ije/31.2.413; Price KC, 1999, OBSTET GYNECOL, V94, P128, DOI 10.1016/S0029-7844(99)00269-0; Ramakrishnan U, 1999, J NUTR, V129, p544S, DOI 10.1093/jn/129.2.544S; Richards H, 2000, J EPIDEMIOL COMMUN H, V54, P714, DOI 10.1136/jech.54.9.714; ROSE G, 1968, BRIT J PREV SOC MED, V22, P12; Rose G, 1982, CARDIOVASCULAR SURVE; Sanderson M, 1998, AM J EPIDEMIOL, V147, P136; Stafford M, 1998, J EPIDEMIOL COMMUN H, V52, P353, DOI 10.1136/jech.52.6.353; Stein AD, 2000, HUM BIOL, V72, P641; SUSSER M, 1994, NUTR REV, V52, P84, DOI 10.1111/j.1753-4887.1994.tb01395.x; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Ware J., 1993, SF 36 HLTH SURVEY MA	40	27	27	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2003	327	7420					898	900A		10.1136/bmj.327.7420.898	http://dx.doi.org/10.1136/bmj.327.7420.898			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563745	Green Published, Bronze			2022-12-24	WOS:000186072100017
J	Schiestl, FP; Peakall, R; Mant, JG; Ibarra, F; Schulz, C; Franke, S; Francke, W				Schiestl, FP; Peakall, R; Mant, JG; Ibarra, F; Schulz, C; Franke, S; Francke, W			The chemistry of sexual deception in an orchid-wasp pollination system	SCIENCE			English	Article							ORGANIC MASS SPECTROMETRY; ATTRACTION; VOLATILES	The "sexually deceptive" orchid Chiloglottis trapeziformis attracts males of its pollinator species, the thynnine wasp Neozeleboria cryptoides, by emitting a unique volatile compound, 2-ethyl-5-propylcyclohexan-1,3-dione, which is also produced by female wasps as a male-attracting sex pheromone.	Univ Hamburg, Inst Organ Chem, D-20146 Hamburg, Germany; Australian Natl Univ, Sch Bot & Zool, Canberra, ACT 0200, Australia	University of Hamburg; Australian National University	Francke, W (corresponding author), Univ Hamburg, Inst Organ Chem, Martin Luther King Pl 6, D-20146 Hamburg, Germany.		Peakall, Rod/C-9623-2009	Peakall, Rod/0000-0001-9407-8404; Schiestl, Florian/0000-0001-7637-6918				ATTYGALLE AB, 1988, ANGEW CHEM INT EDIT, V27, P460, DOI 10.1002/anie.198804601; ATTYGALLE AB, 1994, PURE APPL CHEM, V66, P2323, DOI 10.1351/pac199466102323; Ayasse M, 2003, P ROY SOC B-BIOL SCI, V270, P517, DOI 10.1098/rspb.2002.2271; Bower CC, 1996, AUST J BOT, V44, P15, DOI 10.1071/BT9960015; DAFNI A, 1990, EVOL BIOL, V24, P193; Kullenberg B., 1961, STUDIES OPHRYS POLLI; Mant JG, 2002, EVOLUTION, V56, P888; Pichersky E, 2002, CURR OPIN PLANT BIOL, V5, P237, DOI 10.1016/S1369-5266(02)00251-0; RAGUSO RA, COGNITIVE ECOLOGY PO, p8O; Schiestl FP, 1999, NATURE, V399, P421, DOI 10.1038/20829; Schiestl FP, 2000, J COMP PHYSIOL A, V186, P567, DOI 10.1007/s003590000112; Schiestl FP, 2002, MOLEC METH PLAN ANAL, V21, P173; Stensmyr MC, 2002, NATURE, V420, P625, DOI 10.1038/420625a; VANDEWAL.M, 1967, B SOC CHIM BELG, V76, P111; VANDEWALLE M, 1967, B SOC CHIM BELG, V76, P123; VOGEL S, 1983, ENCY PLANT PHYSL C, V12, P560; Wong BBM, 2002, P ROY SOC B-BIOL SCI, V269, P1529, DOI 10.1098/rspb.2002.2052	17	256	275	2	114	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					437	438		10.1126/science.1087835	http://dx.doi.org/10.1126/science.1087835			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564006				2022-12-24	WOS:000185963200040
J	Deleault, NR; Lucassen, RW; Supattapone, S				Deleault, NR; Lucassen, RW; Supattapone, S			RNA molecules stimulate prion protein conversion	NATURE			English	Article							NUCLEOCAPSID PROTEIN; AMPLIFICATION; HIV-1	Much evidence supports the hypothesis that the infectious agents of prion diseases are devoid of nucleic acid, and instead are composed of a specific infectious protein(1). This protein, PrPSc, seems to be generated by template-induced conformational change of a normally expressed glycoprotein, PrPC (ref. 2). Although numerous studies have established the conversion of PrPC to PrPSc as the central pathogenic event of prion disease, it is unknown whether cellular factors other than PrPC might be required to stimulate efficient PrPSc production. We investigated the biochemical amplification of protease-resistant PrPSc-like protein (PrPres) using a modified version(3) of the protein-misfolding cyclic amplification method(4). Here we report that stoichiometric transformation of PrPC to PrPres in vitro requires specific RNA molecules. Notably, whereas mammalian RNA preparations stimulate in vitro amplification of PrPres, RNA preparations from invertebrate species do not. Our findings suggest that host-encoded stimulatory RNA molecules may have a role in the pathogenesis of prion disease. They also provide a practical approach to improve the sensitivity of diagnostic techniques based on PrPres amplification.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Supattapone, S (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.							BANKS GR, 1974, EUR J BIOCHEM, V47, P499, DOI 10.1111/j.1432-1033.1974.tb03718.x; Caughey B, 1999, METHOD ENZYMOL, V309, P122; Chapon C, 1997, RNA, V3, P1337; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Derrington E, 2002, CR BIOL, V325, P17, DOI 10.1016/S1631-0691(02)01388-4; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LOCKARD RE, 1981, NUCLEIC ACIDS RES, V9, P5125, DOI 10.1093/nar/9.19.5125; Lucassen R, 2003, BIOCHEMISTRY-US, V42, P4127, DOI 10.1021/bi027218d; Moscardini M, 2002, J MOL BIOL, V318, P149, DOI 10.1016/S0022-2836(02)00092-X; Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1999, PRION BIOL DIS; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	16	411	438	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					717	720		10.1038/nature01979	http://dx.doi.org/10.1038/nature01979			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562104				2022-12-24	WOS:000185924500042
J	Yang, H; Luo, GB; Karnchanaphanurach, P; Louie, TM; Rech, I; Cova, S; Xun, LY; Xie, XS				Yang, H; Luo, GB; Karnchanaphanurach, P; Louie, TM; Rech, I; Cova, S; Xun, LY; Xie, XS			Protein conformational dynamics probed by single-molecule electron transfer	SCIENCE			English	Article							NAD(P)H-FLAVIN OXIDOREDUCTASE; ANOMALOUS DIFFUSION; ESCHERICHIA-COLI; KINETICS; PHOTON; RELAXATION	Electron transfer is used as a probe for angstrom-scale structural changes in single protein molecules. In a flavin reductase, the fluorescence of flavin is quenched by a nearby tyrosine residue by means of photo-induced electron transfer. By probing the fluorescence lifetime of the single flavin on a photon-by-photon basis, we were able to observe the variation of flavin-tyrosine distance over time. We could then determine the potential of mean force between the flavin and the tyrosine, and a correlation analysis revealed conformational fluctuation at multiple time scales spanning from hundreds of microseconds to seconds. This phenomenon suggests the existence of multiple interconverting conformers related to the fluctuating catalytic reactivity.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Politecn Milan, Dept Elect & Informat, I-20133 Milan, Italy; CNR, Ctr Elettron Quantist & Strumentaz Elettron, I-20133 Milan, Italy	Harvard University; Washington State University; Polytechnic University of Milan; Consiglio Nazionale delle Ricerche (CNR)	Xie, XS (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	xie@chemistry.harvard.edu	Pakawatpanurut, Pasit/E-5419-2010; Yang, Haw/AHD-0857-2022	Pakawatpanurut, Pasit/0000-0002-7657-4161; Yang, Haw/0000-0003-0268-6352; Rech, Ivan/0000-0002-1430-1010	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061577] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM61577-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; BOUCHAUD JP, 1990, PHYS REP, V195, P127, DOI 10.1016/0370-1573(90)90099-N; COVA S, 1989, REV SCI INSTRUM, V60, P1104, DOI 10.1063/1.1140324; Cova S, 1996, APPL OPTICS, V35, P1956, DOI 10.1364/AO.35.001956; Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740; Edman L, 1996, P NATL ACAD SCI USA, V93, P6710, DOI 10.1073/pnas.93.13.6710; Eggeling C, 1998, P NATL ACAD SCI USA, V95, P1556, DOI 10.1073/pnas.95.4.1556; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; GEHLEN JN, 1994, SCIENCE, V263, P499, DOI 10.1126/science.263.5146.499; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; Ingelman M, 1999, BIOCHEMISTRY-US, V38, P7040, DOI 10.1021/bi982849m; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; Jia YW, 1997, P NATL ACAD SCI USA, V94, P7932, DOI 10.1073/pnas.94.15.7932; Jortner J., 1999, ELECT TRANSFER ISOLA, V106; KLEINFELD D, 1984, BIOCHEMISTRY-US, V23, P5780, DOI 10.1021/bi00319a017; KOLLNER M, 1992, CHEM PHYS LETT, V200, P199, DOI 10.1016/0009-2614(92)87068-Z; Louie TM, 2002, J BIOL CHEM, V277, P39450, DOI 10.1074/jbc.M206339200; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Lu HP, 1997, J PHYS CHEM B, V101, P2753, DOI 10.1021/jp9634518; MARCHI M, 1993, J AM CHEM SOC, V115, P4178, DOI 10.1021/ja00063a041; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; Mataga N, 2000, J PHYS CHEM B, V104, P10667, DOI 10.1021/jp002145y; MCCAMMON JA, 1979, BIOCHEMISTRY-US, V18, P927, DOI 10.1021/bi00573a001; Metzler R, 2000, PHYS REP, V339, P1, DOI 10.1016/S0370-1573(00)00070-3; Metzler R, 1999, PHYS REV LETT, V82, P3563, DOI 10.1103/PhysRevLett.82.3563; Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Nie SM, 1997, ANNU REV BIOPH BIOM, V26, P567, DOI 10.1146/annurev.biophys.26.1.567; SIDERS P, 1984, J CHEM PHYS, V81, P5613, DOI 10.1063/1.447665; Van Den Berg PAW, 2001, SPR S FLUOR, V1, P457; van Oijen AM, 2003, SCIENCE, V301, P1235, DOI 10.1126/science.1084387; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361; Xie XS, 1998, ANNU REV PHYS CHEM, V49, P441, DOI 10.1146/annurev.physchem.49.1.441; Yang H, 2002, J CHEM PHYS, V117, P10965, DOI 10.1063/1.1521154; Zhong DP, 2001, P NATL ACAD SCI USA, V98, P11867, DOI 10.1073/pnas.211440398; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	39	736	748	2	228	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					262	266		10.1126/science.1086911	http://dx.doi.org/10.1126/science.1086911			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551431				2022-12-24	WOS:000185825900035
J	Ho, AS; Sung, JJY; Chan-Yeung, M				Ho, AS; Sung, JJY; Chan-Yeung, M			An outbreak of severe acute respiratory syndrome among hospital workers in a community hospital in Hong Kong	ANNALS OF INTERNAL MEDICINE			English	Article							CORONAVIRUS; SARS; IDENTIFICATION; TRANSMISSION	Background: During outbreaks, hospital workers are at high risk for nosocomial infection with severe acute respiratory syndrome (SARS)-associated coronavirus. Objective: To examine how hospital workers became infected and whether they transmit the virus to their families. Design: Retrospective descriptive study. Setting: 529-bed community hospital in Hong Kong. Patients: 40 hospital workers infected with SARS-associated coronavirus over a 6-week period (25 March through 5 May 2003). Measurements: Percentage of infected hospital workers according to job category. Results: The cumulative incidence was highest among health care assistants, followed by physicians and nurses (8%, 5%, and 4%, respectively). Most hospital workers were infected from direct contact with patients with SARS, who primarily were in general wards and had unsuspected infection. At the time of contact, all hospital workers had used masks but not necessarily other protective devices. Affected hospital workers did not infect their families. Conclusion: Before isolation of all patients with clinically confirmed or suspected SARS, routine use of several protective devices, and training of staff in infection control, many health care workers were infected with SARS from patients with unsuspected cases.	Chinese Univ Hong Kong, Alice Ho Miu Ling Nethersole Hosp, Sha Tin 100083, Peoples R China; Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China	Alice Ho Miu Ling Nethersole Hospital; Chinese University of Hong Kong; University of Hong Kong	Chan-Yeung, M (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, 4-F Professorial Block, Hong Kong, Hong Kong, Peoples R China.	mmwchan@hkucc.hku.hk	Sung, Joseph J. Y./R-3203-2018	Sung, Joseph J. Y./0000-0003-3125-5199				*CDCP, 2003, CDC LAB SEQ GEN NEW; *DEP HLTH, AT PNEUM; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Dwosh HA, 2003, CAN MED ASSOC J, V168, P1415; *HOSP AUTH HONG KO, 2003, SEV AC RESP SYND CAS; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; *PPHB, SUMM SEV AC RESP SAR; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666	16	78	79	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2003	139	7					564	567		10.7326/0003-4819-139-7-200310070-00008	http://dx.doi.org/10.7326/0003-4819-139-7-200310070-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729AP	14530227				2022-12-24	WOS:000185748800004
J	He, K; Merchant, A; Rimin, EB; Rosner, BA; Starripler, M; Willett, WC; Ascherio, A				He, K; Merchant, A; Rimin, EB; Rosner, BA; Starripler, M; Willett, WC; Ascherio, A			Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							FOOD FREQUENCY QUESTIONNAIRE; CORONARY-HEART-DISEASE; UNITED-STATES; CHOLESTEROL; ACID; MEN; ATHEROSCLEROSIS; REPRODUCIBILITY; PROTECTION; VALIDITY		Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	He, K (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Robles-Sardin, Alma E/M-7714-2015; Merchant, Anwar/B-5233-2009	Robles-Sardin, Alma E/0000-0003-2044-7793; 	NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DECATERINA R, 1994, ARTERIOSCLER THROMB, V14, P1829, DOI 10.1161/01.ATV.14.11.1829; DRISS F, 1984, THROMB RES, V36, P389, DOI 10.1016/0049-3848(84)90295-0; ENIG MG, 1983, J AM OIL CHEM SOC, V60, P1788, DOI 10.1007/BF02680357; Gillman MW, 1997, JAMA-J AM MED ASSOC, V278, P2145, DOI 10.1001/jama.278.24.2145; He K, 2002, JAMA-J AM MED ASSOC, V288, P3130, DOI 10.1001/jama.288.24.3130; HEBERT PR, 1995, ARCH INTERN MED, V155, P50, DOI 10.1001/archinte.155.1.50; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; Iso H, 2002, STROKE, V33, P2086, DOI 10.1161/01.STR.0000023890.25066.50; Iso H, 2001, CIRCULATION, V103, P856, DOI 10.1161/01.CIR.103.6.856; KEANEY JF, 1995, PROG CARDIOVASC DIS, V38, P129, DOI 10.1016/S0033-0620(05)80003-9; KEARNEY JF, 1995, PROG CARDIOVASC DIS, V38, P129; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; LaBiche R, 2001, STROKE, V32, P855, DOI 10.1161/01.STR.32.4.855; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Qizilbash N, 1995, LANCET, V346, P1647; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1992, AM J EPIDEMIOL, V135, P1127, DOI [DOI 10.1093/OXFORDJOURNALS.AJE.A116211, DOI 10.1093/OXFORDJOUMALS.AJE.A116211]; SASAKI S, 1995, STROKE, V26, P783, DOI 10.1161/01.STR.26.5.783; SIMON JA, 1995, STROKE, V26, P778, DOI 10.1161/01.STR.26.5.778; SIMON JA, 1995, STROKE, V26, P788; SLOVER HT, 1985, J AM OIL CHEM SOC, V62, P775, DOI 10.1007/BF03028753; TELL GS, 1994, AM J EPIDEMIOL, V139, P979, DOI 10.1093/oxfordjournals.aje.a116947; Walker AE, 1981, STROKE S1, V12, P13; Weinfeld, 1981, STROKE S1, V12, pI13; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	28	131	136	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2003	327	7418					777	781		10.1136/bmj.327.7418.777	http://dx.doi.org/10.1136/bmj.327.7418.777			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729ZQ	14525873	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000185805100017
J	Gravel, S; Jackson, SP				Gravel, S; Jackson, SP			Increased genome instability in aging yeast	CELL			English	Editorial Material								In the September 26 issue of Science, McMurray and Gottschling (2003) report that aged yeast cells display high rates of loss of heterozygosity. Furthermore, they show that this reflects an impaired ability to correctly detect and repair DNA double-strand breaks. These results provide insights into how aging can engender genomic instability in eukaryotic cells.	Univ Cambridge, Inst Canc & Dev Biol, Wellcome Trust Canc Res UK, Cambridge CB2 1QR, England	Cancer Research UK; University of Cambridge	Gravel, S (corresponding author), Univ Cambridge, Inst Canc & Dev Biol, Wellcome Trust Canc Res UK, Cambridge CB2 1QR, England.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937				Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; LOEB LA, 1991, CANCER RES, V51, P3075; McMurray MA, 2003, SCIENCE, V301, P1908, DOI 10.1126/science.1087706; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6	6	2	2	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					1	2		10.1016/S0092-8674(03)00766-9	http://dx.doi.org/10.1016/S0092-8674(03)00766-9			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14531992	Bronze			2022-12-24	WOS:000185815500001
J	Guo, FQ; Okamoto, M; Crawford, NM				Guo, FQ; Okamoto, M; Crawford, NM			Identification of a plant nitric oxide synthase gene involved in hormonal signaling	SCIENCE			English	Article							ABSCISIC-ACID; STOMATAL CLOSURE; GENERATION; PROTEIN; NO	Nitric oxide ( NO) serves as a signal in plants. An Arabidopsis mutant (Atnos1) was identified that had impaired NO production, organ growth, and abscisic acid-induced stomatal movements. Expression of AtNOS1 with a viral promoter in Atnos1 mutant plants resulted in overproduction of NO. Purified AtNOS1 protein used the substrates arginine and nicotinamide adenine dinucleotide phosphate and was activated by Ca2+ and calmodulin-like mammalian endothelial nitric oxide synthase and neuronal nitric oxide synthase, yet it is a distinct enzyme with no sequence similarities to any mammalian isoform. Thus, AtNOS1 encodes a distinct nitric oxide synthase that regulates growth and hormonal signaling in plants.	Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Crawford, NM (corresponding author), Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA.	ncrawford@ucsd.edu	Okamoto, Mamoru/AAF-4265-2019; Bruening, Stefan/B-8505-2011	Okamoto, Mamoru/0000-0002-2989-607X; Guo, Fang-Qing/0000-0001-6889-394X	NIGMS NIH HHS [GM 40672] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040672, R29GM040672] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Beck KF, 1999, J EXP BIOL, V202, P645; Butt YKC, 2003, PLANTA, V216, P762, DOI 10.1007/s00425-002-00926-y; Chandok MR, 2003, CELL, V113, P469, DOI 10.1016/S0092-8674(03)00350-7; CHEN YJ, 1995, J BACTERIOL, V177, P5122, DOI 10.1128/jb.177.17.5122-5128.1995; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Desikan R, 2002, P NATL ACAD SCI USA, V99, P16314, DOI 10.1073/pnas.252461999; Forstermann U, 1998, FASEB J, V12, P773; Garcia-Mata C, 2003, TRENDS PLANT SCI, V8, P20, DOI 10.1016/S1360-1385(02)00009-2; Garcia-Mata C, 2002, PLANT PHYSIOL, V128, P790, DOI 10.1104/pp.011020; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Huang S, 1997, J NEUROCHEM, V69, P2516; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Lamattina L, 2003, ANNU REV PLANT BIOL, V54, P109, DOI 10.1146/annurev.arplant.54.031902.134752; Neill SJ, 2003, NEW PHYTOL, V159, P11, DOI 10.1046/j.1469-8137.2003.00804.x; Neill SJ, 2002, PLANT PHYSIOL, V128, P13, DOI 10.1104/pp.010707; Stohr C, 2002, J EXP BOT, V53, P2293, DOI 10.1093/jxb/erf110; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Wendehenne D, 2001, TRENDS PLANT SCI, V6, P177, DOI 10.1016/S1360-1385(01)01893-3	22	652	730	6	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					100	103		10.1126/science.1086770	http://dx.doi.org/10.1126/science.1086770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526079				2022-12-24	WOS:000185678500044
J	Ono, T; Losada, A; Hirano, M; Myers, MP; Neuwald, AF; Hirano, T				Ono, T; Losada, A; Hirano, M; Myers, MP; Neuwald, AF; Hirano, T			Differential contributions of condensin I and condensin II to mitotic chromosome architecture in vertebrate cells	CELL			English	Article							CHROMATID SEGREGATION; SISTER CHROMATIDS; 13S CONDENSIN; SMC PROTEINS; COMPLEX; COHESIN; XENOPUS; DNA; IDENTIFICATION; ORGANIZATION	The canonical condensin complex (henceforth condensin I) plays an essential role in mitotic chromosome assembly and segregation from yeast to humans. We report here the identification of a second condensin complex (condensin II) from vertebrate cells. Condensins I and II share the same pair of structural maintenance of chromosomes (SMC) subunits but contain different sets of non-SMC subunits. siRNA-mediated depletion of condensin I- or condensin II-specific subunits in HeLa cells produces a distinct, highly characteristic defect in chromosome morphology. Simultaneous depletion of both complexes causes the severest defect. In Xenopus egg extracts, condensin I function is predominant, but lack of condensin II results in the formation of irregularly shaped chromosomes. Condensins I and II show different distributions along the axis of chromosomes assembled in vivo and in vitro. We propose that the two condensin complexes make distinct mechanistic contributions to mitotic chromosome architecture in vertebrate cells.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Hirano, T (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd,POB 100, Cold Spring Harbor, NY 11724 USA.	hirano@cshl.org	Losada, Ana/H-5917-2015; Ono, Takao/C-6065-2017; Hirano, Tatsuya/F-6008-2011	Losada, Ana/0000-0001-5251-3383; Ono, Takao/0000-0002-0498-8293; Hirano, Tatsuya/0000-0002-4219-6473	NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM006747] Funding Source: NIH RePORTER; NCI NIH HHS [CA45508] Funding Source: Medline; NIGMS NIH HHS [GM53926] Funding Source: Medline; NLM NIH HHS [R01 LM006747, LM06747] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; Bhalla N, 2002, MOL BIOL CELL, V13, P632, DOI 10.1091/mbc.01-05-0264; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; Dietzel S, 2001, NAT CELL BIOL, V3, P767, DOI 10.1038/35087089; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Jessberger R, 2002, NAT REV MOL CELL BIO, V3, P767, DOI 10.1038/nrm930; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; Kitajima TS, 2003, SCIENCE, V300, P1152, DOI 10.1126/science.1083634; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Lavoie BD, 2002, J CELL BIOL, V156, P805, DOI 10.1083/jcb.200109056; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Losada A, 2000, J CELL BIOL, V150, P405, DOI 10.1083/jcb.150.3.405; MacCallum DE, 2002, MOL BIOL CELL, V13, P25, DOI 10.1091/mbc.01-09-0441; Maeshima K, 2003, DEV CELL, V4, P467, DOI 10.1016/S1534-5807(03)00092-3; Marshall WF, 2001, CURR BIOL, V11, P569, DOI 10.1016/S0960-9822(01)00180-4; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400; OHNUKI Y, 1968, CHROMOSOMA, V25, P402, DOI 10.1007/BF02327721; Poirier MG, 2002, MOL BIOL CELL, V13, P2170, DOI 10.1091/mbc.01-08-0401; Prieto I, 2001, NAT CELL BIOL, V3, P761, DOI 10.1038/35087082; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; Revenkova E, 2001, MOL CELL BIOL, V21, P6984, DOI 10.1128/MCB.21.20.6984-6998.2001; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Sakai A, 2003, EMBO J, V22, P2764, DOI 10.1093/emboj/cdg247; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Schmiesing JA, 2000, MOL CELL BIOL, V20, P6996, DOI 10.1128/MCB.20.18.6996-7006.2000; Siddiqui NU, 2003, DEVELOPMENT, V130, P3283, DOI 10.1242/dev.00542; Stear JH, 2002, GENE DEV, V16, P1498, DOI 10.1101/gad.989102; Steffensen S, 2001, CURR BIOL, V11, P295, DOI 10.1016/S0960-9822(01)00096-3; Stray JE, 2003, J BIOL CHEM, V278, P26238, DOI 10.1074/jbc.M302699200; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sumner AT., 2003, CHROMOSOMES ORG FUNC; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	52	381	408	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					109	121		10.1016/S0092-8674(03)00724-4	http://dx.doi.org/10.1016/S0092-8674(03)00724-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532007	Bronze			2022-12-24	WOS:000185815500013
J	Ringler, P; Schulz, GE				Ringler, P; Schulz, GE			Self-assembly of proteins into designed networks	SCIENCE			English	Article							CRYSTAL-STRUCTURE; RESOLUTION; DNA	A C-4-symmetric tetrameric aldolase was used to produce a quadratic network consisting of the enzyme as a rigid four-way connector and stiff streptavidin rods as spacers. Each aldolase subunit was furnished with a His 6 tag for oriented binding to a planar surface and two tethered biotins for binding streptavidin in an oriented manner. The networks were improved by starting with composite units and also by binding to nickel-nitrilotriacetic acid-lipid monolayers. The mesh was adjustable in 5-nanometer increments. The production of a net with switchable mesh was initiated with the use of a calcium ion-containing beta-helix spacer that denatured on calcium ion depletion.	Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany	University of Freiburg	Schulz, GE (corresponding author), Univ Freiburg, Inst Organ Chem & Biochem, Albertstr 21, D-79104 Freiburg, Germany.	schulz@bio.chemie.uni-freiburg.de						BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Bischler N, 1998, BIOPHYS J, V74, P1522, DOI 10.1016/S0006-3495(98)77864-6; CHALCROFT JP, 1987, FEBS LETT, V211, P53, DOI 10.1016/0014-5793(87)81273-5; Dotan N, 1999, ANGEW CHEM INT EDIT, V38, P2363, DOI 10.1002/(SICI)1521-3773(19990816)38:16<2363::AID-ANIE2363>3.3.CO;2-4; Drexler KE, 1999, TRENDS BIOTECHNOL, V17, P5, DOI 10.1016/S0167-7799(98)01278-5; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; Keren K, 2002, SCIENCE, V297, P72, DOI 10.1126/science.1071247; Kroemer M, 2002, ACTA CRYSTALLOGR D, V58, P824, DOI 10.1107/S0907444902004614; Michl J, 2002, P NATL ACAD SCI USA, V99, P4788, DOI 10.1073/pnas.052016299; MORALES P, 1995, MAT SCI ENG C-BIOMIM, V2, P173, DOI 10.1016/0928-4931(95)00056-9; Padilla JE, 2001, P NATL ACAD SCI USA, V98, P2217, DOI 10.1073/pnas.041614998; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; Reviakine I, 1998, J STRUCT BIOL, V121, P356, DOI 10.1006/jsbi.1998.4003; Richard C, 2003, SCIENCE, V300, P775, DOI 10.1126/science.1080848; Ringler P, 2002, CHEMBIOCHEM, V3, P463, DOI 10.1002/1439-7633(20020503)3:5<463::AID-CBIC463>3.0.CO;2-P; Scheuring S, 1999, J MICROSC-OXFORD, V193, P28, DOI 10.1046/j.1365-2818.1999.00434.x; Seeman NC, 2003, NATURE, V421, P427, DOI 10.1038/nature01406; Service RF, 2002, SCIENCE, V298, P2322, DOI 10.1126/science.298.5602.2322; Sleytr UB, 2002, PROG COLL POL SCI S, V121, P57; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Whitesides GM, 2002, P NATL ACAD SCI USA, V99, P4769, DOI 10.1073/pnas.082065899; WIESMANN C, 1995, STRUCTURE, V3, P961, DOI 10.1016/S0969-2126(01)00230-1; Yeates TO, 2002, CURR OPIN STRUC BIOL, V12, P464, DOI 10.1016/S0959-440X(02)00350-0	24	238	255	0	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					106	109		10.1126/science.1088074	http://dx.doi.org/10.1126/science.1088074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526081				2022-12-24	WOS:000185678500046
J	Parker, GA; Chubb, JC; Ball, MA; Roberts, GN				Parker, GA; Chubb, JC; Ball, MA; Roberts, GN			Evolution of complex life cycles in helminth parasites	NATURE			English	Article							REPRODUCTION; GROWTH	The fundamental question of how complex life cycles-where there is typically more than one host-evolve in host-parasite systems remains largely unexplored. We suggest that complex cycles in helminths without penetrative infective stages evolve by two essentially different processes, depending on where in the cycle a new host is inserted. In 'upward incorporation', a new definitive host, typically higher up a food web and which preys on the original definitive host, is added. Advantages to the parasite are avoidance of mortality due to the predator, greater body size at maturity and higher fecundity. The original host typically becomes an intermediate host, in which reproduction is suppressed. In 'downward incorporation', a new intermediate host is added at a lower trophic level; this reduces mortality and facilitates transmission to the original definitive host. These two processes should also apply in helminths with penetrative infective stages, although the mathematical conditions differ.	Univ Liverpool, Sch Biol Sci, Populat & Evolut Biol Res Grp, Liverpool L69 7ZB, Merseyside, England; Univ Liverpool, Dept Math Sci, Div Appl Math, Liverpool L69 3BX, Merseyside, England	University of Liverpool; University of Liverpool	Parker, GA (corresponding author), Univ Liverpool, Sch Biol Sci, Populat & Evolut Biol Res Grp, Liverpool L69 7ZB, Merseyside, England.	gap@liverpool.ac.uk	Parker, Geoff/C-4337-2008	Parker, Geoff/0000-0003-4795-6352				Anderson R. C., 2000, Nematode parasites of vertebrates: their development and transmission., DOI 10.1079/9780851994215.0000; BAER JG, 1952, ECOLOGY ANIMAL PARAS; BRIAND F, 1987, SCIENCE, V238, P956, DOI 10.1126/science.3672136; Brooks DR, 1993, PARASCRIPT PARASITES; Brown SP, 2001, J EVOLUTION BIOL, V14, P815, DOI 10.1046/j.1420-9101.2001.00318.x; Charnov Eric L., 1993, P1; EBERMAN B, 1992, AM NAT, V139, P990; Fernandez J.C, 1993, FUNCTIONAL BIOL PARA; Gemmill AW, 1999, J EVOLUTION BIOL, V12, P1148, DOI 10.1046/j.1420-9101.1999.00117.x; HARVEY PH, 1991, PHILOS T R SOC B, V332, P31, DOI 10.1098/rstb.1991.0030; KOZLOWSKI J, 1992, TRENDS ECOL EVOL, V7, P15, DOI 10.1016/0169-5347(92)90192-E; MACKIEWICZ JS, 1972, EXP PARASITOL, V31, P417, DOI 10.1016/0014-4894(72)90103-8; Matsuno K, 1996, J THEOR BIOL, V180, P105, DOI 10.1006/jtbi.1996.0085; MOLNAR K, 1968, FOLIA PARASIT, V14, P83; Morand S, 1996, FUNCT ECOL, V10, P210, DOI 10.2307/2389845; MORAND S, 1995, J ANIM ECOL, V64, P256, DOI 10.2307/5760; Moravec F., 1994, Parasitic nematodes of freshwater fishes of Europe.; Nickol B.B, 1985, BIOL ACANTHOCEPHALA; Parker GA, 2003, J EVOLUTION BIOL, V16, P47, DOI 10.1046/j.1420-9101.2003.00504.x; Poulin R, 2002, TRENDS PARASITOL, V18, P176, DOI 10.1016/S1471-4922(02)02262-6; POULIN R, 1998, EVOLUTIONARY ECOLOGY; Price P.W., 1980, EVOLUTIONARY BIOL PA; REDI F, 1671, EXPT CIRC GENERATION; Roff Derek A., 1992; STUNKARD HW, 1946, BIOL REV, V21, P148, DOI 10.1111/j.1469-185X.1946.tb00321.x; [No title captured]	26	153	158	0	64	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					480	484		10.1038/nature02012	http://dx.doi.org/10.1038/nature02012			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523438				2022-12-24	WOS:000185648100036
J	Caudy, AA; Ketting, RF; Hammond, SM; Denli, AM; Bathoorn, AMP; Tops, BBJ; Silva, JM; Myers, MM; Hannon, GJ; Plasterk, RHA				Caudy, AA; Ketting, RF; Hammond, SM; Denli, AM; Bathoorn, AMP; Tops, BBJ; Silva, JM; Myers, MM; Hannon, GJ; Plasterk, RHA			A micrococcal nuclease homologue in RNAi effector complexes	NATURE			English	Article							STAPHYLOCOCCAL NUCLEASE; INTERFERENCE; COACTIVATOR; CELLS; ELEGANS; PROTEIN; P100; TRANSCRIPTION; CLEAVAGE; SIRNAS	RNA interference (RNAi) regulates gene expression by the cleavage of messenger RNA, by mRNA degradation and by preventing protein synthesis. These effects are mediated by a ribonucleoprotein complex known as RISC (RNA-induced silencing complex)(1). We have previously identified four Drosophila components (short interfering RNAs1, Argonaute 2 (ref. 2), VIG and FXR3) of a RISC enzyme that degrades specific mRNAs in response to a double-stranded-RNA trigger. Here we show that Tudor-SN (tudor staphylococcal nuclease)-a protein containing five staphylococcal/micrococcal nuclease domains and a tudor domain-is a component of the RISC enzyme in Caenorhabditis elegans, Drosophila and mammals. Although Tudor-SN contains non-canonical active-site sequences, we show that purified Tudor-SN exhibits nuclease activity similar to that of other staphylococcal nucleases. Notably, both purified Tudor-SN and RISC are inhibited by a specific competitive inhibitor of micrococcal nuclease. Tudor-SN is the first RISC subunit to be identified that contains a recognizable nuclease domain, and could therefore contribute to the RNA degradation observed in RNAi.	Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Cold Spring Harbor Laboratory	Hannon, GJ (corresponding author), Hubrecht Lab, Ctr Biomed Genet, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		Hannon, Gregory/AAB-3568-2019; Tops, Bastiaan/L-4697-2015	Ketting, Rene/0000-0001-6161-5621; Caudy, Amy/0000-0001-6307-8137; Tops, Bastiaan/0000-0002-1699-8210				Avalos RT, 1997, J VIROL, V71, P2947, DOI 10.1128/JVI.71.4.2947-2958.1997; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Callebaut I, 1997, BIOCHEM J, V321, P125, DOI 10.1042/bj3210125; Capodici J, 2002, J IMMUNOL, V169, P5196, DOI 10.4049/jimmunol.169.9.5196; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; CUATRECA.P, 1967, J BIOL CHEM, V242, P3063; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hirayoshi K, 1999, METHOD ENZYMOL, V304, P351; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Keenan TW, 2000, BBA-GEN SUBJECTS, V1523, P84, DOI 10.1016/S0304-4165(00)00106-9; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Ponting CP, 1997, PROTEIN SCI, V6, P459; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; TONG X, 1995, MOL CELL BIOL, V15, P4735	30	348	380	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					411	414		10.1038/nature01956	http://dx.doi.org/10.1038/nature01956			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508492				2022-12-24	WOS:000185502300044
J	Krummel, EM; Macdonald, RW; Kimpe, LE; Gregory-Eaves, I; Demers, MJ; Smol, JP; Finney, B; Blais, JM				Krummel, EM; Macdonald, RW; Kimpe, LE; Gregory-Eaves, I; Demers, MJ; Smol, JP; Finney, B; Blais, JM			Delivery of pollutants by spawning salmon - Fish dump toxic industrial compounds in Alaskan lakes on their return from the ocean.	NATURE			English	Editorial Material							POLYCHLORINATED-BIPHENYLS; PACIFIC SALMON; SEDIMENTS; IMPACTS		Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada; Inst Ocean Sci, Dept Fisheries & Oceans, Sidney, BC V8L 4B2, Canada; Queens Univ, Dept Biol, Paleoecol Environm Assessment & Res Lab, Kingston, ON K7L 3N6, Canada; Univ Alaska, Inst Marine Sci, Fairbanks, AK 99775 USA	University of Ottawa; Fisheries & Oceans Canada; Queens University - Canada; University of Alaska System; University of Alaska Fairbanks	Krummel, EM (corresponding author), Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada.	jblais@science.ottawa.ca	Blais, Jules/AAV-2321-2020; Macdonald, Robie W/A-7896-2012; Smol, John P/A-8838-2015; Gregory-Eaves, Irene/U-9325-2019	Blais, Jules/0000-0002-7188-3598; Macdonald, Robie W/0000-0002-1141-8520; Gregory-Eaves, Irene/0000-0002-0380-5061; Smol, John/0000-0002-2499-6696				Arkoosh MR, 1998, J AQUAT ANIM HEALTH, V10, P182, DOI 10.1577/1548-8667(1998)010&lt;0182:EOPOFD&gt;2.0.CO;2; Blais JM, 2003, ENVIRON TOXICOL CHEM, V22, P126, DOI [10.1002/etc.5620220116, 10.1897/1551-5028(2003)022&lt;0126:AACOPB&gt;2.0.CO;2]; Burgner R.L., 1991, P1; Ewald G, 1998, ARCTIC, V51, P40; Finney BP, 2000, SCIENCE, V290, P795, DOI 10.1126/science.290.5492.795; *IND NO AFF, 2003, CAN ARCT CONT ASS RE; IWATA H, 1993, ENVIRON SCI TECHNOL, V27, P1080, DOI 10.1021/es00043a007; MacDonald RW, 2000, SCI TOTAL ENVIRON, V254, P93, DOI 10.1016/S0048-9697(00)00434-4; Muir DCG, 1996, ENVIRON SCI TECHNOL, V30, P3609, DOI 10.1021/es960393v; Naiman RJ, 2002, ECOSYSTEMS, V5, P399, DOI 10.1007/s10021-001-0083-3	10	103	108	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					255	256		10.1038/425255a	http://dx.doi.org/10.1038/425255a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	13679906				2022-12-24	WOS:000185370900033
J	Goldacre, MJ; Roberts, SE; Yeates, D				Goldacre, MJ; Roberts, SE; Yeates, D			Case fatality rates for meningococcal disease in an English population, 1963-98: database study	BRITISH MEDICAL JOURNAL			English	Article							ACUTE BACTERIAL-MENINGITIS		Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.							Booy R, 2001, ARCH DIS CHILD, V85, P386, DOI 10.1136/adc.85.5.386; GOLDACRE MJ, 1976, INT J EPIDEMIOL, V5, P343, DOI 10.1093/ije/5.4.343; GOLDACRE MJ, 1976, LANCET, V1, P28; Sorensen HT, 1998, EUR J CLIN MICROBIOL, V17, P690, DOI 10.1007/s100960050162; Wylie PAL, 1997, BRIT MED J, V315, P774, DOI 10.1136/bmj.315.7111.774	5	40	40	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					596	597		10.1136/bmj.327.7415.596	http://dx.doi.org/10.1136/bmj.327.7415.596			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969927	Green Published, Bronze			2022-12-24	WOS:000185358700023
J	Wei, JN; Sung, FC; Lin, CC; Lin, RS; Chiang, CC; Chuang, LM				Wei, JN; Sung, FC; Lin, CC; Lin, RS; Chiang, CC; Chuang, LM			National surveillance for type 2 diabetes mellitus in Taiwanese children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGY; ADOLESCENTS; PREVALENCE; OBESITY; RISK	Context Despite a disturbing trend of increasing prevalence of type 2 diabetes mellitus (DM) in childhood, little is known about the epidemiology of childhood type 2 DM, especially in the Taiwanese population. Objective To study the rate and risk factors for childhood type 2 DM based on a nationwide screening program in Taiwan. Design, Setting, and Participants Screening in 1999 for type 2 DM using urine and blood testing and confirmed by follow-up telephone survey among schoolchildren aged 6 to 18 years in Taiwan, followed by a nested case-control study conducted in 2002 comparing 137 children with type 2 DM with 1000 randomly selected children without diabetes chosen to represent the age and sex distribution of the whole student population. Main Outcome Measures Rate and identification of risk factors associated with childhood type 2 DM. Results The rate of newly identified diabetes was 9.0 per 100000 for boys and 15.3 per 100000 for girls. Follow-up at 3 years revealed that, of 253 children with newly diagnosed diabetes, 24 (9.5%) had type 1 DM, 137 (54.2%) had type 2 DM, and 22 (8.7%) had secondary diabetes. Compared with children aged 6 to 9 years, the odds ratios (ORs) and 95% confidence intervals (CIs) of type 2 DM increased to 6.59 (3.23-13.4) for those aged 13 to 15 years and to 4.59 (2.07-10.2) for those aged 16 to 18 years. The OR (95% CI) of type 2 DM in children with a body mass index in the 95th percentile or higher (obesity) was 18.8 (9.22-38.5) compared with those with a body mass index in less than the 50th percentile. Other factors significantly associated with type 2 DM were hypercholesterolemia (OR, 1.80; 95% CI, 1.04-3.23), blood pressure greater than the 85th percentile (OR, 1.70; 95% CI, 1.07-2.70), and positive family history of diabetes (OR, 3.95; 95% CI, 2.01-7.78). Conclusions Our mass screening program showed that type 2 DM is the leading cause of childhood DM in Taiwan. Obesity is a major risk factor for the development of type 2 DM in children.	Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Publ Hlth, Inst Environm Hlth, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Publ Hlth, Inst Prevent Med, Taipei 10764, Taiwan; Chinese Fdn Hlth, Taipei, Taiwan; Chia Nan Univ Pharm & Sci, Tainan, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; Chia Nan University of Pharmacy & Science	Chuang, LM (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.	leeming@ha.mc.ntu.edu.tw	Chuang, Lee-Ming/AAF-3324-2019	CHUANG, LEE-MING/0000-0003-0978-2662				*AM DIAB ASS, 2003, DIABETES CARE S1, V26, pS21, DOI DOI 10.2337/DIACARE.26.2007.S21; ANDERSSON DKG, 1993, DIABETIC MED, V10, P167, DOI 10.1111/j.1464-5491.1993.tb00036.x; Berg AO, 2003, ANN INTERN MED, V138, P212, DOI 10.7326/0003-4819-138-3-200302040-00014; Bloomgarden ZT, 2000, DIABETES CARE, V23, P1584, DOI 10.2337/diacare.23.10.1584; Boyko EJ, 2000, DIABETES CARE, V23, P465, DOI 10.2337/diacare.23.4.465; Caprio S, 1999, ENDOCRIN METAB CLIN, V28, P731, DOI 10.1016/S0889-8529(05)70099-2; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Dabelea D, 1998, DIABETOLOGIA, V41, P904, DOI 10.1007/s001250051006; Dabelea D, 1999, ENDOCRIN METAB CLIN, V28, P709, DOI 10.1016/S0889-8529(05)70098-0; Dean H, 1998, CLIN PEDIATR, V37, P89, DOI 10.1177/000992289803700205; Fagot-Campagna A, 1999, CLIN CHIM ACTA, V286, P81, DOI 10.1016/S0009-8981(99)00095-9; Forum Health Promotion and Disease Prevention Committee, 2000, ASS CHILDR ANTHR ITS, P33; Friderichsen B, 1997, J PUBLIC HEALTH MED, V19, P55, DOI 10.1093/oxfordjournals.pubmed.a024588; Gavin JR, 1997, DIABETES CARE, V20, P1183; Goran MI, 2001, DIABETES, V50, P2444, DOI 10.2337/diabetes.50.11.2444; Harris SB, 1996, CAN FAM PHYSICIAN, V42, P869; Hosmer D. W., 1989, APPL LOGISTIC REGRES, P132; Jeruc J, 2000, WIEN KLIN WOCHENSCHR, V112, P702; KIDA K, 2003, TYPE 2 DIABETES CHIL; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; KITAGAWA T, 1994, DIABETES RES CLIN PR, V24, pS7, DOI 10.1016/0168-8227(94)90221-6; Kitagawa T, 1998, CLIN PEDIATR, V37, P111, DOI 10.1177/000992289803700208; Kwamura T, 1999, DIABETES, V48, pA168; Moran A, 1999, DIABETES, V48, P2039, DOI 10.2337/diabetes.48.10.2039; *NAT CHOL ED PROGR, 1992, PEDIATRICS, V89, P525; Neufeld ND, 1998, DIABETES CARE, V21, P80, DOI 10.2337/diacare.21.1.80; ORIT PH, 1996, J PEDIATR, V128, P608; OSULLIVAN JB, 1991, DIABETES, V40, P131, DOI 10.2337/diab.40.2.S131; PANDIT MK, 1993, ANN INTERN MED, V118, P529, DOI 10.7326/0003-4819-118-7-199304010-00008; Pihoker C, 1998, CLIN PEDIATR, V37, P97, DOI 10.1177/000992289803700206; Rosenbloom A, 2000, DIABETES CARE, V23, P381; Rosenbloom AL, 1999, DIABETES CARE, V22, P345, DOI 10.2337/diacare.22.2.345; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHINOZAKI T, 1999, JPN J PUBLIC HLTH, V46, P790; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; TAI TY, 1992, INT J EPIDEMIOL, V21, P511, DOI 10.1093/ije/21.3.511; van der Sande MAB, 1999, TROP MED INT HEALTH, V4, P506; Wei JN, 2003, DIABETES RES CLIN PR, V59, P201, DOI 10.1016/S0168-8227(02)00247-4; WILLI SM, 2000, CURR OPIN ENDOCRINOL, V7, P71; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	40	155	168	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2003	290	10					1345	1350		10.1001/jama.290.10.1345	http://dx.doi.org/10.1001/jama.290.10.1345			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DP	12966126	Bronze, Green Published			2022-12-24	WOS:000185188600027
J	Changela, A; Chen, K; Xue, Y; Holschen, J; Outten, CE; O'Halloran, TV; Mondragon, A				Changela, A; Chen, K; Xue, Y; Holschen, J; Outten, CE; O'Halloran, TV; Mondragon, A			Molecular basis of metal-ion selectivity and zeptomolar sensitivity by CueR	SCIENCE			English	Article							MERR METALLOREGULATORY PROTEIN; P-TYPE ATPASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL ACTIVATION; COPPER HOMEOSTASIS; RECEPTOR-SITE; OXIDASE; COPA; DNA	The earliest of a series of copper efflux genes in Escherichia coli are controlled by CueR, a member of the MerR family of transcriptional activators. Thermodynamic calibration of CueR reveals a zeptomolar (10(-21) molar) sensitivity to free Cu+, which is far less than one atom per cell. Atomic details of this extraordinary sensitivity and selectivity for +1 transition-metal ions are revealed by comparing the crystal structures of CueR and a Zn2+-sensing homolog, ZntR. An unusual buried metal-receptor site in CueR restricts the metal to a linear, two-coordinate geometry and uses helix-dipole and hydrogen-bonding interactions to enhance metal binding. This binding mode is rare among metalloproteins but well suited for an ultrasensitive genetic switch.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2205 Tech Dr, Evanston, IL 60208 USA.		Outten, Caryn E./I-9433-2019; O'Halloran, Thomas/ABE-6125-2021; Johnson, Michael D. L./B-4352-2012	Outten, Caryn E./0000-0003-0335-6531; O'Halloran, Thomas/0000-0001-8732-5059; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK061868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038784, R01GM038784, R29GM038784, R01GM051350] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK61868] Funding Source: Medline; NIGMS NIH HHS [GM51350, GM08382, R01 GM051350, GM38784] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Alderighi L, 1999, COORDIN CHEM REV, V184, P311, DOI 10.1016/S0010-8545(98)00260-4; CHEN K, IN PRESS J AM CHEM S; Corazza A, 1996, EUR J BIOCHEM, V236, P697, DOI 10.1111/j.1432-1033.1996.0697d.x; Demple B, 2002, METHOD ENZYMOL, V348, P355, DOI 10.1016/S0076-6879(02)48654-5; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; Godsey MH, 2001, J BIOL CHEM, V276, P47178, DOI 10.1074/jbc.M105819200; Grass G, 2001, BIOCHEM BIOPH RES CO, V286, P902, DOI 10.1006/bbrc.2001.5474; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; Hitomi Y, 2001, J AM CHEM SOC, V123, P8614, DOI 10.1021/ja016146v; Huffman DL, 2002, BIOCHEMISTRY-US, V41, P10046, DOI 10.1021/bi0259960; Khan S, 2002, BIOCHEM BIOPH RES CO, V299, P438, DOI 10.1016/S0006-291X(02)02660-8; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; MARTELL AE, 2001, NATL I STANDARDS TEC, V46; Noll M, 1998, J BIOL CHEM, V273, P21393, DOI 10.1074/jbc.273.33.21393; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OSTERBERG R, 1979, J INORG BIOCHEM, V10, P341, DOI 10.1016/S0162-0134(00)80200-7; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Outten FW, 2001, J BIOL CHEM, V276, P30670, DOI 10.1074/jbc.M104122200; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; Pesce A, 1997, J MOL BIOL, V274, P408, DOI 10.1006/jmbi.1997.1400; Petersen C, 2000, GENE, V261, P289, DOI 10.1016/S0378-1119(00)00509-6; RALSTON DM, 1990, P NATL ACAD SCI USA, V87, P3846, DOI 10.1073/pnas.87.10.3846; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Roberts SA, 2002, P NATL ACAD SCI USA, V99, P2766, DOI 10.1073/pnas.052710499; ROH JH, 1995, BIOCHEM BIOPH RES CO, V212, P1107, DOI 10.1006/bbrc.1995.2083; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P2340, DOI 10.1021/bi00431a053; Stoyanov JV, 2003, J BIOL CHEM, V278, P1407, DOI 10.1074/jbc.C200580200; Stoyanov JV, 2001, MOL MICROBIOL, V39, P502, DOI 10.1046/j.1365-2958.2001.02264.x; UTSCHIG LM, 1995, SCIENCE, V268, P380, DOI 10.1126/science.7716541; Wilmot CM, 1999, SCIENCE, V286, P1724, DOI 10.1126/science.286.5445.1724; WRIGHT JG, 1990, J AM CHEM SOC, V112, P2434, DOI 10.1021/ja00162a062	35	493	508	4	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1383	1387		10.1126/science.1085950	http://dx.doi.org/10.1126/science.1085950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958362				2022-12-24	WOS:000185116400043
J	Deffenbaugh, AE; Scaglione, KM; Zhang, LX; Moore, JM; Buranda, T; Sklar, LA; Skowyra, D				Deffenbaugh, AE; Scaglione, KM; Zhang, LX; Moore, JM; Buranda, T; Sklar, LA; Skowyra, D			Release of ubiquitin-charged Cdc34-S similar to Ub from the RING domain is essential for ubiquitination of the SCFCdc4-bound substrate Sic1	CELL			English	Article							CDC34 SELF-ASSOCIATION; CONJUGATING ENZYME; MULTIUBIQUITIN CHAIN; LIGASE COMPLEX; SACCHAROMYCES-CEREVISIAE; STRUCTURAL BASIS; TERMINAL DOMAIN; E2 ENZYME; F-BOX; SCF	The S. cerevisiae SCFCdc4 is a prototype of RING-type SCF E3s, which recruit substrates for polyubiquitination by the Cdc34 ubiquitin-conjugating enzyme. Current models propose that Cdc34 ubiquitinates the substrate while remaining bound to the RING domain. In contrast, we found that the formation of a ubiquitin thiol ester regulates the Cdc34/SCFCdc4 binding equilibrium by increasing the dissociation rate constant, with only a minor effect on the association rate. By using a F72VCdc34 mutant with increased affinity for the RING domain, we demonstrate that release of ubiquitin-charged Cdc34-Ssimilar toUb from the RING is essential for ubiquitination of the SCFCdc4-bound substrate Sic1. Release of ubiquitin-charged E2 from E3 prior to ubiquitin transfer is a previously unrecognized step in ubiquitination, which can explain both the modification of multiple lysines on the recruited substrate and the extension of polyubiquitin chains. We discuss implications of this finding for function of other ubiquitin ligases.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA	Saint Louis University; University of New Mexico	Skowyra, D (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.			Scaglione, Kenneth/0000-0002-3858-9418	NCI NIH HHS [CA88339] Funding Source: Medline; NIGMS NIH HHS [GM60799/EB00264, GM65267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA088339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065267, R24GM060799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; Buranda T, 1999, J PHYS CHEM B, V103, P3399, DOI 10.1021/jp983842h; Buranda T, 2001, ANAL BIOCHEM, V298, P151, DOI 10.1006/abio.2001.5363; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FELDMAN RM, 1997, CELL, V91, P149; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GOEBL MG, 1994, MOL CELL BIOL, V14, P3022, DOI 10.1128/MCB.14.5.3022; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PTAK C, 1994, J BIOL CHEM, V269, P26539; Ptak C, 2001, MOL CELL BIOL, V21, P6537, DOI 10.1128/MCB.21.19.6537-6548.2001; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Ulrich HD, 2003, J BIOL CHEM, V278, P7051, DOI 10.1074/jbc.M212195200; VanDemark AP, 2002, CURR OPIN STRUC BIOL, V12, P822, DOI 10.1016/S0959-440X(02)00389-5; Varelas X, 2003, MOL CELL BIOL, V23, P5388, DOI 10.1128/MCB.23.15.5388-5400.2003; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	48	75	76	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					611	622		10.1016/S0092-8674(03)00641-X	http://dx.doi.org/10.1016/S0092-8674(03)00641-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678584	Bronze			2022-12-24	WOS:000185193100010
J	Herrera, E; Brown, L; Aruga, J; Rachel, RA; Dolen, G; Mikoshiba, K; Brown, S; Mason, CA				Herrera, E; Brown, L; Aruga, J; Rachel, RA; Dolen, G; Mikoshiba, K; Brown, S; Mason, CA			Zic2 patterns binocular vision by specifying the uncrossed retinal projection	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; LIM HOMEOBOX GENES; OPTIC CHIASM; AXON DIVERGENCE; GANGLION-CELLS; TRANSCRIPTIONAL CODES; ALBINO FERRETS; VISUAL-SYSTEM; SPINAL-CORD; EXPRESSION	During CNS development, combinatorial expression of transcription factors controls neuronal subtype identity and subsequent axonal trajectory. Regulatory genes designating the routing of retinal ganglion cell (RGC) axons at the optic chiasm to the appropriate hemisphere, a pattern critical for proper binocular vision, have not been identified. Here, we show that the zinc finger transcription factor Zic2, a vertebrate homolog of the Drosophila gene odd-paired, is expressed in RGCs with an uncrossed trajectory during the period when this subpopulation grows from the ventrotemporal retina toward the optic chiasm. Loss-and gain-of-function analyses indicate that Zic2 is necessary and sufficient to regulate RGC axon repulsion by cues at the optic chiasm midline. Moreover, Zic2 expression reflects the extent of binocularity in different species, suggesting that Zic2 is an evolutionarily conserved determinant of RGCs that project ipsilaterally. These data provide evidence for transcriptional coding of axon pathfinding at the midline.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan	Columbia University; Columbia University; Columbia University; RIKEN	Mason, CA (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	cam4@columbia.edu	Herrera, Eloísa/A-5377-2008; Aruga, Jun/H-5837-2011; Mikoshiba, Katsuhiko/N-7943-2015; Dolen, Gul/J-3073-2015	Herrera, Eloísa/0000-0001-9525-5441; Aruga, Jun/0000-0001-7936-1375; Dolen, Gul/0000-0003-1780-995X	NATIONAL EYE INSTITUTE [T32EY013933, R01EY015290, R01EY012736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042730] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012736, EY12736, R01 EY015290, T32 EY013933] Funding Source: Medline; NINDS NIH HHS [NS42730] Funding Source: Medline; PHS HHS [P030532] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Aruga J, 2002, J NEUROSCI, V22, P218, DOI 10.1523/JNEUROSCI.22-01-00218.2002; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Brown LY, 2001, HUM MOL GENET, V10, P791, DOI 10.1093/hmg/10.8.791; BROWN LY, 2003, MECH DEVELOP, V3, P361; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Chalupa LM, 1998, J COMP NEUROL, V392, P35, DOI 10.1002/(SICI)1096-9861(19980302)392:1<35::AID-CNE3>3.0.CO;2-Q; Chung KY, 2000, DEVELOPMENT, V127, P2673; COLELLO RJ, 1990, DEVELOPMENT, V108, P515; CUCCHIARO JB, 1991, J COMP NEUROL, V312, P193, DOI 10.1002/cne.903120203; DEITCHER DL, 1994, J NEUROSCI, V14, P486; DRAGER UC, 1985, PROC R SOC SER B-BIO, V224, P57, DOI 10.1098/rspb.1985.0021; Erskine L, 2000, J NEUROSCI, V20, P4975; GalliResta L, 1997, J NEUROSCI, V17, P7831; GUILLERY RW, 1995, J NEUROSCI, V15, P4727; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; HOSKINS SG, 1985, J NEUROSCI, V5, P911; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Kandel ER, 2000, PRINCIPLES NEURAL SC; Kania A, 2000, CELL, V102, P161, DOI 10.1016/S0092-8674(00)00022-2; Kania A, 2003, NEURON, V38, P581, DOI 10.1016/S0896-6273(03)00292-7; Kitaguchi T, 2000, DEVELOPMENT, V127, P4787; Lee KJ, 1999, ANNU REV NEUROSCI, V22, P261, DOI 10.1146/annurev.neuro.22.1.261; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Lustig M, 2001, J COMP NEUROL, V434, P13, DOI 10.1002/cne.1161; Mann F, 2001, BIOESSAYS, V23, P319, DOI 10.1002/bies.1046; Marcus RC, 2000, DEV BIOL, V221, P132, DOI 10.1006/dbio.2000.9660; MARCUS RC, 1995, J NEUROSCI, V15, P3716; Marcus RC, 1996, DEVELOPMENT, V122, P859; Mason C, 2000, J NEUROBIOL, V44, P260, DOI 10.1002/1097-4695(200008)44:2<260::AID-NEU14>3.0.CO;2-H; Nagai T, 2000, P NATL ACAD SCI USA, V97, P1618, DOI 10.1073/pnas.97.4.1618; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; Nakagawa S, 2000, NEURON, V25, P599, DOI 10.1016/S0896-6273(00)81063-6; OLEARY DDM, 1983, DEV BRAIN RES, V10, P93, DOI 10.1016/0165-3806(83)90124-4; Pierani A, 2001, NEURON, V29, P367, DOI 10.1016/S0896-6273(01)00212-4; Plump AS, 2002, NEURON, V33, P219, DOI 10.1016/S0896-6273(01)00586-4; Polyak S., 1957, VERTEBRATE VISUAL SY; Purandare SM, 2002, DEVELOPMENT, V129, P2293; Rachel RA, 2002, J NEUROSCI, V22, P4249, DOI 10.1523/JNEUROSCI.22-11-04249.2002; RICE DS, 1995, J COMP NEUROL, V354, P459, DOI 10.1002/cne.903540312; Rubin JB, 2002, DEVELOPMENT, V129, P2223; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schulte D, 1999, NEURON, V24, P541, DOI 10.1016/S0896-6273(00)81111-3; Shirasaki R, 2002, ANNU REV NEUROSCI, V25, P251, DOI 10.1146/annurev.neuro.25.112701.142916; Thanos S, 2001, BRAIN RES REV, V35, P205, DOI 10.1016/S0165-0173(01)00049-2; THOMPSON ID, 1993, EUR J NEUROSCI, V5, P341, DOI 10.1111/j.1460-9568.1993.tb00502.x; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wang LC, 1995, NEURON, V15, P1349, DOI 10.1016/0896-6273(95)90013-6; Warner SJ, 2003, DEV DYNAM, V226, P702, DOI 10.1002/dvdy.10262; WILLIAMS SE, 2003, IN PRESS NEURON, V39; XIANG MQ, 1995, J NEUROSCI, V15, P4762	55	197	199	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	2003	114	5					545	557		10.1016/S0092-8674(03)00684-6	http://dx.doi.org/10.1016/S0092-8674(03)00684-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678579	Bronze			2022-12-24	WOS:000185193100005
J	Hirota, T; Kunitoku, N; Sasayama, T; Marumoto, T; Zhang, DW; Nitta, M; Hatakeyama, K; Saya, H				Hirota, T; Kunitoku, N; Sasayama, T; Marumoto, T; Zhang, DW; Nitta, M; Hatakeyama, K; Saya, H			Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells	CELL			English	Article							CHROMOSOME SEGREGATION; DEPENDENT MANNER; MAMMALIAN-CELLS; KINASE; CENTROSOMES; MATURATION; SPINDLE; MICROTUBULES; CHECKPOINT; DIVISION	Aurora family kinases contribute to regulation of mitosis. Using RNA interference in synchronized HeLa cells, we now show that Aurora-A is required for mitotic entry. We found that initial activation of Aurora-A in late G2 phase of the cell cycle is essential for recruitment of the cyclin B1-Cdk1 complex to centrosomes, where it becomes activated and commits cells to mitosis. A two-hybrid screen identified the LIM protein Ajuba as an Aurora-A binding protein. Ajuba and Aurora-A interact in mitotic cells and become phosphorylated as they do so. In vitro analyses revealed that Ajuba induces the autophosphorylation and consequent activation of Aurora-A. Depletion of Ajuba prevented activation of Aurora-A at centrosomes in late G2 phase and inhibited mitotic entry. Overall, our data suggest that Ajuba is an essential activator of Aurora-A in mitotic commitment.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Surg, Niigata 9518510, Japan	Kumamoto University; Niigata University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.		Saya, Hideyuki/J-4325-2013	Sasayama, Takashi/0000-0002-5593-9045				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreu V, 1998, COMPUTAT STUDIES, V2, P17; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Pines J, 2001, NAT CELL BIOL, V3, pE3, DOI 10.1038/35050676; Roghi C, 1998, J CELL SCI, V111, P557; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847	22	513	537	1	23	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					585	598		10.1016/S0092-8674(03)00642-1	http://dx.doi.org/10.1016/S0092-8674(03)00642-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678582	Bronze			2022-12-24	WOS:000185193100008
J	Lee, KS; Zhan, XM; Gao, JJ; Ji, Q; Feng, YA; Meganathan, R; Cohen, SN; Georgiou, G				Lee, KS; Zhan, XM; Gao, JJ; Ji, Q; Feng, YA; Meganathan, R; Cohen, SN; Georgiou, G			RraA: a protein inhibitor of RNase E activity that globally modulates RNA abundance in E. coli	CELL			English	Article							DISULFIDE BOND FORMATION; ESCHERICHIA-COLI; MESSENGER-RNA; RIBONUCLEASE-E; GENE-EXPRESSION; RIBOSOMAL-RNA; IN-VIVO; CATALYTIC DOMAIN; DNA MICROARRAY; TERMINAL HALF	Ribonuclease E (RNase E) has a key role in mRNA degradation and the processing of catalytic and structural RNAs in E. coli. We report the discovery of an evolutionarily conserved 17.4 kDa protein, here named RraA (regulator of ribonuclease activity A) that binds to RNase E and inhibits RNase E endonucleolytic cleavages without altering cleavage site specificity or interacting detectably with substrate RNAs. Overexpression of RraA circumvents the effects of an autoregulatory mechanism that normally maintains the RNase E cellular level within a narrow range, resulting in the genome-wide accumulation of RNase E-targeted transcripts. While not required for RraA action the C-terminal RNase E region that serves as a scaffold for formation of a multiprotein degradosome complex modulates the inhibition of RNase E catalytic activity by RraA. Our results reveal a possible mechanism for the dynamic regulation of RNA decay and processing by inhibitory RNase binding proteins.	Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA; Univ Texas, Dept Chem Engn, Austin, TX 78712 USA; Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; No Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Stanford University; Stanford University; Northern Illinois University	Georgiou, G (corresponding author), Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA.		Meganathan, R./A-6878-2009		NIGMS NIH HHS [GM55090, GM 54158, GM64511-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM064511, R01GM054158, R01GM055090] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANEYX F, 1990, J BACTERIOL, V172, P491, DOI 10.1128/JB.172.1.491-494.1990; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bernstein JA, 2002, P NATL ACAD SCI USA, V99, P9697, DOI 10.1073/pnas.112318199; Bessette PH, 2001, J BACTERIOL, V183, P980, DOI 10.1128/JB.183.3.980-988.2001; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; ELISH ME, 1988, J GEN MICROBIOL, V134, P1355; Feng Y, 2001, J BIOL CHEM, V276, P31651, DOI 10.1074/jbc.M102855200; Feng YA, 2002, P NATL ACAD SCI USA, V99, P14746, DOI 10.1073/pnas.202590899; GEORGELLIS D, 1993, MOL MICROBIOL, V9, P375, DOI 10.1111/j.1365-2958.1993.tb01698.x; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GUREVITZ M, 1983, P NATL ACAD SCI-BIOL, V80, P4450, DOI 10.1073/pnas.80.14.4450; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; Jain C, 2002, MOL MICROBIOL, V43, P1053, DOI 10.1046/j.1365-2958.2002.02808.x; JAIN C, 1995, GENE DEV, V9, P84, DOI 10.1101/gad.9.1.84; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kalapos MP, 1997, BIOCHIMIE, V79, P493, DOI 10.1016/S0300-9084(97)82741-1; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P12170, DOI 10.1073/pnas.220414297; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; Lee K, 2003, MOL MICROBIOL, V48, P349, DOI 10.1046/j.1365-2958.2003.03435.x; Lee K, 2002, MOL MICROBIOL, V43, P1445, DOI 10.1046/j.1365-2958.2002.02848.x; Leroy A, 2002, MOL MICROBIOL, V45, P1231, DOI 10.1046/j.1365-2958.2002.03104.x; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Li ZW, 1999, EMBO J, V18, P2878, DOI 10.1093/emboj/18.10.2878; Lin-Chao S, 1999, P NATL ACAD SCI USA, V96, P12406, DOI 10.1073/pnas.96.22.12406; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; Liou GG, 2001, P NATL ACAD SCI USA, V98, P63, DOI 10.1073/pnas.011535498; Lopez PJ, 1999, MOL MICROBIOL, V33, P188, DOI 10.1046/j.1365-2958.1999.01465.x; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MEGANATHAN R, 1996, ESCHERICHIA COLI SAL, P642; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; Ow MC, 2002, GENE DEV, V16, P1102, DOI 10.1101/gad.983502; Ow MC, 2000, MOL MICROBIOL, V38, P854, DOI 10.1046/j.1365-2958.2000.02186.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Qiu J, 1998, APPL ENVIRON MICROB, V64, P4891; Raynal LC, 1999, MOL MICROBIOL, V32, P765, DOI 10.1046/j.1365-2958.1999.01394.x; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Scott DJ, 2000, BIOCHEM J, V352, P539, DOI 10.1042/0264-6021:3520539; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; Sun WM, 2001, BIOCHEMISTRY-US, V40, P5102, DOI 10.1021/bi010022d; TARASEVICIENE L, 1995, J BIOL CHEM, V270, P26391, DOI 10.1074/jbc.270.44.26391; Tsao KL, 1996, GENE, V169, P59, DOI 10.1016/0378-1119(95)00762-8; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770; Walsh AP, 2001, NUCLEIC ACIDS RES, V29, P1864, DOI 10.1093/nar/29.9.1864; ZHAN X, 2002, THESIS U TEXAS AUSTI	62	117	119	6	23	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					623	634		10.1016/j.cell.2003.08.003	http://dx.doi.org/10.1016/j.cell.2003.08.003			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678585	Bronze			2022-12-24	WOS:000185193100011
J	Lipman, EA; Schuler, B; Bakajin, O; Eaton, WA				Lipman, EA; Schuler, B; Bakajin, O; Eaton, WA			Single-molecule measurement of protein folding kinetics	SCIENCE			English	Article							RESONANCE ENERGY-TRANSFER; TRANSFER CONFOCAL MICROSCOPY; FLUORESCENCE SPECTROSCOPY; DYNAMICS; PEPTIDES; TIME	In order to investigate the behavior of single molecules under conditions far from equilibrium, we have coupled a microfabricated laminar-flow mixer to a confocal optical system. This combination enables time-resolved measurement of Forster resonance energy transfer after an abrupt change in solution conditions. Observations of a small protein show the evolution of the intramolecular distance distribution as folding progresses. This technique can expose subpopulations, such as unfolded protein under conditions favoring the native structure, that would be obscured in equilibrium experiments.	NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; Lawrence Livermore Natl Lab, Biosecur Nanosci Lab, Livermore, CA 94550 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Eaton, WA (corresponding author), NIDDKD, Chem Phys Lab, NIH, Bldg 5,Room 104, Bethesda, MD 20892 USA.		Schuler, Benjamin/E-7342-2011; Lipman, Everett/D-1696-2009; Bakajin, Olgica/A-9745-2008	Schuler, Benjamin/0000-0002-5970-4251; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029010, ZIADK029010] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chan CK, 1997, P NATL ACAD SCI USA, V94, P1779, DOI 10.1073/pnas.94.5.1779; Deniz AA, 2000, P NATL ACAD SCI USA, V97, P5179, DOI 10.1073/pnas.090104997; Deniz AA, 1999, P NATL ACAD SCI USA, V96, P3670, DOI 10.1073/pnas.96.7.3670; DOI M, 1996, INTRO POLYM PHYSICS; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; Hagen SJ, 2000, J MOL BIOL, V301, P1019, DOI 10.1006/jmbi.2000.3969; Hagen SJ, 2001, J MOL BIOL, V305, P1161, DOI 10.1006/jmbi.2000.4366; Jia YW, 1999, CHEM PHYS, V247, P69, DOI 10.1016/S0301-0104(99)00127-5; Kauffmann E, 2001, P NATL ACAD SCI USA, V98, P6646, DOI 10.1073/pnas.101122898; Perl D, 1998, NAT STRUCT BIOL, V5, P229, DOI 10.1038/nsb0398-229; Pollack L, 1999, P NATL ACAD SCI USA, V96, P10115, DOI 10.1073/pnas.96.18.10115; Rhoades E, 2003, P NATL ACAD SCI USA, V100, P3197, DOI 10.1073/pnas.2628068100; Schuler B, 2003, NATURE, V421, P94, DOI 10.1038/nature01291; Schuler B, 2002, NATURE, V419, P743, DOI 10.1038/nature01060; Shastry MCR, 1998, NAT STRUCT BIOL, V5, P385, DOI 10.1038/nsb0598-385; Talaga DS, 2000, P NATL ACAD SCI USA, V97, P13021, DOI 10.1073/pnas.97.24.13021; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; Wassenberg D, 1999, J MOL BIOL, V289, P187, DOI 10.1006/jmbi.1999.2772; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; Zhuang XW, 2002, SCIENCE, V296, P1473, DOI 10.1126/science.1069013; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	21	322	334	2	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1233	1235		10.1126/science.1085399	http://dx.doi.org/10.1126/science.1085399			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947198				2022-12-24	WOS:000185003500041
J	Molofsky, AV; Pardal, R; Iwashita, T; Park, IK; Clarke, MF; Morrison, SJ				Molofsky, AV; Pardal, R; Iwashita, T; Park, IK; Clarke, MF; Morrison, SJ			Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation	NATURE			English	Article							ADULT MAMMALIAN FOREBRAIN; TRANSGENIC MICE; TRANSFORMATION; TUMORIGENESIS; P16(INK4A); SENESCENCE; REPRESSION; EXPRESSION; P19(ARF); MEMBERS	Stem cells persist throughout life by self-renewing in numerous tissues including the central(1) and peripheral(2) nervous systems. This raises the issue of whether there is a conserved mechanism to effect self-renewing divisions. Deficiency in the polycomb family transcriptional repressor Bmi-1 leads to progressive postnatal growth retardation and neurological defects(3). Here we show that Bmi-1 is required for the self-renewal of stem cells in the peripheral and central nervous systems but not for their survival or differentiation. The reduced self-renewal of Bmi-1-deficient neural stem cells leads to their postnatal depletion. In the absence of Bmi-1, the cyclin-dependent kinase inhibitor gene p16(Ink4a) is upregulated in neural stem cells, reducing the rate of proliferation. p16(Ink4a) deficiency partially reverses the self-renewal defect in Bmi-1(-/-) neural stem cells. This conserved requirement for Bmi-1 to promote self-renewal and to repress p16(Ink4a) expression suggests that a common mechanism regulates the self-renewal and postnatal persistence of diverse types of stem cell. Restricted neural progenitors from the gut and forebrain proliferate normally in the absence of Bmi-1. Thus, Bmi-1 dependence distinguishes stem cell self-renewal from restricted progenitor proliferation in these tissues.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Morrison, SJ (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Molofsky, Anna Victoria/P-2506-2018; Morrison, Sean/ABD-5326-2021; Nam, Jae Do/F-2201-2013; IBIS, FISIOPATOLOGIA/O-9510-2015; Pardal, Ricardo/C-4370-2015	Molofsky, Anna Victoria/0000-0002-4709-2411; Pardal, Ricardo/0000-0003-1085-0714; Morrison, Sean/0000-0003-1587-8329	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040750] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS040750, R01 NS040750-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Bixby S, 2002, NEURON, V35, P643, DOI 10.1016/S0896-6273(02)00825-5; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; HAUPT Y, 1993, ONCOGENE, V8, P3161; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Morshead CM, 1998, DEVELOPMENT, V125, P2251; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; STRITT TN, 1995, CELL, V80, P661; vanderLugt NMT, 1996, MECH DEVELOP, V58, P153, DOI 10.1016/S0925-4773(96)00570-9; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	27	1045	1133	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					962	967		10.1038/nature02060	http://dx.doi.org/10.1038/nature02060			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14574365	Green Accepted, Green Published			2022-12-24	WOS:000186230600042
J	Blankenberg, S; Rupprecht, HJ; Bickel, C; Torzewski, M; Hafner, G; Tiret, L; Smieja, M; Cambien, F; Meyer, J; Lackner, KJ				Blankenberg, S; Rupprecht, HJ; Bickel, C; Torzewski, M; Hafner, G; Tiret, L; Smieja, M; Cambien, F; Meyer, J; Lackner, KJ		AtheroGene Investigators	Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ERYTHROCYTE GLUTATHIONE-PEROXIDASE; ISCHEMIC-HEART-DISEASE; ENDOTHELIAL DYSFUNCTION; MYOCARDIAL-INFARCTION; ANTIOXIDANT ENZYMES; SERUM SELENIUM; ATHEROSCLEROSIS; CELLS; 5-LIPOXYGENASE; EXPRESSION	BACKGROUND: Cellular antioxidant enzymes such as glutathione peroxidase 1 and superoxide dismutase have a central role in the control of reactive oxygen species. In vitro data and studies in animal models suggest that these enzymes may protect against atherosclerosis, but little is known about their relevance to human disease. METHODS: We conducted a prospective study among 636 patients with suspected coronary artery disease, with a median follow-up period of 4.7 years (maximum, 5.4) to assess the risk of cardiovascular events associated with base-line erythrocyte glutathione peroxidase 1 and superoxide dismutase activity. RESULTS: Glutathione peroxidase 1 activity was among the strongest univariate predictors of the risk of cardiovascular events, whereas superoxide dismutase activity had no association with risk. The risk of cardiovascular events was inversely associated with increasing quartiles of glutathione peroxidase 1 activity (P for trend <0.001); patients in the highest quartile of glutathione peroxidase 1 activity had a hazard ratio of 0.29 (95 percent confidence interval, 0.15 to 0.58; P<0.001), as compared with those in the lowest quartile. Glutathione peroxidase 1 activity was affected by sex and smoking status but retained its predictive power in these subgroups. After adjustment for these and other cardiovascular risk factors, the inverse association between glutathione peroxidase 1 activity and cardiovascular events remained nearly unchanged. CONCLUSIONS: In patients with coronary artery disease, a low level of activity of red-cell glutathione peroxidase 1 is independently associated with an increased risk of cardiovascular events. Glutathione peroxidase 1 activity may have prognostic value in addition to that of traditional risk factors. Furthermore, increasing glutathione peroxidase 1 activity might lower the risk of cardiovascular events.	Johannes Gutenberg Univ Mainz, Dept Med 2, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Clin Chem & Lab Med, D-55131 Mainz, Germany; Univ Paris 06, INSERM, U525, Paris, France; Bundeswehrzent Krankenhaus, Innere Abt, Koblenz, Germany; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; McMaster University	Blankenberg, S (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 2, Langenbeckstr 1, D-55131 Mainz, Germany.	stefan.blankenberg@uni-mainz.de; lackner@zentrallabor.klinik.uni-mainz.de		Blankenberg, Stefan/0000-0001-6488-2362				Alissa EM, 2003, MED SCI MONITOR, V9, pRA9; Andersen HR, 1997, CLIN CHEM, V43, P562; Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Blankenberg S, 2002, CIRCULATION, V106, P24, DOI 10.1161/01.CIR.0000020546.30940.92; Blankenberg S, 2001, CIRCULATION, V104, P1336, DOI 10.1161/hc3701.095949; Dayal S, 2002, ARTERIOSCL THROM VAS, V22, P1996, DOI 10.1161/01.ATV.0000041629.92741.DC; Flohe L, 1988, Basic Life Sci, V49, P663; Forgione MA, 2002, CIRCULATION, V106, P1154, DOI 10.1161/01.CIR.0000026820.87824.6A; Forgione MA, 2002, AM J PHYSIOL-HEART C, V282, pH1255, DOI 10.1152/ajpheart.00598.2001; Forsberg L, 2001, ARCH BIOCHEM BIOPHYS, V389, P84, DOI 10.1006/abbi.2001.2295; Forsberg L, 2000, BLOOD CELL MOL DIS, V26, P423, DOI 10.1006/bcmd.2000.0325; Fukai T, 2002, CARDIOVASC RES, V55, P239, DOI 10.1016/S0008-6363(02)00328-0; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Guo ZM, 2001, ARTERIOSCL THROM VAS, V21, P1131, DOI 10.1161/hq0701.092092; Hussein O, 1997, TRANSPLANTATION, V63, P679, DOI 10.1097/00007890-199703150-00012; Kardinaal AFM, 1997, AM J EPIDEMIOL, V145, P373, DOI 10.1093/oxfordjournals.aje.a009115; Lapenna D, 1998, CIRCULATION, V97, P1930, DOI 10.1161/01.CIR.97.19.1930; Liu DJ, 2000, CHINESE MED J-PEKING, V113, P771; Massafra C, 2002, CLIN ENDOCRINOL, V57, P663, DOI 10.1046/j.1365-2265.2002.01657.x; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Mulholland CW, 1999, QJM-INT J MED, V92, P579, DOI 10.1093/qjmed/92.10.579; OSTER O, 1982, CLIN CHIM ACTA, V124, P277, DOI 10.1016/0009-8981(82)90422-3; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; RAES M, 1987, FREE RADICAL BIO MED, V3, P3, DOI 10.1016/0891-5849(87)90032-3; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rupprecht HJ, 2001, CIRCULATION, V104, P25, DOI 10.1161/hc2601.091703; SALONEN JT, 1988, ATHEROSCLEROSIS, V70, P155, DOI 10.1016/0021-9150(88)90109-8; SALVINI S, 1995, AM J CARDIOL, V76, P1218, DOI 10.1016/S0002-9149(99)80344-0; SHINGU M, 1985, INFLAMMATION, V9, P309, DOI 10.1007/BF00916279; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; Straif D, 2000, BIOCHEM J, V349, P455, DOI 10.1042/0264-6021:3490455; Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091; SUADICANI P, 1992, ATHEROSCLEROSIS, V96, P33, DOI 10.1016/0021-9150(92)90035-F; URSINI F, 1995, METHOD ENZYMOL, V252, P38	37	453	475	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 23	2003	349	17					1605	1613		10.1056/NEJMoa030535	http://dx.doi.org/10.1056/NEJMoa030535			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734ZT	14573732				2022-12-24	WOS:000186088400005
J	Ubersax, JA; Woodbury, EL; Quang, PN; Paraz, M; Blethrow, JD; Shah, K; Shokat, KM; Morgan, DO				Ubersax, JA; Woodbury, EL; Quang, PN; Paraz, M; Blethrow, JD; Shah, K; Shokat, KM; Morgan, DO			Targets of the cyclin-dependent kinase Cdk1	NATURE			English	Article							UNNATURAL NUCLEOTIDE SPECIFICITY; ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; PHOSPHORYLATION; CDC28; UBIQUITINATION; IDENTIFICATION; LOCALIZATION; REPLICATION	The events of cell reproduction are governed by oscillations in the activities of cyclin-dependent kinases (Cdks)(1). Cdks control the cell cycle by catalysing the transfer of phosphate from ATP to specific protein substrates. Despite their importance in cell-cycle control, few Cdk substrates have been identified(2). Here, we screened a budding yeast proteomic library for proteins that are directly phosphorylated by Cdk1 in whole-cell extracts. We identified about 200 Cdk1 substrates, several of which are phosphorylated in vivo in a Cdk1-dependent manner. The identities of these substrates reveal that Cdk1 employs a global regulatory strategy involving phosphorylation of other regulatory molecules as well as phosphorylation of the molecular machines that drive cell-cycle events. Detailed analysis of these substrates is likely to yield important insights into cell-cycle regulation.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Novartis Fdn, Genom Inst, San Diego, CA 92121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Novartis	Morgan, DO (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.			Morgan, David/0000-0001-8753-4416				Agarwal R, 2002, GENE DEV, V16, P1371, DOI 10.1101/gad.971402; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Gartner A, 1998, MOL CELL BIOL, V18, P3681, DOI 10.1128/MCB.18.7.3681; Habelhah H, 2001, J BIOL CHEM, V276, P18090, DOI 10.1074/jbc.M011396200; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Kraybill BC, 2002, J AM CHEM SOC, V124, P12118, DOI 10.1021/ja0264798; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; McMillan JN, 2002, MOL BIOL CELL, V13, P3560, DOI 10.1091/mbc.E02-05-0283; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mortensen EM, 2002, MOL BIOL CELL, V13, P2091, DOI 10.1091/mbc.01-10-0500; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Niswender CM, 2002, J BIOL CHEM, V277, P28916, DOI 10.1074/jbc.M203327200; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Sullivan M, 2001, NAT CELL BIOL, V3, P771, DOI 10.1038/ncb0901-771; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Witucki LA, 2002, CHEM BIOL, V9, P25, DOI 10.1016/S1074-5521(02)00091-1; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	30	717	773	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					859	864		10.1038/nature02062	http://dx.doi.org/10.1038/nature02062			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574415				2022-12-24	WOS:000186118500050
J	Li, L; Parsons, TJ; Power, C				Li, L; Parsons, TJ; Power, C			Breast feeding and obesity in childhood: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OVERWEIGHT; DURATION; PROTECT		Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England	University of London; University College London	Li, L (corresponding author), Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.	L.Li@ich.ucl.ac.uk						BARROS FC, 1990, PAEDIATR PERINAT EP, V4, P267; Beral V, 2003, LANCET, V361, P177, DOI 10.1016/S0140-6736(03)12209-X; BLOCK G, 1989, J NUTR EDUC, V21, P199; Butte NE, 2001, PEDIATR CLIN N AM, V48, P189, DOI 10.1016/S0031-3955(05)70293-5; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Dewey Kathryn G, 2003, J Hum Lact, V19, P9; Dietz WH, 2001, JAMA-J AM MED ASSOC, V285, P2506, DOI 10.1001/jama.285.19.2506; Elliott KG, 1997, OBES RES, V5, P538, DOI 10.1002/j.1550-8528.1997.tb00574.x; FERRI E, 1993, LIFE 33 5 FOLLOW UP; Gillman MW, 2001, JAMA-J AM MED ASSOC, V285, P2461, DOI 10.1001/jama.285.19.2461; Hediger ML, 2001, JAMA-J AM MED ASSOC, V285, P2453, DOI 10.1001/jama.285.19.2453; HUTTLY SRA, 1990, AM J EPIDEMIOL, V132, P572, DOI 10.1093/oxfordjournals.aje.a115693; KRAMER MS, 1981, J PEDIATR-US, V98, P883, DOI 10.1016/S0022-3476(81)80579-3; Parsons TJ, 2003, ARCH DIS CHILD, V88, P793, DOI 10.1136/adc.88.9.793; Tulldahl J, 1999, OBES RES, V7, P431, DOI 10.1002/j.1550-8528.1999.tb00430.x; VANITALLIE TB, 1990, AM J CLIN NUTR, V52, P953, DOI 10.1093/ajcn/52.6.953; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; VICTORA CG, 2003, IN PRESS CAD SAUDE P; von Kries R, 2000, ADV EXP MED BIOL, V478, P29; WELLS JCK, 2003, INT J BODY COMPOSITI, V1, P1; *WHO DIV DIARRH AC, 1991, IND ASS BREAST FEED; *WHO EXP COMM NUTR, 1995, WHO TECHN REP SER, V854	22	72	79	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2003	327	7420					904	905		10.1136/bmj.327.7420.904	http://dx.doi.org/10.1136/bmj.327.7420.904			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563747	Green Published, Bronze			2022-12-24	WOS:000186072100019
J	Townsend, A; Hunt, K; Wyke, S				Townsend, A; Hunt, K; Wyke, S			Managing multiple morbidity in mid-life: a qualitative study of attitudes to drug use	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PRIMARY-CARE; MEDICATIONS; DECISIONS; MEDICINES	Objective To examine attitudes towards drug use among middle aged respondents with high levels of chronic morbidity. Design Qualitative study with detailed interviews. Setting West of Scotland. Participants 23 men and women aged about 50 years with four or more chronic illnesses. Main outcome measure Participants' feelings about long term use of drugs to manage chronic multiple morbidity. Results Drugs occupied a central place in the way people managed their comorbidities. Respondents expressed an aversion to taking drugs, despite acknowledging that they depended on drugs to live as "normal" a life as possible. Respondents expressed ambivalence to their drugs in various ways. Firstly, they adopted both regular and more flexible regimens and might adhere to a regular regimen in treating one condition (such as hypertension) while adopting a flexible regimen in relation to others, in response to their experience of symptoms or varying demands of their daily life. Secondly, they expressed reluctance to take drugs, but an inability to be free of them. Thirdly, drugs both facilitated performance of social roles and served as evidence of an inability to perform such roles. Conclusions Insight into the considerable tension experienced by people managing complex drug regimens to manage multiple chronic illness may help medical carets to support self care practices among patients and to optimise concordance in their use of prescribed drugs.	Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; NHS Educ Scotland, Scottish Sch Primary Care, Edinburgh EH8 9DR, Midlothian, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; NHS Education for Scotland	Hunt, K (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.			Hunt, Kate/0000-0002-5873-3632				[Anonymous], MED ANTHR Q; Benson J, 2002, BRIT MED J, V325, P873, DOI 10.1136/bmj.325.7369.873; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; BRITTEN N, 1994, BRIT J GEN PRACT, V44, P465; BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; Britten N, 1996, MODERN MED LAY PERSP, P48; Britten Nicky, 2002, Health Expect, V5, P256, DOI 10.1046/j.1369-6513.2002.00187.x; CONRAD P, 1985, SOC SCI MED, V20, P29, DOI 10.1016/0277-9536(85)90308-9; Department of Health, 2001, EXP PAT NEW APPR CHR; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; FORD G, 1994, SOC SCI MED, V39, P1037, DOI 10.1016/0277-9536(94)90375-1; Haynes RB, 1996, LANCET, V348, P383; HUNT K, 2000, J EPIDEMIOL COMMUNIT, V54, P786; Macintyre S, 1999, SOC SCI MED, V48, P89, DOI 10.1016/S0277-9536(98)00292-5; Macintyre S, 1989, READINGS NEW PUBLIC, P56; Marinker M, 2003, BRIT MED J, V326, P348, DOI 10.1136/bmj.326.7385.348; Morgan M., 1996, MODERN MED LAY PERSP, P95; *OFF NAT STAT, 2000, LIV BRIT RES 1998 GE; Rogers A, 1998, SOC SCI MED, V47, P1313, DOI 10.1016/S0277-9536(98)00209-3; Royal Pharmaceutical Society of Great Britain, 1997, COMPL CONC ACH SHAR; Starfield B, 2001, BRIT J GEN PRACT, V51, P303; Strauss A., 1998, BASICS QUALITATIVE R; Wyke Sally, 2003, Eur J Gen Pract, V9, P48	23	118	120	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					837	840		10.1136/bmj.327.7419.837	http://dx.doi.org/10.1136/bmj.327.7419.837			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732BP	14551097	Bronze, Green Published, Green Accepted			2022-12-24	WOS:000185921200017
J	Gardai, SJ; Xiao, YQ; Dickinson, M; Nick, JA; Voelker, DR; Greene, KE; Henson, PM				Gardai, SJ; Xiao, YQ; Dickinson, M; Nick, JA; Voelker, DR; Greene, KE; Henson, PM			By binding SIRP alpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation	CELL			English	Article							SURFACTANT-PROTEIN-A; CARBOHYDRATE-RECOGNITION DOMAINS; CELL-SURFACE; ALVEOLAR MACROPHAGES; PSEUDOMONAS-AERUGINOSA; APOPTOTIC CELLS; DEFICIENT MICE; RAT LUNG; C1Q; RECEPTOR	Surfactant proteins A and D (SP-A and SP-D) are lung collectins composed of two regions, a globular head domain that binds PAMPs and a collagenous tail domain that initiates phagocytosis. We provide evidence that SP-A and SP-D act in a dual manner, to enhance or suppress inflammatory mediator production depending on binding orientation. SP-A and SP-D bind SIRPalpha through their globular heads to initiate a signaling pathway that blocks proinflammatory mediator production. In contrast, their collagenous tails stimulate proinflammatory mediator production through binding to calreticulin/CD91. Together a model is implied in which SP-A and SP-D help maintain a non/anti-inflammatory lung environment by stimulating SIRPalpha on resident cells through their globular heads. However, interaction of these heads with PAMPs on foreign organisms or damaged cells and presentation of the collagenous tails in an aggregated state to calreticulin/CD91, stimulates phagocytosis and proinflammatory responses.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Henson, PM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048211, R01GM061031] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48211, GM61031] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen MJ, 2001, INFECT IMMUN, V69, P2037, DOI 10.1128/IAI.69.4.2037-2044.2001; Arias-Diaz J, 2000, SHOCK, V14, P300, DOI 10.1097/00024382-200014030-00010; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; BLAU S, 1994, AM J PHYSIOL, V266, pL148; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Bridges JP, 2000, J BIOL CHEM, V275, P38848, DOI 10.1074/jbc.M005322200; Carter KB, 2000, J BIOL CHEM, V275, P27858; Chiba H, 2001, INFECT IMMUN, V69, P1587, DOI 10.1128/IAI.69.3.1587-1592.2001; Coppolino MG, 1998, INT J BIOCHEM CELL B, V30, P553, DOI 10.1016/S1357-2725(97)00153-2; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; Ernst M, 2002, J EXP MED, V196, P589, DOI 10.1084/jem.20020873; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; GREENE KE, 1996, AM J RESP CRIT CARE, V153, pA662; GREENE KE, 2000, AM THOR SOC 2000 INT; GREENE KE, 1998, AM J RESP CRIT CARE, V157, pA562; Harrod KS, 1999, AM J PHYSIOL-LUNG C, V277, pL580, DOI 10.1152/ajplung.1999.277.3.L580; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712, DOI 10.1152/ajplung.1994.267.6.L712; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279, DOI 10.1165/ajrcmb.20.2.3303; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; Murakami S, 2002, J BIOL CHEM, V277, P6830, DOI 10.1074/jbc.M106671200; Ofek I, 2001, INFECT IMMUN, V69, P24, DOI 10.1128/IAI.69.1.24-33.2001; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Orr AW, 2002, J BIOL CHEM, V277, P20453, DOI 10.1074/jbc.M112091200; Poornima S, 2002, LUNG, V180, P33, DOI 10.1007/s004080000079; REID KBM, 1976, BIOCHEM J, V155, P5, DOI 10.1042/bj1550005; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; Rosseau S, 1999, J IMMUNOL, V163, P4495; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Sim RB, 1998, IMMUNOBIOLOGY, V199, P208, DOI 10.1016/S0171-2985(98)80028-4; Stuart GR, 1997, IMMUNOPHARMACOLOGY, V38, P73, DOI 10.1016/S0162-3109(97)00076-3; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; Tenner AJ, 1998, IMMUNOBIOLOGY, V199, P250, DOI 10.1016/S0171-2985(98)80031-4; van den Berg RH, 1998, J IMMUNOL, V161, P6924; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; WARD JM, 1978, VET PATHOL, V15, P170, DOI 10.1177/030098587801500203; White MK, 2002, EXP CELL RES, V280, P270, DOI 10.1006/excr.2002.5646; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200	50	529	565	0	26	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					13	23		10.1016/S0092-8674(03)00758-X	http://dx.doi.org/10.1016/S0092-8674(03)00758-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14531999	Bronze			2022-12-24	WOS:000185815500005
J	Norris, JM; Barriga, K; Klingensmith, G; Hoffman, M; Eisenbarth, GS; Erlich, HA; Rewers, M				Norris, JM; Barriga, K; Klingensmith, G; Hoffman, M; Eisenbarth, GS; Erlich, HA; Rewers, M			Timing of initial cereal exposure in infancy and risk of islet autoimmunity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; BETA-CELL AUTOIMMUNITY; CELIAC-DISEASE; COWS MILK; YOUNG DAISY; AUTOANTIBODIES; INSULIN; CHILDHOOD; IDDM; ASSOCIATION	Context Dietary exposures in infancy have been implicated, albeit inconsistently, in the etiology of type 1 diabetes mellitus (DM). Objective To examine the association between cereal exposures in the infant diet and appearance of islet autoimmunity (IA). Design Birth cohort study conducted from 1994 to 2002 with a mean follow-up of 4 years. Setting Newborn screening for HLA was done at St Joseph's Hospital in Denver, Colo. First-degree relatives of type 1 DM individuals were recruited from the Denver metropolitan area. Participants We enrolled 1183 children at increased type 1 DM risk, defined as either HLA genotype or having a first-degree relative with type 1 DM, at birth and followed them prospectively. We obtained exposure and outcome measures for 76% of enrolled children. Participants had variable lengths of follow-up (9 months to 9 years). Main Outcome Measures Blood draws for the detection of insulin autoantibody, glutamic acid decarboxylase autoantibody, or IA-2 autoantibody were performed at 9, 15, and 24 months and annually thereafter. Children with A (n=34) were defined as those testing positive for at least 1 of the autoantibodies on 2 or more consecutive visits and who tested positive or had diabetes on their most recent visit. Results Children initially exposed to cereals between ages 0 and 3 months (hazard ratio [HR], 4.32; 95% confidence interval [CI], 2.0-9.35) and those who were exposed at 7 months or older (HR, 5.36; 95% Cl, 2.08-13.8) had increased hazard of A compared with those who were exposed during the fourth through sixth month, after adjustment for HLA genotype, family history of type 1 DM, ethnicity, and maternal age. In children who were positive for the HLA-DRB1*03/04,DQB8 genotype, adjusted HRs Were 5.55 (95% Cl, 1.92-16.03) and 12.53 (95% Cl, 3.19-49.23) for initial cereal exposure between ages 0 to 3 months and at 7 months or older, respectively. Conclusion There maybe a window of exposure to cereals in infancy outside which initial exposure increases A risk in susceptible children.	Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA; Roche Mol Syst Inc, Dept Human Genet, Alameda, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Roche Holding	Norris, JM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, 4200 E 9th Ave,Box B119, Denver, CO 80262 USA.				NIDDK NIH HHS [R01-DK32493, R01-DK49654] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049654, R01DK032493] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison P. D, 1995, SURVIVAL ANAL USING; Ascher H, 2001, ACTA PAEDIATR, V90, P1217, DOI 10.1080/080352501317130209; BJORK E, 1992, DIABETOLOGIA, V35, P490, DOI 10.1007/BF02342450; Couper JJ, 1999, DIABETES, V48, P2145, DOI 10.2337/diabetes.48.11.2145; Haglund B, 1996, DIABETES CARE, V19, P873, DOI 10.2337/diacare.19.8.873; HAYWARD AR, 1992, J LAB CLIN MED, V119, P503; Ho E, 2001, EXP BIOL MED, V226, P103, DOI 10.1177/153537020122600207; Hummel M, 2002, DIABETES CARE, V25, P1111, DOI 10.2337/diacare.25.7.1111; Hummel M, 2000, DIABETES CARE, V23, P969, DOI 10.2337/diacare.23.7.969; Hypponen E, 1999, DIABETES CARE, V22, P1961, DOI 10.2337/diacare.22.12.1961; Ivarsson A, 2002, AM J CLIN NUTR, V75, P914, DOI 10.1093/ajcn/75.5.914; Kimpimaki T, 2001, DIABETOLOGIA, V44, P63, DOI 10.1007/s001250051581; KLEINMAN RE, 1998, PEDIAT NUTR HDB, P43; Knekt P, 1999, J INTERN MED, V245, P99, DOI 10.1046/j.1365-2796.1999.00416.x; KOSTRABA JN, 1993, DIABETES, V42, P288, DOI 10.2337/diabetes.42.2.288; KOSTRABA JN, 1992, EPIDEMIOLOGY, V3, P232, DOI 10.1097/00001648-199205000-00008; LaGasse JM, 2002, DIABETES CARE, V25, P505, DOI 10.2337/diacare.25.3.505; Leslie RDG, 1999, DIABETOLOGIA, V42, P3, DOI 10.1007/s001250051105; MacFarlane AJ, 2003, J BIOL CHEM, V278, P54, DOI 10.1074/jbc.M210636200; Meloni T, 1997, DIABETES CARE, V20, P340, DOI 10.2337/diacare.20.3.340; Norris JM, 1999, J ENDOCRINOL INVEST, V22, P568, DOI 10.1007/BF03343611; Norris JM, 1996, JAMA-J AM MED ASSOC, V276, P609, DOI 10.1001/jama.276.8.609; PEREZBRAVO E, 1996, J MOL MED, V74, P105; Rewers M, 1996, DIABETOLOGIA, V39, P807, DOI 10.1007/s001250050514; Roll U, 1996, DIABETES, V45, P967, DOI 10.2337/diabetes.45.7.967; Scott FW, 2002, DIABETES, V51, P73, DOI 10.2337/diabetes.51.1.73; Ventura A, 2000, J PEDIATR-US, V137, P263, DOI 10.1067/mpd.2000.107160; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; VIRTANEN SM, 1993, DIABETES, V42, P1786, DOI 10.2337/diabetes.42.12.1786; Yu LP, 2000, P NATL ACAD SCI USA, V97, P1701, DOI 10.1073/pnas.040556697; Yu LP, 1996, J CLIN ENDOCR METAB, V81, P4264, DOI 10.1210/jc.81.12.4264; Zhao HX, 2001, DIABETIC MED, V18, P709, DOI 10.1046/j.1464-5491.2001.00554.x	32	344	351	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1713	1720		10.1001/jama.290.13.1713	http://dx.doi.org/10.1001/jama.290.13.1713			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519705	Bronze			2022-12-24	WOS:000185606100020
J	Lilic, M; Galkin, VE; Orlova, A; VanLoock, MS; Egelman, EH; Stebbins, CE				Lilic, M; Galkin, VE; Orlova, A; VanLoock, MS; Egelman, EH; Stebbins, CE			Salmonella SipA polymerizes actin by stapling filaments with nonglobular protein arms	SCIENCE			English	Article							BINDING PROTEIN	Like many bacterial pathogens, Salmonella spp. use a type III secretion system to inject virulence proteins into host cells. The Salmonella invasion protein A ( SipA) binds host actin, enhances its polymerization near adherent extracellular bacteria, and contributes to cytoskeletal rearrangements that internalize the pathogen. By combining x-ray crystallography of SipA with electron microscopy and image analysis of SipA-actin. laments, we show that SipA functions as a "molecular staple," in which a globular domain and two nonglobular "arms" mechanically stabilize the. lament by tethering actin subunits in opposing strands. Deletion analysis of the tethering arms provides strong support for this model.	Rockefeller Univ, Lab Struct Microbiol, New York, NY 10021 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Rockefeller University; University of Virginia	Stebbins, CE (corresponding author), Rockefeller Univ, Lab Struct Microbiol, 1230 York Ave, New York, NY 10021 USA.	stebbins@rockefeller.edu	Stebbins, Erec/N-2565-2018; Galkin, Vitold/AAD-2844-2019; Egelman, Edward H/A-2488-2009	Stebbins, Erec/0000-0001-6229-5308; Egelman, Edward/0000-0003-4844-5212				Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Galkin VE, 2002, NAT STRUCT BIOL, V9, P518, DOI 10.1038/nsb811; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lukoyanova N, 2002, CURR BIOL, V12, P383, DOI 10.1016/S0960-9822(02)00678-4; McGhie EJ, 2001, EMBO J, V20, P2131, DOI 10.1093/emboj/20.9.2131; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitra K, 2000, FEBS LETT, V482, P81, DOI 10.1016/S0014-5793(00)02040-8; PANG T, 1995, TRENDS MICROBIOL, V3, P253, DOI 10.1016/S0966-842X(00)88937-4; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; Tsolis RM, 2000, INFECT IMMUN, V68, P3158, DOI 10.1128/IAI.68.6.3158-3163.2000; Zhang SP, 2002, INFECT IMMUN, V70, P3843, DOI 10.1128/IAI.70.7.3843-3855.2002; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092	18	90	94	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1918	1921		10.1126/science.1088433	http://dx.doi.org/10.1126/science.1088433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512630				2022-12-24	WOS:000185536700054
J	Beltrami, AP; Barlucchi, L; Torella, D; Baker, M; Limana, F; Chimenti, S; Kasahara, H; Rota, M; Musso, E; Urbanek, K; Leri, A; Kajstura, J; Nadal-Ginard, B; Anversa, P				Beltrami, AP; Barlucchi, L; Torella, D; Baker, M; Limana, F; Chimenti, S; Kasahara, H; Rota, M; Musso, E; Urbanek, K; Leri, A; Kajstura, J; Nadal-Ginard, B; Anversa, P			Adult cardiac stem cells are multipotent and support myocardial regeneration	CELL			English	Article							PROGENITOR CELLS; HEART; LINEAGE; TRANSPLANTATION; EXPRESSION; INFARCTION; MYOCYTES; PROLIFERATION; CHIMERISM; FAILURE	The notion of the adult heart as terminally differentiated organ without self-renewal potential has been undermined by the existence of a subpopulation of replicating myocytes in normal and pathological states. The origin and significance of these cells has remained obscure for lack of a proper biological context. We report the existence of Lin(-) c-kit(POS) cells with the properties of cardiac stem cells. They are self-renewing, clonogenic, and multipotent, giving rise to myocytes, smooth muscle, and endothelial cells. When injected into an ischemic heart, these cells or their clonal progeny reconstitute well-differentiated myocardium, formed by blood-carrying new vessels and myocytes with the characteristics of young cells, encompassing similar to70% of the ventricle. Thus, the adult heart, like the brain, is mainly composed of terminally differentiated cells, but is not a terminally differentiated organ because it contains stem cells supporting its regeneration. The existence of these cells opens new opportunities for myocardial repair.	New York Med Coll, Dept Med, Inst Cardiovasc Res, Valhalla, NY 10595 USA; Univ Florida, Dept Physiol & Funct Genom, Gainesville, FL 32611 USA	New York Medical College; State University System of Florida; University of Florida	Anversa, P (corresponding author), New York Med Coll, Dept Med, Inst Cardiovasc Res, Valhalla, NY 10595 USA.	piero_anversa@nymc.edu	Beltrami, Antonio/C-5291-2008	Beltrami, Antonio/0000-0002-0679-2710; TORELLA, Daniele/0000-0002-4915-5084	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065573, R01HL038132, R01HL066923, R01HL039902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015756, R01AG017042] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-65573, HL-38132, HL-66923, HL-65557, HL-39902] Funding Source: Medline; NIA NIH HHS [AG-17042, AG-15756] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alison MR, 2003, J CELL SCI, V116, P599, DOI 10.1242/jcs.00269; Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; Anversa P, 2002, CIRCULATION, V106, pE129, DOI 10.1161/01.CIR.0000035926.40150.D0; Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Frangogiannis NG, 1998, CIRCULATION, V98, P687, DOI 10.1161/01.CIR.98.7.687; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Glaser R, 2002, CIRCULATION, V106, P17, DOI 10.1161/01.CIR.0000021923.58307.8F; Hellermann JP, 2002, AM J MED, V113, P324, DOI 10.1016/S0002-9343(02)01185-3; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; Kasahara H, 1998, CIRC RES, V82, P936, DOI 10.1161/01.RES.82.9.936; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kosaka M, 1998, EXP CELL RES, V245, P245, DOI 10.1006/excr.1998.4211; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kunisada T, 1998, DEVELOPMENT, V125, P2915; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Mahmud N, 2001, BLOOD, V97, P3061, DOI 10.1182/blood.V97.10.3061; MCDONNELL TJ, 1984, CELL TISSUE RES, V235, P583; Mikawa T, 1999, HEART DEV, P19; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Nadal-Ginard B, 2003, CIRC RES, V92, P139, DOI 10.1161/01.RES.0000053618.86362.DF; Nadin BM, 2003, BLOOD, V102, P2436, DOI 10.1182/blood-2003-01-0118; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Rosenthal N, 2003, NEW ENGL J MED, V349, P267, DOI 10.1056/NEJMra020849; RUMYANTSEV PP, 1987, BIOMED BIOCHIM ACTA, V46, pS610; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Sellers SE, 2001, BLOOD, V97, P1888, DOI 10.1182/blood.V97.6.1888; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Teyssier-Le Discorde M, 1999, BRIT J HAEMATOL, V107, P247, DOI 10.1046/j.1365-2141.1999.01725.x; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; Urbanek K, 2003, P NATL ACAD SCI USA, V100, P10440, DOI 10.1073/pnas.1832855100; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387	44	2619	2917	3	340	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					763	776		10.1016/S0092-8674(03)00687-1	http://dx.doi.org/10.1016/S0092-8674(03)00687-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505575	Bronze			2022-12-24	WOS:000185464000013
J	Kim, PW; Sun, ZYJ; Blacklow, SC; Wagner, G; Eck, MJ				Kim, PW; Sun, ZYJ; Blacklow, SC; Wagner, G; Eck, MJ			A zinc clasp structure tethers Lck to T cell coreceptors CD4 and CD8	SCIENCE			English	Article							TYROSINE-PROTEIN-KINASE; AMINO-TERMINAL DOMAIN; CYTOPLASMIC TAIL; SERINE PHOSPHORYLATION; DOWN-REGULATION; COATED PITS; P56LCK; P56(LCK); ANTIGEN; COMPLEX	The T cell coreceptors CD4 and CD8 both associate via their cytoplasmic tails with the N-terminus of the Src-family tyrosine kinase Lck. These interactions require zinc and are critical for T cell development and activation. We examined the folding and solution structures of ternary CD4-Lck-Zn2+ and CD8alpha-LckZn(2+) complexes. The coreceptor tails and the Lck N-terminus are unstructured in isolation but assemble in the presence of zinc to form compactly folded heterodimeric domains. The cofolded complexes have similar "zinc clasp" cores that are augmented by distinct structural elements. A dileucine motif required for clathrin-mediated endocytosis of CD4 is masked by Lck.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Eck, MJ (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.	eck@red.dfci.harvard.edu			NCI NIH HHS [CA080942] Funding Source: Medline; NHLBI NIH HHS [HL61001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080942] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACRES RB, 1986, J BIOL CHEM, V261, P6210; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; COLLINS TL, 1992, J IMMUNOL, V148, P2159; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; Huse M, 1998, J BIOL CHEM, V273, P18729, DOI 10.1074/jbc.273.30.18729; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Kim Philip, UNPUB; Lin RS, 1998, J BIOL CHEM, V273, P32878, DOI 10.1074/jbc.273.49.32878; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALGHETTI S, 1995, P NATL ACAD SCI USA, V92, P349, DOI 10.1073/pnas.92.2.349; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SLECKMAN BP, 1992, P NATL ACAD SCI USA, V89, P7566, DOI 10.1073/pnas.89.16.7566; Trobridge PA, 2001, J IMMUNOL, V166, P809, DOI 10.4049/jimmunol.166.2.809; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEYAND CM, 1987, J IMMUNOL, V138, P1351; Wray V, 1998, BIOCHEMISTRY-US, V37, P8527, DOI 10.1021/bi9723111	26	179	188	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1725	1728		10.1126/science.1085643	http://dx.doi.org/10.1126/science.1085643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500983				2022-12-24	WOS:000185387700045
J	Schroeder, CM; Babcock, HP; Shaqfeh, ESG; Chu, S				Schroeder, CM; Babcock, HP; Shaqfeh, ESG; Chu, S			Observation of polymer conformation hysteresis in extensional flow	SCIENCE			English	Article							COIL-STRETCH TRANSITION; ELONGATIONAL FLOW; HYDRODYNAMIC INTERACTION; FLEXIBLE POLYMERS; LIGHT-SCATTERING; DYNAMICS; BIREFRINGENCE; COEFFICIENTS; POINT; DNA	Highly extensible Escherichia coli DNA molecules in planar extensional flow were visualized in dilute solution by fluorescence microscopy. For a narrow range of flow strengths, the molecules were found in either a coiled or highly extended conformation, depending on the deformation history of the polymer. This conformation hysteresis persists for many polymer relaxation times and is due to conformation-dependent hydrodynamic forces. Polymer conformational free-energy landscapes were calculated from computer simulations and show two free-energy minima for flow strengths near the coil-stretch transition. Hysteresis cycles may directly influence bulk-solution stresses and the development of stress-strain relations for dilute polymer flows.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Chu, S (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.			Schroeder, Charles/0000-0001-6023-2274; Babcock, Hazen/0000-0003-4835-3692				[Anonymous], 1987, DYNAMICS POLYM LIQUI; Babcock HP, 2003, MACROMOLECULES, V36, P4544, DOI 10.1021/ma034073p; BATCHELOR GK, 1970, J FLUID MECH, V44, P419, DOI 10.1017/S002211207000191X; BENTLEY BJ, 1986, J FLUID MECH, V167, P219, DOI 10.1017/S002211208600280X; BRESTKIN YV, 1987, ACTA POLYM, V38, P470, DOI 10.1002/actp.1987.010380803; de Gennes P. G., 1979, SCALING CONCEPTS POL, P128; De Gennes P.-G., 1990, INTRO POLYM DYNAMICS; DEGENNES PG, 1974, J CHEM PHYS, V60, P5030, DOI 10.1063/1.1681018; FAN XJ, 1985, J NON-NEWTON FLUID, V18, P255, DOI 10.1016/0377-0257(85)87002-6; FULLER GG, 1980, RHEOL ACTA, V19, P580, DOI 10.1007/BF01517512; HINCH EJ, 1974, C INT CNRS, V233, P241; HSIEH CC, IN PRESS J RHEOL; Hunkeler D, 1996, POLYMER, V37, P4257, DOI 10.1016/0032-3861(96)00290-X; Jendrejack RM, 2002, J CHEM PHYS, V116, P7752, DOI 10.1063/1.1466831; Larson R. G, 1999, STRUCTURE RHEOLOGY C; Lee EC, 1999, MACROMOLECULES, V32, P3295, DOI 10.1021/ma981277a; Lumley J. L., 1973, Journal of Polymer Science, Macromolecular Reviews, V7, P263, DOI 10.1002/pol.1973.230070104; MAGDA JJ, 1988, J CHEM PHYS, V89, P2504, DOI 10.1063/1.455044; MENASVETA MJ, 1991, MACROMOLECULES, V24, P3427, DOI 10.1021/ma00011a060; Perkins TT, 1997, SCIENCE, V276, P2016, DOI 10.1126/science.276.5321.2016; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; RALLISON JM, 1988, J NON-NEWTON FLUID, V29, P37, DOI 10.1016/0377-0257(88)85049-3; Reif F., 1965, FUNDAMENTALS STAT TH; ROTNE J, 1969, J CHEM PHYS, V50, P4831, DOI 10.1063/1.1670977; Smith DE, 1996, MACROMOLECULES, V29, P1372, DOI 10.1021/ma951455p; Smith DE, 1998, SCIENCE, V281, P1335, DOI 10.1126/science.281.5381.1335; TANNER RI, 1975, T SOC RHEOL, V19, P557, DOI 10.1122/1.549385; TOMS BA, 1948, 1 P INT C RHEOL, V2, P135; VIRK PS, 1975, AICHE J, V21, P625, DOI 10.1002/aic.690210402; WIEST JM, 1989, J CHEM PHYS, V90, P587, DOI 10.1063/1.456457; [No title captured]	31	298	302	4	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1515	1519		10.1126/science.1086070	http://dx.doi.org/10.1126/science.1086070			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970560				2022-12-24	WOS:000185255300044
J	Wardemann, H; Yurasov, S; Schaefer, A; Young, JW; Meffre, E; Nussenzweig, MC				Wardemann, H; Yurasov, S; Schaefer, A; Young, JW; Meffre, E; Nussenzweig, MC			Predominant autoantibody production by early human B cell precursors	SCIENCE			English	Article							IMMUNOGLOBULIN HEAVY; CHAIN GENE; ANTIBODY; EXPRESSION; REPERTOIRE; POLYREACTIVITY; LYMPHOCYTES; SELECTION; REGION; MICE	During B lymphocyte development, antibodies are assembled by random gene segment reassortment to produce a vast number of specificities. A potential disadvantage of this process is that some of the antibodies produced are self-reactive. We determined the prevalence of self-reactive antibody formation and its regulation in human B cells. A majority (55 to 75%) of all antibodies expressed by early immature B cells displayed self-reactivity, including poly-reactive and anti-nuclear specificities. Most of these autoantibodies were removed from the population at two discrete checkpoints during B cell development. Inefficient checkpoint regulation would lead to substantial increases in circulating autoantibodies.	Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, Allogeneic Bone Marrow Transplant Serv, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, Clin Immunol Serv, New York, NY 10021 USA; Cornell Univ, Hosp Special Surg, Weill Med Coll, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Meffre, E (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.	meffree@hss.edu; nussen@mail.rockefeller.edu	Nussenzweig, Michel/AAE-7292-2019	Young, James/0000-0002-0032-6559; Wardemann, Hedda/0000-0003-3921-5933				Aguilera I, 2001, IMMUNOLOGY, V102, P273, DOI 10.1046/j.1365-2567.2001.01159.x; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; BARBAS SM, 1995, P NATL ACAD SCI USA, V92, P2529, DOI 10.1073/pnas.92.7.2529; Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271; Billips LG, 1995, ANN NY ACAD SCI, V764, P1; Casellas R, 2001, SCIENCE, V291, P1541, DOI 10.1126/science.1056600; CROUZIER R, 1995, J IMMUNOL, V154, P4526; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; GUIGOU V, 1991, J IMMUNOL, V146, P1368; ICHIYOSHI Y, 1994, J EXP MED, V180, P885, DOI 10.1084/jem.180.3.885; King LB, 2000, IMMUNOL REV, V176, P86; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; Klonowski KD, 1999, J IMMUNOL, V162, P1566; Landsteiner K, 1936, SPECIFICITY SEROLOGI; Leslie D, 2001, J CLIN INVEST, V108, P1417, DOI 10.1172/JCI200114452; Martin F, 2000, IMMUNOL REV, V175, P70, DOI 10.1034/j.1600-065X.2000.017515.x; Meffre E, 2001, J CLIN INVEST, V108, P879, DOI 10.1172/JCI13051; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; Retter MW, 1998, J EXP MED, V188, P1231, DOI 10.1084/jem.188.7.1231; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; SEIGNEURIN JM, 1988, BLOOD, V71, P581; Shiokawa S, 1999, J IMMUNOL, V162, P6060; Silverstein AM, 2001, NAT IMMUNOL, V2, P279, DOI 10.1038/86280; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; Yu W, 1999, NATURE, V400, P682, DOI 10.1038/23287	34	1448	1516	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1374	1377		10.1126/science.1086907	http://dx.doi.org/10.1126/science.1086907			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12920303				2022-12-24	WOS:000185116400040
J	Ludwig, MG; Vanek, M; Guerini, D; Gasser, JA; Jones, CE; Junker, U; Hofstetter, H; Wolf, RM; Seuwen, K				Ludwig, MG; Vanek, M; Guerini, D; Gasser, JA; Jones, CE; Junker, U; Hofstetter, H; Wolf, RM; Seuwen, K			Proton-sensing G-protein-coupled receptors	NATURE			English	Article							MEDIATED BONE-RESORPTION; ACTIVATION; ACIDOSIS; TISSUE; SPHINGOSYLPHOSPHORYLCHOLINE; NOCICEPTION; RHODOPSIN; CHANNELS; PAIN; PH	Blood pH is maintained in a narrow range around pH 7.4 mainly through regulation of respiration and renal acid extrusion(1,2). The molecular mechanisms involved in pH homeostasis are not completely understood. Here we show that ovarian cancer G-protein-coupled receptor 1 (OGR1), previously described as a receptor for sphingosylphosphorylcholine 3, acts as a proton-sensing receptor stimulating inositol phosphate formation. The receptor is inactive at pH 7.8, and fully activated at pH 6.8-site-directed mutagenesis shows that histidines at the extracellular surface are involved in pH sensing. We find that GPR4, a close relative of OGR1, also responds to pH changes, but elicits cyclic AMP formation. It is known that the skeleton participates in pH homeostasis as a buffering organ, and that osteoblasts respond to pH changes in the physiological range(4), but the pH-sensing mechanism operating in these cells was hitherto not known. We detect expression of OGR1 in osteosarcoma cells and primary human osteoblast precursors, and show that these cells exhibit strong pH-dependent inositol phosphate formation. Immunohistochemistry on rat tissue sections confirms the presence of OGR1 in osteoblasts and osteocytes. We propose that OGR1 and GPR4 are proton-sensing receptors involved in pH homeostasis.	Novartis Inst Biomed Res, CH-4002 Basel, Switzerland; Novartis Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England	Novartis; Novartis	Seuwen, K (corresponding author), Novartis Inst Biomed Res, CH-4002 Basel, Switzerland.		Gasser, Juerg Andreas/AAT-5389-2020	Gasser, Juerg Andreas/0000-0002-0106-364X				AN SZ, 1995, FEBS LETT, V375, P121, DOI 10.1016/0014-5793(95)01196-L; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Brechter AB, 2002, REGUL PEPTIDES, V103, P39, DOI 10.1016/S0167-0115(01)00325-1; Bushinsky DA, 2001, EUR J NUTR, V40, P238, DOI 10.1007/s394-001-8351-5; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Feldman JL, 2003, ANNU REV NEUROSCI, V26, P239, DOI 10.1146/annurev.neuro.26.041002.131103; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GOLDHABER P, 1987, AM J PHYSIOL, V253, pE90, DOI 10.1152/ajpendo.1987.253.1.E90; Heming TA, 2001, CLIN SCI, V101, P267, DOI 10.1042/CS20010139; Ishizaka H, 1999, CIRCULATION, V99, P558, DOI 10.1161/01.CIR.99.4.558; Krieger NS, 2000, AM J PHYSIOL-RENAL, V279, pF1077, DOI 10.1152/ajprenal.2000.279.6.F1077; Meghji S, 2001, AM J PHYSIOL-ENDOC M, V280, pE112, DOI 10.1152/ajpendo.2001.280.1.E112; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; Reeh PW, 1996, PROG BRAIN RES, V113, P143, DOI 10.1016/S0079-6123(08)61085-7; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Sottile V, 2002, BONE, V30, P699, DOI 10.1016/S8756-3282(02)00674-9; Swenson E R, 2001, Respir Care, V46, P342; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	29	482	504	4	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					93	98		10.1038/nature01905	http://dx.doi.org/10.1038/nature01905			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955148				2022-12-24	WOS:000185089200045
J	Callahan, CM; McHorney, CA				Callahan, CM; McHorney, CA			Successful aging and the humility of perspective	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN						Indiana Univ, Ctr Aging Res, Regenstrief Inst, Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Callahan, CM (corresponding author), Indiana Univ, Ctr Aging Res, Regenstrief Inst, Richard L Roudebush Vet Adm Med Ctr, 1050 Wishard Blvd,RG6, Indianapolis, IN 46202 USA.	ccallaha@iupui.edu						Evans R. G., 1994, WHY ARE SOME PEOPLE; Institute of Medicine (US) Committee on Assuring the Health of the Public in the 21st Century, 2002, FUT PUBL HLTH 21 CEN	2	11	12	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			389	390		10.7326/0003-4819-139-5_Part_2-200309021-00001	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00001			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965962				2022-12-24	WOS:000185133800001
J	Ensslin, MA; Shur, BD				Ensslin, MA; Shur, BD			Identification of mouse sperm SED1, a bimotif EGF repeat and discoidin-domain protein involved in sperm-egg binding	CELL			English	Article							COAGULATION-FACTOR-V; ZONA-PELLUCIDA; FACTOR-VIII; CRYSTAL-STRUCTURES; SURFACE; MICE; ZP3; CLONING; ADHESION; BETA-1,4-GALACTOSYLTRANSFERASE	We report the identification of SED1, a protein required for mouse sperm binding to the egg zona pellucida. SED1 is homologous to a small group of secreted cell-matrix adhesive proteins that contain Notch-like EGF repeats and discoidin/F5/8 type C domains. SED1 is expressed in spermatogenic cells and is secreted by the initial segment of the caput epididymis, resulting in SED1 localization on the sperm plasma membrane overlying the acrosome. SED1 binds specifically to the zona pellucida of unfertilized oocytes, but not to the zona of fertilized eggs. Recombinant SED1 and anti-SED1 antibodies competitively inhibit sperm-egg binding, as do truncated SED1 proteins containing a discoidin/C domain. SED1 null males are subfertile and their sperm are unable to bind to the egg coat in vitro. These studies illustrate that Notch-like EGF and discoidin/C domains, protein motifs that facilitate a variety of cellular interactions, participate in gamete recognition as well.	Emory Univ, Sch Med, Dept Cell Biol, Whitehead Inst Biomed Res, Atlanta, GA 30322 USA	Emory University; Massachusetts Institute of Technology (MIT); Whitehead Institute	Shur, BD (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Whitehead Inst Biomed Res, 615 Michael St,Room 405, Atlanta, GA 30322 USA.	barry@cellbio.emory.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023479] Funding Source: NIH RePORTER; NICHD NIH HHS [HD23479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andersen MH, 2000, BIOCHEMISTRY-US, V39, P6200, DOI 10.1021/bi992221r; Andersen MH, 1997, BIOCHEMISTRY-US, V36, P5441, DOI 10.1021/bi963119m; Aviles M, 1997, BIOL REPROD, V57, P1155, DOI 10.1095/biolreprod57.5.1155; Blazar M, 2001, MOL CELL BIOL, V21, P2570, DOI 10.1128/MCB.21.7.2570-2580.2001; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Couto JR, 1996, DNA CELL BIOL, V15, P281, DOI 10.1089/dna.1996.15.281; Ensslin M, 1998, BIOL REPROD, V58, P1057, DOI 10.1095/biolreprod58.4.1057; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; Fusi FM, 1996, MOL HUM REPROD, V2, P169, DOI 10.1093/molehr/2.3.169; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; Haltiwanger RS, 2002, CURR OPIN STRUC BIOL, V12, P593, DOI 10.1016/S0959-440X(02)00371-8; JANSSEN PJ, 1994, J HISTOCHEM CYTOCHEM, V42, P1169, DOI 10.1177/42.8.8027537; Johnston DS, 1998, J BIOL CHEM, V273, P1888, DOI 10.1074/jbc.273.4.1888; Larson JL, 1999, MOL REPROD DEV, V52, P445, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;445::AID-MRD14&gt;3.0.CO;2-6; Lawrence N, 2000, DEVELOPMENT, V127, P3185; Lonhienne T, 2001, J MOL BIOL, V310, P291, DOI 10.1006/jmbi.2001.4774; Lu QX, 1997, DEVELOPMENT, V124, P4121; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NAGDAS SK, 1994, BIOL REPROD, V51, P262, DOI 10.1095/biolreprod51.2.262; Nayernia K, 2002, MOL CELL BIOL, V22, P3046, DOI 10.1128/MCB.22.9.3046-3052.2002; NELLES LP, 1976, ANAL BIOCHEM, V73, P522, DOI 10.1016/0003-2697(76)90202-5; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; Ogura K, 1996, BIOCHEM BIOPH RES CO, V225, P932, DOI 10.1006/bbrc.1996.1274; Oshima K, 2002, EUR J BIOCHEM, V269, P1209, DOI 10.1046/j.1432-1033.2002.02758.x; Pearse RV, 1997, P NATL ACAD SCI USA, V94, P7555, DOI 10.1073/pnas.94.14.7555; Penta K, 1999, J BIOL CHEM, V274, P11101, DOI 10.1074/jbc.274.16.11101; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Rankin TL, 2003, DEV CELL, V5, P33, DOI 10.1016/S1534-5807(03)00195-3; Rankin TL, 1998, DEVELOPMENT, V125, P2415; REITHERMAN RW, 1975, P NATL ACAD SCI USA, V72, P3541, DOI 10.1073/pnas.72.9.3541; ROBAIRE B, 1994, PHYSL REPROD, P999; Shi XD, 2001, DEVELOPMENT, V128, P645; Singson A, 1998, CELL, V93, P71, DOI 10.1016/S0092-8674(00)81147-2; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Trubner M, 1997, ANDROLOGIA, V29, P253; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Wolfer DP, 2002, TRENDS NEUROSCI, V25, P336, DOI 10.1016/S0166-2236(02)02192-6; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; YOUAKIM A, 1994, J CELL BIOL, V126, P1573, DOI 10.1083/jcb.126.6.1573	42	191	201	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2003	114	4					405	417		10.1016/S0092-8674(03)00643-3	http://dx.doi.org/10.1016/S0092-8674(03)00643-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941270	Bronze			2022-12-24	WOS:000184928800005
J	Eckstein-Ludwig, U; Webb, RJ; van Goethem, IDA; East, JM; Lee, AG; Kimura, M; O'Neill, PM; Bray, PG; Ward, SA; Krishna, S				Eckstein-Ludwig, U; Webb, RJ; van Goethem, IDA; East, JM; Lee, AG; Kimura, M; O'Neill, PM; Bray, PG; Ward, SA; Krishna, S			Artemisinins target the SERCA of Plasmodium falciparum	NATURE			English	Article							CALCIUM-PUMP; ANTIMALARIAL; DERIVATIVES; MALARIA; INVITRO; RESISTANCE; RETICULUM; QINGHAOSU; PARASITE; DRUGS	Artemisinins are extracted from sweet wormwood (Artemisia annua) and are the most potent antimalarials available(1), rapidly killing all asexual stages of Plasmodium falciparum(2). Artemisinins are sesquiterpene lactones widely used to treat multidrug-resistant malaria(1), a disease that annually claims 1 million lives. Despite extensive clinical and laboratory experience(3-5) their molecular target is not yet identified. Activated artemisinins form adducts with a variety of biological macromolecules, including haem, translationally controlled tumour protein (TCTP) and other higher-molecular-weight proteins(6). Here we show that artemisinins, but not quinine or chloroquine, inhibit the SERCA orthologue (PfATP6) of Plasmodium falciparum in Xenopus oocytes with similar potency to thapsigargin (another sesquiterpene lactone and highly specific SERCA inhibitor). As predicted, thapsigargin also antagonizes the parasiticidal activity of artemisinin. Desoxyartemisinin lacks an endoperoxide bridge and is ineffective both as an inhibitor of PfATP6 and as an antimalarial. Chelation of iron by desferrioxamine abrogates the antiparasitic activity of artemisinins and correspondingly attenuates inhibition of PfATP6. Imaging of parasites with BODIPY-thapsigargin labels the cytosolic compartment and is competed by artemisinin. Fluorescent artemisinin labels parasites similarly and irreversibly in an Fe2+-dependent manner. These data provide compelling evidence that artemisinins act by inhibiting PfATP6 outside the food vacuole after activation by iron.	St George Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England; Univ Southampton, Dept Biochem & Mol Biol, Southampton SO16 7PX, Hants, England; Osaka City Univ, Sch Med, Radioisotope Ctr, Abeno Ku, Osaka 5458585, Japan; Univ Liverpool, Robert Robinson Labs, Dept Chem, Liverpool L69 7ZD, Merseyside, England; Univ Liverpool, Liverpool Sch Trop Med, Mol & Biochem Parasitol Grp, Liverpool L3 5QA, Merseyside, England	St Georges University London; University of Southampton; Osaka Metropolitan University; University of Liverpool; Liverpool School of Tropical Medicine; University of Liverpool	Krishna, S (corresponding author), St George Hosp, Sch Med, Dept Cellular & Mol Med, Cranmer Terrace, London SW17 0RE, England.	s.krishna@sghms.ac.uk	Ward, Steve/G-6003-2015; Hua, QX/HGE-3640-2022	Ward, Steve/0000-0003-2331-3192; Krishna, Sanjeev/0000-0003-0066-0634				Akompong T, 1999, MOL BIOCHEM PARASIT, V101, P71, DOI 10.1016/S0166-6851(99)00056-0; ALLEN DG, 1985, NATURE, V316, P674, DOI 10.1038/316674a0; ASAWAMAHASAKDA W, 1994, ANTIMICROB AGENTS CH, V38, P1854, DOI 10.1128/AAC.38.8.1854; BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bhisutthibhan J, 1998, J BIOL CHEM, V273, P16192, DOI 10.1074/jbc.273.26.16192; Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; East J M, 1994, Methods Mol Biol, V27, P87; ELLIS DS, 1985, ANN TROP MED PARASIT, V79, P367, DOI 10.1080/00034983.1985.11811933; GU HM, 1984, T ROY SOC TROP MED H, V78, P265, DOI 10.1016/0035-9203(84)90296-7; Hawley SR, 1998, ANTIMICROB AGENTS CH, V42, P682, DOI 10.1128/AAC.42.3.682; Haynes RK, 2003, ANTIMICROB AGENTS CH, V47, P1175, DOI 10.1128/AAC.47.3.1175.2003; Haynes RK, 2001, CURR OPIN INFECT DIS, V14, P719, DOI 10.1097/00001432-200112000-00010; HIEN TT, 1993, LANCET, V341, P603; Jefford CW, 2001, CURR MED CHEM, V8, P1803, DOI 10.2174/0929867013371608; Krishna S, 2001, J BIOL CHEM, V276, P10782, DOI 10.1074/jbc.M010554200; Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7; MESHNICK SR, 1993, ANTIMICROB AGENTS CH, V37, P1108, DOI 10.1128/AAC.37.5.1108; O'Neill PM, 2000, J ORG CHEM, V65, P1578, DOI 10.1021/jo991585m; Olliaro PL, 2001, TRENDS PARASITOL, V17, P122, DOI 10.1016/S1471-4922(00)01838-9; ONO T, 1991, Japanese Journal of Parasitology, V40, P587; Pandey AV, 1999, J BIOL CHEM, V274, P19383, DOI 10.1074/jbc.274.27.19383; Price RN, 1999, ANTIMICROB AGENTS CH, V43, P2943, DOI 10.1128/AAC.43.12.2943; Robert A, 2002, ACCOUNTS CHEM RES, V35, P167, DOI 10.1021/ar990164o; SCHATZMANN HJ, 1953, HELV PHYSIOL PHARM A, V11, P346; Simpson PB, 1997, BIOCHEM J, V325, P239, DOI 10.1042/bj3250239; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272	30	767	805	7	373	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					957	961		10.1038/nature01813	http://dx.doi.org/10.1038/nature01813			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931192				2022-12-24	WOS:000184843600045
J	Ng, SKC				Ng, SKC			Possible role of an animal vector in the SARS outbreak at Amoy Gardens	LANCET			English	Article							TRANSMISSION DYNAMICS; CORONAVIRUS; AGENT	A mass outbreak of severe acute respiratory syndrome (SARS) in the Amoy Gardens housing complex in Hong Kong at the end of March, 2003, affected more than 300 residents in less than a month, and has epidemiologists all over the world puzzled about the mode of transmission of this new disease, which until then was thought to be transmitted solely by respiratory droplets. The source of the outbreak was later traced to an individual with SARS who spent two nights at Amoy Gardens. Official explanations failed to account for the large number of residents infected over a wide area within a short time., A powerful environmental mechanism that efficiently amplified and distributed the causal agent must. have been at work to cause this outbreak. One such mechanism could be an animal vector, most probably roof rats, that was infected by the index patient and subsequently spread the disease to more than 150 households.	Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	Columbia University	Ng, SKC (corresponding author), Unit A-C,11-F,Power Ind Bldg,9-15 Wo Heung St, Shatin, Hong Kong, Peoples R China.	skcng@hotmail.com						BENITEZ MA, 2003, S CHINA MORNING 0528, pC1; Bradsher K, 2003, NY TIMES, pA1; *DEP HLTH HONG KIO, 1908, OUTBR SEV AC RESP SY; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Haijema BJ, 2003, J VIROL, V77, P4528, DOI 10.1128/JVI.77.8.4528-4538.2003; JACBOY RO, 1986, VIRAL MYCOPLASMAL IN, P625; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; *PROF PEST MAN ASS, 2003, ROOF BLACK SHIP RAT; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; *U AZ COOP EXT, 2003, ROOF RAT CONTR HOM O; WHO, 2003, 1 DAT STAB RES SARS; *WHO, 2003, COR NEV BEF SEEN  HU; 2003, MING PAO HONG K 0505, pA11; 2003, MING PAO HONG K 0508, pA4; 2003, S CHINA MORNING 0517; 2003, MING PAO HONG K 0411, pA2	20	66	72	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					570	572		10.1016/S0140-6736(03)14121-9	http://dx.doi.org/10.1016/S0140-6736(03)14121-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932393	Green Published, Bronze			2022-12-24	WOS:000184817600027
J	Dumoulin, M; Last, AM; Desmyter, A; Decanniere, K; Canet, D; Larsson, G; Spencer, A; Archer, DB; Sasse, J; Muyldermans, S; Wyns, L; Redfield, C; Matagne, A; Robinson, CV; Dobson, CM				Dumoulin, M; Last, AM; Desmyter, A; Decanniere, K; Canet, D; Larsson, G; Spencer, A; Archer, DB; Sasse, J; Muyldermans, S; Wyns, L; Redfield, C; Matagne, A; Robinson, CV; Dobson, CM			A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme	NATURE			English	Article							HEREDITARY RENAL AMYLOIDOSIS; ALZHEIMERS-DISEASE; PRION REPLICATION; TRANSTHYRETIN; AGGREGATION; STRATEGIES; VARIANTS; BINDING	Amyloid diseases are characterized by an aberrant assembly of a specific protein or protein fragment into fibrils and plaques that are deposited in various organs and tissues(1-3), often with serious pathological consequences. Non-neuropathic systemic amyloidosis (4-6) is associated with single point mutations in the gene coding for human lysozyme. Here we report that a single-domain fragment of a camelid antibody(7-9) raised against wild-type human lysozyme inhibits the in vitro aggregation of its amyloidogenic variant, D67H. Our structural studies reveal that the epitope includes neither the site of mutation nor most residues in the region of the protein structure that is destabilized by the mutation. Instead, the binding of the antibody fragment achieves its effect by restoring the structural cooperativity characteristic of the wild-type protein. This appears to occur at least in part through the transmission of long-range conformational effects to the interface between the two structural domains of the protein. Thus, reducing the ability of an amyloidogenic protein to form partly unfolded species can be an effective method of preventing its aggregation, suggesting approaches to the rational design of therapeutic agents directed against protein deposition diseases.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QH, England; Free Univ Brussels, Dept Ultrastruct, B-1050 Brussels, Belgium; Inst Food Res, Norwich NR4 7UA, Norfolk, England; Univ Nottingham, Sch Life & Environm Sci, Nottingham NG7 2RD, England; Cent Vet Res Lab, Dubai, U Arab Emirates; Univ Liege, Inst Chim B6, Ctr Ingn Prot, Enzymol Lab, B-4000 Liege, Sart Tilman, Belgium	University of Cambridge; University of Oxford; Universite Libre de Bruxelles; Vrije Universiteit Brussel; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Nottingham; University of Liege	Dobson, CM (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cmd44@cam.ac.uk	Muyldermans, Serge V/C-6418-2016; Muyldermans, Serge/AAC-7374-2019	Muyldermans, Serge V/0000-0002-3678-3575; Muyldermans, Serge/0000-0002-3678-3575; robinson, carol/0000-0001-7829-5505; Redfield, Christina/0000-0001-7297-7708; Matagne, Andre/0000-0001-6417-6791				Aguzzi A, 2001, NAT REV NEUROSCI, V2, P745, DOI 10.1038/35094590; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Branden C., 1999, INTRO PROTEIN STRUCT; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Dobson CM, 2003, NAT REV DRUG DISCOV, V2, P154, DOI 10.1038/nrd1013; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; May BCH, 2003, P NATL ACAD SCI USA, V100, P3416, DOI 10.1073/pnas.2627988100; McCammon MG, 2002, STRUCTURE, V10, P851, DOI 10.1016/S0969-2126(02)00771-2; Morozova-Roche LA, 2000, J STRUCT BIOL, V130, P339, DOI 10.1006/jsbi.2000.4264; Muyldermans S, 2001, J Biotechnol, V74, P277; OHKUBO T, 1991, J BIOCHEM-TOKYO, V110, P1022, DOI 10.1093/oxfordjournals.jbchem.a123672; Pepys MB, 2002, NATURE, V417, P254, DOI 10.1038/417254a; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Spencer A, 1999, PROTEIN EXPRES PURIF, V16, P171, DOI 10.1006/prep.1999.1036; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; Valleix S, 2002, KIDNEY INT, V61, P907, DOI 10.1046/j.1523-1755.2002.00205.x; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Yazaki M, 2003, KIDNEY INT, V63, P1652, DOI 10.1046/j.1523-1755.2003.00904.x	30	202	293	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					783	788		10.1038/nature01870	http://dx.doi.org/10.1038/nature01870			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917687	Green Published			2022-12-24	WOS:000184733900042
J	Kovalenko, A; Chable-Bessia, C; Cantarella, G; Israel, A; Wallach, D; Courtois, G				Kovalenko, A; Chable-Bessia, C; Cantarella, G; Israel, A; Wallach, D; Courtois, G			The tumour suppressor CYLD negatively regulates NF-kappa B signalling by deubiquitination	NATURE			English	Article							KINASE COMPLEX; INTERFERING RNAS; ACTIVATION; IKK; PATHWAYS; ENZYMES; SYSTEM; GAMMA; TRAF2; GENE	NF-kappaB transcription factors have key roles in inflammation, immune response, oncogenesis and protection against apoptosis (1,2). In most cells, these factors are kept inactive in the cytoplasm through association with IkappaB inhibitors. After stimulation by various reagents, IkappaB is phosphorylated by the IkappaB kinase (IKK) complex(3) and degraded by the proteasome, allowing NF-kappaB to translocate to the nucleus and activate its target genes. Here we report that CYLD, a tumour suppressor that is mutated in familial cylindromatosis(4), interacts with NEMO, the regulatory subunit of IKK5,6. CYLD also interacts directly with tumour-necrosis factor receptor (TNFR)-associated factor 2 (TRAF2), an adaptor molecule involved in signalling by members of the family of TNF/ nerve growth factor receptors. CYLD has deubiquitinating activity that is directed towards non-K48-linked polyubiquitin chains, and negatively modulates TRAF-mediated activation of IKK, strengthening the notion that ubiquitination is involved in IKK activation by TRAFs and suggesting that CYLD functions in this process. Truncations of CYLD found in cylindromatosis result in reduced enzymatic activity, indicating a link between impaired deubiquitination of CYLD substrates and human pathophysiology.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Inst Pasteur, CNRS, URA 2582, Unite Biol Mol Express Gen, F-75015 Paris, France; Univ Catania, Dept Expt & Clin Pharmacol, Sch Med, I-95125 Catania, Italy	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Catania	Wallach, D (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Cantarella, Giuseppina/AHD-9609-2022	COURTOIS, Gilles/0000-0003-3117-9595				Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2	22	812	841	5	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					801	805		10.1038/nature01802	http://dx.doi.org/10.1038/nature01802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917691				2022-12-24	WOS:000184733900046
J	Yu, XH; Yu, YK; Liu, BD; Luo, K; Kong, W; Mao, PY; Yu, XF				Yu, XH; Yu, YK; Liu, BD; Luo, K; Kong, W; Mao, PY; Yu, XF			Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL VIF PROTEIN; SOR GENE-PRODUCT; HTLV-III/LAV; TYPE-1 VIF; DNA; SCF; IDENTIFICATION; HYPERMUTATION; LYMPHOCYTES	Human immunodeficiency virus-1 (HIV-1) Vif is essential for viral evasion of host antiviral factor CEM15/APOBEC3G. We report that Vif interacts with cellular proteins Cul5, elongins B and C, and Rbx1 to form an Skp1-cullin-F-box (SCF)-like complex. The ability of Vif to suppress antiviral activity of APOBEC3G was specifically dependent on Cul5-SCF function, allowing Vif to interact with APOBEC3G and induce its ubiquitination and degradation. A Vif mutant that interacted with APOBEC3G but not with Cul5-SCF was functionally inactive. The Cul5-SCF was also required for Vif function in distantly related simian immunodeficiency virus mac. These results indicate that the conserved Cul5-SCF pathway used by Vif is a potential target for antiviral development.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Jilin Univ, Changchun, Peoples R China; Zhejiang Univ, Hangzhou 310027, Peoples R China	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jilin University; Zhejiang University	Yu, XF (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.				NCRR NIH HHS [1S10-RR14702] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014702] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; Gray WM, 2002, PLANT CELL, V14, P2137, DOI 10.1105/tpc.003178; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KAN NC, 1986, SCIENCE, V231, P1553, DOI 10.1126/science.3006245; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LEE TH, 1986, SCIENCE, V231, P1546, DOI 10.1126/science.3006243; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; SODROSKI J, 1986, SCIENCE, V231, P1549, DOI 10.1126/science.3006244; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	27	959	1004	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 7	2003	302	5647					1056	1060		10.1126/science.1089591	http://dx.doi.org/10.1126/science.1089591			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740HE	14564014				2022-12-24	WOS:000186396300052
J	Strachan, MWJ				Strachan, MWJ			Insulin and cognitive function	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE; HYPERINSULINEMIA; POPULATION; MEMORY		Western Gen Hosp, Metab Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Strachan, MWJ (corresponding author), Western Gen Hosp, Metab Unit, Edinburgh EH4 2XU, Midlothian, Scotland.							Craft S, 1996, NEUROBIOL AGING, V17, P123, DOI 10.1016/0197-4580(95)02002-0; Craft S, 1998, NEUROLOGY, V50, P164, DOI 10.1212/WNL.50.1.164; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Galasko D, 2003, NEUROLOGY, V60, P1886, DOI 10.1212/WNL.60.12.1886; KALMIJN S, 1995, DIABETOLOGIA, V38, P1096, DOI 10.1007/BF00402181; KUUSISTO J, 1993, HYPERTENSION, V22, P771, DOI 10.1161/01.HYP.22.5.771; Kuusisto J, 1997, BRIT MED J, V315, P1045, DOI 10.1136/bmj.315.7115.1045; Park CR, 2000, PHYSIOL BEHAV, V68, P509, DOI 10.1016/S0031-9384(99)00220-6; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; Watson GS, 2003, NEUROLOGY, V60, P1899, DOI 10.1212/01.WNL.0000065916.25128.25	10	44	44	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 18	2003	362	9392					1253	1253		10.1016/S0140-6736(03)14615-6	http://dx.doi.org/10.1016/S0140-6736(03)14615-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734CD	14575966				2022-12-24	WOS:000186036900005
J	Abe, E; Marians, RC; Yu, WQ; Wu, XB; Ando, T; Li, YN; Iqbal, J; Eldeiry, L; Rajendren, G; Blair, HC; Davies, TF; Zaidi, M				Abe, E; Marians, RC; Yu, WQ; Wu, XB; Ando, T; Li, YN; Iqbal, J; Eldeiry, L; Rajendren, G; Blair, HC; Davies, TF; Zaidi, M			TSH is a negative regulator of skeletal remodeling	CELL			English	Article							STIMULATING HORMONE-RECEPTOR; THYROID-HORMONE; THYROTROPIN RECEPTOR; OSTEOCLAST DIFFERENTIATION; PHOSPHATASE-ACTIVITY; BONE-MARROW; RANK LIGAND; KAPPA-B; EXPRESSION; CELLS	The established function of thyroid stimulating hormone (TSH) is to promote thyroid follicle development and hormone secretion. The osteoporosis associated with hyperthyroidism is traditionally viewed as a secondary consequence of altered thyroid function. We provide evidence for direct effects of TSH on both components of skeletal remodeling, osteoblastic bone formation, and osteoclastic bone resorption, mediated via the TSH receptor (TSHR) found on osteoblast and osteoclast precursors. Even a 50% reduction in TSHR expression produces profound osteoporosis (bone loss) together with focal osteosclerosis (localized bone formation). TSH inhibits osteoclast formation and survival by attenuating JNK/c-jun and NFkappaB signaling triggered in response to RANK-L and TNFalpha. TSH also inhibits osteoblast differentiation and type 1 collagen expression in a Runx-2- and osterix-independent manner by downregulating Wnt (LRP-5) and VEGF (Flk) signaling. These studies define a role for TSH as a single molecular switch in the independent control of both bone formation and resorption.	CUNY Mt Sinai Sch Med, Dept Med, Mt Sinai Bone Program, New York, NY 10029 USA; Vet Affairs Med Ctr, Bronx, NY 10463 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; Vet Affairs Med Ctr, Pittsburgh, PA 15213 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Zaidi, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Mt Sinai Bone Program, New York, NY 10029 USA.	mone.zaidi@mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007646, R01DK045011, R01DK052464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014917, R01AG023176] Funding Source: NIH RePORTER; NIA NIH HHS [AG23176-01, AG-14917-8] Funding Source: Medline; NIDDK NIH HHS [DK52464, DK45011, DK07646] Funding Source: Medline; PHS HHS [A124671] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; Ando T, 2002, J CLIN INVEST, V110, P1667, DOI 10.1172/JCI200216991; Bagriacik EU, 2000, J IMMUNOL, V164, P6158, DOI 10.4049/jimmunol.164.12.6158; Blair HC, 2002, BIOCHEM J, V364, P329, DOI 10.1042/BJ20020165; BORDIER P, 1967, P ROY SOC MED, V60, P1132, DOI 10.1177/003591576706011P130; BRITTO JM, 1994, ENDOCRINOLOGY, V134, P169, DOI 10.1210/en.134.1.169; Davies T, 2002, J CLIN INVEST, V110, P161, DOI 10.1172/JCI200216234; ENDO T, 1995, J BIOL CHEM, V270, P10833, DOI 10.1074/jbc.270.18.10833; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003-4819-130-9-199905040-00016; Hofbauer LC, 2002, J CELL BIOCHEM, V86, P642, DOI 10.1002/jcb.10242; Inoue M, 1998, THYROID, V8, P1059, DOI 10.1089/thy.1998.8.1059; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kawaida R, 2003, J EXP MED, V197, P1029, DOI 10.1084/jem.20021321; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kohn L D, 1995, Vitam Horm, V50, P287, DOI 10.1016/S0083-6729(08)60658-5; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Marians RC, 2002, P NATL ACAD SCI USA, V99, P15776, DOI 10.1073/pnas.242322099; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Prummel MF, 2000, J CLIN ENDOCR METAB, V85, P4347, DOI 10.1210/jc.85.11.4347; Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279; SATO K, 1987, ENDOCRINOLOGY, V120, P1873, DOI 10.1210/endo-120-5-1873; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Sims NA, 2003, J CLIN INVEST, V111, P1319, DOI 10.1172/JCI200317246; Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200; Sun L, 2003, FASEB J, V17, P369, DOI 10.1096/fj.02-0205com; Takahashi N, 2003, METH MOLEC MED, V80, P129; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Valyasevi RW, 1999, J CLIN ENDOCR METAB, V84, P2557, DOI 10.1210/jc.84.7.2557; Vincent BL, 2001, J BONE MINER RES, V16, pS268; Wang HC, 2003, BLOOD, V101, P119, DOI 10.1182/blood-2002-02-0544; WANG J, 1995, CELL IMMUNOL, V161, P299, DOI 10.1006/cimm.1995.1040; WEBBER DM, 1988, HISTOCHEM J, V20, P269, DOI 10.1007/BF01745605; Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290; Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599; Zelzer E, 2002, DEVELOPMENT, V129, P1893	42	461	506	2	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					151	162		10.1016/S0092-8674(03)00771-2	http://dx.doi.org/10.1016/S0092-8674(03)00771-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567913	Bronze			2022-12-24	WOS:000186039200007
J	Markowitz, JS; Donovan, JL; DeVane, CL; Taylor, RM; Ruan, Y; Wang, JS; Chavin, KD				Markowitz, JS; Donovan, JL; DeVane, CL; Taylor, RM; Ruan, Y; Wang, JS; Chavin, KD			Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERICUM-PERFORATUM; MAJOR DEPRESSION; PHARMACOKINETICS; ALPRAZOLAM; EXTRACT; DEXTROMETHORPHAN; INHIBITION; PLASMA; IMIPRAMINE; PLACEBO	Context St John's wort is a popular herbal product used to treat depression but it has been implicated in drug interactions. Objective To assess the potential of St John's wort administration to alter the activity of the cytochrome P450 (CYP) enzymes extensively involved in drug metabolism. Design, Setting, and Participants Open-label crossover study with fixed treatment order conducted March 2002 to February 2003 in a US general clinical research center involving 12 healthy volunteers (6 men and 6 women) aged 22 to 38 years before and after 14 days of administration of St John's wort. Intervention Participants were given probe drugs (30 mg of dextromethorphan and 2 mg of alprazolam) to establish baseline CYP 3A4 and CYP 2D6 activity. After a minimum 7-day washout period, participants began taking one 300-mg tablet 3 times per day. After 14 days of St John's wort administration, participants were given the probe drugs along with 1 St John's wort tablet to establish postadministration CYP activity; the St John's wort dosing regimen was continued for 48 hours. Main Outcome Measures Changes in plasma pharmacokinetics of alprazolam as a probe for CYP 3A4 activity and the ratio of dextromethorphan to its metabolite, dextrorphan, in urine as a probe for CYP 2D6 activity. Results A 2-fold decrease in the area under the curve for alprazolam plasma concentration vs time (P<.001) and a 2-fold increase in alprazolam clearance (P<.001) were observed following St John's wort administration. Alprazolam elimination half life was shortened from a mean (SD) of 12.4 (3.9) hours to 6.0 (2.4) hours (P<.001). The mean (SD) urinary ratio of dextromethorphan to its metabolite was 0.006 (0.010) at baseline and 0.014 (0.025) after St John's wort administration (P=.26). Conclusions A 14-day course of St John's wort administration significantly induced the activity of CYP 3A4 as measured by changes in alprazolam pharmacokinetics. This suggests that long-term administration of St John's wort may result in diminished clinical effectiveness or increased dosage requirements for all CYP 3A4 substrates, which represent at least 50% of all marketed medications.	Med Univ S Carolina, Inst Psychiat, Lab Drug Disposit & Pharmacogenet, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Surg, Div Transplantat, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Markowitz, JS (corresponding author), Med Univ S Carolina, Inst Psychiat, Lab Drug Disposit & Pharmacogenet, Dept Pharmaceut Sci, RM 246 N,67 President St, Charleston, SC 29425 USA.	markowij@musc.edu	DeVane, Lindsay/B-6645-2012		NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT000511] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001070] Funding Source: NIH RePORTER; NCCIH NIH HHS [R21 AT00511] Funding Source: Medline; NCRR NIH HHS [M01 RR01070-18] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barnes J, 2001, J PHARM PHARMACOL, V53, P583, DOI 10.1211/0022357011775910; BLUMENTHAL M, 2003, HERBALGRAM, V58, P71; Brosen K, 1996, THER DRUG MONIT, V18, P393, DOI 10.1097/00007691-199608000-00014; Constantine GH, 1998, PHARM BIOL, V36, P365, DOI 10.1076/phbi.36.5.365.4651; Cui YY, 2002, J CHROMATOGR B, V780, P129, DOI 10.1016/S1570-0232(02)00439-7; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; de Maat MMR, 2001, AIDS, V15, P420, DOI 10.1097/00002030-200102160-00019; Donovan JL, 2003, FOOD CHEM TOXICOL, V41, P1199, DOI 10.1016/S0278-6915(03)00112-1; Donovan JL, 2003, DRUG METAB DISPOS, V31, P519, DOI 10.1124/dmd.31.5.519; Durr D, 2000, CLIN PHARMACOL THER, V68, P598, DOI 10.1067/mcp.2000.112240; Furukori H, 1998, NEUROPSYCHOPHARMACOL, V18, P364; Gorski JC, 1999, XENOBIOTICA, V29, P931, DOI 10.1080/004982599238173; Greeson JM, 2001, PSYCHOPHARMACOLOGY, V153, P402, DOI 10.1007/s002130000625; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; HENDERSON L, 2003, BR J CLIN PHARM, V55, P112; Hoskins JM, 1997, J CHROMATOGR B, V696, P81, DOI 10.1016/S0378-4347(97)00225-9; Johne A, 2002, J CLIN PSYCHOPHARM, V22, P46, DOI 10.1097/00004714-200202000-00008; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; Kerb R, 1996, ANTIMICROB AGENTS CH, V40, P2087, DOI 10.1128/AAC.40.9.2087; Lecrubier Y, 2002, AM J PSYCHIAT, V159, P1361, DOI 10.1176/appi.ajp.159.8.1361; Liston HL, 2002, J CLIN PSYCHOPHARM, V22, P169, DOI 10.1097/00004714-200204000-00010; Mai I, 2003, NEPHROL DIAL TRANSPL, V18, P819, DOI 10.1093/ndt/gfg002; Markowitz J S, 2001, Psychopharmacol Bull, V35, P53; MARKOWITZ JS, IN PRESS J CLIN PSYC; Markusen A, 2001, ANTIPODE, V33, P39, DOI 10.1111/1467-8330.00160; MILLER RL, 1988, J CHROMATOGR-BIOMED, V430, P180, DOI 10.1016/S0378-4347(00)83150-3; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Obach RS, 2000, J PHARMACOL EXP THER, V294, P88; Perloff MD, 2001, BRIT J PHARMACOL, V134, P1601, DOI 10.1038/sj.bjp.0704399; Perloff MD, 1999, BIOCHEM PHARMACOL, V57, P1227, DOI 10.1016/S0006-2952(99)00054-4; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; SCHMID B, 1985, CLIN PHARMACOL THER, V38, P618, DOI 10.1038/clpt.1985.235; Schmider J, 1999, PHARMACOGENETICS, V9, P725, DOI 10.1097/01213011-199912000-00007; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; Simmen U, 2003, EUR J PHARMACOL, V458, P251, DOI 10.1016/S0014-2999(02)02818-2; Smith DA, 1998, XENOBIOTICA, V28, P1095, DOI 10.1080/004982598238859; SMITH RB, 1984, PSYCHOPHARMACOLOGY, V84, P452, DOI 10.1007/BF00431449; Sugimoto K, 2001, CLIN PHARMACOL THER, V70, P518, DOI 10.1067/mcp.2001.120025; Venkatakrishnan K, 1998, J CLIN PSYCHOPHARM, V18, P256, DOI 10.1097/00004714-199806000-00015; Wang ZQ, 2002, CLIN PHARMACOL THER, V71, P414, DOI 10.1067/mcp.2002.124080; Wang ZQ, 2001, CLIN PHARMACOL THER, V70, P317, DOI 10.1067/mcp.2001.118522; Woelk H, 2000, BMJ-BRIT MED J, V321, P536, DOI 10.1136/bmj.321.7260.536; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; ZHANG Y, 1992, CLIN PHARMACOL THER, V51, P647, DOI 10.1038/clpt.1992.77	46	265	274	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1500	1504		10.1001/jama.290.11.1500	http://dx.doi.org/10.1001/jama.290.11.1500			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129991				2022-12-24	WOS:000185329000033
J	Peretti-Watel, P; Bendiane, MK; Pegliasco, H; Lapiana, JM; Favre, R; Galinier, A; Moatti, JP				Peretti-Watel, P; Bendiane, MK; Pegliasco, H; Lapiana, JM; Favre, R; Galinier, A; Moatti, JP			Doctors' opinions on euthanasia, end of life care, and doctor-patient communication: telephone survey in France	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN-ASSISTED SUICIDE; ATTITUDES		Reg Ctr Dis Control SE, F-13006 Marseille, France; Inst J Paoli I Calmettes, Hlth & Med Res Natl Inst, Unit 379, F-13009 Marseille, France; Departmental Ctr Private Profess, Marseille, France; Assistance Publ Hop Marseille, Med Oncol Serv, Marseille, France; Assistance Publ Hop Marseille, Dept Penitentiary Care, Marseille, France; Univ Aix Marseille 2, Dept Econ, F-13284 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite	Peretti-Watel, P (corresponding author), Reg Ctr Dis Control SE, F-13006 Marseille, France.		Bendiane, Marc-Karim/M-7060-2019; Peretti-Watel, Patrick/P-4535-2017; Bendiane, Marc-Karim K/F-5414-2010	Bendiane, Marc-Karim K/0000-0003-4329-8807				Ben Diane MK, 2003, PRESSE MED, V32, P488; Emanuel EJ, 2000, ANN INTERN MED, V133, P527, DOI 10.7326/0003-4819-133-7-200010030-00011; Grassi L, 1999, J PAIN SYMPTOM MANAG, V17, P188, DOI 10.1016/S0885-3924(98)00155-9; Hermsen MA, 2002, J PAIN SYMPTOM MANAG, V23, P517, DOI 10.1016/S0885-3924(02)00401-3; Seale C, 2000, SOC SCI MED, V51, P917, DOI 10.1016/S0277-9536(00)00071-X	5	39	40	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					595	596		10.1136/bmj.327.7415.595	http://dx.doi.org/10.1136/bmj.327.7415.595			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969926	Bronze, Green Published			2022-12-24	WOS:000185358700022
J	Marambaud, P; Wen, PH; Dutt, A; Shioi, J; Takashima, A; Siman, R; Robakis, NK				Marambaud, P; Wen, PH; Dutt, A; Shioi, J; Takashima, A; Siman, R; Robakis, NK			A CBP binding transcriptional repressor produced by the PS1/is an element of-cleavage of N-cadherin is inhibited by PS1FAD mutations	CELL			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; C-FOS; DROSOPHILA-MELANOGASTER; ADHERENS JUNCTIONS; ADHESION SYSTEM; FACTOR CREB; PRESENILIN-1; CLEAVAGE	Presenilin1 (PS1), a protein implicated in Alzheimer's disease (AD), forms complexes with N-cadherin, a transmembrane protein with important neuronal and synaptic functions. Here, we show that a PS1-dependent T-secretase protease activity promotes an epsilon-like cleavage of N-cadherin to produce its intracellular domain peptide, N-Cad/CTF2. NMDA receptor agonists stimulate N-Cad/CTF2 production suggesting that this receptor regulates the epsilon-cleavage of N-cadherin. N-Cad/ CTF2 binds the transcription factor CBP and promotes its proteasomal degradation, inhibiting CRE-dependent transactivation. Thus, the PS1-dependent epsilon-cleavage product N-Cad/CTF2 functions as a potent repressor of CBP/CREB-mediated transcription. Importantly, PS1 mutations associated with familial AD (FAD) and a gamma-secretase dominant-negative mutation inhibit N-Cad/CTF2 production and upregulate CREB-mediated transcription indicating that FAD mutations cause a gain of transcriptional function by inhibiting production of transcriptional repressor N-Cad/CTF2. These data raise the possibility that FAD mutation-induced transcriptional abnormalities maybe causally related to the dementia associated with FAD.	Mt Sinai Med Ctr, Sch Med, Dept Psychiat, New York, NY 10029 USA; Inst Phys & Chem Res, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Mt Sinai Med Ctr, Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; RIKEN; University of Pennsylvania; Icahn School of Medicine at Mount Sinai	Robakis, NK (corresponding author), Mt Sinai Med Ctr, Sch Med, Dept Psychiat, New York, NY 10029 USA.		Robakis, Nikolaos/AAA-1838-2021	Marambaud, Philippe/0000-0002-8983-1497	NIA NIH HHS [P50 AG005138-190025, AG-17926, R01 AG008200-18, AG-08200, AG-05138, R01 AG017926-05] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG017926, R01AG008200, R01AG017926] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Amtul Z, 2002, NEUROBIOL DIS, V9, P269, DOI 10.1006/nbdi.2001.0473; ANDERSON AJ, 1994, EXP NEUROL, V125, P286, DOI 10.1006/exnr.1994.1031; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Banker G., 1991, CULTURING NERVE CELL; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Dawson TM, 2002, NAT MED, V8, P450, DOI 10.1038/nm0502-450; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Freiman RN, 2002, SCIENCE, V296, P2149, DOI 10.1126/science.1073845; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gillardon F, 1996, BRAIN RES, V706, P169, DOI 10.1016/0006-8993(95)01332-6; Goda Y, 2002, NEURON, V35, P1, DOI 10.1016/S0896-6273(02)00765-1; Goodman RH, 2000, GENE DEV, V14, P1553; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Huntley GW, 2002, CELL, V108, P1, DOI 10.1016/S0092-8674(01)00631-6; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Ludlam WH, 2002, MOL CELL BIOL, V22, P3832, DOI 10.1128/MCB.22.11.3832-3841.2002; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marcus DL, 1998, NEUROBIOL AGING, V19, P393, DOI 10.1016/S0197-4580(98)00077-3; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McLendon C, 2000, FASEB J, V14, P2383; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; Nowotny P, 2000, MOL CELL NEUROSCI, V15, P88, DOI 10.1006/mcne.1999.0805; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Siman R, 2000, J NEUROSCI, V20, P8717; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; ZHANG P, 1992, NEUROSCIENCE, V46, P9, DOI 10.1016/0306-4522(92)90004-L	45	407	420	0	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					635	645		10.1016/j.cell.2003.08.008	http://dx.doi.org/10.1016/j.cell.2003.08.008			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678586	Bronze			2022-12-24	WOS:000185193100012
J	Kile, BT; Hentges, KE; Clark, AT; Nakamura, H; Salinger, AP; Liu, B; Box, N; Stockton, DW; Johnson, RL; Behringer, RR; Bradley, A; Justice, MJ				Kile, BT; Hentges, KE; Clark, AT; Nakamura, H; Salinger, AP; Liu, B; Box, N; Stockton, DW; Johnson, RL; Behringer, RR; Bradley, A; Justice, MJ			Functional genetic analysis of mouse chromosome 11	NATURE			English	Article							RENAL TUBULAR-ACIDOSIS; ETHYL-N-NITROSOUREA; TARGETED DISRUPTION; MEMBRANE SKELETON; MOUSE; MUTATIONS; BAND-3; MUTAGENESIS; GENOME; MICE	Now that the mouse and human genome sequences are complete, biologists need systematic approaches to determine the function of each gene(1,2). A powerful way to discover gene function is to determine the consequence of mutations in living organisms. Large-scale production of mouse mutations with the point mutagen N-ethyl-N-nitrosourea (ENU) is a key strategy for analysing the human genome because mouse mutants will reveal functions unique to mammals, and many may model human diseases(3). To examine genes conserved between human and mouse, we performed a recessive ENU mutagenesis screen that uses a balancer chromosome, inversion chromosome 11 (refs 4, 5). Initially identified in the fruitfly, balancer chromosomes are valuable genetic tools that allow the easy isolation of mutations on selected chromosomes(6). Here we show the isolation of 230 new recessive mouse mutations, 88 of which are on chromosome 11. This genetic strategy efficiently generates and maps mutations on a single chromosome, even as mutations throughout the genome are discovered. The mutations reveal new defects in haematopoiesis, craniofacial and cardiovascular development, and fertility.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	mjustice@bcm.tmc.edu	Kile, Benjamin/GNP-3246-2022; Kile, Benjamin T/F-6593-2011; Box, Neil/F-3591-2010	Kile, Benjamin/0000-0002-8836-8947; Kile, Benjamin T/0000-0002-8836-8947; Box, Neil/0000-0002-3486-0346; Bradley, Allan/0000-0002-2349-8839; Hentges, Kathryn/0000-0001-8917-3765; Liu, Bin/0000-0002-9113-9694				Barrow JR, 1996, DEVELOPMENT, V122, P3817; BEHRINGER RR, 2003, BIOMEDNET; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Conway SJ, 2003, GENESIS, V35, P1, DOI 10.1002/gene.10152; Hentges K, 1999, DEVELOPMENT, V126, P1601; Herron BJ, 2002, NAT GENET, V30, P185, DOI 10.1038/ng812; HITOTSUMACHI S, 1985, P NATL ACAD SCI USA, V82, P6619, DOI 10.1073/pnas.82.19.6619; JAROLIM P, 1995, BLOOD, V85, P634, DOI 10.1182/blood.V85.3.634.bloodjournal853634; JUSTICE MJ, 1999, GENETICS TRANSGENICS, P185; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Karet FE, 1998, P NATL ACAD SCI USA, V95, P6337, DOI 10.1073/pnas.95.11.6337; Kasarskis A, 1998, P NATL ACAD SCI USA, V95, P7485, DOI 10.1073/pnas.95.13.7485; Kile BT, 2003, MAMM GENOME, V14, P81, DOI 10.1007/s00335-002-2160-0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Muller HJ, 1918, GENETICS, V3, P422; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Noveroske JK, 2002, GENESIS, V32, P218, DOI 10.1002/gene.10060; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Rinchik EM, 1999, GENETICS, V152, P373; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SHEDLOVSKY A, 1988, P NATL ACAD SCI USA, V85, P180, DOI 10.1073/pnas.85.1.180; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Zheng BH, 1999, NUCLEIC ACIDS RES, V27, P2354, DOI 10.1093/nar/27.11.2354; Zheng BH, 1999, NAT GENET, V22, P375, DOI 10.1038/11949	30	159	162	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					81	86		10.1038/nature01865	http://dx.doi.org/10.1038/nature01865			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955145				2022-12-24	WOS:000185089200042
J	Matsushita, K; Morrell, CN; Cambien, B; Yang, SX; Yamakuchi, M; Bao, C; Hara, MR; Quick, RA; Cao, W; O'Rourke, B; Lowenstein, JM; Pevsner, J; Wagner, DD; Lowenstein, CJ				Matsushita, K; Morrell, CN; Cambien, B; Yang, SX; Yamakuchi, M; Bao, C; Hara, MR; Quick, RA; Cao, W; O'Rourke, B; Lowenstein, JM; Pevsner, J; Wagner, DD; Lowenstein, CJ			Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimdide-sensitive factor	CELL			English	Article							WEIBEL-PALADE BODIES; HUMAN-ENDOTHELIAL-CELLS; VON-WILLEBRAND-FACTOR; MEMBRANE-FUSION; TRANSPORT VESICLES; YEAST VACUOLES; KNOCKOUT MICE; P-SELECTIN; PROTEIN; NSF	Nitric oxide (NO) inhibits vascular inflammation, but the molecular basis for its anti-inflammatory properties is unknown. We show that NO inhibits exocytosis of Weibel-Palade bodies, endothelial granules that mediate vascular inflammation and thrombosis, by regulating the activity of N-ethylmaleimide-sensitive factor (NSF). NO inhibits NSF disassembly of soluble NSF attachment protein receptor (SNARE) complexes by nitrosylating critical cysteine residues of NSF. NO may regulate exocytosis in a variety of physiological processes, including vascular inflammation, neuro-transmission, thrombosis, and cytotoxic T lymphocyte cell killing.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Comparat Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; Brandeis University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Lowenstein, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.			Cambien, Beatrice/0000-0002-6914-0525; Lowenstein, Charles/0000-0003-0485-7514; O'Rourke, Brian/0000-0002-5548-4853	NCRR NIH HHS [RR07002, T32 RR007002] Funding Source: Medline; NHLBI NIH HHS [R01 HL078635-04, P01 HL065608-050003, P01 HL065608, R01 HL63706-04, HL074945, R01 HL074061-04, P01 HL56091, R37 HL41002, P01 HL65608, R37 HL041002, R01 HL063706, P01 HL056091-100003, K08 HL074945, P01 HL056091, R01 HL078635, R01 HL074061] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [T32RR007002] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078635, P01HL056091, K08HL074945, R01HL063706, R37HL041002, R01HL074061, P01HL065608] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BONFANTI R, 1989, BLOOD, V73, P1109; Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Huber D, 2002, BLOOD, V99, P3637, DOI 10.1182/blood.V99.10.3637; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JAFFREY SR, 2001, SCI STKE; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kuhlencordt PJ, 2001, CIRCULATION, V103, P3099, DOI 10.1161/01.CIR.103.25.3099; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Littleton JT, 1995, INVERTEBR NEUROSCI, V1, P3, DOI 10.1007/BF02331827; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; May AP, 2001, J BIOL CHEM, V276, P21991, DOI 10.1074/jbc.R100013200; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Qian ZP, 2001, CIRCULATION, V104, P2369, DOI 10.1161/hc4401.098471; RADOMSKI MW, 1993, THROMB HAEMOSTASIS, V70, P36; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Ruggeri ZM, 1997, J CLIN INVEST, V100, pS41; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; Schweizer FE, 1998, SCIENCE, V279, P1203, DOI 10.1126/science.279.5354.1203; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; VISCHER UM, 1993, BLOOD, V82, P1184, DOI 10.1182/blood.V82.4.1184.1184; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; WAGNER DD, 1993, THROMB HAEMOSTASIS, V70, P105; Walev I, 2001, P NATL ACAD SCI USA, V98, P3185, DOI 10.1073/pnas.051429498; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; Weiss EJ, 2002, BLOOD, V100, P3240, DOI 10.1182/blood-2002-05-1470; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247	51	357	378	0	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 17	2003	115	2					139	150		10.1016/S0092-8674(03)00803-1	http://dx.doi.org/10.1016/S0092-8674(03)00803-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567912	Green Accepted, Bronze			2022-12-24	WOS:000186039200006
J	Huh, WK; Falvo, JV; Gerke, LC; Carroll, AS; Howson, RW; Weissman, JS; O'Shea, EK				Huh, WK; Falvo, JV; Gerke, LC; Carroll, AS; Howson, RW; Weissman, JS; O'Shea, EK			Global analysis of protein localization in budding yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; SUBCELLULAR-LOCALIZATION; FLUORESCENT PROTEIN; MASS-SPECTROMETRY; GENE DELETION; CELL-WALL; SCALE; ORGANIZATION; PHOSPHATASE; EXPRESSION	A fundamental goal of cell biology is to define the functions of proteins in the context of compartments that organize them in the cellular environment. Here we describe the construction and analysis of a collection of yeast strains expressing full-length, chromosomally tagged green fluorescent protein fusion proteins. We classify these proteins, representing 75% of the yeast proteome, into 22 distinct subcellular localization categories, and provide localization information for 70% of previously unlocalized proteins. Analysis of this high-resolution, high-coverage localization data set in the context of transcriptional, genetic, and protein-protein interaction data helps reveal the logic of transcriptional co-regulation, and provides a comprehensive view of interactions within and between organelles in eukaryotic cells.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	O'Shea, EK (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, 600 16th St, San Francisco, CA 94143 USA.		Huh, Won-Ki/AAQ-6767-2021	Weissman, Jonathan/0000-0003-2445-670X				Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Bergmann S, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.031902; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r22; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r23; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DOLINSKI K, 2003, GENOME DATABASE; Drawid A, 2000, TRENDS GENET, V16, P426, DOI 10.1016/S0168-9525(00)02108-9; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hodges PE, 2002, NUCLEIC ACIDS RES, V30, P137, DOI 10.1093/nar/30.1.137; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; Rabitsch KP, 2003, DEV CELL, V4, P535, DOI 10.1016/S1534-5807(03)00086-8; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; San-Segundo PA, 1999, CELL, V97, P313, DOI 10.1016/S0092-8674(00)80741-2; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Taylor SW, 2003, TRENDS BIOTECHNOL, V21, P82, DOI 10.1016/S0167-7799(02)00037-9; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VANBERKEL MAA, 1994, FEBS LETT, V349, P135, DOI 10.1016/0014-5793(94)00631-8; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	48	3156	5246	11	396	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					686	691		10.1038/nature02026	http://dx.doi.org/10.1038/nature02026			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562095				2022-12-24	WOS:000185924500033
J	Sollner, C; Burghammer, M; Busch-Nentwich, E; Berger, J; Schwarz, H; Riekel, C; Nicolson, T				Sollner, C; Burghammer, M; Busch-Nentwich, E; Berger, J; Schwarz, H; Riekel, C; Nicolson, T			Control of crystal size and lattice formation by starmaker in otolith biomineralization	SCIENCE			English	Article							EAR DEVELOPMENT; FISH OTOLITHS; MAJOR PROTEIN; ZEBRAFISH; MACROMOLECULES; DIMENSIONS; MUTATIONS; OTOCONIA; MATRIX; DSPP	The stone-like otoliths from the ears of teleost fishes are involved in balance and hearing and consist of calcium carbonate crystallites embedded in a protein framework. We report that a previously unknown gene, starmaker, is required in zebrafish for otolith morphogenesis. Reduction of starmaker activity by injection of modified antisense oligonucleotides causes a change in the crystal lattice structure and thus a change in otolith morphology. The expression pattern of starmaker, along with the presence of the protein on the growing otolith, suggest that the expression levels of starmaker control the shape of the otoliths.	Max Planck Inst Entwicklungsbiol, Microscopy Unit, D-72076 Tubingen, Germany; European Synchrotron Radiat Facil, F-38073 Grenoble, France	Max Planck Society; European Synchrotron Radiation Facility (ESRF)	Nicolson, T (corresponding author), Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Portland, OR 97201 USA.	nicolson@ohsu.edu						Bekele H, 1999, J AM CHEM SOC, V121, P7266, DOI 10.1021/ja991416j; Belcher AM, 1996, NATURE, V381, P56, DOI 10.1038/381056a0; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Borelli G, 2001, CALCIFIED TISSUE INT, V69, P356, DOI 10.1007/s00223-001-2016-8; Campana SE, 1999, MAR ECOL PROG SER, V188, P263, DOI 10.3354/meps188263; Draper BW, 2001, GENESIS, V30, P154, DOI 10.1002/gene.1053; Everett LA, 2001, HUM MOL GENET, V10, P153, DOI 10.1093/hmg/10.2.153; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; FAY RR, 1984, SCIENCE, V225, P951, DOI 10.1126/science.6474161; Haddon C, 1996, J COMP NEUROL, V365, P113, DOI 10.1002/(SICI)1096-9861(19960129)365:1<113::AID-CNE9>3.0.CO;2-6; Hurle B, 2003, HUM MOL GENET, V12, P777, DOI 10.1093/hmg/ddg087; LOWENSTAM HA, 1981, SCIENCE, V211, P1126, DOI 10.1126/science.7008198; Lowenstam HA, 1989, BIOMINERALIZATION; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; NEILSON JD, 1985, FISH B-NOAA, V83, P81; PANNELLA G, 1971, SCIENCE, V173, P1124, DOI 10.1126/science.173.4002.1124; Pisam M, 2002, CELL TISSUE RES, V310, P163, DOI 10.1007/s00441-002-0622-z; POPPER A, 1993, INNER EAR LATERAL LI, P99; POTE KG, 1993, BIOCHEMISTRY-US, V32, P5017, DOI 10.1021/bi00070a007; RADTKE RL, 1982, FISH B-NOAA, V80, P201; Riekel C, 2000, REP PROG PHYS, V63, P233, DOI 10.1088/0034-4885/63/3/201; Riley BB, 1997, DEV BIOL, V191, P191, DOI 10.1006/dbio.1997.8736; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; Wang YX, 1998, P NATL ACAD SCI USA, V95, P15345, DOI 10.1073/pnas.95.26.15345; WEINER S, 1991, TRENDS BIOCHEM SCI, V16, P252, DOI 10.1016/0968-0004(91)90098-G; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	27	228	231	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					282	286		10.1126/science.1088443	http://dx.doi.org/10.1126/science.1088443			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551434				2022-12-24	WOS:000185825900041
J	Sears, MR; Greene, JM; Willan, AR; Wiecek, EM; Taylor, DR; Flannery, EM; Cowan, JO; Herbison, GP; Silva, PA; Poulton, R				Sears, MR; Greene, JM; Willan, AR; Wiecek, EM; Taylor, DR; Flannery, EM; Cowan, JO; Herbison, GP; Silva, PA; Poulton, R			A longitudinal, population-based, cohort study of childhood asthma followed to adulthood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; LUNG-FUNCTION; AIRWAY HYPERRESPONSIVENESS; NEW-ZEALAND; WHEEZING ILLNESS; BIRTH COHORT; ATOPY; PREVALENCE; CHILDREN; LIFE	BACKGROUND: The outcome of childhood asthma in adults has been described in high-risk cohorts, but few population-based studies have reported the risk factors for persistence and relapse. METHODS: We assessed children born from April 1972 through March 1973 in Dunedin, New Zealand, repeatedly from 9 to 26 years of age with questionnaires, pulmonary-function tests, bronchial-challenge testing, and allergy testing. RESULTS: By the age of 26 years, 51.4 percent of 613 study members with complete respiratory data had reported wheezing at more than one assessment. Eighty-nine study members (14.5 percent) had wheezing that persisted from childhood to 26 years of age, whereas 168 (27.4 percent) had remission, but 76 (12.4 percent) subsequently relapsed by the age of 26. Sensitization to house dust mites predicted the persistence of wheezing (odds ratio, 2.41; P=0.001) and relapse (odds ratio, 2.18; P=0.01), as did airway hyperresponsiveness (odds ratio for persistence, 3.00; P<0.001; odds ratio for relapse, 3.03; P<0.001). Female sex predicted the persistence of wheezing (odds ratio, 1.71; P=0.03), as did smoking at the age of 21 years (odds ratio, 1.84; P=0.01). The earlier the age at onset, the greater the risk of relapse (odds ratio, 0.89 per year of increase in the age at onset; P<0.001). Pulmonary function was consistently lower in those with persistent wheezing than in those without persistent wheezing. CONCLUSIONS: In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission. The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset. These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Dunedin Multidisciplinary Hlth & Dev Res Unit, Dunedin, New Zealand	McMaster University; McMaster University; University of Otago; University of Otago	Sears, MR (corresponding author), McMaster Univ & St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.			Herbison, Graham Peter/0000-0002-5684-024X				Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BURNEY PGJ, 1987, CHEST, V91, P79; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Grol MH, 1996, ALLERGY, V51, P855; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830, DOI 10.1164/ajrccm.160.6.9812100; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; Sears MR, 1997, EUR RESPIR J, V10, P51, DOI 10.1183/09031936.97.10010051; SEARS MR, 1994, BRIT MED J, V309, P72, DOI 10.1136/bmj.309.6947.72; Silva P., 1996, CHILD ADULT DUNEDIN; SINCLAIR SW, 1980, NEW ZEAL MED J, V91, P1; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; Ulrik CS, 1996, RESP MED, V90, P623, DOI 10.1016/S0954-6111(96)90021-9; Xuan W, 2000, AM J RESP CRIT CARE, V161, P1820, DOI 10.1164/ajrccm.161.6.9809118; Xuan W, 2002, THORAX, V57, P104, DOI 10.1136/thorax.57.2.104	28	914	934	1	60	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1414	1422		10.1056/NEJMoa022363	http://dx.doi.org/10.1056/NEJMoa022363			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	729JF	14534334				2022-12-24	WOS:000185769500004
J	Howitz, KT; Bitterman, KJ; Cohen, HY; Lamming, DW; Lavu, S; Wood, JG; Zipkin, RE; Chung, P; Kisielewski, A; Zhang, LL; Scherer, B; Sinclair, DA				Howitz, KT; Bitterman, KJ; Cohen, HY; Lamming, DW; Lavu, S; Wood, JG; Zipkin, RE; Chung, P; Kisielewski, A; Zhang, LL; Scherer, B; Sinclair, DA			Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan	NATURE			English	Article							CALORIE RESTRICTION; TRANS-RESVERATROL; PROTEIN SIR2; YEAST SIR2; NAD; LONGEVITY; P53; DEACETYLASES; NICOTINAMIDE; INHIBITION	In diverse organisms, calorie restriction slows the pace of ageing and increases maximum lifespan. In the budding yeast Saccharomyces cerevisiae, calorie restriction extends lifespan by increasing the activity of Sir2 (ref. 1), a member of the conserved sirtuin family of NAD(+)-dependent protein deacetylases(2-6). Included in this family are SIR-2.1, a Caenorhabditis elegans enzyme that regulates lifespan(7), and SIRT1, a human deacetylase that promotes cell survival by negatively regulating the p53 tumour suppressor(8-10). Here we report the discovery of three classes of small molecules that activate sirtuins. We show that the potent activator resveratrol, a polyphenol found in red wine, lowers the Michaelis constant of SIRT1 for both the acetylated substrate and NAD(+), and increases cell survival by stimulating SIRT1-dependent deacetylation of p53. In yeast, resveratrol mimics calorie restriction by stimulating Sir2, increasing DNA stability and extending lifespan by 70%. We discuss possible evolutionary origins of this phenomenon and suggest new lines of research into the therapeutic use of sirtuin activators.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; BIOMOL Res Labs Inc, Plymouth Meeting, PA 19462 USA	Harvard University; Harvard Medical School	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		Lamming, Dudley/O-7191-2015	Lamming, Dudley/0000-0002-0079-4467; Cohen, Haim Y./0000-0002-6613-8710; Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [P01 AG027916, R01 AG028730, R13 AG033466, R01 AG019972, R37 AG028730, R01 AG019719] Funding Source: Medline; NIGMS NIH HHS [R01 GM068072] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028730, P01AG027916, R37AG028730, R01AG019719, R13AG033466, R01AG019972] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Dong ZG, 2003, MUTAT RES-FUND MOL M, V523, P145, DOI 10.1016/S0027-5107(02)00330-5; Ferguson LR, 2001, MUTAT RES-FUND MOL M, V475, P89, DOI 10.1016/S0027-5107(01)00073-2; GLOSSMANN H, 1981, N-S ARCH PHARMACOL, V317, P100, DOI 10.1007/BF00506266; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jazwinski SM, 2000, ANN NY ACAD SCI, V908, P21; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Middleton E, 2000, PHARMACOL REV, V52, P673; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Nicolini G, 2001, NEUROSCI LETT, V302, P41, DOI 10.1016/S0304-3940(01)01654-8; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Pandey R, 2002, NUCLEIC ACIDS RES, V30, P5036, DOI 10.1093/nar/gkf660; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 2002, MECH AGEING DEV, V123, P857, DOI 10.1016/S0047-6374(02)00023-4; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Stojanovic S, 2001, ARCH BIOCHEM BIOPHYS, V391, P79, DOI 10.1006/abbi.2001.2388; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X	30	2891	3076	17	505	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2003	425	6954					191	196		10.1038/nature01960	http://dx.doi.org/10.1038/nature01960			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12939617				2022-12-24	WOS:000185236000046
J	Fujii, N; Graybiel, AM				Fujii, N; Graybiel, AM			Representation of action sequence boundaries by macaque prefrontal cortical neurons	SCIENCE			English	Article							BASAL GANGLIA; CORTEX; MOVEMENTS; SACCADES; MODEL	Complex biological systems such as human language and the genetic code are characterized by explicit markers at the beginning and end of functional sequences. We report here that macaque prefrontal cortical neurons exhibit phasic peaks of spike activity that occur at the beginning and endpoint of sequential oculomotor saccade performance and have the properties of dynamic start- and end-state encoders accompanying responses to sequential actions. Sequence bounding may thus reflect a general mechanism for encoding biological information.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Graybiel, AM (corresponding author), MIT, Dept Brain & Cognit Sci, 45 Carleton St,E25-618, Cambridge, MA 02139 USA.			Graybiel, Ann/0000-0002-4326-7720	NATIONAL EYE INSTITUTE [R01EY012848] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012848, EY12848] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Averbeck BB, 2002, P NATL ACAD SCI USA, V99, P13172, DOI 10.1073/pnas.162485599; Bair W, 2002, J NEUROSCI, V22, P3189, DOI 10.1523/JNEUROSCI.22-08-03189.2002; Beiser DG, 1998, J NEUROPHYSIOL, V79, P3168, DOI 10.1152/jn.1998.79.6.3168; Bor D, 2003, NEURON, V37, P361, DOI 10.1016/S0896-6273(02)01171-6; Braitenberg V, 1997, BEHAV BRAIN SCI, V20, P229, DOI 10.1017/S0140525X9700143X; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Curran T., 1995, PSYCHE, V2, P12; Dehaene S, 1997, P NATL ACAD SCI USA, V94, P13293, DOI 10.1073/pnas.94.24.13293; Dreher JC, 2002, EUR J NEUROSCI, V16, P1609, DOI 10.1046/j.1460-9568.2002.02212.x; Duffy CJ, 1997, EXP BRAIN RES, V114, P472, DOI 10.1007/PL00005656; FUJII N, 2001, SOC NEUR ABSTR, V27; Fuster J. M., 1999, MEMORY CEREBRAL CORT; Grafton ST, 1998, J NEUROSCI, V18, P9420; Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843; KROGH A, 1994, NUCLEIC ACIDS RES, V22, P4768, DOI 10.1093/nar/22.22.4768; Lashley K. S., 1951, CEREBRAL MECH BEHAV; Leon MI, 1999, NEURON, V24, P415, DOI 10.1016/S0896-6273(00)80854-5; MAKHOUL J, 1995, P NATL ACAD SCI USA, V92, P9956, DOI 10.1073/pnas.92.22.9956; Miller EK, 2002, PHILOS T R SOC B, V357, P1123, DOI 10.1098/rstb.2002.1099; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Schall JD, 2002, PHILOS T ROY SOC B, V357, P1073, DOI 10.1098/rstb.2002.1098; Sipser, 2013, INTRO THEORY COMPUTA; Tanji J, 2001, ANNU REV NEUROSCI, V24, P631, DOI 10.1146/annurev.neuro.24.1.631; Toni I, 1998, NEUROIMAGE, V8, P50, DOI 10.1006/nimg.1998.0349; Ward G, 1997, Q J EXP PSYCHOL-A, V50, P49, DOI 10.1080/027249897392224; Watanabe M, 1996, NATURE, V382, P629, DOI 10.1038/382629a0; Zacks JM, 2001, NAT NEUROSCI, V4, P651, DOI 10.1038/88486	27	133	135	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1246	1249		10.1126/science.1086872	http://dx.doi.org/10.1126/science.1086872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947203				2022-12-24	WOS:000185003500046
J	Saunders, A; Werner, J; Andrulis, ED; Nakayama, T; Hirose, S; Reinberg, D; Lis, JT				Saunders, A; Werner, J; Andrulis, ED; Nakayama, T; Hirose, S; Reinberg, D; Lis, JT			Tracking FACT and the RNA polymerase II elongation complex through chromatin in vivo	SCIENCE			English	Article							HEAT-SHOCK GENES; TRANSCRIPTION ELONGATION; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; REMODELING PROTEIN; DNASE-I; SPT5; NUCLEOSOME; PROMOTER; LOCALIZATION	RNA polymerase II (Pol II) transcription through nucleosomes is facilitated in vitro by the protein complex FACT (Facilitates Chromatin Transcription). Here we show that FACT is associated with actively transcribed Pol II genes on Drosophila polytene chromosomes. FACT displays kinetics of recruitment and of chromosome tracking in vivo similar to Pol II and elongation factors Spt5 and Spt6. Interestingly, FACT does not colocalize with Pol III-transcribed genes, which are known to undergo nucleosome transfer rather than disassembly in vitro. Our observations are consistent with FACT being restricted to transcription that involves nucleosome disassembly mechanisms.	Cornell Univ, Ithaca, NY 14850 USA; Natl Inst Genet, Dept Dev Genet, Mishima, Shizuoka 4118540, Japan; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Howard Hughes Med Inst, Piscataway, NJ 08854 USA	Cornell University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lis, JT (corresponding author), Cornell Univ, Biotechnol Bldg, Ithaca, NY 14850 USA.	jtl10@cornell.edu	Hirose, Susumu/I-8865-2019	Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025232, R37GM025232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2002, MOL CELL, V9, P451, DOI 10.1016/S1097-2765(02)00487-2; Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Armstrong JA, 2002, EMBO J, V21, P5245, DOI 10.1093/emboj/cdf517; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; BOEHM AK, IN PRESS MOL CELL BI; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; COSTLOW N, 1984, MOL CELL BIOL, V4, P1853, DOI 10.1128/MCB.4.9.1853; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Formosa T, 2003, CURR TOP MICROBIOL, V274, P171; Formosa T, 2002, GENETICS, V162, P1557; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Lindstrom DL, 2003, MOL CELL BIOL, V23, P1368, DOI 10.1128/MCB.23.4.1368-1378.2003; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Pei Y, 2002, J BIOL CHEM, V277, P19639, DOI 10.1074/jbc.M200015200; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SCHWARTZ BE, IN PRESS METHODS ENZ; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; SIMON JA, 1985, CHROMOSOMA, V93, P26, DOI 10.1007/BF01259442; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Takada S, 2000, CELL, V101, P459, DOI 10.1016/S0092-8674(00)80857-0; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403	32	225	234	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2003	301	5636					1094	1096		10.1126/science.1085712	http://dx.doi.org/10.1126/science.1085712			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934007				2022-12-24	WOS:000184872400039
J	Xie, ZG; Sanada, K; Samuels, BA; Shih, H; Tsai, LH				Xie, ZG; Sanada, K; Samuels, BA; Shih, H; Tsai, LH			Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration	CELL			English	Article							FOCAL ADHESION KINASE; CENTRAL-NERVOUS-SYSTEM; ASPERGILLUS-NIDULANS; CYTOPLASMIC DYNEIN; TYROSINE KINASE; GENE-TRANSFER; CEREBRAL-CORTEX; P35/CDK5 KINASE; MICE LACKING; BRAIN	The serine/threonine kinase Cdk5 plays an essential role in neuronal positioning during corticogenesis, but the underlying mechanisms are unknown. In nonneuronal cells, the tyrosine kinase FAK is a major regulator of cell motility through focal adhesions. It is unclear whether FAK plays a role in brain development. Here, we show that FAK phosphorylation by Cdk5 at S732 is important for microtubule organization, nuclear movement, and neuronal migration. In cultured neurons, S732-phosphorylated FAK is enriched along a centrosome-associated microtubule fork that abuts the nucleus. Overexpression of the nonphosphorylatable mutant FAK S732A results in disorganization of the microtubule fork and impairment of nuclear movement in vitro, and neuronal positioning defects in vivo. These observations are reminiscent of what is seen in the Cdk5-deficient mice. Taken together, these results suggest that Cdk5 phosphorylation of FAK is critical for neuronal migration through regulation of a microtubule fork important for nuclear translocation.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Program Neurosci, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute	Tsai, LH (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		SANADA, YOSHIKADO/G-5014-2014	Xie, Zhigang/0000-0002-7190-992X; Sanada, Kamon/0000-0002-0280-8957	NINDS NIH HHS [NS37007] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037007] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams NC, 2002, DEVELOPMENT, V129, P965; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; Anton ES, 1999, NEURON, V22, P277, DOI 10.1016/S0896-6273(00)81089-2; Beckwith SM, 1998, J CELL BIOL, V143, P1239, DOI 10.1083/jcb.143.5.1239; Bornens M, 1999, METHOD CELL BIOL, V61, P13; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Contestabile A, 2003, INT J DEV NEUROSCI, V21, P83, DOI 10.1016/S0736-5748(02)00126-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; de Rouvroit CL, 2001, MECH DEVELOP, V105, P47, DOI 10.1016/S0925-4773(01)00396-3; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Georges-Labouesse E, 1998, CURR BIOL, V8, P983, DOI 10.1016/S0960-9822(98)70402-6; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Graus-Porta D, 2001, NEURON, V31, P367, DOI 10.1016/S0896-6273(01)00374-9; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hatten ME, 2002, SCIENCE, V297, P1660, DOI 10.1126/science.1074572; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kesavapany S, 2001, EUR J NEUROSCI, V13, P241, DOI 10.1046/j.1460-9568.2001.01376.x; Keshvara L, 2002, J NEUROSCI, V22, P4869, DOI 10.1523/JNEUROSCI.22-12-04869.2002; Ko J, 2001, J NEUROSCI, V21, P6758; Kwon YT, 2000, CURR BIOL, V10, P363, DOI 10.1016/S0960-9822(00)00411-5; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; McEvilly RJ, 2002, SCIENCE, V295, P1528, DOI 10.1126/science.1067132; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Morris NR, 1998, TRENDS CELL BIOL, V8, P467, DOI 10.1016/S0962-8924(98)01389-0; Nadarajah B, 2002, NAT REV NEUROSCI, V3, P423, DOI 10.1038/nrn845; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patzke H, 2003, J NEUROSCI, V23, P2769; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Reiner O, 1998, INT J MOL MED, V1, P849; Reinsch S, 1998, J CELL SCI, V111, P2283; Renaudin A, 1999, J NEUROSCI RES, V55, P458, DOI 10.1002/(SICI)1097-4547(19990215)55:4<458::AID-JNR6>3.0.CO;2-D; RIVAS RJ, 1995, J NEUROSCI, V15, P981; Ross ME, 2001, ANNU REV NEUROSCI, V24, P1041, DOI 10.1146/annurev.neuro.24.1.1041; Saito T, 2001, DEV BIOL, V240, P237, DOI 10.1006/dbio.2001.0439; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; Stevens GR, 1996, J NEUROSCI RES, V46, P445, DOI 10.1002/(SICI)1097-4547(19961115)46:4<445::AID-JNR6>3.3.CO;2-D; Sugitani Y, 2002, GENE DEV, V16, P1760, DOI 10.1101/gad.978002; Tabata H, 2001, NEUROSCIENCE, V103, P865, DOI 10.1016/S0306-4522(01)00016-1; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Walsh CA, 2000, CURR OPIN GENET DEV, V10, P270, DOI 10.1016/S0959-437X(00)00076-9; Xiang X, 1999, CURR GENET, V35, P626, DOI 10.1007/s002940050461; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; Zheng C, 1996, SCIENCE, V272, P417, DOI 10.1126/science.272.5260.417	62	241	251	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					469	482		10.1016/S0092-8674(03)00605-6	http://dx.doi.org/10.1016/S0092-8674(03)00605-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941275	Bronze			2022-12-24	WOS:000184928800010
J	Choi, CH; Hiromura, M; Usheva, A				Choi, CH; Hiromura, M; Usheva, A			Transcription factor IIB acetylates itself to regulate transcription	NATURE			English	Article							RNA-POLYMERASE-II; PROTEIN; BINDING; AUTOACYLATION; ACYLATION; TFIIB	Acetylation is a well-known regulatory post-translational modification(1), but a biological function for acetylation in regulating basal transcription factors has not been reported. Here we show that the general transcription factor TFIIB, which is required for the initiation of eukaryotic polymerase II transcription(2), is acetylated. TFIIB is also an autoacetyltransferase, although it shares no sequence homology with any known acetyltransferases. In the absence of other enzymes, it binds acetyl-coenzyme A (acetyl-CoA), and catalyses the transfer of the acetyl group onto a specific lysine residue (K238). Both recombinant and cellular TFIIB can autoacetylate, markedly stabilizing the interaction between TFIIB and transcription factor TFIIF and activating transcription in vitro and in cells. A K238A mutant, which cannot be autoacetylated, does not show this activation of transcription. Our findings suggest that there is a regulatory pathway controlling acetylation of TFIIB, and they link acetyl-CoA with basal gene transcription.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Endocrinol Div, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Usheva, A (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Endocrinol Div, 99 Brookline Ave, Boston, MA 02215 USA.							BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Luger K, 1999, METHOD ENZYMOL, V304, P3; MAYER RT, 1974, J CHROMATOGR, V90, P390, DOI 10.1016/S0021-9673(00)92549-4; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Veit M, 1998, BBA-LIPID LIPID MET, V1394, P90, DOI 10.1016/S0005-2760(98)00097-6; YAMASHITA A, 1995, BIOCHEM J, V312, P301, DOI 10.1042/bj3120301; Yan Y, 2002, NAT STRUCT BIOL, V9, P862, DOI 10.1038/nsb849	18	41	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					965	969		10.1038/nature01899	http://dx.doi.org/10.1038/nature01899			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931194				2022-12-24	WOS:000184843600047
J	Nishimura, MT; Stein, M; Hou, BH; Vogel, JP; Edwards, H; Somerville, SC				Nishimura, MT; Stein, M; Hou, BH; Vogel, JP; Edwards, H; Somerville, SC			Loss of a callose synthase results in salicylic acid-dependent disease resistance	SCIENCE			English	Article							PERONOSPORA-PARASITICA; DEFENSE RESPONSES; ARABIDOPSIS; MUTANT	Plants attacked by pathogens rapidly deposit callose, a beta-1,3-glucan, at wound sites. Traditionally, this deposition is thought to reinforce the cell wall and is regarded as a defense response. Surprisingly, here we found that powdery mildew resistant 4 (pmr4), a mutant lacking pathogen-induced callose, became resistant to pathogens, rather than more susceptible. This resistance was due to mutation of a callose synthase, resulting in a loss of the induced callose response. Double-mutant analysis indicated that blocking the salicylic acid ( SA) defense signaling pathway was sufficient to restore susceptibility to pmr4 mutants. Thus, callose or callose synthase negatively regulates the SA pathway.	Carnegie Inst, Dept Plant Biol, Stanford, CA 94305 USA; Western Illinois Univ, Dept Biol Sci, Macomb, IL 61455 USA	Carnegie Institution for Science; Western Illinois University	Somerville, SC (corresponding author), Carnegie Inst, Dept Plant Biol, Stanford, CA 94305 USA.		Bruening, Stefan/B-8505-2011; Vogel, John P/B-3176-2009	Stein, Monica/0000-0002-1926-4212; Vogel, John/0000-0003-1786-2689; Nishimura, Marc Tad/0000-0003-4666-6900				Aist J. R., 1991, The fungal spore and disease initiation in plants and animals., P321; AIST JR, 1976, ANNU REV PHYTOPATHOL, V14, P145, DOI 10.1146/annurev.py.14.090176.001045; Aviv DH, 2002, PLANT J, V29, P381, DOI 10.1046/j.0960-7412.2001.01225.x; Cano-Delgado A, 2003, PLANT J, V34, P351, DOI 10.1046/j.1365-313X.2003.01729.x; Donofrio NM, 2001, MOL PLANT MICROBE IN, V14, P439, DOI 10.1094/MPMI.2001.14.4.439; Ellis C, 2002, PLANT CELL, V14, P1557, DOI 10.1105/tpc.002022; GASPAR Y, COMMUNICATION; Glazebrook J, 2001, CURR OPIN PLANT BIOL, V4, P301, DOI 10.1016/S1369-5266(00)00177-1; Keen NT, 2000, ANNU REV PHYTOPATHOL, V38, P31, DOI 10.1146/annurev.phyto.38.1.31; Nawrath C, 2002, PLANT CELL, V14, P275, DOI 10.1105/tpc.010376; Nickle TC, 1998, PLANT J, V15, P321, DOI 10.1046/j.1365-313X.1998.00212.x; Ostergaard L, 2002, PLANT MOL BIOL, V49, P559, DOI 10.1023/A:1015558231400; RAAB TK, COMMUNICATION; Rairdan GJ, 2001, MOL PLANT MICROBE IN, V14, P1235, DOI 10.1094/MPMI.2001.14.10.1235; Spoel SH, 2003, PLANT CELL, V15, P760, DOI 10.1105/tpc.009159; STEIN MA, UNPUB; Stone BA, 1992, CHEM BIOL 1 3 BETA G; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vogel J, 2000, P NATL ACAD SCI USA, V97, P1897, DOI 10.1073/pnas.030531997; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; Zhu YM, 2003, PLANT PHYSIOL, V132, P494, DOI 10.1104/pp.103.020420	21	487	514	1	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					969	972		10.1126/science.1086716	http://dx.doi.org/10.1126/science.1086716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920300				2022-12-24	WOS:000184755900041
J	Chiti, F; Stefani, M; Taddei, N; Ramponi, G; Dobson, CM				Chiti, F; Stefani, M; Taddei, N; Ramponi, G; Dobson, CM			Rationalization of the effects of mutations on peptide and protein aggregation rates	NATURE			English	Article							X-RAY-DIFFRACTION; TAU-PROTEIN; MISFOLDING DISEASES; ALZHEIMERS-DISEASE; INCLUSION-BODIES; ALPHA-SYNUCLEIN; FTDP-17 MUTANTS; AMYLOID FIBRILS; PRION PROTEIN; POLYMERIZATION	In order for any biological system to function effectively, it is essential to avoid the inherent tendency of proteins to aggregate and form potentially harmful deposits(1-4). In each of the various pathological conditions associated with protein deposition, such as Alzheimer's and Parkinson's diseases, a specific peptide or protein that is normally soluble is deposited as insoluble aggregates generally referred to as amyloid(2,3). It is clear that the aggregation process is generally initiated from partially or completely unfolded forms of the peptides and proteins associated with each disease. Here we show that the intrinsic effects of specific mutations on the rates of aggregation of unfolded polypeptide chains can be correlated to a remarkable extent with changes in simple physicochemical properties such as hydrophobicity, secondary structure propensity and charge. This approach allows the pathogenic effects of mutations associated with known familial forms of protein deposition diseases to be rationalized, and more generally enables prediction of the effects of mutations on the aggregation propensity of any polypeptide chain.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Cambridge; University of Florence	Dobson, CM (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.			Taddei, Niccolo/0000-0003-2513-1018; STEFANI, MASSIMO/0000-0002-4490-1922				Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carrio MM, 2002, J BIOTECHNOL, V96, P3, DOI 10.1016/S0168-1656(02)00032-9; Chiti F, 2002, P NATL ACAD SCI USA, V99, P16419, DOI 10.1073/pnas.212527999; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Esler WP, 1996, BIOCHEMISTRY-US, V35, P13914, DOI 10.1021/bi961302+; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Li L, 2002, J BIOL CHEM, V277, P41390, DOI 10.1074/jbc.M206334200; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Nacharaju P, 1999, FEBS LETT, V447, P195, DOI 10.1016/S0014-5793(99)00294-X; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Orpiszewski J, 1999, J MOL BIOL, V289, P413, DOI 10.1006/jmbi.1999.2768; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Sakagashira S, 2000, AM J PATHOL, V157, P2101, DOI 10.1016/S0002-9440(10)64848-1; Salmona M, 1999, BIOCHEM J, V342, P207, DOI 10.1042/0264-6021:3420207; Street AG, 1999, P NATL ACAD SCI USA, V96, P9074, DOI 10.1073/pnas.96.16.9074; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Symmons MF, 1997, FEBS LETT, V412, P397, DOI 10.1016/S0014-5793(97)00809-0; Thompson AJ, 2001, BBA-PROTEIN STRUCT M, V1544, P242, DOI 10.1016/S0167-4838(00)00225-9; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200	30	882	904	0	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					805	808		10.1038/nature01891	http://dx.doi.org/10.1038/nature01891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917692				2022-12-24	WOS:000184733900047
J	Prinz, M; Heikenwalder, M; Junt, T; Schwarz, P; Glatzel, M; Heppner, FL; Fu, YX; Lipp, M; Aguzzi, A				Prinz, M; Heikenwalder, M; Junt, T; Schwarz, P; Glatzel, M; Heppner, FL; Fu, YX; Lipp, M; Aguzzi, A			Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; SYMPATHETIC INNERVATION; GERMINAL-CENTERS; MICE; SCRAPIE; REPLICATION; SUSCEPTIBILITY; EXPRESSION; INFECTION; RECEPTOR	Peripheral infection is the natural route of transmission in most prion diseases(1). Peripheral prion infection is followed by rapid prion replication in lymphoid organs, neuroinvasion(2) and progressive neurological disease. Both immune cells and nerves are involved in pathogenesis(3,4), but the mechanisms of prion transfer from the immune to the nervous system are unknown. Here we show that ablation of the chemokine receptor CXCR5 juxtaposes follicular dendritic cells (FDCs) to major splenic nerves, and accelerates the transfer of intraperitoneally administered prions into the spinal cord. Neuroinvasion velocity correlated exclusively with the relative locations of FDCs and nerves: transfer of CXCR5(-/-) bone marrow to wild-type mice induced perineural FDCs and enhanced neuroinvasion, whereas reciprocal transfer to CXCR5(-/-) mice abolished them and restored normal efficiency of neuroinvasion. Suppression of lymphotoxin signalling depleted FDCs, abolished splenic infectivity, and suppressed acceleration of pathogenesis in CXCR5(-/-) mice. This suggests that prion neuroimmune transition occurs between FDCs and sympathetic nerves, and relative positioning of FDCs and nerves controls the efficiency of peripheral prion infection.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; Max Delbruck Ctr Mol Med, Dept Mol Tumor Genet & Immunogenet, D-13092 Berlin, Germany	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Chicago; University of Chicago; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Glatzel, Markus/V-8844-2019; Lipp, Martin/G-2235-2010; Junt, Tobias/AAE-4389-2021; Heppner, Frank/ABH-8393-2020; Heikenwalder, Mathias/AAA-2269-2020; Glatzel, Markus/G-3356-2011; Aguzzi, Adriano/A-3351-2008	Glatzel, Markus/0000-0002-7720-8817; Heppner, Frank/0000-0001-9816-8917; Glatzel, Markus/0000-0002-7720-8817; Aguzzi, Adriano/0000-0002-0344-6708; Lipp, Martin/0000-0002-0087-2672; fu, yang-xin/0000-0001-8441-6617				Aguzzi A, 1997, LANCET, V349, P742, DOI 10.1016/S0140-6736(97)22011-8; Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Aguzzi A, 2001, NAT REV NEUROSCI, V2, P745, DOI 10.1038/35094590; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; CARLSON SL, 1995, J NEUROSCI, V15, P5892; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; FELTEN D L, 1988, Brain Behavior and Immunity, V2, P293, DOI 10.1016/0889-1591(88)90031-1; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Glatzel M, 2001, NEURON, V31, P25, DOI 10.1016/S0896-6273(01)00331-2; HEINEN E, 1995, CURR TOP MICROBIOL, V201, P15; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; Kaeser PS, 2001, J VIROL, V75, P7097, DOI 10.1128/JVI.75.15.7097-7106.2001; Karrer U, 2000, J IMMUNOL, V164, P768, DOI 10.4049/jimmunol.164.2.768; KIMBERLIN RH, 1989, VIRUS RES, V12, P201, DOI 10.1016/0168-1702(89)90039-7; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Oldstone MBA, 2002, J VIROL, V76, P4357, DOI 10.1128/JVI.76.9.4357-4363.2002; Prinz M, 2002, P NATL ACAD SCI USA, V99, P919, DOI 10.1073/pnas.022626399; Prusiner S B, 1981, Adv Exp Med Biol, V134, P385; Race R, 2000, J VIROL, V74, P828, DOI 10.1128/JVI.74.2.828-833.2000; Voigt I, 2000, EUR J IMMUNOL, V30, P560, DOI 10.1002/1521-4141(200002)30:2<560::AID-IMMU560>3.0.CO;2-T; Wu Q, 2001, J EXP MED, V193, P1327, DOI 10.1084/jem.193.11.1327	29	170	175	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	2003	425	6961					957	962		10.1038/nature02072	http://dx.doi.org/10.1038/nature02072			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	737KY	14562059				2022-12-24	WOS:000186230600041
J	Sivars, U; Aivazian, D; Pfeffer, SR				Sivars, U; Aivazian, D; Pfeffer, SR			Yip3 catalyses the dissociation of endosomal Rab-GDI complexes	NATURE			English	Article							GOLGI MEMBRANE-PROTEIN; PRENYLATED RAB; NUCLEOTIDE EXCHANGE; BINDING PROTEIN; GTPASES; INHIBITOR; IDENTIFICATION; TRANSPORT; INTERACTS; RECEPTOR	Human cells contain more than 60 small G proteins of the Rab family, which are localized to the surfaces of distinct membrane compartments and regulate transport vesicle formation, motility, docking and fusion(1-3). Prenylated Rabs also occur in the cytosol bound to GDI(4,5) (guanine nucleotide dissociation inhibitor), which binds to Rabs in their inactive state. Prenyl Rab-GDI complexes contain all of the information necessary to direct Rab delivery onto distinct membrane compartments(6-8). The late endosomal, prenyl Rab9 binds GDI with very high affinity(9), which led us to propose that there might be a 'GDI-displacement factor' to catalyse dissociation of Rab-GDI complexes and to enable transfer of Rabs from GDI onto membranes(6,10). Indeed, we have previously shown that endosomal membranes contain a proteinaceous factor that can act in this manner(10). Here we show that the integral membrane protein, Yip3, acts catalytically to dissociate complexes of endosomal Rabs bound to GDI, and to deliver them onto membranes. We propose that the conserved Yip proteins serve as GDI-displacement factors for the targeting of Rab GTPases in eukaryotic cells.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Pfeffer, SR (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.							Abdul-Ghani M, 2001, J BIOL CHEM, V276, P6225, DOI 10.1074/jbc.M009073200; BARROWMAN J, 2002, J BIOL CHEM, V278, P1978; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; Calero M, 2002, BIOCHEM BIOPH RES CO, V290, P676, DOI 10.1006/bbrc.2001.6242; Calero M, 2002, FEBS LETT, V515, P89, DOI 10.1016/S0014-5793(02)02442-0; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lin JL, 2001, J BIOL CHEM, V276, P41733, DOI 10.1074/jbc.M103475200; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Matern H, 2000, EMBO J, V19, P4485, DOI 10.1093/emboj/19.17.4485; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; SHAPIRO AD, 1995, J BIOL CHEM, V270, P11085, DOI 10.1074/jbc.270.19.11085; SOLDATI T, 1995, J BIOL CHEM, V270, P25541, DOI 10.1074/jbc.270.43.25541; SOLDATI T, 1995, METHOD ENZYMOL, V257, P253; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; Tang BL, 2001, J BIOL CHEM, V276, P40008, DOI 10.1074/jbc.M106189200; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	26	195	207	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					856	859		10.1038/nature02057	http://dx.doi.org/10.1038/nature02057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574414				2022-12-24	WOS:000186118500049
J	Zhang, JW; Niu, C; Ye, L; Huang, HY; He, X; Tong, WG; Ross, J; Haug, J; Johnson, T; Feng, JQ; Harris, S; Wiedemann, LM; Mishina, Y; Li, LH				Zhang, JW; Niu, C; Ye, L; Huang, HY; He, X; Tong, WG; Ross, J; Haug, J; Johnson, T; Feng, JQ; Harris, S; Wiedemann, LM; Mishina, Y; Li, LH			Identification of the haematopoietic stem cell niche and control of the niche size	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-2; DROSOPHILA-OVARY; IN-VIVO; DIFFERENTIATION; OSTEOBLAST; CADHERIN; LINEAGES; PROLIFERATION; MESODERM; MARROW	Haematopoietic stem cells (HSCs) are a subset of bone marrow cells that are capable of self-renewal and of forming all types of blood cells (multi-potential)(1). However, the HSC 'niche'-the in vivo regulatory microenvironment where HSCs reside-and the mechanisms involved in controlling the number of adult HSCs remain largely unknown. The bone morphogenetic protein (BMP) signal has an essential role in inducing haematopoietic tissue during embryogenesis(2,3). We investigated the roles of the BMP signalling pathway in regulating adult HSC development in vivo by analysing mutant mice with conditional inactivation of BMP receptor type IA (BMPRIA). Here we show that an increase in the number of spindle-shaped N-cadherin(+)CD45(-) osteoblastic (SNO) cells correlates with an increase in the number of HSCs. The long-term HSCs are found attached to SNO cells. Two adherens junction molecules, N-cadherin and beta-catenin, are asymmetrically localized between the SNO cells and the long-term HSCs. We conclude that SNO cells lining the bone surface function as a key component of the niche to support HSCs, and that BMP signalling through BMPRIA controls the number of HSCs by regulating niche size.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA; Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA	Stowers Institute for Medical Research; University of Missouri System; University of Missouri Kansas City; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Kansas; University of Kansas Medical Center	Li, LH (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.		Wiedemann, Leanne/E-3316-2010	Wiedemann, Leanne/0000-0002-0964-4676; Li, Linheng/0000-0001-9963-430X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071004] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Askenasy N, 2002, STEM CELLS, V20, P501, DOI 10.1634/stemcells.20-6-501; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Charbord P, 2001, THERAPIE, V56, P383; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Davidson AJ, 2000, CURR TOP DEV BIOL, V50, P45, DOI 10.1016/S0070-2153(00)50003-9; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; El-Badri NS, 1998, EXP HEMATOL, V26, P110; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; Hay E, 2000, J CELL PHYSIOL, V183, P117, DOI 10.1002/(SICI)1097-4652(200004)183:1<117::AID-JCP14>3.0.CO;2-#; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Mishina Y, 2002, GENESIS, V32, P69, DOI 10.1002/gene.10038; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; Puch S, 2001, J CELL SCI, V114, P1567; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Simmons PJ, 2001, HEMATOPOIESIS DEV AP, P718; Song XQ, 2002, P NATL ACAD SCI USA, V99, P14813, DOI 10.1073/pnas.232389399; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; SZILVASSY SJ, 2002, HAEMATOPOIETIC STEM, P167; Taichman RUSSELL S., 2000, Hematology, V4, P421; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Visnjic D, 2001, J BONE MINER RES, V16, P2222, DOI 10.1359/jbmr.2001.16.12.2222; WEISSMAN IL, 1994, CELL, V76, P207, DOI 10.1016/0092-8674(94)90329-8; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328	31	2193	2340	4	167	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					836	841		10.1038/nature02041	http://dx.doi.org/10.1038/nature02041			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574412	Bronze			2022-12-24	WOS:000186118500045
J	Kadan-Lottick, NS; Ness, KK; Bhatia, S; Gurney, JG				Kadan-Lottick, NS; Ness, KK; Bhatia, S; Gurney, JG			Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LYMPHOID LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; RACIAL-DIFFERENCES; CHILDREN; CANCER; WHITE; BLACK; CURE	Context The role of race/ethnicity in survival of children with acute lymphoblastic leukemia (ALL) is unclear, with some studies reporting poorer survival among minority children and others reporting equivalent survival across race/ethnicity in the modern, risk-stratified treatment era. Objective To investigate the relation between race/ethnicity and survival in a large, population-based analysis of incident ALL cases in the United States. Design, Population, and Setting This study included 4952 individuals diagnosed with ALL between 1973 and 1999 at age 19 years or younger. ALL cases were identified from 9 population-based registries of the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Main Outcome Measures Survival probabilities were compared among white, black, Hispanic, Asian/Pacific Islander, and American Indian/Alaskan Native children. Kaplan-Meier curves and proportional hazard ratios from Cox regression analysis were calculated, accounting for treatment era (1973-1982, 1983-1989, and 1990-1999), age at diagnosis (<1, 1-9, and 10-19 years), and sex. Results Although overall 5-year survival probabilities improved with each successive treatment era, differences according to race/ethnicity persisted. For 1990-1999, 5-year survival was 84% for white children, 81 % for Asian/Pacific Islander children, 75% for black children, and 72% for both American Indian/Alaskan Native children and Hispanic children. The largest difference by race/ethnicity was observed among children diagnosed between ages 1 and 9 years. Compared with white children, after adjusting for treatment era, age at diagnosis, and sex, children of black, Hispanic, and American Indian/Alaskan Native descent had hazard ratios of 1.50 (95% Cl, 1.0-2.2; P=.03), 1.83 (95% Cl, 1.4-2.4; P<.001), and 1.90 (95% Cl, 0.8-4.6; P=.16). Conclusions Black, Hispanic, and American Indian/Alaskan Native children with ALL have worse survival than white and Asian/Pacific Islander children, even in the contemporary treatment era. Future work must delineate the social and biological factors, including any differences in pharmacokinetics associated with chemotherapeutic agents, that account for disparities in outcome.	Univ Minnesota, Div Pediat Epidemiol & Clin Res, Minneapolis, MN 55455 USA; Yale Univ, Div Pediat Hematol Oncol, New Haven, CT USA; City Hope Natl Med Ctr, Div Pediat, Duarte, CA 91010 USA	University of Minnesota System; University of Minnesota Twin Cities; Yale University; City of Hope	Gurney, JG (corresponding author), Univ Minnesota, Div Pediat Epidemiol & Clin Res, Mayo Mail Code 715,420 Delaware St SE, Minneapolis, MN 55455 USA.		Ness, Kirsten K/N-2550-2018; Kadan-Lottick, Nina Singh/HGE-5850-2022	Ness, Kirsten K/0000-0002-2084-1507; Kadan-Lottick, Nina Singh/0000-0002-6857-396X				ALLISON PD, 1999, LOGISTIC REGRESSION, P30; ALLISON PD, 1999, LOGISTIC REGRESSION, P113; Bach PB, 2002, JAMA-J AM MED ASSOC, V287, P2106, DOI 10.1001/jama.287.16.2106; Bhatia S, 2002, BLOOD, V100, P1957, DOI 10.1182/blood-2002-02-0395; Brenner MK, 1999, SEMIN HEMATOL, V36, P73; COLLETT D, 1991, MODELING BINARY DATA, P16; *DCCPS NAT CANC I, 2002, SURV EP END RES PROG; FALLETTA JM, 1984, PATHOGENESIS LEUKEMI, P191; FOUCAR K, 1991, CANCER-AM CANCER SOC, V67, P2125, DOI 10.1002/1097-0142(19910415)67:8<2125::AID-CNCR2820670820>3.0.CO;2-A; Hord MH, 1996, CANCER-AM CANCER SOC, V77, P563; MARUBINI E, 1985, ANAL SURVIVAL DATA C, P41; McKinney PA, 1999, BRIT J CANCER, V80, P1844, DOI 10.1038/sj.bjc.6690609; MCLEOD HL, 1994, CLIN PHARMACOL THER, V55, P15, DOI 10.1038/clpt.1994.4; *NCI, SEER STAT VERS 4 2; *NCI, CANC CONTR POP SCI S; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; Percy C., 1990, INT CLASSIFICATION D; PINKEL D, 1993, LEUKEMIA, V7, pS146; Pollock BH, 2000, J CLIN ONCOL, V18, P813, DOI 10.1200/JCO.2000.18.4.813; Powell JE, 2000, BRIT J CANCER, V82, P1568; PRATT JA, 1988, J CLIN EPIDEMIOL, V41, P367, DOI 10.1016/0895-4356(88)90144-8; PUI CH, 1995, JAMA-J AM MED ASSOC, V273, P633, DOI 10.1001/jama.273.8.633; REAMAN GH, 1984, PATHOGENESIS LEUKEMI, P163; Ries LA, 2002, SEER CANC STAT REV 1; Rivera-Luna R, 2000, J CLIN ONCOL, V18, P2349; *SAS I, SAS VERS 8 2; SATHER H, 1984, PATHOGENESIS LEUKEMI, P179; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; SMITH MA, 1999, NIH PUB; Walker A H, 1998, Hum Mutat, V12, P289; WALTERS TR, 1972, CANCER, V29, P210, DOI 10.1002/1097-0142(197201)29:1<210::AID-CNCR2820290131>3.0.CO;2-U; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C	32	163	164	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2003	290	15					2008	2014		10.1001/jama.290.15.2008	http://dx.doi.org/10.1001/jama.290.15.2008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CX	14559954	Bronze			2022-12-24	WOS:000185924200024
J	Apesteguia, S; Novas, FE				Apesteguia, S; Novas, FE			Large Cretaceous sphenodontian from Patagonia provides insight into lepidosaur evolution in Gondwana	NATURE			English	Article							JURASSIC KOTA FORMATION; CENTRAL MEXICO; DIAPSIDA; REPTILIA; RHYNCHOCEPHALIA	Sphenodontian reptiles successfully radiated during Triassic and Jurassic times, but were driven almost to extinction during the Cretaceous period(1). The sparse Early Cretaceous record of sphenodontians has been interpreted as reflecting the decline of the group in favour of lizards, their suspected ecological successors(2). However, recent discoveries in Late Cretaceous beds in Patagonia partially modify this interpretation. Numerous skeletons of a new sphenodontian, Priosphenodon avelasi gen. et sp. nov., were collected from a single locality in the Cenomanian-Turonian Candeleros Formation, where it is more abundant than any other tetrapod group recorded in the quarry (for example, Crocodyliformes, Serpentes, Dinosauria and Mammalia)(3,4). Adult specimens of Priosphenodon reached one metre in length, larger than any previously known terrestrial sphenodontian. Here we propose, using available evidence, that sphenodontians were not a minor component of the Cretaceous terrestrial ecosystems of South America, and that their ecological replacement by squamates was delayed until the early Tertiary. The new discovery helps to bridge the considerable gap in the fossil record (around 120 million years) that separates the Early Cretaceous sphenodontians(5-7) from their living relatives (Sphenodon).	Museo Argentino Ciencias Nat Bernardino Rivadavia, RA-1405 Buenos Aires, DF, Argentina	Museo Argentino de Ciencias Naturales Bernardino Rivadavia (MACN)	Apesteguia, S (corresponding author), Museo Argentino Ciencias Nat Bernardino Rivadavia, Av Angel Gallardo 470, RA-1405 Buenos Aires, DF, Argentina.		Apesteguía, Sebastian/F-4034-2018	Apesteguía, Sebastian/0000-0002-0414-0524				ALBINO A, 1 C OA REIG VERT BAS; APESTEGUIA S, IN PRESS C ARG PAL B; APESTEGUIA S, IN PRESS 1 C OA REIG; APESTEGUIA S, 2002, AMEGHINIANA, V39, pR5; Baez A. M., 1977, ACTA GEOLOGICA LILLO, V14, P149; Barbera C., 1992, Memorie della Societa Geologica Italiana, V41, P567; Broschinski Annette, 1996, Annales de Paleontologie, V82, P147; Carroll RL, 1988, VERTEBRATE PALEONTOL; Estes R., 1985, GREAT AM BIOTIC INTE, P139; Evans SE, 2002, J VERTEBR PALEONTOL, V22, P299, DOI 10.1671/0272-4634(2002)022[0299:FLFTJK]2.0.CO;2; Evans SE, 1997, J VERTEBR PALEONTOL, V17, P45, DOI 10.1080/02724634.1997.10010952; Evans SE, 2001, ZOOL J LINN SOC-LOND, V133, P309, DOI 10.1006/zjls.2000.0266; Evans Susan E., 1998, Neues Jahrbuch fuer Geologie und Palaeontologie Monatshefte, V6, P349; FRASER NC, 1988, PHILOS T ROY SOC B, V321, P125, DOI 10.1098/rstb.1988.0092; FRASER NC, 1989, ZOOL J LINN SOC-LOND, V96, P413, DOI 10.1111/j.1096-3642.1989.tb02521.x; GALLINA P.A., 2002, AMEGHINIANA, V39, p10R; Haeckel E, 1866, GEN MORPHOLOGIE ORGA; HUGO C, 1999, I GEOL REC NAT SEGEM, V309, P1; Novas F. E., 1999, AMEGHINIANA, V36, p16R; POL D, IN PRESS C ARG PALEO; RASMUSSEN TE, 1981, J PALEONTOL, V55, P1109; Reynoso VH, 1997, J VERTEBR PALEONTOL, V17, P52, DOI 10.1080/02724634.1997.10010953; Reynoso VH, 2000, J PALEONTOL, V74, P133, DOI 10.1666/0022-3360(2000)074<0133:AUASRD>2.0.CO;2; Rich T.H.V., 1983, Transactions of the Geological Society of South Africa, V86, P281; Smith Krister T., 2001, Journal of Vertebrate Paleontology, V21, p102A; THROCKMORTON GS, 1981, J PALEONTOL, V55, P586; WILLISTON S. W., 1925, OSTEOLOGY REPTILES; Wu X.-C., 1991, THESIS MCGILL U; Zils Wolfgang, 1995, Documenta Naturae, V97, P1	29	84	87	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					609	612		10.1038/nature01995	http://dx.doi.org/10.1038/nature01995			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534584				2022-12-24	WOS:000185801000034
J	Ito, S; Stuphorn, V; Brown, JW; Schall, JD				Ito, S; Stuphorn, V; Brown, JW; Schall, JD			Performance monitoring by the anterior cingulate cortex during saccade countermanding	SCIENCE			English	Article							SUPPLEMENTARY EYE FIELD; REWARD; MOVEMENT; MACAQUE; DOPAMINE; MONKEY	Consensus is emerging that the medial frontal lobe of the brain is involved in monitoring performance, but precisely what is monitored remains unclear. A saccade-countermanding task affords an experimental dissociation of neural signals of error, reinforcement, and conflict. Single-unit activity was monitored in the anterior cingulate cortex of monkeys performing this task. Neurons that signaled errors were found, half of which responded to the omission of earned reinforcement. A further diversity of neurons signaled earned or unexpected reinforcement. No neurons signaled the form of conflict engendered by interruption of saccade preparation produced in this task. These results are consistent with the hypothesis that the anterior cingulate cortex monitors the consequences of actions.	Vanderbilt Univ, Dept Psychol, Vanderbilt Vis Res Ctr, Ctr Integrat & Cognit Neurosci, Nashville, TN 37203 USA; Washington Univ, Dept Psychol, St Louis, MO 63130 USA	Vanderbilt University; Washington University (WUSTL)	Schall, JD (corresponding author), Vanderbilt Univ, Dept Psychol, Vanderbilt Vis Res Ctr, Ctr Integrat & Cognit Neurosci, Wilson Hall, Nashville, TN 37203 USA.	jeffrey.d.schall@vanderbilt.edu	Brown, Joshua/G-2867-2011		NEI NIH HHS [P30-EY008126] Funding Source: Medline; NIMH NIH HHS [R01-MH55806] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH055806] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BECKER W, 1979, VISION RES, V19, P967, DOI 10.1016/0042-6989(79)90222-0; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brown J, 1999, J NEUROSCI, V19, P10502; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Dayan P, 2002, NEURON, V36, P285, DOI 10.1016/S0896-6273(02)00963-7; Gehring WJ, 2002, SCIENCE, V295, P2279, DOI 10.1126/science.1066893; HANES DP, 1995, VISUAL NEUROSCI, V12, P929, DOI 10.1017/S0952523800009482; Hanes DP, 1998, J NEUROPHYSIOL, V79, P817, DOI 10.1152/jn.1998.79.2.817; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; HUERTA MF, 1990, J COMP NEUROL, V293, P299, DOI 10.1002/cne.902930211; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Luppino G, 2003, EUR J NEUROSCI, V17, P559, DOI 10.1046/j.1460-9568.2003.02476.x; McPeek RM, 2003, J NEUROPHYSIOL, V89, P2577, DOI 10.1152/jn.00657.2002; Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1; NIKI H, 1979, BRAIN RES, V171, P213, DOI 10.1016/0006-8993(79)90328-7; Pare M, 2003, J NEUROSCI, V23, P6480; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; SCHALL JD, 1993, VISUAL NEUROSCI, V10, P385, DOI 10.1017/S0952523800003771; Scheffers MK, 2000, J EXP PSYCHOL HUMAN, V26, P141, DOI 10.1037/0096-1523.26.1.141; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Shidara M, 2002, SCIENCE, V296, P1709, DOI 10.1126/science.1069504; Shima K, 1998, SCIENCE, V282, P1335, DOI 10.1126/science.282.5392.1335; Stuphorn V, 2000, NATURE, V408, P857, DOI 10.1038/35048576	23	427	433	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					120	122		10.1126/science.1087847	http://dx.doi.org/10.1126/science.1087847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526085				2022-12-24	WOS:000185678500050
J	Hudson, MM; Mertens, AC; Yasui, Y; Hobbie, W; Chen, HG; Gurney, JG; Yeazel, M; Recklitis, CJ; Marina, N; Robison, LR; Oeffinger, KC				Hudson, MM; Mertens, AC; Yasui, Y; Hobbie, W; Chen, HG; Gurney, JG; Yeazel, M; Recklitis, CJ; Marina, N; Robison, LR; Oeffinger, KC		Childhood Canc Survivor Study Inve	Health status of adult long-term survivors of childhood cancer - A report from the childhood cancer survivor study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SIBLING ADAPTATION; ADOLESCENT CANCER; HODGKINS-DISEASE; LATE MORTALITY; LATE DEATHS; DIAGNOSIS; LEUKEMIA; SYSTEM; CURE	Context Adult survivors of childhood cancer are at risk for medical and psychosocial sequelae that may adversely affect their health status. Objectives To compare the health status of adult survivors of childhood cancer and siblings and to identify factors associated with adverse outcomes. Design, Setting, and Participants Health status was assessed in 9535 adult participants of the Childhood Cancer Survivor Study, a cohort of long-term survivors of childhood cancer who were diagnosed between 1970 and 1986. A randomly selected cohort of the survivors' siblings (n=2916) served as a comparison group. Main Outcome Measures Six health status domains were assessed: general health, mental health, functional status, activity limitations, cancer-related pain, and cancer-related anxiety/fears. The first 4 domains were assessed in the control group. Results Survivors were significantly more likely to report adverse general health (odds ratio [OR], 2.5; 95% confidence interval [Cl], 2.1-3.0; P<.001), mental health (OR, 1.8; 95% Cl, 1.6-2.1; P<.001), activity limitations (OR, 2.7; 95% Cl, 2.3-3.3; P<.001), and functional impairment(OR, 5.2; 95% Cl, 4.1-6.6; P<.001), compared with siblings. Forty-four percent of survivors reported at least 1 adversely affected health status domain. Sociodemographic factors associated with reporting at least 1 adverse health status domain included being female (OR, 1.4; 95% Cl, 1.3-1.6; P<.001), lower level of educational attainment (OR, 2.0; 95% Cl, 1.8-2.2; P<.001), and annual income less than $20000 (OR, 1.8; 95% Cl, 1.6-2.1; P<.001). Relative to those survivors with childhood leukemia, an increased risk was observed for at least 1 adverse health status domain among those with bone tumors (OR, 2.1; 95% CI, 1.8-2.5; P<.001), central nervous system tumors (OR, 1.7; 95% Cl, 1.5-2.0; P<.001), and sarcomas (OR, 1.2; 95% Cl, 1.1-1.5; P=.01). Conclusion Clinicians caring for adult survivors of childhood cancer should be aware of the substantial risk for adverse health status, especially among females, those with low educational attainment, and those with low household incomes.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN 38163 USA; Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Family Practice, Minneapolis, MN USA; Univ Minnesota, Dept Biostat, Minneapolis, MN USA; Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA; Childrens Hosp Philadelphia, Dept Oncol, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Stanford Univ, Med Ctr, Dept Pediat, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Dept Family Practice & Community Med, Dallas, TX USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Fred Hutchinson Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Harvard University; Dana-Farber Cancer Institute; Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hudson, MM (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	melissa.hudson@stjude.org	Hudson, Melissa M/N-4441-2018; Robison, Leslie/N-8122-2018; Yasui, Yutaka/E-2564-2015; Marina, Neyssa/B-7449-2009	Hudson, Melissa M/0000-0001-6984-2407; Yasui, Yutaka/0000-0002-7717-8638; Recklitis, Christopher/0000-0003-1336-8261; Marina, Neyssa/0000-0002-7195-8887	NATIONAL CANCER INSTITUTE [P30CA021765, U24CA055727] Funding Source: NIH RePORTER; NCI NIH HHS [U24 CA055727, CA 21765, 5U24-CA-55727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson DM, 2001, CANCER-AM CANCER SOC, V92, P2709, DOI 10.1002/1097-0142(20011115)92:10<2709::AID-CNCR1625>3.0.CO;2-D; Barbarin OA, 1995, J PSYCHOSOC ONCOL, V13, P1, DOI 10.1300/J077V13N03_01; *CDCP, 1993, NAT HLTH INT SURV; *CDCP, 1993, BEH RISK FACT SURV S; Chen E, 1998, J Health Psychol, V3, P23, DOI 10.1177/135910539800300102; Crom DB, 1999, INT J CANCER, P25; Derogatis LR, 1993, BRIEF SYMPTOM INVENT; Diggle P., 2002, ANAL LONGITUDINAL DA, DOI DOI 10.2307/2983303; Dolgin MJ, 1997, J PSYCHOSOC ONCOL, V15, P1, DOI 10.1300/J077v15n01_01; DREYER ZE, 2002, PRINCIPLES PRACTICE, P1431; Elkin TD, 1997, MED PEDIATR ONCOL, V29, P582, DOI 10.1002/(SICI)1096-911X(199712)29:6<582::AID-MPO13>3.0.CO;2-8; Ettner SL, 1996, J HEALTH ECON, V15, P67, DOI 10.1016/0167-6296(95)00032-1; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; GARRE ML, 1994, AM J PEDIAT HEMATOL, V16, P143; GREEN DM, 1994, MED PEDIATR ONCOL, V22, P91, DOI 10.1002/mpo.2950220206; Green DM, 1999, J CLIN ONCOL, V17, P3207, DOI 10.1200/JCO.1999.17.10.3207; Gurney JG, 2003, CANCER-AM CANCER SOC, V97, P663, DOI 10.1002/cncr.11095; Hankin BL, 1999, ANN MED, V31, P372, DOI 10.3109/07853899908998794; HAVERMANS T, 1994, CHILD CARE HLTH DEV, V20, P309, DOI 10.1111/j.1365-2214.1994.tb00393.x; HAWKINS MM, 1990, ARCH DIS CHILD, V65, P1356, DOI 10.1136/adc.65.12.1356; Hobbie WL, 2000, J CLIN ONCOL, V18, P4060, DOI 10.1200/JCO.2000.18.24.4060; HORWITZ WA, 1990, J CLIN CHILD PSYCHOL, V4, P462; Hudson MM, 1998, J CLIN ONCOL, V16, P3592, DOI 10.1200/JCO.1998.16.11.3592; Hudson MM, 1997, J CLIN ONCOL, V15, P2205, DOI 10.1200/JCO.1997.15.6.2205; Kadan-Lottick NS, 2002, JAMA-J AM MED ASSOC, V287, P1832, DOI 10.1001/jama.287.14.1832; Marina N, 1997, PEDIATR CLIN N AM, V44, P1021, DOI 10.1016/S0031-3955(05)70543-5; Mertens AC, 2001, J CLIN ONCOL, V19, P3163, DOI 10.1200/JCO.2001.19.13.3163; NICHOLSON HS, 1994, CANCER, V73, P3094; ROBERTSON CM, 1994, BRIT MED J, V309, P162, DOI 10.1136/bmj.309.6948.162; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; ROURKE M, 2002, 7 INT C LONG TERM CO; Rourke M T, 1999, J Pediatr Oncol Nurs, V16, P126, DOI 10.1177/104345429901600303; Sahler OJZ, 1997, J DEV BEHAV PEDIATR, V18, P233; SAHLER OJZ, 1994, J DEV BEHAV PEDIATR, V15, P353; Sloper P, 1996, J CHILD PSYCHOL PSYC, V37, P597, DOI 10.1111/j.1469-7610.1996.tb01446.x; Zabora J, 2001, PSYCHOSOMATICS, V42, P241, DOI 10.1176/appi.psy.42.3.241; Zebrack BJ, 2002, PEDIATRICS, V110, P42, DOI 10.1542/peds.110.1.42; Zeltzer LK, 1997, J CLIN ONCOL, V15, P547, DOI 10.1200/JCO.1997.15.2.547	38	589	594	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2003	290	12					1583	1592		10.1001/jama.290.12.1583	http://dx.doi.org/10.1001/jama.290.12.1583			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	723ZK	14506117	Bronze			2022-12-24	WOS:000185461300023
J	Mora, S; Redberg, RF; Cui, YD; Whiteman, MK; Flaws, JA; Sharrett, AR; Blumenthal, RS				Mora, S; Redberg, RF; Cui, YD; Whiteman, MK; Flaws, JA; Sharrett, AR; Blumenthal, RS			Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women - A 20-year follow-up of the lipid research clinics prevalence study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-RATE RECOVERY; NORTH-AMERICAN MEN; PHYSICAL-ACTIVITY; CAUSE MORTALITY; CARDIORESPIRATORY FITNESS; PROGNOSTIC VALUE; RISK ASSESSMENT; DISEASE; CARDIOLOGY; STATEMENT	Context The value of exercise testing in women has been questioned. Objective To determine the prognostic value of exercise testing in a population: based cohort of asymptomatic women followed up for 20 years. Design and Setting Near-maximal Bruce-protocol treadmill test data from the Lipid Research Clinics Prevalence Study (1972-1976) with follow-up through 1995. Participants A total of 2994 asymptomatic North American women, aged 30 to 80 years, without known cardiovascular disease. Main Outcome Measures Cardiovascular and all-cause mortality. Results There were 427 (14%) deaths during 20 years of follow-up, of which 147 were due to cardiovascular causes. Low exercise capacity, low heart rate recovery (HRR), and not achieving target heart rate were independently associated with increased all-cause and cardiovascular mortality. There was no increased cardiovascular death risk for exercise-induced ST-segment depression (age-adjusted hazard ratio, 1.02; 95% confidence interval [CI], 0.57-1.80; P=96). The age-adjusted hazard ratio for cardiovascular death for every metabolic equivalent (MET) decrement in exercise capacity was 1.20 (95% Cl, 1.18-1.30; P<.001); for every 10 beats per minute decrement in HRR, the hazard ratio was 1.36 (95% Cl, 1.19-1.55; P<.001). After adjusting for multiple other risk factors, women who were below the median for both exercise capacity and HRR had a 3.5-fold increased risk of cardiovascular death (95% Cl, 1.57-7.86; P=.002) compared with those above the median for both variables. Among women with low risk Framingham scores, those with below median levels of both exercise capacity and HRR had significantly increased risk compared with women who had above median levels of these 2 exercise variables, 44.5 and 3.5 cardiovascular deaths per 10000 person-years, respectively (hazard ratio for cardiovascular death, 12.93; 95% Cl, 5.62-29.73; P<.001). Conclusion The prognostic value of exercise testing in asymptomatic women derives not from electrocardiographic ischemia but from fitness-related variables.	Johns Hopkins Med Inst, Dept Med, Ciccarone Prevent Cardiol Ctr, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore	Blumenthal, RS (corresponding author), Johns Hopkins Univ Hosp, Ciccarone Prevent Cardiol Ctr, Div Cardiol, Carnegie 538,600 N Wolfe St, Baltimore, MD 21287 USA.	rblument@jhmi.edu	Blumenthal, Roger S/H-3223-2018	Blumenthal, Roger S/0000-0003-1910-3168; Flaws, Jodi/0000-0001-5579-9268; Mora, Samia/0000-0001-6283-0980	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007024] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07024] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramson JL, 2002, ARCH INTERN MED, V162, P1286, DOI 10.1001/archinte.162.11.1286; Albert CM, 2003, CIRCULATION, V107, P2096, DOI 10.1161/01.CIR.0000065223.21530.11; ALLEN WH, 1980, CIRCULATION, V62, P522, DOI 10.1161/01.CIR.62.3.522; *AM HEART ASS, 2002, HEART DIS STROK STAT; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; BILLMAN GE, 1984, CIRCULATION, V69, P1182, DOI 10.1161/01.CIR.69.6.1182; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bokhari S, 2002, J AM COLL CARDIOL, V40, P1092, DOI 10.1016/S0735-1097(02)02111-3; BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; BRUCE RA, 1983, J AM COLL CARDIOL, V2, P565, DOI 10.1016/S0735-1097(83)80286-1; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Cheng YLJ, 2003, DIABETES CARE, V26, P2052, DOI 10.2337/diacare.26.7.2052; Cole CR, 2000, ANN INTERN MED, V132, P552, DOI 10.7326/0003-4819-132-7-200004040-00007; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; Cui YD, 2001, ARCH INTERN MED, V161, P1413, DOI 10.1001/archinte.161.11.1413; De Leo V, 2000, MATURITAS, V36, P43, DOI 10.1016/S0378-5122(00)00123-7; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; Elhendy A, 2002, AM J CARDIOL, V90, P95, DOI 10.1016/S0002-9149(02)02428-1; Gibbons RJ, 2002, CIRCULATION, V106, P1883, DOI 10.1161/01.CIR.0000034670.06526.15; GORDON DJ, 1986, CIRCULATION, V74, P252, DOI 10.1161/01.CIR.74.2.252; Greenland P, 2001, CIRCULATION, V104, P1863, DOI 10.1161/hc4201.097189; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; IMAI K, 1994, J AM COLL CARDIOL, V24, P1529, DOI 10.1016/0735-1097(94)90150-3; Jouven X, 2000, NEW ENGL J MED, V343, P826, DOI 10.1056/NEJM200009213431201; KANNEL WB, 1985, AM HEART J, V109, P876, DOI 10.1016/0002-8703(85)90653-2; Kwok Y, 1999, AM J CARDIOL, V83, P660, DOI 10.1016/S0002-9149(98)00963-1; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; Mosca L, 1999, CIRCULATION, V99, P2480, DOI 10.1161/01.CIR.99.18.2480; Mosca L, 1997, CIRCULATION, V96, P2468; Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858; Nishime EO, 2000, JAMA-J AM MED ASSOC, V284, P1392, DOI 10.1001/jama.284.11.1392; Palinkas A, 2002, EUR HEART J, V23, P1587, DOI 10.1053/euhj.2002.3170; Partington S, 2003, AM HEART J, V145, P139, DOI 10.1067/mhj.2003.60; Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032; RAUTAHARJU PM, 1986, J AM COLL CARDIOL, V8, P1, DOI 10.1016/S0735-1097(86)80084-5; Rice T, 2002, CIRCULATION, V105, P1904, DOI 10.1161/01.CIR.0000014969.85364.9F; Rosenwinkel Eric T., 2001, Cardiology Clinics, V19, P369, DOI 10.1016/S0733-8651(05)70223-X; Shetler K, 2001, J AM COLL CARDIOL, V38, P1980, DOI 10.1016/S0735-1097(01)01652-7; *STAT CORP, 2001, STATA REF MAN REL 7; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; 1997, ARCH INTERN MED, V157, P2413	44	375	395	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2003	290	12					1600	1607		10.1001/jama.290.12.1600	http://dx.doi.org/10.1001/jama.290.12.1600			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	723ZK	14506119	Bronze			2022-12-24	WOS:000185461300025
J	Colombani, J; Raisin, S; Pantalacci, S; Radimerski, T; Montagne, J; Leopold, P				Colombani, J; Raisin, S; Pantalacci, S; Radimerski, T; Montagne, J; Leopold, P			A nutrient sensor mechanism controls Drosophila growth	CELL			English	Article							INSULIN-LIKE PEPTIDES; CELL-GROWTH; DIRECT TARGET; S6 KINASE; FAT-BODY; SIZE; RHEB; TOR; PROLIFERATION; TRANSLATION	Organisms modulate their growth according to nutrient availability. Although individual cells in a multicellular animal may respond directly to nutrient levels, growth of the entire organism needs to be coordinated. Here, we provide evidence that in Drosophila, coordination of organismal growl, originates from the fat body, an insect organ that retains endocrine and storage functions of the vertebrate liver. In a genetic screen for growth modifiers, we identified slimfast, a gene that encodes an amino acid transporter. Remarkably, downregulation of slimfast specifically within the fat body causes a global growth defect similar to that seen in Drosophila raised under poor nutritional conditions. This involves TSC/TOR signaling in the fat body, and a remote inhibition of organismal growth via local repression of P13-kinase signaling in peripheral tissues. Our results demonstrate that the fat body functions as a nutrient sensor that restricts global growth through a humoral mechanism.	Inst Signaling Dev Biol & Canc Res, UMR 6543, CNRS, F-06108 Nice 2, France; Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Friedrich Miescher Institute for Biomedical Research	Leopold, P (corresponding author), Inst Signaling Dev Biol & Canc Res, UMR 6543, CNRS, F-06108 Nice 2, France.	leopold@unice.fr		Colombani, Julien/0000-0002-8250-4899				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Boisclair YR, 2001, J ENDOCRINOL, V170, P63, DOI 10.1677/joe.0.1700063; Britton JS, 1998, DEVELOPMENT, V125, P2149; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Butler AA, 2001, ANNU REV PHYSIOL, V63, P141, DOI 10.1146/annurev.physiol.63.1.141; Campbell LE, 1999, BIOCHEM J, V344, P433, DOI 10.1042/0264-6021:3440433; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CRACE CJ, 1991, UPSALA J MED SCI, V96, P17, DOI 10.3109/03009739109179255; DAVIS KT, 1977, SCIENCE, V196, P438, DOI 10.1126/science.403606; Dean R.L., 1985, P155; Duan C, 2002, J ENDOCRINOL, V175, P41, DOI 10.1677/joe.0.1750041; Efstratiadis A, 1998, INT J DEV BIOL, V42, P955; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garofalo RS, 2002, TRENDS ENDOCRIN MET, V13, P156, DOI 10.1016/S1043-2760(01)00548-3; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hennig KM, 2002, GENESIS, V34, P107, DOI 10.1002/gene.10139; Huang H, 1999, DEVELOPMENT, V126, P5365; Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kawamura K, 1999, DEVELOPMENT, V126, P211; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimball Sr, 2000, COLD SPRING HARBOR M, V39, P561; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Martin JF, 2000, MECH DEVELOP, V92, P155, DOI 10.1016/S0925-4773(99)00338-X; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Raisin S, 2003, GENETICS, V164, P1015; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Stern D, 2001, CURR BIOL, V11, pR917, DOI 10.1016/S0960-9822(01)00554-1; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zinke I, 2002, EMBO J, V21, P6162, DOI 10.1093/emboj/cdf600; Zinke I, 1999, DEVELOPMENT, V126, P5275	51	572	585	2	69	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	2003	114	6					739	749		10.1016/S0092-8674(03)00713-X	http://dx.doi.org/10.1016/S0092-8674(03)00713-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	724AL	14505573	Bronze			2022-12-24	WOS:000185464000011
J	Harrison, T; Samuel, BU; Akompong, T; Hamm, H; Mohandas, N; Lomasney, JW; Haldar, K				Harrison, T; Samuel, BU; Akompong, T; Hamm, H; Mohandas, N; Lomasney, JW; Haldar, K			Erythrocyte G protein-coupled receptor signaling in malarial infection	SCIENCE			English	Article							PLASMODIUM-FALCIPARUM; CHOLESTEROL; TRANSDUCTION; RAFTS	Erythrocytic mechanisms involved in malarial infection are poorly understood. We have found that signaling via the erythrocyte beta2-adrenergic receptor and heterotrimeric guanine nucleotide - binding protein (Galphas) regulated the entry of the human malaria parasite Plasmodium falciparum. Agonists that stimulate cyclic adenosine 3', 5'-monophosphate production led to an increase in malarial infection that could be blocked by specific receptor antagonists. Moreover, peptides designed to inhibit Galphas protein function reduced parasitemia in P. falciparum cultures in vitro, and beta-antagonists reduced parasitemia of P. berghei infections in an in vivo mouse model. Thus, signaling via the erythrocyte beta2-adrenergic receptor and Galphas may regulate malarial infection across parasite species.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37240 USA; New York Blood Ctr, New York, NY 10021 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Vanderbilt University; New York Blood Center	Lomasney, JW (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 Chicago Ave, Chicago, IL 60611 USA.	j-lomasney@northwestern.edu; k-haldar@northwestern.edu	Haldar, Kasturi/C-6685-2014; Hamm, Heidi E/G-2374-2014		NEI NIH HHS [EY10291, EY06062] Funding Source: Medline; NHLBI NIH HHS [HL03961, HL69630, HL55591] Funding Source: Medline; NIAID NIH HHS [AI39071] Funding Source: Medline; NIDDK NIH HHS [DK32094] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006062, R01EY010291] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069630, R29HL055591, R01HL055591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Brittain JE, 2001, J CLIN INVEST, V107, P1555, DOI 10.1172/JCI10817; CHASIS JA, 1989, BLOOD, V74, P1112, DOI 10.1182/blood.V74.3.1112.1112; Desai SA, 1997, P NATL ACAD SCI USA, V94, P2045, DOI 10.1073/pnas.94.5.2045; DVORAK JA, 1975, SCIENCE, V187, P748, DOI 10.1126/science.803712; Dyer M, 2000, MOL BIOCHEM PARASIT, V110, P435, DOI 10.1016/S0166-6851(00)00312-1; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556; Maack K, 2001, BRIT J PHARMACOL, V132, P1817, DOI 10.1038/sj.bjp.0703992; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Nagao E, 2002, EXP PARASITOL, V102, P57, DOI 10.1016/S0014-4894(02)00143-1; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; PETERS W, 1984, ANN TROP MED PARASIT, V78, P561, DOI 10.1080/00034983.1984.11811866; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Samuel BU, 2001, J BIOL CHEM, V276, P29319, DOI 10.1074/jbc.M101268200; SCHRIER SL, 1985, CLIN HAEMATOL, V14, P1; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200	23	120	123	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1734	1736		10.1126/science.1089324	http://dx.doi.org/10.1126/science.1089324			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500986				2022-12-24	WOS:000185387700048
J	Stelter, P; Ulrich, HD				Stelter, P; Ulrich, HD			Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; SPONTANEOUS MUTATION; YEAST; GENE; RAD6; POLYMERASE; EUKARYOTES; PROTEIN; ENCODES	Protein modification by ubiquitin is emerging as a signal for various biological processes in eukaryotes, including regulated proteolysis, but also for non-degradative functions such as protein localization, DNA repair and regulation of chromatin structure(1-4). A small ubiquitin-related modifier (SUMO) uses a similar conjugation system that sometimes counteracts the effects of ubiquitination(5). Ubiquitin and SUMO compete for modification of proliferating cell nuclear antigen (PCNA), an essential processivity factor for DNA replication and repair(6). Whereas multi-ubiquitination is mediated by components of the RAD6 pathway and promotes error-free repair, SUMO modification is associated with replication(6-9). Here we show that RAD6-mediated mono-ubiquitination of PCNA activates translesion DNA synthesis by the damage-tolerant polymerases eta and zeta in yeast. Moreover, polymerase zeta is differentially affected by mono-ubiquitin and SUMO modification of PCNA. Whereas ubiquitination is required for damage-induced mutagenesis, both SUMO and mono-ubiquitin contribute to spontaneous mutagenesis in the absence of DNA damage. Our findings assign a function to SUMO during S phase and demonstrate how ubiquitin and SUMO, by regulating the accuracy of replication and repair, contribute to overall genomic stability.	Max Planck Inst Terr Microbiol, D-35043 Marburg, Germany	Max Planck Society	Ulrich, HD (corresponding author), Max Planck Inst Terr Microbiol, Karl von Frisch Str, D-35043 Marburg, Germany.			Ulrich, Helle D./0000-0003-0431-2223				Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BROODBAKKER JTW, 1983, OPHTHALMIC PAED GEN, V2, P95, DOI 10.3109/13816818309007797; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; HASTINGS PJ, 1976, NATURE, V264, P719, DOI 10.1038/264719a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; Lawrence CW, 2001, PHILOS T R SOC B, V356, P41, DOI 10.1098/rstb.2000.0001; LAWRENCE CW, 1976, GENETICS, V82, P207; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; McDonald JP, 1997, GENETICS, V147, P1557; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; QUAH SK, 1980, GENETICS, V96, P819; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Ulrich HD, 2002, EUKARYOT CELL, V1, P1, DOI 10.1128/EC.1.1.1-10.2002; von Borstel RC, 1998, GENETICS, V148, P1647; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R	30	657	682	7	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2003	425	6954					188	191		10.1038/nature01965	http://dx.doi.org/10.1038/nature01965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968183				2022-12-24	WOS:000185236000045
J	Schwab, SR; Li, KC; Kang, C; Shastri, N				Schwab, SR; Li, KC; Kang, C; Shastri, N			Constitutive display of cryptic translation products by MHC class I molecules	SCIENCE			English	Article							NEWLY SYNTHESIZED PROTEINS; DENDRITIC CELLS; DEGRADATION; INITIATION; ANTIGENS; PEPTIDES; GENERATION; GENE; H60	Major histocompatibility complex (MHC) class I molecules display tens of thousands of peptides on the cell surface, derived from virtually all endogenous proteins, for inspection by cytotoxic T cells (CTLs). We show that, in normal mouse cells, MHC I molecules present a peptide encoded in the 3' "untranslated" region. Despite its rarity, the peptide elicits CTL responses and induces self-tolerance, establishing that immune surveillance extends well beyond conventional polypeptides. Furthermore, translation of this cryptic peptide occurs by a previously unknown mechanism that decodes the CUG initiation codon as leucine rather than the canonical methionine.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Shastri, N (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.			Schwab, Susan/0000-0002-0834-0822				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; Choi EY, 2002, IMMUNITY, V17, P593, DOI 10.1016/S1074-7613(02)00428-4; Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296-474; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; Malarkannan S, 2000, IMMUNITY, V13, P333, DOI 10.1016/S1074-7613(00)00033-9; Malarkannan S, 1998, J IMMUNOL, V161, P3501; Malarkannan S, 1999, IMMUNITY, V10, P681, DOI 10.1016/S1074-7613(00)80067-9; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; Rajbhandary Uttam L., 1995, P511; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Scott D, 2000, IMMUNITY, V12, P711, DOI 10.1016/S1074-7613(00)80221-6; Shastri N, 2002, ANNU REV IMMUNOL, V20, P463, DOI 10.1146/annurev.immunol.20.100301.064819; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Yewdell J, 2002, MOL IMMUNOL, V39, P139, DOI 10.1016/S0161-5890(02)00097-4	19	93	95	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1367	1371		10.1126/science.1085650	http://dx.doi.org/10.1126/science.1085650			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958358				2022-12-24	WOS:000185116400038
J	Danial, NN; Gramm, CF; Scorrano, L; Zhang, CY; Krauss, S; Ranger, AM; Datta, SR; Greenberg, ME; Licklider, LJ; Lowell, BB; Gygi, SP; Korsmeyer, SJ				Danial, NN; Gramm, CF; Scorrano, L; Zhang, CY; Krauss, S; Ranger, AM; Datta, SR; Greenberg, ME; Licklider, LJ; Lowell, BB; Gygi, SP; Korsmeyer, SJ			BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis	NATURE			English	Article							ALDRICH-SYNDROME PROTEIN; GLUCOSE-HOMEOSTASIS; CELL-SURVIVAL; TOM COMPLEX; PHOSPHORYLATION; GROWTH; DEATH; GENE; BETA; CHROMATOGRAPHY	Glycolysis and apoptosis are considered major but independent pathways that are critical for cell survival(1-4). The activity of BAD, a pro-apoptotic BCL-2 family member, is regulated by phosphorylation in response to growth/survival factors(5-8). Here we undertook a proteomic analysis to assess whether BAD might also participate in mitochondrial physiology. In liver mitochondria, BAD resides in a functional holoenzyme complex together with protein kinase A(7) and protein phosphatase 1 (PP1) catalytic units(9), Wiskott-Aldrich family member WAVE-1 as an A kinase anchoring protein(10), and glucokinase (hexokinase IV)(11). BAD is required to assemble the complex in that Bad-deficient hepatocytes lack this complex, resulting in diminished mitochondria-based glucokinase activity and blunted mitochondrial respiration in response to glucose. Glucose deprivation results in dephosphorylation of BAD, and BAD-dependent cell death. Moreover, the phosphorylation status of BAD helps regulate glucokinase activity. Mice deficient for BAD or bearing a non-phosphorylatable BAD(3SA) mutant(12) display abnormal glucose homeostasis including profound defects in glucose tolerance. This combination of proteomics, genetics and physiology indicates an unanticipated role for BAD in integrating pathways of glucose metabolism and apoptosis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Neurobiol,Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Korsmeyer, SJ (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, 44 Binney St, Boston, MA 02115 USA.		Scorrano, Luca/K-3967-2019; Scorrano, Luca/A-6652-2008	Scorrano, Luca/0000-0002-8515-8928; Scorrano, Luca/0000-0002-8515-8928; Datta, Sandeep/0000-0002-8068-3862				Abdul KM, 2000, BIOCHEM BIOPH RES CO, V276, P1028, DOI 10.1006/bbrc.2000.3589; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Garland JM, 1997, J BIOL CHEM, V272, P4680, DOI 10.1074/jbc.272.8.4680; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Licklider LJ, 2002, ANAL CHEM, V74, P3076, DOI 10.1021/ac025529o; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Murata T, 1997, FEBS LETT, V406, P109, DOI 10.1016/S0014-5793(97)00253-6; Niswender KD, 1997, J BIOL CHEM, V272, P22564, DOI 10.1074/jbc.272.36.22564; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Postic C, 2001, RECENT PROG HORM RES, V56, P195, DOI 10.1210/rp.56.1.195; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	30	551	573	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					952	956		10.1038/nature01825	http://dx.doi.org/10.1038/nature01825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931191				2022-12-24	WOS:000184843600044
J	Li, DK; Liu, LY; Douh, R				Li, DK; Liu, LY; Douh, R			Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							ASPIRIN	Objective To evaluate whether prenatal use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with increased risk of miscarriage. Design Population based cohort study. Prenatal use of NSAIDs, aspirin, and paracetamol (acetaminophen) ascertained by in-person interview. Setting Kaiser Permanente Medical Care Program, a healthcare delivery system, in the San Francisco area of the United States. Participants 1055 pregnant women recruited and interviewed immediately after their positive pregnancy test. Median gestational age at entry to the study was 40 days. Main outcome measures Pregnancy outcomes up to 20 weeks of gestation. Results 53 women (5%) reported prenatal NSAID use around conception or during pregnancy. After adjustment for potential confounders, prenatal NSAID use was associated with an 80% increased risk of miscarriage (adjusted hazard ratio 1.8 (95% confidence interval 1.0 to 3.2)). The association was stronger if the initial NSAID use was around the time of conception or if NSAID use lasted more than a week. Prenatal aspirin use was similarly associated with an increased risk of miscarriage. However, prenatal use of paracetamol, pharmacologically different from NSAIDs and aspirin, was not associated with increased risk of miscarriage regardless of timing and duration of use. Conclusion Prenatal use of NSAIDs and aspirin increased the risk of miscarriage. These findings need confirmation in studies designed specifically to examine the apparent association.	Kaiser Permanente, Kaiser Fdn Res Inst, Div Res, Oakland, CA 94612 USA	Kaiser Permanente	Li, DK (corresponding author), Kaiser Permanente, Kaiser Fdn Res Inst, Div Res, 2000 Broadway, Oakland, CA 94612 USA.							ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Brooks P., 1998, AM J MED, V104, p9S, DOI DOI 10.1016/S0002-9343(97)00204-0; DAWOOD MY, 1993, AM J OBSTET GYNECOL, V169, P1255; Hernandez-Diaz Sonia, 2001, American Journal of Medicine, V110, p20S; HERTZPICCIOTTO I, 1990, EPIDEMIOL REV, V12, P108, DOI 10.1093/oxfordjournals.epirev.a036049; Howards PP, 2002, AM J EPIDEMIOL, V155, ps35; Janssen NM, 2000, ARCH INTERN MED, V160, P610, DOI 10.1001/archinte.160.5.610; Li DK, 2002, EPIDEMIOLOGY, V13, P9, DOI 10.1097/00001648-200201000-00004; Nielsen GL, 2001, BRIT MED J, V322, P266, DOI 10.1136/bmj.322.7281.266; Setter S M, 2001, Home Care Provid, V6, P100, DOI 10.1067/mhc.2001.116262; STREISSGUTH AP, 1987, TERATOLOGY, V35, P211, DOI 10.1002/tera.1420350207; TM Therneau., 2000, MODELING SURVIVAL DA, DOI DOI 10.1007/978; vanderWeiden RMF, 1996, AM J OBSTET GYNECOL, V174, P1614, DOI 10.1016/S0002-9378(96)70616-6; vanderWeiden RMF, 1997, BRIT J RHEUMATOL, V36, P605; VANDERWEIDEN RMF, 1991, HUM REPROD, V6, P436, DOI 10.1093/oxfordjournals.humrep.a137354; WERLER MM, 1989, NEW ENGL J MED, V321, P1639, DOI 10.1056/NEJM198912143212404; [No title captured]	17	208	221	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					368	371		10.1136/bmj.327.7411.368	http://dx.doi.org/10.1136/bmj.327.7411.368			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919986	Green Published, Bronze			2022-12-24	WOS:000184864200016
J	Hocker, M; Hohenberger, P				Hocker, M; Hohenberger, P			Helicobacter pylori virulence factors - one part of a big picture	LANCET			English	Review							CLINICAL-RELEVANCE; BABA2; ADHESIN; VACA; CAGA; ATTACHMENT; INFECTION; GENES; RISK	Context At least half the world's population is infected with Helicobacter pylori, although only 10-20% of carriers develop gastric diseases, ranging from ulcer to MALT-lymphoma and adenocarcinoma (MALT is mucosa-associated lymphoid tissue). The clinical outcome of H pylori infection is determined by a complex interaction of environmental influences and host and microbial virulence factors'. H pylori genotypes carrying the babA2 gene, encoding a bacterial adhesin mediating interaction With gastric epithelial cells, have enhanced pathogenicity. Moreover, coexistence of babA2 with other, bacterial virulence factors further worsens clinical outcomes. Starting point To further elucidate the clinical relevance of babA2-genopositive H pylori strains, Carlo-Frederico Zambon and colleagues analysed the association of babA2 genotypes with gastritis, gastroduodenal ulcer disease, or intestinal metaplasia in 167 infected Italian individuals. The coexistence of babA2 with other potentially disease-related H pylori genes, such as cag4, vacA, or oipA, correlated with clinical outcome. 36% of H pylori strains were babA2 genopositive, and abundance of babA2 was associated with the genomic presence of the other potential virulence-factor genes. H pylon strains carrying babA2, cagA, and the vacA genotype s1m1 were associated with the highest risk of developing intestinal metaplasia, whereas this condition was rarely (<10%) associated with strains with a cagA-, babA2-, vacA s2m2 genotype. Whilst the risk-of developing more serious gastric lesions increased as the number of virulence factor genes accumulated in a given H pylori strain, there was no indication of any one specific bacterial gene-pattern being associated with a particular clinical disease. Where next? Identifying the factors responsible for the enhanced pathogenicity of H pylori leading to development of life-threatening diseases in a subset of infected individuals is a mandatory task for the future. Identification of virulence-associated H pylori genes and investigation of their clinical relevance in large prospective studies will help to define such, strains with increased pathogenicity. The value of H pylori genotypes as predictors of disease outcome is limited, because the pathogenic impact of bacterial virulence factors, is greatly influenced by coexisting environmental and host factors.	Charite Univ Med Berlin, Robert Rossle Klin, Div Surg & Surg Oncol, D-13125 Berlin, Germany; Charite Univ Med Berlin, Dept Gastroenterol & Hepatol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hohenberger, P (corresponding author), Charite Univ Med Berlin, Robert Rossle Klin, Div Surg & Surg Oncol, Campus Berlin Buch, D-13125 Berlin, Germany.	hohenberger@rrk.charite-buch.de						Bjorkholm B, 2003, J INTERN MED, V253, P102, DOI 10.1046/j.1365-2796.2003.01119.x; Blaser MJ, 2001, J CLIN INVEST, V107, P767, DOI 10.1172/JCI12672; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Gerhard M, 1999, P NATL ACAD SCI USA, V96, P12778, DOI 10.1073/pnas.96.22.12778; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Israel DA, 2001, ALIMENT PHARM THER, V15, P1271, DOI 10.1046/j.1365-2036.2001.01052.x; Maeda S, 1998, GUT, V42, P338, DOI 10.1136/gut.42.3.338; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Megraud F, 2001, DIGEST DIS, V19, P99, DOI 10.1159/000050662; Mizushima T, 2001, J CLIN MICROBIOL, V39, P2463, DOI 10.1128/JCM.39.7.2463-2465.2001; Nogueira C, 2001, AM J PATHOL, V158, P647, DOI 10.1016/S0002-9440(10)64006-0; Parsonnent J., 1998, GUT               S1, V43, P3247; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Podzorski RP, 2003, DIAGN MICR INFEC DIS, V46, P83, DOI 10.1016/S0732-8893(03)00034-8; Prinz C, 2001, CANCER RES, V61, P1903; Rad R, 2003, J INFECT DIS, V188, P272, DOI 10.1086/376458; Sheu BS, 2003, GUT, V52, P927, DOI 10.1136/gut.52.7.927; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; Zambon CF, 2003, J CLIN PATHOL, V56, P287, DOI 10.1136/jcp.56.4.287	24	92	101	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2003	362	9391					1231	1233		10.1016/S0140-6736(03)14547-3	http://dx.doi.org/10.1016/S0140-6736(03)14547-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568748				2022-12-24	WOS:000185924100027
J	Beheregaray, LB; Ciofi, C; Geist, D; Gibbs, JP; Caccone, A; Powell, JR				Beheregaray, LB; Ciofi, C; Geist, D; Gibbs, JP; Caccone, A; Powell, JR			Genes record a prehistoric volcano eruption in the Galapagos	SCIENCE			English	Article							POPULATIONS; TORTOISES; HISTORY		Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA; Univ Idaho, Dept Geol Sci, Moscow, ID 83844 USA; SUNY Coll Environm Sci & Forestry, Syracuse, NY 13210 USA; Yale Univ, Yale Inst Biospher Studies, New Haven, CT 06520 USA	Yale University; Idaho; University of Idaho; State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; Yale University	Beheregaray, LB (corresponding author), Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia.	luciano.beheregaray@bio.mq.edu.au	Caccone, Adalgisa/AAE-4238-2021; Beheregaray, Luciano B/A-8621-2008; Beheregaray, Luciano/AAY-6384-2021; Ciofi, Claudio/AAH-9461-2019	Caccone, Adalgisa/0000-0002-8949-9260; Beheregaray, Luciano B/0000-0003-0944-3003; Beheregaray, Luciano/0000-0003-0944-3003; CIOFI, CLAUDIO/0000-0001-8537-8659				BEHEREGARAY LB, UNPUB; Caccone A, 2002, EVOLUTION, V56, P2052; CARSON HL, 1990, P NATL ACAD SCI USA, V87, P7055, DOI 10.1073/pnas.87.18.7055; Ciofi C, 2002, MOL ECOL, V11, P2265, DOI 10.1046/j.1365-294X.2002.01617.x; GEIST D, 1994, B VOLCANOL, V56, P243, DOI 10.1007/BF00302078; MACFARLAND C G, 1974, Biological Conservation, V6, P118, DOI 10.1016/0006-3207(74)90024-X; Pritchard Peter C.H., 1996, Chelonian Research Monographs, V1, P1	7	60	72	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2003	302	5642					75	75		10.1126/science.1087486	http://dx.doi.org/10.1126/science.1087486			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526072				2022-12-24	WOS:000185678500036
J	Tournaire-Roux, C; Sutka, M; Javot, H; Gout, E; Gerbeau, P; Luu, DT; Bligny, R; Maurel, C				Tournaire-Roux, C; Sutka, M; Javot, H; Gout, E; Gerbeau, P; Luu, DT; Bligny, R; Maurel, C			Cytosolic pH regulates root water transport during anoxic stress through gating of aquaporins	NATURE			English	Article							PLASMA-MEMBRANE AQUAPORINS; PLANT-CELLS; PHOSPHORYLATION; PERMEABILITY; CHANNELS; INHIBITION; EXPRESSION; TIP	Flooding of soils results in acute oxygen deprivation (anoxia) of plant roots during winter in temperate latitudes, or after irrigation(1), and is a major problem for agriculture. One early response of plants to anoxia and other environmental stresses is down-regulation of water uptake due to inhibition of the water permeability (hydraulic conductivity) of roots (Lp(r))(2-5). Root water uptake is mediated largely by water channel proteins (aquaporins) of the plasma membrane intrinsic protein (PIP) subgroup(6-8). These aquaporins may mediate stress-induced inhibition of Lp(r)(2,4,9) but the mechanisms involved are unknown. Here we delineate the whole-root and cell bases for inhibition of water uptake by anoxia and link them to cytosol acidosis. We also uncover a molecular mechanism for aquaporin gating by cytosolic pH. Because it is conserved in all PIPs, this mechanism provides a basis for explaining the inhibition of Lp(r) by anoxia and possibly other stresses. More generally, our work opens new routes to explore pH-dependent cell signalling processes leading to regulation of water transport in plant tissues or in animal epithelia(10).	Univ Montpellier 2, INRA, CNRS, Unite Mixte Rech 5004, F-34060 Montpellier 1, France; Ecole Natl Agron, F-34060 Montpellier, France; CEA, Physiol Cellulaire Vegetale, F-38054 Grenoble 9, France	INRAE; Institut Agro; Montpellier SupAgro; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Maurel, C (corresponding author), Univ Montpellier 2, INRA, CNRS, Unite Mixte Rech 5004, Pl Viala, F-34060 Montpellier 1, France.		Javot, Helene/AAX-8986-2021	Javot, Helene/0000-0002-4577-2747; Tournaire Roux, Colette/0000-0002-2966-5597; Luu, Doan Trung/0000-0001-9765-2125				Baxter-Burrell A, 2002, SCIENCE, V296, P2026, DOI 10.1126/science.1071505; BIRNER TP, 1993, PLANTA, V190, P474, DOI 10.1007/BF00224786; Clarkson DT, 2000, J EXP BOT, V51, P61, DOI 10.1093/jexbot/51.342.61; Felle HH, 2001, PLANT BIOLOGY, V3, P577, DOI 10.1055/s-2001-19372; Gerbeau P, 2002, PLANT J, V30, P71, DOI 10.1046/j.1365-313X.2002.01268.x; Gout E, 2001, PLANT PHYSIOL, V125, P912, DOI 10.1104/pp.125.2.912; Han ZQ, 1998, J BIOL CHEM, V273, P6001, DOI 10.1074/jbc.273.11.6001; Javot H, 2002, ANN BOT-LONDON, V90, P301, DOI 10.1093/aob/mcf199; Javot H, 2003, PLANT CELL, V15, P509, DOI 10.1105/tpc.008888; Johansson I, 1998, PLANT CELL, V10, P451, DOI 10.1105/tpc.10.3.451; Kamaluddin M, 2001, J EXP BOT, V52, P739, DOI 10.1093/jexbot/52.357.739; Lacombe B, 2000, FEBS LETT, V466, P351, DOI 10.1016/S0014-5793(00)01093-0; Martre P, 2002, PLANT PHYSIOL, V130, P2101, DOI 10.1104/pp.009019; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777; PARISI M, 1984, AM J PHYSIOL, V246, pC157, DOI 10.1152/ajpcell.1984.246.1.C157; Siefritz F, 2002, PLANT CELL, V14, P869, DOI 10.1105/tpc.000901; Steudle E, 1998, J EXP BOT, V49, P775, DOI 10.1093/jexbot/49.322.775; SUBBAIAH CC, 1994, PLANT CELL, V6, P1747, DOI 10.1105/tpc.6.12.1747; Tomos AD, 1999, ANNU REV PLANT PHYS, V50, P447, DOI 10.1146/annurev.arplant.50.1.447; VARAPETIAN BB, 1997, ANN BOT SA, V79, P3; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631; ZHANG WH, 1991, AUST J PLANT PHYSIOL, V18, P603, DOI 10.1071/PP9910603; Zhang WH, 1999, PLANT PHYSIOL, V120, P849, DOI 10.1104/pp.120.3.849	26	495	533	6	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2003	425	6956					393	397		10.1038/nature01853	http://dx.doi.org/10.1038/nature01853			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508488				2022-12-24	WOS:000185502300040
J	Neuberger, J; Price, D				Neuberger, J; Price, D			Role of living liver donation in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							TRANSPLANTATION; DONOR; ADULT; EXPERIENCE; SELECTION; HEALTH		Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England; De Montfort Univ, Leicester LE1 9BH, Leics, England	University of Birmingham; De Montfort University	Neuberger, J (corresponding author), Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England.							Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919; Baker A, 1999, BRIT J SURG, V86, P200, DOI 10.1046/j.1365-2168.1999.00991.x; Beavers KL, 2001, LIVER TRANSPLANT, V7, P943, DOI 10.1053/jlts.2001.28443; Broering DC, 2003, J HEPATOL, V38, pS119, DOI 10.1016/S0168-8278(03)00009-6; Brown RS, 2003, NEW ENGL J MED, V348, P818, DOI 10.1056/NEJMsa021345; DAVIES MH, 1992, GUT, V33, P1397, DOI 10.1136/gut.33.10.1397; FISHER NC, 2002, BRIT MED J, V325, P512; Johnson E M, 1997, Clin Transpl, P231; Kahn J, 2002, TRANSPLANTATION, V74, P421, DOI 10.1097/00007890-200208150-00026; Karliova M, 2002, TRANSPLANTATION, V73, P1799, DOI 10.1097/00007890-200206150-00017; Malago M, 2001, LIVER TRANSPLANT, V7, P921, DOI 10.1053/jlts.2001.28301; Marcos A, 2000, LIVER TRANSPLANT, V6, pS59, DOI 10.1053/jlts.2000.19011; Marcos A, 2000, TRANSPLANTATION, V69, P2410, DOI 10.1097/00007890-200006150-00034; Neuberger J, 1999, LANCET, V354, P1636, DOI 10.1016/S0140-6736(99)90002-8; NEUBERGER J, IN PRESS TRANSPLANTA; RAIA S, 1989, LANCET, V2, P497; Ross LF, 2002, TRANSPLANTATION, V74, P418; Shiffman ML, 2002, LIVER TRANSPLANT, V8, P174, DOI 10.1053/jlts.2002.30981; Williams RS, 2003, EUR J GASTROEN HEPAT, V15, P7, DOI 10.1097/00042737-200301000-00003	19	15	15	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 20	2003	327	7416					676	679		10.1136/bmj.327.7416.676	http://dx.doi.org/10.1136/bmj.327.7416.676			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724AC	14500445	Green Published			2022-12-24	WOS:000185463100029
J	Brosnan, SF; de Waal, FBM				Brosnan, SF; de Waal, FBM			Monkeys reject unequal pay	NATURE			English	Article							HUMAN COOPERATION; ULTIMATUM GAME; CAPUCHINS; SOCIOLOGY; BEHAVIOR; ALTRUISM; FAIRNESS; PUZZLE	During the evolution of cooperation it may have become critical for individuals to compare their own efforts and pay-offs with those of others. Negative reactions may occur when expectations are violated. One theory proposes that aversion to inequity can explain human cooperation within the bounds of the rational choice model(1), and may in fact be more inclusive than previous explanations(2-8). Although there exists substantial cultural variation in its particulars, this 'sense of fairness' is probably a human universal(9,10) that has been shown to prevail in a wide variety of circumstances(11-13). However, we are not the only cooperative animals(14), hence inequity aversion may not be uniquely human. Many highly cooperative nonhuman species seem guided by a set of expectations about the outcome of cooperation and the division of resources(15,16). Here we demonstrate that a nonhuman primate, the brown capuchin monkey (Cebus apella), responds negatively to unequal reward distribution in exchanges with a human experimenter. Monkeys refused to participate if they witnessed a conspecific obtain a more attractive reward for equal effort, an effect amplified if the partner received such a reward without any effort at all. These reactions support an early evolutionary origin of inequity aversion.	Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA	Emory University	Brosnan, SF (corresponding author), Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.							ANDREONI J, 1995, AM ECON REV, V85, P891; Andreoni J, 2002, GAME ECON BEHAV, V40, P1, DOI 10.1006/game.2001.0904; Brosnan SF, 2002, HUM NATURE-INT BIOS, V13, P129, DOI 10.1007/s12110-002-1017-2; de Waal F., 1996, GOOD NATURED ORIGINS; de Waal F.B.M., 2002, NEUROPSYCHOLOGIA, V1492, P1; de Waal FBM, 1997, J COMP PSYCHOL, V111, P370, DOI 10.1037/0735-7036.111.4.370; de Waal FBM, 2000, NATURE, V404, P563, DOI 10.1038/35007138; DiBitetti MS, 1997, ANIM BEHAV, V54, P199, DOI 10.1006/anbe.1996.0416; Dugatkin L.A., 1997, COOPERATION ANIMALS; Falk A, 2003, ECON INQ, V41, P20, DOI 10.1093/ei/41.1.20; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; Fehr E, 2003, NATURE, V422, P137, DOI 10.1038/nature01474; Fehr E, 2003, NATURE, V421, P912, DOI 10.1038/421912a; Frank R.H., 2001, EVOLUTION CAPACITY C, P57; Frank Robert H., 1988, PASSIONS REASON STRA; Henrich J, 2000, AM ECON REV, V90, P973, DOI 10.1257/aer.90.4.973; Henrich J, 2001, AM ECON REV, V91, P73, DOI 10.1257/aer.91.2.73; Hirshleifer J., 1987, LATEST BEST ESSAYS E, P307; Johnson DDP, 2003, NATURE, V421, P911, DOI 10.1038/421912a; KAHNEMAN D, 1986, AM ECON REV, V76, P728; Mendres KA, 2000, ANIM BEHAV, V60, P523, DOI 10.1006/anbe.2000.1512; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Nesse R., 2001, EVOLUTION CAPACITY C, P120; Nesse R. M., 2001, EVOLUTION CAPACITY C, P1; Roberts G, 1998, NATURE, V394, P175, DOI 10.1038/28160; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Tinklepaugh OL, 1928, J COMP PSYCHOL, V8, P197, DOI 10.1037/h0075798; WENEKIND C, 2000, SCIENCE, V200, P850; Zizzo D. J., 2001, ANN DECONOMIE STATIS, V63, P39, DOI DOI 10.2307/20076295	30	687	705	7	411	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					297	299		10.1038/nature01963	http://dx.doi.org/10.1038/nature01963			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	722JA	13679918				2022-12-24	WOS:000185370900046
J	Ruggeri, M; Tosetto, A; Frezzato, M; Rodeghiero, F				Ruggeri, M; Tosetto, A; Frezzato, M; Rodeghiero, F			The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis	ANNALS OF INTERNAL MEDICINE			English	Article							APPARENT POLYCYTHEMIA; OLMSTED COUNTY; POPULATION; DIAGNOSIS; RISK; EPIDEMIOLOGY; MANAGEMENT; MINNESOTA; SURVIVAL; RANGES	Background: The clinical relevance of mild erythrocytosis (hematocrit > 0.48 in women or > 0.51 in men) or thrombocytosis (platelet count > 400 x 10(9) cells/L) in asymptomatic persons is uncertain. Objective: To estimate the frequency of polycythemia vera or essential thrombocythemia in persons with erythrocytosis or thrombocytosis in a general population. Design: Cohort study. Setting: Vicenza, Italy. Participants: 10000 community dwellers age 18 to 65 years and enrolled in the Vicenza Thrombophilia and Atherosclerosis project. Measurements: Platelet count and hematocrit at baseline in all participants and at second follow-up if baseline results were abnormal. Measurement of erythrocyte sedimentation rate, peripheral arterial saturation, serum erythropoietin level, and leukocyte alkaline phosphatase level; chest radiography; abdominal ultrasonography; and occult fecal blood testing were done in persons with confirmed high hematocrit or platelet counts. Polycythemia vera and essential thrombocythemia were diagnosed according to the Polycythemia Study Group criteria. Results: At baseline examination, 1 person had polycythemia vera, 1 had essential thrombocythemia, 88 had erythrocytosis, and 99 had thrombocytosis. Second examination confirmed erythrocytosis in 40% (95% Cl, 29% to 51%) and thrombocytosis in 8% (Cl, 4% to 15%) of those with abnormal baseline results. Among persons with confirmed abnormalities, further evaluation revealed 11 with idiopathic erythrocytosis, 2 with polycythemia vera (3/ 10 000 [Cl, 0.6 to 8.7/10 000]), and 3 with essential thrombocythemia (4/10 000 [Cl, 1.09 to 10.2/10 000]). After 5 years of follow-up, 1 additional person with a high platelet count developed essential thrombocythemia, and no persons developed hemorrhagic or thrombotic complications. Conclusions: The prevalences of polycythemia vera and essential thrombocythemia were higher than expected in this general population. However, the risks for developing polycythemia vera, essential thrombocythemia, or associated vascular complications in persons with erythrocytosis or thrombocytosis were low.	San Bortolo Hosp, Dept Hematol, I-36100 Vicenza, Italy	ULSS 8 Berica; Ospedale San Bortolo di Vicenza	Rodeghiero, F (corresponding author), San Bortolo Hosp, Dept Hematol, I-36100 Vicenza, Italy.	rodeghiero@hemato.ven.it	Tosetto, Alberto/AAM-3200-2020; Tosetto, Alberto/AAB-9320-2022	Tosetto, Alberto/0000-0002-0119-5204; 				ANIA BJ, 1994, AM J HEMATOL, V47, P89, DOI 10.1002/ajh.2830470205; BERGLUND S, 1992, EUR J HAEMATOL, V48, P20; Berk PD, 1997, SEMIN HEMATOL, V34, P77; BERLIN NI, 1975, SEMIN HEMATOL, V12, P339; CARLI PM, 1994, NOUV REV FR HEMATOL, V36, P147; CHAITER Y, 1992, LEUKEMIA LYMPHOMA, V7, P251, DOI 10.3109/10428199209053630; CORTELAZZO S, 1995, NEW ENGL J MED, V332, P1132, DOI 10.1056/NEJM199504273321704; DOUGAN LE, 1981, CANCER, V48, P866, DOI 10.1002/1097-0142(19810801)48:3<866::AID-CNCR2820480334>3.0.CO;2-Y; Fairbanks VF, 2000, EUR J HAEMATOL, V65, P285, DOI 10.1034/j.1600-0609.2000.065005285.x; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; Hills, 1993, STAT MODELS EPIDEMIO; Lengfelder E, 1998, BRIT J HAEMATOL, V100, P15, DOI 10.1046/j.1365-2141.1998.00529.x; Mesa RA, 1999, AM J HEMATOL, V61, P10, DOI 10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.3.CO;2-9; MESSINEZY M, 1993, EUR J HAEMATOL, V51, P125; MODAN B, 1965, BLOOD-J HEMATOL, V26, P657, DOI 10.1182/blood.V26.5.657.657; MODAN B, 1971, BLOOD-J HEMATOL, V37, P172, DOI 10.1182/blood.V37.2.172.172; Murphy S, 1997, SEMIN HEMATOL, V34, P29; MURPHY S, 1986, SEMIN HEMATOL, V23, P177; Najean Y, 1998, HEMATOL CELL THER, V40, P159; PROCHAZKA AV, 1986, BRIT J CANCER, V53, P59, DOI 10.1038/bjc.1986.9; RIUNITI O, 1995, ANN INTERN MED, V123, P656, DOI 10.7326/0003-4819-123-9-199511010-00003; Rodeghiero F, 1996, THROMB HAEMOSTASIS, V76, P226; Ruggeri M, 1998, BRIT J HAEMATOL, V103, P772; SILVERSTEIN MN, 1971, MAYO CLIN PROC, V46, P751; Streiff MB, 2002, BLOOD, V99, P1144, DOI 10.1182/blood.V99.4.1144; Tefferi A, 1999, MAYO CLIN PROC, V74, P159, DOI 10.4065/74.2.159	26	49	51	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2003	139	6					470	475		10.7326/0003-4819-139-6-200309160-00009	http://dx.doi.org/10.7326/0003-4819-139-6-200309160-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721PE	13679323				2022-12-24	WOS:000185324100002
J	Yamashita, YM; Jones, DL; Fuller, MT				Yamashita, YM; Jones, DL; Fuller, MT			Orientation of asymmetric stem cell division by the APC tumor suppressor and centrosome	SCIENCE			English	Article							DROSOPHILA APC2; MITOTIC SPINDLES; SELF-RENEWAL; PROTEIN; MICROTUBULES; CAPTURE; ENCODES	Stem cell self-renewal can be specified by local signals from the surrounding microenvironment, or niche. However, the relation between the niche and the mechanisms that ensure the correct balance between stem cell self-renewal and differentiation is poorly understood. Here, we show that dividing Drosophila male germline stem cells use intracellular mechanisms involving centrosome function and cortically localized Adenomatous Polyposis Coli tumor suppressor protein to orient mitotic spindles perpendicular to the niche, ensuring a reliably asymmetric outcome in which one daughter cell remains in the niche and self-renews stem cell identity, whereas the other, displaced away, initiates differentiation.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Fuller, MT (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.	fuller@cmgm.stanford.edu		Yamashita, Yukiko/0000-0001-5541-0216; Fuller, Margaret T/0000-0002-3804-4987	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053074] Funding Source: NIH RePORTER; NIDDK NIH HHS [1P01 DK53074] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akong K, 2002, DEV BIOL, V250, P71, DOI 10.1006/dbio.2002.0777; BLENZ M, 2001, NATURE CELL BIOL, V3, pE67; Bloom K, 2001, CURR BIOL, V11, pR326, DOI 10.1016/S0960-9822(01)00176-2; Deng W, 1997, DEV BIOL, V189, P79, DOI 10.1006/dbio.1997.8669; HEUER JG, 1995, DEVELOPMENT, V121, P3861; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; Jones D. B., UNPUB; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Li KJ, 1996, CELL, V85, P585, DOI 10.1016/S0092-8674(00)81258-1; Liakopoulos D, 2003, CELL, V112, P561, DOI 10.1016/S0092-8674(03)00119-3; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; Megraw TL, 2001, CURR BIOL, V11, P116, DOI 10.1016/S0960-9822(01)00017-3; Miller RK, 1998, J CELL BIOL, V140, P377, DOI 10.1083/jcb.140.2.377; Schuyler SC, 2001, J CELL SCI, V114, P247; Segal M, 2001, TRENDS CELL BIOL, V11, P160, DOI 10.1016/S0962-8924(01)01954-7; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Yu X, 1999, NAT CELL BIOL, V1, P144, DOI 10.1038/11064	23	553	576	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1547	1550		10.1126/science.1087795	http://dx.doi.org/10.1126/science.1087795			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970569				2022-12-24	WOS:000185255300054
J	Spies, M; Bianco, PR; Dillingham, MS; Handa, N; Baskin, RJ; Kowalczykowski, SC				Spies, M; Bianco, PR; Dillingham, MS; Handa, N; Baskin, RJ; Kowalczykowski, SC			A molecular throttle: The recombination hotspot chi controls DNA translocation by the RecBCD helicase	CELL			English	Article							HOT SPOT ACTIVITY; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; RECA PROTEIN; ENZYME; RECOGNITION; SEQUENCE; DEGRADATION; MUTATION; POLARITY	RecBCD enzyme is a heterotrimeric helicase/nuclease that initiates homologous recombination at double-stranded DNA breaks. Several of its activities are regulated by the DNA sequence chi (5'-GCTGGTGG-3'), which is recognized in cis by the translocating enzyme. When RecBCD enzyme encounters chi, the intensity and polarity of its nuclease activity are changed, and the enzyme gains the ability to load RecA protein onto the chi-containing, unwound single-stranded DNA. Here, we show that interaction with chi also affects translocation by RecBCD enzyme. By observing translocation of individual enzymes along single molecules of DNA, we could see RecBCD enzyme pause precisely at chi. Furthermore, and more unexpectedly, after pausing at chi, the enzyme continues translocating but at approximately one-half the initial rate. We propose that interaction with chi results in an enzyme in which one of the two motor subunits, likely the RecD motor, is uncoupled from the holoenzyme to produce the slower translocase.	Univ Calif Davis, Ctr Genet & Dev, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Ctr Genet & Dev, Microbiol Sect, Davis, CA 95616 USA.		Handa, Naofumi/H-6640-2017	Handa, Naofumi/0000-0003-3695-1871; Dillingham, Mark/0000-0002-4612-7141; Spies, Maria/0000-0002-7375-8037	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347, R01GM064745] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064745, GM-64745, GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1999, J BIOL CHEM, V274, P27139, DOI 10.1074/jbc.274.38.27139; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; Arnold DA, 1998, J BIOL CHEM, V273, P16476, DOI 10.1074/jbc.273.26.16476; ARNOLD DA, 1999, ENCY LIFE SCI; Bianco PR, 1997, P NATL ACAD SCI USA, V94, P6706, DOI 10.1073/pnas.94.13.6706; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1995, J BIOL CHEM, V270, P16360, DOI 10.1074/jbc.270.27.16360; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; Dohoney KM, 2001, NATURE, V409, P370, DOI 10.1038/35053124; KORANGY F, 1994, BIOCHEMISTRY-US, V33, P9552, DOI 10.1021/bi00198a022; KUZMINOV A, 1994, EMBO J, V13, P2764, DOI 10.1002/j.1460-2075.1994.tb06570.x; LAM ST, 1974, GENETICS, V77, P425; LARSSON A, 1994, J AM CHEM SOC, V116, P8459, DOI 10.1021/ja00098a004; LEBOWITZ J, 1985, THESIS J HOPKINS U B; MYERS RS, 1995, P NATL ACAD SCI USA, V92, P6244, DOI 10.1073/pnas.92.14.6244; RINKEN R, 1992, J BACTERIOL, V174, P5424, DOI 10.1128/JB.174.16.5424-5429.1992; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1975, MOL GEN GENET, V140, P29, DOI 10.1007/BF00268986; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; Taylor AF, 2003, NATURE, V423, P889, DOI 10.1038/nature01674; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; Taylor AF, 1999, GENE DEV, V13, P890, DOI 10.1101/gad.13.7.890; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226	30	146	151	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					647	654		10.1016/S0092-8674(03)00681-0	http://dx.doi.org/10.1016/S0092-8674(03)00681-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678587	Bronze			2022-12-24	WOS:000185193100013
J	Kuroda, H; Maliga, P				Kuroda, H; Maliga, P			The plastid clpP1 protease gene is essential for plant development	NATURE			English	Article							ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; PHOTOSYSTEM-II; TOBACCO; TRANSFORMATION; GENOME; RNA; RECOMBINATION; CHLOROPLASTS; MUTAGENESIS	Plastids of higher plants are semi-autonomous cellular organelles that have their own genome and transcription-translation machinery(1). Examples of plastid functions are photosynthesis and biosynthesis of starch, amino acids, lipids and pigments(2). Plastid functions are encoded in similar to120 plastid genes(1) and similar to3,000 nuclear genes(2,3). Although many embryo and seedling lethal nuclear genes are required for chloroplast biogenesis(4-6), until now deletion of plastid genes either had no phenotypic consequence (8 genes), or caused a mutant phenotype but did not affect viability (13 genes)(7-10). Here we identify an essential plastid gene. By using the CRE-lox site-specific recombination system(11,12) we have deleted clpP1 (caseinolytic protease P1), one of the three genes (clpP1, ycf1 and ycf2) whose disruption had previously only been possible in a fraction of the 1,000-10,000 plastid genome copies in a cell(7,13). Loss of the clpP1 gene product, the ClpP1 protease subunit(14), results in ablation of the shoot system of tobacco plants, suggesting that ClpP1-mediated protein degradation is essential for shoot development.	Rutgers State Univ, Waksman Inst Microbiol, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Plant Biol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Maliga, P (corresponding author), Rutgers State Univ, Waksman Inst Microbiol, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.							Adam Z, 2002, TRENDS PLANT SCI, V7, P451, DOI 10.1016/S1360-1385(02)02326-9; Bock Ralph, 2002, V63, P106; Budziszewski GJ, 2001, GENETICS, V159, P1765; Cahoon AB, 2003, PLANT CELL PHYSIOL, V44, P93, DOI 10.1093/pcp/pcg003; Corneille S, 2001, PLANT J, V27, P171, DOI 10.1046/j.1365-313x.2001.01068.x; CORNEILLE S, IN PRESS PLANT J; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Hager M, 2002, J BIOL CHEM, V277, P14031, DOI 10.1074/jbc.M112053200; Hajdukiewicz PTJ, 2001, PLANT J, V27, P161, DOI 10.1046/j.1365-313x.2001.01067.x; HAN CD, 1992, EMBO J, V11, P4037, DOI 10.1002/j.1460-2075.1992.tb05497.x; HESS WR, 1993, EMBO J, V12, P563, DOI 10.1002/j.1460-2075.1993.tb05688.x; Kuroda H, 2002, PLANT PHYSIOL, V129, P1600, DOI 10.1104/pp.004986; Leister D, 2003, TRENDS GENET, V19, P47, DOI 10.1016/S0168-9525(02)00003-3; Marechal Eric, 2002, Trends Plant Sci, V7, P99, DOI 10.1016/S1360-1385(02)02248-3; Martin W, 2002, P NATL ACAD SCI USA, V99, P12246, DOI 10.1073/pnas.182432999; McElver J, 2001, GENETICS, V159, P1751; Ow DW, 2002, PLANT MOL BIOL, V48, P183, DOI 10.1023/A:1013718106742; Peltier JB, 2001, J BIOL CHEM, V276, P16318, DOI 10.1074/jbc.M010503200; Shikanai T, 2001, PLANT CELL PHYSIOL, V42, P264, DOI 10.1093/pcp/pce031; Springer PS, 2000, PLANT CELL, V12, P1007, DOI 10.1105/tpc.12.7.1007; STAUB JM, 1993, EMBO J, V12, P601, DOI 10.1002/j.1460-2075.1993.tb05692.x; SUGIURA M, 1992, PLANT MOL BIOL, V19, P149, DOI 10.1007/BF00015612; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; Swiatek M, 2003, CURR GENET, V43, P45, DOI 10.1007/s00294-003-0369-4; Swiatek M, 2003, MOL GENET GENOMICS, V268, P699, DOI 10.1007/s00438-002-0791-1; WALBOT V, 1979, P NATL ACAD SCI USA, V76, P2760, DOI 10.1073/pnas.76.6.2760; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401; Zubko MK, 1998, PLANT J, V15, P265, DOI 10.1046/j.1365-313X.1998.00195.x	30	146	151	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					86	89		10.1038/nature01909	http://dx.doi.org/10.1038/nature01909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955146				2022-12-24	WOS:000185089200043
J	Sung, BJ; Hwang, KY; Jeon, YH; Lee, JI; Heo, YS; Kim, JH; Moon, J; Yoon, JM; Hyun, YL; Kim, E; Eum, SJ; Park, SY; Lee, JO; Lee, TG; Ro, S; Cho, JM				Sung, BJ; Hwang, KY; Jeon, YH; Lee, JI; Heo, YS; Kim, JH; Moon, J; Yoon, JM; Hyun, YL; Kim, E; Eum, SJ; Park, SY; Lee, JO; Lee, TG; Ro, S; Cho, JM			Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules	NATURE			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CGMP-BINDING; INHIBITORS; MECHANISM; COMPLEX; PDE5	Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cyclic AMP and cyclic GMP(1-3). As essential regulators of cyclic nucleotide signalling with diverse physiological functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction(4-7). Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolysing activity in human corpus cavernosum tissue. It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction. Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available(8,9). Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra). These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacological profiles.	CrystalGenom Inc, Div Drug Discovery, Taejon 305390, South Korea; Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea	Yokohama City University; Korea Advanced Institute of Science & Technology (KAIST)	Ro, S (corresponding author), CrystalGenom Inc, Div Drug Discovery, Daedeok Biocommunity, Taejon 305390, South Korea.	sgro@crystalgenomics.com; jmcho@crystalgenomics.com	Lee, Jie-Oh/AAG-4302-2020; Jeon, Young Ho/F-4483-2011; Lee, Jie-Oh/C-1581-2011	Lee, Jie-Oh/0000-0001-6519-6049				BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; Corbin JD, 2002, INT J CLIN PRACT, V56, P453; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lee JY, 2002, J NANOPART RES, V4, P53, DOI 10.1023/A:1020107522135; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Orme M W, 2002, [No title captured], Patent No. [WO 0236593, 0236593]; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rotella DP, 2002, NAT REV DRUG DISCOV, V1, P674, DOI 10.1038/nrd893; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; SEKHAR KR, 1996, PHOSPHODIESTERASE IN, P135; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Young JM, 2002, EXPERT OPIN INV DRUG, V11, P1487, DOI 10.1517/13543784.11.10.1487	23	207	222	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					98	102		10.1038/nature01914	http://dx.doi.org/10.1038/nature01914			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955149				2022-12-24	WOS:000185089200046
J	Velicer, GJ; Yu, YTN				Velicer, GJ; Yu, YTN			Evolution of novel cooperative swarming in the bacterium Myxococcus xanthus	NATURE			English	Article							CELL-INTERACTIONS; SOCIAL MOTILITY; GLIDING MOTILITY; GENE; MULTICELLULARITY; EXPRESSION; EXCITATION; COHESION; FIBRILS; SYSTEMS	Cooperation among individuals is necessary for evolutionary transitions to higher levels of biological organization(1-3). In such transitions, groups of individuals at one level (such as single cells) cooperate to form selective units at a higher level (such as multicellular organisms). Though the evolution of cooperation is difficult to observe directly in higher eukaryotes, microorganisms do offer such an opportunity(4). Here we report the evolution of novel cooperative behaviour in experimental lineages of the bacterium Myxococcus xanthus. Wild-type strains of M. xanthus exhibit socially dependent swarming across soft surfaces(5) by a mechanism known as 'S-motility' that requires the presence of extracellular type IV pili(6). In lineages of M. xanthus unable to make pili, a new mechanistic basis for cooperative swarming evolved. Evolved swarming is mediated, at least in part, by enhanced production of an extracellular fibril matrix that binds cells-and their evolutionary interests-together. Though costly to individuals, fibril production greatly enhanced population expansion in groups of interconnected cells. These results show that fundamental transitions to primitive cooperation can readily occur in bacteria.	Max Planck Inst Dev Biol, Dept Evolutionary Biol, D-72076 Tubingen, Germany; Max Planck Inst Dev Biol, Dept Prot Evolut, D-72076 Tubingen, Germany	Max Planck Society; Max Planck Society	Velicer, GJ (corresponding author), Max Planck Inst Dev Biol, Dept Evolutionary Biol, Spemannstr 35, D-72076 Tubingen, Germany.							ARNOLD JW, 1988, J BACTERIOL, V170, P5765, DOI 10.1128/jb.170.12.5765-5770.1988; BEHMLANDER RM, 1994, J BACTERIOL, V176, P6295, DOI 10.1128/jb.176.20.6295-6303.1994; BEHMLANDER RM, 1991, J BACTERIOL, V173, P7810, DOI 10.1128/jb.173.24.7810-7820.1991; Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI 10.1515/9781400858712; Cramton SE, 2001, INFECT IMMUN, V69, P4079, DOI 10.1128/IAI.69.6.4079-4085.2001; Crespi BJ, 2001, TRENDS ECOL EVOL, V16, P178, DOI 10.1016/S0169-5347(01)02115-2; DANA JR, 1993, J BACTERIOL, V175, P3636, DOI 10.1128/jb.175.11.3636-3647.1993; HODGKIN J, 1979, MOL GEN GENET, V171, P177, DOI 10.1007/BF00270004; Kearns DB, 2001, TRENDS MICROBIOL, V9, P126, DOI 10.1016/S0966-842X(01)01948-5; Kearns DB, 2002, J BACTERIOL, V184, P1678, DOI 10.1128/JB.184.6.1678-1684.2002; Kearns DB, 2000, P NATL ACAD SCI USA, V97, P11505, DOI 10.1073/pnas.210448597; Krause J., 2002, LIVING GROUPS; Lancero H, 2002, J BACTERIOL, V184, P1462, DOI 10.1128/JB.184.5.1462-1465.2002; Li YN, 2003, P NATL ACAD SCI USA, V100, P5443, DOI 10.1073/pnas.0836639100; Michod RE, 2001, HEREDITY, V86, P1, DOI 10.1046/j.1365-2540.2001.00808.x; Pfeiffer T, 2003, P NATL ACAD SCI USA, V100, P1095, DOI 10.1073/pnas.0335420100; Queller DC, 2003, SCIENCE, V299, P105, DOI 10.1126/science.1077742; Rainey PB, 2003, NATURE, V425, P72, DOI 10.1038/nature01906; Rodriguez AM, 1999, J BACTERIOL, V181, P4381, DOI 10.1128/JB.181.14.4381-4390.1999; SHI WY, 1993, P NATL ACAD SCI USA, V90, P3378, DOI 10.1073/pnas.90.8.3378; SHIMKETS LJ, 1986, J BACTERIOL, V166, P842, DOI 10.1128/jb.166.3.842-848.1986; Shimkets LJ, 1999, ANNU REV MICROBIOL, V53, P525, DOI 10.1146/annurev.micro.53.1.525; Smith J. M., 1995, MAJOR TRANSITIONS EV; Velicer GJ, 1998, P NATL ACAD SCI USA, V95, P12376, DOI 10.1073/pnas.95.21.12376; Velicer GJ, 2003, TRENDS MICROBIOL, V11, P330, DOI 10.1016/S0966-842X(03)00152-5; Velicer GJ, 2002, J BACTERIOL, V184, P2719, DOI 10.1128/JB.184.10.2719-2727.2002; Wolgemuth C, 2002, CURR BIOL, V12, P369, DOI 10.1016/S0960-9822(02)00716-9; Wu SS, 1996, J BACTERIOL, V178, P5817, DOI 10.1128/jb.178.19.5817-5821.1996; WU SS, 1995, MOL MICROBIOL, V18, P547, DOI 10.1111/j.1365-2958.1995.mmi_18030547.x; Wu SS, 1997, J BACTERIOL, V179, P7748, DOI 10.1128/jb.179.24.7748-7758.1997	30	132	136	3	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					75	78		10.1038/nature01908	http://dx.doi.org/10.1038/nature01908			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955143				2022-12-24	WOS:000185089200040
J	Mercer, CH; Fenton, KA; Johnson, AM; Wellings, K; Macdowall, W; McManus, S; Nanchahal, K; Erens, B				Mercer, CH; Fenton, KA; Johnson, AM; Wellings, K; Macdowall, W; McManus, S; Nanchahal, K; Erens, B			Sexual function problems and help seeking behaviour in Britain: national probability sample survey	BRITISH MEDICAL JOURNAL			English	Article							ERECTILE DYSFUNCTION; PREVALENCE; QUESTIONNAIRE; POPULATION		UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, Ctr Infect Dis Epidemiol, London WC1E 6AU, England; UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England; Hlth Protect Agcy, Ctr Communicable Dis Surveillance, HIV STI Div, London NW9 5EQ, England; Univ London London Sch Hyg & Trop Med, Ctr Sexual & Reprod Hlth Res, London WC1E 7HT, England; Natl Ctr Social Res, Hlth Res Grp, London EC1V 0AX, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; Health Protection Agency; University of London; London School of Hygiene & Tropical Medicine	Mercer, CH (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, Ctr Infect Dis Epidemiol, London WC1E 6AU, England.	cmercer@gum.ucl.ac.uk	McManus, Sally/HGD-4860-2022; McManus, Sally/S-4697-2019	McManus, Sally/0000-0003-2711-0819; Erens, Bob/0000-0002-4430-954X; Macdowall, Wendy/0000-0001-5868-8336; Erens, Robert/0000-0002-3054-504X; Mercer, Catherine/0000-0002-4220-5034; Nanchahal, Kiran/0000-0001-8812-7628; Johnson, Anne/0000-0003-1330-7100				Akkus E, 2002, EUR UROL, V41, P298, DOI 10.1016/S0302-2838(02)00027-1; CRENSHAW TL, 1996, SEXUAL PHARM DRUGS A; Daker-White G, 2002, ARCH SEX BEHAV, V31, P197, DOI 10.1023/A:1014743304566; Dunn KM, 1998, FAM PRACT, V15, P519, DOI 10.1093/fampra/15.6.519; ERENS B, 2001, NATL SURVEY SEXUAL A, V2; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Finkelhor D, 1991, VIOLENCE AM PUBLIC H, P79; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Humphery S, 2001, FAM PRACT, V18, P516, DOI 10.1093/fampra/18.5.516; Johnson AM, 2001, LANCET, V358, P1835, DOI 10.1016/S0140-6736(01)06883-0; Kell P, 2001, INT J STD AIDS, V12, P395, DOI 10.1258/0956462011923183; Kinsey A, 1948, SEXUAL BEHAV HUMAN M, DOI 10.1037/t17515-000; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; MCCORMICK A, 1995, MORBIDITY STAT GEN P; MERCER CH, 2003, IN PRESS BMJ; Mirone V, 2002, EUR UROL, V41, P294, DOI 10.1016/S0302-2838(02)00005-2; Moreira ED, 2001, UROLOGY, V58, P583, DOI 10.1016/S0090-4295(01)01274-2; Moynihan R, 2003, BRIT MED J, V326, P45, DOI 10.1136/bmj.326.7379.45; PEACH C, 1998, ETHNICITY 1991 CENSU, V2, P206; REYNOLDS CF, 1988, PSYCHIAT RES, V24, P231, DOI 10.1016/0165-1781(88)90106-0; Simons JS, 2001, ARCH SEX BEHAV, V30, P177, DOI 10.1023/A:1002729318254; TAYLOR JF, 1994, ARCH SEX BEHAV, V23, P627, DOI 10.1007/BF01541816; Tiefer L, 2000, J SEX RES, V37, P273, DOI 10.1080/00224490009552048; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; World Health Organization, 1992, INT STAT CLASS DIS R	26	262	264	0	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 23	2003	327	7412					426	427		10.1136/bmj.327.7412.426	http://dx.doi.org/10.1136/bmj.327.7412.426			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715YY	12933730	Green Accepted, Green Submitted, Green Published			2022-12-24	WOS:000185003100020
J	Lloyd-Williams, M; Dennis, M; Taylor, F; Baker, I				Lloyd-Williams, M; Dennis, M; Taylor, F; Baker, I			Is asking patients in palliative care, "Are you depressed?" appropriate? Prospective study	BRITISH MEDICAL JOURNAL			English	Article							SINGLE QUESTION; TERMINALLY ILL		Univ Liverpool, Sch Med, Dept Primary Care, Liverpool L69 3GB, Merseyside, England; Univ Leicester, Leicester Gen Hosp, Dept Psychiat, Leicester LE5 4PW, Leics, England; LOROS Hospice, Leicester LE3 9QE, Leics, England	University of Liverpool; University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester	Lloyd-Williams, M (corresponding author), Univ Liverpool, Sch Med, Dept Primary Care, Liverpool L69 3GB, Merseyside, England.							Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; Hotopf M, 2002, PALLIATIVE MED, V16, P81, DOI 10.1191/02169216302pm507oa; Lloyd-Williams M, 1999, PALLIATIVE MED, V13, P243, DOI 10.1191/026921699676753309; MAHONEY J, 1994, J AM GERIATR SOC, V42, P1006; Watkins C, 2001, BRIT MED J, V323, P1159, DOI 10.1136/bmj.323.7322.1159	5	54	54	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					372	373		10.1136/bmj.327.7411.372	http://dx.doi.org/10.1136/bmj.327.7411.372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919988	Green Published, Bronze			2022-12-24	WOS:000184864200018
J	Abram, NJ; Gagan, MK; McCulloch, MT; Chappell, J; Hantoro, WS				Abram, NJ; Gagan, MK; McCulloch, MT; Chappell, J; Hantoro, WS			Coral reef death during the 1997 Indian Ocean dipole linked to Indonesian wildfires	SCIENCE			English	Article							WATER; IRON; PHYTOPLANKTON; PACIFIC; BIOMASS; FIRES; FRACTIONATION; LANTHANIDES; TEMPERATURE; ECOSYSTEMS	Geochemical anomalies and growth discontinuities in Porites corals from western Sumatra, Indonesia, record unanticipated reef mortality during anomalous Indian Ocean Dipole upwelling and a giant red tide in 1997. Sea surface temperature reconstructions show that although some past upwelling events have been stronger, there were no analogous episodes of coral mortality during the past 7000 years, indicating that the 1997 red tide was highly unusual. We show that iron fertilization by the 1997 Indonesian wild. res was sufficient to produce the extraordinary red tide, leading to reef death by asphyxiation. These findings highlight tropical wild. res as an escalating threat to coastal marine ecosystems.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Indonesian Inst Sci, Res & Dev Ctr Geotechnol, Bandung 40135, Indonesia	Australian National University; Indonesian Institute of Sciences	Abram, NJ (corresponding author), Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia.		Abram, Nerilie/AAT-5171-2021; McCulloch, Malcolm T/C-3651-2009; Gagan, Michael/L-5014-2018	McCulloch, Malcolm T/0000-0003-1538-1558; Gagan, Michael/0000-0002-8279-323X; Abram, Nerilie/0000-0003-1246-2344				Aronson RB, 2000, NATURE, V405, P36, DOI 10.1038/35011132; Bau M, 1997, MAR CHEM, V56, P123, DOI 10.1016/S0304-4203(96)00091-6; BEHRA P, 1990, NATURE, V344, P419, DOI 10.1038/344419a0; Bishop JKB, 2002, SCIENCE, V298, P817, DOI 10.1126/science.1074961; Byrne R.H., 1996, HANDB PHYSI, V23, P497; DARRIGO RD, 1994, TERR ATMOS OCIAN SCI, V5, P349; EATON P, 2001, FOREST FIRES REGIONA; Frogner P, 2001, GEOLOGY, V29, P487, DOI 10.1130/0091-7613(2001)029<0487:FPOVAI>2.0.CO;2; Gagan MK, 1998, SCIENCE, V279, P1014, DOI 10.1126/science.279.5353.1014; Gao Y, 2001, GEOPHYS RES LETT, V28, P29, DOI 10.1029/2000GL011926; GENIN A, 1995, NATURE, V377, P507, DOI 10.1038/377507a0; Gruber N, 1999, GLOBAL BIOGEOCHEM CY, V13, P307, DOI 10.1029/1999GB900019; Harvell CD, 1999, SCIENCE, V285, P1505, DOI 10.1126/science.285.5433.1505; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; INDRAWADI, 2000, 9 INT COR REEF S A, V16, P86; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Johnson KS, 2001, GEOPHYS RES LETT, V28, P1247, DOI 10.1029/2000GL012433; Joint I, 2000, J EXP MAR BIOL ECOL, V250, P233, DOI 10.1016/S0022-0981(00)00199-4; Kinkade C, 1997, DEEP-SEA RES PT I, V44, P581, DOI 10.1016/S0967-0637(97)00002-2; Koe LCC, 2001, ATMOS ENVIRON, V35, P2723, DOI 10.1016/S1352-2310(00)00395-2; Levine JS, 1999, GEOPHYS RES LETT, V26, P815, DOI 10.1029/1999GL900067; Maenhaut W, 2002, NUCL INSTRUM METH B, V189, P259, DOI 10.1016/S0168-583X(01)01054-0; Measures CI, 1999, DEEP-SEA RES PT II, V46, P1597, DOI 10.1016/S0967-0645(99)00037-5; Murtugudde RG, 1999, J GEOPHYS RES-OCEANS, V104, P18351, DOI 10.1029/1999JC900135; Nakajima T, 1999, GEOPHYS RES LETT, V26, P2421, DOI 10.1029/1999GL900208; Roberts CM, 2002, SCIENCE, V295, P1280, DOI 10.1126/science.1067728; Saji NH, 1999, NATURE, V401, P360, DOI 10.1038/43854; SHOLKOVITZ ER, 1994, GEOCHIM COSMOCHIM AC, V58, P1567, DOI 10.1016/0016-7037(94)90559-2; Siegert F, 2001, NATURE, V414, P437, DOI 10.1038/35106547; Sieh K, 1999, GEOPHYS RES LETT, V26, P3141, DOI 10.1029/1999GL005409; SIMPSON CJ, 1993, CORAL REEFS, V12, P185, DOI 10.1007/BF00334478; SUNDA WG, 1995, MAR CHEM, V50, P189, DOI 10.1016/0304-4203(95)00035-P; TOMASCIK T, 1997, ECOLOGY INDONESIAN S, V8, P1249; Walsh JJ, 2001, J GEOPHYS RES-OCEANS, V106, P11597, DOI 10.1029/1999JC000123; Webster PJ, 1999, NATURE, V401, P356, DOI 10.1038/43848; Wilkinson C., 2000, STATUS CORAL REEFS W; WYNDHAM TD, UNPUB; Yamasoe MA, 2000, ATMOS ENVIRON, V34, P1641, DOI 10.1016/S1352-2310(99)00329-5; Zachariasen J, 1999, J GEOPHYS RES-SOL EA, V104, P895, DOI 10.1029/1998JB900050	39	170	180	5	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					952	955		10.1126/science.1083841	http://dx.doi.org/10.1126/science.1083841			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920295				2022-12-24	WOS:000184755900035
J	O'Reilly, CM; Alin, SR; Plisnier, PD; Cohen, AS; McKee, BA				O'Reilly, CM; Alin, SR; Plisnier, PD; Cohen, AS; McKee, BA			Climate change decreases aquatic ecosystem productivity of Lake Tanganyika, Africa	NATURE			English	Article							ORGANIC-MATTER; ISOTOPIC COMPOSITION; WATER; INDICATORS; SEDIMENTS; CHEMISTRY; CARBON	Although the effects of climate warming on the chemical and physical properties of lakes have been documented(1), biotic and ecosystem-scale responses to climate change have been only estimated or predicted by manipulations and models(1). Here we present evidence that climate warming is diminishing productivity in Lake Tanganyika, East Africa. This lake has historically supported a highly productive pelagic fishery that currently provides 25-40% of the animal protein supply for the populations of the surrounding countries(2). In parallel with regional warming patterns since the beginning of the twentieth century, a rise in surface-water temperature has increased the stability of the water column. A regional decrease in wind velocity has contributed to reduced mixing, decreasing deep-water nutrient upwelling and entrainment into surface waters. Carbon isotope records in sediment cores suggest that primary productivity may have decreased by about 20%, implying a roughly 30% decrease in fish yields. Our study provides evidence that the impact of regional effects of global climate change on aquatic ecosystem functions and services can be larger than that of local anthropogenic activity or overfishing.	Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Namur Univ, Dept Biol, B-5000 Namur, Belgium; Royal Museum Cent Africa, B-3080 Tervuren, Belgium; Tulane Univ, Dept Earth & Environm Sci, New Orleans, LA 70118 USA	University of Arizona; University of Namur; Royal Museum for Central Africa; Tulane University	O'Reilly, CM (corresponding author), Vassar Coll, Environm Sci Program, Poughkeepsie, NY 12603 USA.		Plisnier, Pierre-Denis/ABG-2933-2020; Alin, Simone/J-6836-2017	Alin, Simone/0000-0002-8283-1910				BEAUCHAMP R. S. A., 1939, INTERNAL REV GES HYDROBIOL U HYDROGR, V39, P316, DOI 10.1002/iroh.19390390303; BEAUCHAMP RSA, 1953, J ECOL, V41, P226, DOI 10.2307/2257037; Brenner M, 1999, J PALEOLIMNOL, V22, P205, DOI 10.1023/A:1008078222806; Coulter GW, 1991, LAKE TANGANYIKA ITS; Craig H., 1974, LAKE TANGANYIKA GEOC; DEGENS ET, 1971, NATURWISSENSCHAFTEN, V58, P229, DOI 10.1007/BF00602986; DUBOIS J. T., 1958, HYDROBIOLOGIA, V10, P215, DOI 10.1007/BF00142188; EDMOND JM, 1993, LIMNOL OCEANOGR, V38, P725, DOI 10.4319/lo.1993.38.4.0725; Goddard L, 1999, J GEOPHYS RES-ATMOS, V104, P19099, DOI 10.1029/1999JD900326; HECKY RE, 1994, LIMNOL OCEANOGR, V39, P1476, DOI 10.4319/lo.1994.39.6.1476; Hodell DA, 1998, LIMNOL OCEANOGR, V43, P200, DOI 10.4319/lo.1998.43.2.0200; Houghton J. T., 2001, CLIMATE CHANGE 2001; Hulme M, 2001, CLIM RES, V17, P145, DOI 10.3354/cr017145; IDSO SB, 1973, LIMNOL OCEANOGR, V18, P681, DOI 10.4319/lo.1973.18.4.0681; LEHMAN J. T., 1998, ENV CHANGE RESPONSE, P157; Mannini P., 1998, GEOGRAPHICAL DISTRIB; MARQUARDSEN H, 1916, MITTEILUNGEN DTSCH S, V29, P97; McKnight Diane, 1996, Limnology and Oceanography, V41, P815; MEYERS PA, 1993, ORG GEOCHEM, V20, P867, DOI 10.1016/0146-6380(93)90100-P; Molsa H, 1999, HYDROBIOLOGIA, V407, P1, DOI 10.1023/A:1003712708969; NIXON SW, 1988, LIMNOL OCEANOGR, V33, P1005, DOI 10.4319/lo.1988.33.4_part_2.1005; O'Reilly CM, 2002, LIMNOL OCEANOGR, V47, P306, DOI 10.4319/lo.2002.47.1.0306; PATTERSON G, 1995, FISHERY POTENTIAL PR, P1; Plisnier PD, 1999, HYDROBIOLOGIA, V407, P45, DOI 10.1023/A:1003762119873; Popp BN, 1998, GEOCHIM COSMOCHIM AC, V62, P69, DOI 10.1016/S0016-7037(97)00333-5; Shirakihara Kunio, 1992, African Study Monographs, V13, P57; TALBOT MR, 1992, EARTH PLANET SC LETT, V110, P23, DOI 10.1016/0012-821X(92)90036-U; van Zwieten PAM, 2002, FISH RES, V54, P329, DOI 10.1016/S0165-7836(01)00267-3; VANMEEL L, 1987, CONTRIBUTION LIMNOLO, V2; VANMEEL LIJ, 1987, CONTRIBUTION LIMNOLO, V1; VERBURG P, 1997, HYDRODYNAMICS LAKE T	31	439	478	13	251	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					766	768		10.1038/nature01833	http://dx.doi.org/10.1038/nature01833			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917682				2022-12-24	WOS:000184733900037
J	Van Laere, AS; Nguyen, M; Braunschweig, M; Nezer, C; Collette, C; Moreau, L; Archibald, AL; Haley, CS; Buys, N; Tally, M; Andersson, G; Georges, M; Andersson, L				Van Laere, AS; Nguyen, M; Braunschweig, M; Nezer, C; Collette, C; Moreau, L; Archibald, AL; Haley, CS; Buys, N; Tally, M; Andersson, G; Georges, M; Andersson, L			A regulatory mutation in IGF2 causes a major QTL effect on muscle growth in the pig	NATURE			English	Article							QUANTITATIVE TRAIT LOCI; INCREASED OVULATION RATE; GENETIC DISSECTION; IDENTIFICATION; DELETION; MASS; PHENOTYPE; SKELETAL; ELEMENT; CATTLE	Most traits and disorders have a multifactorial background indicating that they are controlled by environmental factors as well as an unknown number of quantitative trait loci (QTLs)(1,2). The identification of mutations underlying QTLs is a challenge because each locus explains only a fraction of the phenotypic variation(3,4). A paternally expressed QTL affecting muscle growth, fat deposition and size of the heart in pigs maps to the IGF2 (insulin-like growth factor 2) region(5,6). Here we show that this QTL is caused by a nucleotide substitution in intron 3 of IGF2. The mutation occurs in an evolutionarily conserved CpG island that is hypomethylated in skeletal muscle. The mutation abrogates in vitro interaction with a nuclear factor, probably a repressor, and pigs inheriting the mutation from their sire have a threefold increase in IGF2 messenger RNA expression in postnatal muscle. Our study establishes a causal relationship between a single-base-pair substitution in a non-coding region and a QTL effect. The result supports the long-held view that regulatory mutations are important for controlling phenotypic variation(7).	Swedish Univ Agr Sci, Dept Anim Breeding & Genet, BMC, SE-75124 Uppsala, Sweden; Uppsala Univ, Dept Med Biochem & Microbiol, BMC, SE-75124 Uppsala, Sweden; Univ Liege, Fac Vet Med, Dept Genet, B-4000 Liege, Belgium; Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; Gentec, B-9255 Buggenhout, Belgium; Tally Consulting, SE-11458 Stockholm, Sweden	Swedish University of Agricultural Sciences; Uppsala University; University of Liege; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Georges, M (corresponding author), Swedish Univ Agr Sci, Dept Anim Breeding & Genet, BMC, Box 597, SE-75124 Uppsala, Sweden.		Haley, Chris S/F-3110-2013; Van+Laere, Anne-Sophie/ADZ-7821-2022; Andersson, Goran/AAK-6564-2020	Andersson, Goran/0000-0001-5131-3144; Archibald, Alan/0000-0001-9213-1830; Haley, Chris/0000-0002-9811-0210; Buys, Nadine/0000-0002-7313-3088; Georges, Michel/0000-0003-4124-2375				Amarger V, 2002, MAMM GENOME, V13, P388, DOI 10.1007/s00335-001-3059-x; Anderson SI, 2000, MAMM GENOME, V11, P811, DOI 10.1007/s003350010155; Andersson L, 2001, NAT REV GENET, V2, P130, DOI 10.1038/35052563; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Darvasi A, 2002, TRENDS GENET, V18, P489, DOI 10.1016/S0168-9525(02)02767-1; de Koning DJ, 2000, P NATL ACAD SCI USA, V97, P7947, DOI 10.1073/pnas.140216397; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; ENGEMANN S, 2002, METHODS MOL BIOL, V181; Evans GJ, 2003, GENETICS, V164, P621; Florini JR, 1995, DIABETES REV, V3, P73; Freking BA, 2002, GENOME RES, V12, P1496, DOI 10.1101/gr.571002; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; Giuffra E, 2000, GENETICS, V154, P1785; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Greally JM, 1997, MAMM GENOME, V8, P805, DOI 10.1007/s003359900583; Grisart B, 2002, GENOME RES, V12, P222, DOI 10.1101/gr.224202; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; HALEY CS, 1994, GENETICS, V136, P1195; Jeon JT, 1999, NAT GENET, V21, P157, DOI 10.1038/5938; Kashuk C, 2002, GENOME RES, V12, P333, DOI 10.1101/gr.211202; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Mackay TFC, 2001, NAT REV GENET, V2, P11, DOI 10.1038/35047544; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; Mulsant P, 2001, P NATL ACAD SCI USA, V98, P5104, DOI 10.1073/pnas.091577598; Nezer C, 1999, NAT GENET, V21, P155, DOI 10.1038/5935; Nezer C, 2003, GENETICS, V165, P277; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Pailhoux E, 2001, NAT GENET, V29, P453, DOI 10.1038/ng769	29	673	725	2	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					832	836		10.1038/nature02064	http://dx.doi.org/10.1038/nature02064			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574411				2022-12-24	WOS:000186118500044
J	Loya, WM; Pregitzer, KS; Karberg, NJ; King, JS; Giardina, CP				Loya, WM; Pregitzer, KS; Karberg, NJ; King, JS; Giardina, CP			Reduction of soil carbon formation by tropospheric ozone under increased carbon dioxide levels	NATURE			English	Article							GROWTH; TREES; ALLOCATION; PLANTS; ASPEN	In the Northern Hemisphere, ozone levels in the troposphere have increased by 35 per cent over the past century(1), with detrimental impacts on forest(2,3) and agricultural(4) productivity, even when forest productivity has been stimulated by increased carbon dioxide levels'. In addition to reducing productivity, increased tropospheric ozone levels could alter terrestrial carbon cycling by lowering the quantity and quality of carbon inputs to soils. However, the influence of elevated ozone levels on soil carbon formation and decomposition are unknown. Here we examine the effects of elevated ozone levels on the formation rates of total and decay-resistant acid-insoluble soil carbon under conditions of elevated carbon dioxide levels in experimental aspen (Populus tremuloides) stands and mixed aspen-birch (Betula papyrifera) stands. With ambient concentrations of ozone and carbon dioxide both raised by 50 per cent, we find that the formation rates of total and acid-insoluble soil carbon are reduced by 50 per cent relative to the amounts entering the soil when the forests were exposed to increased carbon dioxide alone. Our results suggest that, in a world with elevated atmospheric carbon dioxide concentrations, global-scale reductions in plant productivity due to elevated ozone levels will also lower soil carbon formation rates significantly.	Michigan Technol Univ, Sch Forest Resources & Environm Sci, Houghton, MI 49931 USA; US Forest Serv, USDA, N Cent Res Stn, Houghton, MI 49931 USA	Michigan Technological University; United States Department of Agriculture (USDA); United States Forest Service	Loya, WM (corresponding author), Michigan Technol Univ, Sch Forest Resources & Environm Sci, Houghton, MI 49931 USA.		Giardina, Christian P/C-3120-2011	Giardina, Christian P/0000-0002-3431-5073				Andersen CP, 2003, NEW PHYTOL, V157, P213, DOI 10.1046/j.1469-8137.2003.00674.x; CHAMEIDES WL, 1994, SCIENCE, V264, P74, DOI 10.1126/science.264.5155.74; COLEMAN MD, 1995, TREE PHYSIOL, V15, P593, DOI 10.1093/treephys/15.9.593; DICKSON RE, 2000, NC214 USDA; Findlay S, 1996, ECOL APPL, V6, P269, DOI 10.2307/2269570; Gregg JW, 2003, NATURE, V424, P183, DOI 10.1038/nature01728; *IPCC SECR, 2001, IPCC CLIM CHANG 2001; King JS, 2001, OECOLOGIA, V128, P237, DOI 10.1007/s004420100656; Larson JL, 2002, SOIL SCI SOC AM J, V66, P1848, DOI 10.2136/sssaj2002.1848; Leavitt SW, 1996, RADIOCARBON, V38, P231, DOI 10.1017/S0033822200017604; MCLAUGHLIN SB, 1995, NATURE, V374, P252, DOI 10.1038/374252a0; Paul EA, 1997, SOIL SCI SOC AM J, V61, P1058, DOI 10.2136/sssaj1997.03615995006100040011x; Percy KE, 2002, NATURE, V420, P403, DOI 10.1038/nature01028; Phillips RL, 2002, OECOLOGIA, V131, P236, DOI 10.1007/s00442-002-0868-x; *US EPA, LAT FIND NAT AIR QUA	15	105	113	4	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					705	707		10.1038/nature02047	http://dx.doi.org/10.1038/nature02047			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562100				2022-12-24	WOS:000185924500038
J	Ashida, H; Saito, Y; Kojima, C; Kobayashi, K; Ogasawara, N; Yokota, A				Ashida, H; Saito, Y; Kojima, C; Kobayashi, K; Ogasawara, N; Yokota, A			A functional link between RuBisCO-like protein of Bacillus and photosynthetic RuBisCO	SCIENCE			English	Article							METHIONINE SALVAGE PATHWAY; COMPLETE GENOME SEQUENCE; RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; CHLOROBIUM-TEPIDUM; ARCHAEON; SITE	The genomes of several nonphotosynthetic bacteria, such as Bacillus subtilis, and some Archaea include genes for proteins with sequence homology to the large subunit of ribulose bisphosphate carboxylase/oxygenase (RuBisCO). We found that such a RuBisCO-like protein (RLP) from B. subtilis catalyzed the 2,3-diketo-5-methylthiopentyl-1-phosphate enolase reaction in the methionine salvage pathway. A growth-defective mutant, in which the gene for this RLP had been disrupted, was rescued by the gene for RuBisCO from the photosynthetic bacterium Rhodospirillum rubrum. Thus, the photosynthetic RuBisCO from R. rubrum retains the ability to function in the methionine salvage pathway in B. subtilis.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Res Inst Innovat Technol Earth, Plant Mol Physiol Lab, Kyoto 6190292, Japan	Nara Institute of Science & Technology; Research Institute of Innovative Technology for the Earth	Yokota, A (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	yokota@bs.aist-nara.ac.jp	Kojima, Chojiro/AFV-4592-2022; Saito, Yohtaro/C-9838-2017; Ogasawara, Naotake/B-7971-2011	Saito, Yohtaro/0000-0002-1024-5154; Kojima, Chojiro/0000-0003-2723-8249				Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; ASHIDA H, UNPUB; Avigad G, 1975, Methods Enzymol, V41, P27; CHEN YR, 1995, J BIOL CHEM, V270, P11741, DOI 10.1074/jbc.270.20.11741; Cleland WW, 1998, CHEM REV, V98, P549, DOI 10.1021/cr970010r; Dai Y, 2001, BIOCHEMISTRY-US, V40, P6379, DOI 10.1021/bi010110y; Eisen JA, 2002, P NATL ACAD SCI USA, V99, P9509, DOI 10.1073/pnas.132181499; ELLIS RJ, 1979, TRENDS BIOCHEM SCI, V4, P241, DOI 10.1016/0968-0004(79)90212-3; Ezaki S, 1999, J BIOL CHEM, V274, P5078, DOI 10.1074/jbc.274.8.5078; FURFINE ES, 1988, J BIOL CHEM, V263, P9598; GRUNDY JF, 2002, BACILLUS SUBTILIS IT, P245; Hanson TE, 2001, P NATL ACAD SCI USA, V98, P4397, DOI 10.1073/pnas.081610398; Hartman H, 1998, ORIGINS LIFE EVOL B, V28, P515, DOI 10.1023/A:1006548904157; Heilbronn J, 1999, J BACTERIOL, V181, P1739, DOI 10.1128/JB.181.6.1739-1747.1999; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; LARSON EM, 1995, BIOCHEMISTRY-US, V34, P4531, DOI 10.1021/bi00014a005; Moszer I, 1999, CURR OPIN MICROBIOL, V2, P524, DOI 10.1016/S1369-5274(99)00011-9; Murphy BA, 2002, J BACTERIOL, V184, P2314, DOI 10.1128/JB.184.8.2314-2318.2002; MYERS RW, 1993, J BIOL CHEM, V268, P24785; Roy Harry, 2000, VVolume 9, P53; Sekowska A, 2001, BMC Microbiol, V1, P15, DOI 10.1186/1471-2180-1-15; Sekowska A, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-8; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; Watson GMF, 1997, FEMS MICROBIOL LETT, V146, P13, DOI 10.1016/S0378-1097(96)00417-X; Watson GMF, 1999, J BACTERIOL, V181, P1569, DOI 10.1128/JB.181.5.1569-1575.1999; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WRAY JW, 1995, J BIOL CHEM, V270, P3147, DOI 10.1074/jbc.270.7.3147	29	143	155	3	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					286	290		10.1126/science.1086997	http://dx.doi.org/10.1126/science.1086997			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	14551435				2022-12-24	WOS:000185825900042
J	Harper, SM; Neil, LC; Gardner, KH				Harper, SM; Neil, LC; Gardner, KH			Structural basis of a phototropin light switch	SCIENCE			English	Article							PHOTOACTIVE YELLOW PROTEIN; SIGNAL-TRANSDUCTION; RHIZOBIUM-MELILOTI; CHEMICAL-SHIFT; LOV2 DOMAIN; PAS DOMAIN; BINDING; RECEPTOR; KINASE; PHOTOCYCLE	Phototropins are light-activated kinases important for plant responses to blue light. Light initiates signaling in these proteins by generating a covalent protein . flavin mononucleotide (FMN) adduct within sensory Per-ARNT-Sim ( PAS) domains. We characterized the light-dependent changes of a phototropin PAS domain by solution nuclear magnetic resonance spectroscopy and found that an alpha helix located outside the canonical domain plays a key role in this activation process. Although this helix associates with the PAS core in the dark, photoinduced changes in the domain structure disrupt this interaction. We propose that this mechanism couples light-dependent bond formation to kinase activation and identifies a signaling pathway conserved among PAS domains.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gardner, KH (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Gardner, Kevin H./K-7802-2012; Gardner, Kevin/K-5493-2019	Gardner, Kevin H./0000-0002-8671-2556; 	NCI NIH HHS [CA90601] Funding Source: Medline; NIGMS NIH HHS [GM08297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Briggs WR, 2002, TRENDS PLANT SCI, V7, P204, DOI 10.1016/S1360-1385(02)02245-8; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Christie JM, 2002, PLANT J, V32, P205, DOI 10.1046/j.1365-313X.2002.01415.x; Corchnoy SB, 2003, J BIOL CHEM, V278, P724, DOI 10.1074/jbc.M209119200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Creighton T.E., 1984, PROTEINS STRUCTURE M; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; Crosson S, 2003, BIOCHEMISTRY-US, V42, P2, DOI 10.1021/bi026978l; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fedorov R, 2003, BIOPHYS J, V84, P2474, DOI 10.1016/S0006-3495(03)75052-8; GILLESGONZALEZ MA, 1993, J BIOL CHEM, V268, P16293; Harper S. R., UNPUB; Hellingwerf KJ, 2003, J PHYS CHEM A, V107, P1082, DOI 10.1021/jp027005y; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; MONSON EK, 1995, J BIOL CHEM, V270, P5243, DOI 10.1074/jbc.270.10.5243; Rubinstenn G, 1999, J MAGN RESON, V137, P443, DOI 10.1006/jmre.1999.1705; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; Rutter J, 2001, P NATL ACAD SCI USA, V98, P8991, DOI 10.1073/pnas.161284798; Sakamoto K, 2002, PLANT CELL, V14, P1723, DOI 10.1105/tpc.003293; Salomon M, 2000, BIOCHEMISTRY-US, V39, P9401, DOI 10.1021/bi000585+; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; Swartz TE, 2002, BIOCHEMISTRY-US, V41, P7183, DOI 10.1021/bi025861u; Swartz TE, 2001, J BIOL CHEM, V276, P36493, DOI 10.1074/jbc.M103114200; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; WISHART DS, 1994, J BIOMOL NMR, V4, P171	29	605	621	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1541	1544		10.1126/science.1086810	http://dx.doi.org/10.1126/science.1086810			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970567				2022-12-24	WOS:000185255300052
J	Hastings, A				Hastings, A			Metapopulation persistence with age-dependent disturbance or succession	SCIENCE			English	Article							CANADIAN BOREAL FOREST; LANDSCAPE-SCALE TEST; HABITAT DESTRUCTION; DYNAMICS; MANAGEMENT; COEXISTENCE; MODEL; BIRDS; FROG	Simple metapopulation models with random disturbances are used in species conservation or management, relying on the condition for persistence that the per-patch colonization rate be greater than the per-patch extinction rate. For a general model incorporating the role of succession or patch age - dependent extinction, I show that persistence requires the per-patch colonization rate to be greater than the inverse of mean patch age, where age is the time since the patch became available for colonization. Because mean patch age can be arbitrarily large relative to the extinction rate, currently persisting metapopulations may be persisting despite small colonization rates, and management approaches that do not consider the role of mean patch age may unnecessarily doom populations to extinction.	Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA	University of California System; University of California Davis	Hastings, A (corresponding author), Univ Calif Davis, Dept Environm Sci & Policy, 1 Shields Ave, Davis, CA 95616 USA.		Hastings, Alan/O-6864-2019; Hastings, Alan/A-7423-2008	Hastings, Alan/0000-0002-0717-8026; 				Amarasekare P, 2001, J THEOR BIOL, V209, P333, DOI 10.1006/jtbi.2001.2269; Bengtsson J, 2000, FOREST ECOL MANAG, V132, P39, DOI 10.1016/S0378-1127(00)00378-9; Bergeron Y, 2002, SILVA FENN, V36, P81, DOI 10.14214/sf.553; Bergeron Y, 2001, CAN J FOREST RES, V31, P384, DOI 10.1139/cjfr-31-3-384; Bergman KO, 2002, BIOL CONSERV, V108, P361, DOI 10.1016/S0006-3207(02)00104-0; Carlson A, 2000, P ROY SOC B-BIOL SCI, V267, P1311, DOI 10.1098/rspb.2000.1143; Ellner SP, 2003, ECOLOGY, V84, P882, DOI 10.1890/0012-9658(2003)084[0882:EOSDOM]2.0.CO;2; Feller W., 1971, INTRO PROBABILITY TH, V2; GULVE PS, 1994, ECOLOGY, V75, P1357, DOI 10.2307/1937460; Gyllenberg M, 1997, THEOR POPUL BIOL, V52, P198, DOI 10.1006/tpbi.1997.1333; Hanski I., 1999, METAPOPULATION ECOLO; HASTINGS A, 1994, ANNU REV ECOL SYST, V25, P167; HASTINGS A, 1991, BIOL J LINN SOC, V42, P57, DOI 10.1111/j.1095-8312.1991.tb00551.x; Johnson MP, 2000, P ROY SOC B-BIOL SCI, V267, P1967, DOI 10.1098/rspb.2000.1237; Johnson MP, 2000, OIKOS, V88, P67, DOI 10.1034/j.1600-0706.2000.880108.x; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; Lewis OT, 2001, CONSERV BIOL, V15, P389, DOI 10.1046/j.1523-1739.2001.015002389.x; Lindenmayer D, 2002, FOREST ECOL MANAG, V155, P319, DOI 10.1016/S0378-1127(01)00569-2; Lindenmayer DB, 2001, OIKOS, V92, P445, DOI 10.1034/j.1600-0706.2001.920306.x; Lindenmayer DB, 2001, J APPL ECOL, V38, P36, DOI 10.1046/j.1365-2664.2001.00558.x; NEE S, 1992, J ANIM ECOL, V61, P37, DOI 10.2307/5506; PAINE RT, 1981, ECOL MONOGR, V51, P145, DOI 10.2307/2937261; Poulsen BO, 2002, BIODIVERS CONSERV, V11, P1551, DOI 10.1023/A:1016839518172; PULLIAM HR, 1988, AM NAT, V132, P652, DOI 10.1086/284880; Richards SA, 1999, ECOL APPL, V9, P880, DOI 10.1890/1051-0761(1999)009[0880:OFMFMC]2.0.CO;2; Spence JR, 2001, TRENDS ECOL EVOL, V16, P591, DOI 10.1016/S0169-5347(01)02335-7; Stelter C, 1997, J ANIM ECOL, V66, P508, DOI 10.2307/5945; Wahlberg N, 2002, ECOGRAPHY, V25, P224, DOI 10.1034/j.1600-0587.2002.250210.x; Whitman AA, 1998, BIOTROPICA, V30, P449, DOI 10.1111/j.1744-7429.1998.tb00079.x	29	59	60	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1525	1526		10.1126/science.1087570	http://dx.doi.org/10.1126/science.1087570			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970563				2022-12-24	WOS:000185255300047
J	Murray, L; Watson, P; Johnston, B; Sloan, J; Mainie, IML; Gavin, A				Murray, L; Watson, P; Johnston, B; Sloan, J; Mainie, IML; Gavin, A			Risk of adenocarcinoma in Barrett's oesophagus: population based study	BRITISH MEDICAL JOURNAL			English	Article							CANCER-RISK; SURVEILLANCE		Queens Univ Belfast, Dept Epidemiol & Publ Hlth, No Ireland Canc Registry, Belfast BT12 6BJ, Antrim, North Ireland; Royal Hosp Trust, Belfast BT12 6BA, Antrim, North Ireland; Ulster Hosp, Belfast BT16 1RB, Antrim, North Ireland	Queens University Belfast	Murray, L (corresponding author), Queens Univ Belfast, Dept Epidemiol & Publ Hlth, No Ireland Canc Registry, Belfast BT12 6BJ, Antrim, North Ireland.							Conio M, 2001, GUT, V48, P304, DOI 10.1136/gut.48.3.304; Gross CP, 1999, AM J GASTROENTEROL, V94, P3440, DOI 10.1111/j.1572-0241.1999.01606.x; Macdonald CE, 2000, BMJ-BRIT MED J, V321, P1252, DOI 10.1136/bmj.321.7271.1252; Provenzale D, 1999, AM J GASTROENTEROL, V94, P2043; Shaheen NJ, 2000, GASTROENTEROLOGY, V119, P333, DOI 10.1053/gast.2000.9302	5	90	95	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					534	535		10.1136/bmj.327.7414.534	http://dx.doi.org/10.1136/bmj.327.7414.534			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958113	Green Published, Bronze			2022-12-24	WOS:000185283700018
J	Luo, HBR; Huang, YE; Chen, JMC; Saiardi, A; Iijima, M; Ye, KQ; Huang, YF; Nagata, E; Devreotes, P; Snyder, SH				Luo, HBR; Huang, YE; Chen, JMC; Saiardi, A; Iijima, M; Ye, KQ; Huang, YF; Nagata, E; Devreotes, P; Snyder, SH			Inositol pyrophosphates mediate chemotaxis in Dictyostelium via pleckstrin homology domain-PtdIns (3,4,5)P3 interactions	CELL			English	Article							DIPHOSPHOINOSITOL PENTAKISPHOSPHATE; SACCHAROMYCES-CEREVISIAE; HEXAKISPHOSPHATE KINASE/; SIGNAL-TRANSDUCTION; TUMOR-SUPPRESSOR; EXCHANGE FACTOR; LEADING-EDGE; PROTEIN; BINDING; CELLS	Inositol phosphates are well-known signaling molecules, whereas the inositol pyrophosphates, such as diphosphoinositol pentakisphosphate (InsP7/IP7) and bis-diphosphoinositol tetrakisphosphate (InsP8/IP8), are less well characterized. We demonstrate physiologic regulation of Dictyostelium chemotaxis by InsP7 mediated by its competition with PtdIns(3,4,5)P3 for binding pleckstrin homology (PH) domain-containing proteins. Chemoattractant stimulation triggers rapid and sustained elevations in InsP7/InsP8 levels. Depletion of InsP7 and InsP8 by deleting the gene for InsP6 kinase (InsP6K/IP6K), which converts inositol hexakisphosphate (InsP6/IP6) to InsP7, causes rapid aggregation of mutant cells and increased sensitivity to cAMP. Chemotaxis is mediated by membrane translocation of certain PH domain-containing proteins via specific binding to PtdIns(3,4,5)P3. InsP7 competes for PH domain binding with PtdIns(3,4,5)P3 both in vitro and in vivo. InsP7 depletion enhances PH domain membrane translocation and augments downstream chemotactic signaling activity.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Emory University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.				NIDA NIH HHS [DA-00074] Funding Source: Medline; NIGMS NIH HHS [GM-28007] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028007, R01GM028007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Couchman JR, 2002, J BIOL CHEM, V277, P49296, DOI 10.1074/jbc.M209679200; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; HUANG KN, 1995, GENETICS, V141, P1275; Huang YE, 2003, MOL BIOL CELL, V14, P1913, DOI 10.1091/mbc.E02-10-0703; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; KONIJN TM, 1970, EXPERIENTIA, V26, P367, DOI 10.1007/BF01896891; Laussmann T, 2000, EUR J BIOCHEM, V267, P2447, DOI 10.1046/j.1432-1327.2000.01264.x; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; Luo HR, 2001, NEURON, V31, P439, DOI 10.1016/S0896-6273(01)00384-1; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Williams RSB, 1999, EMBO J, V18, P2734, DOI 10.1093/emboj/18.10.2734; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	45	156	162	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 5	2003	114	5					559	572		10.1016/S0092-8674(03)00640-8	http://dx.doi.org/10.1016/S0092-8674(03)00640-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678580	Bronze			2022-12-24	WOS:000185193100006
J	Volkov, I; Banavar, JR; Hubbell, SP; Maritan, A				Volkov, I; Banavar, JR; Hubbell, SP; Maritan, A			Neutral theory and relative species abundance in ecology	NATURE			English	Article							SAMPLING THEORY	The theory of island biogeography(1) asserts that an island or a local community approaches an equilibrium species richness as a result of the interplay between the immigration of species from the much larger metacommunity source area and local extinction of species on the island (local community). Hubbell(2) generalized this neutral theory to explore the expected steady-state distribution of relative species abundance (RSA) in the local community under restricted immigration. Here we present a theoretical framework for the unified neutral theory of biodiversity(2) and an analytical solution for the distribution of the RSA both in the metacommunity (Fisher's log series) and in the local community, where there are fewer rare species. Rare species are more extinction-prone, and once they go locally extinct, they take longer to re-immigrate than do common species. Contrary to recent assertions(3), we show that the analytical solution provides a better fit, with fewer free parameters, to the RSA distribution of tree species on Barro Colorado Island, Panama(4), than the lognormal distribution(5,6).	Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Univ Georgia, Dept Plant Biol, Athens, GA 30602 USA; Smithsonian Trop Res Inst, Balboa, Panama; Scuola Int Super Studi Avanzati, SISSA, I-34014 Trieste, Italy; INFM, Trieste, Italy; Abdus Salam Int Ctr Theoret Phys, Trieste, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University System of Georgia; University of Georgia; Smithsonian Institution; Smithsonian Tropical Research Institute; International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Abdus Salam International Centre for Theoretical Physics (ICTP)	Banavar, JR (corresponding author), Penn State Univ, Dept Phys, 104 Davey Lab, University Pk, PA 16802 USA.	banavar@psu.edu; shubbell@dogwood.botany.uga.edu	Volkov, Igor/GVT-6571-2022	Maritan, Amos/0000-0002-3535-7873				[Anonymous], 1968, INTRO PROBABILITY TH; Bell G, 2001, SCIENCE, V293, P2413, DOI 10.1126/science.293.5539.2413; BOSWELL MT, 1979, STAT DISTRIBUTIONS E, P3; CARACO T, 1979, STATISTICAL DISTRIBU, P371; Chave J, 2002, AM NAT, V159, P1, DOI 10.1086/324112; Condit R, 2002, SCIENCE, V295, P666, DOI 10.1126/science.1066854; EWENS WJ, 1972, THEOR POPUL BIOL, V3, P87, DOI 10.1016/0040-5809(72)90035-4; Fisher RA, 1943, J ANIM ECOL, V12, P42, DOI 10.2307/1411; Hubbell Stephen P., 2001, V32, pi; KARLIN S, 1972, THEOR POPUL BIOL, V3, P113, DOI 10.1016/0040-5809(72)90036-6; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; Kimura M, 1985, NEUTRAL THEORY MOL E; Kimura M., 1971, THEORETICAL ASPECTS; MAC ARTHUR ROBERT H., 1967; MANOKARAN N, 1992, STAND TABLES SPECIES; May R.M., 1975, P81; McGill BJ, 2003, NATURE, V422, P881, DOI 10.1038/nature01583; McKane A, 2000, PHYS REV E, V62, P8466, DOI 10.1103/PhysRevE.62.8466; Morse P. M., 1953, METHODS THEORETICA 1; PRESS WH, 1993, NUMERICAL RECIPES C; PRESTON FW, 1948, ECOLOGY, V29, P254, DOI 10.2307/1930989; Rao C. R., 1971, STATISTICAL ECOLOGY, V1, P131; Roughgarden J, 1986, COMMUNITY ECOL, P333; Sugihara G, 2003, P NATL ACAD SCI USA, V100, P5246, DOI 10.1073/pnas.0831096100; TILMAN D, 1988; Van Kampen N G, 2001, STOCHASTIC PROCESSES; WATTERSON GA, 1974, THEOR POPUL BIOL, V6, P217, DOI 10.1016/0040-5809(74)90025-2; Weiher E., 1999, ECOLOGICAL ASSEMBLY	28	542	578	6	400	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2003	424	6952					1035	1037		10.1038/nature01883	http://dx.doi.org/10.1038/nature01883			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944964	Green Submitted			2022-12-24	WOS:000184984200038
J	Panageas, KS; Schrag, D; Riedel, E; Bach, PB; Begg, CB				Panageas, KS; Schrag, D; Riedel, E; Bach, PB; Begg, CB			The effect of clustering of outcomes on the association of procedure volume and surgical outcomes	ANNALS OF INTERNAL MEDICINE			English	Article							NEW-YORK-STATE; HOSPITAL VOLUME; SURGEON VOLUME; RADICAL PROSTATECTOMY; CANCER RESECTION; BREAST-CANCER; COLON-CANCER; MORTALITY; SURVIVAL; MODELS	Background: A large body of literature documents associations between the volume of cases a hospital or surgeon treats and clinical outcomes. Most of these studies have used conventional statistical methods that do not recognize the fact that hospitals or surgeons with similar volumes may have very different outcomes because of systematic differences in processes of care, a phenomenon that exaggerates the true statistical significance of the effect of volume on outcome. Objective: To describe methods to assess the degree of this "clustering" of outcomes and to explore the impact of available statistical techniques that correct for clustering. Design: Reanalysis of 3 previously published volume-outcome studies. Setting: Medicare beneficiaries 65 years of age or older undergoing surgery for colon, prostate, or rectal cancer in the population defined by the Surveillance, Epidemiology, and End Results cancer registries during 1992 to 1996. Patients: 3 data sets were analyzed to assess the impact of surgeon volume on outcomes: 1) 24 166 colectomies performed by 2682 surgeons, 2) 10 737 prostatectomies performed by 999 surgeons, and 3) 2603 rectal resections performed by 1141 surgeons. Measurements: Volume-outcome trends were analyzed by a conventional method (logistic regression) and corrected for clustering. Two widely used statistical methods for analyzing clustered data, a random-effects model and generalized estimating equations, were used and compared, and the degree of clustering was presented graphically. Results: Substantial clustering was observed in the analyses involving morbidity end points. The 2 statistical techniques produced noticeably different results in some analyses. Conclusions: The presence of clustering represents variations in outcomes among providers with similar volumes. Thus, in volume-outcome studies, the degree of clustering of outcomes should be characterized because it may provide insight into variations in quality of care.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Begg, CB (corresponding author), Mem Sloan Kettering Canc Ctr, 307 E 63rd St 3rd Floor, New York, NY 10021 USA.	beggc@mskcc.org		Schrag, Deborah/0000-0002-4334-5717	NCI NIH HHS [CA08748, CA83950, CA90226] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA090226, K07CA083950] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM MED ASS, 1999, CURR PROC TERM; ASHBY M, 1992, STAT MED, V11, P67, DOI 10.1002/sim.4780110108; Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Begg CB, 2003, J CLIN ONCOL, V21, P393, DOI 10.1200/JCO.2003.11.022; Begg CB, 2002, NEW ENGL J MED, V346, P1138, DOI 10.1056/NEJMsa011788; Birkmeyer JD, 1999, SURGERY, V126, P178, DOI 10.1067/msy.1999.98741; Birkmeyer JD, 2001, SURGERY, V130, P415, DOI 10.1067/msy.2001.117139; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; Choti M A, 1998, J Gastrointest Surg, V2, P11, DOI 10.1016/S1091-255X(98)80098-X; Dimick JB, 2001, ANN THORAC SURG, V72, P334, DOI 10.1016/S0003-4975(01)02781-3; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; Edwards EB, 1999, NEW ENGL J MED, V341, P2049, DOI 10.1056/NEJM199912303412703; Glasgow RE, 1999, ARCH SURG-CHICAGO, V134, P30, DOI 10.1001/archsurg.134.1.30; Glasgow RE, 1996, WESTERN J MED, V165, P294; GREEN SB, 1995, AM J EPIDEMIOL, V142, P587, DOI 10.1093/oxfordjournals.aje.a117679; Greenfield S, 2002, ANN INTERN MED, V136, P111, DOI 10.7326/0003-4819-136-2-200201150-00008; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Hannan EL, 1998, STROKE, V29, P2292, DOI 10.1161/01.STR.29.11.2292; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; Hu JC, 2003, J CLIN ONCOL, V21, P401, DOI 10.1200/JCO.2003.05.169; Kee F, 1999, BRIT MED J, V318, P1381, DOI 10.1136/bmj.318.7195.1381; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; McGrath PD, 2000, JAMA-J AM MED ASSOC, V284, P3139, DOI 10.1001/jama.284.24.3139; Polednak AP, 1999, AM J PUBLIC HEALTH, V89, P946, DOI 10.2105/AJPH.89.6.946; POTOSKY AL, 1993, MED CARE, V31, P732; RODRIGUEZ G, 1995, J ROY STAT SOC A STA, V158, P73, DOI 10.2307/2983404; Roohan PJ, 1998, AM J PUBLIC HEALTH, V88, P454, DOI 10.2105/AJPH.88.3.454; Schrag D, 2000, JAMA-J AM MED ASSOC, V284, P3028, DOI 10.1001/jama.284.23.3028; Schrag D, 2003, J SURG ONCOL, V83, P68, DOI 10.1002/jso.10244; Schrag D, 2002, ANN SURG, V236, P583, DOI 10.1097/00000658-200211000-00008; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; *WHO, 1990, INT CLASS DIS ONC; Yao SL, 1999, J NATL CANCER I, V91, P1950, DOI 10.1093/jnci/91.22.1950	42	275	276	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 21	2003	139	8					658	665		10.7326/0003-4819-139-8-200310210-00009	http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734DW	14568854				2022-12-24	WOS:000186040800004
J	Dahan, M; Levi, S; Luccardini, C; Rostaing, P; Riveau, B; Triller, A				Dahan, M; Levi, S; Luccardini, C; Rostaing, P; Riveau, B; Triller, A			Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking	SCIENCE			English	Article							LATERAL MOVEMENTS; IN-VIVO; SYNAPSES; GEPHYRIN; MEMBRANE; MICROSCOPY; NEURONS	Semiconductor quantum dots (QDs) are nanometer-sized fluorescent probes suitable for advanced biological imaging. We used QDs to track individual glycine receptors (GlyRs) and analyze their lateral dynamics in the neuronal membrane of living cells for periods ranging from milliseconds to minutes. We characterized multiple diffusion domains in relation to the synaptic, perisynaptic, or extrasynaptic GlyR localization. The entry of GlyRs into the synapse by diffusion was observed and further confirmed by electron microscopy imaging of QD-tagged receptors.	Ecole Normale Super, CNRS, UMR 8552, Lab Kastler Brossel, F-75005 Paris, France; Univ Paris 06, F-75005 Paris, France; Ecole Normale Super, INSERM, U497, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; College de France; Ecole Normale Superieure (ENS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Dahan, M (corresponding author), Ecole Normale Super, CNRS, UMR 8552, Lab Kastler Brossel, 24 Rue Lhomond, F-75005 Paris, France.		Dahan, Maxime/F-1740-2010; LEVI, SABINE/AAX-5607-2020	Levi, Sabine/0000-0002-9927-0945; TRILLER, Antoine/0000-0002-7530-1233; Dahan, Maxime/0000-0002-4943-2491				Borgdorff AJ, 2002, NATURE, V417, P649, DOI 10.1038/nature00780; Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194; Dumoulin A, 2000, EUR J NEUROSCI, V12, P3883, DOI 10.1046/j.1460-9568.2000.00271.x; Empedocles S, 1999, ACCOUNTS CHEM RES, V32, P389, DOI 10.1021/ar9501939; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Gready JE, 1997, PROTEIN SCI, V6, P983, DOI 10.1002/pro.5560060504; Harms GS, 2001, BIOPHYS J, V80, P2396, DOI 10.1016/S0006-3495(01)76209-1; HARVEY K, 2002, RECEPTOR ION CHANNEL, pCH8; HURTLEY SM, 2003, SCIENCE, V300; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; Rasmussen H, 2002, MOL CELL NEUROSCI, V19, P201, DOI 10.1006/mcne.2001.1074; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; SCHRODER S, 1991, BIOCHEMISTRY-US, V30, P42, DOI 10.1021/bi00215a007; Serge A, 2002, J NEUROSCI, V22, P3910, DOI 10.1523/JNEUROSCI.22-10-03910.2002; Tardin C, 2003, EMBO J, V22, P4656, DOI 10.1093/emboj/cdg463; Thompson RE, 2002, BIOPHYS J, V82, P2775, DOI 10.1016/S0006-3495(02)75618-X; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; Ueda M, 2001, SCIENCE, V294, P864, DOI 10.1126/science.1063951; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764	25	1220	1284	2	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					442	445		10.1126/science.1088525	http://dx.doi.org/10.1126/science.1088525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14564008				2022-12-24	WOS:000185963200042
J	Nam, JM; Thaxton, CS; Mirkin, CA				Nam, JM; Thaxton, CS; Mirkin, CA			Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins	SCIENCE			English	Article							PROSTATE-SPECIFIC ANTIGEN; POLYMERASE-CHAIN-REACTION; IMMUNO-PCR; DNA; ASSAY; TIME; AMPLIFICATION; DIAGNOSIS	An ultrasensitive method for detecting protein analytes has been developed. The system relies on magnetic microparticle probes with antibodies that specifically bind a target of interest [prostate-specific antigen (PSA) in this case] and nanoparticle probes that are encoded with DNA that is unique to the protein target of interest and antibodies that can sandwich the target captured by the microparticle probes. Magnetic separation of the complexed probes and target followed by dehybridization of the oligonucleotides on the nanoparticle probe surface allows the determination of the presence of the target protein by identifying the oligonucleotide sequence released from the nanoparticle probe. Because the nanoparticle probe carries with it a large number of oligonucleotides per protein binding event, there is substantial amplification and PSA can be detected at 30 attomolar concentration. Alternatively, a polymerase chain reaction on the oligonucleotide bar codes can boost the sensitivity to 3 attomolar. Comparable clinically accepted conventional assays for detecting the same target have sensitivity limits of similar to3 picomdar, six orders of magnitude less sensitive than what is observed with this method.	Northwestern Univ, Dept Chem, Evanston, IL 60201 USA; Northwestern Univ, Inst Nanotechnol, Evanston, IL 60201 USA	Northwestern University; Northwestern University	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60201 USA.		Nam, Jwa-Min/F-2062-2019; Abrams, William R/A-5782-2008; Mirkin, Chad A/E-3911-2010	Nam, Jwa-Min/0000-0002-7891-8482; Mirkin, Chad/0000-0002-6634-7627				Black MH, 2000, CLIN CANCER RES, V6, P467; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536; Demers LM, 2000, ANAL CHEM, V72, P5535, DOI 10.1021/ac0006627; Ferguson RA, 1996, CLIN CHEM, V42, P675; GIBBS RA, 1991, CURR OPIN BIOTECH, V2, P69, DOI 10.1016/0958-1669(91)90063-B; Haab BB, 2001, GENOME BIOL, V2; HENDRICKSON ER, 1995, NUCLEIC ACIDS RES, V23, P522, DOI 10.1093/nar/23.3.522; MacBeath G, 2000, SCIENCE, V289, P1760; McKie A, 2002, J IMMUNOL METHODS, V270, P135, DOI 10.1016/S0022-1759(02)00325-3; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Nam JM, 2002, J AM CHEM SOC, V124, P3820, DOI 10.1021/ja0178766; Niemeyer CM, 1999, NUCLEIC ACIDS RES, V27, P4553, DOI 10.1093/nar/27.23.4553; Niemeyer CM, 2002, TRENDS BIOTECHNOL, V20, P395, DOI 10.1016/S0167-7799(02)02022-X; Ries LA, 2002, SEER CANC STAT REV 1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758; Schweitzer B, 2000, P NATL ACAD SCI USA, V97, P10113, DOI 10.1073/pnas.170237197; STANFORD JL, 1999, NIH PUBLICATION; Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757; YU H, 1995, CLIN CHEM, V41, P430; ZHOU H, 1993, NUCLEIC ACIDS RES, V21, P6038, DOI 10.1093/nar/21.25.6038; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	23	2142	2302	22	936	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1884	1886		10.1126/science.1088755	http://dx.doi.org/10.1126/science.1088755			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512622				2022-12-24	WOS:000185536700044
J	Coureux, PD; Wells, AL; Menetry, J; Yengo, CM; Morris, CA; Sweeney, HL; Houdusse, A				Coureux, PD; Wells, AL; Menetry, J; Yengo, CM; Morris, CA; Sweeney, HL; Houdusse, A			A structural state of the myosin V motor without bound nucleotide	NATURE			English	Article							SMOOTH-MUSCLE MYOSIN; X-RAY STRUCTURES; CRYSTAL-STRUCTURE; LIGHT-CHAIN; ACTIN; BINDING; SUBFRAGMENT-1; DOMAIN; DELETION; CLOSURE	The myosin superfamily of molecular motors use ATP hydrolysis and actin-activated product release to produce directed movement and force(1). Although this is generally thought to involve movement of a mechanical lever arm attached to a motor core(1,2), the structural details of the rearrangement in myosin that drive the lever arm motion on actin attachment are unknown. Motivated by kinetic evidence that the processive unconventional myosin, myosin V, populates a unique state in the absence of nucleotide and actin, we obtained a 2.0 Angstrom structure of a myosin V fragment. Here we reveal a conformation of myosin without bound nucleotide. The nucleotide-binding site has adopted new conformations of the nucleotide-binding elements that reduce the affinity for the nucleotide. The major cleft in the molecule has closed, and the lever arm has assumed a position consistent with that in an actomyosin rigor complex. These changes have been accomplished by relative movements of the subdomains of the molecule, and reveal elements of the structural communication between the actin-binding interface and nucleotide-binding site of myosin that underlie the mechanism of chemo-mechanical transduction.	CNRS, UMR 144, Inst Curie, F-75248 Paris 05, France; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; University of Pennsylvania	Houdusse, A (corresponding author), CNRS, UMR 144, Inst Curie, 26 Rue Ulm, F-75248 Paris 05, France.	lsweeney@mail.med.upenn.edu; anne.houdusse@curie.fr	Sweeney, H Lee/F-1862-2010; Ménétrey, Julie/AAM-6408-2021					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer CB, 2000, J BIOL CHEM, V275, P38494, DOI 10.1074/jbc.M005585200; COATES JH, 1985, BIOCHEM J, V232, P351, DOI 10.1042/bj2320351; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Houdusse A, 2001, CURR OPIN STRUC BIOL, V11, P182, DOI 10.1016/S0959-440X(00)00188-3; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kollmar M, 2002, EMBO J, V21, P2517, DOI 10.1093/emboj/21.11.2517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sasaki N, 1999, J BIOL CHEM, V274, P37840, DOI 10.1074/jbc.274.53.37840; Sasaki N, 2000, J BIOL CHEM, V275, P38705, DOI 10.1074/jbc.M001966200; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; Titus MA, 1997, CURR BIOL, V7, pR301, DOI 10.1016/S0960-9822(06)00143-6; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u	30	238	239	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					419	423		10.1038/nature01927	http://dx.doi.org/10.1038/nature01927			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508494				2022-12-24	WOS:000185502300046
J	Winickoff, DE; Winickoff, RN				Winickoff, DE; Winickoff, RN			The charitable trust as a model for genomic biobanks	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INFORMED CONSENT; TISSUE		Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard University; Massachusetts General Hospital	Winickoff, DE (corresponding author), Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA.							Annas GJ, 2000, NEW ENGL J MED, V342, P1830, DOI 10.1056/NEJM200006153422412; Annas GJ, 2001, JAMA-J AM MED ASSOC, V286, P2326, DOI 10.1001/jama.286.18.2326; Ashburn TT, 2000, ARCH INTERN MED, V160, P3377, DOI 10.1001/archinte.160.22.3377; Barnes M, 2002, J LAW MED ETHICS, V30, P390, DOI 10.1111/j.1748-720X.2002.tb00408.x; Beskow LM, 2001, JAMA-J AM MED ASSOC, V286, P2315, DOI 10.1001/jama.286.18.2315; BOGERT GG, 1992, LAW TRUSTS TRUSTEES, P323; CONNOLLY A, 2002, BOSTON BUSINESS 1122; Eiseman E., 1999, HDB HUMAN TISSUE SOU; Faden Ruth R., 1986, HIST THEORY INFORMED, P151; GOTTLIEB K, 1998, STORED TISSUE SAMPLE; Greely H T, 1999, Wake Forest Law Rev, V34, P737; Greely H T, 1997, Houst Law Rev, V33, P1397; Harrison CH, 2002, AM J LAW MED, V28, P77; Jeffers BR, 2001, ADV NURS SCI, V24, P32, DOI 10.1097/00012272-200112000-00005; Kaiser J, 2002, SCIENCE, V298, P1158, DOI 10.1126/science.298.5596.1158; KOLATA G, 2000, NY TIMES        0317, pA1; Malone T, 2002, J NATL CANCER I, V94, P769; *NAT BIOETH ADV CO, 2001, ETH POL ISS RES INV, pR17; *NAT RES COUNC COM, 1997, EV HUM GEN DIV; National Bioethics Advisory Commission, 1999, RES INV HUM BIOL MAT; Nelkin D, 1998, HASTINGS CENT REP, V28, P30, DOI 10.2307/3528230; *OFF INSP GEN, 1998, I REV BOARDS EM IND; *OFF INSP GEN, 1998, I REV BOARDS TIM REF; Olden K, 2000, NAT REV GENET, V1, P149, DOI 10.1038/35038586; Rose Hilary, 2001, COMMODIFICATION BIOI; Rosenberg R., 2001, BOSTON GLOBE    0221, pD4; Rothstein MA, 2002, J LAW MED ETHICS, V30, P105, DOI 10.1111/j.1748-720X.2002.tb00726.x; Shalala D, 2000, NEW ENGL J MED, V343, P808, DOI 10.1056/NEJM200009143431112; Singer Joseph, 2000, ENTITLEMENT PARADOXE, p[29, 38]; Smaglik P, 2000, NATURE, V407, P821, DOI 10.1038/35038209; Steinbrook R, 2002, NEW ENGL J MED, V346, P1842, DOI 10.1056/NEJMp020046; Steinbrook R, 2002, NEW ENGL J MED, V346, P1425, DOI 10.1056/NEJM200205023461828; Winickoff David E, 2003, Jurimetrics, V43, P187	33	141	141	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1180	1184		10.1056/NEJMsb030036	http://dx.doi.org/10.1056/NEJMsb030036			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	722HQ	13679534				2022-12-24	WOS:000185369700014
J	Bertomeu, A; Garcia-Vidal, O; Farre, X; Galobart, A; Vazquez, M; Laguna, JC; Ros, E				Bertomeu, A; Garcia-Vidal, O; Farre, X; Galobart, A; Vazquez, M; Laguna, JC; Ros, E			Preclinical coronary atherosclerosis in a population with low incidence of myocardial infarction: cross sectional autopsy study	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE MORTALITY		Inst Med Legal Catalunya, E-08911 Badalona, Spain; Hosp St Jaume, E-08370 Barcelona, Spain; Ctr Nacl Invest Oncol, E-28029 Madrid, Spain; Hosp Municipal Badalona, E-08911 Badalona, Spain; Univ Barcelona, Fac Farm, Dept Farmacol, E-08028 Barcelona, Spain; Inst Invest Biomed August Pi & Sunyer, Serv Nutr & Dietet, Unidad Lipidos, E-08036 Barcelona, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bertomeu, A (corresponding author), Inst Med Legal Catalunya, C Prim 32-40, E-08911 Badalona, Spain.		Vázquez-Carrera, Manuel/H-2612-2015; Laguna, JCLaguna - Juan C./C-5481-2017; Farré, Xavier/M-9768-2014	Vázquez-Carrera, Manuel/0000-0001-7138-8207; Laguna, JCLaguna - Juan C./0000-0002-7082-0704; Farré, Xavier/0000-0001-8702-4643; Ros, Emilio/0000-0002-2573-1294				ALVAREZ FV, 2003, ENFERMEDADES CARDIOV; Law M, 1999, BRIT MED J, V318, P1471, DOI 10.1136/bmj.318.7196.1471; MARRUGAT J, 1998, CARDIOVASCULAR RISK, V8, P196; McGill HC, 2000, AM J CLIN NUTR, V72, p1307S, DOI 10.1093/ajcn/72.5.1307s; Tunstall-Pedoe H, 2000, LANCET, V355, P688, DOI 10.1016/S0140-6736(99)11181-4	5	21	21	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					591	592		10.1136/bmj.327.7415.591	http://dx.doi.org/10.1136/bmj.327.7415.591			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969923	Bronze, Green Published			2022-12-24	WOS:000185358700019
J	Schadt, CW; Martin, AP; Lipson, DA; Schmidt, SK				Schadt, CW; Martin, AP; Lipson, DA; Schmidt, SK			Seasonal dynamics of previously unknown fungal lineages in tundra soils	SCIENCE			English	Article							ALPINE ECOSYSTEM; CO2 EFFLUX; DIVERSITY; EVOLUTION; NITROGEN; BUDGETS; WINTER; N2O	The finding that microbial communities are active under snow has changed the estimated global rates of biogeochemical processes beneath seasonal snow packs. We used microbiological and molecular techniques to elucidate the phylogenetic composition of undersnow microbial communities in Colorado, the United States. Here, we show that tundra soil microbial biomass reaches its annual peak under snow, and that fungi account for most of the biomass. Phylogenetic analysis of tundra soil fungi revealed a high diversity of fungi and three novel clades that constitute major new groups of fungi (divergent at the subphylum or class level). An abundance of previously unknown fungi that are active beneath the snow substantially broadens our understanding of both the diversity and biogeochemical functioning of fungi in cold environments.	Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	University of Colorado System; University of Colorado Boulder; California State University System; San Diego State University	Schmidt, SK (corresponding author), Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA.		Schadt, Christopher/M-8746-2019; Schadt, Christopher W./B-7143-2008; Schmidt, Steven K/G-2771-2010	Schadt, Christopher/0000-0001-8759-2448; Schadt, Christopher W./0000-0001-8759-2448; Schmidt, Steven K/0000-0002-9175-2085				Brooks PD, 1997, OECOLOGIA, V110, P403, DOI 10.1007/s004420050175; Brown J.H., 1998, BIOGEOGRAPHY; Eriksson OE., 2001, MYCONET, V7, P1; Fahnestock JT, 1999, GLOBAL BIOGEOCHEM CY, V13, P775, DOI 10.1029/1999GB900006; Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889; Jaeger CH, 1999, ECOLOGY, V80, P1883, DOI 10.1890/0012-9658(1999)080[1883:SPONBP]2.0.CO;2; Lipson DA, 2002, MICROB ECOL, V43, P307, DOI 10.1007/s00248-001-1057-x; Lipson DA, 1999, ECOLOGY, V80, P1623; LIPSON DA, UNPUB; MELILLO JM, 1995, GLOBAL BIOGEOCHEM CY, V9, P407; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; SCHADT CW, UNPUB; SCHMIDT SK, IN PRESS BIOGEOCHEMI; SOMMERFELD RA, 1993, NATURE, V361, P140, DOI 10.1038/361140a0; Vandenkoornhuyse P, 2002, SCIENCE, V295, P2051, DOI 10.1126/science.295.5562.2051; VILGALYS R, COMMUNICATION; Zimov SA, 1996, CLIMATIC CHANGE, V33, P111, DOI 10.1007/BF00140516	18	445	505	5	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1359	1361		10.1126/science.1086940	http://dx.doi.org/10.1126/science.1086940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958355				2022-12-24	WOS:000185116400035
J	Ojo, AO; Held, PJ; Port, FK; Wolfe, RA; Leichtman, AB; Young, EW; Arndorfer, J; Christensen, L; Merion, RM				Ojo, AO; Held, PJ; Port, FK; Wolfe, RA; Leichtman, AB; Young, EW; Arndorfer, J; Christensen, L; Merion, RM			Chronic renal failure after transplantation of a nonrenal organ	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYCLOSPORINE NEPHROTOXICITY; LIVER-TRANSPLANTATION; CARDIAC TRANSPLANTATION; HEART-TRANSPLANTATION; RISK-FACTORS; RECIPIENTS; TACROLIMUS; INSUFFICIENCY; IMPAIRMENT; SURVIVAL	Background: Transplantation of nonrenal organs is often complicated by chronic renal disease with multifactorial causes. We conducted a population-based cohort analysis to evaluate the incidence of chronic renal failure, risk factors for it, and the associated hazard of death in recipients of nonrenal transplants. Methods: Pretransplantation and post-transplantation clinical variables and data from a registry of patients with end-stage renal disease (ESRD) were linked in order to estimate the cumulative incidence of chronic renal failure (defined as a glomerular filtration rate of 29 ml per minute per 1.73 m(2) of body-surface area or less or the development of ESRD) and the associated risk of death among 69,321 persons who received nonrenal transplants in the United States between 1990 and 2000. Results: During a median follow-up of 36 months, chronic renal failure developed in 11,426 patients (16.5 percent). Of these patients, 3297 (28.9 percent) required maintenance dialysis or renal transplantation. The five-year risk of chronic renal failure varied according to the type of organ transplanted -- from 6.9 percent among recipients of heart-lung transplants to 21.3 percent among recipients of intestine transplants. Multivariate analysis indicated that an increased risk of chronic renal failure was associated with increasing age (relative risk per 10-year increment, 1.36; P<0.001), female sex (relative risk among male patients as compared with female patients, 0.74; P<0.001), pretransplantation hepatitis C infection (relative risk, 1.15; P<0.001), hypertension (relative risk, 1.18; P<0.001), diabetes mellitus (relative risk, 1.42; P<0.001), and postoperative acute renal failure (relative risk, 2.13; P<0.001). The occurrence of chronic renal failure significantly increased the risk of death (relative risk, 4.55; P<0.001). Treatment of ESRD with kidney transplantation was associated with a five-year risk of death that was significantly lower than that associated with dialysis (relative risk, 0.56; P=0.02). Conclusions: The five-year risk of chronic renal failure after transplantation of a nonrenal organ ranges from 7 to 21 percent, depending on the type of organ transplanted. The occurrence of chronic renal failure among patients with a nonrenal transplant is associated with an increase by a factor of more than four in the risk of death.	Univ Michigan, Sch Med, Div Nephrol, Sci Registry Transplant Recipients, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ojo, AO (corresponding author), Univ Michigan, Sch Med, Div Nephrol, Sci Registry Transplant Recipients, 3914 Taubman Ctr,Box 0364, Ann Arbor, MI 48109 USA.	aojo@umich.edu			NIDDK NIH HHS [K24 DK62234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK062234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arend SM, 1997, NEPHROL DIAL TRANSPL, V12, P1672, DOI 10.1093/ndt/12.8.1672; Baid S, 2000, TRANSPLANTATION, V70, P255, DOI 10.1097/00007890-200007270-00001; Bennett WM, 1996, INT J CLIN PHARM TH, V34, P515; Bennett WM, 1996, KIDNEY INT, V50, P1089, DOI 10.1038/ki.1996.415; Brown RS, 1996, TRANSPLANTATION, V62, P1788, DOI 10.1097/00007890-199612270-00018; BRUNNER FP, 1988, NEPHROL DIAL TRANSPL, V3, P585, DOI 10.1093/oxfordjournals.ndt.a091710; Coopersmith CM, 2001, SURGERY, V130, P457, DOI 10.1067/msy.2001.115834; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; English RF, 2002, AM J TRANSPLANT, V2, P769, DOI 10.1034/j.1600-6143.2002.20811.x; Fisher NC, 1998, TRANSPLANTATION, V66, P59, DOI 10.1097/00007890-199807150-00010; GARCIAGARCIA G, 1985, AM J KIDNEY DIS, V5, P10, DOI 10.1016/S0272-6386(85)80129-3; Goldstein DJ, 1997, TRANSPLANTATION, V63, P664, DOI 10.1097/00007890-199703150-00009; GONWA TA, 1992, J HEART LUNG TRANSPL, V11, P926; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; GREENBERG A, 1987, AM J KIDNEY DIS, V9, P12, DOI 10.1016/S0272-6386(87)80156-7; GREENBERG A, 1990, TRANSPLANTATION, V50, P589, DOI 10.1097/00007890-199010000-00012; Israni A, 2002, AM J KIDNEY DIS, V39, DOI 10.1053/ajkd.2002.31427; IWATSUKI S, 1984, TRANSPLANT P, V17, P191; Kasiske BL, 1998, AM J KIDNEY DIS, V32, pS142, DOI 10.1053/ajkd.1998.v32.pm9820472; KASISKE BL, 1993, MINER ELECTROL METAB, V19, P186; Khanna A, 2002, KIDNEY INT, V62, P2257, DOI 10.1046/j.1523-1755.2002.00668.x; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; MAUGER EA, 1995, STAT MED, V14, P1553, DOI 10.1002/sim.4780141406; MCCAULEY J, 1990, NEPHRON, V55, P121, DOI 10.1159/000185938; MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018; Molmenti EP, 2001, TRANSPLANTATION, V71, P267, DOI 10.1097/00007890-200101270-00018; MYERS BD, 1986, KIDNEY INT, V30, P964, DOI 10.1038/ki.1986.280; MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103; *NAT I DIAB DIG KI, 2001, REN DAT SYST USRDS 2, P204; PATTISON JM, 1995, AM J KIDNEY DIS, V26, P643, DOI 10.1016/0272-6386(95)90602-9; PLATZ KP, 1994, TRANSPLANTATION, V58, P170, DOI 10.1097/00007890-199405820-00007; PORAYKO MK, 1995, TRANSPLANT P, V27, P1114; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; PUSCHETT JB, 1990, AM J NEPHROL, V10, P296, DOI 10.1159/000168123; RIMOLA A, 1987, GASTROENTEROLOGY, V93, P148, DOI 10.1016/0016-5085(87)90327-1; Ruilope LM, 2001, J AM COLL CARDIOL, V38, P1782, DOI 10.1016/S0735-1097(01)01627-8; SAKHUJA V, 1995, TRANSPL P, V27, P2728; Satchithananda DK, 2002, J HEART LUNG TRANSPL, V21, P651, DOI 10.1016/S1053-2498(01)00411-9; Sehgal AR, 1998, AM J KIDNEY DIS, V31, P593, DOI 10.1053/ajkd.1998.v31.pm9531174; SEHGAL V, 1995, AM J KIDNEY DIS, V26, P193, DOI 10.1016/0272-6386(95)90174-4; Shlipak MG, 2002, ANN INTERN MED, V137, P555, DOI 10.7326/0003-4819-137-7-200210010-00006; Trompeter R, 2002, PEDIATR NEPHROL, V17, P141, DOI 10.1007/s00467-001-0795-9; van Gelder T, 1998, NEPHROL DIAL TRANSPL, V13, P2322, DOI 10.1093/ndt/13.9.2322; VANBUREN DH, 1994, J AM SOC NEPHROL, V4, pS17; Waller JR, 2002, TRANSPLANT P, V34, P1587, DOI 10.1016/S0041-1345(02)03033-6; WASER M, 1993, J HEART LUNG TRANSPL, V12, P846; WHEATLEY HC, 1987, TRANSPLANTATION, V43, P641, DOI 10.1097/00007890-198705000-00007; Wilkinson AH, 1999, J AM SOC NEPHROL, V10, P1136; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; YOUNG EW, 1994, KIDNEY INT, V46, P1216, DOI 10.1038/ki.1994.387; ZALTZMAN JS, 1992, TRANSPLANTATION, V54, P875, DOI 10.1097/00007890-199211000-00021	51	1600	1645	1	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					931	940		10.1056/NEJMoa021744	http://dx.doi.org/10.1056/NEJMoa021744			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954741	Bronze			2022-12-24	WOS:000185081400004
J	Nurse, P				Nurse, P			Understanding cells	NATURE			English	Editorial Material									Canc Res UK, Cell Cycle Lab, London WC2A 3PX, England	Cancer Research UK	Nurse, P (corresponding author), Canc Res UK, Cell Cycle Lab, Lincolns Inn Fields, London WC2A 3PX, England.							BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bray D, 2002, P NATL ACAD SCI USA, V99, P7, DOI 10.1073/pnas.022641699; Guet CC, 2002, SCIENCE, V296, P1466, DOI 10.1126/science.1067407; Kauffman S. A., 1993, ORIGINS ORDER SELF O; NOVAK B, 1993, J CELL SCI, V106, P1153; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6	6	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					883	883		10.1038/424883a	http://dx.doi.org/10.1038/424883a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931164	Bronze			2022-12-24	WOS:000184843600019
J	Khot, UN; Khot, MB; Bajzer, CT; Sapp, SK; Ohman, EM; Brener, SJ; Ellis, SG; Lincoff, AM; Topol, EJ				Khot, UN; Khot, MB; Bajzer, CT; Sapp, SK; Ohman, EM; Brener, SJ; Ellis, SG; Lincoff, AM; Topol, EJ			Prevalence of conventional risk factors in. patients with coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; DIRECTIONAL ATHERECTOMY; ATHEROSCLEROSIS RISK; PRIMARY PREVENTION; DIABETES-MELLITUS; FOLLOW-UP; MORTALITY; STROKE	Context It is commonly suggested that more than 50% of patients with coronary heart disease (CHD) lack any of the conventional risk factors (cigarette smoking, diabetes, hyperlipidemia, and hypertension). This claim implies that other factors play a significant role in CHID and has led to considerable interest in nontraditional risk factors and genetic causes of CHD. Objective To determine the prevalence of the 4 conventional risk factors among patients with CHD. Design, Setting, and Patients In 2002-2003, we analyzed data for 122458 patients enrolled in 14 international randomized clinical trials of CHD conducted during the prior decade. Patients included 76716 with ST-elevation myocardial infarction, 35527 with unstable angina/non-ST-elevation myocardial infarction, and 10215 undergoing percutaneous coronary intervention. Main Outcome Measures Prevalence of each conventional risk factor and number of conventional risk factors present among patients with CHID, compared between men and women and by age at trial entry. Results Among patients with CHD, at least 1 of the 4 conventional risk factors was present in 84.6% of women and 80.6% of men. In younger patients (men : :55 years and women : 65 years) and most patients presenting either with unstable angina or for percutaneous coronary intervention, only 10% to 15% of patients lacked any of the 4 conventional risk factors. This pattern was largely independent of sex, geographic region, trial entry criteria, or prior CHD. Premature CHD was related to cigarette smoking in men and cigarette smoking and diabetes in women. Smoking decreased the age at the time of CHD event (at trial entry) by nearly 1 decade in all risk factor combinations. Conclusions In direct contrast with conventional,thinking, 80% to 90% of patients with CHID have conventional risk factors. Although research on nontraditional risk factors and genetic causes of heart disease is important, clinical medicine, public health policies, and research efforts should place significant emphasis on the 4 conventional risk factors and the lifestyle behaviors causing them to reduce the epidemic of CHD.	Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Univ N Carolina, Sch Med, Dept Med, Div Cardiol, Chapel Hill, NC USA	Cleveland Clinic Foundation; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Khot, UN (corresponding author), Indiana Heart Phys, 112 N 17th Ave,Suite 300, Beech Grove, IN 46107 USA.	khot@cvresearch.net	Manoj, Deepa/AAE-7083-2021	Topol, Eric/0000-0002-1478-4729				ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BOWLIN SJ, 1993, J CLIN EPIDEMIOL, V46, P561, DOI 10.1016/0895-4356(93)90129-O; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Dobs AS, 1999, AM J EPIDEMIOL, V150, P1055, DOI 10.1093/oxfordjournals.aje.a009929; Fager G, 1997, ARTERIOSCL THROM VAS, V17, P3527, DOI 10.1161/01.ATV.17.12.3527; Franse LV, 2001, DIABETES CARE, V24, P2065, DOI 10.2337/diacare.24.12.2065; Futterman L G, 1998, Am J Crit Care, V7, P240; Grundy SM, 1998, CIRCULATION, V97, P1876, DOI 10.1161/01.CIR.97.18.1876; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Harrington RA, 2002, CIRCULATION, V105, P316; Hennekens CH, 1998, CIRCULATION, V97, P1095, DOI 10.1161/01.CIR.97.11.1095; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HOLMES DR, 1995, CIRCULATION, V91, P1966, DOI 10.1161/01.CIR.91.7.1966; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; Hyman DJ, 2000, ARCH INTERN MED, V160, P2281, DOI 10.1001/archinte.160.15.2281; JEFFREY S, INTER HEART LARGEST; Jha P, 1996, J AM COLL CARDIOL, V27, P1335, DOI 10.1016/0735-1097(96)00018-6; Jomini V, 2002, J AM COLL CARDIOL, V40, P676, DOI 10.1016/S0735-1097(02)02017-X; Kannel WB, 1998, AM HEART J, V136, P205, DOI 10.1053/hj.1998.v136.90226; Kannel William B, 2002, Am J Geriatr Cardiol, V11, P101, DOI 10.1111/j.1076-7460.2002.00995.x; Keil U, 1998, EUR HEART J, V19, P1197, DOI 10.1053/euhj.1998.1089; KNOPP RH, 2002, TXB CARDIOVASCULAR M, P175; Lefkowitz RJ, 2001, JAMA-J AM MED ASSOC, V285, P581, DOI 10.1001/jama.285.5.581; Levi F, 2002, HEART, V88, P119, DOI 10.1136/heart.88.2.119; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Magnus P, 2001, ARCH INTERN MED, V161, P2657, DOI 10.1001/archinte.161.22.2657; McKechnie RS, 2002, ACC CURR J REV, V11, P32; NIETO FJ, 1995, ARCH INTERN MED, V155, P677, DOI 10.1001/archinte.155.7.677; Norhammar A, 2002, LANCET, V359, P2140, DOI 10.1016/S0140-6736(02)09089-X; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; Prasad A, 2002, CIRCULATION, V106, P184, DOI 10.1161/01.CIR.0000021125.83697.21; Prevention CfDCa, 2000, BEH RISK FACT SURV S; ROBINSON K, 2002, TXB CARDIOVASCULAR M, P200; Simoons ML, 1997, LANCET, V349, P1429; Simoons ML, 2001, LANCET, V357, P1915; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; Tavazzi L, 1999, AM HEART J, V138, pS48, DOI 10.1016/S0002-8703(99)70320-0; Tcheng JE, 1997, LANCET, V349, P1422; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Topol EJ, 1996, NEW ENGL J MED, V335, P775; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; Topol EJ, 2001, LANCET, V357, P1905; *US DEP HHS, 1990, DHHS PUBL CDC; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; WORTH RM, 1975, AM J EPIDEMIOL, V102, P481, DOI 10.1093/oxfordjournals.aje.a112186	55	974	1039	2	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					898	904		10.1001/jama.290.7.898	http://dx.doi.org/10.1001/jama.290.7.898			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928466				2022-12-24	WOS:000184828800026
J	Lee, KH; Dinner, AR; Tu, C; Campi, G; Raychaudhuri, S; Varma, R; Sims, TN; Burack, WR; Wu, H; Kanagawa, O; Markiewicz, M; Allen, PM; Dustin, ML; Chakraborty, AK; Shaw, AS				Lee, KH; Dinner, AR; Tu, C; Campi, G; Raychaudhuri, S; Varma, R; Sims, TN; Burack, WR; Wu, H; Kanagawa, O; Markiewicz, M; Allen, PM; Dustin, ML; Chakraborty, AK; Shaw, AS			The immunological synapse balances T cell receptor signaling and degradation	SCIENCE			English	Article							CD2-ASSOCIATED PROTEIN; ANTIGEN RECEPTOR; DOWN-MODULATION; ACTIVATION; DYNAMICS; TRANSDUCTION; STIMULATION; SPECIFICITY; COMPLEXES	The immunological synapse is a specialized cell-cell junction between T cell and antigen-presenting cell surfaces. It is characterized by a central cluster of antigen receptors, a ring of integrin family adhesion molecules, and temporal stability over hours. The role of this specific organization in signaling for T cell activation has been controversial. We use in vitro and in silico experiments to determine that the immunological synapse acts as a type of adaptive controller that both boosts T cell receptor triggering and attenuates strong signals.	NYU, Skirball Inst Biomol Med, Program Mol Pathogenesis, New York, NY 10016 USA; NYU, Dept Pathol, New York, NY 10016 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci & Mat Sci Div, Berkeley, CA 94720 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA	New York University; New York University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Washington University (WUSTL); Roche Holding; Genentech; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Dustin, ML (corresponding author), NYU, Skirball Inst Biomol Med, Program Mol Pathogenesis, New York, NY 10016 USA.		Dustin, Michael/AAM-4611-2020; Varma, Rajat/I-1209-2012	Varma, Rajat/0000-0001-5131-0402; Lee, Kyeong-Hee/0000-0002-9455-4201; Raychaudhuri, Subhadip/0000-0002-9873-6475; Dustin, Michael/0000-0003-4983-6389; Raychaudhuri, Subhadip/0000-0003-3426-8382				Chan C, 2001, P NATL ACAD SCI USA, V98, P5758, DOI 10.1073/pnas.101113698; Coombs D, 2002, NAT IMMUNOL, V3, P926, DOI 10.1038/ni838; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Freiberg BA, 2002, NAT IMMUNOL, V3, P911, DOI 10.1038/ni836; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Itoh Y, 1999, J IMMUNOL, V162, P2073; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Lanzavecchia A, 2000, CURR OPIN IMMUNOL, V12, P92, DOI 10.1016/S0952-7915(99)00056-4; Lee K. T., UNPUB; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; Martin S, 1998, EUR J IMMUNOL, V28, P2991, DOI 10.1002/(SICI)1521-4141(199810)28:10<2991::AID-IMMU2991>3.3.CO;2-2; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Qi SY, 2001, P NATL ACAD SCI USA, V98, P6548, DOI 10.1073/pnas.111536798; Schrum AG, 2002, J EXP MED, V196, P793, DOI 10.1084/jem.20020158; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Stefanova I, 2003, NAT IMMUNOL, V4, P248, DOI 10.1038/ni895; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	29	437	454	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 14	2003	302	5648					1218	1222		10.1126/science.1086507	http://dx.doi.org/10.1126/science.1086507			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	742XW	14512504				2022-12-24	WOS:000186544300057
J	Schwarz, DS; Hutvagner, G; Du, T; Xu, ZS; Aronin, N; Zamore, PD				Schwarz, DS; Hutvagner, G; Du, T; Xu, ZS; Aronin, N; Zamore, PD			Asymmetry in the assembly of the RNAi enzyme complex	CELL			English	Article							DOUBLE-STRANDED-RNA; SHORT-INTERFERING RNAS; MESSENGER-RNA; GENE-EXPRESSION; HAIRPIN RNAS; C-ELEGANS; DROSOPHILA; SIRNAS; DICER; MICRORNAS	A key step in RNA interference (RNAi) is assembly of the RISC, the protein-siRNA complex that mediates target RNA cleavage. Here, we show that the two strands of an siRNA duplex are not equally eligible for assembly into RISC. Rather, both the absolute and relative stabilities of the base pairs at the 5' ends of the two siRNA strands determine the degree to which each strand participates in the RNAi pathway. siRNA duplexes can be functionally asymmetric, with only one of the two strands able to trigger RNAi. Asymmetry is the hallmark of a related class of small, single-stranded, noncoding RNAs, microRNAs (miRNAs). We suggest that single-stranded miRNAs are initially generated as siRNA-like duplexes whose structures predestine one strand to enter the RISC and the other strand to be destroyed. Thus, the common step of RISC assembly is an unexpected source of asymmetry for both siRNA function and miRNA biogenesis.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Zamore, PD (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	phillip.zamore@umassmed.edu	Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618; Hutvagner, Gyorgy/0000-0002-7231-9446	NIGMS NIH HHS [GM62862-01, GM65236-01] Funding Source: Medline; NINDS NIH HHS [R21 NS44952-01, R01 NS38194] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062862, R01GM065236, R37GM062862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038194, R21NS044952] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amarzguioui M, 2003, NUCLEIC ACIDS RES, V31, P589, DOI 10.1093/nar/gkg147; Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Boutla A, 2001, CURR BIOL, V11, P1776, DOI 10.1016/S0960-9822(01)00541-3; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Catalanotto C, 2002, GENE DEV, V16, P790, DOI 10.1101/gad.222402; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Crow JP, 1997, J NEUROCHEM, V69, P1936; Dalmay T, 2001, EMBO J, V20, P2069, DOI 10.1093/emboj/20.8.2069; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Haley B, 2003, METHODS, V30, P330, DOI 10.1016/S1046-2023(03)00052-5; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE SK, 1993, LAND DEGRAD REHABIL, V4, P1, DOI 10.1002/ldr.3400040102; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Myers JW, 2003, NAT BIOTECHNOL, V21, P324, DOI 10.1038/nbt792; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Tijsterman M, 2002, SCIENCE, V295, P694, DOI 10.1126/science.1067534; TURNER DH, 1987, J AM CHEM SOC, V109, P3783, DOI 10.1021/ja00246a047; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Wu-Scharf D, 2000, SCIENCE, V290, P1159, DOI 10.1126/science.290.5494.1159; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582; ZUKER M, 2003, NUCLEIC ACIDS RES, V31, P1	71	1986	2317	6	272	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	2003	115	2					199	208		10.1016/S0092-8674(03)00759-1	http://dx.doi.org/10.1016/S0092-8674(03)00759-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567917	Bronze			2022-12-24	WOS:000186039200011
J	Ghaemmaghami, S; Huh, W; Bower, K; Howson, RW; Belle, A; Dephoure, N; O'Shea, EK; Weissman, JS				Ghaemmaghami, S; Huh, W; Bower, K; Howson, RW; Belle, A; Dephoure, N; O'Shea, EK; Weissman, JS			Global analysis of protein expression in yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; GENE DELETION; GENOME; IDENTIFICATION; ORGANIZATION	The availability of complete genomic sequences and technologies that allow comprehensive analysis of global expression profiles of messenger RNA(1-3) have greatly expanded our ability to monitor the internal state of a cell. Yet biological systems ultimately need to be explained in terms of the activity, regulation and modification of proteins-and the ubiquitous occurrence of posttranscriptional regulation makes mRNA an imperfect proxy for such information. To facilitate global protein analyses, we have created a Saccharomyces cerevisiae fusion library where each open reading frame is tagged with a high-affinity epitope and expressed from its natural chromosomal location. Through immunodetection of the common tag, we obtain a census of proteins expressed during log-phase growth and measurements of their absolute levels. We find that about 80% of the proteome is expressed during normal growth conditions, and, using additional sequence information, we systematically identify misannotated genes. The abundance of proteins ranges from fewer than 50 to more than 10(6) molecules per cell. Many of these molecules, including essential proteins and most transcription factors, are present at levels that are not readily detectable by other proteomic techniques nor predictable by mRNA levels or codon bias measurements.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	jsw1@itsa.ucsf.edu	Huh, Won-Ki/AAQ-6767-2021; Dephoure, Noah/N-7818-2014	Dephoure, Noah/0000-0001-5802-2657; Weissman, Jonathan/0000-0003-2445-670X; Ghaemmaghami, Sina/0000-0002-8696-2950				Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Bergmann S, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.031902; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Das S, 1997, NATURE, V385, P29, DOI 10.1038/385029a0; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Goffeau A, 2000, FEBS LETT, V480, P37, DOI 10.1016/S0014-5793(00)01775-0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; GRANTHAM R, 1980, NUCLEIC ACIDS RES, V8, P1893, DOI 10.1093/nar/8.9.1893; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Harrison PM, 2002, NUCLEIC ACIDS RES, V30, P1083, DOI 10.1093/nar/30.5.1083; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kowalczuk M, 1999, YEAST, V15, P1031, DOI 10.1002/(SICI)1097-0061(199908)15:11<1031::AID-YEA431>3.0.CO;2-G; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Washburn MP, 2003, P NATL ACAD SCI USA, V100, P3107, DOI 10.1073/pnas.0634629100; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhang CT, 2000, NUCLEIC ACIDS RES, V28, P2804, DOI 10.1093/nar/28.14.2804	29	2872	6775	9	586	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	2003	425	6959					737	741		10.1038/nature02046	http://dx.doi.org/10.1038/nature02046			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562106				2022-12-24	WOS:000185924500046
J	Jones, JM; Datta, P; Srinivasula, SM; Ji, WZ; Gupta, S; Zhang, ZJ; Davies, E; Hajnoczky, G; Saunders, TL; Van Keuren, ML; Fernandes-Alnemri, T; Meisler, MH; Alnemri, ES				Jones, JM; Datta, P; Srinivasula, SM; Ji, WZ; Gupta, S; Zhang, ZJ; Davies, E; Hajnoczky, G; Saunders, TL; Van Keuren, ML; Fernandes-Alnemri, T; Meisler, MH; Alnemri, ES			Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice	NATURE			English	Article							APOPTOSIS-INDUCING FACTOR; SERINE-PROTEASE; REGULATES APOPTOSIS; CASPASE ACTIVITY; CHROMOSOME 2P13; CELL-DEATH; INHIBITOR; OMI/HTRA2; SEQUENCE; XIAP	The mouse mutant mnd2 (motor neuron degeneration 2) exhibits muscle wasting, neurodegeneration, involution of the spleen and thymus, and death by 40 days of age(1,2). Degeneration of striatal neurons, with astrogliosis and microglia activation, begins at around 3 weeks of age, and other neurons are affected at later stages'. Here we have identified the mnd2 mutation as the missense mutation Ser276Cys in the protease domain of the nuclear-encoded mitochondrial serine protease Omi (also known as HtrA2 or Prss25). Protease activity of Omi is greatly reduced in tissues of mnd2 mice but is restored in mice rescued by a bacterial artificial chromosome transgene containing the wildtype Omi gene. Deletion of the PDZ domain partially restores protease activity to the inactive recombinant Omi protein carrying the Ser276Cys mutation, suggesting that the mutation impairs substrate access or binding to the active site pocket. Loss of Omi protease activity increases the susceptibility of mitochondria to induction of the permeability transition, and increases the sensitivity of mouse embryonic fibroblasts to stress-induced cell death. The neurodegeneration and juvenile lethality in mnd2 mice result from this defect in mitochondrial Omi protease.	Thomas Jefferson Univ Hosp, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ Hosp, Dept Pathol & Cell Biol, Philadelphia, PA 19107 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Div Med & Mol Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Biomed Res Core Facil, Transgen Anim Model Core, Ann Arbor, MI 48109 USA	Jefferson University; Jefferson University; Jefferson University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Alnemri, ES (corresponding author), Thomas Jefferson Univ Hosp, Ctr Apoptosis Res, Philadelphia, PA 19107 USA.		Gupta, Sanjeev/AAG-9749-2020; gupta, sanjeev/B-2824-2008; Alnemri, Emad S/B-4526-2010	Gupta, Sanjeev/0000-0002-4691-6853; gupta, sanjeev/0000-0002-4691-6853; Saunders, Thom/0000-0003-2015-101X				Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jang KH, 1996, J MICROBIOL BIOTECHN, V6, P36; Jang W, 1999, GENOME RES, V9, P53; Jang W, 1997, BIOCHEM BIOPH RES CO, V231, P344, DOI 10.1006/bbrc.1997.6095; Jang WH, 1997, GENOMICS, V40, P506, DOI 10.1006/geno.1996.4593; Ji WZ, 2001, MAMM GENOME, V12, P456, DOI 10.1007/s003350020032; JONES JM, 1993, GENOMICS, V16, P669, DOI 10.1006/geno.1993.1246; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Maurizi MR, 2002, NAT STRUCT BIOL, V9, P410, DOI 10.1038/nsb0602-410; Rathke-Hartlieb S, 2002, EXP NEUROL, V175, P87, DOI 10.1006/exnr.2002.7868; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Weber JS, 1998, GENOMICS, V54, P107, DOI 10.1006/geno.1998.5496; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903	29	297	309	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					721	727		10.1038/nature02052	http://dx.doi.org/10.1038/nature02052			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14534547	Green Published			2022-12-24	WOS:000185924500043
J	de Waal, A; Whiteside, A				de Waal, A; Whiteside, A			New variant famine: AIDS and food crisis in southern Africa	LANCET			English	Article							MORTALITY	Southern Africa is undergoing a food crisis of surprising scale and novelty. The familiar culprits of drought and mismanagement of national strategies are implicated. However, this crisis is distinct from conventional drought-induced food shortages with respect to those vulnerable to starvation, and the course of impoverishment and recovery. We propose that these new aspects to the food crisis can be attributed largely to the HIV/AIDS epidemic in the region. We present evidence that we are facing a new variant famine. We have used frameworks drawn from famine theory to examine the implications. HIV/AIDS has created a new category of highly vulnerable households-namely, those with Ill adults or those whose adults have died. The general burden of care in both AIDS-affected and non-AIDS-affected households has reduced the viability of farming livelihoods. The sensitivity of rural communities to external shocks such as drought has increased, and their resilience has declined. The prospects for a sharp decline into severe famine are increased, and possibilities for recovery reduced.	Univ Natal, Hlth Econ & HIV AIDS Res Div, ZA-4041 Durban, South Africa; UN Econ Commiss Africa, Commiss HIV AIDS & Governance Africa, Addis Ababa, Ethiopia	University of Kwazulu Natal; UN Economic Commission for Africa (UNECA)	Whiteside, A (corresponding author), Univ Natal, Hlth Econ & HIV AIDS Res Div, ZA-4041 Durban, South Africa.							[Anonymous], 1992, AIDS AFRICA; Barnett T., 2002, AIDS 21 CENTURY DIS; Baylies C, 2002, DEV CHANGE, V33, P611, DOI 10.1111/1467-7660.00272; CALDWELL JC, 1977, DROUGHT AFRICA, V2; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; DAVIES S, 1995, ADAPTABLE LIVELIHOOD; de Waal A., 1989, FAMINE KILLS DARFUR; DEVEREUX S, 2002, IDS B, V33, P88; DEWAAL A, 1990, DEV CHANGE, V21, P469, DOI 10.1111/j.1467-7660.1990.tb00384.x; DEWAAL A, 1989, POP STUD-J DEMOG, V43, P5, DOI 10.1080/0032472031000143826; Dyson T., 2002, FAMINE DEMOGRAPHY PE; Eldridge C, 2002, IDS BULL-I DEV STUD, V33, P79, DOI 10.1111/j.1759-5436.2002.tb00047.x; HADDAD L, 2001, 112 INT FOOD POL RES; KWARAMBA P, 1998, 19 EC ADV PROJ; Macintyre Kate, 2002, FAMINE DEMOGRAPHY PE; ROSEN S, 2002, SHIFTING BURDEN HIV; Rugalema G., 2000, Review of African Political Economy, P537, DOI 10.1080/03056240008704488; *SAV CHILDR FUND, 2002, HARARE           MAR; Semba RD, 1999, BRIT J NUTR, V81, P181, DOI 10.1017/S0007114599000379; Sen, 1981, POVERTY FAMINES ESSA; *SO AFR DEV COMM, 2003, UNPUB VULN ASS COMM; STANECKI K, 2003, M EMP EV DEM SOC IMP; SWIFT J, 1993, IDS BULL-I DEV STUD, V24, P1, DOI 10.1111/j.1759-5436.1993.mp24004001.x; *UN ADM COMM COORD, 1998, SCN NEWS, V17, P3; *UNICEF USAID UNAI, 2002, CHILDR BRINK 2002 JO; WATKINS SC, 1985, POPUL DEV REV, V11, P647, DOI 10.2307/1973458; WEBB D, 1999, SAFAIDS NEWS; World Development Movement, 2002, STRUCT DAM CAUS CONS	28	212	214	0	39	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1234	1237		10.1016/S0140-6736(03)14548-5	http://dx.doi.org/10.1016/S0140-6736(03)14548-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732CW	14568749				2022-12-24	WOS:000185924100028
J	Multani, DS; Briggs, SP; Chamberlin, MA; Blakeslee, JJ; Murphy, AS; Johal, GS				Multani, DS; Briggs, SP; Chamberlin, MA; Blakeslee, JJ; Murphy, AS; Johal, GS			Loss of an MDR transporter in compact stalks of maize br2 and sorghum dw3 mutants	SCIENCE			English	Article							GENES	Agriculturally advantageous reduction in plant height is usually achieved by blocking the action or production of gibberellins. Here, we describe a different dwarfing mechanism found in maize brachytic2 (br2) mutants characterized by compact lower stalk internodes. The height reduction in these plants results from the loss of a P-glycoprotein that modulates polar auxin transport in the maize stalk. The sorghum ortholog of br2 is dwarf3 (dw3), an unstable mutant of long-standing commercial interest and concern. A direct duplication within the dw3 gene is responsible for its mutant nature and also for its instability, because it facilitates unequal crossing-over at the locus.	Purdue Univ, Dept Bot & Plant Pathol, W Lafayette, IN 47907 USA; Pioneer HiBred Int Inc, Johnston, IA 50131 USA; Diversa Corp, San Diego, CA 92121 USA; Purdue Univ, Dept Hort, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; DuPont; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Johal, GS (corresponding author), Purdue Univ, Dept Bot & Plant Pathol, W Lafayette, IN 47907 USA.	gjohal@purdue.edu	Johal, Guri/F-5056-2017; Blakeslee, Joshua/G-4420-2011	Johal, Guri/0000-0001-8101-8410; Multani, Dilbag/0000-0003-2343-4613				Hedden P, 2003, TRENDS GENET, V19, P5, DOI 10.1016/S0168-9525(02)00009-4; Karper RE, 1932, AM NAT, V66, P511, DOI 10.1086/280457; Khush GS, 2001, NAT REV GENET, V2, P815, DOI 10.1038/35093585; Langham, 1940, MAIZE GENET COOP NEW, V14, P21; Leng ER, 1951, MAIZE GENET NEWSL, V25, P31; Mullet JE, 2002, CURR OPIN PLANT BIOL, V5, P118, DOI 10.1016/S1369-5266(02)00232-7; Murphy AS, 2002, PLANT PHYSIOL, V128, P935, DOI 10.1104/pp.010519; Noh B, 2003, NATURE, V423, P999, DOI 10.1038/nature01716; Noh B, 2001, PLANT CELL, V13, P2441, DOI 10.1105/tpc.13.11.2441; PARKER KE, 1990, PLANT PHYSIOL, V94, P1763, DOI 10.1104/pp.94.4.1763; QUINBY JR, 1954, AGRON J, V46, P211, DOI 10.2134/agronj1954.00021962004600050007x; QUINBY JR, 1963, GRAIN SORGH RES UT C, V3, P18; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Sidler M, 1998, PLANT CELL, V10, P1623, DOI 10.1105/tpc.10.10.1623; STEIN OL, 1955, AM J BOT, V42, P885, DOI 10.2307/2485286; TARTOF KD, 1988, GENETICS, V120, P1; Vogler H, 2003, CURR OPIN PLANT BIOL, V6, P51, DOI 10.1016/S1369-5266(02)00013-4	17	348	393	13	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					81	84		10.1126/science.1086072	http://dx.doi.org/10.1126/science.1086072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	14526073				2022-12-24	WOS:000185678500038
J	Ziegler, AG; Schmid, S; Huber, D; Hummel, M; Bonifacio, E				Ziegler, AG; Schmid, S; Huber, D; Hummel, M; Bonifacio, E			Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BETA-CELL AUTOIMMUNITY; CELIAC-DISEASE PATIENTS; COWS MILK; GERMAN BABYDIAB; ISLET AUTOIMMUNITY; IMMUNE-RESPONSE; GENETIC RISK; YOUNG DAISY; T-CELLS; INSULIN	Context Dietary factors modifying type 1 diabetes mellitus (DM) risk have been proposed, but little is known if they trigger the islet autoimmunity that precedes clinical disease. Objective To determine whether breastfeeding duration, food supplementation, or age at introduction of gluten-containing foods influences the risk of developing islet autoantibodies. Design and Setting Prospective natural history cohort study conducted from 1989 to 2003 in inpatient/outpatient clinics in Germany. Participants The BABYDIAB study follows newborn children of parents with type 1 DM. Eligibility requirements were met in 1610 children. Blood samples were obtained at birth, age 9 months, 2, 5, and 8 years. Dropout rate was 14.4% by age 5 years. Breastfeeding data were obtained by prospective questionnaires (91% complete), and food supplementation data were obtained by family interview (72% for food supplementation and 80% for age of gluten introduction). Main Outcome Measure Development of islet autoantibodies (insulin, glutamic acid decarboxylase, or IA-2 antibodies) in 2 consecutive blood samples. Results Life-table islet autoantibody frequency was 5.8% (SE, 0.6%) by age 5 years. Reduced total or exclusive breastfeeding duration did not significantly increase the risk of developing islet autoantibodies. Food supplementation with gluten-containing foods before age 3 months, however, was associated with significantly increased islet autoantibody risk (adjusted hazard ratio, 4.0; 95% confidence interval, 1.4-11.5; P=.01 vs children who received only breast milk until age 3 months). Four of 17 children who received gluten foods before age 3 months developed islet autoantibodies (life-table 5-year risk, 24%; SE, 10%). All 4 children had the high-risk DRB1*03/04,DQB1*0302 genotype. Early exposure to gluten did not significantly increase the risk of developing celiac disease-associated autoantibodies. Children who first received gluten foods after age 6 months did not have increased risks for islet or celiac disease autoantibodies. Conclusion Ensuring compliance to infant feeding guidelines is a possible way to reduce the risk of development of type 1 DM autoantibodies.	Diabet Res Inst & Hosp Munchen Schwabing, Munich, Germany; Ist Sci San Raffaele, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Ziegler, AG (corresponding author), Diabet Res Inst, Koelner Pl 1, D-80804 Munich, Germany.		Bonifacio, Ezio/E-7700-2010; Ziegler, Anette-Gabriele/M-4614-2014; Hummel, Sandra/Q-3538-2016	Bonifacio, Ezio/0000-0002-8704-4713; Ziegler, Anette-Gabriele/0000-0002-6290-5548; 				Atkinson MA, 1997, J AM COLL NUTR, V16, P334, DOI 10.1080/07315724.1997.10718694; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; Bingley PJ, 2003, DIABETES, V52, P1128, DOI 10.2337/diabetes.52.5.1128; BORCHJOHNSEN K, 1984, LANCET, V2, P1083; Cavallo MG, 1996, LANCET, V348, P926, DOI 10.1016/S0140-6736(95)12065-3; Challacombe DN, 1997, ARCH DIS CHILD, V77, P206, DOI 10.1136/adc.77.3.206; Couper JJ, 1999, DIABETES, V48, P2145, DOI 10.2337/diabetes.48.11.2145; Cronin CC, 1997, LANCET, V349, P1096, DOI 10.1016/S0140-6736(96)09153-2; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Funda DP, 1999, DIABETES-METAB RES, V15, P323; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; GRECO L, 1985, J PEDIATR GASTR NUTR, V4, P52, DOI 10.1097/00005176-198502000-00010; Hummel M, 2000, DIABETOLOGIA, V43, P1005, DOI 10.1007/s001250051483; Hummel M, 2000, DIABETES CARE, V23, P969, DOI 10.2337/diacare.23.7.969; Ivarsson A, 2000, ACTA PAEDIATR, V89, P165, DOI 10.1080/080352500750028771; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; Kimpimaki T, 2001, DIABETOLOGIA, V44, P63, DOI 10.1007/s001250051581; LESLIE RDG, 1994, DIABETES, V43, P843, DOI 10.2337/diabetes.43.7.843; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; MacFarlane AJ, 2003, J BIOL CHEM, V278, P54, DOI 10.1074/jbc.M210636200; Naserke HE, 1999, J CLIN ENDOCR METAB, V84, P1239, DOI 10.1210/jc.84.4.1239; Norris JM, 2002, DIABETES, V51, pA234; Norris JM, 1996, JAMA-J AM MED ASSOC, V276, P609, DOI 10.1001/jama.276.8.609; Schenker M, 1999, DIABETOLOGIA, V42, P671, DOI 10.1007/s001250051214; Strobel S, 1998, IMMUNOL TODAY, V19, P173, DOI 10.1016/S0167-5699(97)01239-5; Vaarala O, 1999, DIABETES, V48, P1389, DOI 10.2337/diabetes.48.7.1389; Vaarala O, 1996, DIABETES, V45, P178, DOI 10.2337/diabetes.45.2.178; van de Wal Y, 1998, P NATL ACAD SCI USA, V95, P10050, DOI 10.1073/pnas.95.17.10050; Ventura A, 2000, J PEDIATR-US, V137, P263, DOI 10.1067/mpd.2000.107160; WEILE B, 1995, J PEDIATR GASTR NUTR, V21, P64, DOI 10.1097/00005176-199507000-00011; Ziegler AG, 1999, DIABETES, V48, P460, DOI 10.2337/diabetes.48.3.460	32	362	373	0	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1721	1728		10.1001/jama.290.13.1721	http://dx.doi.org/10.1001/jama.290.13.1721			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519706	Bronze			2022-12-24	WOS:000185606100021
J	Bray, D				Bray, D			Molecular networks: The top-down view	SCIENCE			English	Editorial Material							SMALL-WORLD	Network theory can give a useful overview of how a biological system works. But to make testable predictions, we need the details.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Bray, D (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.							Alon U, 2003, SCIENCE, V301, P1866, DOI 10.1126/science.1089072; Barabasi A. L., 2002, FORMULA UNIVERSAL LA; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Fell D., 1997, UNDERSTANDING CONTRO; HINTON GE, 1992, SCI AM, V267, P145, DOI 10.1038/scientificamerican0992-144; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; KACSER H, 1973, S SOC EXP BIOL, V32, P65; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Wagner A, 2001, P ROY SOC B-BIOL SCI, V268, P1803, DOI 10.1098/rspb.2001.1711; Wagner A, 2001, MOL BIOL EVOL, V18, P1283, DOI 10.1093/oxfordjournals.molbev.a003913; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	15	143	153	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1864	1865		10.1126/science.1089118	http://dx.doi.org/10.1126/science.1089118			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512614				2022-12-24	WOS:000185536700036
J	Fortey, R; Chatterton, B				Fortey, R; Chatterton, B			A Devonian trilobite with an eyeshade	SCIENCE			English	Article							LENSES		Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2E3, Canada	Natural History Museum London; University of Oxford; University of Alberta	Fortey, R (corresponding author), Nat Hist Museum, Dept Palaeontol, Cromwell Rd, London SW7 5BD, England.	raf@nhm.ac.uk						Clarkson E.N.K., 1979, Palaeontology (Oxford), V22, P1; CLARKSON ENK, 1975, NATURE, V254, P613; Gal J, 2000, VISION RES, V40, P843, DOI 10.1016/S0042-6989(99)00216-3; McCormick T, 1998, PALEOBIOLOGY, V24, P235; MILLER WH, 1979, HDB SENSORY PHYSL, V7, P70; MORZADEC P, 1995, NEUES JB GEOL PAL, P577; STOCKTON W L, 1976, Paleobiology, V2, P304; TOWE KM, 1973, SCIENCE, V179, P1007, DOI 10.1126/science.179.4077.1007	8	12	13	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1689	1689		10.1126/science.1088713	http://dx.doi.org/10.1126/science.1088713			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500973				2022-12-24	WOS:000185387700034
J	Wardle, DA; Yeates, GW; Barker, GM; Bellingham, PJ; Bonner, KI; Williamson, WM				Wardle, DA; Yeates, GW; Barker, GM; Bellingham, PJ; Bonner, KI; Williamson, WM			Island biology and ecosystem functioning in epiphytic soil communities	SCIENCE			English	Article							SPECIES-DIVERSITY; MODEL SYSTEMS; POPULATIONS; ABUNDANCE; DYNAMICS; FOREST	Although island attributes such as size and accessibility to colonizing organisms can influence community structure, the consequences of these for ecosystem functioning are little understood. A study of the suspended soils of spatially discrete epiphytes or treetop "islands" in the canopies of New Zealand rainforest trees revealed that different components of the decomposer community responded either positively or negatively to island size, as well as to the tree species that the islands occurred in. This in turn led to important differences between islands in the rates of ecosystem processes driven by the decomposer biota. This system serves as a model for better understanding how attributes of both real and habitat islands may affect key ecosystem functions through determining the community structure of organisms that drive these functions.	Swedish Univ Agr Sci, Fac Forestry, Dept Forest Vegetat Ecol, S-90183 Umea, Sweden; Landcare Res, Lincoln, New Zealand; Landcare Res, Palmerston North, New Zealand; Landcare Res, Hamilton, New Zealand	Swedish University of Agricultural Sciences; Landcare Research - New Zealand; Landcare Research - New Zealand; Landcare Research - New Zealand	Wardle, DA (corresponding author), Swedish Univ Agr Sci, Fac Forestry, Dept Forest Vegetat Ecol, S-90183 Umea, Sweden.	david.wardle@svek.slu.se	Barker, Gary M/C-9974-2011; Bellingham, Peter/AAP-4302-2020; Wardle, David A./F-6031-2011	Barker, Gary M/0000-0002-0049-9804; Wardle, David A./0000-0002-0476-7335				Anderson WB, 1999, OECOLOGIA, V118, P324, DOI 10.1007/s004420050733; Armbruster P, 2002, OIKOS, V96, P225, DOI 10.1034/j.1600-0706.2002.960204.x; Collinge SK, 2000, ECOLOGY, V81, P2211, DOI 10.1890/0012-9658(2000)081[2211:EOGFOI]2.0.CO;2; Gonzalez A, 1998, SCIENCE, V281, P2045, DOI 10.1126/science.281.5385.2045; Gonzalez A, 2002, J ANIM ECOL, V71, P594, DOI 10.1046/j.1365-2656.2002.00625.x; Grime J. P., 2001, PLANT STRATEGIES VEG; LAWTON JH, 1994, OIKOS, V71, P367, DOI 10.2307/3545824; Levine JM, 2000, SCIENCE, V288, P852, DOI 10.1126/science.288.5467.852; Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; Loreau M., 2002, BIODIVERSITY ECOSYST, P294; MAC ARTHUR ROBERT H., 1967; MOEED A, 1983, NEW ZEAL J ECOL, V6, P39; NADKARNI NM, 1994, AM ZOOL, V34, P70; Richardson BA, 2000, J TROP ECOL, V16, P167, DOI 10.1017/S0266467400001346; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SCHOENER TW, 1983, SCIENCE, V219, P1353, DOI 10.1126/science.219.4590.1353; Setala H, 2002, ECOL RES, V17, P207, DOI 10.1046/j.1440-1703.2002.00480.x; SIMBERLOFF D, 1976, ECOLOGY, V57, P629, DOI 10.2307/1936179; Spiller DA, 1997, OIKOS, V78, P15, DOI 10.2307/3545795; Tscharntke T, 2002, ECOL APPL, V12, P354, DOI 10.1890/1051-0761(2002)012[0354:COSHFT]2.0.CO;2; Vitousek PM, 2002, J BIOGEOGR, V29, P573, DOI 10.1046/j.1365-2699.2002.00707.x; Vitousek PM, 1995, ISLANDS BIOL DIVERSI; Wardle DA, 2002, J BIOGEOGR, V29, P583, DOI 10.1046/j.1365-2699.2002.00708.x; Wardle DA, 1997, SCIENCE, V277, P1296, DOI 10.1126/science.277.5330.1296; Wardle DA., 2002, COMMUNITIES ECOSYSTE, P7; WHITTAKER R.J., 1998, ISLAND BIOGEOGRAPHY	26	70	77	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1717	1720		10.1126/science.1087809	http://dx.doi.org/10.1126/science.1087809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500981				2022-12-24	WOS:000185387700043
J	Arnold, DH; Johnston, A				Arnold, DH; Johnston, A			Motion-induced spatial conflict	NATURE			English	Article							PERCEIVED POSITION; CONTRAST; PATTERN; JITTER; SPEED	Borders defined by small changes in brightness (luminance contrast) or by differences in colour (chromatic contrast) appear to move more slowly than those defined by strong luminance contrast(1-4). As spatial coding is influenced by motion(5-7), if placed in close proximity, the different types of moving border might appear to drift apart(8). Using this configuration, we show here that observers instead report a clear illusory spatial jitter of the low-luminance-contrast boundary. This visible interaction between motion and spatial-position coding occurred at a characteristic rate (similar to22.3 Hz), although the stimulus motion was continuous and invariant. The jitter rate did not vary with the speed of movement. The jitter was not due to small involuntary movements of the eyes, because it only occurred at a specific point within the stimulus, the low-luminance-contrast boundary. These findings show that the human visual system contains a neural mechanism that periodically resolves the spatial conflict created by adjacent moving borders that have the same physical but different perceptual speeds.	UCL, Dept Psychol, London WC1E 6BT, England; UCL, Inst Cognit Neurosci, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Arnold, DH (corresponding author), UCL, Dept Psychol, Gower St, London WC1E 6BT, England.	derek.arnold@ucl.ac.uk	Johnston, Alan/B-5393-2008	Johnston, Alan/0000-0001-9026-1199; Arnold, Derek/0000-0003-1027-6222				Anstis S, 2001, PERCEPTION, V30, P785, DOI 10.1068/p3211; Anstis S. M., 1983, COLOUR VISION PHYSL, P155; Blakemore MR, 1999, PERCEPTION, V28, P33, DOI 10.1068/p2722; BRIDGEMAN B, 1991, VISION RES, V31, P1903, DOI 10.1016/0042-6989(91)90185-8; CAMPBELL FW, 1959, J PHYSIOL-LONDON, V145, P579, DOI 10.1113/jphysiol.1959.sp006164; CAVANAGH P, 1984, J OPT SOC AM A, V1, P893, DOI 10.1364/JOSAA.1.000893; DEVALOIS RL, 1991, VISION RES, V31, P1619, DOI 10.1016/0042-6989(91)90138-U; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; Engel AK, 2001, TRENDS COGN SCI, V5, P16, DOI 10.1016/S1364-6613(00)01568-0; Helmholtz H., 1962, TREATISE PHYSL OPTIC; Murakami I, 2003, VISION RES, V43, P957, DOI 10.1016/S0042-6989(03)00070-1; Murakami I, 1998, NATURE, V395, P798, DOI 10.1038/27435; Nguyen-Tri D, 2003, PERCEPTION, V32, P627, DOI 10.1068/p3228; Nishida S, 1999, NATURE, V397, P610, DOI 10.1038/17600; Sherrington CS, 1918, BRAIN, V41, P332, DOI 10.1093/brain/41.3-4.332; THOMPSON P, 1982, VISION RES, V22, P377, DOI 10.1016/0042-6989(82)90153-5; Von Grunau M W, 1976, Vision Res, V16, P397, DOI 10.1016/0042-6989(76)90203-0; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; Whitney D, 2000, NAT NEUROSCI, V3, P954, DOI 10.1038/78878; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115	20	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					181	184		10.1038/nature01955	http://dx.doi.org/10.1038/nature01955			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968181				2022-12-24	WOS:000185236000043
J	Higginson, IJ; Thompson, M				Higginson, IJ; Thompson, M			Children and young people who die from cancer: epidemiology and place of death in England (1995-9)	BRITISH MEDICAL JOURNAL			English	Article									Kings Coll London, Guys Kings & St Thomass Sch Med, Dept Palliat Care & Policy, London SE5 9RJ, England	University of London; King's College London	Higginson, IJ (corresponding author), Kings Coll London, Guys Kings & St Thomass Sch Med, Dept Palliat Care & Policy, London SE5 9RJ, England.	irene.higginson@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				Bleyer WA, 2002, MED PEDIATR ONCOL, V38, P1, DOI 10.1002/mpo.1257; Edwards J, 2001, Int J Palliat Nurs, V7, P485; Feudtner C, 2002, PEDIATRICS, V109, P656, DOI 10.1542/peds.109.4.656; GOLDMAN A, 1990, ARCH DIS CHILD, V65, P641, DOI 10.1136/adc.65.6.641; Higginson IJ, 1998, PALLIATIVE MED, V12, P353, DOI 10.1191/026921698672530176	5	33	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2003	327	7413					478	479		10.1136/bmj.327.7413.478	http://dx.doi.org/10.1136/bmj.327.7413.478			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LA	12946969	Green Published, Bronze			2022-12-24	WOS:000185088900015
J	Jin, HJ; Kaplan, DL				Jin, HJ; Kaplan, DL			Mechanism of silk processing in insects and spiders	NATURE			English	Article							BOMBYX-MORI SILK; FIBROIN SOLUTION; SOLID-STATE; FIBERS; WATER; BIOMATERIALS; ORGANIZATION; SPECTROSCOPY; GENE; NMR	Silk spinning by insects and spiders leads to the formation of fibres that exhibit high strength and toughness(1). The lack of understanding of the protein processing in silk glands has prevented the recapitulation of these properties in vitro from reconstituted or genetically engineered silks. Here we report the identification of emulsion formation and micellar structures from aqueous solutions of reconstituted silkworm silk fibroin as a first step in the process to control water and protein-protein interactions. The sizes (100-200 nm diameter) of these structures could be predicted from hydrophobicity plots of silk protein primary sequence(2). These micelles subsequently aggregated into larger 'globules' and gel-like states as the concentration of silk fibroin increased, while maintaining solubility owing to the hydrophilic regions of the protein interspersed among the larger hydrophobic regions. Upon physical shearing or stretching structural transitions, increased birefringence and morphological alignment were demonstrated, indicating that this process mimics the behaviour of similar native silk proteins in vivo. Final morphological features of these silk materials are similar to those observed in native silkworm fibres.	Tufts Univ, Dept Biol & Chem Engn, Medford, MA 02155 USA; Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA	Tufts University; Tufts University	Kaplan, DL (corresponding author), Tufts Univ, Dept Biol & Chem Engn, Medford, MA 02155 USA.							Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142-9612(02)00353-8; Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142-9612(02)00156-4; ASAKURA T, 1985, MACROMOLECULES, V18, P1841, DOI 10.1021/ma00152a009; AUVRAY X, 1992, LANGMUIR, V8, P2671, DOI 10.1021/la00047a017; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; ISHIDA M, 1990, MACROMOLECULES, V23, P88, DOI 10.1021/ma00203a017; Jin HJ, 2002, BIOMACROMOLECULES, V3, P1233, DOI 10.1021/bm025581u; Knight DP, 2002, PHILOS T R SOC B, V357, P155, DOI 10.1098/rstb.2001.1030; Knight DP, 1999, P ROY SOC B-BIOL SCI, V266, P519, DOI 10.1098/rspb.1999.0667; Kwon KW, 2002, POLYMER, V43, P3353, DOI 10.1016/S0032-3861(02)00155-6; Lele AK, 2001, CHEM ENG SCI, V56, P5793, DOI 10.1016/S0009-2509(01)00288-3; MAGOSHI J, 1979, J POLYM SCI POL PHYS, V17, P515, DOI 10.1002/pol.1979.180170315; MALSTOM M, 1992, MACROMOLECULES, V25, P5440; MINOURA N, 1990, BIOMATERIALS, V11, P430, DOI 10.1016/0142-9612(90)90100-5; MITA K, 1994, J MOL EVOL, V38, P583; Ochi A, 2002, BIOMACROMOLECULES, V3, P1187, DOI 10.1021/bm020056g; Perez-Rigueiro J, 1998, J APPL POLYM SCI, V70, P2439, DOI 10.1002/(SICI)1097-4628(19981219)70:12<2439::AID-APP16>3.0.CO;2-J; Poza P, 2002, ENG FRACT MECH, V69, P1035, DOI 10.1016/S0013-7944(01)00120-5; Putthanarat S, 2000, POLYMER, V41, P7735, DOI 10.1016/S0032-3861(00)00036-7; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; Seidel A, 2000, MACROMOLECULES, V33, P775, DOI 10.1021/ma990893j; Shen Y, 1998, MACROMOLECULES, V31, P8857, DOI 10.1021/ma980281j; Sofia S, 2001, J BIOMED MATER RES, V54, P139, DOI 10.1002/1097-4636(200101)54:1<139::AID-JBM17>3.0.CO;2-7; Tanaka T, 1998, POLYM INT, V45, P175, DOI 10.1002/(SICI)1097-0126(199802)45:2<175::AID-PI883>3.0.CO;2-K; Valluzzi R, 1999, J PHYS CHEM B, V103, P11382, DOI 10.1021/jp991363s; van Beek JD, 2002, P NATL ACAD SCI USA, V99, P10266, DOI 10.1073/pnas.152162299; Viney C, 1997, SUPRAMOL SCI, V4, P75, DOI 10.1016/S0968-5677(96)00059-4; Vollrath F, 2001, NATURE, V410, P541, DOI 10.1038/35069000; Wilson D, 2000, BIOPHYS J, V78, P2690, DOI 10.1016/S0006-3495(00)76813-5; Yamada H, 2001, MAT SCI ENG C-BIO S, V14, P41, DOI 10.1016/S0928-4931(01)00207-7; Zhou CZ, 2000, NUCLEIC ACIDS RES, V28, P2413, DOI 10.1093/nar/28.12.2413	31	1039	1103	41	775	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1057	1061		10.1038/nature01809	http://dx.doi.org/10.1038/nature01809			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944968				2022-12-24	WOS:000184984200044
J	Beye, M; Hasselmann, M; Fondrk, MK; Page, RE; Omholt, SW				Beye, M; Hasselmann, M; Fondrk, MK; Page, RE; Omholt, SW			The gene csd is the primary signal for sexual development in the honeybee and encodes an SR-type protein	CELL			English	Article							APIS-MELLIFERA; DROSOPHILA-MELANOGASTER; TRANSFORMER GENE; PREMESSENGER RNA; MUSCA-DOMESTICA; LOCUS REGION; SPLICE SITE; DIFFERENTIATION; EVOLUTION; GENOME	Haplodiploid organisms comprise about 20% of animals. Males develop from unfertilized eggs while females are derived from fertilized eggs. The underlying mechanisms of sex determination, however, appear to be diverse and are poorly understood. We have dissected the complementary sex determiner (csd) locus in the honeybee to understand its molecular basis. In this species, csd acts as the primary sex-determining signal with several alleles segregating in populations. Males are hemizygous and females are heterozygous at this locus; nonreproducing diploid males occur when the locus is homozygous. We have characterized csd by positional cloning and repression analysis. csd alleles are highly variable and no transcription differences were found between sexes. These results establish csd as a primary signal that governs sexual development by its allelic composition. Structural similarity of csd with tra genes of Dipteran insects suggests some functional relation of what would otherwise appear to be unrelated sex-determination mechanisms.	Univ Halle Wittenberg, Inst Zool, Biozentrum, D-06120 Halle Saale, Germany; Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Agr Univ Norway, Dept Anim Sci, N-1432 As, Norway	Martin Luther University Halle Wittenberg; University of California System; University of California Davis; Norwegian University of Life Sciences	Beye, M (corresponding author), Univ Halle Wittenberg, Inst Zool, Biozentrum, Weinberg Weg 22, D-06120 Halle Saale, Germany.		Hasselmann, Martin/E-7681-2014; Hasselmann, Martin/ABB-6485-2021	Hasselmann, Martin/0000-0003-3305-4024				ADAMS J, 1977, GENETICS, V86, P583; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bell G, 1982, MASTERPIECE NATURE E; BELOTE JM, 1989, DEV GENET, V10, P143, DOI 10.1002/dvg.1020100304; Beye M, 1998, GENOMICS, V49, P317, DOI 10.1006/geno.1998.5253; Beye M, 1999, GENETICS, V153, P1701; Beye M, 2002, INSECT MOL BIOL, V11, P527, DOI 10.1046/j.1365-2583.2002.00361.x; BEYE M, 1994, NATURWISSENSCHAFTEN, V81, P460; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; Bull J. J., 1983, EVOLUTION SEX DETERM; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; BUTLER B, 1986, EMBO J, V5, P3607, DOI 10.1002/j.1460-2075.1986.tb04689.x; Casselton LA, 2002, HEREDITY, V88, P142, DOI 10.1038/sj.hdy.6800035; Charlesworth D, 2002, CURR BIOL, V12, pR424, DOI 10.1016/S0960-9822(02)00915-6; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; COOK JM, 1993, HEREDITY, V71, P421, DOI 10.1038/hdy.1993.157; CROZIER RH, 1971, AM NAT, V105, P399, DOI 10.1086/282733; Dauwalder B, 1996, P NATL ACAD SCI USA, V93, P9004, DOI 10.1073/pnas.93.17.9004; Dauwalder B, 1998, EMBO J, V17, P6049, DOI 10.1093/emboj/17.20.6049; DRESCHER W, 1964, J HERED, V55, P90; Dubendorfer A, 2002, INT J DEV BIOL, V46, P75; DZIERZON A, 1845, EICHSTADTER BIENENZE, V1, P109; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hasselmann M, 2001, INSECT MOL BIOL, V10, P605, DOI 10.1046/j.0962-1075.2001.00300.x; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; HILFIKERKLEINER D, 1993, GENETICS, V134, P1187; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; Hunter CP, 1999, CURR BIOL, V9, pR440, DOI 10.1016/S0960-9822(99)80276-0; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kennedy CF, 1998, MOL CELL BIOL, V18, P5425, DOI 10.1128/MCB.18.9.5425; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kristensen Niels P., 1995, Zoologische Beitraege, V36, P83; LAIDLAW HH, 1956, GENETICS, V41, P179; Laidlaw HH., 1997, QUEEN REARING BEE BR; Lasko P, 2000, J CELL BIOL, V150, pF51, DOI 10.1083/jcb.150.2.F51; MACKENSEN OTTO, 1955, JOUR HEREDITY, V46, P72; Maine EM, 2001, DEV BIOL, V239, P177, DOI 10.1006/dbio.2001.0394; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; Marin I, 1998, SCIENCE, V281, P1990, DOI 10.1126/science.281.5385.1990; McAllister BF, 2000, GENETICS, V154, P1711; MCKEOWN M, 1987, CELL, V48, P489, DOI 10.1016/0092-8674(87)90199-1; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; Mount SM, 2000, J CELL BIOL, V150, pF37, DOI 10.1083/jcb.150.2.F37; OISHI K, 1993, GENETICA, V88, P119, DOI 10.1007/BF02424468; OMHOLT SW, 1995, APIDOLOGIE, V26, P297, DOI 10.1051/apido:19950404; Pane A, 2002, DEVELOPMENT, V129, P3715; PENG YSC, 1992, J INVERTEBR PATHOL, V60, P127, DOI 10.1016/0022-2011(92)90085-I; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Schutt C, 2000, DEVELOPMENT, V127, P667; Snodgrass R.E., 1956, ANATOMY HONEYBEE; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Staden R, 2000, Methods Mol Biol, V132, P115; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WALLDORF U, 1990, FEBS LETT, V267, P245, DOI 10.1016/0014-5793(90)80936-D; Whiting PW, 1943, GENETICS, V28, P365; WILKINS AS, 1995, BIOESSAYS, V17, P71, DOI 10.1002/bies.950170113; Willhoeft U, 1996, GENETICS, V144, P737; Wilson EB, 1905, SCIENCE, V22, P500, DOI 10.1126/science.22.564.500	63	364	399	3	73	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					419	429		10.1016/S0092-8674(03)00606-8	http://dx.doi.org/10.1016/S0092-8674(03)00606-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941271	Bronze			2022-12-24	WOS:000184928800006
J	Coull, JAM; Boudreau, D; Bachand, K; Prescott, SA; Nault, F; Sik, A; De Koninck, P; De Koninck, Y				Coull, JAM; Boudreau, D; Bachand, K; Prescott, SA; Nault, F; Sik, A; De Koninck, P; De Koninck, Y			Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain	NATURE			English	Article							CHRONIC CONSTRICTION INJURY; RAT SCIATIC-NERVE; DORSAL-HORN; SELECTIVE LOSS; GABA; MODEL; INHIBITION; EXCITATION; CORD; PHARMACOLOGY	Modern pain-control theory(1) predicts that a loss of inhibition (disinhibition) in the dorsal horn of the spinal cord is a crucial substrate for chronic pain syndromes(2). However, the nature of the mechanisms that underlie such disinhibition has remained controversial(3-6). Here we present evidence for a novel mechanism of disinhibition following peripheral nerve injury. It involves a trans-synaptic reduction in the expression of the potassium-chloride exporter KCC2, and the consequent disruption of anion homeostasis in neurons of lamina I of the superficial dorsal horn, one of the main spinal nociceptive output pathways(7). In our experiments, the resulting shift in the transmembrane anion gradient caused normally inhibitory anionic synaptic currents to be excitatory, substantially driving up the net excitability of lamina I neurons. Local blockade or knock-down of the spinal KCC2 exporter in intact rats markedly reduced the nociceptive threshold, confirming that the reported disruption of anion homeostasis in lamina I neurons was sufficient to cause neuropathic pain.	Univ Laval Robert Giffard, Ctr Rech, Quebec City, PQ G1J 2G3, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	Laval University; McGill University	De Koninck, Y (corresponding author), Univ Laval Robert Giffard, Ctr Rech, Quebec City, PQ G1J 2G3, Canada.		Boudreau, Dominic/I-8144-2012; De Koninck, Yves/C-2659-2008	De Koninck, Yves/0000-0002-5779-9330				BERNANDER O, 1991, P NATL ACAD SCI USA, V88, P11569, DOI 10.1073/pnas.88.24.11569; Blomqvist A, 2000, J COMP NEUROL, V428, P1; CODERRE TJ, 1994, PAIN, V59, P345, DOI 10.1016/0304-3959(94)90020-5; CODERRE TJ, 1992, J NEUROSCI, V12, P3665; COOK AJ, 1987, NATURE, V325, P151, DOI 10.1038/325151a0; EBIHARA S, 1995, J PHYSIOL-LONDON, V484, P77, DOI 10.1113/jphysiol.1995.sp020649; Farber NB, 2002, MOL PSYCHIATR, V7, P726, DOI 10.1038/sj.mp.4001087; Ganguly K, 2001, CELL, V105, P521, DOI 10.1016/S0092-8674(01)00341-5; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Hwang JH, 1997, PAIN, V70, P15, DOI 10.1016/S0304-3959(96)03249-6; Keller AF, 2001, J NEUROSCI, V21, P7871, DOI 10.1523/JNEUROSCI.21-20-07871.2001; Kontinen VK, 2001, ANESTHESIOLOGY, V94, P333, DOI 10.1097/00000542-200102000-00024; LIGHT AR, 1992, INITIAL PROCESSING P; Malan TP, 2002, ANESTHESIOLOGY, V96, P1161, DOI 10.1097/00000542-200205000-00020; Martin TJ, 2001, J PHARMACOL EXP THER, V299, P811; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002; Mosconi T, 1996, PAIN, V64, P37, DOI 10.1016/0304-3959(95)00077-1; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Pitcher GM, 2000, EUR J NEUROSCI, V12, P2006, DOI 10.1046/j.1460-9568.2000.00087.x; Polgar E, 2003, PAIN, V104, P229, DOI 10.1016/S0304-3959(03)00011-3; Prescott SA, 2002, J PHYSIOL-LONDON, V539, P817, DOI 10.1113/jphysiol.2001.013437; Rabben T, 1999, J PHARMACOL EXP THER, V289, P1060; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Rudomin P, 1999, EXP BRAIN RES, V129, P1, DOI 10.1007/s002210050933; Serpell MG, 2002, PAIN, V99, P557, DOI 10.1016/S0304-3959(02)00255-5; Somers DL, 2002, NEUROSCI LETT, V323, P171, DOI 10.1016/S0304-3940(02)00157-X; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	30	770	809	1	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					938	942		10.1038/nature01868	http://dx.doi.org/10.1038/nature01868			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931188				2022-12-24	WOS:000184843600041
J	Huber, C; Eisenreich, W; Hecht, S; Wachtershausher, G				Huber, C; Eisenreich, W; Hecht, S; Wachtershausher, G			A possible primordial peptide cycle	SCIENCE			English	Article							AMINO-ACIDS; ENZYMES; ORIGIN; LIFE	alpha-Amino acids can undergo peptide formation by activation with carbon monoxide (CO) under hot aqueous conditions in the presence of freshly coprecipitated colloidal (Fe,Ni)S. We now show that CO-driven peptide formation proceeds concomitantly with CO-driven, N-terminal peptide degradation by racemizing N-terminal hydantoin and urea derivatives to alpha-amino acids. This establishes a peptide cycle with closely related anabolic and catabolic segments. The hydantoin derivative is a purin-related heterocycle. The (Fe,Ni)S-dependent urea hydrolysis could have been the evolutionary precursor of the nickel-enzyme urease. The results support the theory of a chemoautotrophic origin of life with a CO-driven, (Fe,Ni)S-dependent primordial metabolism.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Wachtershausher, G (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				Huber C, 1998, SCIENCE, V281, P670, DOI 10.1126/science.281.5377.670; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Kricheldorf H. R., 1987, ALPHA AMINOACID N CA; Syldatk C, 1999, APPL MICROBIOL BIOT, V51, P293, DOI 10.1007/s002530051395; Taillades J, 1998, ORIGINS LIFE EVOL B, V28, P61, DOI 10.1023/A:1006566810636; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452	7	181	187	5	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					938	940		10.1126/science.1086501	http://dx.doi.org/10.1126/science.1086501			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920291				2022-12-24	WOS:000184755900030
J	Pandolfi, JM; Bradbury, RH; Sala, E; Hughes, TP; Bjorndal, KA; Cooke, RG; McArdle, D; McClenachan, L; Newman, MJH; Paredes, G; Warner, RR; Jackson, JBC				Pandolfi, JM; Bradbury, RH; Sala, E; Hughes, TP; Bjorndal, KA; Cooke, RG; McArdle, D; McClenachan, L; Newman, MJH; Paredes, G; Warner, RR; Jackson, JBC			Global trajectories of the long-term decline of coral reef ecosystems	SCIENCE			English	Article							CLIMATE-CHANGE; BELIZE; DISEASES; ECOLOGY; FUTURE; SCALE	Degradation of coral reef ecosystems began centuries ago, but there is no global summary of the magnitude of change. We compiled records, extending back thousands of years, of the status and trends of seven major guilds of carnivores, herbivores, and architectural species from 14 regions. Large animals declined before small animals and architectural species, and Atlantic reefs declined before reefs in the Red Sea and Australia, but the trajectories of decline were markedly similar worldwide. All reefs were substantially degraded long before outbreaks of coral disease and bleaching. Regardless of these new threats, reefs will not survive without immediate protection from human exploitation over large spatial scales.	Natl Museum Nat Hist, Dept Paleobiol, Washington, DC 20013 USA; Australian Natl Univ, Ctr Resource & Environm Studies, Canberra, ACT 0200, Australia; Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biodivers & Conservat, La Jolla, CA 92093 USA; James Cook Univ, Ctr Coral Reef Biodivers, Sch Marine Biol, Townsville, Qld 4811, Australia; Univ Florida, Archie Carr Ctr Sea Turtle Res, Dept Zool, Gainesville, FL 32611 USA; Smithsonian Trop Res Inst, Ctr Trop Paleoecol & Archaeol, Balboa, Panama; Univ Calif Santa Barbara, Calif Sea Grant, Cooperat Extens, Santa Barbara, CA 93105 USA; Univ Calif Santa Barbara, Dept Ecol Evolut & Marine Biol, Santa Barbara, CA 93106 USA	Smithsonian Institution; Smithsonian National Museum of Natural History; Australian National University; University of California System; University of California San Diego; Scripps Institution of Oceanography; James Cook University; State University System of Florida; University of Florida; Smithsonian Institution; Smithsonian Tropical Research Institute; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Pandolfi, JM (corresponding author), Natl Museum Nat Hist, Dept Paleobiol, MRC-121,POB 37012, Washington, DC 20013 USA.	pandolfi.john@nmnh.si.edu	Hughes, Terry P/L-4721-2013; Pandolfi, John M/A-3121-2009; Warner, Robert R./M-5342-2013	Hughes, Terry P/0000-0002-5257-5063; Pandolfi, John M/0000-0003-3047-6694; Warner, Robert R./0000-0002-3299-5685; Bradbury, Roger/0000-0002-0940-3493; Bjorndal, Karen/0000-0002-6286-1901				Aronson RB, 1998, CORAL REEFS, V17, P223, DOI 10.1007/s003380050122; Aronson RB, 2000, NATURE, V405, P36, DOI 10.1038/35011132; Aronson RB, 2002, ECOL MONOGR, V72, P233, DOI 10.1890/0012-9615(2002)072[0233:TESOST]2.0.CO;2; Brown BE, 1997, ADV MAR BIOL, V31, P221, DOI DOI 10.1016/S0065-2881(08)60224-2; Connell JH, 1997, ECOL MONOGR, V67, P461, DOI 10.1890/0012-9615(1997)067[0461:AYSOCA]2.0.CO;2; GOREAU TF, 1959, ECOLOGY, V40, P67, DOI 10.2307/1929924; Harvell CD, 1999, SCIENCE, V285, P1505, DOI 10.1126/science.285.5433.1505; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; HUGHES TP, 1994, SCIENCE, V265, P1547, DOI 10.1126/science.265.5178.1547; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Jackson JBC, 2001, P NATL ACAD SCI USA, V98, P5411, DOI 10.1073/pnas.091092898; Knowlton N, 2001, P NATL ACAD SCI USA, V98, P5419, DOI 10.1073/pnas.091092998; LEWIS JB, 1984, CORAL REEFS, V3, P117, DOI 10.1007/BF00301955; McClanahan TR, 2002, SCOPE SER, V60, P111; Richardson LL, 1998, TRENDS ECOL EVOL, V13, P438, DOI 10.1016/S0169-5347(98)01460-8; ROGERS CS, 1990, MAR ECOL PROG SER, V62, P185, DOI 10.3354/meps062185; Wolanski E, 2003, AM SCI, V91, P44, DOI 10.1511/2003.11.843; [No title captured]	19	1372	1433	21	1006	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					955	958		10.1126/science.1085706	http://dx.doi.org/10.1126/science.1085706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920296				2022-12-24	WOS:000184755900036
J	Brummelkamp, TR; Nijman, SMB; Dirac, AMG; Bernards, R				Brummelkamp, TR; Nijman, SMB; Dirac, AMG; Bernards, R			Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappa B	NATURE			English	Article							NECROSIS-FACTOR; DEUBIQUITINATING ENZYMES; TNF; MECHANISMS; KINASE; CANCER	Protein modification by the conjugation of ubiquitin moieties-ubiquitination- plays a major part in many biological processes, including cell cycle and apoptosis(1). The enzymes that mediate ubiquitin-conjugation have been well-studied, but much less is known about the ubiquitin-specific proteases that mediate deubiquitination of cellular substrates(2,3). To study this gene family, we designed a collection of RNA interference vectors to suppress 50 human de-ubiquitinating enzymes, and used these vectors to identify de-ubiquitinating enzymes in cancer-relevant pathways. We report here that inhibition of one of these enzymes, the familial cylindromatosis tumour suppressor gene (CYLD)(4), having no known function, enhances activation of the transcription factor NF-kappaB. We show that CYLD binds to the NEMO (also known as IKKgamma) component of the IkappaB kinase (IKK) complex, and appears to regulate its activity through de-ubiquitination of TRAF2, as TRAF2 ubiquitination can be modulated by CYLD. Inhibition of CYLD increases resistance to apoptosis, suggesting a mechanism through which loss of CYLD contributes to oncogenesis. We show that this effect can be relieved by aspirin derivatives that inhibit NF-kappaB activity(5), which suggests a therapeutic intervention strategy to restore growth control in patients suffering from familial cylindromatosis.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	高, 雨莉/HGU-8187-2022	Bernards, Rene/0000-0001-8677-3423				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Chung JY, 2002, J CELL SCI, V115, P679; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; VANBALKOM IDC, 1994, J MED GENET, V31, P321, DOI 10.1136/jmg.31.4.321; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	27	784	819	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2003	424	6950					797	801		10.1038/nature01811	http://dx.doi.org/10.1038/nature01811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917690	Green Published			2022-12-24	WOS:000184733900045
J	Nobrega, MA; Ovcharenko, I; Afzal, V; Rubin, EM				Nobrega, MA; Ovcharenko, I; Afzal, V; Rubin, EM			Scanning human gene deserts for long-range enhancers	SCIENCE			English	Article							DROSOPHILA DACHSHUND; EXPRESSION		US Dept Energy Joint Genome Inst, Walnut Creek, CA 94598 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Nobrega, MA (corresponding author), US Dept Energy Joint Genome Inst, Walnut Creek, CA 94598 USA.				NHLBI NIH HHS [HL66728] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Caubit X, 1999, DEV DYNAM, V214, P66, DOI 10.1002/(SICI)1097-0177(199901)214:1<66::AID-DVDY7>3.0.CO;2-7; Davis RJ, 1999, DEV GENES EVOL, V209, P526, DOI 10.1007/s004270050285; Ghanem N, 2003, GENOME RES, V13, P533, DOI 10.1101/gr.716103; KOTHARY R, 1988, NATURE, V335, P435, DOI 10.1038/335435a0; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Machon O, 2002, NEUROSCIENCE, V112, P951, DOI 10.1016/S0306-4522(02)00053-2	6	464	484	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	2003	302	5644					413	413		10.1126/science.1088328	http://dx.doi.org/10.1126/science.1088328			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732UD	14563999	Green Submitted			2022-12-24	WOS:000185963200032
J	Pearson, BJ; Doe, CQ				Pearson, BJ; Doe, CQ			Regulation of neuroblast competence in Drosophila	NATURE			English	Article							CELL-FATE DETERMINATION; CENTRAL-NERVOUS-SYSTEM; TRANSCRIPTION FACTORS; CEREBRAL-CORTEX; RETINA; CNS; PROJECTIONS; SEQUENCE; LINEAGES; BINDING	Individual neural progenitors generate different cell types in a reproducible order in the retina(1-3), cerebral cortex(4-6) and probably in the spinal cord(7). It is unknown how neural progenitors change over time to generate different cell types. It has been proposed that progenitors undergo progressive restriction(8) or transit through distinct competence states(9,10); however, the underlying molecular mechanisms remain unclear. Here we investigate neural progenitor competence and temporal identity using an in vivo genetic system-Drosophila neuroblasts-where the Hunchback transcription factor is necessary and sufficient to specify early-born cell types(11). We show that neuroblasts gradually lose competence to generate early-born fates in response to Hunchback, similar to progressive restriction models(8), and that competence to acquire early-born fates is present in mitotic precursors but is lost in post-mitotic neurons. These results match those observed in vertebrate systems, and establish Drosophila neuroblasts as a model system for the molecular genetic analysis of neural progenitor competence and plasticity.	Univ Oregon 1254, Howard Hughes Med Inst, Inst Neurosci & Mol Biol, Eugene, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon	Doe, CQ (corresponding author), Univ Oregon 1254, Howard Hughes Med Inst, Inst Neurosci & Mol Biol, Eugene, OR 97403 USA.			Pearson, Bret/0000-0002-3473-901X				ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; BUENZOW DE, 1995, DEV BIOL, V170, P338, DOI 10.1006/dbio.1995.1219; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Desai AR, 2000, DEVELOPMENT, V127, P2863; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; Kambadur R, 1998, GENE DEV, V12, P246, DOI 10.1101/gad.12.2.246; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Landgraf M, 1997, J NEUROSCI, V17, P9642; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; MCCONNELL SK, 1989, TRENDS NEUROSCI, V12, P342, DOI 10.1016/0166-2236(89)90041-6; Perron M, 1998, DEV BIOL, V199, P185, DOI 10.1006/dbio.1998.8939; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; Rapaport DH, 2001, J NEUROBIOL, V49, P129, DOI 10.1002/neu.1070; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; Schmid A, 1999, DEVELOPMENT, V126, P4653; Skeath JB, 1998, DEVELOPMENT, V125, P1857; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; Yang XH, 1997, GENE DEV, V11, P1396, DOI 10.1101/gad.11.11.1396; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	23	160	162	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2003	425	6958					624	628		10.1038/nature01910	http://dx.doi.org/10.1038/nature01910			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534589				2022-12-24	WOS:000185801000039
J	Winter, Y; Lopez, J; von Helversen, O				Winter, Y; Lopez, J; von Helversen, O			Ultraviolet vision in a bat	NATURE			English	Article							PHOTORECEPTORS; SENSITIVITY; LIGHT	Most mammals, with the exception of primates, have dichromatic vision and correspondingly limited colour perception(1). Ultraviolet vision was discovered in mammals only a decade ago(2), and in the few rodents and marsupials where it has been found, ultraviolet light is detected by an independent photoreceptor(2,3). Bats orient primarily by echolocation, but they also use vision. Here we show that a phyllostomid flower bat, Glossophaga soricina, is colour-blind but sensitive to ultraviolet light down to a wavelength of 310 nm. Behavioural experiments revealed a spectral-sensitivity function with maxima at 510 nm (green) and above 365 nm (ultraviolet). A test for colour vision was negative. Chromatic adaptation had the same threshold-elevating effects on ultraviolet and visible test lights, indicating that the same photoreceptor is responsible for both response peaks (ultraviolet and green). Thus, excitation of the beta-band of the visual pigment is the most likely cause of ultraviolet sensitivity. This is a mechanism for ultraviolet vision that has not previously been demonstrated in intact mammalian visual systems.	Univ Munich, Dept Biol, D-80333 Munich, Germany; Max Planck Res Ctr Ornithol, D-82305 Seewiesen, Germany; Univ San Carlos, Escuela Biol, Guatemala City 01012, Guatemala; Univ Erlangen Nurnberg, Inst Zool, D-91058 Erlangen, Germany	University of Munich; Max Planck Society; Universidad de San Carlos de Guatemala; University of Erlangen Nuremberg	Winter, Y (corresponding author), Univ Munich, Dept Biol, Luisenstr 14, D-80333 Munich, Germany.	winter@zi.biologie.uni-muenchen.de	Vazquez-Dominguez, Guillermo GVD/L-7818-2014	Winter, York/0000-0002-7828-1872				Arrese CA, 2002, CURR BIOL, V12, P657, DOI 10.1016/S0960-9822(02)00772-8; Biedinger N, 1993, TROP SUBTROP PFLANZE, V86, P1; CHASE J, 1983, ANIM BEHAV, V31, P526, DOI 10.1016/S0003-3472(83)80075-X; Douglas R.H., 1999, P95; Dyer AG, 1999, J COMP PHYSIOL A, V185, P445, DOI 10.1007/s003590050405; Govardovskii VI, 2000, VISUAL NEUROSCI, V17, P509, DOI 10.1017/S0952523800174036; GRISWOLD MS, 1992, VISION RES, V32, P1739, DOI 10.1016/0042-6989(92)90166-G; JACOBS GH, 1992, AM ZOOL, V32, P544; JACOBS GH, 1994, VISION RES, V34, P1433, DOI 10.1016/0042-6989(94)90144-9; JACOBS GH, 1991, NATURE, V353, P655, DOI 10.1038/353655a0; JACOBS GH, 1993, BIOL REV, V68, P413, DOI 10.1111/j.1469-185X.1993.tb00738.x; KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061; MORTON RA, 1972, HDB SENSORY PHYSIOLO, V7, P33; NEUMEYER C, 1988, FARBENSEHEN GOLDFISC; REMY M, 1989, BEHAV NEUROSCI, V103, P170, DOI 10.1037/0735-7044.103.1.170; SMITH H, 1982, ANNU REV PLANT PHYS, V33, P481, DOI 10.1146/annurev.pp.33.060182.002405; SUTHERS R, 1969, BIOL BULL, V137, P535, DOI 10.2307/1540174; VONCAMPENHAUSE C, 1986, NATURWISSENSCHAFTEN, V73, P674; Winter Y, 1999, J EXP BIOL, V202, P1917	19	103	107	3	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	2003	425	6958					612	614		10.1038/nature01971	http://dx.doi.org/10.1038/nature01971			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729XU	14534585				2022-12-24	WOS:000185801000035
J	Sharma, MR; Koc, EC; Datta, PP; Booth, TM; Spremulli, LL; Agrawal, RK				Sharma, MR; Koc, EC; Datta, PP; Booth, TM; Spremulli, LL; Agrawal, RK			Structure of the mammalian mitochondrial ribosome reveals an expanded functional role for its component proteins	CELL			English	Article							COLI 70S RIBOSOME; 3-DIMENSIONAL CRYOELECTRON MICROSCOPY; TRANSFER-RNA; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; COMPARATIVE SEQUENCE; TRANSLATION SYSTEM; CRYSTAL-STRUCTURE; MESSENGER-RNA	The mitochondrial ribosome is responsible for the biosynthesis of protein components crucial to the generation of ATP in the eukaryotic cell. Because the protein:RNA ratio in the mitochondrial ribosome (similar to69:similar to31) is the inverse of that of its prokaryotic counterpart (similar to33:similar to67), it was thought that the additional and/or larger proteins of the mitochondrial ribosome must compensate for the shortened rRNAs. Here, we present a three-dimensional cryo-electron microscopic map of the mammalian mitochondrial 55S ribosome carrying a tRNA at its P site, and we find that instead, many of the proteins occupy new positions in the ribosome. Furthermore, unlike cytoplasmic ribosomes, the mitochondrial ribosome possesses inter-subunit bridges composed largely of proteins; it has a gatelike structure at its mRNA entrance, perhaps involved in recruiting unique mitochondrial mRNAs; and it has a polypeptide exit tunnel that allows access to the solvent before the exit site, suggesting a unique nascent-polypeptide exit mechanism.	New York State Dept Hlth, Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA	State University of New York (SUNY) System; Wadsworth Center; University of North Carolina; University of North Carolina Chapel Hill; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Agrawal, RK (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Div Mol Med, Empire State Plaza, Albany, NY 12201 USA.	agrawal@wadsworth.org			NIGMS NIH HHS [GM32734, GM61576, R01 GM061576] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734, R01GM061576] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-2; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; Dube P, 1998, J MOL BIOL, V279, P403, DOI 10.1006/jmbi.1998.1804; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Frank J, 2000, METHOD ENZYMOL, V317, P276; FRANK J, 2001, S QUANT BIOL, V66, P67; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Gabashvili IS, 2001, MOL CELL, V8, P181, DOI 10.1016/S1097-2765(01)00293-3; Gomez-Lorenzo MG, 2000, EMBO J, V19, P2710, DOI 10.1093/emboj/19.11.2710; Gray MW, 2001, GENOME BIOL, V2; Hanada T, 2001, GENES CELLS, V6, P1019, DOI 10.1046/j.1365-2443.2001.00491.x; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koc EC, 2000, J BIOL CHEM, V275, P32585, DOI 10.1074/jbc.M003596200; Koc EC, 2001, FEBS LETT, V492, P166, DOI 10.1016/S0014-5793(01)02250-5; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; Mears JA, 2002, J MOL BIOL, V321, P215, DOI 10.1016/S0022-2836(02)00568-5; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; O'Brien TW, 2002, GENE, V286, P73, DOI 10.1016/S0378-1119(01)00808-3; O'Brien TW, 2000, J BIOL CHEM, V275, P18153, DOI 10.1074/jbc.M909762199; OBRIEN TW, 1990, BIOCHIM BIOPHYS ACTA, V1050, P174, DOI 10.1016/0167-4781(90)90162-U; OBRIEN TW, 1971, J BIOL CHEM, V246, P3409; Ohtsuki T, 2002, FEBS LETT, V514, P37, DOI 10.1016/S0014-5793(02)02328-1; OJALA DK, 1980, NATURE, V287, P79, DOI 10.1038/287079a0; Orlova EV, 1997, J MOL BIOL, V271, P417, DOI 10.1006/jmbi.1997.1182; Patel VB, 2001, J BIOL CHEM, V276, P6739, DOI 10.1074/jbc.M005781200; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; REMME J, 1989, EUR J BIOCHEM, V183, P281, DOI 10.1111/j.1432-1033.1989.tb14925.x; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; Spahn CMT, 2000, STRUCTURE, V8, P937, DOI 10.1016/S0969-2126(00)00185-4; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Stuart RA, 2002, BBA-MOL CELL RES, V1592, P79, DOI 10.1016/S0167-4889(02)00266-5; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Suzuki T, 2001, J BIOL CHEM, V276, P21724, DOI 10.1074/jbc.M100432200; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wittmann-Liebold B., 1985, STRUCTURE FUNCTION G, P326; WOLSTENHOLME D, 1992, ANIMAL MITOCHONDRIAL, P173; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	54	274	287	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	2003	115	1					97	108		10.1016/S0092-8674(03)00762-1	http://dx.doi.org/10.1016/S0092-8674(03)00762-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532006	Green Published, Bronze			2022-12-24	WOS:000185815500012
J	Hviid, A; Stellfeld, M; Wohlfahrt, J; Melbye, M				Hviid, A; Stellfeld, M; Wohlfahrt, J; Melbye, M			Association between thimerosal-containing vaccine and autism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPULATION; REGISTER; MERCURY	Context Mercuric compounds are nephrotoxic and neurotoxic at high doses. Thimerosal, a preservative used widely in vaccine formulations, contains ethylmercury. Thus it has been suggested that childhood vaccination with thimerosal-containing vaccine could be causally related to neurodevelopmental disorders such as autism. Objective To determine whether vaccination with a thimerosal-containing vaccine is associated with development of autism. Design, Setting, and Participants Population-based cohort study of all children born in Denmark from January 1, 1990, until December 31, 1996 (N =467450) comparing children vaccinated with a thimerosal-containing vaccine with children vaccinated with a thimerosal-free formulation of the same vaccine. Main Outcome Measures Rate ratio (RR) for autism and other autistic-spectrum disorders, including trend with dose of ethylmercury. Results During 2986654 person-years, we identified 440 autism cases and 787 cases of other autistic-spectrum disorders. The risk of autism and other autistic-spectrum disorders did not differ significantly between children vaccinated with thimerosal-containing vaccine and children vaccinated with thimerosal-free vaccine (RR, 0.85 [95% confidence interval (0), 0.60-1.20] for autism; RR, 1.12 [95% Cl, 0.88-1.43] for other autistic-spectrum disorders). Furthermore, we found no evidence of a dose-response association (increase in RR per 25 mug of ethylmercury, 0.98 [95% Cl, 0.90-1.06] for autism and 1.03 [95% Cl, 0.98-1.09] for other autistic-spectrum disorders). Conclusion The results do not support a causal relationship between childhood vaccination with thimerosal-containing vaccines and development of autistic-spectrum disorders.	Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark; Statens Serum Inst, Dept Med, DK-2300 Copenhagen, Denmark	Aarhus University; Statens Serum Institut; Statens Serum Institut	Hviid, A (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.		Hviid, Anders/AAH-4319-2020	Hviid, Anders/0000-0002-7509-9127; melbye, mads/0000-0001-8264-6785				Andersen TF, 1999, DAN MED BULL, V46, P263; Ball LK, 2001, PEDIATRICS, V107, P1147, DOI 10.1542/peds.107.5.1147; Bertrand J, 2001, PEDIATRICS, V108, P1155, DOI 10.1542/peds.108.5.1155; Clarkson TW, 1997, CRIT REV CL LAB SCI, V34, P369, DOI 10.3109/10408369708998098; Hills, 1993, STAT MODELS EPIDEMIO; Knudsen LB, 1998, DAN MED BULL, V45, P320; Madsen KM, 2002, NEW ENGL J MED, V347, P1477, DOI 10.1056/NEJMoa021134; MALIG C, 1996, 6 IIVRS; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Pichichero ME, 2002, LANCET, V360, P1737, DOI 10.1016/S0140-6736(02)11682-5; Plesner A M, 1994, Ugeskr Laeger, V156, P7497; Ronne T, 1997, Ugeskr Laeger, V159, P1584; Stratton K, 2001, IMMUNIZATION SAFETY	13	175	183	0	108	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2003	290	13					1763	1766		10.1001/jama.290.13.1763	http://dx.doi.org/10.1001/jama.290.13.1763			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	726NQ	14519711				2022-12-24	WOS:000185606100026
J	Fewell, JH				Fewell, JH			Social insect networks	SCIENCE			English	Editorial Material							DIVISION-OF-LABOR; COLLECTIVE DECISION-MAKING; SELF-ORGANIZATION; SELECTION; EVOLUTION; COLONIES; RECRUITMENT; BEE	Social insect colonies have many of the properties of adaptive networks. The simple rules governing how local interactions among individuals translate into group behaviors are found across social groups, giving social insects the potential to have a profound impact on our understanding of the interplay between network dynamics and social evolution.	Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Fewell, JH (corresponding author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.	j.fewell@asu.edu						Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Alon U, 2003, SCIENCE, V301, P1866, DOI 10.1126/science.1089072; Barabasi A. L., 2002, FORMULA UNIVERSAL LA; Beshers SN, 2001, ANNU REV ENTOMOL, V46, P413, DOI 10.1146/annurev.ento.46.1.413; Bonabeau E, 1998, J THEOR BIOL, V195, P157, DOI 10.1006/jtbi.1998.0789; Bray D, 2003, SCIENCE, V301, P1864, DOI 10.1126/science.1089118; CAMAZINE S, 1993, BEHAV ECOL SOCIOBIOL, V32, P265, DOI 10.1007/BF00166516; Camazine S., 2001, SELF ORG BIOL SYSTEM, DOI DOI 10.1515/9780691212920; Fewell JH, 1999, EVOL ECOL RES, V1, P537; FEWELL JH, 1992, BEHAV ECOL SOCIOBIOL, V30, P387, DOI 10.1007/BF00176173; Gordon DM, 2002, AM NAT, V159, P509, DOI 10.1086/339461; GOSS S, 1989, NATURWISSENSCHAFTEN, V76, P579, DOI 10.1007/BF00462870; GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469; Hemelrijk CK, 2002, BIOL BULL-US, V202, P283, DOI 10.2307/1543480; Hemelrijk CK, 2002, ETHOLOGY, V108, P655, DOI 10.1046/j.1439-0310.2002.00812.x; HOGEWEG P, 1983, BEHAV ECOL SOCIOBIOL, V12, P271, DOI 10.1007/BF00302895; Holldobler B., 1990, pi; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Moore AJ, 1997, EVOLUTION, V51, P1352, DOI 10.1111/j.1558-5646.1997.tb01458.x; NAUMANN K, 1991, BEHAV ECOL SOCIOBIOL, V29, P321, DOI 10.1007/BF00165956; Pacala SW, 1996, EVOL ECOL, V10, P127, DOI 10.1007/BF01241782; Page RE, 2002, NATURWISSENSCHAFTEN, V89, P91, DOI 10.1007/s00114-002-0299-x; Page RE, 1998, APIDOLOGIE, V29, P171, DOI 10.1051/apido:19980110; Robson SK, 1999, INFORMATION PROCESSING IN SOCIAL INSECTS, P239; Saffre F, 1999, J THEOR BIOL, V198, P507, DOI 10.1006/jtbi.1999.0927; Seeley TD, 1997, AM NAT, V150, pS22, DOI 10.1086/286048; SEELEY TD, 1991, BEHAV ECOL SOCIOBIOL, V28, P277, DOI 10.1007/BF00175101; Sole R, 2000, SIGNS LIFE COMPLEXIT; SOLE R, 2000, SANTA FE WORKING PAP; Theraulaz G, 1998, P ROY SOC B-BIOL SCI, V265, P327, DOI 10.1098/rspb.1998.0299; Wilson DS, 1997, AM NAT, V149, P336, DOI 10.1086/285993; Wilson DS, 1997, AM NAT, V150, pS1, DOI 10.1086/286046	32	204	205	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2003	301	5641					1867	1870		10.1126/science.1088945	http://dx.doi.org/10.1126/science.1088945			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512616				2022-12-24	WOS:000185536700038
J	McMurray, MA; Gottschling, DE				McMurray, MA; Gottschling, DE			An age-induced switch to a hyper-recombinational state	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; MITOTIC RECOMBINATION; GENE CONVERSION; LIFE-SPAN; YEAST; MUTATION; CELLS; REPLICATION; TELOMERE; CANCER	There is a strong correlation between age and cancer, but the mechanism by which this phenomenon occurs is unclear. We chose Saccharomyces cerevisiae to examine one of the hallmarks of cancer-genomic instability as a function of cellular age. As diploid yeast mother cells aged, an similar to100-fold increase in loss of heterozygosity (LOH) occurred. Extending life-span altered neither the onset nor the frequency of age-induced LOH; the switch to hyper-LOH appears to be on its own clock. In young cells, LOH occurs by reciprocal recombination, whereas LOH in old cells was nonreciprocal, occurring predominantly in the old mother's progeny. Thus, nuclear genomes may be inherently unstable with age.	Univ Washington, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Gottschling, DE (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACUNA G, 1994, ENVIRON MOL MUTAGEN, V24, P307, DOI 10.1002/em.2850240408; Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Aguilera A, 2000, YEAST, V16, P731, DOI 10.1002/1097-0061(20000615)16:8<731::AID-YEA586>3.0.CO;2-L; Cairns J, 2002, P NATL ACAD SCI USA, V99, P10567, DOI 10.1073/pnas.162369899; Cost GJ, 1996, YEAST, V12, P939, DOI 10.1002/(SICI)1097-0061(199608)12:10<939::AID-YEA988>3.3.CO;2-C; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991; FOGEL S, 1963, GENETICS, V48, P321; Frank SA, 2003, GENETICS, V163, P1527; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; Jazwinski SM, 2001, MECH AGEING DEV, V122, P865, DOI 10.1016/S0047-6374(01)00244-5; JUDD SR, 1988, GENETICS, V118, P401; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; MCMURRAY MA, UNPUB; Morley A, 1998, ANN NY ACAD SCI, V854, P20, DOI 10.1111/j.1749-6632.1998.tb09888.x; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; ROMAN H, 1956, COLD SPRING HARB SYM, V21, P175, DOI 10.1101/SQB.1956.021.01.015; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; ZIMMERMANN FK, 1975, MUTAT RES, V31, P71, DOI 10.1016/0165-1161(75)90069-2	25	178	181	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1908	1911		10.1126/science.1087706	http://dx.doi.org/10.1126/science.1087706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	14512629				2022-12-24	WOS:000185536700051
J	Holland, A; Whittington, J; Hinton, E				Holland, A; Whittington, J; Hinton, E			The paradox of Prader-Willi syndrome: a genetic model of starvation	LANCET			English	Article							GROWTH-HORMONE; ACYLATED PEPTIDE; IMPRINTED GENES; GHRELIN; LEPTIN; FETAL; ILLNESS; OBESITY; PEOPLE; WOMEN	The neurodevelopmental disorder, Prader-Willi syndrome, is generally regarded as a genetic model of obesity. Although the values of some hypothalamic neuropeptides are as expected in obesity, and should result in satiety, we propose that abnormal hypothalamic pathways mean that these are ineffective. We postulate that the body incorrectly interprets the absence of satiation as starvation, and therefore, paradoxically, this syndrome should be redefined as one of starvation that manifests as obesity in a food-rich environment. Also, this syndrome is generally believed to be a contiguous gene disorder, which results from the absence of expression of the paternally derived alleles of maternally imprinted genes on chromosome 15 (15q11-13). We argue, however, that the whole phenotype can be explained by one mechanism and, by implication, the failure of expression of the paternal allele of a single maternally imprinted gene that controls energy balance. We suggest clinical and laboratory approaches to test our hypotheses.	Sect Dev Psychiat, Cambridge CB2 2AH, England		Holland, A (corresponding author), Sect Dev Psychiat, Douglas House, Cambridge CB2 2AH, England.	ajh1008@cam.ac.uk		Hinton, Elanor/0000-0003-2793-8552				Bajoria R, 2002, PLACENTA, V23, P103, DOI 10.1053/plac.2001.0769; Boer H, 2002, LANCET, V359, P135, DOI 10.1016/S0140-6736(02)07340-3; Casanueva Felipe F, 2002, Rev Endocr Metab Disord, V3, P325, DOI 10.1023/A:1020901624103; Chanoine JP, 2002, J PEDIATR GASTR NUTR, V35, P282, DOI 10.1097/00005176-200209000-00009; Date Y, 2000, BIOCHEM BIOPH RES CO, V275, P477, DOI 10.1006/bbrc.2000.3342; DelPparigi A, 2002, J CLIN ENDOCR METAB, V87, P5461, DOI 10.1210/jc.2002-020871; Gallagher RC, 2002, AM J HUM GENET, V71, P669, DOI 10.1086/342408; Ge YL, 2002, BRAIN RES, V957, P42, DOI 10.1016/S0006-8993(02)03583-7; Goldstone AP, 2002, J CLIN ENDOCR METAB, V87, P927, DOI 10.1210/jc.87.2.927; Goldstone AP, 2002, AM J CLIN NUTR, V75, P468, DOI 10.1093/ajcn/75.3.468; Holland AJ, 2003, PSYCHOL MED, V33, P141, DOI 10.1017/S0033291702006736; HOLLAND AJ, 1993, INT J OBESITY, V17, P527; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lobie PE, 2000, GROWTH HORM IGF RES, V10, P51; Miozzo M, 2002, BIOL NEONATE, V81, P217, DOI 10.1159/000056752; Muller J, 1997, ACTA PAEDIATR, V86, P58; Reik W, 2001, NOVART FDN SYMP, V237, P19, DOI 10.1002/0470846666.ch3; Schwartz MW, 2002, NATURE, V418, P595, DOI 10.1038/418595a; Tolle V, 2003, J CLIN ENDOCR METAB, V88, P109, DOI 10.1210/jc.2002-020645; WHITMAN BY, 2001, 4 TRIENN IPWSO SCI C	20	58	64	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 20	2003	362	9388					989	991		10.1016/S0140-6736(03)14370-X	http://dx.doi.org/10.1016/S0140-6736(03)14370-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14511934				2022-12-24	WOS:000185489600023
J	Rainey, PB; Rainey, K				Rainey, PB; Rainey, K			Evolution of cooperation and conflict in experimental bacterial populations	NATURE			English	Article							COMPETITION; DIVERGENCE; DIVERSITY; ORIGIN	A fundamental problem in biology is the evolutionary transition from single cells to multicellular life forms(1-3). During this transition the unit of selection shifts from individual cells to groups of cooperating cells(1,3,4). Although there is much theory(5-15), there are few empirical studies(16). Here we describe an evolutionary transition that occurs in experimental populations of Pseudomonas fluorescens propagated in a spatially heterogeneous environment(17). Cooperating groups are formed by over-production of an adhesive polymer(18), which causes the interests of individuals to align with those of the group. The costs and benefits of cooperation, plus evolutionary susceptibility to defecting genotypes, were analysed to determine conformation to theory(1,3,12). Cooperation was costly to individuals, but beneficial to the group. Defecting genotypes evolved in populations founded by the cooperating type and were fitter in the presence of this type than in its absence. In the short term, defectors sabotaged the viability of the group; but these findings nevertheless show that transitions to higher orders of complexity are readily achievable, provide insights into the selective conditions, and facilitate experimental analysis of the evolution of individuality.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England; Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand	University of Oxford; University of Auckland	Rainey, PB (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	p.rainey@auckland.ac.nz	Rainey, Paul/A-3207-2008	Rainey, Paul/0000-0003-0879-5795				AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Bell G., 1985, ORIGIN EVOLUTION SEX, P221; Bonner JT., 2000, 1 SIGNALS EVOLUTION; Boraas ME, 1998, EVOL ECOL, V12, P153, DOI 10.1023/A:1006527528063; Buckling A, 2000, NATURE, V408, P961, DOI 10.1038/35050080; Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI 10.1515/9781400858712; Dawkins R, 1976, SELFISH GENE; Ferriere R, 1996, AM NAT, V147, P692, DOI 10.1086/285875; Foster KR, 2002, P ROY SOC B-BIOL SCI, V269, P2357, DOI 10.1098/rspb.2002.2163; FRANK SA, 1995, NATURE, V377, P520, DOI 10.1038/377520a0; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Kassen R, 2000, NATURE, V406, P508, DOI 10.1038/35020060; Kerszberg M, 1998, J THEOR BIOL, V193, P535, DOI 10.1006/jtbi.1998.0714; KOUFOPANOU V, 1993, P ROY SOC B-BIOL SCI, V254, P107, DOI 10.1098/rspb.1993.0134; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; Maynard Smith J., 1988, EVOLUTIONARY PROGR, P219; Michod RE., 1999, DARWINIAN DYNAMICS; Pfeiffer T, 2003, P NATL ACAD SCI USA, V100, P1095, DOI 10.1073/pnas.0335420100; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Queller DC, 2003, SCIENCE, V299, P105, DOI 10.1126/science.1077742; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Smith J, 2001, P ROY SOC B-BIOL SCI, V268, P61, DOI 10.1098/rspb.2000.1330; Smith J. M., 1995, MAJOR TRANSITIONS EV; Sober E., 1998, OTHERS EVOLUTION PSY; Spiers AJ, 2002, GENETICS, V161, P33; Velicer GJ, 2003, NATURE, V425, P75, DOI 10.1038/nature01908; Williams G. C., 1966, P307; WILSON DS, 1975, P NATL ACAD SCI USA, V72, P143, DOI 10.1073/pnas.72.1.143; Wolf JB, 2003, P NATL ACAD SCI USA, V100, P4655, DOI 10.1073/pnas.0635741100; WOLPERT L, 1990, BIOL J LINN SOC, V39, P109, DOI 10.1111/j.1095-8312.1990.tb00506.x	31	394	402	1	239	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					72	74		10.1038/nature01906	http://dx.doi.org/10.1038/nature01906			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955142				2022-12-24	WOS:000185089200039
J	Hamilton, SR; Bobrowicz, P; Bobrowicz, B; Davidson, RC; Li, HJ; Mitchell, T; Nett, JH; Rausch, S; Stadheim, TA; Wischnewski, H; Wildt, S; Gerngross, TU				Hamilton, SR; Bobrowicz, P; Bobrowicz, B; Davidson, RC; Li, HJ; Mitchell, T; Nett, JH; Rausch, S; Stadheim, TA; Wischnewski, H; Wildt, S; Gerngross, TU			Production of complex human glycoproteins in yeast	SCIENCE			English	Article							LINKED GLYCOSYLATION; PICHIA-PASTORIS; OLIGOSACCHARIDES; GOLGI	We report the humanization of the glycosylation pathway in the yeast Pichia pastoris to secrete a human glycoprotein with uniform complex N-glycosylation. The process involved eliminating endogenous yeast glycosylation pathways, while properly localizing five active eukaryotic proteins, including mannosidases I and II, N-acetylglucosaminyl transferases I and II, and uridine 5'-diphosphate (UDP)-N-acetylglucosamine transporter. Targeted localization of the enzymes enabled the generation of a synthetic in vivo glycosylation pathway, which produced the complex human N-glycan N-acetylglucosamine(2)-mannose(3)-N-acetylglucosamine(2) (GlcNAc(2)Man(3)GlcNAc(2)). The ability to generate human glycoproteins with homogeneous N-glycan structures in a fungal host is a step toward producing therapeutic glycoproteins and could become a tool for elucidating the structure-function relation of glycoproteins.	Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Gerngross, TU (corresponding author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM066690] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R43GM66690-1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; Cregg JM, 2000, MOL BIOTECHNOL, V16, P23, DOI 10.1385/MB:16:1:23; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; FOSTER JM, 1995, GENE, V154, P183, DOI 10.1016/0378-1119(94)00867-R; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200	7	283	404	4	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1244	1246		10.1126/science.1088166	http://dx.doi.org/10.1126/science.1088166			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947202				2022-12-24	WOS:000185003500045
J	Stovring, H; Andersen, M; Beck-Nielsen, H; Green, A; Vach, W				Stovring, H; Andersen, M; Beck-Nielsen, H; Green, A; Vach, W			Rising prevalence of diabetes: Evidence from a Danish pharmaco-epidemiological database.	LANCET			English	Article								The prevalence of diabetes has Increased worldwide. We have undertaken an epidemiological analysis of drug-treated diabetes In a well defined community. We present estimates of prevalence, incidence, and mortality of patients with such diabetes during 1993-99, based on data for all 470 000 people living in the county of Fyn, Denmark. Although prevalence increased (odds ratio: female, 1.026 [95% CI 1.020-1.032]; male, 1.041 [1.036-1.047]), mortality in those treated declined (rate ratio: female, 0.976 [95% CI 0.952-1.001]; male, 0.966 [0.943-0.990]). We did not identify a clear trend for incidence. Future research into the causes of rising diabetes prevalence should take this fall in mortality into account to avoid incorrect conclusions about the relation between western lifestyle and the growing number of diabetics.	Univ So Denmark, Res Unit Gen Practice, DK-5000 Odense, Denmark; Aarhus Univ, Natl Ctr Registerbased Res, Aarhus, Denmark; Aarhus Univ, Dept Epidemiol & Social Med, DK-8000 Aarhus C, Denmark; Univ So Denmark, Inst Publ Hlth, Odense, Denmark; Univ So Denmark, Dept Stat & Demog, Odense, Denmark; Odense Univ Hosp, Diabet Res Ctr, DK-5000 Odense, Denmark	University of Southern Denmark; Aarhus University; Aarhus University; University of Southern Denmark; University of Southern Denmark; University of Southern Denmark; Odense University Hospital	Stovring, H (corresponding author), Univ So Denmark, Res Unit Gen Practice, DK-5000 Odense, Denmark.		Støvring, Henrik/I-4683-2012; Støvring, Henrik/H-5754-2019; Vach, Werner/F-2512-2011; Andersen, Morten/H-3555-2011	Støvring, Henrik/0000-0002-5821-2351; Støvring, Henrik/0000-0002-5821-2351; Vach, Werner/0000-0003-1865-8399; Andersen, Morten/0000-0001-7029-2860				*DAN MED AG, 1998, ANT FORBR ANT 1994 1; HALLAS J, 1994, EUR J CLIN PHARMACOL, V47, P367; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; *WHO, 2001, ATC DDDS GUID ATC CL; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	5	74	77	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					537	538		10.1016/S0140-6736(03)14116-5	http://dx.doi.org/10.1016/S0140-6736(03)14116-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932388				2022-12-24	WOS:000184817600013
J	Tonks, A				Tonks, A			Commentary: Information for patients: What happens during cognitive behaviour therapy for bulimia	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ Unified, London WC1H 9JR, England		Tonks, A (corresponding author), BMJ Unified, London WC1H 9JR, England.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					382	382		10.1136/bmj.327.7411.382	http://dx.doi.org/10.1136/bmj.327.7411.382			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919995	Green Published			2022-12-24	WOS:000184864200024
J	Calvi, LM; Adams, GB; Weibrecht, KW; Weber, JM; Olson, DP; Knight, MC; Martin, RP; Schipani, E; Divieti, P; Bringhurst, FR; Milner, LA; Kronenberg, HM; Scadden, DT				Calvi, LM; Adams, GB; Weibrecht, KW; Weber, JM; Olson, DP; Knight, MC; Martin, RP; Schipani, E; Divieti, P; Bringhurst, FR; Milner, LA; Kronenberg, HM; Scadden, DT			Osteoblastic cells regulate the haematopoietic stem cell niche	NATURE			English	Article							BONE-MARROW; GROWTH-FACTOR; SELF-RENEWAL; NOTCH; LINEAGE	Stem cell fate is influenced by specialized microenvironments that remain poorly defined in mammals(1-3). To explore the possibility that haematopoietic stem cells derive regulatory information from bone, accounting for the localization of haematopoiesis in bone marrow, we assessed mice that were genetically altered to produce osteoblast-specific, activated PTH/PTHrP receptors (PPRs)(4). Here we show that PPR-stimulated osteoblastic cells that are increased in number produce high levels of the Notch ligand jagged 1 and support an increase in the number of haematopoietic stem cells with evidence of Notch1 activation in vivo. Furthermore, ligand-dependent activation of PPR with parathyroid hormone (PTH) increased the number of osteoblasts in stromal cultures, and augmented ex vivo primitive haematopoietic cell growth that was abrogated by gamma-secretase inhibition of Notch activation. An increase in the number of stem cells was observed in wild-type animals after PTH injection, and survival after bone marrow transplantation was markedly improved. Therefore, osteoblastic cells are a regulatory component of the haematopoietic stem cell niche in vivo that influences stem cell function through Notch activation. Niche constituent cells or signalling pathways provide pharmacological targets with therapeutic potential for stem-cell-based therapies.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Canc Ctr, Partners AIDS Res Ctr,Ctr Regenerat Med & Technol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02114 USA; Univ Rochester, Sch Med, Dept Med, Endocrine Unit, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Pediat, Ctr Human Genet & Mol Pediat Dis, Rochester, NY 14642 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Rochester; University of Rochester	Scadden, DT (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Canc Ctr, Partners AIDS Res Ctr,Ctr Regenerat Med & Technol, Boston, MA 02114 USA.	scadden.david@mgh.harvard.edu	Calvi, Laura/P-6988-2019	Calvi, Laura/0000-0001-6969-239X; Divieti Pajevic, Paola/0000-0001-9853-9837; Weber, Jonathan/0000-0002-6015-8454	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK064381] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK064381, K08 DK064381-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cui YF, 1996, CELL PROLIFERAT, V29, P243, DOI 10.1046/j.1365-2184.1996.00999.x; Giri N, 2001, EXP HEMATOL, V29, P779, DOI 10.1016/S0301-472X(01)00646-4; GONG JK, 1978, SCIENCE, V199, P1443, DOI 10.1126/science.75570; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Karanu FN, 2001, BLOOD, V97, P1960, DOI 10.1182/blood.V97.7.1960; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; LORD BI, 1990, INT J CELL CLONING, V8, P317, DOI 10.1002/stem.5530080501; LORD BI, 1975, BLOOD, V46, P65; Pereira RMR, 2002, J CELL BIOCHEM, V85, P252, DOI 10.1002/jcb.10125; PLOEMACHER RE, 1991, BLOOD, V78, P2527; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518; TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677; Taichman RS, 2001, BRIT J HAEMATOL, V112, P438, DOI 10.1046/j.1365-2141.2001.02568.x; Taichman RUSSELL S., 2000, Hematology, V4, P421; Tran J, 2000, NATURE, V407, P754, DOI 10.1038/35037613; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 2003, BLOOD, V101, P1784, DOI 10.1182/blood-2002-06-1862; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	26	2587	2743	5	188	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	2003	425	6960					841	846		10.1038/nature02040	http://dx.doi.org/10.1038/nature02040			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14574413	Bronze			2022-12-24	WOS:000186118500046
J	Elia, AEH; Rellos, P; Haire, LF; Chao, JW; Ivins, FJ; Hoepker, K; Mohammad, D; Cantley, LC; Smerdon, SJ; Yaffe, MB				Elia, AEH; Rellos, P; Haire, LF; Chao, JW; Ivins, FJ; Hoepker, K; Mohammad, D; Cantley, LC; Smerdon, SJ; Yaffe, MB			The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain	CELL			English	Article							PHOSPHOSERINE/THREONINE-BINDING DOMAINS; SACCHAROMYCES-CEREVISIAE CDC5; TYROSINE KINASE HCK; CELL-CYCLE; STRUCTURAL BASIS; PROTEIN-KINASE; M-PHASE; CRYSTAL-STRUCTURE; UBIQUITIN LIGASE; MAMMALIAN-CELLS	Polo-like kinases (Plks) perform crucial functions in cell-cycle progression and multiple stages of mitosis. Plks are characterized by a C-terminal noncatalytic region containing two tandem Polo boxes, termed the Polo-box domain (PBD), which has recently been implicated in phosphodependent substrate targeting. We show that the PBDs of human, Xenopus, and yeast Plks all recognize similar phosphoserine/threonine-containing motifs. The 1.9 Angstrom X-ray structure of a human Plk1 PBD-phosphopeptide complex shows that the Polo boxes each comprise beta(6)alpha structures that associate to form a 12-stranded beta sandwich domain. The phosphopeptide binds along a conserved, positively charged cleft located at the edge of the Polo-box interface. Mutations that specifically disrupt phosphodependent interactions abolish cell-cycle-dependent localization and provide compelling phenotypic evidence that PBD-phospholigand binding is necessary for proper mitotic progression. In addition, phosphopeptide binding to the PBD stimulates kinase activity in full-length Plk1, suggesting a conformational switching mechanism for Plk regulation and a dual functionality for the PBD.	Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Beth Israel Deaconess Hosp, Sch Med, Dept Cell Biol,Div Signal Transduct, Boston, MA 02215 USA	MRC National Institute for Medical Research; Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Smerdon, SJ (corresponding author), Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Smerdon, Stephen/0000-0001-5688-8465	NIGMS NIH HHS [R01 GM056203, GM60594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594, R01GM056203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Conn CW, 2000, CANCER RES, V60, P6826; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Grallert A, 2002, EMBO J, V21, P3096, DOI 10.1093/emboj/cdf294; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1999, P NATL ACAD SCI USA, V96, P14360, DOI 10.1073/pnas.96.25.14360; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; LIU XQ, 1993, ONCOGENE, V8, P1119; Ma S, 2003, MOL CANCER RES, V1, P376; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reynolds N, 2003, J CELL SCI, V116, P1377, DOI 10.1242/jcs.00314; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2000, METHOD ENZYMOL, V328, P157, DOI 10.1016/S0076-6879(00)28397-3; Yaffe MB, 2001, STRUCTURE, V9, pR33, DOI 10.1016/S0969-2126(01)00580-9; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7	50	589	606	1	39	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 3	2003	115	1					83	95		10.1016/S0092-8674(03)00725-6	http://dx.doi.org/10.1016/S0092-8674(03)00725-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	730ED	14532005	Bronze			2022-12-24	WOS:000185815500011
J	Tang, XD; Xu, R; Reynolds, MF; Garcia, ML; Heinemann, SH; Hoshi, T				Tang, XD; Xu, R; Reynolds, MF; Garcia, ML; Heinemann, SH; Hoshi, T			Haem can bind to and inhibit mammalian calcium-dependent Slo1 BK channels	NATURE			English	Article							CA2+-ACTIVATED K+ CHANNELS; CRYSTAL-STRUCTURE; MEMBRANE	Haem is essential for living organisms, functioning as a crucial element in the redox-sensitive reaction centre in haemproteins(1). During the biogenesis of these proteins, the haem cofactor is typically incorporated enzymatically into the haem pockets of the apo-haemprotein as the functionally indispensable prosthetic group(2,3). A class of ion channel, the large-conductance calcium-dependent Slo1 BK channels, possesses a conserved haem-binding sequence motif. Here we present electrophysiological and structural evidence showing that haem directly regulates cloned human Slo1 channels and wild-type BK channels in rat brain. Both oxidized and reduced haem binds to the hSlo1 channel protein and profoundly inhibits transmembrane K+ currents by decreasing the frequency of channel opening. This direct regulation of the BK channel identifies a previously unknown role of haem as an acute signalling molecule.	Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; St Josephs Univ, Dept Chem, Philadelphia, PA 19131 USA; Merck Res Labs, Dept Ion Channels, Rahway, NJ 07065 USA; Univ Jena, Fac Med, Res Unit Mol & Cellular Biophys, D-07747 Jena, Germany	University of Pennsylvania; Saint Joseph's University; Merck & Company; Friedrich Schiller University of Jena	Hoshi, T (corresponding author), Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA.	hoshi@hoshi.org		Heinemann, Stefan H./0000-0002-4144-0251				Blackmon BJ, 2002, ARCH BIOCHEM BIOPHYS, V407, P196, DOI 10.1016/S0003-9861(02)00471-X; BRAUTIGAN DL, 1977, J BIOL CHEM, V252, P574; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; Dore S, 2002, FREE RADICAL BIO MED, V32, P1276, DOI 10.1016/S0891-5849(02)00805-5; Granick S, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P33; Gribkoff VK, 2001, NAT MED, V7, P471, DOI 10.1038/86546; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; More C, 1999, BIOSPECTROSCOPY, V5, pS3, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S3::AID-BSPY2>3.0.CO;2-P; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Ricci AJ, 2000, J PHYSIOL-LONDON, V524, P423, DOI 10.1111/j.1469-7793.2000.00423.x; SHAKLAI N, 1985, BIOCHIM BIOPHYS ACTA, V821, P355, DOI 10.1016/0005-2736(85)90106-3; Siemen D, 1999, BIOCHEM BIOPH RES CO, V257, P549, DOI 10.1006/bbrc.1999.0496; Taketani S, 1998, J BIOL CHEM, V273, P31388, DOI 10.1074/jbc.273.47.31388; Tang XD, 2001, J GEN PHYSIOL, V117, P253, DOI 10.1085/jgp.117.3.253; Worthington MT, 2001, AM J PHYSIOL-GASTR L, V280, pG1172, DOI 10.1152/ajpgi.2001.280.6.G1172; Xu WH, 2002, SCIENCE, V298, P1029, DOI 10.1126/science.1074360; Yermolaieva O, 2001, BIOPHYS J, V80, p237A; ZhuGe R, 2000, J GEN PHYSIOL, V116, P845, DOI 10.1085/jgp.116.6.845	19	224	234	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					531	535		10.1038/nature02003	http://dx.doi.org/10.1038/nature02003			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14523450				2022-12-24	WOS:000185648100049
J	Murphy, G				Murphy, G			Lost for words	NATURE			English	News Item							DEVELOPMENTAL DYSLEXIA; CHILDREN; REMEDIATION; DISRUPTION; SYSTEMS; BRAIN		Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	Imperial College London	Murphy, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.							Eden GF, 2002, NAT NEUROSCI, V5, P1080, DOI 10.1038/nn946; LIVINGSTONE MS, 1991, P NATL ACAD SCI USA, V88, P7943, DOI 10.1073/pnas.88.18.7943; Nicolson RI, 1999, LANCET, V353, P1662, DOI 10.1016/S0140-6736(98)09165-X; Ramus F, 2003, BRAIN, V126, P841, DOI 10.1093/brain/awg076; Ramus F, 2003, CURR OPIN NEUROBIOL, V13, P212, DOI 10.1016/S0959-4388(03)00035-7; Shaywitz BA, 2002, BIOL PSYCHIAT, V52, P101, DOI 10.1016/S0006-3223(02)01365-3; Shaywitz SE, 2003, BIOL PSYCHIAT, V54, P25, DOI 10.1016/S0006-3223(02)01836-X; Shaywitz SE, 1998, P NATL ACAD SCI USA, V95, P2636, DOI 10.1073/pnas.95.5.2636; Stein J, 2001, Dyslexia, V7, P12, DOI 10.1002/dys.186; STEIN JF, 1982, BRIT J OPHTHALMOL, V66, P332, DOI 10.1136/bjo.66.5.332; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; Temple E, 2003, P NATL ACAD SCI USA, V100, P2860, DOI 10.1073/pnas.0030098100	12	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					340	342		10.1038/425340a	http://dx.doi.org/10.1038/425340a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508456				2022-12-24	WOS:000185502300012
J	Cool, CD; Rai, PR; Yeager, ME; Hernandez-Saavedra, D; Serls, AE; Bull, TM; Geraci, MW; Brown, KK; Routes, JM; Tuder, RM; Voelkel, NF				Cool, CD; Rai, PR; Yeager, ME; Hernandez-Saavedra, D; Serls, AE; Bull, TM; Geraci, MW; Brown, KK; Routes, JM; Tuder, RM; Voelkel, NF			Expression of human herpesvirus 8 in primary pulmonary hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; ENDOTHELIAL GROWTH-FACTOR; TGF-BETA RECEPTOR; KAPOSIS-SARCOMA; PLEXIFORM LESIONS; DNA-SEQUENCES; GERMLINE MUTATIONS; PROTEIN; GENE; GENOME	BACKGROUND: Severe pulmonary hypertension constitutes a group of diseases characterized by complex, lumen-occluding vascular lesions that develop in genetically susceptible persons. The only viral infection associated with severe pulmonary hypertension has been that due to human immunodeficiency virus type 1, but neither the viral genome nor viral antigens have been demonstrated in pathologic lesions. METHODS: We examined lung-tissue samples from 16 patients with sporadic primary pulmonary hypertension and 14 patients with secondary pulmonary hypertension for evidence of infection with human herpesvirus 8 (HHV-8). HHV-8 infection was ascertained immunohistochemically with use of an antibody directed against latency-associated nuclear antigen 1 (LANA-1), and a polymerase-chain-reaction (PCR) assay was performed on lung DNA to detect the viral cyclin gene of HHV-8. Sequence analysis was also performed. RESULTS: In lung tissue from 10 of 16 patients with primary pulmonary hypertension (62 percent), cells within the plexiform lesions as well as cells outside the lesions were positive for LANA-1 on immunohistochemical analysis. Tissue from the same 10 patients contained viral cyclin on PCR analysis. No LANA-1 was detected in lung tissue from patients with secondary pulmonary hypertension, although one such patient had PCR evidence of viral cyclin. Plexiform lesions from patients with primary pulmonary hypertension had a histologic and immunohistochemical resemblance to cutaneous Kaposi's sarcoma lesions. CONCLUSIONS: The spectrum of trigger factors and molecular mechanisms leading to severe pulmonary hypertension and the formation of plexiform lesions is apparently wide, including both genetic and epigenetic factors. Our data suggest that infection with the vasculotropic virus HHV-8 may have a pathogenetic role in primary pulmonary hypertension.	Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Pulm Hypertens Ctr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Webb Waring Inst, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Johns Hopkins Univ, Dept Pathol, Cardiopulm Div, Baltimore, MD USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; Johns Hopkins University	Voelkel, NF (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Pulm Hypertens Ctr, Box C272,4200 E 9th Ave, Denver, CO 80262 USA.	norbert.voelkel@uchsc.edu	Routes, john/AAA-4833-2021; Brown, Kevin/ABF-2544-2020; Hernandez-Saavedra, Daniel/AGO-1286-2022	Routes, john/0000-0001-8378-3773; Hernandez-Saavedra, Daniel/0000-0003-1449-944X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003911] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL66524, K08 HL03911] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; BULL TM, IN PRESS EUR RESP J; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Eddahibi S, 2000, AM J RESP CRIT CARE, V162, P1493, DOI 10.1164/ajrccm.162.4.2003124; Fakhari FD, 2002, J VIROL, V76, P6213, DOI 10.1128/JVI.76.12.6213-6223.2002; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Geraci MW, 2001, CIRC RES, V88, P555, DOI 10.1161/01.RES.88.6.555; HUMBERT M, 1995, AM J RESP CRIT CARE, V151, P1628, DOI 10.1164/ajrccm.151.5.7735624; Judde JG, 2000, JNCI-J NATL CANCER I, V92, P729, DOI 10.1093/jnci/92.9.729; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Lee SD, 1998, J CLIN INVEST, V101, P927, DOI 10.1172/JCI1910; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; LOSCALZO J, 1992, NEW ENGL J MED, V327, P117, DOI 10.1056/NEJM199207093270209; Machado RD, 2001, AM J HUM GENET, V68, P92, DOI 10.1086/316947; Masood R, 2002, AM J PATHOL, V160, P23, DOI 10.1016/S0002-9440(10)64344-1; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Mehta NJ, 2000, CHEST, V118, P1133, DOI 10.1378/chest.118.4.1133; METTE SA, 1992, AM REV RESPIR DIS, V145, P1196, DOI 10.1164/ajrccm/145.5.1196; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Pan LX, 2001, J MOL DIAGN, V3, P32, DOI 10.1016/S1525-1578(10)60647-2; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHULZ TF, 1998, HUMAN TUMOR VIRUSES, P87; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SPEICH R, 1991, CHEST, V100, P1268, DOI 10.1378/chest.100.5.1268; Thomson JR, 2000, J MED GENET, V37, P741, DOI 10.1136/jmg.37.10.741; Tuder RM, 1998, J LAB CLIN MED, V132, P16, DOI 10.1016/S0022-2143(98)90020-8; Tuder RM, 2001, J PATHOL, V195, P367, DOI 10.1002/path.953; TUDER RM, 1994, AM J PATHOL, V144, P275; Tuder RM, 2001, CLIN CHEST MED, V22, P405, DOI 10.1016/S0272-5231(05)70280-X; Voelkel NF, 2002, CRIT CARE MED, V30, pS251, DOI 10.1097/00003246-200205001-00013; Voelkel NF, 1995, EUR RESPIR J, V8, P2129, DOI 10.1183/09031936.95.08122129; Weiss R A, 1998, J Natl Cancer Inst Monogr, P51; Yeager ME, 1999, CIRCULATION, V100, P587; Zur Hausen H, 2001, ONCOGENE, V20, P7820, DOI 10.1038/sj.onc.1204958; BLAST 2 SEQUENES	44	213	221	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2003	349	12					1113	1122		10.1056/NEJMoa035115	http://dx.doi.org/10.1056/NEJMoa035115			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722HQ	13679525				2022-12-24	WOS:000185369700004
J	Kirwan, CC; Nath, E; Byrne, GJ; McCollum, CN				Kirwan, CC; Nath, E; Byrne, GJ; McCollum, CN			Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER		Wythenshawe Hosp, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Byrne, GJ (corresponding author), Wythenshawe Hosp, Educ & Res Bldg, Manchester M23 9LT, Lancs, England.		Kirwan, Cliona/HHZ-8872-2022	Kirwan, Cliona/0000-0002-1725-4790; Byrne, Ged/0000-0002-8194-7540				FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; GOODNOUGH LT, 1984, CANCER-AM CANCER SOC, V54, P1264, DOI 10.1002/1097-0142(19841001)54:7<1264::AID-CNCR2820540706>3.0.CO;2-R; Jilma B, 2003, BRIT MED J, V326, P93, DOI 10.1136/bmj.326.7380.93; Thodiyil PA, 2001, ACTA HAEMATOL-BASEL, V106, P73, DOI 10.1159/000046592; WEISS RB, 1981, CANCER TREAT REP, V65, P677	5	33	33	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2003	327	7415					597	598		10.1136/bmj.327.7415.597	http://dx.doi.org/10.1136/bmj.327.7415.597			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722CW	12969928	Green Published, Bronze			2022-12-24	WOS:000185358700024
J	Bendjennat, M; Boulaire, J; Jascur, T; Brickner, H; Barbier, V; Sarasin, A; Fotedar, A; Fotedar, R				Bendjennat, M; Boulaire, J; Jascur, T; Brickner, H; Barbier, V; Sarasin, A; Fotedar, A; Fotedar, R			UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE ARREST; HUMAN FIBROBLASTS; G(1) ARREST; P53 PROTEIN; IN-VITRO; P21; PCNA; RADIATION; INHIBITION	p53-mediated increase in cyclin-dependent kinase inhibitor p21(WAF1) protein is thought to be the major mediator of cell cycle arrest after DNA damage. Previously p21 protein levels have been reported to increase or to decrease after UV irradiation. We show that p21 protein is degraded after irradiation of a variety of cell types with low but not high doses of UV. Cell cycle arrest occurs despite p21 degradation via Tyr(15) inhibitory phosphorylation of cdk2 and differs from the classical p21-dependent checkpoint elicited by ionizing radiation. In contrast to the basal turnover of p21, degradation of p21 switches to ubiquitin/Skp2-dependent proteasome pathway following UV irradiation. ATR activation after UV irradiation is essential for signaling p21 degradation. Finally, UV-induced p21 degradation is essential for optimal DNA repair. These results provide novel insight into regulation of p21 protein and its role in the cellular response to DNA damage.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Inst Gustave Roussy, F-94805 Villejuif, France; Inst Biol Struct JP Ebel, F-38027 Grenoble, France	UNICANCER; Gustave Roussy; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fotedar, A (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Rd, San Diego, CA 92121 USA.	afotedar@skcc.org; fotedar@ibs.fr	Boulaire, Jerome/A-5954-2009		NATIONAL CANCER INSTITUTE [R01CA074435, R01CA092321] Funding Source: NIH RePORTER; NCI NIH HHS [CA74435, CA92321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Adimoolam S, 2001, J BIOL CHEM, V276, P25813, DOI 10.1074/jbc.M102240200; Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Boulaire J, 2000, PATHOL BIOL, V48, P190; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLEAVER JE, 1981, DNA REPAIR LABORATOR, P277; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fotedar R, 1996, ONCOGENE, V12, P2155; Freedman DA, 1999, CANCER RES, V59, P1; Geyer RK, 2000, CELL GROWTH DIFFER, V11, P149; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Rieber M, 2000, INT J CANCER, V86, P462, DOI 10.1002/(SICI)1097-0215(20000515)86:4<462::AID-IJC3>3.0.CO;2-B; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	51	220	225	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	2003	114	5					599	610		10.1016/j.cell.2003.08.001	http://dx.doi.org/10.1016/j.cell.2003.08.001			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	719FN	13678583	Bronze			2022-12-24	WOS:000185193100009
J	Brogan, KV				Brogan, KV			James	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Cornell Univ, Joan & Sanford I Weill Med Coll, New York, NY 10021 USA	Cornell University	Brogan, KV (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, New York, NY 10021 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1221	1222		10.1001/jama.290.9.1221	http://dx.doi.org/10.1001/jama.290.9.1221			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12953010	Bronze			2022-12-24	WOS:000185090400023
J	Sox, CM; Cooper, WO; Koepsell, TD; DiGiuseppe, DL; Christakis, DA				Sox, CM; Cooper, WO; Koepsell, TD; DiGiuseppe, DL; Christakis, DA			Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPROVING PRIMARY-CARE; PENICILLIN PROPHYLAXIS; ORAL PENICILLIN; PRESCRIPTION; SERVICES; URBAN	Context It is recommended that children younger than 5 years with sickle cell disease (SCD) take daily prophylactic antibiotics to prevent pneumococcal infections; however, how much prophylactic medication they actually are dispensed is unclear. Objectives To measure the amount of prophylactic antibiotics dispensed to young children with SCD and to investigate factors associated with increased delivery of medication. Design, Setting, and Patients Retrospective longitudinal study conducted January 1995 through December 1999 using Tennessee and Washington State Medicaid administrative claims and encounter data. Children (N=261) who had 1 inpatient or 2 outpatient claims or encounters listing an International Classification of Diseases, Ninth Revision, Clinical Modification code for SCD, were younger than 4 years at study entry (mean age, 1.4 years), and were continuously enrolled in Medicaid for a 1-year period. Main Outcome Measure Number of days during a 365-day period covered by prescription fills for a penicillin or macrolide antibiotic, or for trimethoprimsulfamethoxazole. Results In a 365-day period, patients were dispensed a mean of 148.4 (SD, 121.3; median, 114; interquartile range [IQR], 39-247) days of prophylactic medication. The total amount of medication dispensed varied widely: 10.3% of patients received none and 21.5% received more than 270 days of medication. In a 365-day period, a mean of 12.7 (SD, 10.5; range, 0-40) prophylactic prescriptions were filled per patient. The median prescription duration was 10 days. In a multivariate linear regression model adjusting for state, sex, age at study entry, inclusion year, residence in urban community, outpatient inclusion encounter, required prescription co-payment, and number of outpatient visits for nonpreventive care, each preventive visit was associated with 12.0 (95% confidence interval [CI], 2.3-21.7) additional days of prophylactic antibiotics, and each emergency department visit was associated with 10.0 (95% CI, 1.2-18.8) additional days. Conclusions Publicly insured children with SCD may receive inadequate antibiotic prophylaxis against pneumococcal infections, placing them at increased risk of morbidity and mortality; however, increased numbers of outpatient visits for preventive care are associated with improved provision of prophylactic antibiotics.	Univ Washington, Robert Wood Johnson Clin Scholars Program, Hlth Sci Ctr H220, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Inst Child Hlth, Seattle, WA USA; Vanderbilt Univ, Dept Pediat, Nashville, TN USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Vanderbilt University	Sox, CM (corresponding author), Univ Washington, Robert Wood Johnson Clin Scholars Program, Hlth Sci Ctr H220, Dept Pediat, Box 357183, Seattle, WA 98195 USA.	colinsox@u.washington.edu		Sox, Colin/0000-0002-0249-9656				Abramson JS, 2000, PEDIATRICS, V106, P367, DOI 10.1542/peds.106.2.367; Abramson JS, 2000, PEDIATRICS, V106, P362; Berkovitch M, 1998, BRIT J CLIN PHARMACO, V45, P605, DOI 10.1046/j.1365-2125.1998.00730.x; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; BUCHANAN GR, 1982, PEDIATRICS, V70, P926; Carson JL, 2000, PHARMACOEPIDEM DR S, P307; Christakis DA, 2001, AMBUL PEDIATR, V1, P99, DOI 10.1367/1539-4409(2001)001<0099:CAQOCF>2.0.CO;2; Cooper WO, 2002, AMBUL PEDIATR, V2, P375, DOI 10.1367/1539-4409(2002)002<0375:OCUACI>2.0.CO;2; Cooper WO, 2002, OBSTET GYNECOL, V100, P101, DOI 10.1016/S0029-7844(02)02001-X; Cooper WO, 2001, ARCH PEDIAT ADOL MED, V155, P1111, DOI 10.1001/archpedi.155.10.1111; *COUNC REG NETW GE, 1995, NAT NEWB SCREEN REP; CUMMINS D, 1991, BRIT MED J, V302, P989, DOI 10.1136/bmj.302.6783.989; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; GURWITZ JH, 1993, AM J PUBLIC HEALTH, V83, P711, DOI 10.2105/AJPH.83.5.711; Haque A, 2000, J RURAL HEALTH, V16, P43, DOI 10.1111/j.1748-0361.2000.tb00435.x; JOHNSON RE, 1991, J AM GERIATR SOC, V39, P1079, DOI 10.1111/j.1532-5415.1991.tb02872.x; Kuhlthau K, 2001, PEDIATRICS, V108, P906, DOI 10.1542/peds.108.4.906; Lane PA, 2002, PEDIATRICS, V109, P526; Li STT, 2003, ARCH PEDIAT ADOL MED, V157, P475, DOI 10.1001/archpedi.157.5.475; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; MILNE RIG, 1990, BRIT MED J, V300, P371, DOI 10.1136/bmj.300.6721.371; Morrill R, 1999, URBAN GEOGR, V20, P727, DOI 10.2747/0272-3638.20.8.727; OVERTURF GD, 1977, AM J DIS CHILD, V131, P784, DOI 10.1001/archpedi.1977.02120200066014; PEGELOW CH, 1991, J PEDIATR-US, V118, P736, DOI 10.1016/S0022-3476(05)80036-8; STEINER JF, 1988, MED CARE, V26, P814, DOI 10.1097/00005650-198808000-00007; Teach SJ, 1998, ARCH PEDIAT ADOL MED, V152, P274	28	47	47	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1057	1061		10.1001/jama.290.8.1057	http://dx.doi.org/10.1001/jama.290.8.1057			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715FA	12941678	Bronze			2022-12-24	WOS:000184958900024
J	Foerster, K; Delhey, K; Johnsen, A; Lifjeld, JT; Kempenaers, B				Foerster, K; Delhey, K; Johnsen, A; Lifjeld, JT; Kempenaers, B			Females increase offspring heterozygosity and fitness through extra-pair matings	NATURE			English	Article							TIT PARUS-CAERULEUS; BLUE TIT; MATE CHOICE; GENETIC SIMILARITY; PATERNITY; MICROSATELLITES; POPULATIONS; POLYANDRY; PARENTAGE; BENEFITS	Females in a variety of species commonly mate with multiple males, and there is evidence that they benefit by producing offspring of higher genetic quality(1-3); however, the nature of these genetic benefits is debated(1-4). Enhanced offspring survival or quality can result from intrinsic effects of paternal genes- 'good genes'-or from interactions between the maternal and paternal genomes-'compatible genes'(1-5). Evidence for the latter process is accumulating(2,6): matings between relatives lead to decreased reproductive success, and the individual level of inbreeding-measured as average heterozygosity-is a strong fitness predictor(7-13). Females should thus benefit from mating with genetically dissimilar males(2,14). In many birds, social monogamy restricts mate choice, but females may circumvent this by pursuing extra-pair copulations(15,16). Here we show that female blue tits, Parus caeruleus, increase the heterozygosity of their progeny through extra-pair matings. Females thereby produce offspring of higher reproductive value, because less inbred individuals have increased survival chances, a more elaborate male secondary sexual trait (crown colour) and higher reproductive success. The cost of inbreeding may therefore be an important factor driving the evolution of female extra-pair mating.	Max Planck Res Ctr Ornithol, D-82305 Starnberg, Germany; Univ Oslo, Zool Museum, N-0318 Oslo, Norway	Max Planck Society; University of Oslo	Kempenaers, B (corresponding author), Max Planck Res Ctr Ornithol, POB 1564, D-82305 Starnberg, Germany.		Lifjeld, Jan T/B-1978-2008; Delhey, Kaspar/AAZ-5362-2020; Delhey, Kaspar/F-6515-2010; Foerster, Katharina/AAX-3894-2020	Lifjeld, Jan T/0000-0002-9172-9985; Delhey, Kaspar/0000-0001-5190-5406; Johnsen, Arild/0000-0003-4864-6284; Kempenaers, Bart/0000-0002-7505-5458				Amos W, 2001, P ROY SOC B-BIOL SCI, V268, P2021, DOI 10.1098/rspb.2001.1751; Andersson S, 1998, P ROY SOC B-BIOL SCI, V265, P445, DOI 10.1098/rspb.1998.0315; Aparicio JM, 2001, ANIM BEHAV, V62, P1001, DOI 10.1006/anbe.2001.1840; Bensch S, 1997, MOL ECOL, V6, P91, DOI 10.1046/j.1365-294X.1997.00150.x; Blomqvist D, 2002, NATURE, V419, P613, DOI 10.1038/nature01104; Brown JL, 1997, BEHAV ECOL, V8, P60, DOI 10.1093/beheco/8.1.60; Coltman DW, 1998, P ROY SOC B-BIOL SCI, V265, P803, DOI 10.1098/rspb.1998.0363; Dawson DA, 2000, MOL ECOL, V9, P1941, DOI 10.1046/j.1365-294x.2000.01094-14.x; Fridolfsson AK, 1997, HEREDITAS, V126, P127, DOI 10.1111/j.1601-5223.1997.00127.x; Hansson B, 2001, P ROY SOC B-BIOL SCI, V268, P1287, DOI 10.1098/rspb.2001.1640; Hansson B, 2002, MOL ECOL, V11, P2467, DOI 10.1046/j.1365-294X.2002.01644.x; Hoglund J, 2002, P ROY SOC B-BIOL SCI, V269, P711, DOI 10.1098/rspb.2001.1937; Hunt S, 1999, ANIM BEHAV, V58, P809, DOI 10.1006/anbe.1999.1214; JAMIESON A, 1994, ANIM GENET, V25, P37, DOI 10.1111/j.1365-2052.1994.tb00401.x; Jennions MD, 2000, BIOL REV, V75, P21, DOI 10.1017/S0006323199005423; Kempenaers B, 1997, BEHAV ECOL, V8, P481, DOI 10.1093/beheco/8.5.481; Kempenaers B, 1996, P ROY SOC B-BIOL SCI, V263, P179, DOI 10.1098/rspb.1996.0029; KEMPENAERS B, 1992, NATURE, V357, P494, DOI 10.1038/357494a0; MITTON JB, 1993, HEREDITY, V71, P59, DOI 10.1038/hdy.1993.107; Pemberton J.M., 1999, MICROSATELLITES EVOL, P151; Petrie M, 1998, TRENDS ECOL EVOL, V13, P52, DOI 10.1016/S0169-5347(97)01232-9; Pusey A, 1996, TRENDS ECOL EVOL, V11, P201, DOI 10.1016/0169-5347(96)10028-8; Sheldon BC, 1999, NATURE, V402, P874, DOI 10.1038/47239; STOCKLEY P, 1993, P ROY SOC B-BIOL SCI, V254, P173, DOI 10.1098/rspb.1993.0143; Thornhill N.W., 1993, NATURAL HIST INBREED; Tregenza T, 2002, NATURE, V415, P71, DOI 10.1038/415071a; Tregenza T, 2000, MOL ECOL, V9, P1013, DOI 10.1046/j.1365-294x.2000.00964.x; TURELLI M, 1983, GENETICS, V104, P191; Zeh JA, 1996, P ROY SOC B-BIOL SCI, V263, P1711, DOI 10.1098/rspb.1996.0250; Zeh JA, 2001, ANIM BEHAV, V61, P1051, DOI 10.1006/anbe.2000.1705	30	396	402	6	245	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					714	717		10.1038/nature01969	http://dx.doi.org/10.1038/nature01969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562103				2022-12-24	WOS:000185924500041
J	Uehlein, N; Lovisolo, C; Siefritz, F; Kaldenhoff, R				Uehlein, N; Lovisolo, C; Siefritz, F; Kaldenhoff, R			The tobacco aquaporin NtAQP1 is a membrane CO2 pore with physiological functions	NATURE			English	Article							NICOTIANA-TABACUM; EXPRESSION; PERMEABILITY; LEAVES; MALATE; PLANTS	Aquaporins, found in virtually all living organisms, are membrane-intrinsic proteins that form water-permeable complexes. The mammalian aquaporin AQP1 has also shown CO2 permeability when expressed heterologously in Xenopus oocytes(1), although whether this is a biochemical curiosity or of physiological significance is a matter of debate(2,3). Here we report that, in the same expression system, a CO2 permeability comparable to that of the human AQP1 is observed for the tobacco plasma membrane aquaporin NtAQP1. NtAQP1 facilitates CO2 membrane transport in the homologous plant system at the cellular level, and has a significant function in photosynthesis and in stomatal opening. NtAQP1 overexpression heightens membrane permeability for CO2 and water, and increases leaf growth. The results indicate that NtAQP1-related CO2 permeability is of physiological importance under conditions where the CO2 gradient across a membrane is small, as is the case between the atmosphere and the inside of a plant cell.	Inst Bot, D-64287 Darmstadt, Germany; Univ Turin, Dept Agr & Pomol, I-10095 Grugliaso, Italy	University of Turin	Kaldenhoff, R (corresponding author), Inst Bot, Schnittspahnstr 3, D-64287 Darmstadt, Germany.		Lovisolo, Claudio/A-6610-2010	Lovisolo, Claudio/0000-0001-8825-2904				Biela A, 1999, PLANT J, V18, P565, DOI 10.1046/j.1365-313X.1999.00474.x; Cooper GJ, 2002, J PHYSIOL-LONDON, V542, P17, DOI 10.1113/jphysiol.2002.023218; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Evans JR, 1996, PLANT PHYSIOL, V110, P339, DOI 10.1104/pp.110.2.339; Gallois P, 1995, Methods Mol Biol, V49, P39; Gatz C, 1997, ANNU REV PLANT PHYS, V48, P89, DOI 10.1146/annurev.arplant.48.1.89; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; HEDRICH R, 1994, PLANT J, V6, P741, DOI 10.1046/j.1365-313X.1994.6050741.x; Hedrich R, 2001, PLANTA, V213, P594, DOI 10.1007/s004250100524; KAISER WM, 1982, PLANTA, V154, P538, DOI 10.1007/BF00402997; MANSFIELD TA, 1990, ANNU REV PLANT PHYS, V41, P55, DOI 10.1146/annurev.pp.41.060190.000415; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Otto B, 2000, PLANTA, V211, P167, DOI 10.1007/s004250000275; RASCHKE K, 1975, ANNU REV PLANT PHYS, V26, P309, DOI 10.1146/annurev.pp.26.060175.001521; RASCHKE K, 1972, PLANT PHYSIOL, V49, P229, DOI 10.1104/pp.49.2.229; Siefritz F, 2002, PLANT CELL, V14, P869, DOI 10.1105/tpc.000901; Verkman AS, 2002, J PHYSIOL-LONDON, V542, P31, DOI 10.1113/jphysiol.2002.024398; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686	18	471	527	8	120	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	2003	425	6959					734	737		10.1038/nature02027	http://dx.doi.org/10.1038/nature02027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14520414				2022-12-24	WOS:000185924500045
J	Grynszpan, D				Grynszpan, D			Lessons from the French heatwave	LANCET			English	Editorial Material							MORTALITY; WAVE		The Lancet, London NW1 7BY, England		Grynszpan, D (corresponding author), The Lancet, London NW1 7BY, England.							*COMM AFF CULT FAM, 2003, COMPT REND, V58; Hemon D., 2003, SURMORTALITE LIEE CA; *I VEILL SAN, 2003, IMP SAN VAG CHAL FRA; Klinenberg E., 2002, HEAT WAVE SOCIAL AUT; Lalande F., 2003, MISSION EXPERTISE EV; Naughton MP, 2002, AM J PREV MED, V22, P221, DOI 10.1016/S0749-3797(02)00421-X; Weisskopf MG, 2002, AM J PUBLIC HEALTH, V92, P830, DOI 10.2105/AJPH.92.5.830	7	33	33	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 11	2003	362	9391					1169	1170		10.1016/S0140-6736(03)14555-2	http://dx.doi.org/10.1016/S0140-6736(03)14555-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732CW	14568735				2022-12-24	WOS:000185924100005
J	Kennedy, JG				Kennedy, JG			"Doc, tell me what I need to know" - a doctor's perspective	BRITISH MEDICAL JOURNAL			English	Article									Cedar Brook Practice, Middlesex UB4 8DD, England		Kennedy, JG (corresponding author), Cedar Brook Practice, 11 Kingshill Close, Middlesex UB4 8DD, England.							*DEP HLTH, 2001, EXP PAT NEW APPR CHR, P12; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; National Audit Office, 1993, REP PRESCR GEN MED P; Say RE, 2003, BMJ-BRIT MED J, V327, P542, DOI 10.1136/bmj.327.7414.542	5	8	10	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2003	327	7419					862	863		10.1136/bmj.327.7419.862	http://dx.doi.org/10.1136/bmj.327.7419.862			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732BP	14551108	Green Published			2022-12-24	WOS:000185921200030
J	Stenzel-Poore, MP; Stevens, SL; Xiong, ZG; Lessov, NS; Harrington, CA; Mori, M; Meller, R; Rosenzweig, HL; Tobar, E; Shaw, TE; Chu, XP; Simon, RP				Stenzel-Poore, MP; Stevens, SL; Xiong, ZG; Lessov, NS; Harrington, CA; Mori, M; Meller, R; Rosenzweig, HL; Tobar, E; Shaw, TE; Chu, XP; Simon, RP			Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states	LANCET			English	Article							PROTEIN-SYNTHESIS; BRAIN INJURY; INHIBITION; CHANNEL; STROKE; MICE; SUPPRESSION; MACROPHAGES; ELONGATION; EXPRESSION	Background Molecular mechanisms of neuroprotection that lead to ischaemic tolerance are incompletely understood. Identification of genes involved in the process would provide insight into cell survival and therapeutic approaches for stroke. We developed a mouse model of neuroprotection in stroke and did gene expression profiling to identify potential neuroprotective genes and their associated pathways. Methods Eight mice per condition were subjected to occlusion of the middle cerebral artery for 15 min (preconditioning), 60 min (injurious ischaemia), or preconditioning followed 72 h later by injurious ischaemia. RNA was extracted from the cortical regions of the ischaemic and non-ischaemic hemispheres. Three pools per condition were generated, and RNA was hybridised to oligonucleotide microarrays for comparison of ischaemic and non-ischaemic hemispheres. Real-time PCR and western blots were used to validate results. Follow-up experiments were done to address the biological relevance of findings. Findings Microarray analysis revealed changes in gene expression with little overlap among the conditions of injurious ischaemia, ischaemic preconditioning, or both. Injurious ischaemia induced upregulation of gene expression; 49 (86%) of 57 genes regulated showed increased expression in the ischaemic hemisphere. By contrast, preconditioning followed by injurious ischaemia resulted in pronounced downregulation; 47 (77%) of 61 regulated genes showed lower expression. Preconditioning resulted in transcriptional changes involved in suppression of metabolic pathways and immune responses, reduction of ion-channel activity, and decreased blood coagulation. Interpretation Preconditioning reprogrammes the response to ischaemic injury. Similar changes reported by others support an evolutionarily conserved endogenous response to decreased blood flow and oxygen limitation such as seen during hibernation.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Oregon Stroke Ctr, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Biostat & Bioinformat Shared Resource Canc Inst, Portland, OR 97201 USA; Robert S Dow Neurobiol Labs, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Stenzel-Poore, MP (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, L220,3181 Sam Jackson Pk Rd, Portland, OR 97239 USA.			Chu, Xiang-Ping/0000-0002-6781-0468	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024728, P01NS035965, R01NS039492] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39492, NS24728, NS35965] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; BUCK LT, 1993, AM J PHYSIOL, V265, pR1020, DOI 10.1152/ajpregu.1993.265.5.R1020; Chen Y, 2001, BIOCHEMISTRY-US, V40, P11565, DOI 10.1021/bi010649w; DIRNAGL U, IN PRESS TRENDS NEUR; Drew KL, 2001, FREE RADICAL BIO MED, V31, P563, DOI 10.1016/S0891-5849(01)00628-1; Esfandiari A, 1997, DEV NEUROSCI-BASEL, V19, P312, DOI 10.1159/000111227; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; FRERICHS KU, 1994, J CEREBR BLOOD F MET, V14, P193, DOI 10.1038/jcbfm.1994.26; Frerichs KU, 1999, ACT NEUR S, V73, P57; Frerichs KU, 1998, P NATL ACAD SCI USA, V95, P14511, DOI 10.1073/pnas.95.24.14511; Frerichs KU, 1998, J CEREBR BLOOD F MET, V18, P168, DOI 10.1097/00004647-199802000-00007; Ghai HS, 1999, AM J PHYSIOL-REG I, V277, pR887, DOI 10.1152/ajpregu.1999.277.3.R887; HASLBERGER A, 1988, CIRC SHOCK, V26, P185; Heusch G, 2000, TRENDS CARDIOVAS MED, V10, P108, DOI 10.1016/S1050-1738(00)00058-X; Hill JK, 1999, BRAIN RES, V820, P45, DOI 10.1016/S0006-8993(98)01140-8; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Iadecola C, 2001, J CEREBR BLOOD F MET, V21, P1436, DOI 10.1097/00004647-200112000-00008; Kasischke K, 1999, STROKE, V30, P1256, DOI 10.1161/01.STR.30.6.1256; Kersten JR, 1997, ANESTHESIOLOGY, V87, P361, DOI 10.1097/00000542-199708000-00024; Lin H, 2002, CIRCULATION, V105, P1962, DOI 10.1161/01.CIR.0000015365.49180.05; LOPASCHUK GD, 1989, CIRC RES, V65, P378, DOI 10.1161/01.RES.65.2.378; MONCADA S, 1983, STROKE, V14, P157, DOI 10.1161/01.STR.14.2.157; Rudolf J, 1999, J CHILD NEUROL, V14, P543, DOI 10.1177/088307389901400813; Shnyra A, 1998, J IMMUNOL, V160, P3729; SIMON RP, 1993, NEUROSCI LETT, V163, P135, DOI 10.1016/0304-3940(93)90364-Q; SRERE HK, 1995, AM J PHYSIOL-REG I, V268, pR1507, DOI 10.1152/ajpregu.1995.268.6.R1507; STOREY KB, 1990, Q REV BIOL, V65, P145, DOI 10.1086/416717; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; Weih M, 1999, STROKE, V30, P1851, DOI 10.1161/01.STR.30.9.1851; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012	30	313	334	2	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 27	2003	362	9389					1028	1037		10.1016/S0140-6736(03)14412-1	http://dx.doi.org/10.1016/S0140-6736(03)14412-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725WD	14522533				2022-12-24	WOS:000185564600010
J	Sanchez-Villagra, MR; Aguilera, O; Horovitz, I				Sanchez-Villagra, MR; Aguilera, O; Horovitz, I			The anatomy of the world's largest extinct rodent	SCIENCE			English	Article							LONG BONES	Phoberomys is reported to be the largest rodent that ever existed, although it has been known only from isolated teeth and fragmentary postcranial bones. An exceptionally complete skeleton of Phoberomys pattersoni was discovered in a rich locality of fossil vertebrates in the Upper Miocene of Venezuela. Reliable body mass estimates yield similar to 700 kilograms, more than 10 times the mass of the largest living rodent, the capybara. With Phoberomys, Rodentia becomes one of the mammalian orders with the largest size range, second only to diprotodontian marsupials. Several postcranial features support an evolutionary relationship of Phoberomys with pakaranas from the South American rodent radiation. The associated fossil fauna is diverse and suggests that Phoberomys lived in marginal lagoons and wetlands.	Univ Tubingen, D-72076 Tubingen, Germany; Univ Nacl Expt Francisco Miranda, CICBA, Coro 4101, Estado Falcon, Venezuela; Univ Calif Los Angeles, Dept Organism Biol Ecol & Evolut, Los Angeles, CA 90095 USA	Eberhard Karls University of Tubingen; University of California System; University of California Los Angeles	Sanchez-Villagra, MR (corresponding author), Univ Tubingen, Morgenstelle 28, D-72076 Tubingen, Germany.	marcelo.sanchez@uni-tuebingen.de	Aguilera, Orangel/D-5055-2013					[Anonymous], 1999, WALKERS MAMMALS WORL; BERTRAM JEA, 1990, J MORPHOL, V204, P157, DOI 10.1002/jmor.1052040205; Biknevicius A.R., 1993, American Museum Novitates, V3079, P1; BIKNEVICIUS AR, 1993, J MAMMAL, V74, P95, DOI 10.2307/1381908; de Paula Couto C., 1979, TRATADO PALEOMASTOZO; DEMES B, 1989, FOLIA PRIMATOL, V52, P58, DOI 10.1159/000156381; Flynn JJ, 1998, TRENDS ECOL EVOL, V13, P449, DOI 10.1016/S0169-5347(98)01457-8; FRANCIS J C, 1966, Kraglieviana, V1, P89; Huchon D, 2001, MOL PHYLOGENET EVOL, V20, P238, DOI 10.1006/mpev.2001.0961; Kay R., 1997, VERTEBRATE PALEONTOL; KRAGLIEVICH LUCAS, 1932, ANALES SOC CIENT ARGENTINA, V114, P155; LANDRY STUART O., 1957, UNIV CALIFORNIA PUBL ZOOL, V56, P1; McKenna MC, 1997, CLASSIFICATION MAMMA; *MIN EN MIN, 1997, MIN EN MIN B GEOL; MONES A, 1980, Ameghiniana, V17, P277; Mones Alvaro, 1997, Comunicaciones Paleontologicas del Museo de Historia Natural de Montevideo, V2, P1; NEGRI FR, 1999, B MUSEU PARAENSE EMI, V11, P1; SANCHEZVILLAGRA MR, UNPUB; Springer MS, 2001, P NATL ACAD SCI USA, V98, P6241, DOI 10.1073/pnas.111551998; Starck D., 1995, LEHRBUCH SPEZIELLE 5; Vucetich MG, 1999, CR ACAD SCI II A, V329, P763; Wood R.C., 1976, Breviora, VNo. 436, P1	22	91	97	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1708	1710		10.1126/science.1089332	http://dx.doi.org/10.1126/science.1089332			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500978				2022-12-24	WOS:000185387700040
J	Khosla, S; Melton, LJ; Dekutoski, MB; Oberg, AL; Riggs, BL				Khosla, S; Melton, LJ; Dekutoski, MB; Oberg, AL; Riggs, BL			Incidence of childhood distal forearm fractures over 30 years - A population-based study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFINED POPULATION; PHYSICAL-ACTIVITY; OSTEOPOROSIS PREVENTION; LIMB FRACTURES; SUBSEQUENT HIP; BONE MASS; CHILDREN; GROWTH; EPIDEMIOLOGY; CALCIUM	Context The incidence of distal forearm fractures in children peaks around the time of the pubertal growth spurt, possibly because physical activity increases at the time of a transient deficit in cortical bone mass due to the increased calcium demand during maximal skeletal growth. Changes in physical activity or diet may therefore influence risk of forearm fracture. Objective To determine whether there has been a change in the incidence of distal forearm fractures in children in recent years. Design, Setting and Patients Population-based study among Rochester, Minn, residents younger than 35 years with distal forearm fractures in 1969-1971, 19791981, 1989-1991, and 1999-2001. Main Outcome Measure Estimated incidence of distal forearm fractures in 4 time periods. Results Comparably age- and sex-adjusted annual incidence rates per 100000 increased from 263.3 (95% confidence interval [Cl], 231.1-295.4) in 1969-1971 to 322.3 (95% Cl, 285.3-359.4) in 1979-1981 and to 399.8 (95% Cl, 361.0-438.6) in 19891991 before leveling off at 372.9 (95% Cl, 339.1-406.7) in 1999-2001. Age-adjusted incidence rates per 100000 were 32% greater Among male residents in 1999-2001 compared with 1969-1971 (409.4 [95% Cl, 359.9-459.0] vs 309.4 [95% Cl, 259.3-359.5]; P=.01) and 56% greater among female residents in the same time periods (334.3 [95% Cl, 288.6-380.1] vs 214.6 [95% Cl, 174.9-254.4]; P<.001). The peak incidence and greatest increase occurred between ages 11 and 14 years in boys and 8 and 11 years in girls. Conclusions There has been a statistically significant increase in the incidence of distal forearm fractures in children and adolescents, but whether this is due to changing patterns of physical activity, decreased bone acquisition due to poor calcium intake, or both is unclear at present. Given the large number of childhood fractures, however, studies are needed to define the cause(s) of this increase.	Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Div Metab Endocrinol & Nutr, Endocrine Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Orthoped Surg, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Melton, LJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, 200 1st St SW, Rochester, MN 55905 USA.		Khosla, Sundeep/AAE-6170-2020	Khosla, Sundeep/0000-0002-2936-4372	NIAMS NIH HHS [AR30582] Funding Source: Medline; NIA NIH HHS [AG04875] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004875] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bailey DA, 2000, J BONE MINER RES, V15, P2245, DOI 10.1359/jbmr.2000.15.11.2245; Bailey DA, 1999, J BONE MINER RES, V14, P1672, DOI 10.1359/jbmr.1999.14.10.1672; BAILEY DA, 1989, J BONE JOINT SURG AM, V71A, P1225, DOI 10.2106/00004623-198971080-00016; Baker SS, 1999, PEDIATRICS, V104, P1152, DOI 10.1542/peds.104.5.1152; BENGNER U, 1985, ACTA ORTHOP SCAND, V56, P158, DOI 10.3109/17453678508994345; BERGSTRALH EJ, 1992, TECHNICAL REPORT SER; BORRUD L, 1997, NUTR WEEK       0418, P4; Bryant RJ, 1999, J AM COLL NUTR, V18, p406S, DOI 10.1080/07315724.1999.10718905; BUHR AJ, 1959, LANCET, V1, P531; CALVO MS, 1993, J NUTR, V123, P1627, DOI 10.1093/jn/123.9.1627; *COMM PROF HOSP AC, 1998, INT CLASS DIS 9 REV, V1; COOPER C, 1995, J BONE MINER RES, V10, P940; Cooper C, 2001, OSTEOPOROSIS INT, V12, P623, DOI 10.1007/s001980170061; Cuddihy MT, 1999, OSTEOPOROSIS INT, V9, P469, DOI 10.1007/s001980050172; DONALDSON LJ, 1990, J EPIDEMIOL COMMUN H, V44, P241, DOI 10.1136/jech.44.3.241; GARRAWAY WM, 1979, MAYO CLIN PROC, V54, P701; GARRAWAY WM, 1979, MAYO CLIN PROC, V54, P708; Golden NH, 2000, ARCH PEDIAT ADOL MED, V154, P542, DOI 10.1001/archpedi.154.6.542; Goulding A, 1998, J BONE MINER RES, V13, P143, DOI 10.1359/jbmr.1998.13.1.143; Goulding A, 2000, J BONE MINER RES, V15, P2011, DOI 10.1359/jbmr.2000.15.10.2011; HAGINO H, 1989, ARCH ORTHOP TRAUM SU, V109, P43, DOI 10.1007/BF00441909; Jonsson B, 1999, ACTA ORTHOP SCAND, V70, P129, DOI 10.3109/17453679909011249; Kemper HCG, 2000, BONE, V27, P847, DOI 10.1016/S8756-3282(00)00397-5; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; KRAMHOFT M, 1988, ACTA ORTHOP SCAND, V59, P557, DOI 10.3109/17453678809148784; LANDIN LA, 1983, ACTA ORTHOP SCAND, V54, P1; LAURITZEN JB, 1993, OSTEOPOROSIS INT, V3, P133, DOI 10.1007/BF01623274; MALLMIN H, 1993, CALCIFIED TISSUE INT, V52, P269, DOI 10.1007/BF00296650; Melton LJ, 1997, NEW ENGL J MED, V337, P1466, DOI 10.1056/NEJM199711133372012; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Melton LJ, 1999, OSTEOPOROSIS INT, V9, P29, DOI 10.1007/s001980050113; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P111; MMCCULLAGH P, 1983, GEN LINEAR MODELS, P127; *NAT RES COUNC, 1989, REC DIET ALL, P174; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Oskam J, 1998, INJURY, V29, P353, DOI 10.1016/S0020-1383(97)00212-X; PARFITT AM, 1994, OSTEOPOROSIS INT, V4, P382, DOI 10.1007/BF01622201; Powell EC, 1996, PEDIATR EMERG CARE, V12, P259, DOI 10.1097/00006565-199608000-00006; Rauch F, 2001, J BONE MINER RES, V16, P1547, DOI 10.1359/jbmr.2001.16.8.1547; Riggs BL, 2002, J BONE MINER RES, V17, P11, DOI 10.1359/jbmr.2002.17.1.11; Tiderius CJ, 1999, ACTA ORTHOP SCAND, V70, P622, DOI 10.3109/17453679908997853; US Department of Agriculture, 1998, 962 USDA NAT FOOD SU; *USDA, 1993, 8711 USDA NAT FOOD C, P1; WONG PCN, 1965, ACTA ORTHOP SCAND, V36, P153, DOI 10.3109/17453676508989381	44	301	308	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2003	290	11					1479	1485		10.1001/jama.290.11.1479	http://dx.doi.org/10.1001/jama.290.11.1479			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721RE	13129988	Bronze			2022-12-24	WOS:000185329000030
J	Biggins, JB; Onwueme, KC; Thorson, JS				Biggins, JB; Onwueme, KC; Thorson, JS			Resistance to enediyne antitumor antibiotics by calC self-sacrifice	SCIENCE			English	Article							DNA CLEAVAGE; CALICHEAMICIN; ACTIVATION; BINDING; AGENTS	Antibiotic self-resistance mechanisms, which include drug elimination, drug modi. cation, target modi. cation, and drug sequestration, contribute substantially to the growing problem of antibiotic resistance among pathogenic bacteria. Enediynes are among the most potent naturally occurring antibiotics, yet the mechanism of resistance to these toxins has remained a mystery. We characterize an enediyne self-resistance protein that reveals a self-sacrificing paradigm for resistance to highly reactive antibiotics, and thus another opportunity for nonpathogenic or pathogenic bacteria to evade extremely potent small molecules.	Univ Wisconsin, Sch Pharm, Pharmaceut Sci Div, Lab Biosynthet Chem, Madison, WI 53705 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med, Sloan Kettering Div, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA	University of Wisconsin System; University of Wisconsin Madison; Cornell University; Memorial Sloan Kettering Cancer Center	Thorson, JS (corresponding author), Univ Wisconsin, Sch Pharm, Pharmaceut Sci Div, Lab Biosynthet Chem, 777 Highland Ave, Madison, WI 53705 USA.	jsthorson@pharmacy.wisc.edu	Thorson, Jon S/L-3696-2013	Thorson, Jon S/0000-0002-7148-0721; Biggins, John B./0000-0002-0825-3593	NCI NIH HHS [CA84374] Funding Source: Medline; NIAID NIH HHS [AI52218] Funding Source: Medline; NIGMS NIH HHS [GM58196] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052218, R37AI052218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058196] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlert J, 2002, SCIENCE, V297, P1173, DOI 10.1126/science.1072105; BERGMAN RG, 1973, ACCOUNTS CHEM RES, V6, P25, DOI 10.1021/ar50061a004; Biggins JB, 2000, P NATL ACAD SCI USA, V97, P13537, DOI 10.1073/pnas.240460997; Chatterjee M, 1996, J AM CHEM SOC, V118, P1938, DOI 10.1021/ja953162h; CHATTERJEE M, 1993, J AM CHEM SOC, V115, P3374, DOI 10.1021/ja00061a064; DAVIES MJ, 1997, RADICAL MEDIATED PRO, pCH2; DEVOSS JJ, 1990, J AM CHEM SOC, V112, P4554, DOI 10.1021/ja00167a069; Durr F. E., 1995, ENEDIYNE ANTIBIOTICS; ERMACORA MR, 1992, P NATL ACAD SCI USA, V89, P6383, DOI 10.1073/pnas.89.14.6383; GOLDBERG IH, 1997, ENEDIYNE ANTIBIOTICS, pCH16; HOYER D, 1990, J AM CHEM SOC, V112, P3249, DOI 10.1021/ja00164a076; Jones GB, 2000, ORG LETT, V2, P1863, DOI 10.1021/ol005926q; Jones GB, 2000, ORG LETT, V2, P811, DOI 10.1021/ol0055566; Kumar CV, 2002, P NATL ACAD SCI USA, V99, P5810, DOI 10.1073/pnas.082119599; McDonald LA, 1996, J AM CHEM SOC, V118, P10898, DOI 10.1021/ja961122n; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; MYERS AG, 1994, J AM CHEM SOC, V116, P1255, DOI 10.1021/ja00083a012; Oku N, 2003, J AM CHEM SOC, V125, P2044, DOI 10.1021/ja0296780; Plourde G, 2002, BIOORG MED CHEM LETT, V12, P2985; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; Tenover FC, 2001, CLIN INFECT DIS, V33, pS108, DOI 10.1086/321834; Thorson JS, 2000, CURR PHARM DESIGN, V6, P1841, DOI 10.2174/1381612003398564; Walsh C., 2003, ANTIBIOTICS ACTIONS; Waugh DS, 1996, J BIOMOL NMR, V8, P184; Whitwam RE, 2000, J AM CHEM SOC, V122, P1556, DOI 10.1021/ja993612w	25	71	74	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1537	1541		10.1126/science.1086695	http://dx.doi.org/10.1126/science.1086695			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12970566				2022-12-24	WOS:000185255300051
J	Yin, Y; Manoury, B; Fahraeus, R				Yin, Y; Manoury, B; Fahraeus, R			Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1	SCIENCE			English	Article							CLASS-I MOLECULES; NUCLEAR ANTIGEN-1; PEPTIDE; DEGRADATION; TRANSLATION; INITIATION; PROTEINS; DRIPS; CELLS	The glycine-alanine repeat domain (GAr) of Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1) prevents major histocompatibility complex (MHC) class I restricted presentation of EBNA1 epitopes to cytotoxic T cells. This effect has previously been attributed to the ability of GAr to inhibit its own proteasomal degradation. Here we show, both in vitro and in vivo, that GAr also inhibits messenger RNA translation of EBNA1 in cis and that this effect can be distinguished from its effect on proteasomal degradation. Hence, inhibition of messenger RNA translation, but not protein degradation, is essential to prevent antigen presentation on MHC class I molecules. Thus, by minimizing translation of the EBNA1 transcript, cells expressing EBNA1 avoid cytotoxic T cell recognition. At the same time, blocking degradation maintains the EBNA1 expression level.	Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; Univ Dundee, Fac Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Fahraeus, R (corresponding author), Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland.		fahraeus, robin/K-8726-2014	Manoury, Benedicte/0000-0001-7784-3389; , robin/0000-0003-0402-8492				Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; Blake N, 2000, J IMMUNOL, V165, P7078, DOI 10.4049/jimmunol.165.12.7078; CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; DILLNER J, 1984, P NATL ACAD SCI-BIOL, V81, P4652, DOI 10.1073/pnas.81.15.4652; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6021; Khanna R, 1995, VIROLOGY, V214, P633, DOI 10.1006/viro.1995.0076; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; PEERY T, 2000, TRANSLATIONAL CONTRO; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Wu H, 2002, J VIROL, V76, P2480, DOI 10.1128/JVI.76.5.2480-2490.2002; Yewdell JW, 2002, NAT IMMUNOL, V3, P1019, DOI 10.1038/ni1102-1019; Yewdell JW, 1996, J IMMUNOL, V157, P1823; Yewdell JW, 2001, J CELL SCI, V114, P845; Yin Y.G., UNPUB	23	203	219	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1371	1374		10.1126/science.1088902	http://dx.doi.org/10.1126/science.1088902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958359				2022-12-24	WOS:000185116400039
J	Iglehart, JK				Iglehart, JK			Prescription-drug coverage for Medicare beneficiaries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	4	4	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					923	925		10.1056/NEJMp038139	http://dx.doi.org/10.1056/NEJMp038139			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954738				2022-12-24	WOS:000185081400001
J	Wusthoff, C				Wusthoff, C			The dilemma of confidentiality in Huntington disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISCLOSURE		Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wusthoff, C (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.			Wusthoff, Courtney/0000-0002-1882-5567				ADAMS J, 1990, J MED ETHICS, V16, P195; BALL D, 1993, J MED GENET, V30, P1028; Bernstein T, 1994, RADON RENTAL HOUSING; BLOCH M, 1993, AM J MED GENET, V47, P368, DOI 10.1002/ajmg.1320470314; Evers-Kiebooms G, 1998, PATIENT EDUC COUNS, V35, P15, DOI 10.1016/S0738-3991(98)00086-X; Hakimian R, 2000, GENET TEST, V4, P359, DOI 10.1089/109065700750065090; Knoppers BM, 1998, AM J HUM GENET, V62, P474; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, SCREEN COUNS GEN CON	8	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1219	1220		10.1001/jama.290.9.1219	http://dx.doi.org/10.1001/jama.290.9.1219			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12953009				2022-12-24	WOS:000185090400022
J	Belotserkovskaya, R; Oh, S; Bondarenko, VA; Orphanides, G; Studitsky, VM; Reinberg, D				Belotserkovskaya, R; Oh, S; Bondarenko, VA; Orphanides, G; Studitsky, VM; Reinberg, D			FACT facilitates transcription-dependent nucleosome alteration	SCIENCE			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; IN-VIVO; ELONGATION; CHROMATIN; PROTEIN; COMPLEX; POB3; SSRP1; CDC68	The FACT (facilitates chromatin transcription) complex is required for transcript elongation through nucleosomes by RNA polymerase II (Pol II) in vitro. Here, we show that FACT facilitates Pol II-driven transcription by destabilizing nucleosomal structure so that one histone H2A-H2B dimer is removed during enzyme passage. We also demonstrate that FACT possesses intrinsic histone chaperone activity and can deposit core histones onto DNA. Importantly, FACT activity requires both of its constituent subunits and is dependent on the highly acidic C terminus of its larger subunit, Spt16. These findings define the mechanism by which Pol II can transcribe through chromatin without disrupting its epigenetic status.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Dept Biochem,Div Nucl Acids enzymol, Piscataway, NJ 08854 USA; Wayne State Univ, Sch Med, Dept Biochem, Detroit, MI 48201 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Wayne State University	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Dept Biochem,Div Nucl Acids enzymol, Piscataway, NJ 08854 USA.		Studitsky, Vasily/A-9382-2014; Bondarenko, Vladimir/AFY-8370-2022	Reinberg, Danny/0000-0003-4288-2016	NIGMS NIH HHS [GM37120, GM58650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037120, R37GM037120, R01GM058650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELOTSERKOVSKAY.R, UNPUB; BONDARENKO VA, UNPUB; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Evans DRH, 1998, GENETICS, V150, P1393; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; Formosa T, 2002, GENETICS, V162, P1557; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Lindstrom DL, 2001, GENETICS, V159, P487; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; SAUNDERS, 2003, SCIENCE, V301, P1094; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; TENHEGGELERBORDIER B, 1995, EMBO J, V14, P2561, DOI 10.1002/j.1460-2075.1995.tb07254.x; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; XU QL, 1993, MOL CELL BIOL, V13, P7553, DOI 10.1128/MCB.13.12.7553; Yarnell AT, 2001, J BIOL CHEM, V276, P25736, DOI 10.1074/jbc.M101208200	28	629	645	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1090	1093		10.1126/science.1085703	http://dx.doi.org/10.1126/science.1085703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934006				2022-12-24	WOS:000184872400038
J	van Ommeren, M; Saxena, S; Loretti, A; Saraceno, B				van Ommeren, M; Saxena, S; Loretti, A; Saraceno, B			Ensuring care for patients in custodial psychiatric hospitals in emergencies	LANCET			English	Editorial Material									WHO, Dept Mental Hlth & Subst Dependence, CH-1211 Geneva, Switzerland; WHO, Hlth Act Crises, CH-1211 Geneva, Switzerland	World Health Organization; World Health Organization	van Ommeren, M (corresponding author), WHO, Dept Mental Hlth & Subst Dependence, Ave Appia, CH-1211 Geneva, Switzerland.	vanommerenm@who.int		Saraceno, Benedetto/0000-0001-7119-5712				BISE G, 2001, MALADES MENTAUX GUER; Silove D, 2000, LANCET, V355, P1548, DOI 10.1016/S0140-6736(00)02177-2; WEISS MG, IN PRESS J NERV MENT; World Health Organisation, 2001, MENT DIS AFF ON 4 PE	4	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					574	574		10.1016/S0140-6736(03)14123-2	http://dx.doi.org/10.1016/S0140-6736(03)14123-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	712UW	12938670				2022-12-24	WOS:000184817600029
J	Limpens, E; Franken, C; Smit, P; Willemse, J; Bisseling, T; Geurts, R				Limpens, E; Franken, C; Smit, P; Willemse, J; Bisseling, T; Geurts, R			LysM domain receptor kinases regulating rhizobial Nod factor-induced infection	SCIENCE			English	Article							MEDICAGO-TRUNCATULA CONTROLS; FACTOR-PERCEPTION; NODULATION FACTOR; MELILOTI; SIGNAL; SPECIFICITY; RESISTANCE; GENOMES; GENES; ENTRY	The rhizobial infection of legumes has the most stringent demand toward Nod factor structure of all host responses, and therefore a specific Nod factor entry receptor has been proposed. The SYM2 gene identfied in certain ecotypes of pea (Pisum sativum) is a good candidate for such an entry receptor. We exploited the close phylogenetic relationship of pea and the model legume Medicago truncatula to identify genes specifically involved in rhizobial infection. The SYM2 orthologous region of M. truncatula contains 15 putative receptor-like genes, of which 7 are LysM domain-containing receptor-like kinases (LYKs). Using reverse genetics in M. truncatula, we show that two LYK genes are specifically involved in infection thread formation. This, as well as the properties of the LysM domains, strongly suggests that they are Nod factor entry receptors.	Univ Wageningen & Res Ctr, Dept Plant Sci, Mol Biol Lab, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research	Bisseling, T (corresponding author), Univ Wageningen & Res Ctr, Dept Plant Sci, Mol Biol Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.		Willemse, Joost/B-1861-2008; Bisseling, Ton/A-2421-2013; poinssot, benoit/B-2569-2009	Willemse, Joost/0000-0001-9312-6021; poinssot, benoit/0000-0001-5890-4318				Amon P, 1998, PLANT CELL, V10, P781; ARDOUREL M, 1994, PLANT CELL, V6, P1357, DOI 10.1105/tpc.6.10.1357; Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; Ben Amor B, 2003, PLANT J, V34, P495, DOI 10.1046/j.1365-313X.2003.01743.x; Boisson-Dernier A, 2001, MOL PLANT MICROBE IN, V14, P695, DOI 10.1094/MPMI.2001.14.6.695; Catoira R, 2001, DEVELOPMENT, V128, P1507; Cheng HP, 1998, J BACTERIOL, V180, P5183, DOI 10.1128/JB.180.19.5183-5191.1998; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; Cullimore JV, 2001, TRENDS PLANT SCI, V6, P24, DOI 10.1016/S1360-1385(00)01810-0; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; FIRMIN JL, 1993, MOL MICROBIOL, V10, P351, DOI 10.1111/j.1365-2958.1993.tb01961.x; Gage DJ, 2002, J BACTERIOL, V184, P7042, DOI 10.1128/JB.184.24.7042-7046.2002; Geurts R, 1997, PLANT PHYSIOL, V115, P351, DOI 10.1104/pp.115.2.351; Geurts R, 2002, PLANT CELL, V14, pS239, DOI 10.1105/tpc.002451; GEURTS R, UNPUB; Gualtieri G, 2002, PLANT MOL BIOL, V50, P225, DOI 10.1023/A:1016085523752; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LIE TA, 1984, PLANT SOIL, V82, P415, DOI 10.1007/BF02184279; LIMPENS E, UNPUBLISHED; McCallum CM, 2000, PLANT PHYSIOL, V123, P439, DOI 10.1104/pp.123.2.439; Oldroyd GED, 2001, PLANT J, V28, P191, DOI 10.1046/j.1365-313X.2001.01149.x; Walker SA, 2000, MOL PLANT MICROBE IN, V13, P754, DOI 10.1094/MPMI.2000.13.7.754; Young ND, 2003, CURR OPIN PLANT BIOL, V6, P199, DOI 10.1016/S1369-5266(03)00006-2	23	536	579	6	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					630	633		10.1126/science.1090074	http://dx.doi.org/10.1126/science.1090074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	12947035				2022-12-24	WOS:000186119900055
J	Thayer, SP; di Magliano, MP; Heiser, PW; Nielsen, CM; Roberts, DJ; Lauwers, GY; Qi, YP; Gysin, S; Fernandez-del Castillo, CF; Yajnik, V; Antoniu, B; McMahon, M; Warshaw, AL; Hebrok, M				Thayer, SP; di Magliano, MP; Heiser, PW; Nielsen, CM; Roberts, DJ; Lauwers, GY; Qi, YP; Gysin, S; Fernandez-del Castillo, CF; Yajnik, V; Antoniu, B; McMahon, M; Warshaw, AL; Hebrok, M			Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis	NATURE			English	Article							SONIC-HEDGEHOG; INTRAEPITHELIAL NEOPLASIA; SIGNALING PATHWAY; DUCT LESIONS; NEURAL-TUBE; EXPRESSION; GENE; ADENOCARCINOMA; INACTIVATION; CYCLOPAMINE	Hedgehog signalling-an essential pathway during embryonic pancreatic development, the misregulation of which has been implicated in several forms of cancer-may also be an important mediator in human pancreatic carcinoma(1-8). Here we report that sonic hedgehog, a secreted hedgehog ligand, is abnormally expressed in pancreatic adenocarcinoma and its precursor lesions: pancreatic intraepithelial neoplasia (PanIN). Pancreata of Pdx-Shh mice (in which Shh is misexpressed in the pancreatic endoderm) develop abnormal tubular structures, a phenocopy of human PanIN-1 and -2. Moreover, these PanIN-like lesions also contain mutations in K-ras and overexpress HER-2/neu, which are genetic mutations found early in the progression of human pancreatic cancer. Furthermore, hedgehog signalling remains active in cell lines established from primary and metastatic pancreatic adenocarcinomas. Notably, inhibition of hedgehog signalling by cyclopamine induced apoptosis and blocked proliferation in a subset of the pancreatic cancer cell lines both in vitro and in vivo. These data suggest that this pathway may have an early and critical role in the genesis of this cancer, and that maintenance of hedgehog signalling is important for aberrant proliferation and tumorigenesis.	Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Calif San Francisco, Dept Med, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hebrok, M (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.		Roberts, Drucilla/AAB-6379-2022; Castillo, Carlos Fenandez-del/AAO-2602-2020	Heiser, Patrick/0000-0002-8831-4973; Pasca di Magliano, Marina/0000-0001-9632-9035	NICHD NIH HHS [R29 HD034448-02] Funding Source: Medline; NIDDK NIH HHS [R01 DK060533] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD034448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060533] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Day JD, 1996, HUM PATHOL, V27, P119, DOI 10.1016/S0046-8177(96)90364-0; Hardcastle Z, 1998, DEVELOPMENT, V125, P2803; HASEGAWA Y, 1995, ONCOGENE, V10, P1441; Hebrok M, 2000, DEVELOPMENT, V127, P4905; Hebrok M, 2003, MECH DEVELOP, V120, P45, DOI 10.1016/S0925-4773(02)00331-3; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ito Y, 2002, INT J ONCOL, V20, P1263; Jaffee EM, 1998, CANCER J SCI AM, V4, P194; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Lee J, 1997, DEVELOPMENT, V124, P2537; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; ROBERTS DJ, 2000, DEV GASTROINTESTINAL, P1; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sasaki H, 1997, DEVELOPMENT, V124, P1313; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Wilentz RE, 1998, CANCER RES, V58, P4740; Wilentz RE, 2000, CANCER RES, V60, P2002	30	1192	1320	2	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 23	2003	425	6960					851	856		10.1038/nature02009	http://dx.doi.org/10.1038/nature02009			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735ME	14520413	Green Accepted			2022-12-24	WOS:000186118500048
J	Victora, CG; Barros, FC; Lima, RC; Horta, BL; Wells, J				Victora, CG; Barros, FC; Lima, RC; Horta, BL; Wells, J			Anthropometry and body composition of 18 year old men according to duration of breast feeding: birth cohort study from Brazil	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OVERWEIGHT	Objective To assess the association between duration of breast feeding and measures of adiposity in adolescence. Design Population based birth cohort study. Setting Pelotas, a city of 320 000 inhabitants in a relatively developed area in southern Brazil. Participants All newborn infants in the city's hospitals were enrolled in 1982; 78.8% (2250) of all male participants were located at age 18 years when enrolling in the national army. Main outcome measures Weight, height, sitting height, subscapular and triceps skinfolds, and body composition (body fat, lean mass). Results Neither the duration of total breast feeding nor that of predominant breast feeding (breast milk plus non-nutritive fluids) showed consistent associations with anthropometric or body composition indices. After adjustment for confounding factors, the only significant associations were a greater than 50% reduction in obesity among participants breast fed for three to five months compared with all other breastfeeding categories (P = 0.007) and a linear decreasing trend in obesity with increasing duration of predominant breast feeding (P = 0.03). Similar significant effects were not observed for other measures of adiposity. Borderline direct associations also occurred between total duration of breast feeding and adult height (P = 0.06). Conclusions The significant reduction in obesity among children breast fed for three to five months is difficult to interpret, as no a priori hypothesis existed regarding a protective effect of intermediate duration of breast feeding. The findings indicate that, in this population, breast feeding has no marked protective effect against adolescent adiposity.	Univ Fed Pelotas, Post Grad Programme Epidemiol, BR-96001970 Pelotas, RS, Brazil; PAHO WHO, Latin Amer Ctr Perinatol & Human Dev, Montevideo, Uruguay; Univ Catolica Pelotas, Fac Med, Pelotas, RS, Brazil; Univ London, Inst Child Hlth, London WC1N 1EH, England	Universidade Federal de Pelotas; Universidade Catolica de Pelotas; Universidade Federal de Pelotas; University of London; University College London	Victora, CG (corresponding author), Univ Fed Pelotas, Post Grad Programme Epidemiol, CP 464, BR-96001970 Pelotas, RS, Brazil.	cvictora@terra.com.br	Victora, Cesar Gomes/Y-2455-2019; Horta, Bernardo/A-7604-2008; Barros, Fernando C/D-4857-2013; Victora, Cesar G/D-4476-2013; Wells, Jonathan/A-4604-2009	Victora, Cesar Gomes/0000-0002-2465-2180; Horta, Bernardo/0000-0001-9843-412X; Victora, Cesar G/0000-0002-2465-2180; Wells, Jonathan/0000-0003-0411-8025				BARROS FC, 1990, PAEDIATR PERINAT EP, V4, P267; Beral V, 2003, LANCET, V361, P177, DOI 10.1016/S0140-6736(03)12209-X; BLOCK G, 1989, J NUTR EDUC, V21, P199; Butte NE, 2001, PEDIATR CLIN N AM, V48, P189, DOI 10.1016/S0031-3955(05)70293-5; Dewey Kathryn G, 2003, J Hum Lact, V19, P9; Dietz WH, 2001, JAMA-J AM MED ASSOC, V285, P2506, DOI 10.1001/jama.285.19.2506; Elliott KG, 1997, OBES RES, V5, P538, DOI 10.1002/j.1550-8528.1997.tb00574.x; Gillman MW, 2001, JAMA-J AM MED ASSOC, V285, P2461, DOI 10.1001/jama.285.19.2461; Hediger ML, 2001, JAMA-J AM MED ASSOC, V285, P2453, DOI 10.1001/jama.285.19.2453; KRAMER MS, 1981, J PEDIATR-US, V98, P883, DOI 10.1016/S0022-3476(81)80579-3; Tulldahl J, 1999, OBES RES, V7, P431, DOI 10.1002/j.1550-8528.1999.tb00430.x; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; VICTORA CG, 2003, IN PRESS CAD SAUDE P; *WHO DIV DIARRH AC, 1991, IND ASS BREAST FEED; *WHO EXP COMM NUTR, 1995, WHO TECHN REP SER, V854	15	99	110	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2003	327	7420					901	904		10.1136/bmj.327.7420.901	http://dx.doi.org/10.1136/bmj.327.7420.901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734RV	14563746	Bronze, Green Published			2022-12-24	WOS:000186072100018
J	Hu, QD; Ang, BT; Karsak, M; Hu, WP; Cui, XY; Duka, T; Takeda, Y; Chia, W; Sankar, N; Ng, YK; Ling, EA; Maciag, T; Small, D; Trifonova, R; Kopan, R; Okano, H; Nakafuku, M; Chiba, S; Hirai, H; Aster, JC; Schachner, M; Pallen, CJ; Watanabe, K; Xiao, ZC				Hu, QD; Ang, BT; Karsak, M; Hu, WP; Cui, XY; Duka, T; Takeda, Y; Chia, W; Sankar, N; Ng, YK; Ling, EA; Maciag, T; Small, D; Trifonova, R; Kopan, R; Okano, H; Nakafuku, M; Chiba, S; Hirai, H; Aster, JC; Schachner, M; Pallen, CJ; Watanabe, K; Xiao, ZC			F3/contactin acts as a functional ligand for notch during oligodendrocyte maturation	CELL			English	Article							ADHESION MOLECULE; NEURITE OUTGROWTH; FYN KINASE; RECEPTOR; EXPRESSION; CELLS; CONTACTIN; MOUSE; DIFFERENTIATION; F3	Axon-derived molecules are temporally and spatially required as positive or negative signals to coordinate oligodendrocyte differentiation. Increasing evidence suggests that, in addition to the inhibitory Jagged1/ Notch1 signaling cascade, other pathways act via Notch to mediate oligodendrocyte differentiation. The GPI-linked neural cell recognition molecule F3/contactin is clustered during development at the paranodal region, a vital site for axoglial interaction. Here, we show that F3/contactin acts as a functional ligand of Notch. This trans-extracellular interaction triggers gamma-secre-tase-dependent nuclear translocation of the Notch intracellular domain. F3/Notch signaling promotes oligodendrocyte precursor cell differentiation and upregulates the myelin-related protein MAG in OLN-93 cells. This can be blocked by dominant negative Notch1, Notch2, and two Deltex1 mutants lacking the RING-H2 finger motif, but not by dominant-negative RBP-J or Hes1 antisense oligonucleotides. Expression of constitutively active Notch1 or Notch2 does not upregulate MAG. Thus, F3/contactin specifically initiates a Notch/Deltex1 signaling pathway that promotes oligodendrocyte maturation and myelination.	Tokyo Metropolitan Inst Gerontol, Dept Cell Recognit, Tokyo 1730015, Japan; Singapore Gen Hosp, Dept Clin Res, Singapore 169608, Singapore; Natl Univ Singapore, Dept Anat, Singapore 117597, Singapore; Natl Inst Neurosci, Dept Neurosurg, Singapore 306433, Singapore; Univ Hamburg, Zentrum Mol Neurobiol, D-20251 Hamburg, Germany; Singapore Gen Hosp, Dept Obstet & Gynecol, Singapore 169608, Singapore; Natl Canc Ctr, Singapore 169610, Singapore; Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04469 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; Keio Univ, Sch Med, Dept Physiol, Tokyo 1608582, Japan; Univ Tokyo, Grad Sch Med, Tokyo 1130033, Japan; Univ Tokyo, Dept Cell Therapy Transplantat Med & Hematol, Tokyo 1138655, Japan; Univ Tokyo, Dept Oncol, Tokyo 1138655, Japan; Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA; Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 1M9, Canada	Tokyo Metropolitan Institute of Gerontology; Singapore General Hospital; National University of Singapore; National Neuroscience Institute (NNI); University of Hamburg; University Medical Center Hamburg-Eppendorf; Singapore General Hospital; National Cancer Centre Singapore (NCCS); Maine Medical Center; Washington University (WUSTL); Washington University (WUSTL); Keio University; University of Tokyo; University of Tokyo; University of Tokyo; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of British Columbia	Xiao, ZC (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Cell Recognit, Tokyo 1730015, Japan.		Kopan, Raphael/AFG-3275-2022; Kopan, Raphael/AAF-1357-2022; Okano, Hideyuki/I-7584-2019; xiao, zhicheng/A-1529-2011; Nakafuku, Masato/J-3068-2013	Pallen, Catherine/0000-0002-3576-5295; Nakafuku, Masato/0000-0001-7783-9005; Kopan, Raphael/0000-0002-0350-2730; Karsak, Meliha/0000-0001-6612-6317	NCRR NIH HHS [RR 15555] Funding Source: Medline; NHLBI NIH HHS [HL35627, HL32348] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL032348] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Berglund EO, 1999, NEURON, V24, P739, DOI 10.1016/S0896-6273(00)81126-5; BOGLER O, 1997, CURRENT PROTOCOLS NE, DOI UNSP 3.4.1-3.4.9; COLELLO RJ, 1998, CURRENT PROTOCOLS NE, DOI UNSP 3.12.7-3.12.10; Dale JK, 2003, BIOESSAYS, V25, P200, DOI 10.1002/bies.10253; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.0.CO;2-N; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Faivre-Sarrailh C, 2000, J CELL BIOL, V149, P491, DOI 10.1083/jcb.149.2.491; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; Genoud S, 2002, J CELL BIOL, V158, P709, DOI 10.1083/jcb.200202002; Girault JA, 2002, CURR OPIN NEUROBIOL, V12, P476, DOI 10.1016/S0959-4388(02)00370-7; HEMANN C, 1994, DNA CELL BIOL, V13, P437, DOI 10.1089/dna.1994.13.437; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; Jack C, 2001, MOL BRAIN RES, V87, P166, DOI 10.1016/S0169-328X(01)00010-9; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Kabos P, 2002, J BIOL CHEM, V277, P8763, DOI 10.1074/jbc.C100758200; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Kato H, 1997, DEVELOPMENT, V124, P4133; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Kishi N, 2001, INT J DEV NEUROSCI, V19, P21, DOI 10.1016/S0736-5748(00)00071-X; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; Koch T, 1997, GLIA, V19, P199, DOI 10.1002/(SICI)1098-1136(199703)19:3<199::AID-GLIA3>3.0.CO;2-V; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Matsuno K, 2002, DEVELOPMENT, V129, P1049; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Revest JM, 1999, ADV EXP MED BIOL, V468, P309; RichterLandsberg C, 1996, J NEUROSCI RES, V45, P161, DOI 10.1002/(SICI)1097-4547(19960715)45:2<161::AID-JNR8>3.0.CO;2-8; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimazaki K, 1998, NEUROSCI LETT, V245, P117, DOI 10.1016/S0304-3940(98)00179-7; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; TSIOTRA PC, 1993, GENOMICS, V18, P562, DOI 10.1016/S0888-7543(05)80357-X; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707	44	289	302	1	21	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 17	2003	115	2					163	175		10.1016/S0092-8674(03)00810-9	http://dx.doi.org/10.1016/S0092-8674(03)00810-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	734DD	14567914	Bronze			2022-12-24	WOS:000186039200008
J	Biju, SD; Bossuyt, F				Biju, SD; Bossuyt, F			New frog family from India reveals an ancient biogeographical link with the Seychelles	NATURE			English	Article							PHYLOGENETIC-RELATIONSHIPS; MADAGASCAN; AMPHIBIA	About 96% of the more than 4,800 living anuran species(1) belong to the Neobatrachia or advanced frogs(2-4). Because of the extremely poor representation of these animals in the Mesozoic fossil record, hypotheses on their early evolution have to rely largely on extant taxa(5-7). Here we report the discovery of a burrowing frog from India that is noticeably distinct from known taxa in all anuran families. Phylogenetic analyses of 2.8 kilobases of mitochondrial and nuclear DNA unambiguously designate this frog as the sister taxon of Sooglossidae, a family exclusively occurring on two granitic islands of the Seychelles archipelago(8). Furthermore, molecular clock analyses(9) uncover the branch leading to both taxa as an ancient split in the crown-group Neobatrachia. Our discovery discloses a lineage that may have been more diverse on Indo-Madagascar in the Cretaceous period, but now only comprises four species on the Seychelles and a sole survivor in India. Because of its very distinct morphology and an inferred origin that is earlier than several neobatrachian families(10), we recognize this frog as a new family.	Free Univ Brussels, Dept Biol, Unit Ecol & Systemat, B-1050 Brussels, Belgium; Trop Bot Garden & Res Inst, Thiruvananthapuram 695562, Kerala, India	Universite Libre de Bruxelles; Vrije Universiteit Brussel; KSCSTE-Jawaharlal Nehru Tropical Botanic Garden & Research Institute (JNTBGRI)	Bossuyt, F (corresponding author), Free Univ Brussels, Dept Biol, Unit Ecol & Systemat, Pleinlaan 2, B-1050 Brussels, Belgium.	fbossuyt@vub.ac.be		Bossuyt, Franky/0000-0001-6804-9271				Avise JC, 1999, P NATL ACAD SCI USA, V96, P7358, DOI 10.1073/pnas.96.13.7358; BENTON MJ, 1997, VERTEBRATE PALAEONTO, P1; Bossuyt F, 2000, P NATL ACAD SCI USA, V97, P6585, DOI 10.1073/pnas.97.12.6585; Bossuyt F, 2001, SCIENCE, V292, P93, DOI 10.1126/science.1058875; COFFIN MF, 1992, AAPG MEMOIR, V53, P207; Duellman WE, 1986, BIOL AMPHIBIANS, P1; Feller AE, 1998, MOL PHYLOGENET EVOL, V9, P509, DOI 10.1006/mpev.1998.0500; Ford Linda S., 1993, Herpetological Monographs, V7, P94, DOI 10.2307/1466954; FROST DR, 2002, AMPHIBIAN SPECIES WO; Gao KQ, 2003, NATURE, V422, P424, DOI 10.1038/nature01491; HAY JM, 1995, MOL BIOL EVOL, V12, P928; Hay WW, 1999, GEOL S AM S, P1; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Krause DW, 2001, NATURE, V412, P497, DOI 10.1038/35087649; Krause DW, 1997, NATURE, V390, P504, DOI 10.1038/37343; Lemmon AR, 2002, P NATL ACAD SCI USA, V99, P10516, DOI 10.1073/pnas.162224399; Lynch J. D., 1971, Misc Publs Mus nat Hist Univ Kansas, VNo. 53, P1; NUSSBAUM RA, 1980, HERPETOLOGICA, V36, P1; NUSSBAUM RA, 1979, CARYOLOGIA, V32, P279, DOI 10.1080/00087114.1979.10796793; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Ruta M, 2003, BIOL REV, V78, P251, DOI 10.1017/S1464793102006103; Ruvinsky I, 1996, MOL PHYLOGENET EVOL, V5, P533, DOI 10.1006/mpev.1996.0048; Savage J.M., 1973, EVOLUTIONARY BIOL AN, P351; SPINAR Z V, 1985, Amphibia-Reptilia, V6, P363, DOI 10.1163/156853885X00353; Swofford DL, 2002, PAUP PHYLOGENETIC AN; Thorne JL, 2002, SYST BIOL, V51, P689, DOI 10.1080/10635150290102456; TYLER MJ, 1985, HERPETOLOGICA, V41, P173; Wilkinson M, 2002, MOL PHYLOGENET EVOL, V23, P401, DOI 10.1016/S1055-7903(02)00031-3	28	248	269	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	2003	425	6959					711	714		10.1038/nature02019	http://dx.doi.org/10.1038/nature02019			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732DA	14562102				2022-12-24	WOS:000185924500040
J	Chan, SP; Kao, DI; Tsai, WY; Cheng, SC				Chan, SP; Kao, DI; Tsai, WY; Cheng, SC			The Prp19p-associated complex in spliceosome activation	SCIENCE			English	Article							PRE-MESSENGER-RNA; SM-LIKE PROTEINS; SMALL NUCLEAR RNAS; U6 SNRNA; REQUIRES ATP; YEAST; SITE; ASSOCIATION; COMPONENTS; PRP19	During spliceosome activation, a large structural rearrangement occurs that involves the release of two small nuclear RNAs, U1 and U4, and the addition of a protein complex associated with Prp19p. We show here that the Prp19p-associated complex is required for stable association of U5 and U6 with the spliceosome after U4 is dissociated. Ultraviolet crosslinking analysis revealed the existence of two modes of base pairing between U6 and the 5' splice site, as well as a switch of such base pairing from one to the other that required the Prp19p-associated complex during spliceosome activation. Moreover, a Prp19p-dependent structural change in U6 small nuclear ribonucleoprotein particles was detected that involves destabilization of Sm-like (Lsm) proteins to bring about interactions between the Lsm binding site of U6 and the intron sequence near the 5' splice site, indicating dynamic association of Lsm with U6 and a direct role of Lsm proteins in activation of the spliceosome.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai, Taiwan; Acad Sinica, Inst Mol Biol, Nankang, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Cheng, SC (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai, Taiwan.	mbscc@ccvax.sinica.edu.tw	Cheng, Soo-Chen/AAZ-7956-2021	Cheng, Soo-Chen/0000-0002-7570-9415; Chan, Shih-Peng/0000-0001-6322-2821				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; Brow DA, 2002, ANNU REV GENET, V36, P333, DOI 10.1146/annurev.genet.36.043002.091635; Burge CB, 1999, RNA WORLD, P525; Chen CH, 2002, NUCLEIC ACIDS RES, V30, P1029, DOI 10.1093/nar/30.4.1029; Chen CH, 2001, J BIOL CHEM, V276, P488, DOI 10.1074/jbc.M006958200; Chen HR, 1998, MOL CELL BIOL, V18, P2196, DOI 10.1128/MCB.18.4.2196; Chen JYF, 2001, MOL CELL, V7, P227, DOI 10.1016/S1097-2765(01)00170-8; CHENG SC, 1994, NUCLEIC ACIDS RES, V22, P1548, DOI 10.1093/nar/22.9.1548; Kim CH, 1996, RNA, V2, P995; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; Makarov EM, 2002, SCIENCE, V298, P2205, DOI 10.1126/science.1077783; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; Ohi MD, 2002, MOL CELL BIOL, V22, P2011, DOI 10.1128/MCB.22.7.2011-2024.2002; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; Staley JP, 1999, MOL CELL, V3, P55, DOI 10.1016/S1097-2765(00)80174-4; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; TARN WY, 1993, MOL CELL BIOL, V13, P1883, DOI 10.1128/MCB.13.3.1883; TARN WY, 1994, EMBO J, V13, P2421, DOI 10.1002/j.1460-2075.1994.tb06527.x; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; Wang Q, 2003, J BIOL CHEM, V278, P7875, DOI 10.1074/jbc.M210839200; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	28	243	244	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					279	282		10.1126/science.1086602	http://dx.doi.org/10.1126/science.1086602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	12970570				2022-12-24	WOS:000185825900040
J	Shi, Y; Evans, JE; Rock, KL				Shi, Y; Evans, JE; Rock, KL			Molecular identification of a danger signal that alerts the immune system to dying cells	NATURE			English	Article							URATE MONOHYDRATE CRYSTALS; MONOSODIUM URATE; PARTICULATE ANTIGENS; ENDOGENOUS ADJUVANTS; DENDRITIC CELLS; URIC-ACID; SOLUBILITY; MACROPHAGES; GOUT	In infections, microbial components provide signals that alert the immune system to danger and promote the generation of immunity(1,2). In the absence of such signals, there is often no immune response or tolerance may develop. This has led to the concept that the immune system responds only to antigens perceived to be associated with a dangerous situation such as infection(3,4). Danger signals are thought to act by stimulating dendritic cells to mature so that they can present foreign antigens and stimulate T lymphocytes(2,5-7). Dying mammalian cells have also been found to release danger signals of unknown identity(8-11). Here we show that uric acid is a principal endogenous danger signal released from injured cells. Uric acid stimulates dendritic cell maturation and, when co-injected with antigen in vivo, significantly enhances the generation of responses from CD8(+) T cells. Eliminating uric acid in vivo inhibits the immune response to antigens associated with injured cells, but not to antigens presented by activated dendritic cells. Our findings provide a molecular link between cell injury and immunity and have important implications for vaccines, autoimmunity and inflammation.	Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Proteom & Mass Spectrometry Facil, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Rock, KL (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA.	kenneth.rock@umassmed.edu	Shi, Yan/Y-6642-2019					Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; BOSMANSKY K, 1984, Z RHEUMATOL, V43, P59; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1; FIDDIS RW, 1983, ANN RHEUM DIS, V42, P12, DOI 10.1136/ard.42.Suppl_1.12; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Hunter RL, 2002, VACCINE, V20, pS7, DOI 10.1016/S0264-410X(02)00164-0; IWATA H, 1989, J UROLOGY, V142, P1095, DOI 10.1016/S0022-5347(17)39003-1; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, COLD SH Q B, V54, P1; Jeha S, 2001, SEMIN HEMATOL, V38, P4, DOI 10.1053/shem.2001.29017; KIPPEN I, 1974, ANN RHEUM DIS, V33, P313, DOI 10.1136/ard.33.4.313; Koka RM, 2000, AM J PHYSIOL-RENAL, V278, pF989, DOI 10.1152/ajprenal.2000.278.6.F989; Landis RC, 2002, ARTHRITIS RHEUM, V46, P3026, DOI 10.1002/art.10614; LOEB JN, 1972, ARTHRITIS RHEUM-US, V15, P189, DOI 10.1002/art.1780150209; Majno G, 1996, CELLS TISSUES DIS PR; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5; Shi Y, 2002, EUR J IMMUNOL, V32, P155, DOI 10.1002/1521-4141(200201)32:1<155::AID-IMMU155>3.0.CO;2-P; Shi Y, 2000, P NATL ACAD SCI USA, V97, P14590, DOI 10.1073/pnas.260497597; SMYTH CJ, 1998, GOUT HYPERURICEMIA O; TAK HK, 1980, ARTHRITIS RHEUM, V23, P574, DOI 10.1002/art.1780230509; TALBOTT JH, 1976, GOUT URIC ACID METAB; Vidard L, 1996, J IMMUNOL, V156, P2809; Yagnik DR, 2000, ARTHRITIS RHEUM, V43, P1779, DOI 10.1002/1529-0131(200008)43:8<1779::AID-ANR14>3.0.CO;2-2	26	1272	1350	2	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2003	425	6957					516	521		10.1038/nature01991	http://dx.doi.org/10.1038/nature01991			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727FN	14520412				2022-12-24	WOS:000185648100046
J	Lee, Y; Ahn, C; Han, JJ; Choi, H; Kim, J; Yim, J; Lee, J; Provost, P; Radmark, O; Kim, S; Kim, VN				Lee, Y; Ahn, C; Han, JJ; Choi, H; Kim, J; Yim, J; Lee, J; Provost, P; Radmark, O; Kim, S; Kim, VN			The nuclear RNase III Drosha initiates microRNA processing	NATURE			English	Article							RIBONUCLEASE-III; INTERFERENCE; EXPRESSION; DICER; IDENTIFICATION; MATURATION; PROTEINS; ENCODES; GENES	Hundreds of small RNAs of similar to22 nucleotides, collectively named microRNAs (miRNAs), have been discovered recently in animals and plants(1-10). Although their functions are being unravelled(1,2,11-13), their mechanism of biogenesis remains poorly understood. miRNAs are transcribed as long primary transcripts (pri-miRNAs) whose maturation occurs through sequential processing events: the nuclear processing of the pri-miRNAs into stem-loop precursors of similar to70 nucleotides (pre-miRNAs), and the cytoplasmic processing of pre-miRNAs into mature miRNAs(14). Dicer, a member of the RNase III superfamily of bidentate nucleases, mediates the latter step(15-19), whereas the processing enzyme for the former step is unknown. Here we identify another RNase III, human Drosha, as the core nuclease that executes the initiation step of miRNA processing in the nucleus. Immunopurified Drosha cleaved pri-miRNA to release pre-miRNA in vitro. Furthermore, RNA interference of Drosha resulted in the strong accumulation of pri-miRNA and the reduction of pre-miRNA and mature miRNA in vivo. Thus, the two RNase III proteins, Drosha and Dicer, may collaborate in the stepwise processing of miRNAs, and have key roles in miRNA-mediated gene regulation in processes such as development and differentiation.	Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea; CHU Laval, Ctr Rech, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Laval University; Karolinska Institutet	Lee, Y (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea.		Han, Jinju/D-9091-2017; Provost, Patrick/G-2786-2010	Provost, Patrick/0000-0002-6099-6562; Kim, Jaekwang/0000-0002-7312-4077; HAN, Jinju/0000-0003-1844-2301				Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Filippov V, 2000, GENE, V245, P213, DOI 10.1016/S0378-1119(99)00571-5; Fortin KR, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-26; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Wu HJ, 2000, J BIOL CHEM, V275, P36957, DOI 10.1074/jbc.M005494200; Zamore PD, 2001, MOL CELL, V8, P1158, DOI 10.1016/S1097-2765(01)00418-X; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	30	3660	4062	9	517	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 25	2003	425	6956					415	419		10.1038/nature01957	http://dx.doi.org/10.1038/nature01957			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	724TG	14508493				2022-12-24	WOS:000185502300045
J	Mukherjee, JS				Mukherjee, JS			HIV-1 care in resource-poor settings: a view from Haiti	LANCET			English	Editorial Material							HAART		Harvard Univ, Sch Med, Div Social Med & Hlth Inequal, Partners Hlth, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Partners Healthcare System	Mukherjee, JS (corresponding author), Harvard Univ, Sch Med, Div Social Med & Hlth Inequal, Partners Hlth, Boston, MA 02115 USA.							[Anonymous], 1916, PYGMALION; Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145; *FUND FUND, CURR FUND CRIS; Gilks C, 2001, B WORLD HEALTH ORGAN, V79, P1154; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6	5	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 20	2003	362	9388					994	995		10.1016/S0140-6736(03)14373-5	http://dx.doi.org/10.1016/S0140-6736(03)14373-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	724LT	14513853				2022-12-24	WOS:000185489600026
J	Marler, JR; Goldstein, LB				Marler, JR; Goldstein, LB			Medicine - Stroke - tPA and the clinic	SCIENCE			English	Editorial Material							ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; PRACTICE GUIDELINES; RT-PA; STATEMENT		Natl Inst Neurol Disorders & Stroke, Clin Trials, Bethesda, MD 20817 USA; Duke Univ, Duke Ctr Cerebrovasc Dis, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Ctr Clin Hlth Policy Res, Stroke Policy Program, Durham, NC 27710 USA; Vet Adm Med Ctr, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Marler, JR (corresponding author), Natl Inst Neurol Disorders & Stroke, Clin Trials, Bethesda, MD 20817 USA.	marlerj@ninds.nih.gov						Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Alberts MJ, 2000, JAMA-J AM MED ASSOC, V283, P3102, DOI 10.1001/jama.283.23.3102; Barber PA, 2001, NEUROLOGY, V56, P1015, DOI 10.1212/WNL.56.8.1015; Crocco T J, 1999, Prehosp Emerg Care, V3, P201, DOI 10.1080/10903129908958937; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; Goldstein L B, 1999, J Stroke Cerebrovasc Dis, V8, P349, DOI 10.1016/S1052-3057(99)80010-X; Goldstein LB, 2000, STROKE, V31, P66, DOI 10.1161/01.STR.31.1.66; Katzan IL, 2003, STROKE, V34, P799, DOI 10.1161/01.STR.0000056944.42686.1E; Kidwell CS, 2000, STROKE, V31, P71, DOI 10.1161/01.STR.31.1.71; LaMonte MP, 2003, STROKE, V34, P725, DOI 10.1161/01.STR.0000056945.36583.37; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; Lopez-Yunez AR, 2001, STROKE, V32, P12, DOI 10.1161/01.STR.32.1.12; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; *NIH, IN PRESS NIH PUBL; Villar-Cordova C, 1998, NEUROLOGY, V50, P1491, DOI 10.1212/WNL.50.5.1491; ZIVIN JA, 1985, SCIENCE, V230, P1289, DOI 10.1126/science.3934754	17	50	54	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1677	1677		10.1126/science.1090270	http://dx.doi.org/10.1126/science.1090270			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	14500967				2022-12-24	WOS:000185387700028
J	Williams, BG; Dye, C				Williams, BG; Dye, C			Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS	SCIENCE			English	Article							HIV-INFECTION; CELL DECLINE; AIDS; SURVIVAL; THERAPY; PROGRESSION; EVOLUTION; PREDICT; AFRICA; TIME	Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/ AIDS) has dramatically increased the incidence of tuberculosis (TB) in sub-Saharan Africa, where up to 60% of TB patients are coinfected with HIV and each year 200,000 TB deaths are attributable to HIV coinfection. Now HIV threatens control of TB in Asia, Eastern Europe, and Latin America. Antiretroviral ( ARV) drugs can prevent TB by preserving immunity, but cohort analysis shows that early therapy, plus high levels of coverage and compliance, will be needed to avert a significant fraction of TB cases. However, ARV drugs could enhance the treatment of TB, and TB programs provide an important entry point for the treatment of HIV/ AIDS.	WHO, Communicable Dis, CH-1211 Geneva 27, Switzerland	World Health Organization	Williams, BG (corresponding author), WHO, Communicable Dis, CH-1211 Geneva 27, Switzerland.	williamsbg@who.int	Dye, Christopher/AIC-4659-2022	Williams, Brian/0000-0002-3174-4876; Dye, Christopher/0000-0002-2957-1793				ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; Babiker A, 2000, LANCET, V355, P1131, DOI 10.1016/S0140-6736(00)02061-4; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Cohen J, 2002, SCIENCE, V296, P2320, DOI 10.1126/science.296.5577.2320; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; CURRIE CSM, IN PRESS AIDS; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Dorrucci M, 1999, EUR J EPIDEMIOL, V15, P317, DOI 10.1023/A:1007503018729; DRABICK JJ, 1992, AIDS RES HUM RETROV, V8, P2039, DOI 10.1089/aid.1992.8.2039; EASTERBROOK PJ, 1993, AIDS, V7, P959, DOI 10.1097/00002030-199307000-00009; Gottlieb GS, 2002, J INFECT DIS, V185, P905, DOI 10.1086/339295; Harries AD, 2001, INT J TUBERC LUNG D, V5, P1109; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; Lepri AC, 1997, J INFECT DIS, V175, P775, DOI 10.1086/513970; Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001; Markowitz N, 1997, ANN INTERN MED, V126, P123, DOI 10.7326/0003-4819-126-2-199701150-00005; McNeil AJ, 1996, STAT MED, V15, P75, DOI 10.1002/(SICI)1097-0258(19960115)15:1&lt;75::AID-SIM142&gt;3.0.CO;2-8; Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011; MSF, 2002, EQ ACC SCAL HIV AIDS; Pilheu JA, 1997, INT J TUBERC LUNG D, V1, P422; Raviglione MC, 2002, LANCET, V359, P775, DOI 10.1016/S0140-6736(02)07880-7; Salamon R, 2002, J ACQ IMMUN DEF SYND, V29, P149, DOI 10.1097/00042560-200202010-00007; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; Tan Darrell HS, 2003, BMC Int Health Hum Rights, V3, P2, DOI 10.1186/1472-698X-3-2; *UNAIDS, 2003, UNAIDS0226E UNAIDS; *WHO, 2003, WHOCDSTB2001287; WILLIAMS BG, UNPUB; World Health Organization, 2002, SCAL ANT THER RES LT; Yamashita TE, 2001, AIDS, V15, P735, DOI 10.1097/00002030-200104130-00009; Yazdanpanah Y, 2001, INT J EPIDEMIOL, V30, P864, DOI 10.1093/ije/30.4.864	31	181	191	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1535	1537		10.1126/science.1086845	http://dx.doi.org/10.1126/science.1086845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12920302				2022-12-24	WOS:000185255300050
J	Eaves, AA; Palmer, AR				Eaves, AA; Palmer, AR			Reproduction - Widespread cloning in echinoderm larvae	NATURE			English	Editorial Material							EVOLUTION		Univ Alberta, Dept Biol Sci, Physiol & Cell Biol Grp, Edmonton, AB T6G 2E9, Canada; Univ Alberta, Dept Biol Sci, Systemat & Evolut Grp, Edmonton, AB T6G 2E9, Canada; Bamfield Marine Sci Ctr, Bamfield, BC V0R 1B0, Canada	University of Alberta; University of Alberta; Simon Fraser University	Eaves, AA (corresponding author), Univ Alberta, Dept Biol Sci, Physiol & Cell Biol Grp, Edmonton, AB T6G 2E9, Canada.	aeaves@ualberta.ca	Palmer, A. Richard/A-3593-2010	Palmer, A. Richard/0000-0002-7579-3899				Balser EJ, 1998, BIOL BULL-US, V194, P187, DOI 10.2307/1543049; BOSCH I, 1989, NATURE, V337, P169, DOI 10.1038/337169a0; Cameron CB, 2000, P NATL ACAD SCI USA, V97, P4469, DOI 10.1073/pnas.97.9.4469; Davidson EH, 1998, DEVELOPMENT, V125, P3269; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; JAECKLE WB, 1994, BIOL BULL, V186, P62, DOI 10.2307/1542036; Knott KE, 2003, BIOL BULL-US, V204, P246, DOI 10.2307/1543596; Lacalli TC, 2000, INVERTEBR BIOL, V119, P234; MacBride EW, 1921, NATURE, V106, P501; Mortensen T., 1921, STUDIES DEV LARVAL F; Vickery MS, 2000, BIOL BULL, V199, P298, DOI 10.2307/1543186	11	61	62	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2003	425	6954					146	146		10.1038/425146a	http://dx.doi.org/10.1038/425146a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12968170	Bronze			2022-12-24	WOS:000185236000032
J	Hupert, N; Bearman, GML; Mushlin, AI; Callahan, MA				Hupert, N; Bearman, GML; Mushlin, AI; Callahan, MA			Accuracy of screening for inhalational anthrax after a bioterrorist attack	ANNALS OF INTERNAL MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; NEW-YORK-CITY; RESPIRATORY SYNCYTIAL VIRUS; CLINICAL-FEATURES; BIOLOGICAL WEAPON; INFLUENZA-A; MANAGEMENT; DIAGNOSIS; INFECTION; EPIDEMIC	Background: Bioterrorism using anthrax claimed five lives in the United States in 2001 and remains a potential public health threat. In the aftermath of a large-scale anthrax attack, mass screening to identify early inhalational anthrax may improve both the management of individual cases and the efficiency of health resource utilization. Purpose: To develop the evidence base for outpatient anthrax screening protocols by quantifying differences in clinical presentation between inhalational anthrax and common viral respiratory tract infections. Design: Review, compilation, and data extraction from English-language case reports of inhalational anthrax and epidemiologic studies of influenza and other viral respiratory infections. Data Sources: 13 reports of 28 cases of inhalational anthrax from 1920 to 2001 and 5 studies reporting on the clinical features of 2762 cases of influenza and 1932 cases of noninfluenza viral respiratory disease. Data Synthesis: Characterization of presenting clinical symptoms in anthrax and viral disease and calculation of likelihood ratios for the presence of selected clinical features. Results: Fever and cough do not reliably discriminate between inhalational anthrax and viral respiratory tract infection. Features suggestive of anthrax include the presence of nonheadache neurologic symptoms (positive likelihood ratio cannot be calculated), dyspnea (positive likelihood ratio, 5.3 [95% Cl, 3.7 to 7.4]), nausea or vomiting (positive likelihood ratio, 5.1 [Cl, 3.0 to 8.5]), and finding of any abnormality on lung auscultation (positive likelihood ratio, 8.1 [Cl, 5.3 to 12.5]). In contrast, rhinorrhea (positive likelihood ratio, 0.2 [Cl, 0.1 to 0.4]) and sore throat (positive likelihood ratio, 0.2 [Cl, 0.1 to 0.5]) are more suggestive of viral respiratory tract infection. Conclusion: Inhalational anthrax has characteristic clinical features that are distinct from those seen in common viral respiratory tract infections. Screening protocols based on these features may improve rapid identification of patients with presumptive inhalational anthrax in the setting of a large-scale anthrax attack.	Cornell Univ, Weill Med Coll, Dept Publ Hlth, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY USA	Cornell University; NewYork-Presbyterian Hospital	Hupert, N (corresponding author), Cornell Univ, Weill Med Coll, Dept Publ Hlth, 3rd Floor,411 E 69th St, New York, NY 10021 USA.	nah2005@med.cornell.edu	Bearman, Gonzalo/ABB-2443-2020		PHS HHS [290-00-0013] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barakat LA, 2002, JAMA-J AM MED ASSOC, V287, P863, DOI 10.1001/jama.287.7.863; Bartlett JG, 2002, CLIN INFECT DIS, V35, P851, DOI 10.1086/341902; Bloem K, 2001, PUBLIC HEALTH REP, V116, P34; Boivin G, 2000, CLIN INFECT DIS, V31, P1166, DOI 10.1086/317425; Borio L, 2001, JAMA-J AM MED ASSOC, V286, P2554, DOI 10.1001/jama.286.20.2554; BRACHMAN PS, 1961, NEW ENGL J MED, V265, P203, DOI 10.1056/NEJM196108032650501; Brookmeyer R, 2002, SCIENCE, V295, P1861, DOI 10.1126/science.1068474; Brooksher WR, 1920, J AMER MED ASSOC, V74, P323, DOI 10.1001/jama.1920.26210050002012a; Carrat F, 1999, CLIN INFECT DIS, V28, P283, DOI 10.1086/515117; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P909; Church DL, 2002, CLIN INFECT DIS, V34, P790, DOI 10.1086/338960; COWDERY JS, 1947, ARCH PATHOL, V43, P396; Fine AD, 2001, CLIN INFECT DIS, V32, P1784, DOI 10.1086/320747; Gerberding JL, 2002, JAMA-J AM MED ASSOC, V287, P898, DOI 10.1001/jama.287.7.898; GOLD H, 1955, ARCH INTERN MED, V96, P387, DOI 10.1001/archinte.1955.00250140109012; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Govaert TME, 1998, FAM PRACT, V15, P16, DOI 10.1093/fampra/15.1.16; Grinberg LM, 2001, MODERN PATHOL, V14, P482, DOI 10.1038/modpathol.3880337; HAIGHT TH, 1952, AM J MED SCI, V224, P57, DOI 10.1097/00000441-195207000-00009; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; Hall CB, 2001, CLIN INFECT DIS, V33, P792, DOI 10.1086/322657; Hupert N, 2002, MED DECIS MAKING, V22, pS17, DOI 10.1177/027298902237709; Inglesby TV, 2002, JAMA-J AM MED ASSOC, V287, P2236, DOI 10.1001/jama.287.17.2236; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604; Kaufmann AF, 1997, EMERG INFECT DIS, V3, P83, DOI 10.3201/eid0302.970201; Khan AS, 2000, LANCET, V356, P1179, DOI 10.1016/S0140-6736(00)02769-0; Kuehnert MJ, 2003, CLIN INFECT DIS, V36, P328, DOI 10.1086/346035; LAFORCE FM, 1969, ARCH ENVIRON HEALTH, V18, P798, DOI 10.1080/00039896.1969.10665490; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Marrie TJ, 1996, AM J MED, V101, P508, DOI 10.1016/S0002-9343(96)00255-0; Mayer TA, 2001, JAMA-J AM MED ASSOC, V286, P2549, DOI 10.1001/jama.286.20.2549; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; Metlay JP, 2003, ANN INTERN MED, V138, P109, DOI 10.7326/0003-4819-138-2-200301210-00012; Mina B, 2002, JAMA-J AM MED ASSOC, V287, P858, DOI 10.1001/jama.287.7.858; Monto AS, 2000, ARCH INTERN MED, V160, P3243, DOI 10.1001/archinte.160.21.3243; MOOLENAAR RL, 1995, CLIN INFECT DIS, V21, P643, DOI 10.1093/clinids/21.3.643; *NIH OFF PUBL HLTH, 2001, OPT POST PREV INH AN; Oliveira EC, 2001, CHEST, V119, P1717, DOI 10.1378/chest.119.6.1717; Plotkin SA, 2002, AM J MED, V112, P4, DOI 10.1016/S0002-9343(01)01050-6; PLOTKIN SA, 2002, AM J MED, V112, P2, DOI DOI 10.1016/S0002-9343(01)01050-6; Sackett D. L, 2000, EVIDENCE BASED MED T; SEVERN M, 1976, BRIT MED J, V1, P748, DOI 10.1136/bmj.1.6012.748; Shafazand S, 1999, CHEST, V116, P1369, DOI 10.1378/chest.116.5.1369; SUFFIN SC, 1978, HUM PATHOL, V9, P594, DOI 10.1016/S0046-8177(78)80140-3; Swartz MN, 2001, NEW ENGL J MED, V345, P1621, DOI 10.1056/NEJMra012892; van Elden LJR, 2001, BRIT J GEN PRACT, V51, P630; VESSAL K, 1975, CLIN RADIOL, V26, P471, DOI 10.1016/S0009-9260(75)80100-0; Vlahov D, 2002, J URBAN HEALTH, V79, P2, DOI 10.1093/jurban/79.1.2; Yang Q K, 1979, Zhonghua Fang She Xue Za Zhi, V13, P242; Zambon M, 2001, ARCH INTERN MED, V161, P2116, DOI 10.1001/archinte.161.17.2116; 2001, MMWR MORB MORTAL WKL, V50, P1077; 2001, MMWR MORB MORTAL WKL, V50, P893; 2001, MMWR MORB MORTAL WKL, V50, P984; 1928, N ENGL J MED, V198, P148	56	33	33	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				337	345		10.7326/0003-4819-139-5_Part_1-200309020-00009	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965942				2022-12-24	WOS:000185037500004
J	Katou, Y; Kanoh, Y; Bando, M; Noguchi, H; Tanaka, H; Ashikari, T; Sugimoto, K; Shirahige, K				Katou, Y; Kanoh, Y; Bando, M; Noguchi, H; Tanaka, H; Ashikari, T; Sugimoto, K; Shirahige, K			S-phase checkpoint proteins Tof1 and Mrc1 form a stable replication-pausing complex	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; CHROMOSOME-VI; PROGRESSION; GENOME; YEAST; TRANSCRIPTION; LOCATION; ORIGINS; KINASE	The checkpoint regulatory mechanism has an important role in maintaining the integrity of the genome(1-5). This is particularly important in S phase of the cell cycle, when genomic DNA is most susceptible to various environmental hazards(3,6,7). When chemical agents damage DNA, activation of checkpoint signalling pathways results in a temporary cessation of DNA replication. A replication-pausing complex is believed to be created at the arrested forks to activate further checkpoint cascades, leading to repair of the damaged DNA. Thus, checkpoint factors are thought to act not only to arrest replication but also to maintain a stable replication complex at replication forks(6-9). However, the molecular mechanism coupling checkpoint regulation and replication arrest is unknown. Here we demonstrate that the checkpoint regulatory proteins Tof1 and Mrc1 interact directly with the DNA replication machinery in Saccharomyces cerevisiae. When hydroxyurea blocks chromosomal replication, this assembly forms a stable pausing structure that serves to anchor subsequent DNA repair events.	Yokohama City Univ, RIKEN, Genom Sci Ctr,Human Genome Res Grp, Genome Struct & Funct Team, Kanagawa 2300045, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Kanagawa 2300045, Japan; Yokohama City Univ, Kihara Inst Biol Res, Div Biochem, Totsuka Ku, Kanagawa 2440813, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Totsuka Ku, Kanagawa 2440813, Japan; Suntory Ltd, Inst Adv Technol, Shimamoto, Osaka 6188503, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4640814, Japan	RIKEN; Yokohama City University; Yokohama City University; Yokohama City University; Yokohama City University; Suntory Holdings Ltd; Nagoya University	Shirahige, K (corresponding author), Yokohama City Univ, RIKEN, Genom Sci Ctr,Human Genome Res Grp, Genome Struct & Funct Team, 1-7-22 Suehiro Cho, Kanagawa 2300045, Japan.			Shirahige, Katsuhiko/0000-0002-7862-1144				Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Cimbora DM, 2000, MOL CELL BIOL, V20, P5581, DOI 10.1128/MCB.20.15.5581-5591.2000; De Antoni A, 2000, GENE, V246, P179, DOI 10.1016/S0378-1119(00)00083-4; Foss EJ, 2001, GENETICS, V157, P567; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lengronne A, 2001, NUCLEIC ACIDS RES, V29, P1433, DOI 10.1093/nar/29.7.1433; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Schubeler D, 2002, NAT GENET, V32, P438, DOI 10.1038/ng1005; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; SHIRAHIGE K, 1993, MOL CELL BIOL, V13, P5043, DOI 10.1128/MCB.13.8.5043; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Yamashita M, 1997, GENES CELLS, V2, P655, DOI 10.1046/j.1365-2443.1997.1530351.x; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	26	531	546	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1078	1083		10.1038/nature01900	http://dx.doi.org/10.1038/nature01900			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944972				2022-12-24	WOS:000184984200049
J	Egan, ES; Waldor, MK				Egan, ES; Waldor, MK			Distinct replication requirements for the two vibrio cholerae chromosomes	CELL			English	Article							ESCHERICHIA-COLI CHROMOSOME; PLASMID DNA-REPLICATION; DAM METHYLTRANSFERASE; PROTEIN; ORIGIN; INITIATION; BACTERIAL; SEQUENCE; BINDING; GENOME	Studies of prokaryotic chromosome replication have focused almost exclusively on organisms with one chromosome. We defined and characterized the origins of replication of the two Vibrio cholerae chromosomes, oriCI(vc), and oriCII(vc). OriCII(vc) differs from the origin assigned by bioinformatic analysis and is unrelated to oriCI(vc). OriCII(vc)-based replication requires an internal 12 base pair repeat and two hypothetical genes that flank oriCII(vc). One of these genes is conserved among diverse genera of the family Vibrionaceae and encodes an origin binding protein. The other gene codes for an RNA and not a protein. OriCII(vc)- but not oriCI(vc)-based replication is negatively regulated by a DNA sequence adjacent to oriCII(vc). There is an unprecedented requirement for DNA adenine methyltransferase in both oriCI(vc)- and oriCII(vc)-based replication. Our studies of replication in V. cholerae indicate that microorganisms having multiple chromosomes may utilize unique mechanisms for the control of replication.	Tufts Univ, Sch Med, Dept Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Genet, Boston, MA 02111 USA; Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University; Howard Hughes Medical Institute	Waldor, MK (corresponding author), Tufts Univ, Sch Med, Dept Microbiol, 136 Harrison Ave, Boston, MA 02111 USA.			Waldor, Matthew/0000-0003-1843-7000	NIAID NIH HHS [AI-42347] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042347, R37AI042347] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELES A, 1993, J BACTERIOL, V175, P7801, DOI 10.1128/JB.175.24.7801-7807.1993; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; Boye E, 2000, EMBO REP, V1, P479, DOI 10.1093/embo-reports/kvd116; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Cabezon E, 1997, MOL GEN GENET, V254, P400, DOI 10.1007/s004380050432; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; Chattoraj DK, 2000, MOL MICROBIOL, V37, P467, DOI 10.1046/j.1365-2958.2000.01986.x; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; Guo FB, 2003, NUCLEIC ACIDS RES, V31, P1780, DOI 10.1093/nar/gkg254; HANSEN EB, 1986, P NATL ACAD SCI USA, V83, P4423, DOI 10.1073/pnas.83.12.4423; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; JENSEN MR, 1990, J MOL BIOL, V215, P257, DOI 10.1016/S0022-2836(05)80344-4; Julio SM, 2001, INFECT IMMUN, V69, P7610, DOI 10.1128/IAI.69.12.7610-7615.2001; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Kitagawa R, 1996, MOL MICROBIOL, V19, P1137, DOI 10.1046/j.1365-2958.1996.453983.x; KITATSUKAMOTO K, 1993, INT J SYST BACTERIOL, V43, P8, DOI 10.1099/00207713-43-1-8; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; LobnerOlesen A, 1996, EMBO J, V15, P5999; LOBNEROLESEN A, 1992, MOL MICROBIOL, V6, P1841, DOI 10.1111/j.1365-2958.1992.tb01356.x; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; Marinus M.G., 1996, E COLI SALMONELLA CE, P782; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Moyer KE, 2001, MOL MICROBIOL, V41, P311, DOI 10.1046/j.1365-2958.2001.02517.x; NOVICK RP, 1987, MICROBIOL REV, V51, P381, DOI 10.1128/MMBR.51.4.381-395.1987; PAPP PP, 1994, J BIOL CHEM, V269, P23563; PEARSON GDN, 1993, P NATL ACAD SCI USA, V90, P3750, DOI 10.1073/pnas.90.8.3750; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Slominska M, 2001, MOL MICROBIOL, V40, P1371, DOI 10.1046/j.1365-2958.2001.02480.x; Trucksis M, 1998, P NATL ACAD SCI USA, V95, P14464, DOI 10.1073/pnas.95.24.14464; Weitao T, 2000, EMBO REP, V1, P494; Yamaichi Y, 1999, MOL MICROBIOL, V31, P1513, DOI 10.1046/j.1365-2958.1999.01296.x; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	37	135	140	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					521	530		10.1016/S0092-8674(03)00611-1	http://dx.doi.org/10.1016/S0092-8674(03)00611-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941279	Bronze			2022-12-24	WOS:000184928800014
